background
surviv
sr
age
yr
initi
white
blood
cell
count
ball
patient
ds
improv
time
enrol
therapeut
trial
enhanc
support
care
object
assess
contemporari
outcom
ds
patient
srall
designmethod
cog
util
induct
ind
postinduct
assign
refin
risk
group
srlow
sraverag
av
srhigh
base
leukemia
genet
earli
respons
ds
patient
receiv
riskstratifi
therapi
addit
support
care
guidelin
includ
leucovorin
rescu
intrathec
methotrex
mainten
highli
encourag
hospit
highrisk
block
neutrophil
recoveri
srav
patient
underw
random
endind
standard
sc
vs
intensifi
consolid
ic
standard
interim
mainten
im
delay
intensif
di
vs
intensifi
imdi
imdi
random
close
due
superior
result
escal
iv
methotrex
mtx
im
sr
patient
treat
ccg
patient
enrol
subsequ
receiv
escal
iv
mtx
im
srhigh
ds
patient
nonrandomli
receiv
ic
singl
intensifi
imdi
vs
doubl
imdi
given
nond
patient
srlow
ds
nond
patient
particip
random
addit
pegaspargas
dose
consolid
im
result
enrol
sr
ball
patient
ds
ds
patient
patient
end
induct
avail
result
differ
proport
patient
rapid
earli
respons
slow
earli
respons
ds
nond
patient
p
risk
distribut
significantli
differ
p
ds
vs
nond
patient
srlow
vs
srav
vs
srhigh
vs
ef
sr
ball
patient
ds
vs
nond
vs
p
os
ds
vs
nond
patient
vs
p
ind
mortal
ds
patient
initi
excess
addit
treatment
modif
made
decreas
ef
risk
group
ds
vs
nond
patient
srlow
vs
srav
vs
srhigh
vs
ds
prognost
multivari
analys
account
risk
group
conclus
treatment
modif
addit
support
care
srall
ds
patient
excel
ef
os
similar
patient
without
ds
equival
risk
group
background
monosomi
delet
del
common
cytogenet
abnorm
pediatr
background
patient
relaps
pediatr
solid
tumor
cn
malign
therapeut
option
frequent
die
diseas
chimer
antigen
receptor
car
cell
shown
promis
treat
hematolog
malign
yet
translat
success
solid
tumor
partial
due
pauciti
identifi
differenti
express
cell
surfac
molecul
solid
tumor
object
use
tumor
specif
antibodi
loo
et
al
aim
gener
novel
car
target
checkpoint
molecul
overexpress
high
level
mani
pediatr
solid
tumor
designmethod
pediatr
tumor
microarray
stain
express
immunohistochemistri
ihc
secondgener
car
contain
endodomain
gener
use
variabl
region
antibodi
previous
shown
tumor
specif
bind
use
clinic
set
without
offtumor
effect
test
sever
model
lethal
pediatr
malign
result
express
tumor
stain
sampl
demonstr
high
homogen
level
express
includ
ewe
sarcoma
rhabdomyosarcoma
diffus
intrins
pontin
glioma
wilm
tumor
medulloblastoma
cell
demonstr
robust
cell
kill
cytokin
product
vitro
cell
line
deriv
histolog
singl
dose
intraven
administ
cell
mediat
complet
regress
establish
osteosarcoma
ewe
sarcoma
orthotop
xenograft
result
significantli
improv
surviv
model
mice
treat
control
cell
die
tumor
addit
test
univers
fatal
metastat
model
osteosarcoma
wherea
untreat
mice
die
lung
metastas
treat
mice
surviv
greater
six
month
order
test
car
traffic
cn
cross
blood
brain
barrier
mice
orthotop
inject
medulloblastoma
posterior
fossa
treat
control
aspho
abstract
cell
two
differ
xenograft
model
medulloblastoma
daoy
mediat
regress
tumor
significantli
extend
surviv
gener
effect
novel
therapeut
mani
pediatr
solid
tumor
brain
tumor
first
report
car
target
therapi
could
transform
children
high
risk
diseas
lack
effect
therapeut
option
clinic
trial
relaps
pediatr
solid
tumor
cn
malign
plan
myelodysplast
syndrom
md
frequent
aris
context
inherit
bone
marrow
failur
bmf
syndrom
shwachman
diamond
syndrom
sd
monosomi
associ
high
grade
md
propens
progress
acut
myelogen
leukemia
major
caus
morbid
mortal
patient
inherit
bmf
develop
nontranspl
strategi
treat
bone
marrow
failur
without
simultan
stimul
outgrowth
malign
clone
remain
major
challeng
object
aim
studi
investig
molecular
consequ
del
context
bmf
goal
develop
effect
treatment
designmethod
studi
biolog
molecular
consequ
monosomydel
bmf
induc
pluripot
stem
cell
gener
sd
patient
sdsipsc
delet
mdsassoci
region
long
arm
chromosom
introduc
use
previous
publish
modifi
crelox
approach
result
sd
ipsc
phenocopi
bone
marrow
failur
slow
prolifer
impair
hematopoiet
differenti
next
explor
whether
delet
confer
rel
fit
advantag
within
context
bone
marrow
failur
prolifer
sdsdel
ipsc
reduc
isogen
sd
ipsc
normal
control
without
increas
cell
death
sdsdel
demonstr
reduc
hematopoiet
differenti
compar
isogen
sd
cell
data
demonstr
delet
fail
confer
rel
growth
advantag
rel
isogen
sd
ipsc
result
impair
hematopoiesi
gain
insight
mechan
clonal
evolut
sd
perform
rna
sequenc
rnaseq
sdsdel
ipsc
express
tgf
pathway
downstream
target
reduc
sdsdel
ipsc
compar
isogen
sd
ipsc
singl
cell
rnaseq
analysi
primari
sd
bone
marrow
cell
confirm
tgf
pathway
hyperactiv
sd
western
blot
analysi
show
increas
level
sd
ipsc
compar
sdsdel
normal
control
total
level
unchang
pharmacolog
target
tfg
small
molecul
inhibitor
result
select
improv
sd
hematopoiet
coloni
format
myeloid
differenti
without
stimul
outgrowth
isogen
sdsdel
cell
normal
control
result
demonstr
del
revers
tgf
pathway
hyperactiv
sd
furthermor
inhibit
tgf
select
rescu
hematopoiesi
sd
isogen
cell
suggest
potenti
strategi
treat
bone
marrow
failur
without
stimul
clonal
outgrowth
background
standard
therapi
medulloblastoma
consist
treatment
alkyl
agent
radiat
surgic
resect
although
statist
signific
increas
surviv
report
regimen
recur
becom
resist
class
agent
ultim
lead
mortal
larg
number
somat
mutat
observ
recurr
medulloblastoma
rm
alkyl
agent
radiat
treatment
high
mutat
rate
tumor
twofold
effect
larg
number
nonsynonym
mutat
role
driver
still
caus
function
tumor
antigen
increas
neoantigen
burden
immunogen
moreov
tumor
gain
mutat
canon
noncanon
dna
repair
pathway
lead
gain
number
mutat
seen
case
glioblastoma
lead
even
higher
acceler
mutat
rate
evid
suggest
high
mutat
load
caus
higher
neoantigen
burden
therebi
make
tumor
suscept
immun
checkpoint
inhibit
propos
post
therapi
recurr
medulloblastoma
gain
mutat
signatur
immunophenotyp
malign
demonstr
clinic
respons
immun
checkpoint
therapi
object
rm
molecular
signatur
ident
tumor
high
immunogen
clinic
respons
immun
check
point
inhibit
rm
immun
inflammatori
phenotyp
harbor
high
percentag
tumor
infiltr
lymphocyt
til
macrophag
monocyt
designmethod
test
hypothesi
download
raw
bam
file
previous
publish
data
intern
cancer
genom
consortium
icgc
set
match
primari
recurr
medulloblastoma
case
form
discoveri
cohort
call
somat
variant
use
gatk
pipelin
broad
institut
valid
key
find
procur
human
medulloblastoma
specimen
conduct
whole
exom
sequenc
primari
assay
util
assess
immunogen
immunohistochem
ihc
stain
formalin
fix
embed
recurr
medulloblastoma
tissu
identifi
til
tumor
associ
macrophag
marker
dlt
dyspnea
grade
hypoxia
grade
dlt
observ
cohort
advers
event
gener
mild
moder
consist
safeti
profil
observ
adult
across
desc
cohort
plasma
concentr
doseproport
steadi
state
concentr
lower
day
vs
day
mean
system
exposur
cohort
greater
compar
adult
mg
bid
pk
pd
relationship
tazemetostat
exposur
level
peripher
blood
monocyt
granulocyt
observ
desc
phase
consist
signific
postdos
reduct
occur
dose
analysi
twelv
patient
treat
confirm
inhibit
maxim
inhibit
dose
show
confirm
object
respons
crpr
per
recistrano
patient
es
n
chordoma
n
atrt
n
background
previou
studi
establish
platelet
fibrin
ogen
axi
promot
metastat
potenti
imped
clearanc
newli
form
micrometastas
natur
killer
nk
cell
howev
multipl
import
question
remain
includ
potenti
fibrin
ogen
promot
metastasi
interact
cell
platelet
eg
inflammatori
cell
fundament
question
whether
fibrin
polymer
requir
metastasi
object
determin
role
fibrin
polymer
fibrin
ogen
engag
integrin
iib
metastasi
designmethod
perform
experiment
spontan
metastasi
assay
immunocompet
mice
carri
specif
fibrinogen
structurefunct
alter
result
express
mutant
fibrinogen
lack
bind
motif
leukocyt
integrin
fib
significantli
decreas
metastat
potenti
rel
wildtyp
fibrinogen
suggest
role
fibrin
ogen
inflammatori
cell
interact
mediat
metastasi
directli
determin
import
thrombinmedi
fibrin
polymer
metastasi
analyz
metastat
potenti
fibaek
mice
carri
form
fibrinogen
essenti
lock
solubl
state
due
mutat
chain
thrombin
cleavag
site
metastat
potenti
fibaek
mice
diminish
rel
control
mice
speak
import
thrombinmedi
fibrin
polymer
metastat
process
howev
fibaek
mice
retain
signific
metastat
potenti
rel
complet
fibrinogen
defici
indic
fibrinogen
monom
retain
signific
prometastat
properti
order
better
defin
role
fibrin
ogen
platelet
interact
metastasi
compar
metastat
potenti
control
fib
mice
carri
form
fibrinogen
lack
chain
bind
motif
platelet
integrin
iib
surprisingli
mutat
impact
metastat
potenti
togeth
studi
suggest
fibrinogen
play
multifacet
role
metastasi
fibrin
ogen
leukocyt
interact
mediat
appear
role
metastasi
previou
studi
show
macrophag
promot
metastat
potenti
circul
tumor
cell
may
repres
least
one
import
express
cell
type
whose
prometastat
behavior
influenc
fibrin
ogen
interact
studi
show
thrombinmedi
fibrin
polymer
promot
metastasi
solubl
fibrinogen
retain
signific
prometastat
capac
surprisingli
loss
fibrinogen
chain
iib
bind
motif
impact
metastasi
given
establish
import
platelet
metastasi
find
suggest
fibrin
ogen
capabl
platelet
stabil
mechan
independ
iib
bind
motif
platelet
may
bind
polymer
fibrin
site
andor
fibrin
interact
matrix
protein
capabl
bind
iib
suffici
support
platelet
function
requir
metastasi
role
platelet
hemostasi
thrombosi
well
defin
becom
increasingli
evid
platelet
also
assist
host
defens
inflamm
platelet
particip
innat
immun
system
direct
antimicrobi
activ
interact
effector
cell
kapur
adapt
immun
system
platelet
recruit
costimul
tcell
promot
bcell
differenti
antibodi
class
switch
question
remain
mechan
influenc
platelet
immun
function
development
regul
preliminari
studi
pali
lab
reveal
signific
differ
embryon
versu
adult
platelet
gene
express
includ
regul
immun
inflammatori
respons
major
histocompat
complex
class
express
cell
surfac
except
red
blood
cell
molecular
chaperon
marker
inflamm
highli
express
platelet
alpha
granul
preliminari
data
morrel
lab
reveal
mass
releas
platelet
activ
drive
monocyt
differenti
inflammatori
phenotyp
tgfb
receptor
signal
therefor
sought
determin
whether
development
chang
platelet
express
mediat
differ
plateletmedi
monocyt
activ
trilineag
hematopoiesi
predomin
earli
myeloid
precursor
full
matur
microarray
elan
sbd
sequenc
deletiondupl
analys
neg
immunolog
evalu
signific
agammaglobulinemia
absenc
memori
b
cell
gene
primari
immunodefici
panel
reveal
two
variant
unknown
one
previous
report
associ
parent
test
demonstr
parent
heterozygos
centromer
instabl
confirm
mitogen
stimul
lymphocyt
show
characterist
multibranch
chromosom
contain
least
arm
chromosom
join
near
centromer
decondens
region
triradi
configur
note
diagnosi
syndrom
made
patient
start
monthli
intraven
immunoglobulin
ivig
prophylaxi
pneumocysti
jiroveci
pneumonia
respiratori
syncyti
viru
initi
match
sibl
hsct
plan
demonstr
diagnosi
high
grade
osteosarcoma
patient
start
multiag
chemotherapi
plan
whole
femur
prosthesi
time
local
control
case
osteosarcoma
describ
literatur
patient
median
age
year
rang
year
slightli
male
predomin
case
femur
common
site
involv
case
four
patient
die
metastat
diseas
despit
surgeri
multiag
chemotherapi
conclus
repres
major
risk
factor
develop
malign
uncommonli
osteosarcoma
adolesc
adult
report
rare
case
extens
involv
osteosarcoma
left
femur
child
known
diagnosi
present
alert
pediatr
oncologist
monitor
bone
tumor
patient
physic
exam
detail
medic
histori
hasbro
children
hospit
provid
rhode
island
unit
state
background
dysautonomia
paraneoplast
syndrom
commonli
describ
adult
malign
despit
current
therapi
aim
symptom
manag
often
debilit
present
case
girl
initi
present
autonom
dysfunct
subsequ
found
hodgkin
lymphoma
object
describ
hodgkin
lymphoma
present
dysautonomia
discuss
symptom
manag
rituximab
designmethod
case
report
yearoldgirl
present
sever
symptom
orthostat
hypotens
necessit
prone
posit
prevent
syncop
episod
addit
report
anhidrosi
xerostomia
urinari
retent
constip
unmanag
peripher
neuropath
pain
despit
multipl
analgesia
medic
initi
suspect
symptom
caus
atyp
present
guillainbarr
syndrom
treat
intraven
immunoglobulin
g
without
respons
due
suspicion
paraneoplast
syndrom
positron
emiss
testcat
scan
petct
perform
reveal
widespread
fdgavid
nodal
splenic
diseas
patholog
thoracoscop
biopsi
mediastin
lymph
node
demonstr
classic
hodgkin
lymphoma
classifi
stage
ivb
paraneoplast
panel
obtain
first
cycl
chemotherapi
reveal
elev
antiamphiphysin
antibodi
glutam
acid
decarboxylas
gad
antibodi
therapi
initi
abepc
doxorubicin
bleomycin
etoposid
prednison
cyclophosphamid
vincristin
held
given
signific
neuropathi
due
persist
autonom
symptom
follow
first
cycl
presenc
antiamphiphysin
gad
antibodi
rituximab
incorpor
treatment
follow
two
cycl
abepc
rapid
earli
respons
fdgpetct
complet
addit
three
cycl
abdpc
end
therapi
imag
demonstr
complet
respons
singl
persist
mildli
fdgpet
avid
lymph
node
deauvil
antibodi
neg
continu
treatment
mainten
rituximab
signific
improv
resolut
orthostat
hypotens
time
patient
ambul
assist
constip
urinari
retent
fulli
resolv
peripher
neuropathi
xerostomia
anhidrosi
improv
conclus
rare
case
pediatr
hodgkin
lymphoma
patient
develop
dysautonomia
associ
antiamphiphysin
glutam
acid
decarboxylas
antibodi
subsequ
manag
chemotherapi
rituximab
clinician
suspici
paraneoplast
syndrom
neurolog
disord
fail
improv
standard
treatment
result
lab
obtain
outsid
hospit
one
month
prior
present
show
absolut
neutrophil
count
anc
hemoglobin
gdl
present
institut
day
fever
hepatomegali
cm
costal
margin
white
plaqu
tongu
circumferenti
perian
ulcer
lab
signific
anc
hemoglobin
gdl
antigranulocyt
antibodi
test
posit
bone
marrow
biopsi
show
arrest
neutrophil
matur
initi
filgrastim
mcgkgday
anc
increas
repeat
bone
marrow
biopsi
demonstr
left
shift
myelopoiesi
biopsi
oral
lesion
demonstr
invas
actinomyc
prompt
prolong
cours
antibiot
biopsi
oral
anal
lesion
report
myeloid
sarcoma
without
mll
rearrang
chemotherapi
initi
due
complet
resolut
lesion
within
week
initi
filgrastim
appropri
antibiot
coverag
develop
lesion
concern
malign
test
common
gene
associ
sever
congenit
neutropenia
autoimmun
lymphoprolif
syndrom
neg
immunoglobulin
level
measur
ageappropri
vaccin
respons
normal
lymphocyt
subpopul
analysi
indic
select
defici
posit
tlymphocyt
absolut
cell
count
sever
combin
immunodefici
panel
genedx
show
compound
heterozyg
mutat
result
male
infant
born
larg
thigh
mass
child
clinic
well
asid
restrict
movement
affect
leg
mri
show
mass
expand
pelvi
without
lesion
interventionalradiolog
guid
core
biopsi
mass
report
highgrad
spindl
cell
sarcoma
without
rearrang
surgeri
defer
concern
would
result
excess
morbid
mass
treat
vincristin
dactinomycin
per
infantil
fibrosarcoma
protocol
month
therapi
signific
chang
size
mass
note
physic
exam
imag
repeat
biopsi
obtain
confirm
diagnosi
allow
expand
tumor
test
biopsi
show
triphas
distribut
adipos
fibrou
mesenchym
tissu
consist
fhi
rare
sarcomat
foci
addit
chemotherapi
defer
child
follow
clinic
tumor
remain
approxim
size
still
unresect
next
gener
sequenc
tumor
util
panel
base
technolog
reveal
fusion
consist
braf
activ
mutat
mutat
confirm
fluoresc
situ
hybrid
fish
probe
braf
braf
mek
inhibitor
pursu
treatment
decreas
size
tumor
allow
resect
conclus
braf
mutat
character
varieti
malign
inhibit
braf
downstream
signal
compon
produc
promis
result
varieti
patient
first
case
report
braf
mutat
fhi
although
manag
fhi
typic
surgic
suggest
potenti
therapeut
target
may
allow
improv
surgic
outcom
especi
case
upfront
surgeri
would
result
unaccept
morbid
genet
sequenc
fhi
rare
tumor
import
tool
potenti
identifi
mutat
amen
target
therapi
background
icf
rare
autosom
recess
disord
character
hypoor
agammaglobulinemia
often
opportunist
infect
suggest
tcell
dysfunct
categor
subtyp
base
mutat
dna
methyl
mutat
helicaselymphoid
specif
hell
gene
requir
tcell
prolifer
particip
de
novo
dna
methyl
characterist
icf
type
approxim
report
case
icf
less
percent
character
malign
report
angiosarcoma
acut
lymphoblast
leukemia
hodgkin
lymphoma
describ
diagnosi
manag
patient
neuroblastoma
neutropenia
previous
describ
object
describ
novel
phenotyp
mutat
manag
expand
understand
diseas
result
month
week
prematur
male
bronchopulmonari
diseas
failur
thrive
present
acut
respiratori
failur
set
recent
viral
bronchiol
associ
chronic
diarrhea
subsequ
diagnos
multipl
infect
includ
pjp
pneumonia
noroviru
parainfluenza
rhinoviru
pseudemon
cellul
present
profound
neutropenia
agammaglobulinemia
presenc
b
cell
lymphocyt
phenotyp
ct
reveal
paraspin
mass
mibgavid
studi
strongli
suggest
neuroblastoma
bone
marrow
normocellular
neg
malign
howev
reveal
mark
granulocyt
hypoplasia
matur
arrest
concern
sever
congenit
less
like
immunemedi
neutropenia
metastat
workup
neg
whole
exom
sequenc
reveal
homozyg
variant
unknown
signific
c
c
hell
gene
portend
work
diagnosi
syndrom
immunoglobulin
supplement
pentamidin
prophylaxi
gcsf
initi
abl
discontinu
gcsf
month
treatment
neuroblastoma
initi
categor
met
criteria
observ
howev
followup
mri
reveal
interv
growth
near
spinal
canal
underw
tumor
resect
confirm
mycn
nonamplifi
favor
histolog
neuroblastoma
infecti
prophylaxi
immunolog
support
initi
incur
two
hospit
first
gtube
cellul
second
parainfluenza
respiratori
ill
stabl
neutrophil
count
gcsf
remain
remiss
neuroblastoma
current
plan
proceed
bone
marrow
transplant
immunodefici
conclus
previous
describ
neutropenia
neuroblastoma
report
describ
novel
mutat
phenotyp
manag
thereof
also
reveal
potenti
cur
role
bone
marrow
transplant
diseas
staten
island
univers
hospit
northwel
health
staten
island
new
york
unit
state
background
desmoid
tumor
rare
tumor
aris
highli
differenti
fibroblast
occur
isol
part
diseas
spectrum
famili
adenomat
polyposi
fap
fap
mutat
codon
typic
correl
increas
extraintestin
diseas
desmoid
tumor
upper
gastrointestin
polyp
describ
patient
larg
intraabdomin
desmoid
tumor
heterozyg
apc
gene
mutat
awar
patient
report
germlin
apc
mutat
present
desmoid
tumor
object
discuss
novel
apc
mutat
present
rare
case
designmethod
review
clinic
present
genet
analysi
manag
rare
tumor
femal
signific
medic
histori
present
abdomin
asymmetri
intermitt
pain
report
urinari
urgenc
short
breath
earli
satieti
decreas
appetit
weight
loss
cours
month
ct
scan
abdomen
demonstr
abdomin
tumor
abut
local
organ
presenc
bowel
obstruct
biopsi
reveal
spindl
cell
neoplasm
favor
fibromatosi
known
famili
histori
fap
colon
cancer
desmoid
tumor
apc
gene
mutat
analysi
demonstr
heterozyg
gene
variant
due
size
locat
tumor
initi
deem
unresect
patient
start
cours
monthli
liposom
doxorubicin
toler
initi
cycl
well
interv
ct
cycl
chemotherapi
reveal
decreas
tumor
volum
variabl
exist
phenotyp
present
regard
locat
afp
mutat
locu
fap
mutat
associ
desmoid
tumor
typic
chang
codon
region
patient
present
heterozyg
mutat
result
missens
mutat
codon
due
chang
polar
size
mutat
consid
conserv
natur
awar
one
report
mutat
occur
individu
person
famili
histori
colon
cancer
awar
patient
desmoid
tumor
also
germlin
apc
gene
mutat
case
report
highlight
apc
gene
mutat
welldescrib
awar
case
mutat
report
patient
desmoid
tumor
futur
evalu
track
mutat
may
lead
determin
clinic
signific
background
time
advanc
care
plan
locat
death
associ
increas
death
home
rather
hospit
case
howev
complex
manag
symptom
control
prevent
famili
achiev
goal
keep
child
hospit
home
end
life
ascit
sequela
mani
condit
includ
malign
might
lead
signific
morbid
increasingli
intervent
procedur
util
peritoneoven
denver
shunt
place
intern
one
end
periton
space
buri
within
major
vessel
svc
oneway
valv
pump
buri
skin
allow
patient
pump
fluid
periton
vascular
space
shunt
use
frequent
adult
seen
much
use
pediatr
oncolog
patient
object
describ
case
termin
ill
patient
refractori
wilm
tumor
ivc
involv
receiv
symptomat
relief
denver
shunt
placement
result
femal
diagnos
relaps
refractori
metastat
wilm
tumor
pulmonari
hepat
involv
tumor
extens
hepat
vein
ivc
multipl
chemotherapeut
regimen
palli
radiat
ivc
administ
diseas
continu
progress
lead
pressur
portal
vein
portal
hypertens
result
ascit
caus
patient
signific
pain
difficult
manag
patient
code
statu
chang
dnrdni
discuss
mother
identifi
desir
child
die
home
comfort
possibl
peritoneoven
shunt
place
order
control
patient
pain
avoid
frequent
medic
procedur
therapi
despit
initi
anxieti
patient
abl
util
pump
achiev
signific
improv
ascit
pain
abl
spend
remain
six
week
life
home
ascit
common
phenomenon
end
stage
diseas
peritoneoven
shunt
treatment
modal
may
consid
allow
pain
control
end
life
pediatr
oncolog
patient
ascit
procedur
rel
low
risk
allow
selfcontrol
pump
maintain
comfort
easi
enough
use
patient
famili
background
extraneur
metastas
enm
pediatr
glioblastoma
multiform
gbm
rare
estim
frequenc
etiolog
factor
includ
multipl
neurosurg
procedur
sarcomat
dedifferenti
occurr
serious
affect
patient
qualiti
life
surviv
enm
well
document
adult
pediatr
case
previous
summar
year
old
male
cerebr
gbm
develop
extens
diseas
outsid
neuraxi
approxim
month
post
initi
present
time
diseas
progress
metastas
includ
exracrani
tempor
lesion
cervic
mediastin
lymph
node
bilater
lung
nodul
larg
pleuralbas
soft
tissu
metastat
focu
identifi
imag
patient
present
respiratori
distress
secondari
right
tension
pneumothorax
recogn
manag
promptli
summar
main
report
case
literatur
better
defin
risk
factor
evalu
propos
mechan
underli
system
metastas
designmethod
perform
literatur
review
pubm
databas
use
term
gbm
enm
patient
year
age
met
weiss
criteria
diagnosi
enm
primari
cn
tumor
includ
result
patient
fulfil
two
three
weiss
criteria
confirm
gbm
primari
site
enm
tempor
soft
tissu
cervic
lymph
node
display
histopatholog
featur
similar
primari
cn
tumor
intrathorac
adenopathi
lung
nodul
detect
upon
chest
imag
workup
respiratori
distress
assum
repres
addit
metastat
foci
literatur
review
identifi
pediatr
patient
enm
gbm
median
age
year
rang
year
slight
femal
predomin
femal
vs
male
common
site
metastas
report
pleuralung
bone
lymph
node
liver
patient
metastas
associ
csf
shunt
conclus
pediatr
oncologist
increas
index
suspicion
care
patient
gbm
particularli
undergon
shunt
procedur
present
system
symptom
includ
boni
pain
respiratori
chang
transamin
cytopenia
prompt
time
investig
enm
although
enm
cn
tumor
carri
poor
prognosi
diagnosi
potenti
therapeut
import
treatment
metastat
lesion
may
allevi
symptom
improv
qualiti
life
addit
studi
may
warrant
evalu
incid
enm
provid
valuabl
insight
pathogenesi
biolog
highgrad
glioma
nicklau
children
hospit
miami
florida
unit
state
background
sinusoid
obstruct
syndrom
so
report
patient
undergo
intens
chemotherapi
complic
posthematopoiet
stem
cell
transplant
so
may
complic
portal
hypertens
hepatoren
diseas
multiorgan
failur
howev
despit
treatment
may
potenti
complic
anticip
patient
histori
so
report
two
patient
histori
so
present
postprocedur
bleed
gastric
tube
placement
believ
present
may
associ
previou
diagnosi
so
designmethod
pubm
search
done
search
terminolog
includ
sinusoid
obstruct
syndrom
defibrotid
bleed
paper
relev
case
select
literatur
review
result
case
yearold
femal
histori
desmosplast
medulloblastoma
statuspost
resect
intens
chemotherapi
diagnos
so
one
month
second
part
plan
tandem
transplant
manag
paracentesi
defibrotid
due
malnourish
patient
gastric
tube
placement
month
complet
therapi
episod
upper
gastrointestin
bleed
postop
g
tube
site
case
similarli
yearold
male
diagnos
anaplast
medulloblastoma
statu
post
resect
adjuv
multiag
chemotherapi
treatment
cours
complic
so
second
cycl
induct
chemotherapi
respond
cours
defibrotid
likewis
patient
major
bleed
event
gtube
site
approxim
two
month
so
diagnosi
defibrotid
discontinu
case
gtube
placement
patient
previou
histori
bleed
disord
relev
famili
histori
addit
comprehens
laboratori
evalu
within
normal
limit
procedur
so
blockag
fluid
liver
lead
congest
ascit
ischemia
liver
postsinusoid
portal
hypertens
two
relat
caus
so
consid
explan
gtube
bleed
similar
patient
close
monitor
postop
possibl
surgic
intervent
delay
so
process
evolv
nicklau
children
hospit
miami
florida
unit
state
background
develop
treatment
relat
acut
myeloid
leukemia
taml
myelodysplast
syndrom
tmd
potenti
complic
cytotox
chemotherapi
radiat
therapi
incid
develop
tamltmd
vari
depend
treatment
regimen
use
cutan
myeloid
sarcoma
ms
common
present
extramedullari
leukemia
usual
occur
set
aml
report
rare
case
cutan
ms
adolesc
femal
success
treatment
ovarian
yolk
sac
tumor
yst
stage
bep
bleomycin
etoposid
cisplatin
therapi
ms
manag
biopsi
close
observ
designmethod
pubm
search
conduct
queri
includ
tamltmd
cytotox
agent
cutan
myeloid
sarcoma
regress
relev
paper
select
literatur
review
yearold
femal
diagnos
left
ovarian
yolk
sac
tumor
underw
left
salpingooophorectomi
success
complet
cycl
bep
month
routin
followup
month
initi
treatment
ovarian
yst
note
small
nontend
indur
nodul
left
side
upper
back
approxim
diamet
punch
biopsi
skin
nodul
perform
patholog
posit
cutan
myeloid
sarcoma
time
next
followup
less
one
month
later
skin
lesion
resolv
two
subsequ
bone
marrow
aspir
perform
one
month
apart
neg
leukem
involv
md
examin
workup
includ
whole
bodi
pet
ct
scan
neg
evid
diseas
although
cutan
ms
regard
herald
system
myeloid
diseas
rather
local
process
patient
monitor
period
physic
exam
laboratori
evalu
remain
free
diseas
four
year
present
cutan
ms
without
treatment
spontan
regress
ms
previous
report
author
would
like
stress
conserv
approach
close
observ
could
option
cutan
ms
even
histori
chemotherapi
exposur
nesreen
ali
iman
sidhom
sonia
soliman
sherin
salem
nation
cancer
institut
cairounivers
egypt
children
cancer
hospit
egypt
egypt
background
acut
leukemia
commonest
malign
childhood
coincident
occurr
leukemia
hemophilia
extrem
rare
hemophilia
congenit
rare
x
link
bleed
disord
main
complic
two
diseas
bleed
diathesi
may
lifethreaten
due
mani
factor
defici
coagul
factor
hemophil
patient
thrombocytopenia
diseas
chemotherapi
leukem
patient
certain
cytotox
drug
asparaginas
may
result
coagul
disord
infect
may
lead
dissemin
intravascular
coagul
object
report
case
imper
set
treatment
guidelin
prevent
bleed
optim
therapeut
approach
patient
designmethod
seventeen
year
old
boy
present
children
cancer
hospit
egypt
june
pallor
multipl
ecchymosesh
diagnos
precursor
b
acut
lymphoblast
leukemia
cerebrospin
fluid
csf
free
chromosom
analysi
reveal
hypodiploidi
xy
moder
type
hemophilia
sinc
birth
factor
viii
level
time
diagnosi
coagul
profil
reveal
prolong
partial
thromboplastin
time
normal
factor
viii
low
prothrombin
concentr
prothrombin
time
second
virolog
screen
hepat
b
core
iggigm
hb
ag
hiv
hc
igg
igm
negativeth
patient
start
induct
total
xv
sjcrh
protocol
factor
viii
unitkg
given
present
bone
marrow
aspir
bma
csf
prophylact
intramuscular
asparaginas
inject
intrathec
bma
given
immedi
within
hour
procedur
platelet
transfus
given
regularli
maintain
platelet
count
minim
residu
diseas
flow
cytometri
induct
result
patient
receiv
induct
reintensif
chemotherapi
without
major
bleed
event
reveal
success
guidelin
prevent
bleed
develop
earli
relaps
mainten
clone
receiv
salvag
chemotherapi
nt
achiev
remiss
die
diseas
resist
clone
develop
leukemia
top
hemophilia
major
problem
bleed
complic
chemotherapi
prevent
regular
prophylact
factor
viii
platelet
concentr
transfus
good
support
care
life
threat
bleed
complic
may
correl
sever
hemophilia
need
collect
data
biolog
leukem
cell
complic
caus
death
optim
care
patient
background
mucoepidermoid
carcinoma
mec
rare
malign
aris
exocrin
gland
upper
aerodigest
tract
tracheobronchi
tree
convent
mec
diagnosi
base
histolog
prognosi
base
extent
resect
detect
metastas
mec
character
transloc
chromosom
result
fusion
gene
occur
case
fusion
transcript
recogn
favor
impact
diseas
featur
prognosi
mec
howev
recent
studi
indic
high
grade
mec
fusion
posit
multipl
genom
imbal
studi
much
detail
owe
rariti
mec
tumor
definit
data
relat
clinic
prognost
signific
molecular
marker
limit
object
identifi
presenc
absenc
fusion
tissu
patient
analyz
incid
fusion
mec
case
children
young
adult
retriev
iowa
cancer
registri
determin
fusion
statu
correl
clinic
patholog
outcom
data
cohort
designmethod
describ
case
yearold
caucasian
male
present
recurr
pneumonia
persist
cough
radiograph
evid
right
lobar
collaps
bronchoscopi
reveal
endobronchi
lesion
patient
underw
right
upper
lobe
sleev
resect
patholog
report
consist
low
grade
mucoepidermoid
carcinoma
retriev
archiv
formalinfix
paraffinembed
ffpe
specimen
pediatr
young
adult
mec
case
age
report
iowa
use
iowa
cancer
registri
test
fusion
index
case
ffpe
specimen
done
use
customdesign
laboratori
valid
next
gener
sequenc
ng
assay
abil
detect
novel
fusion
partner
clinic
patholog
outcom
data
age
sex
tumor
site
tumor
size
nodal
metastas
clinic
stage
histolog
grade
treatment
follow
analyz
correl
fusion
statu
fusion
test
posit
index
patient
obtain
irb
approv
test
fusion
archiv
ffpe
specimen
correl
clinic
patholog
outcom
data
conclus
fusion
frequent
event
mec
prognost
potenti
therapeut
applic
adult
result
studi
may
enlighten
clinic
manag
mec
children
young
adult
children
merci
hospit
kansa
citi
missouri
unit
state
background
mutat
gene
associ
rare
syndrom
compris
myelodysplasia
infect
restrict
growth
adren
hypoplasia
genit
phenotyp
enteropathi
mirag
syndrom
diagnosi
made
exom
sequenc
largest
report
case
seri
eleven
patient
diagnos
mirag
syndrom
two
develop
loss
chromosom
given
potent
growth
restrict
activ
mutant
loss
chromosom
consid
first
document
adapt
aneuploidi
mechan
human
led
myelodysplast
syndrom
md
death
occur
relat
complic
year
age
object
report
case
mirag
syndrom
congenit
thrombocytopenia
progress
bone
marrow
failur
manag
uniqu
bone
marrow
transplant
result
male
born
week
gestat
prenat
diagnosi
iugr
two
vessel
cord
oligohydramnio
found
ambigu
genitalia
adren
insuffici
partial
panhypopituitar
congenit
thrombocytopenia
bone
marrow
show
absenc
megakaryocyt
precursor
sever
thrombocytopenia
present
birth
bone
marrow
evalu
demonstr
hypocellular
marrow
markedli
reduc
megakaryocyt
myeloid
precursor
evid
myelodysplasia
requir
gastric
tube
placement
failur
thrive
laryng
cleft
repair
develop
focal
segment
glomerulosclerosi
mpl
gene
test
congenit
amegakaryocyt
thrombocytopenia
neg
test
fanconi
anemia
shwachmandiamond
syndrom
dyskeratosi
congenita
also
neg
approxim
cell
loss
heterozygos
chromosom
exom
sequenc
show
heterozyg
de
novo
gain
function
variant
identifi
gene
confirm
sanger
sequenc
consist
diagnosi
mirag
syndrom
year
age
develop
pancytopenia
requir
frequent
transfus
platelet
pack
red
blood
cell
underw
success
bone
marrow
transplant
year
age
without
signific
complic
remain
transfus
independ
without
cytopenia
greater
month
bone
marrow
transplant
conclus
imper
pursu
work
persist
congenit
thrombocytopenia
stepwis
multidisciplinari
manner
best
knowledg
first
case
mirag
syndrom
associ
bone
marrow
failur
treat
bone
marrow
transplant
due
individu
rariti
mirag
syndrom
pediatr
myelodysplast
syndrom
import
maintain
index
suspicion
given
associ
explor
bone
marrow
transplant
therapeut
option
result
patient
demonstr
diseas
regress
initi
continu
without
diseas
progress
month
regimen
well
toler
minim
side
effect
dri
skin
ctcae
grade
transient
episod
brief
erythrodysesthesia
ctaca
grade
resolv
spontan
combin
sorafenib
capecitabin
effect
well
toler
adolesc
patient
flhcc
observ
although
singl
patient
lend
support
test
novel
oral
chemotherapi
regimen
patient
flhcc
diseas
effect
standard
chemotherapi
approach
background
epsteinbarr
viru
ebv
ubiquit
viru
associ
broad
rang
malign
due
oncogen
potenti
histori
organ
bone
marrow
transplant
immunosuppress
therapi
primari
acquir
immunodefici
syndrom
increas
risk
ebvassoci
tumor
epsteinbarr
viru
associ
smooth
muscl
tumor
ebvsmt
uniqu
rare
neoplasm
typic
discov
immunocompromis
patient
inform
relat
pathogenesi
therapeut
option
limit
case
report
case
seri
adult
patient
sever
gene
express
pathway
ebv
util
notabl
mammalian
target
rapamycin
mtor
pathway
mtor
pathway
perform
key
role
integr
variou
cell
growth
signal
factor
regul
protein
synthesi
metabol
relat
smooth
muscl
prolifer
sirolimu
immun
modul
therapi
target
mtor
pathway
block
activ
lymphocyt
object
sever
case
report
demonstr
shortterm
clinic
remiss
ebvsmt
adult
patient
use
sirolimu
report
first
case
longterm
background
bilater
neuroblastoma
character
neuroblastoma
aris
adren
gland
rare
present
littl
data
genet
makeup
twomonthold
patient
diagnos
bilater
neuroblastoma
clinic
risk
assign
base
biopsi
left
adren
lesion
show
mycn
amplif
unfavor
genet
marker
treatment
regimen
intensifi
accordingli
cours
chemotherapi
tumor
excis
patient
went
receiv
stem
cell
transplant
immunotherapi
knowledg
genet
similar
two
tumor
unclear
whether
biopsi
right
lesion
would
yield
similar
result
whether
bilater
biopsi
need
risk
assess
bilater
neuroblastoma
object
util
whole
exom
sequenc
we
character
genom
signatur
bilater
adren
neuroblastoma
excis
follow
chemotherapi
treatment
designmethod
paraffinembed
sampl
left
l
right
r
tumor
underw
we
broad
institut
analyz
result
data
includ
somat
variant
call
indel
mutat
copi
number
variant
cnv
use
ingenu
softwar
evalu
compar
differ
two
tumor
sampl
preliminari
analysi
data
show
import
descript
inform
two
tumor
sampl
somat
mutat
r
tumor
cell
mutat
l
tumor
cell
two
common
somat
mutat
present
cnv
call
r
tumor
l
tumor
cnv
common
two
tumor
tumor
cnv
call
fold
higher
frequenc
gain
versu
loss
median
size
common
cnv
rang
bp
cancerrel
gene
increas
copi
number
includ
transcript
factor
receptor
signal
transduct
pathway
histon
methyl
protein
conclus
preliminari
analysi
we
result
two
adren
tumor
show
genom
diverg
tumor
tissu
expos
chemotherapi
prior
excis
difficult
determin
whether
genom
diverg
result
independ
origin
tumor
subsequ
adapt
chemotherapi
clonal
cell
popul
high
number
common
cnv
two
tumor
point
common
cell
origin
howev
low
number
common
somat
mutat
fit
pictur
futur
studi
help
elucid
question
we
origin
biopsi
tissu
provid
inform
tumor
mutat
prior
effect
chemotherapi
baylor
colleg
medicin
houston
texa
unit
state
background
although
signific
improv
overal
surviv
rate
children
cancer
mani
children
still
die
ill
complic
secondari
treatment
research
surround
death
children
succumb
diseas
warrant
ensur
provid
best
care
possibl
patient
object
case
seri
aim
explor
pediatr
cancer
death
focus
perhap
extrem
case
high
intens
end
life
care
explor
patient
know
die
like
die
evid
resuscit
dnr
order
case
despit
patient
grim
prognosi
great
likelihood
death
limit
place
resuscit
method
patient
continu
end
life
care
pediatr
intens
care
unit
picu
primari
medic
record
children
cancer
diagnosi
die
februari
januari
picu
dnr
order
seven
day
earlier
prior
death
medic
histori
includ
diseasedirect
treatment
histori
respons
particular
attent
event
surround
termin
admiss
result
eight
patient
met
criteria
studi
repres
cancer
patient
die
time
period
die
icu
averag
time
dnr
death
day
day
day
averag
length
termin
admiss
day
day
day
averag
time
diagnosi
dnr
month
month
month
averag
time
diagnosi
death
month
month
month
conclus
case
highlight
journey
patient
famili
provid
endur
lead
death
medic
care
complex
absolut
encount
care
patient
decis
around
limit
withdraw
medic
care
made
context
prior
journey
case
help
understand
complex
death
two
seemingli
opposit
ideal
congruent
event
anticip
death
case
show
need
improv
anticipatori
guidanc
surround
death
greater
consider
deescal
care
death
expect
hospit
sick
children
toronto
ontario
canada
background
rhabdomyosarcoma
rm
common
soft
tissu
sarcoma
children
embryon
erm
alveolar
arm
repres
common
subtyp
arm
tumor
associ
inferior
outcom
compar
erm
character
case
chromosom
transloc
creation
fusion
gene
respect
increasingli
clear
fusion
statu
import
poor
prognost
factor
thu
histolog
classif
tend
replac
fusion
statu
particularli
term
risk
stratif
contrast
arm
recurr
chromosom
alter
erm
howev
multipl
numer
chromosom
chang
frequent
tumour
gain
chromosom
found
emr
karyotyp
moreov
erm
tumor
show
frequent
allel
loss
chromosom
region
frequent
involv
recent
novel
gene
fusion
describ
also
erm
tumour
fusion
involv
mainli
gene
rearrang
partner
variabl
includ
ie
pax
srf
tead
object
present
patient
die
consequ
brain
metastas
therapi
set
rm
identif
new
transloc
designmethod
case
report
retrospect
review
literatur
report
case
pelvic
embryon
rhabdomyosarcoma
old
boy
treat
per
cog
arst
intermedi
risk
group
unfortun
found
larg
cerebellar
tumour
cours
chemotherapi
treatment
subsequ
pass
away
novel
transloc
chromosom
observ
metaphas
cell
gband
analysi
autopsi
sampl
brain
lesion
breakpoint
transloc
estim
addit
clonal
chromosom
abnorm
tumour
cell
conclus
erm
tumor
fusion
gene
involv
exclus
describ
patient
less
month
age
seem
associ
spindl
cell
histolog
favor
outcom
patient
novel
transloc
found
clinic
patient
dismal
outcom
studi
indic
inquir
whether
find
signific
term
prognosi
patient
children
nation
medic
center
washington
district
columbia
unit
state
background
iatrogen
immunodeficiencyassoci
lymphoprolif
disord
lpd
group
lymphoid
prolifer
lymphoma
well
known
associ
immunosuppress
state
disord
commonli
occur
follow
hematopoiet
solid
organ
transplant
call
posttranspl
lymphoprolif
disord
ptld
case
also
describ
treatment
autoimmun
rheumatolog
disord
immunosuppress
immunomodulatori
medic
disord
strongli
associ
infect
epsteinbarr
viru
ebv
result
impair
immun
function
immunosuppress
state
phenomenon
well
document
autoimmun
condit
case
affect
pediatr
patient
antileukemia
chemotherapi
lack
background
atyp
teratoidrhabdoid
tumor
atrt
central
nervou
system
cn
children
younger
year
old
preval
account
pediatr
cn
tumor
patient
leptomening
dissemin
rhabdomyosarcoma
common
soft
tissu
tumor
childhood
repres
pediatr
cancer
rare
metastas
even
directli
extend
cn
typic
case
cn
involv
aris
either
paramening
area
primari
site
primari
spinal
mening
rhabdomyosarcoma
extrem
rare
object
object
describ
two
uniqu
cn
malign
present
rare
primari
leptomening
diseas
designmethod
case
femal
present
vomit
fatigu
listless
despit
normal
head
ct
brain
mri
csf
show
hypoglycorrhachia
mild
pleocytosi
ceftriaxon
start
develop
nuchal
rigid
cranial
nerv
vii
palsi
repeat
brain
mri
show
evolv
leptomening
enhanc
concern
mening
gradual
develop
worsen
opisthotonu
ultim
brain
biopsi
tempor
lobe
consist
atrt
case
male
present
new
gener
tonicclon
seizur
activ
intermitt
headach
photophobia
phonophobia
vomit
brain
mri
signific
enhanc
interpenducular
suprasellar
cistern
extend
optic
nerv
chiasm
consist
mening
neurosurgeri
ultim
place
lumbar
drain
hydrocephalu
tissu
biopsi
demonstr
primari
mening
rhabdomyosacroma
result
case
patient
tempor
lobe
biopsi
demonstr
grade
iv
malign
tumor
cell
consist
atyp
teratoidrhabdoid
tumor
fish
demonstr
homozyg
delet
start
chemotherapi
per
dana
farber
atrt
protocol
ultim
discharg
home
hospic
case
patient
lumbar
arachnoid
biopsi
demonstr
cellular
tumor
consist
group
iiia
embryon
rhabdomyosarcoma
immunostain
posit
desmin
myogenin
neural
marker
ema
gfap
highlight
mening
without
neural
compon
tumor
complet
craniospin
radiat
total
lumbar
boost
total
current
receiv
chemotherapi
per
protocol
conclus
two
case
particularli
instruct
similar
initi
present
neuroimag
differ
uniqu
diagnos
univers
iowa
iowa
citi
iowa
unit
state
background
fusion
caus
phlike
bcell
acut
lymphoblast
leukemia
ball
philadelphia
posit
phenotyp
without
bcrabl
transloc
one
sever
mutat
associ
phlike
ball
lead
downstream
overexpress
tyrosin
kinas
fusion
account
children
phlike
ball
patient
phlike
ball
previous
poorer
outcom
convent
chemotherapi
addit
tyrosin
kinas
inhibitor
tki
like
imatinib
improv
outcom
mani
patient
predict
tki
sensit
mutat
object
review
clinic
characterist
outcom
two
case
phlike
ball
univers
iowa
stead
famili
children
hospit
compar
outcom
similar
case
report
literatur
designmethod
retrospect
chart
review
perform
two
case
phlike
ball
diagnos
treat
univers
iowa
stead
famili
children
hospit
result
patient
male
diagnos
year
age
high
wbc
count
posit
gene
fusion
patient
cn
present
patient
cn
neg
neither
testicular
involv
start
treatment
accord
cog
protocol
peripher
blast
clear
induct
day
induct
day
end
induct
bone
marrow
bone
marrow
mrd
dasatinib
start
induct
day
induct
day
still
remiss
end
consolid
bone
marrow
cell
cultur
tki
resist
show
best
respons
dasatinib
proceed
car
tcell
therapi
follow
tbibas
match
unrel
donor
bone
marrow
transplant
neg
mrd
end
consolid
continu
chemotherapi
accord
dasatinib
arm
patient
current
clinic
well
patient
tyrosin
kinas
gene
fusion
similar
initi
clinic
cours
patient
persist
diseas
end
induct
almost
blast
signific
reduct
diseas
burden
start
tki
show
good
respons
addit
dasatinib
find
suggest
respons
convent
chemotherapi
may
potenti
effect
tki
may
predict
overal
outcom
like
addit
factor
must
taken
account
determin
respons
tki
patient
phlike
ball
yet
identifi
background
medulloblastoma
common
malign
brain
tumor
childhood
classic
medulloblastoma
present
welldefin
mass
lesion
cerebellum
high
rate
metastat
dissemin
primari
leptomening
medulloblastoma
plmb
exceedingli
rare
type
medulloblastoma
present
dismal
prognosi
patient
present
isol
leptomening
diseas
without
associ
mass
knowledg
three
pediatr
three
adult
case
plmb
age
year
report
die
within
month
diagnosi
first
case
plmb
report
molecular
classif
object
report
case
pediatr
patient
plmb
histopatholog
molecular
character
perform
describ
patient
treatment
clinic
cours
designmethod
retrospect
review
patient
electron
medic
record
review
literatur
boy
present
headach
vomit
diplopia
fatigu
physic
examin
reveal
upward
gaze
palsi
leftsid
extrem
facial
weak
ataxia
magnet
reson
imag
mri
brain
reveal
diffus
cerebellar
leptomening
enhanc
edema
without
identifi
mass
moder
hydrocephalu
mri
spine
cerebr
spinal
fluid
analysi
normal
diagnosi
cerebel
render
patient
underw
placement
ventriculoperiton
shunt
extens
infecti
neurolog
rheumatolog
oncolog
workup
identifi
etiolog
empir
antibiot
highdos
steroid
intraven
immunoglobulin
therapi
yield
minim
improv
two
month
later
repeat
mri
brain
perform
declin
mental
statu
demonstr
progress
thicken
cerebellar
leptomening
diseas
suboccipit
craniectomi
decompress
cerebellar
biopsi
perform
patholog
examin
reveal
diagnosi
plmb
classic
histolog
nonwntnonshh
without
gainamplif
mycmycn
wild
type
pattern
craniospin
radiat
cgi
cgi
boost
posterior
fossa
deliv
concurr
carboplatinvincristin
six
week
two
month
follow
chemoradi
mri
brain
demonstr
significantli
reduc
patholog
leptomening
enhanc
cerebellum
patient
await
initi
system
chemotherapi
recov
surgic
wound
infect
conclus
plmb
extrem
rare
consid
patient
cerebel
diffus
leptomening
involv
refractori
medic
manag
etiolog
identifi
cerebellar
biopsi
recommend
earli
enabl
time
treatment
improv
outcom
molecular
classif
perform
case
plmb
character
diseas
inform
treatment
decis
improv
clinic
outcom
background
primari
intracerebr
osteosarcoma
extrem
rare
limit
case
report
gain
function
associ
noonan
syndrom
increas
risk
multipl
cancer
type
includ
brain
tumor
osteosarcoma
never
describ
mutat
report
mani
cancer
oncogen
tumor
suppressor
howev
mutat
describ
osteosarcoma
pdgfra
growth
factor
receptor
whose
activ
implic
sever
malign
pdgfra
concurr
mutat
describ
glioblastoma
known
link
holoprosencephali
noonan
syndrom
osteosarcoma
report
case
multifoc
intracerebr
osteosarcoma
child
lobar
holoprosencephali
chronic
subdur
hemorrhag
discuss
genet
chang
found
tumor
designmethod
sevenyearold
caucasian
femal
known
diagnosi
lobar
holoprosencephali
chronic
subdur
hemorrhag
well
control
seizur
disord
present
statu
epilepticu
shortli
complet
antibiot
therapi
infect
subdur
hematoma
mri
show
diffus
dural
thicken
mass
lesion
frontal
lobe
tempor
lobe
parasagitt
region
largest
contigu
subdur
space
none
lesion
associ
bone
mri
direct
neurosurg
visual
tissu
obtain
concern
recurr
infect
result
diagnosi
high
grade
osteosarcoma
dna
analysi
perform
help
guid
treatment
choic
result
standard
metastat
workup
neg
skelet
primari
tumor
metastat
lesion
outsid
brain
treat
high
dose
methotrex
two
cycl
per
modifi
despit
maxim
support
care
quickli
develop
rapid
tumor
growth
well
intratumor
hemorrhag
result
herniat
death
respiratori
failur
three
month
diagnosi
tumor
gene
sequenc
discov
three
mutat
describ
role
cancer
pdgfra
vr
loss
exon
conclus
knowledg
primari
multifoc
extraosseu
intracerebr
osteosarcoma
previous
describ
despit
known
cn
penetr
high
dose
methotrex
tumor
prove
resist
aggress
holoprosencephali
associ
multitud
known
genet
driver
none
found
case
furthermor
genet
chang
tumor
typic
osteosarcoma
pdgfra
overexpress
describ
osteosarcoma
clearli
correl
wors
overal
surviv
research
requir
determin
role
osteosarcoma
background
anaplast
lymphoma
kinas
alk
encod
receptor
tyrosin
kinas
whose
activ
induc
pathway
associ
cell
prolifer
angiogenesi
cell
surviv
alk
rearrang
rare
neuroblastoma
alk
mutat
gene
amplif
occur
frequent
alk
mutat
found
associ
increas
alk
protein
express
associ
wors
prognosi
alk
commonli
mutat
neuroblastoma
three
hotspot
rearrang
mostli
associ
lung
adenocarcinoma
case
nonlung
cancer
found
never
report
neuroblastoma
multimod
therapi
report
success
manag
treatment
relat
iron
overload
result
old
male
present
abdomin
swell
ct
show
right
kidney
mass
bilater
lung
nodul
underw
right
radic
nephrectomi
lymph
node
sampl
patholog
review
central
reveal
wilm
tumor
diffus
anaplasia
rhabdomyosarcoma
aris
within
stromal
compon
node
posit
receiv
adjuv
intens
chemotherapi
radiat
hemiabdomen
whole
lung
chemotherapi
regimen
vincristin
doxorubicin
cyclophosphamid
per
cog
altern
carboplatin
etoposid
per
cog
revis
treatment
complic
multipl
episod
fever
neutropenia
anorexia
requir
gtube
placement
posttherapi
persist
neutropenia
thrombocytopenia
without
relat
complic
everi
month
evalu
underw
bone
marrow
reveal
normocellular
marrow
matur
trilineag
hematopoiesi
evalu
bone
marrow
failur
syndrom
unrev
start
month
therapi
posttherapi
imag
show
splenomegali
receiv
unit
pack
red
blood
cell
durat
therapi
diagnos
iron
overload
base
serum
ferritin
imag
includ
mri
receiv
therapeut
phlebotomi
year
normal
serum
iron
studi
heart
liver
iron
concentr
year
complet
therapi
evid
recurr
diseas
asymptomat
cytopenia
persist
evid
iron
overload
conclus
though
rare
develop
clonal
sarcomat
transform
occur
wilm
tumor
patient
tumor
success
treat
intens
multimod
therapi
target
diffus
anaplast
wilm
rhabdomyosarcomat
compon
treatmentrel
iron
overload
pediatr
patient
solid
tumor
success
treat
phlebotomi
consider
given
screen
patient
solid
tumor
receiv
multipl
pack
red
cell
transfus
iron
overload
complet
cancer
therapi
primari
children
hospit
univers
utah
salt
lake
citi
utah
unit
state
background
malign
solid
tumor
less
frequent
encount
infant
primit
myxoid
mesenchym
tumor
infanc
pmmti
myofibroblast
malign
case
rare
report
literatur
cure
achiev
major
case
surgic
resect
howev
treatment
unresect
case
remain
enigma
recent
publish
literatur
postul
newli
discov
bcor
duplic
found
pmmti
tumorigen
via
epigenet
pathway
molecular
signatur
resembl
clear
cell
sarcoma
kidney
ccsk
grow
number
bcor
mutat
sarcoma
similar
chemotherapeut
backbon
local
control
use
ccsk
propos
unresect
subset
pmmti
util
approach
monthold
relaps
diseas
remain
diseas
free
month
howev
given
rariti
diseas
lack
publish
literatur
known
standard
care
treatment
unresect
andor
recurr
ppmti
report
case
unresect
recurr
pmmti
rare
infant
tumor
less
case
report
designmethod
medic
record
radiolog
studi
patholog
literatur
review
result
patient
monthold
femal
present
constip
lower
extrem
weak
first
week
life
mri
demonstr
larg
lumbar
epidur
mass
spinal
cord
imping
given
prolong
day
neurolog
symptom
locat
emerg
chemotherapi
initi
biopsi
show
bcor
posit
primit
myxoid
mesenchym
tumor
infanc
pmmti
treat
ifosfamid
carboplatin
etoposid
demonstr
clinic
radiograph
respons
gave
two
addit
cycl
cyclophosphamid
carboplatin
etoposid
surgic
resect
feasibl
follow
two
postsurg
cycl
chemotherapi
unfortun
four
month
posttherapi
mri
demonstr
two
new
lesion
unresect
paraspin
soft
tissu
mass
left
iliopsoa
groov
mass
given
bcor
associ
report
success
therapi
vincristin
doxorubicin
cyclophosphamid
altern
ifosfamid
etoposid
elect
incorpor
vincaalkaloid
anthracyclin
regimen
treat
vdcie
plan
radiat
consolid
conclus
pmmti
local
aggress
tumor
surgic
resect
cur
amend
resect
best
care
practic
still
determin
report
case
pmmti
initi
respons
chemotherapi
cur
second
case
conclus
demonstr
chemorespons
bcor
mutat
seem
common
featur
cancer
role
pathogenesi
target
area
investig
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
atyp
teratoidrhabdoid
tumor
atrt
central
nervou
system
cn
tumor
commonli
occur
young
children
wide
accept
standard
care
atrt
patient
surviv
rate
improv
histor
poor
patient
metastat
diseas
spine
diagnosi
wors
prognosi
patient
year
old
presenc
metastat
diseas
often
result
use
craniospin
radiat
import
correctli
identifi
metastat
diseas
diagnosi
aid
decis
make
prognost
therapeut
implic
mr
imag
diagnosi
use
identifi
metastat
diseas
howev
present
case
diffus
leptomening
enhanc
spontan
resolv
resect
primari
supratentori
atrt
object
describ
resolut
diffus
leptomening
enhanc
resect
primari
atrt
tumor
prior
adjuv
therapi
result
male
present
month
histori
vomit
weight
loss
regress
gross
motor
development
mileston
left
hemiparesi
brain
mri
demonstr
cm
solid
cystic
right
atrial
mass
diffus
restrict
postcontrast
enhanc
smooth
diffus
enhanc
note
along
surfac
brainstem
within
interpeduncular
fossa
spine
mri
demonstr
diffus
circumferenti
postcontrast
enhanc
along
surfac
entir
spinal
cord
patient
underw
success
near
total
surgic
resect
primari
mass
patholog
confirm
loss
stain
tumor
cell
consist
diagnosi
atrt
immedi
adjuv
radiat
chemotherapi
given
repeat
imag
complet
day
resect
brain
mr
demonstr
expect
postop
chang
within
surgic
caviti
without
definit
residu
mass
leptomening
enhanc
spine
mr
demonstr
complet
resolut
previous
seen
circumferenti
enhanc
along
entir
spinal
cord
csf
evalu
time
neg
tumor
cell
recoveri
surgeri
chemotherapi
treatment
initi
conclus
leptomening
enhanc
time
diagnosi
atrt
histor
consid
clear
evid
metastat
diseas
case
rais
question
previous
accept
etiolog
imag
chang
suggest
widespread
leptomening
enhanc
care
interpret
futur
patient
similar
imag
find
set
clinician
consid
repeat
imag
follow
primari
surgic
resect
order
provid
appropri
prognost
inform
inform
therapeut
decis
poster
primari
ewe
sarcoma
cervic
cord
mimick
cauda
equina
syndrom
sucharita
bhaumik
joshua
chan
nyu
winthrop
hospit
mineola
new
york
unit
state
background
ewe
sarcoma
es
malign
primari
bone
tumor
usual
involv
long
bone
primari
es
spine
quit
uncommon
locat
cervic
spine
even
rare
cauda
equina
syndrom
ce
symptom
due
damag
bundl
nerv
end
spinal
cord
known
cauda
equina
low
back
pain
radiat
shoot
pain
leg
paraplegia
loss
bowel
bladder
control
often
occur
lesion
lumbosacr
spine
treatment
highdos
steroid
may
provid
pain
relief
improv
neurolog
function
reduc
edema
await
diagnost
studi
object
demonstr
unusu
clinic
present
emerg
manag
cervic
es
present
ce
like
symptom
year
old
male
present
left
side
posterior
neck
mass
soon
develop
weak
left
arm
urinari
stool
retent
inabl
walk
bear
weight
leg
physic
exam
left
temperooccipit
fix
nontend
nonfluctu
mass
note
well
motor
sensori
impair
left
upper
extrem
bilater
spastic
paraplegia
loss
sphincter
control
mri
cervic
spine
show
left
cervic
tumor
moth
eaten
appear
involv
vertebr
bodi
adjac
muscl
displac
vital
structur
neck
compress
cervic
spinal
cord
thorac
lumbosacr
spine
diseas
involv
due
rapidli
worsen
spinal
cord
compress
emerg
treat
high
dose
steroid
gain
back
function
extrem
regain
bowel
bladder
control
elimin
need
urgent
neurosurg
intervent
result
biopsi
neck
mass
show
small
blue
round
cell
consist
es
gene
rearrang
stage
work
reveal
addit
metastat
involv
initi
treatment
local
es
system
chemotherapi
radiotherapi
excel
respons
treatment
far
conclus
first
known
case
non
metastat
primari
cervic
es
mimick
ce
acut
enlarg
mass
present
rapidli
progress
neurolog
deficit
due
compress
anterior
spinothalam
tract
unusu
present
ce
without
lumbodors
involv
import
consid
cervic
lesion
earli
rapid
steroid
initi
consid
await
biopsi
result
prevent
worsen
cord
compress
follow
es
focus
treatment
increas
chanc
success
outcom
initi
improv
steroid
may
confus
tumor
lymphoma
children
merci
hospit
kansa
citi
missouri
unit
state
background
von
willebrand
diseas
vwd
rel
common
bleed
disord
high
degre
genotyp
phenotyp
variat
bleed
usual
mucocutan
sever
includ
muscl
joint
bleed
especi
type
vwd
patient
common
bleed
manag
consist
desmopressin
antifibrinolyt
andor
plasmaderiv
antihemophil
factorvon
willebrand
factor
ahfvwf
complex
recombin
vwf
becom
avail
last
year
anaphylaxi
inhibitor
develop
vwd
rare
object
describ
rare
clinic
manifest
anaphylaxi
factor
concentr
patient
sever
type
vwd
result
femal
sever
type
vwd
baselin
vwag
activ
factor
viii
fviii
origin
present
heavi
menstrual
bleed
hmb
lead
anemia
requir
blood
transfus
underw
placement
levonorgestrelreleas
intrauterin
devic
lngiud
began
norethindron
hmb
continu
despit
lngiud
increas
norethindron
dose
plasma
deriv
ahfvwf
complex
administ
previous
receiv
follow
infus
patient
develop
anaphylaxi
hive
wheez
tachycardia
itch
requir
dose
diphenhydramin
dose
hydrocortison
resolut
symptom
subsequ
receiv
recombin
vwf
without
incid
howev
due
low
fviii
level
also
requir
treatment
full
length
recombin
fviii
product
develop
hive
itch
infus
sinc
receiv
recombin
vwf
recombin
fviiifc
fusion
protein
without
allerg
reaction
evid
inhibitor
recent
postinfus
vwf
level
factor
viii
conclus
anaphylaxi
plasma
deriv
factor
product
document
far
less
frequent
within
vwd
popul
compar
hemophilia
typic
seen
larg
gene
delet
usual
type
diseas
therefor
similar
type
vwd
patient
sever
diseas
may
benefit
gene
sequenc
unclear
patient
case
aspect
treatment
allerg
react
plasmaderiv
ahfvwf
full
length
recombin
fviii
recombin
vwf
recombin
fviiifc
fusion
protein
hypothes
may
allerg
epitop
fviii
b
domain
presenc
fc
fusion
may
protect
effect
investig
includ
genet
analysi
plan
nodul
biopsi
consist
neuroendocrin
carcinoma
larg
cell
type
next
gener
sequenc
reveal
fusion
receiv
convent
cytotox
chemotherapi
regimen
cisplatindoxorubicin
capecitabinetemozolomid
doxorubicinetoposid
achiev
minim
respons
follow
rapid
diseas
progress
massiv
ascit
renal
failur
secondari
bilater
ureter
obstruct
result
base
prior
genom
test
therapi
singl
agent
mek
inhibitor
trametinib
initi
produc
rapid
dramat
respons
greatli
reduc
diseas
burden
site
resolut
ascit
return
complet
normal
activ
within
month
respons
last
approxim
month
tumor
progress
therapi
erk
inhibitor
ineffect
patient
expir
progress
diseas
locat
chromosom
braf
oncogen
part
rasmapk
pathway
involv
cellular
prolifer
differenti
migrat
apoptosi
braf
mutat
recogn
wide
rang
adult
malign
thyroid
cancer
nonsmal
cell
lung
cancer
cholangiocarcinoma
ovarian
cancer
multipl
myeloma
braf
mutat
also
describ
adult
neuroendocrin
carcinoma
colon
trametinib
highli
specif
inhibitor
downstream
mediat
braf
pathway
demonstr
activ
number
tumor
includ
advanc
melanoma
glioma
trametinib
chosen
patient
base
atyp
braf
fusion
believ
first
document
case
success
use
neuroendocrin
carcinoma
pediatr
popul
conclus
case
demonstr
presenc
braf
fusion
case
pediatr
neuroendocrin
carcinoma
signific
respons
singl
agent
mek
inhibit
context
case
rais
question
whether
combin
target
inhibitor
addit
either
convent
chemotherapi
braf
inhibitor
might
offer
better
approach
therapi
current
treatment
option
albani
medic
center
albani
new
york
unit
state
background
warm
autoimmun
hemolyt
anemia
waiha
character
autoantibodi
occasion
complement
bind
protein
antigen
surfac
red
blood
cell
temperatur
oc
result
target
destruct
describ
case
year
old
male
histori
evan
syndrom
poor
immun
respons
vaccin
lymphoid
hyperplasia
present
alter
mental
statu
sever
anemia
found
warm
igg
pan
agglutinin
evid
intra
extravascular
hemolysi
cours
complic
respiratori
failur
requir
intub
pulmonari
emboli
enterococcu
bacteremia
hypertens
receiv
multipl
transfus
transient
increas
hemoglobin
aiha
refractori
multipl
round
treatment
high
dose
steroid
ivig
rituximab
cyclophosphamid
bortezomib
plasma
exchang
mycophenol
mofetil
mmf
object
given
refractori
natur
patient
aiha
decis
made
trial
eculizumab
monoclon
antibodi
target
complement
prevent
cleavag
activ
shown
effect
treatment
atyp
hemolyt
urem
syndrom
hemolysi
due
igm
cold
agglutinin
prior
eculizumab
infus
assay
significantli
elev
designmethod
patient
given
two
dose
eculizimab
day
apart
result
hemoglobin
steadili
rose
independ
red
cell
transfus
correspond
decreas
reticulocyt
count
ldh
level
patient
remain
stabl
normal
hemoglobin
gdl
mainten
steroid
mmf
although
definit
conclud
eculizumab
directli
caus
recoveri
clinic
cours
posteculizumab
suggest
may
efficaci
treatment
aiha
genet
test
show
monoallel
frameshift
mutat
gene
monoallel
missens
mutat
gene
given
role
immunodefici
autoimmun
thought
patient
phenotyp
due
haploinsuffici
current
consid
hematopoiet
stem
cell
transplant
st
joseph
region
medic
center
paterson
new
jersey
unit
state
background
heterozyg
thalassemia
typic
manifest
thalassemia
minor
character
mild
microcyt
hypochrom
anemia
minim
clinic
ramif
coinherit
globin
gene
triplic
report
exacerb
clinic
hematolog
phenotyp
ofthalassemia
trait
due
increas
alphanonalphachain
imbal
report
phenotyp
rang
asymptomat
thalassemia
minor
moder
thalassemia
intermedia
usual
diagnos
adulthood
without
transfus
depend
combin
describ
mediterranean
european
asian
popul
rare
report
hispan
object
report
two
case
unusu
severethalassemia
intermedia
hispan
patient
heterozygos
triplic
globin
gene
thalassemia
allel
result
case
sixteenmonthold
male
mexican
descent
present
persist
microcyt
anemia
jaundic
peripher
smear
show
nucleat
rbc
basophil
stippl
target
cell
hemoglobin
electrophoresi
reveal
globin
gene
test
reveal
heterozygos
mutat
ivsii
given
unusu
sever
anemia
gene
test
perform
show
globin
gene
anti
triplic
four
year
splenomegali
bilater
maxillari
promin
head
ct
show
irregular
contour
parietooccipit
region
due
medullari
expans
due
signific
persist
anemia
progress
boni
deform
skull
patient
began
chronic
transfus
age
eight
famili
declin
splenectomycas
fifteenyearold
femal
peruvian
honduran
descent
present
evalu
prior
cholecystectomi
gallston
recurr
ruq
pain
father
known
thalassemia
trait
hb
gdl
hypochromia
microcytosi
target
cell
electrophoresi
indic
thalassemia
trait
confirm
gene
test
heterozyg
mutat
codon
c
given
jaundic
gallston
globin
gene
analysi
order
show
triplic
ruq
pain
resolv
postcholecystectomi
develop
persist
pain
splenomegali
began
hydroxyurea
increas
gammaglobin
product
decreas
excess
alpha
chain
discontinu
due
hematolog
toxic
due
recurr
luq
pain
progress
splenomegali
underw
laparoscop
splenectomi
age
resolut
symptom
improv
hemoglobin
conclus
globin
gene
test
consid
thalassemia
carrier
atyp
clinic
present
includ
hispan
patient
wide
variabl
phenotyp
express
anti
mutat
andthalassemia
trait
suggest
interplay
genet
factor
remain
undefin
clinic
signific
present
amongst
certain
subject
two
case
make
imper
identifi
factor
aid
phenotyp
predict
genet
counsel
ashley
bonheur
shivakumar
subramaniyam
jogarao
vedula
sucharita
bhaumik
nyu
winthrop
hospit
mineola
new
york
unit
state
background
wilm
tumor
wt
one
common
solid
malign
neoplasm
children
divers
rang
gene
mechan
implic
wt
pathogenesi
predispos
syndrom
result
disrupt
gene
crucial
renal
gonad
embryogenesi
anoth
gene
gene
locu
area
imprint
tumor
suppressor
gene
chromosom
seen
patient
anaplast
histolog
addit
gene
whole
partial
chromosom
gain
loss
well
loss
heterozygos
loh
commonli
seen
genet
marker
appear
predict
outcom
incorpor
assign
riskdirect
therapi
patient
loh
chromosom
treat
intens
chemotherapi
associ
increas
risk
relaps
mortal
object
describ
new
complex
transloc
involv
chromosom
case
pediatr
wt
designmethod
fouryear
old
femal
present
abdomin
pain
emesi
exam
patient
firm
larg
abdomin
mass
radiolog
studi
reveal
complex
lobul
right
renal
mass
right
radic
nephrectomi
perform
histopatholog
studi
show
wt
triphas
histolog
featur
blastema
predomin
invas
lymphovascular
perinephr
adipos
tissu
perinephr
lymph
node
involv
anaplasia
chest
ct
scan
show
bilater
lung
metastas
tumor
cytogenet
show
abnorm
karyotyp
complex
transloc
rearrang
occur
due
transloc
chromosom
band
insert
region
pcr
base
genotyp
use
microsatellit
marker
addit
identifi
loh
chromosom
patient
treat
high
risk
stage
iv
wilm
tumor
favor
histolog
receiv
intens
chemotherapi
radiat
therapi
flank
lung
remiss
month
evid
recurr
surveil
scan
complex
transloc
associ
wt
rigor
studi
question
studi
whether
relationship
recurr
potenti
complex
transloc
compar
common
chromosom
abnorm
knowledg
molecular
patholog
genet
chang
wt
help
develop
new
target
therapi
well
new
biomark
aid
diagnosi
risk
stratif
monitor
treatment
relaps
result
weekold
girl
refer
evalu
abnorm
newborn
screen
mother
known
carrier
hb
khartoum
trait
father
known
carrier
thalassemia
trait
patient
hemoglobin
quantif
perform
capillari
zone
electrophoresi
show
hbf
hb
variant
detect
hba
hb
variant
ran
zone
pattern
consist
mother
hb
alkalin
agaros
gel
electrophoresi
band
pattern
show
fs
acid
agaros
gel
electrophoresi
pattern
show
vf
later
test
reveal
abnorm
isopropanol
stabil
precipit
minut
electrophoresi
pattern
consist
pattern
previous
report
hb
khartoum
clinic
patient
healthi
activ
child
follow
two
year
signific
anemia
outsid
physiolog
nadir
hemolyt
episod
bilirubin
level
alway
within
normal
rang
conclus
best
knowledg
report
case
hb
khartoum
thalassemia
prolin
arginin
substitut
hb
khartoum
introduc
charg
group
chain
site
contact
result
unstabl
chain
dissoci
monom
favor
format
methemoglobin
lead
hemoglobin
instabl
wonder
unstabl
hemoglobin
might
result
clinic
hemolysi
challeng
oxid
stress
period
infect
howev
two
year
follow
patient
never
hemolyt
episod
two
year
age
hbf
hb
khartoum
whether
hbf
elev
protect
oxid
stress
remain
determin
continu
follow
child
univers
puerto
rico
medic
scienc
campu
san
juan
puerto
rico
unit
state
background
gangliosidosi
lysosom
disord
caus
galactosidas
defici
due
mutat
gene
rare
autosom
recess
neurodegen
disord
incid
live
birth
worldwid
neurolog
disord
three
clinic
form
type
infantil
form
character
psychomotor
regress
age
month
visceromegali
hepatosplenomegali
macular
cherri
red
spot
facial
skelet
abnorm
seizur
profound
intellectu
disabl
present
femal
type
acut
lymphocyt
leukemia
designmethod
diagnos
gm
type
month
age
famili
histori
remark
older
sister
gm
type
diagnost
studi
reveal
homozyg
exon
gene
sequenc
variant
defin
predict
amino
acid
substitut
result
patient
present
hospit
petechia
lower
extrem
pallor
intermitt
tracheal
bleed
physic
examin
show
hemodynam
stabl
girl
chronic
ill
depend
mechan
ventil
sever
mental
retard
scatter
petechia
upper
lower
extrem
laboratori
workup
reveal
sever
normocyt
anemia
hgb
immatur
peripher
cell
thrombocytopenia
serum
chemistri
reveal
increas
ldh
increas
hepat
enzym
ast
normal
uric
acid
level
evid
coagulopathi
chest
x
ray
unremark
except
evid
chronic
pulmonari
ill
abdomin
sonogram
hepatosplenomegali
hospit
bone
marrow
aspir
biopsi
perform
diagnost
b
cell
acut
lymphoblast
leukemia
lymphoblast
orderli
myeloiderythroid
matur
flow
cytometri
b
lymphoblast
aberr
phenotyp
cw
bacut
lymphoblast
leukemia
karyotyp
reveal
hyperdiploid
femal
favor
prognosi
cytogenet
fish
hyperdiploid
extra
copi
igh
bcrabl
transloc
famili
orient
new
diagnosi
dismal
prognosi
conjunct
primari
condit
parent
agre
chemotherapi
treatment
support
treatment
date
evid
literatur
previous
describ
associ
leukemia
life
expect
patient
primari
condit
null
therefor
correl
leukemia
might
coincident
find
patient
open
possibl
malign
part
type
thu
malign
diagnosi
consid
part
medic
lifetim
cours
univers
south
florida
tampa
florida
unit
state
background
hematolog
manifest
relat
hiv
infect
uncommon
thrombocytopenia
estim
preval
pathophysiolog
like
multifactori
studi
suggest
primari
mechan
may
immunolog
result
acceler
platelet
destruct
addit
theori
suggest
infect
megakaryocyt
may
also
play
role
caus
inadequ
platelet
product
treatment
hivrel
thrombocytopenia
challeng
firstlin
treatment
includ
initi
optim
antiretrovir
therapi
immunoglobulin
ivig
glucocorticoid
howev
approach
effect
patient
second
line
treatment
option
less
well
studi
particularli
pediatr
popul
object
aim
present
discuss
case
year
old
patient
perinat
acquir
infect
persist
thrombocytopenia
fail
first
line
therapi
show
normal
platelet
count
novel
thrombopoietin
receptor
agonist
eltrombopag
designmethod
retrospect
chart
review
case
patient
medic
record
conduct
addit
thorough
literatur
review
perform
topic
includ
pathophysiolog
hiv
relat
thrombocytopenia
treatment
modal
patient
requir
monthli
ivig
infus
year
show
sustain
respons
often
platelet
count
drop
less
infus
initi
mg
eltrombopag
daili
patient
show
sustain
increas
platelet
count
rang
brief
week
laps
eltrombopag
treatment
platelet
count
drop
upon
reiniti
therapi
count
increas
patient
remain
asymptomat
ivig
one
year
undetect
hiv
viral
load
greater
cell
count
side
effect
grade
laboratori
abnorm
report
conclus
treatment
hivrel
thrombocytopenia
challeng
first
line
therapi
includ
ivig
glucocorticoid
effect
patient
sever
treatment
modal
util
includ
antid
immunoglobulin
dapson
danazol
interferon
alfa
vincristin
thrombopoet
growth
factor
includ
romiplostim
eltrombopag
splenectomi
less
well
studi
repres
first
report
case
pediatr
patient
hiv
show
posit
respons
eltrombopag
sustain
improv
platelet
count
advers
effect
treatment
eltrombopag
may
safe
altern
first
line
therapi
patient
hiv
refractori
thrombocytopenia
howev
addit
studi
need
univers
illinoi
colleg
medicin
peoria
peoria
illinoi
unit
state
background
achromobact
xylosoxidan
gram
neg
rod
peritrich
flagella
caus
rare
opportunist
infect
commonli
encount
immunocompromis
patient
primarili
associ
uncompl
bacteremia
catherassoci
infect
pneumonia
report
bacteremia
associ
xylosoxidan
nosocomi
associ
neoplasm
occur
mainli
adult
report
infect
xylosoxidan
children
associ
cystic
fibrosi
report
case
septic
shock
xylosoxidan
bacteremia
pneumonia
pediatr
oncolog
popul
object
describ
rare
case
xylosoxidan
septic
shock
pediatr
patient
relaps
neuroblastoma
result
old
boy
histori
stage
iv
highrisk
neuroblastoma
underw
standard
frontlin
therapi
chemotherapi
hematopoiet
stem
cell
transplant
radiat
therapi
immunotherapi
follow
dfmo
trial
mainten
followup
scan
demonstr
relaps
subsequ
treat
addit
chemotherapi
surgic
resect
mibg
therapi
crizotinib
fusion
final
ifosfamid
carboplatin
etoposid
ice
develop
neutropen
fever
start
cefepim
vancomycin
fluconazol
blood
cultur
initi
neg
day
fever
previous
schedul
pet
scan
perform
hospit
show
new
pulmonari
opac
respiratori
symptom
therapi
escal
meropenem
vancomycin
amphotericin
emerg
bronchoscopi
perform
day
bacteri
fungal
cultur
remain
neg
overnight
develop
tachypnea
satur
upper
requir
nasal
cannula
irguid
lung
biopsi
perform
next
day
flexibl
bronchoscopi
done
remov
blood
clot
airway
patient
place
ventil
femor
line
place
granulocyt
order
pressor
start
deterior
presum
septic
shock
arteri
femor
line
place
patient
continu
hemodynam
instabl
multipl
pressor
follow
day
blood
respiratori
cultur
return
posit
result
day
start
iti
inhibitor
bu
continu
undetect
month
initi
iti
therapi
patient
iti
highdos
plasmaderiv
factor
viii
von
willebrand
factor
vwf
complex
well
toler
effect
genet
analysi
confirm
larg
factor
viii
gene
duplic
exon
believ
patient
develop
inhibitor
quickli
exposur
day
due
possibl
mutat
caus
frameshift
introduc
prematur
termin
codon
might
function
similar
delet
factor
viii
gene
pose
highest
risk
inhibitor
develop
patient
sever
hemophilia
variant
identifi
previous
two
unrel
patient
diagnos
sever
hemophilia
duplic
list
dbsnp
variant
databas
observ
gener
popul
databas
case
prove
effect
method
patient
sever
hemophilia
inhibitor
also
show
research
need
identifi
patient
risk
inhibitor
develop
background
mercaptopurin
prodrug
core
compon
mainten
chemotherapi
patient
diagnosi
acut
lymphoblast
leukemia
suppress
neutrophil
count
use
demonstr
adequ
dose
phase
therapi
bone
marrow
suppress
mediat
activ
metabolit
wherea
metabolit
nucleotid
shown
caus
hepatotox
allopurinol
use
infrequ
mainten
therapi
set
skew
metabol
adequ
myelosuppress
difficult
achiev
due
excess
hepat
toxic
given
combin
allopurinol
reduc
dose
may
result
increas
level
decreas
level
object
describ
characterist
clinic
cours
patient
treat
allopurinol
reduc
dose
mainten
chemotherapi
perform
retrospect
chart
review
patient
aflac
cancer
blood
disord
center
children
healthcar
atlanta
new
diagnos
b
tcell
receiv
allopurinol
mainten
chemotherapi
identifi
eleven
patient
bcell
tcell
receiv
allopurinol
adjunct
therapi
mainten
chemotherapi
singl
institut
patient
receiv
adjunct
allopurinol
week
median
week
reduc
full
dose
ten
patient
genet
test
thiopurin
smethyltransferas
tpmt
wildtyp
genotyp
associ
normal
enzym
level
indic
allopurinol
use
commonli
unfavor
metabolit
level
transamin
n
pancreat
n
hyperbilirubinemia
n
favor
metabolit
shift
achiev
patient
liver
enzym
improv
patient
transamin
initi
allopurinolreduc
three
patient
experienc
pancreat
mainten
recurr
initi
allopurinol
patient
previous
report
six
patient
develop
pancytopenia
allopurinol
two
patient
develop
pancytopenia
sever
enough
requir
allopurinol
cessat
four
patient
develop
isol
anemia
hgb
gdl
without
thrombocytopenia
sever
neutropenia
patient
experienc
recurr
leukemia
overal
treatment
allopurinol
reduc
dose
success
produc
favor
metabolit
distribut
reduc
toxic
therapi
gener
toler
howev
major
notabl
side
effect
pancytopenia
two
case
sever
enough
stop
allopurinol
treatment
anemia
may
promin
allopurinol
usag
allopurinol
effect
variabl
among
individu
patient
despit
normal
tpmt
genotyp
baylor
colleg
medicin
houston
texa
unit
state
background
congenit
sideroblast
anemia
bcell
immunodefici
period
fever
development
delay
syndrom
sifd
rare
inherit
sideroblast
anemia
syndrom
first
describ
clinic
similar
case
genet
variat
identifi
caus
object
present
unusu
present
patient
sifd
complic
diagnosi
concomit
alpha
thalassemia
trait
designmethod
retrospect
chart
review
five
month
old
male
infant
refer
hematolog
center
evalu
elev
hemoglobin
bart
identifi
newborn
screen
despit
numer
attempt
blood
work
unabl
collect
seven
month
age
microcyt
anemia
hemoglobin
gdl
mean
corpuscular
volum
fl
sever
would
expect
alpha
thalassemia
trait
variant
hemoglobin
identifi
isoelectr
focus
high
perform
liquid
chromatographi
nine
month
age
develop
growth
failur
intermitt
emesi
fever
development
delay
predominantli
gross
motor
hear
loss
disproport
larg
head
coars
thin
hair
next
ten
month
seen
numer
specialist
seemingli
unconnect
problem
includ
sensorineur
hear
loss
elev
liver
enzym
growth
hormon
defici
alpha
globin
analysi
reveal
delet
two
alpha
globin
gene
month
age
admit
one
week
fever
jaundic
emesi
peripher
blood
smear
show
microcyt
hypochrom
anemia
mark
anisopoikilocytosi
includ
target
cell
elliptocyt
tear
drop
spherocyt
poikilocyt
mark
polychromasia
coars
basophil
stippl
given
inconsist
laboratori
find
diagnosi
alpha
thalassemia
trait
clinic
syndrom
find
bone
marrow
biopsi
perform
reveal
rare
ring
sideroblast
one
month
later
whole
exom
sequenc
reveal
splice
variant
g
novel
missens
variant
consist
sifd
hemoglobin
bart
newborn
screen
moder
sever
microcyt
anemia
direct
initi
diagnost
workup
toward
variant
alpha
thalassemia
addit
medic
condit
develop
focu
shift
unifi
syndrom
compar
previous
describ
case
patient
diagnos
older
age
present
anemia
rather
episod
febril
ill
rare
sideroblast
bone
marrow
examin
diagnosi
case
led
identif
novel
variant
sister
similar
milder
featur
sifd
rare
diseas
variabl
phenotyp
sever
make
diagnosi
challeng
without
high
index
suspicion
crucial
appropri
manag
wiseman
blood
chakraborti
blood
background
cholelithiasi
uncommon
childhood
cholelithiasi
known
occur
frequent
children
predisposit
includ
femal
sex
obes
parenter
nutrit
previou
abdomin
surgeri
use
oral
contracept
famili
histori
gallston
chronic
hemolyt
anemia
hepatobiliari
diseas
exposur
specif
drug
although
occasion
case
report
link
cholelithiasi
childhood
leukemia
leukemia
therapi
preval
risk
factor
cholelithiasi
patient
childhood
leukemia
remain
unclear
object
estim
preval
cholelithiasi
patient
diagnos
childhood
acut
lymphoblast
leukemia
evalu
possibl
risk
factor
develop
cholelithiasi
patient
childhood
perform
computerassist
review
electron
medic
record
patient
diagnos
b
tcell
children
healthcar
atlanta
period
patient
diagnos
cholelithiasi
cholecyst
cholecystectomi
identifi
possibl
risk
factor
age
sex
bmi
histori
abdomin
surgeri
parenter
nutrit
use
abstract
patient
underli
chronic
hemolyt
anemia
preexist
gallbladd
diseas
exclud
result
seventeen
case
cholelithiasi
case
cholecyst
without
document
cholelithiasi
identifi
among
patient
cholelithiasi
femal
median
age
diagnosi
cholelithiasi
rang
year
seven
patient
symptom
refer
cholelithiasi
time
diagnosi
median
age
leukemia
diagnosi
among
patient
rang
year
median
interv
diagnosi
leukemia
gallbladd
diseas
year
four
patient
bmi
percentil
age
two
patient
prior
histori
intraabdomin
surgeri
patient
receiv
oral
contracept
pill
six
patient
receiv
parenter
nutrit
day
document
famili
histori
cholelithiasi
seven
patient
receiv
cholelithiasi
direct
therapi
two
patient
manag
medic
manag
endoscop
retrograd
cholangiopancreatogram
stone
extract
cholecystectomi
studi
estim
preval
cholelithiasi
childhood
lymphoblast
leukemia
higher
report
preval
gener
pediatr
popul
although
cohort
size
small
appear
therapi
support
care
modal
associ
like
play
larger
role
develop
cholelithiasi
known
predispos
factor
gener
popul
studi
warrant
background
uncommon
side
effect
intraven
immunoglobulin
ivig
administr
clinic
appar
sometim
sever
hemolysi
describ
sever
case
coombsposit
hemolyt
anemia
secondari
ivig
administr
ivig
blood
deriv
manufactur
pool
individu
plasma
donat
ivig
abotyp
restrict
antia
antib
antia
b
isoagglutinin
detect
object
describ
rare
seriou
type
transfus
reaction
lead
gross
hemolysi
ivig
administr
result
male
past
medic
histori
obstruct
sleep
apnea
obes
admit
pediatr
intens
care
unit
adenovir
pneumonia
subsequ
respiratori
failur
requir
mechan
ventil
complex
hospit
cours
mani
complic
includ
acut
respiratori
distress
syndrom
ard
septicshock
coombsposit
hemolyt
anemia
patient
treat
commerci
ivig
baxterbaxalta
daili
five
day
two
isol
episod
sever
hemolysi
relat
ivig
administr
requir
multipl
transfus
pack
red
blood
cell
prbc
examin
pretransfus
peripher
blood
smear
show
spherocytosi
rouleaux
format
larg
clump
rbc
aggreg
patient
blood
type
classifi
blood
group
rhneg
initi
prbc
transfus
type
subsequ
patient
coomb
test
found
posit
use
polyspecif
antiigg
type
sera
patient
antibodi
screen
reagent
group
screen
cell
neg
rule
autoimmun
hemolyt
anemia
howev
type
specif
antia
antibodi
detect
plasma
well
acid
elud
prepar
coombsposit
red
blood
cell
conclud
patient
hemolysi
due
antia
antibodi
presum
aris
ivig
patient
rbc
transfus
chang
oneg
blood
hemolyt
process
resolv
patient
ultim
die
due
complic
ard
although
hemolysi
known
side
effect
ivig
rare
consid
decid
administ
ivig
addit
rare
describ
pediatr
popul
ivig
use
treatment
grow
number
medic
condit
due
critic
natur
mani
patient
hemolysi
secondari
ivig
may
consid
continu
blood
transfus
patient
specif
blood
type
may
use
crucial
rememb
sever
hemolysi
occur
ivig
import
transfus
blood
group
rhneg
blood
applic
univers
maryland
medic
center
children
hospit
baltimor
maryland
unit
state
background
coagulopathi
welldescrib
complic
acut
promyelocyt
leukemia
apml
remain
lead
caus
induct
failur
treatment
coagulopathi
associ
apml
shown
rapidli
improv
multipl
organ
dysfunct
syndrom
mod
apml
includ
acut
respiratori
distress
syndrom
ard
associ
infect
traumat
injuri
malign
infiltr
cytokin
releas
syndrom
mechan
ventil
longer
suffici
extracorpor
membran
oxygen
ecmo
consid
howev
coagulopathi
sever
endorgan
damag
malign
rel
contraind
initi
treatment
report
case
femal
present
respiratori
failur
dissemin
intravascular
coagulopathi
dic
intracrani
hemorrhag
mod
diagnos
apml
success
treat
ecmo
therapi
designmethod
retrospect
case
analysi
literatur
review
patient
femal
admit
respiratori
failur
alter
mental
statu
follow
fall
shortli
prior
present
initi
laboratori
valu
notabl
pancytopenia
dic
acut
renal
failur
noncontrast
head
ct
show
left
tempor
lobe
intraparenchym
hemorrhag
diagnos
apml
peripher
smear
later
confirm
fish
start
immedi
highrisk
induct
chemotherapi
per
cog
protocol
includ
alltran
retino
acid
arsen
trioxid
idarubicin
dexamethason
cvvhd
requir
acut
renal
failur
despit
maxim
respiratori
support
remain
hypoxem
oxygen
index
ratio
ecmo
initi
hour
start
induct
hour
admiss
coagulopathi
resolv
day
induct
ecmo
discontinu
day
mechan
ventil
cvvhd
stop
day
continu
improv
eventu
achiev
remiss
neurolog
side
effect
despit
rel
contraind
ecmo
patient
success
treat
ecmo
without
signific
neurolog
side
effect
correct
coagulopathi
multifactori
restor
adequ
oxygen
deliveri
via
ecmo
improv
endotheli
function
success
organ
support
allow
suffici
respons
induct
chemotherapi
atra
lead
termin
differenti
leukem
blast
complement
contact
system
activ
contact
ecmo
circuitri
case
illustr
ecmo
still
consid
patient
despit
coagulopathi
end
organ
damag
sinai
hospit
baltimor
baltimor
maryland
unit
state
background
primari
polycythemia
vera
extrem
rare
diagnosi
pediatr
patient
defin
mark
elev
red
blood
cell
due
erythropoietinindepend
mechan
present
disord
rang
asymptomat
person
sever
thrombot
event
buddchiari
syndrom
cerebrovascular
stroke
mutat
gene
found
adult
pediatr
patient
polycythemia
vera
howev
mutat
less
commonli
identifi
pediatr
patient
describ
otherwis
healthi
femal
present
significantli
elev
total
erythrocyt
count
hemoglobin
platelet
incident
discov
upon
routin
annual
blood
work
obtain
pediatrician
designmethod
report
discuss
rare
case
demonstr
cellular
marrow
trilineag
hematopoiesi
dysplasia
cytogenet
assess
hemoglobin
platelet
count
recov
leukopenia
neutropenia
persist
followup
evalu
three
month
reveal
fever
ongo
cytopenia
onemonth
nodular
skin
rash
trunk
extrem
resembl
erythema
nodosum
hepat
peak
alt
ast
respect
follow
clinic
evalu
skin
biopsi
perform
remark
atyp
lymphocyt
within
subcuti
tcell
marker
high
posit
perforin
immunoperoxidas
stain
neg
stain
ebv
note
result
consist
sptcl
addit
evalu
support
diagnosi
hlh
stage
evalu
perform
petct
show
widespread
hypermetabol
subcutan
activ
leg
trunk
skull
diffus
marrow
hyperplasia
bone
marrow
demonstr
involv
precursor
bcell
acut
lymphoblast
leukemia
mll
gene
rearranag
skin
biopsi
retrospect
stain
tdt
neg
result
blood
smear
taken
time
skin
biopsi
demonstr
leukem
cell
conclus
first
report
patient
sptcl
synchron
malign
patient
well
current
mainten
phase
treatment
skin
diseas
resolv
petct
possibl
present
function
chanc
possibl
underli
immun
dysfunct
cancer
predisposit
warrant
investig
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
hereditari
xerocytosi
hx
rare
red
blood
cell
rbc
dehydr
disord
character
variabl
hemolysi
propens
iron
overload
hx
often
misdiagnos
hereditari
spherocytosi
hs
splenectomi
cur
hs
rel
contraind
hx
due
substanti
thromboembol
risk
signifi
import
delin
diseas
blood
smear
abnorm
variabl
often
insuffici
make
accur
diagnosi
osmoticgradi
ektacytometri
genet
confirm
critic
distinguish
overlap
disord
object
describ
famili
hx
initi
misdiagnos
hs
discuss
import
distinguish
disord
util
ektacytometri
make
distinct
designmethod
caucasian
male
diagnos
hs
present
prolong
neonat
jaundic
start
first
day
life
describ
mild
scleral
icteru
histori
intermitt
jaundic
dark
urin
without
need
transfus
father
patern
uncl
patern
grandmoth
diagnos
hs
childhood
underw
cholecystectomi
addit
father
underw
splenectomi
abdomin
pain
child
blood
count
reveal
compens
anemia
hb
gmdl
reticulocytosi
arc
increas
mcv
fl
mchc
gmdl
blood
smear
show
increas
polychromasia
poikilocytosi
rare
spherocyt
stomatocyt
child
normal
ferritin
father
iron
overload
ferritin
ngml
despit
prior
transfus
osmoticgradi
ektacytometri
profil
child
father
rbc
show
characterist
leftshift
bellshap
curv
decreas
omin
ohyp
diagnost
hx
famili
current
undergo
genet
studi
despit
clinic
similar
hs
hx
distinguish
diseas
signific
manag
implic
hx
disord
rbc
permeabl
caus
shorten
rbc
surviv
stomatocyt
blood
smear
rais
suspicion
hx
insuffici
make
accur
diagnosi
identifi
characterist
biomechan
membran
properti
use
osmoticgradi
ektacytometri
gold
standard
clinic
diagnosi
confirm
molecular
studi
hs
hx
easili
reliabl
distinguish
use
ektacytometri
disord
distinct
curv
repres
differ
rbc
deform
pattern
hx
diagnosi
made
counsel
famili
splenectomi
risk
thromboembol
significantli
increas
hx
compar
hs
father
diagnos
iron
overload
conclus
hx
commonli
misdiagnos
hs
case
highlight
import
make
distinct
util
osmoticgradi
ektacytometri
reliabl
distinguish
condit
penn
state
health
children
hospit
hershey
pennsylvania
unit
state
background
relaps
acut
myeloid
leukemia
aml
present
isol
central
nervou
system
myeloid
sarcoma
cn
ms
rare
treatment
welldefin
thiotepa
vinorelbin
topotecan
clofarabin
tvtc
success
reinduct
therapi
induc
remiss
prior
hematopoiet
stem
cell
transplant
hsct
object
describ
experi
util
tvtc
therapi
two
children
extramedullari
diseas
initi
diagnosi
present
relaps
aml
intracrani
myeloid
sarcoma
result
case
monthold
femal
diagnos
neg
aml
complet
treatment
per
children
oncolog
group
cog
studi
low
risk
arm
without
bortezomib
cerebr
spinal
fluid
csf
neg
diagnosi
fish
test
posit
gene
delet
unknown
signific
mrd
undetect
induct
remain
undetect
cycl
nine
month
therapi
recurr
headach
prompt
mri
imag
reveal
two
posterior
fossa
mass
csf
bone
marrow
test
neg
stereotact
biopsi
larger
mass
confirm
recurr
aml
patient
underw
two
cycl
tvtc
total
seven
dose
intrathec
cytarabin
almost
near
resolut
cn
ms
complet
cranial
radiat
proceed
allogen
stem
cell
transplant
unrel
cord
marrow
donor
diseas
free
approxim
day
yearold
femal
diagnos
mll
neg
aml
complet
treatment
per
cog
studi
low
risk
arm
without
bortezomib
csf
neg
diagnosi
mrd
undetect
induct
complet
therapi
without
complic
two
month
therapi
retrospect
analysi
diagnost
bone
marrow
cytogenet
laboratori
test
new
panel
identifi
novel
partner
reveal
cryptic
insert
transloc
four
month
therapi
acut
mental
statu
chang
prompt
mri
imag
reveal
two
intracrani
ms
lumbar
spine
involv
resect
larger
lesion
symptomat
relief
confirm
fusion
csf
posit
blast
marrow
neg
relaps
diseas
patient
complet
two
cycl
tvtc
total
seven
dose
cytarabin
near
resolut
cn
diseas
mm
contrast
enhanc
medulla
receiv
craniospin
radiat
await
improv
cardiac
function
proceed
hsct
conclus
tvtc
success
reinduct
regimen
relaps
aml
cn
ms
prior
hsct
background
acut
sever
anemia
lifethreaten
medic
condit
differenti
quit
broad
possibl
etiolog
acut
sever
anemia
includ
autoimmun
hemolyt
anemia
aiha
atyp
hemolyt
urem
syndrom
ahu
autoimmun
hemolyt
anemia
antibodymedi
process
target
protein
antigen
locat
surfac
red
blood
cell
treatment
option
aiha
includ
corticosteroid
patient
respons
requir
splenectomi
atyp
hemolyt
urem
syndrom
medic
urgenc
defin
triad
microangiopath
hemolyt
anemia
thrombocytopenia
acut
kidney
injuri
etiolog
usual
due
genet
caus
less
commonli
due
autoantibodi
idiopath
reason
prognosi
poor
object
differenti
autoimmun
hemolyt
anemia
atyp
hemolyt
urem
syndrom
timesensit
diagnost
dilemma
patient
critic
condit
import
delin
vastli
alter
therapeut
option
designmethod
discuss
two
case
highlight
diagnost
workup
involv
differenti
atyp
hemolyt
urem
syndrom
autoimmun
hemolyt
anemia
patient
male
present
extremi
sever
anemia
urem
encephalopathi
sever
acut
renal
injuri
requir
hemodialysi
multipl
blood
transfus
patient
b
male
also
present
extremi
respiratori
failur
secondari
adenovirusrhinovirusenteroviru
acut
progress
renal
failur
microangiopath
hemolyt
anemia
requir
hemodialysi
cardiorespiratori
support
patient
underw
full
hematolog
infecti
diseas
workup
subsequ
laboratori
studi
confirm
enteropathogen
ecoli
epec
patient
stool
blood
cultur
remain
neg
renal
biopsi
result
consist
pigment
nephropathi
bloodwork
indic
posit
direct
coomb
patient
ultim
treat
steroid
signific
improv
patient
b
also
includ
full
hematolog
workup
includ
activ
ahu
genet
panel
well
full
infecti
diseas
workup
subsequ
laboratori
test
reveal
blood
cultur
grow
streptococcu
pneumonia
activ
adult
ref
rang
normal
complement
level
imag
find
also
support
diagnosi
ahu
manag
critic
ill
patient
acut
sever
anemia
requir
thorough
hematolog
infecti
diseas
workup
molecular
genet
help
definit
diagnosi
ahu
util
result
limit
time
overlap
clinic
present
patient
extremi
due
acut
sever
hemolyt
anemia
progress
renal
failur
present
rather
broad
differenti
timesensit
treatment
prognost
implic
favor
respons
steroid
delin
aiha
hu
background
aciduria
rare
metabol
disord
character
development
delay
hypotonia
biallel
mutat
dehydrogenas
isocitr
dehydrogenas
metaphys
chondromatosi
aciduria
mchga
type
previous
report
seven
patient
omim
pmid
three
somat
mosaic
variant
isocitr
dehydrogenas
describ
boy
mchga
subsequ
develop
acut
myeloid
leukemia
aml
found
variant
leukem
bone
marrow
sampl
report
first
case
aml
metabol
disord
designmethod
hispan
boy
present
short
statur
development
delay
abnorm
skin
pigment
unilater
congenit
cataract
workup
reveal
multipl
skelet
enchondromatosi
elev
urin
acid
level
diagnos
mchga
pathogen
variant
identifi
peripher
blood
germlin
test
biopsi
skin
lesion
declin
famili
two
year
later
present
streptococc
sepsi
pancytopenia
blast
note
peripher
smear
bone
marrow
morpholog
consist
acut
myelomonocyt
leukemia
blast
chromosom
analysi
show
normal
xy
molecular
test
pyrosequenc
reveal
variant
mosaic
patient
treat
per
cog
studi
end
induct
bone
marrow
aspir
hemodilut
obviou
residu
diseas
flow
cytometri
sensit
morpholog
previous
identifi
variant
longer
detect
limit
detect
although
target
therapi
aml
mutat
current
phase
clinic
trial
adult
safeti
efficaci
data
use
inhibitor
children
treatment
ivosidenib
therefor
current
option
patient
conclus
first
case
aml
report
rare
metabol
disord
somat
variant
identifi
three
mchga
case
mutat
lead
accumul
glioma
aml
without
confirm
germlin
mutat
somat
mosaic
test
multipl
specimen
sourc
specul
patient
underli
somat
mutat
associ
mchga
subsequ
led
leukemogenesi
present
first
case
associ
increas
index
suspicion
develop
aml
children
metabol
disord
associ
variant
background
congenit
combin
defici
vitamin
kdepend
coagul
factor
vkcfd
rare
heterogen
autosom
recess
bleed
disord
vkcfd
caus
mutat
gene
either
gammaglutamyl
carboxylas
ggcx
vitamin
k
epoxid
reductas
complex
vkorc
respons
gammacarboxyl
vitamin
k
depend
protein
vkdp
allow
activ
clinic
present
rang
bleed
intracrani
hemorrhag
date
vkcfd
report
patient
worldwid
object
report
case
girl
novel
homozyg
mutat
ggcx
gene
highlight
clinic
biochem
characterist
review
literatur
girl
consanguin
emirati
parent
present
hospit
histori
bleed
punctur
site
receiv
secondmonth
vaccin
associ
episod
mild
mucos
bleed
review
system
neg
jaundic
steatorrhea
failur
thrive
physic
exam
unremark
investig
reveal
markedli
prolong
pt
aptt
high
inr
fibrinogen
hemoglobin
platelet
alway
normal
activ
vitamin
kdepend
factor
includ
fii
fvii
fix
fx
protein
c
low
measur
protein
induc
vitamin
k
absenc
pivkaii
done
came
high
associ
mild
elev
liver
enzym
normal
liver
function
test
pictur
support
vitamin
k
defici
result
start
oral
vitamin
k
supplement
mgday
respond
partial
vitamin
k
requir
higher
dose
stabil
inr
exclud
acquir
caus
due
requir
high
dose
vitamin
k
mutat
either
ggcx
vkorc
gene
suspect
genet
analysi
conduct
reveal
novel
missens
homozyg
mutat
ggcx
gene
confirm
diagnosi
combin
defici
vitamin
kdepend
clot
factor
type
asymptomat
parent
heterozyg
mutat
result
current
stabl
mgday
vitamin
k
supplement
conclus
vkcfd
rare
bleed
disord
overal
good
prognosi
due
avail
sever
effect
therapeut
option
function
mutat
gene
unknown
patient
demonstr
partial
respons
vitamin
k
supplement
suggest
presenc
residu
carboxyl
capac
possibl
role
gene
enzymesubstr
interact
univers
alabama
birmingham
birmingham
alabama
unit
state
background
zinc
finger
transcript
factor
play
critic
role
regul
hematopoiesi
lymphat
angiogenesi
mutat
lead
defici
gd
link
varieti
clinic
condit
patient
gd
strike
predisposit
develop
myelodysplast
syndrom
md
acut
myeloid
leukemia
aml
chronic
myelomonocyt
leukemia
cmml
acut
lymphoblast
leukemia
associ
gd
although
associ
bcell
gd
previous
report
object
describ
uniqu
associ
defici
tcell
young
child
result
femal
present
oneweek
histori
fever
malais
signific
past
medic
histori
verruca
plantari
selfresolv
leukopenia
associ
febril
ill
signific
famili
histori
includ
sister
neutropenia
human
papilloma
viru
hpv
infect
mother
neutropenia
monocytopenia
atyp
mycobacteri
infect
hpv
infect
peripher
blood
reveal
hemoglobin
gdl
hematocrit
platelet
white
blood
cell
neutrophil
lymphocyt
monocyt
patient
underw
bone
marrow
biopsi
demonstr
lymphoblast
infiltr
flow
cytometri
analysi
demonstr
monoclon
lymphoid
blast
popul
coexpress
nuclear
tdt
howev
lack
express
hladr
myeloperoxidas
find
consist
tcell
aberr
myeloid
marker
cytogenet
analysi
reveal
xx
dic
patient
began
treatment
per
children
oncolog
group
achiev
remiss
end
induct
cours
therapi
complic
episod
fever
reciproc
junction
tachycardia
asparaginaseassoci
thrombosi
viral
mening
recurr
episod
verruca
plantari
resist
streptococcu
pneumonia
haemophilu
parainfluenza
infect
caus
chronic
cough
later
also
found
low
igm
level
complet
therapi
develop
monocytopenia
lymphocyt
subset
panel
reveal
absent
b
cell
decreas
number
natur
killer
nk
cell
invers
workup
includ
sequenc
analysi
show
heterozyg
nonsens
mutat
tc
refer
like
result
haploinsuffici
patient
continu
remiss
receiv
monthli
immunoglobulin
replac
azithromycin
atyp
mycobacteri
prophylaxi
surveil
bone
marrow
biopsi
shown
evid
md
leukemia
howev
demonstr
persist
hypocellular
possibl
undergo
allogen
bone
marrow
transplant
activ
discuss
given
cur
potenti
clinician
awar
tcell
may
associ
defici
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
treatment
sever
hemophilia
center
factor
viii
fviii
replac
therapi
develop
alloantibodi
inhibitor
fviii
signific
treatment
complic
occur
mani
patient
high
titer
inhibitor
render
treatment
factor
viii
ineffect
necessit
use
bypass
agent
may
achiev
hemostasi
efficaci
consid
substanti
ramif
inhibitor
develop
treatment
erad
inhibitor
great
import
achiev
adequ
hemostasi
patient
popul
desensit
immun
toler
induct
iti
primari
method
inhibitor
elimin
howev
patient
respond
iti
immunomodul
may
consid
next
line
therapi
although
controversi
remain
regard
agent
select
use
object
incomplet
data
use
immunomodul
therapi
inhibitor
erad
sever
hemophilia
present
case
pediatr
patient
sever
hemophilia
high
titer
inhibitor
fail
initi
iti
therapi
better
illustr
potenti
treatment
option
futur
designmethod
retrospect
chart
review
perform
patient
sever
hemophilia
cincinnati
children
hospit
medic
center
result
caucasian
male
sever
hemophilia
secondari
intron
invers
initi
diagnos
follow
extens
bleed
circumcis
birth
identifi
inhibitor
bethesda
unit
bu
month
age
exposur
day
treatment
fail
multipl
attempt
iti
recombin
plasmaderiv
pd
fviii
advanc
immunomodul
therapi
combin
pdfviii
howev
demonstr
anaphylaxi
rituximab
ofatumumab
underw
toler
rituximab
receiv
six
month
cours
partial
respons
nadir
bu
month
follow
last
dose
rituximab
rise
inhibitor
titer
bu
found
mycophenol
mofetil
mmf
initi
subsequ
inhibitor
stabil
decreas
titer
bu
cours
follow
year
mmf
well
toler
without
major
side
effect
infect
throughout
therapi
conclus
develop
inhibitor
fviii
consider
complic
patient
sever
hemophilia
use
immunomodulatori
therapi
follow
iti
failur
remain
controversi
mmf
well
studi
patient
popul
report
case
patient
success
treat
mmf
minim
side
effect
prospect
studi
consid
defin
role
mmf
immunomodul
therapi
background
syndrom
ds
children
aml
ds
aml
higher
cure
rate
nond
counterpart
outcom
refractoryrelaps
case
howev
remain
dismal
somat
mutat
gene
encod
transcript
factor
ds
aml
patient
respons
observ
hypersensit
ds
aml
blast
cytosin
arabinosid
arac
view
excel
surviv
rate
approach
ds
aml
patient
ongo
children
oncolog
group
cog
studi
seek
determin
feasibl
treat
standard
risk
minim
residu
diseasemrd
neg
ds
aml
patient
use
reduc
dose
decreas
arac
backbon
although
result
japanes
trial
approach
promis
north
american
european
data
conflict
although
chromosom
rearrang
ds
aml
appear
carri
advers
prognost
signific
nond
aml
monosomi
ds
aml
patient
associ
moder
wors
outcom
isochromosom
howev
rare
report
previou
case
ds
aml
object
report
institut
experi
earli
relaps
involv
case
ds
aml
patient
treat
per
reduc
dose
arac
arm
studi
designmethod
herebi
report
diseas
cours
cytogenet
ds
aml
patient
patient
month
old
caucasian
femal
mutat
neg
aml
patient
old
caucasian
male
whose
chromosom
analysi
reveal
isochromosom
copi
long
arm
chromosom
patient
achiev
neg
mrd
induct
chemotherapi
thioguanin
lowdos
arac
daunorubicin
proceed
per
reduc
dose
arac
arm
patient
relaps
immedi
complet
chemotherapi
salvag
chemotherapi
mitoxantronehigh
dose
arac
hidac
fail
induc
second
remiss
patient
subsequ
die
diseas
patient
relaps
within
month
end
therapi
patient
underw
salvag
chemotherapi
util
hidac
backbon
remain
diseas
remiss
note
earli
relaps
follow
reduc
dose
arac
regimen
ds
aml
children
suggest
test
gata
mutat
chromosom
rearrang
may
play
use
role
develop
futur
riskstratifi
treatment
strategi
ds
aml
univers
rochest
rochest
new
york
unit
state
background
develop
countri
centuri
sever
nutrit
defici
often
consid
differenti
diagnosi
unexplain
childhood
anemia
asid
iron
defici
anemia
vitamin
defici
sever
enough
impact
hematopoiesi
uncommon
gener
pediatr
popul
present
uniqu
case
infant
present
intermitt
emesi
failur
thrive
ftt
development
delay
macrocyt
anemia
neutropenia
initi
concern
congenit
bone
marrow
failur
syndrom
instead
discov
underli
potenti
famili
defici
object
describ
uniqu
case
infant
defici
outlin
import
includ
defici
differenti
diagnosi
unexplain
megaloblast
anemia
children
exclus
breastf
infant
present
gastroenterolog
evalu
due
persist
emesi
poor
weight
gain
cours
month
histori
notabl
delay
development
mileston
hypoact
mark
pallor
prompt
hematolog
evalu
reveal
concern
macrocyt
anemia
hemoglobin
gdl
mcv
reticulocytopenia
l
neutropenia
anc
otherwis
reassur
physic
examin
laboratori
evalu
notabl
discoveri
undetect
level
mark
hyperhomocysteinemia
moll
hemoglobin
hgb
continu
declin
gdl
first
day
present
requir
red
blood
cell
rbc
transfus
within
day
initi
daili
cyanocobalamin
inject
result
robust
reticulocytosi
respons
improv
hgb
immedi
normal
neutrophil
count
resolut
hyperhomocysteinemia
addit
histori
laboratori
evalu
patient
mother
reveal
concurr
asymptomat
matern
defici
well
histori
need
supplement
matern
grandfath
rais
concern
inherit
etiolog
despit
rariti
vitamindefici
hematolog
abnorm
gener
pediatr
popul
defici
consid
potenti
caus
otherwis
unexplain
megaloblast
anemia
especi
set
concurr
ftt
neurodevelopment
delay
detail
famili
histori
obtain
case
may
help
prevent
patient
clinic
sequela
defici
discov
sooner
patient
experienc
favor
clinic
respons
supplement
attest
import
vitamin
earli
childhood
growth
develop
background
pegasparaginas
univers
util
treatment
pediatr
acut
lymphoblast
leukemia
despit
high
efficaci
diseas
associ
hypersensit
allergi
patient
protract
anaphylaxi
describ
circumst
sever
food
allergi
ongo
allergen
exposur
howev
yet
describ
relat
pegasparaginas
describ
first
report
case
protract
anaphylaxi
pegasparaginas
administr
provid
guidanc
time
cours
manag
protract
anaphylaxi
well
evid
erwinia
asparaginas
may
safe
administ
even
high
risk
popul
object
provid
guidanc
regard
durat
cours
manag
protract
sever
anaphylaxi
pegasparaginas
therapi
year
old
male
high
risk
present
consolid
therapi
pegasparaginas
intramuscular
vincristin
one
hour
administr
develop
gener
hive
angioedema
given
diphenhydramin
quickli
develop
progress
hive
angioedema
subject
throat
chest
tight
wheez
treat
diphenhydramin
epinephrin
albuterol
methylprednisolon
resolut
symptom
one
hour
later
symptom
recur
patient
becam
hypotens
retreat
methylprednisolon
epinephrin
transfer
pediatr
intens
care
unit
picu
picu
place
epinephrin
drip
continu
methylprednisolon
diphenhydramin
cetirizin
albuterol
ranitidin
epinephrin
drip
success
discontinu
hour
medic
gradual
wean
cours
two
week
note
patient
st
segment
chang
electrocardiogram
first
hour
anaphylaxi
associ
normal
ventricular
function
per
echocardiogram
resolv
within
one
week
patient
subsequ
toler
multipl
dose
erwinia
asparaginas
intramuscular
without
premed
patient
acut
manag
pediatr
intens
care
unit
steroid
antihistamin
continu
infus
epinephrin
symptom
consist
sever
anaphylaxi
includ
hive
angioedema
throat
chest
tight
wheez
hypotens
persist
total
four
day
final
resolv
thu
far
toler
multipl
dose
erwinia
asparaginas
without
symptom
allergi
hypersensit
anaphylaxi
protract
sever
anaphylaxi
pegasparaginas
therapi
success
manag
multiag
therapi
includ
antihistamin
steroid
continu
infus
epinephrin
rechalleng
altern
form
asparaginas
may
toler
even
patient
protract
anaphylaxi
pegasparaginas
ucsf
benioff
children
hospit
oakland
oakland
california
unit
state
background
vincristin
vcr
wide
use
pediatr
cancer
unlik
cytotox
agent
hematopoiet
toxic
uncommon
vcrinduc
anemia
observ
mechan
well
studi
vinca
alkaloidinduc
membran
chang
seen
earli
studi
hereditari
spherocytosi
hs
anecdot
case
suggest
vcr
may
increas
hemolysi
patient
describ
case
involv
sever
vcrinduc
anemia
patient
hs
explan
mechan
object
describ
mechan
vcrinduc
anemia
hs
designmethod
case
report
yearold
femal
hs
diagnos
tlymphoblast
lymphoma
requir
pack
red
blood
cell
prbc
transfus
neonat
thereaft
done
well
without
episod
acut
hemolysi
aplasia
complet
blood
count
cbc
demonstr
compens
hemolysi
requir
transfus
commenc
chemotherapi
start
mainten
receiv
mani
prbc
transfus
averag
patient
intermitt
drop
hemoglobin
hb
correl
particular
agent
stabl
mild
splenomegali
clear
pattern
emerg
mainten
hb
gdl
monthli
clinic
visit
receiv
vcr
intermitt
intrathec
methotrex
corticosteroid
within
day
hb
drop
gdl
reticulocyt
count
decreas
transfus
day
correct
hb
reticulocyt
hb
return
baselin
white
blood
cell
platelet
count
chang
vcr
blood
sampl
pre
immedi
post
day
post
vcr
analyz
rbc
characterist
marker
hemolysi
significantli
differ
ektacytometri
show
ident
curv
indic
chang
rbc
deform
vitro
incub
patient
blood
sampl
vcr
also
affect
osmot
deform
confirm
chang
rbc
rigid
unlik
reason
drop
hb
data
indic
dysregul
erythropoiesi
respons
anemia
vcr
rather
damag
peripher
rbc
patient
mainten
therapi
lymphoblast
lymphoma
caus
sever
anemia
like
temporari
reduct
erythropoiesi
patient
normal
rbc
surviv
low
reticulocyt
count
notic
howev
patient
decreas
rbc
surviv
brisk
reticulocytosi
disrupt
rbc
gener
appar
conclus
vcr
administr
patient
rbc
disord
warrant
close
observ
potenti
sever
vcrinduc
anemia
background
addit
tyrosin
kinas
inhibitor
tki
convent
chemotherapi
improv
outcom
pediatr
patient
philadelphia
chromosomeposit
ph
acut
lymphoblast
leukemia
howev
remain
increas
risk
relaps
compar
type
childhood
typic
relaps
diseas
philadelphia
chromosom
persist
sever
mechan
resist
involv
acquir
mutat
chimer
oncoprotein
report
object
describ
uniqu
case
pediatr
patient
ph
bprecursor
relaps
bprecursor
without
philadelphia
chromosom
result
boy
diagnos
ph
bprecursor
presenc
transloc
cytogenet
fluoresc
situ
hybrid
fish
respect
addit
abnorm
includ
gain
loss
one
copi
remiss
bone
marrow
neg
minim
residu
diseas
mrd
achiev
end
induct
dasatinib
esphal
chemotherapi
backbon
durat
tki
therapi
two
year
post
diagnosi
nearli
one
year
complet
therapi
cytopenia
prompt
bone
marrow
investig
relaps
bprecursor
establish
immunophenotyp
howev
fish
analysi
identifi
rearrang
moreov
quantit
revers
transcriptas
pcr
neg
fusion
transcript
fish
analysi
bone
marrow
reveal
multipl
addit
copi
monoallel
loss
similar
initi
diagnost
sampl
patient
reinduc
per
anticip
ph
relaps
howev
confirm
loss
ph
clone
tki
therapi
reiniti
due
posit
mrd
end
reinduct
therapi
patient
salvag
blinatumomab
therapi
subsequ
underw
allogen
stem
cell
transplant
sibl
donor
conclus
first
known
report
pediatr
patient
ph
bprecursor
develop
recurr
bprecursor
without
philadelphia
chromosom
persist
find
gain
loss
make
unlik
second
unrel
bprecursor
develop
follow
success
treatment
origin
diseas
case
highlight
possibl
genet
distinct
subclon
present
onset
diseas
share
abnorm
contain
philadelphia
chromosom
nevertheless
subclon
harbor
leukemogen
potenti
absenc
express
plausibl
predomin
clone
present
diagnosi
effect
treat
dasatinib
extinguish
clone
persist
face
tki
therapi
background
ligneou
conjunct
rare
form
pseudomembran
conjunct
develop
specif
patient
type
plasminogen
defici
lack
plasmin
activ
patient
result
defect
fibrinolysi
format
fibrinrich
membran
materi
mass
develop
palpebr
conjunctiva
well
site
bodycurr
manag
involv
surgic
excis
mass
usual
complic
multipl
recurr
recent
use
topic
plasminogen
concentr
help
delay
recurr
current
concentr
commerci
avail
report
omani
girl
hypoplasminogenemia
requir
optim
plasminogen
level
time
surgeri
delay
prevent
recurr
object
case
report
periop
use
ffp
versu
cryopricipit
transfus
altern
replac
plasminogen
surgic
excis
ligneou
conjunct
designmethod
pharmacokinet
studi
perform
assess
plasminogen
recoveri
ffp
mlkg
precipit
transfus
result
plasminogen
level
remain
subnorm
either
ffp
cryoprecipit
administr
ffp
maximum
concentr
reach
almost
normal
although
halflif
plasminogen
known
day
patient
seem
high
catabol
rate
receiv
cryoprecipit
plasminogen
level
reach
basal
level
within
hour
better
recoveri
profil
ffp
opt
give
ffp
surgeri
periop
manag
includ
ffp
transfus
hour
one
day
day
post
oper
follow
mlkg
daili
day
mlkg
postop
day
topic
treatment
initi
use
antibiot
steroid
ed
day
surgeri
follow
heparin
ed
second
day
follow
use
topic
heparin
cyclosporin
prednisolon
topic
lubric
eye
drop
variabl
durat
clinic
pictur
remain
stabl
almost
year
post
oper
start
develop
recurr
ligneou
lesion
background
ponatinib
ariad
pharmaceut
gener
multitarget
tyrosin
kinas
inhibitor
tki
approv
treatment
adult
chronic
myeloid
leukemia
cml
philadelphia
chromosomeposit
acut
lymphoblast
leukemia
ph
resist
intoler
tki
ponatinib
numer
drugdrug
interact
black
box
warn
associ
seriou
advers
vascular
event
hepatotox
reason
ponatinib
use
confin
specif
highrisk
popul
howev
patient
prove
refractori
therapi
potenti
benefit
ponatinib
may
outweigh
risk
date
ponatinib
studi
pediatricadolesc
young
adult
aya
popul
furthermor
literatur
describ
use
ponatinib
alon
combin
agent
pediatr
oncolog
patient
scarc
object
describ
singl
institut
experi
use
ponatinib
pediatr
patient
ph
designmethod
two
case
ponatinib
use
pediatr
ph
patient
resist
tki
identifi
institut
describ
peripher
blood
sampl
obtain
patient
identifi
fusion
transcript
sanger
sequenc
use
identifi
resist
mutat
result
first
case
femal
receiv
upfront
multiag
chemotherapi
plu
dasatinib
ph
relaps
confirm
endoftherapi
bone
marrow
evalu
thu
bcrabl
mutat
test
perform
reveal
mutat
ponatinib
initi
discontinu
one
week
due
clinic
signific
fluid
retent
peripher
edema
bilater
pleuralpericardi
effus
second
case
lateadolesc
femal
ph
relaps
stem
cell
transplant
sct
follow
relaps
tki
therapi
includ
imatinib
dasatinib
due
persist
bcrabl
fusion
transcript
despit
tki
therapi
switch
ponatinib
shortli
follow
initi
ponatinib
develop
diffus
maculopapular
rash
persist
despit
dose
reduct
result
ultim
discontinu
drug
bcrabl
mutat
test
identifi
resistanceconf
mutat
date
scant
exist
literatur
detail
use
ponatinib
pediatr
patient
appropri
dose
undefin
side
effect
profil
well
describ
particularli
use
concurr
chemotherapeut
agent
thu
case
seri
report
respons
toxic
ponatinib
pediatr
ph
patient
import
clinic
implic
addit
first
report
pediatr
ph
patient
document
mutat
underscor
import
bcrabl
mutat
test
particularli
time
relaps
cooper
univers
hospit
camden
new
jersey
unit
state
background
disord
rare
autosom
domin
diseas
encompass
sever
subtyp
may
hegglin
anomali
epstein
syndrom
fechtner
syndrom
sebastian
syndrom
heterozyg
mutat
seen
gene
encod
nonmuscl
myosin
heavi
chain
iia
nmmhciia
involv
cell
motil
well
function
maintain
cellular
shape
integr
present
mainli
character
macrothrombocytopenia
variou
relat
express
exist
nephriti
often
lead
renal
failur
cataract
sensorineur
deaf
girl
histori
extens
dental
cari
hyperact
speech
delay
due
suspect
hear
loss
incident
found
thrombocytopenia
time
genet
evalu
bruis
excess
bleed
respond
observ
immunoglobulin
steroid
therapi
platelet
count
remain
persist
low
kul
underw
extens
evalu
rule
platelet
disord
vs
coagul
defect
peripher
smear
show
enlarg
platelet
giemsa
stain
inclus
bodi
note
granulocyt
platelet
aggreg
platelet
surfac
glycoprotein
flow
cytometri
neg
coagul
profil
also
normal
object
case
report
summar
complex
diagnos
pediatr
patient
designmethod
sinc
unifi
diagnosi
clinic
present
appar
whole
exom
sequenc
we
undertaken
result
we
reveal
heterozyg
pathogen
variant
locat
exon
gene
gene
alter
explain
patient
clinic
featur
macrothrombocytopenia
hear
loss
mutat
patern
inherit
father
demonstr
mosaic
asymptomat
normal
platelet
count
morpholog
show
enlarg
platelet
inclus
bodi
granulocyt
deal
patient
mild
symptom
bleed
diathesi
evid
persist
macrothrombocytopenia
consid
platelet
disord
belong
help
delin
certain
predispos
syndrom
guid
clinic
manag
patient
like
benefit
earli
genet
test
receiv
support
therapi
we
highlight
syndrom
provid
inform
recurr
risk
famili
renal
hear
abnorm
indistinguish
epstein
fechtner
syndrom
pathogen
variant
differ
genotypephenotyp
correl
impli
patient
may
either
syndrom
although
clinic
featur
compat
nephriti
yet
manifest
patient
monitor
close
longterm
progress
diseas
treatment
initi
accordingli
present
old
femal
evalu
genet
birth
due
prenat
microcephali
chromosom
microarray
normal
age
develop
standard
risk
prebcel
acut
lymphoblast
leukemia
complet
treatment
well
interim
remain
complet
clinic
remiss
treatment
exhibit
development
delay
neurocognit
deficit
age
height
weight
centil
head
circumfer
centil
approxim
standard
deviat
mean
correspond
centil
girl
bone
age
appropri
distinct
triangular
face
micrognathia
point
nose
resembl
seckellik
syndrom
patient
also
clinodactyli
toe
zygodactyl
triradiu
involv
left
toe
tendenc
sydney
line
right
palm
radial
loop
left
middl
finger
patient
uniqu
clinic
present
prompt
thorough
genet
evalu
led
novel
find
feel
clinic
signific
regard
develop
malign
designmethod
whole
exom
sequenc
we
perform
patient
well
biolog
parent
trio
de
novo
heterozyg
mutat
gene
potenti
relat
phenotyp
discov
variant
caus
frameshift
start
codon
chang
amino
acid
lysin
residu
creat
prematur
stop
codon
posit
new
read
frame
denot
variant
predict
caus
loss
normal
protein
function
via
protein
truncat
nonsensemedi
mrna
decay
conclus
member
protocadherin
famili
import
celltocel
adhes
synapt
function
central
nervou
system
highli
express
area
brain
involv
higher
cortic
function
speech
aberr
express
protocadherin
associ
develop
malign
mani
organ
system
regard
leukemia
methyl
statu
gene
diagnosi
implic
prognosi
could
use
biomark
predict
relaps
patient
de
novo
mutat
clinic
present
uniqu
previous
present
literatur
feel
mutat
clinic
signific
find
may
shed
light
role
gene
develop
hematopoeit
malign
background
acquir
hemophilia
aha
uncommon
potenti
lifethreaten
hemorrhag
diseas
character
sudden
onset
bleed
patient
neither
person
famili
histori
bleed
dyscrasia
usual
seen
adult
autoimmun
diseas
solid
tumor
lymphoprolif
diseas
pregnanc
postpartum
period
occurr
pediatr
popul
rare
report
report
case
otherwis
healthi
teenag
found
aha
present
acut
onset
atraumat
soft
tissu
hematoma
result
old
male
middl
eastern
descent
histori
congenit
absenc
right
extern
ear
otherwis
good
gener
health
present
emerg
depart
three
day
histori
progress
worsen
right
lower
leg
pain
swell
paresthesia
without
preced
histori
trauma
evalu
pediatr
orthoped
servic
document
significantli
elev
compart
pressur
necessit
immedi
fourcompart
fasciotomi
preoper
lab
signific
prolong
activ
partial
thromboplastin
time
aptt
second
normal
prothrombin
time
pt
intern
normal
ratio
inr
ptt
correct
mix
studi
suggest
presenc
circul
anticoagul
factor
xii
xi
normal
rang
factor
ix
elev
factor
viii
level
fviii
inhibitor
level
bethesda
unit
confirm
diagnosi
aha
work
autoimmun
diseas
neg
bleed
surgic
hemostasi
manag
recombin
factor
vii
novoseven
mcgkg
everi
hour
hour
post
oper
gradual
interv
prolong
factor
viii
antibodi
erad
manag
prednison
mgkgday
factor
viii
inhibitor
level
normal
day
hospit
recombin
factor
vii
discontinu
steroid
gradual
taper
discontinu
discharg
hospit
day
conclus
acquir
hemophilia
like
underdiagnos
condit
pediatr
typic
seen
adult
underli
autoimmun
diseas
solid
tumor
lymphoprolif
diseas
pregnanc
postpartum
period
pediatr
case
may
identifi
etiolog
case
highlight
import
consid
diagnosi
patient
unexplain
bleed
regardless
age
interven
earli
prevent
advers
consequ
univers
oklahoma
oklahoma
citi
oklahoma
unit
state
background
myeloid
neoplasm
associ
eosinophilia
rare
subtyp
chronic
leukemia
character
clonal
eosinophilia
true
incid
unknown
due
rariti
possibl
classif
idiopath
hypereosinophilia
syndrom
common
chromosom
aberr
involv
plateletderiv
growth
factor
receptor
pdgfr
report
one
rare
case
pediatr
patient
pediatr
manag
entiti
deriv
adult
case
report
case
seri
object
describ
case
chronic
leukemia
present
eosinophilia
result
previous
healthi
year
old
caucasian
male
present
sever
week
histori
migrat
joint
pain
splenomegali
abnorm
blood
count
leukocytosi
thrombocytopenia
absolut
eosinophilia
white
blood
cell
differenti
show
myeloid
precursor
suggest
chronic
myeloid
leukemia
bone
marrow
evalu
show
blast
eosinophil
bcrabl
test
neg
rule
cml
fish
analysi
eosinophil
clonal
reveal
delet
gene
result
fusion
gene
diagnost
myeloid
neoplasm
eosinophilia
associ
pdgfr
abnorm
treatment
start
tyrosin
kinas
inhibitor
tki
imatinib
daili
within
month
fish
analysi
fusion
gene
neg
approxim
month
daili
imatinib
switch
mainten
dose
weekli
approxim
month
sinc
diagnosi
well
mainten
imatinib
revis
classif
chronic
eosinophil
leukemia
myeloid
lymphoid
neoplasm
associ
eosinophilia
rearrang
pdgfra
pdgfrb
common
abnorm
fusion
gene
less
common
abnorm
includ
fusion
gene
point
mutat
featur
chronic
eosinophil
leukemia
includ
absolut
eosinophilia
splenomegali
elev
vitamin
tryptas
level
organ
damag
eosinophil
infiltr
cytokin
releas
patient
rearrang
mutat
involv
pdgfra
usual
respons
imatinib
start
dose
well
studi
establish
expert
recommend
coadministr
corticosteroid
first
day
imatinib
therapi
patient
histori
cardiac
involv
andor
elev
serum
troponin
level
prevent
myocardi
necrosi
rare
complic
imatinib
therapi
eosinophil
patient
fortun
patient
cardiac
involv
date
exhibit
sign
chronic
tki
toxic
conclus
myeloid
neoplasm
eosinophilia
constitut
rare
form
chronic
leukemia
often
associ
pdgfr
abnorm
usual
respons
tyrosin
kinas
inhibitor
therapi
walter
reed
nation
militari
medic
center
bethesda
maryland
unit
state
background
germlin
mutat
rare
caus
constitut
bone
marrow
failur
uniqu
propens
clonal
evolut
monosomi
md
object
previou
case
seri
demonstr
divers
clinic
outcom
patient
germlin
mutat
case
present
novel
mutat
addit
case
highlight
challeng
clinic
decis
make
patient
gene
mutat
known
clonal
evolut
toward
monosomi
risk
progress
myeloid
malign
also
known
selfcorrect
uniparent
disomi
inactiv
mutat
result
diseas
remiss
designmethod
retrospect
chart
review
review
literatur
perform
dna
isol
peripher
blood
use
whole
exom
sequenc
peripher
blood
sampl
patient
mother
father
show
mutat
skin
biopsi
patient
parent
evalu
uniparent
disomi
new
mutat
determin
pathogen
novel
mutat
specif
mutant
dna
transfect
embryon
kidney
cell
line
assess
role
inhibit
cell
prolifer
patient
present
month
age
pancytopenia
hypocellular
bone
marrow
set
sepsi
evid
dysfunct
immun
activ
hemophagocytosi
elev
solubl
simultan
sever
hypogammaglobulinemia
analysi
peripher
blood
show
increas
chromosom
breakag
normal
telomer
length
normal
flow
cytometri
gene
test
primari
hemophagocyt
lymphohistiocytosi
inherit
bone
marrow
failur
neg
patient
recov
present
ill
repeat
bone
marrow
biopsi
demonstr
improv
cellular
myelodysplasia
cytogenet
signific
monsomi
exom
test
demonstr
novel
mutat
patient
continu
requir
intermitt
ivig
fail
demonstr
appropri
leukocytosi
intermitt
infect
repeat
bone
marrow
evalu
cours
month
patient
demonstr
evid
evolut
toward
selfcorrect
persist
monosomi
clone
patient
schedul
undergo
match
unrel
donor
bone
marrow
transplant
case
highlight
uniqu
clinic
pictur
associ
constitut
marrow
failur
clonal
evolut
secondari
novel
mutat
thought
caus
pancytopenia
inhibit
cellular
prolifer
often
result
develop
monosomi
rescu
hematopoiesi
risk
malign
background
notabl
lab
develop
flow
cytometricbas
assay
custom
robot
platform
test
fdaapprov
drug
anticanc
activ
individu
patient
tumor
cell
person
assay
potenti
method
identifi
novel
agent
drug
combin
treat
aml
patient
fail
standard
therapi
object
present
case
teen
underw
success
treatment
relaps
aml
postsct
bortezomib
panobinostat
dexamethasonea
regimen
select
base
upon
result
notabl
lab
test
result
male
isol
bone
marrow
relaps
month
complet
schedul
therapi
relaps
aml
posit
achiev
second
remiss
neg
mrd
underw
match
sibl
donor
bmt
busulfancyclophosphamid
condit
bma
perform
day
mrd
posit
repeat
bma
done
day
show
mrd
start
sorafenib
day
receiv
donor
lymphocyt
infus
dli
day
receiv
cycl
azacitadin
aza
follow
dli
marrow
mrd
flow
sorafenib
alon
sorafenib
dli
sorafenib
azadli
respect
treatment
complic
varicella
mening
grade
skin
agvhd
febril
neutropenia
c
difficil
coliti
metapneumoviru
pneumonia
despit
extrem
low
level
leukemia
marrow
mrd
notabl
lab
test
perform
patient
leukemia
cell
marrow
collect
azadlisorafenib
reveal
sensit
leukem
blast
combin
bortezomib
panobinostat
dexamethason
prolong
cytopenia
multipl
infecti
complic
persist
posit
mrd
discontinu
azadlisorafenib
day
start
bortezomib
iv
day
panobinostat
mg
po
day
dexamethason
mg
po
day
chemotherapi
cycl
start
day
later
toler
treatment
without
side
effect
resolut
rash
cytopenia
achiev
full
donor
chimer
neg
complet
remiss
morpholog
flow
two
cycl
notabl
lab
test
power
tool
evalu
sensit
small
popul
leukem
blast
novel
drug
therapi
result
notabl
lab
test
may
serv
use
guid
treatment
select
failur
standard
aml
therapi
patient
achiev
morpholog
mrd
remiss
postsct
bortezomib
panobinostat
dexamethasonea
regimen
predict
efficaci
base
upon
notabl
lab
result
maria
ahmadnabi
christin
knoll
sanjay
shah
esteban
gomez
lori
wagner
phoenix
children
hospit
phoenix
arizona
unit
state
background
develop
inhibitor
patient
factor
ix
defici
fixd
wellrecogn
complic
occur
patient
within
subset
small
percentag
develop
anaphylaxi
factor
desensit
cyclophosphamid
alkyl
agent
use
manag
variou
oncolog
malign
report
use
factor
viii
desensit
previous
unreport
use
desensit
patient
fixd
rituximab
anticd
antibodi
howev
use
object
induc
immun
toler
patient
inhibitor
factor
ix
either
novel
report
method
use
cyclophosphamid
andor
rituximab
report
case
seri
patient
phoenix
children
hospit
fixd
achiev
cyclophosphamid
andor
rituximab
result
patient
one
year
old
male
sever
fixd
time
desensit
inhibitor
level
bu
desensit
cyclophosphamid
admit
infus
recombin
factor
ix
experienc
minor
symptom
intoler
includ
urticari
rash
selflimit
hemarthrosi
right
elbow
day
respond
novo
toler
remaind
infus
without
issu
continu
recombin
factor
ix
daili
return
clinic
monthli
cyclophosphamid
month
develop
urticaria
hemarthrosi
spontan
muscl
bleed
temper
zantac
zyrtec
solumedrol
benadryl
remain
without
recurr
inhibitor
howev
intermitt
hemarthrosi
ankl
thereaft
requir
prophylact
twice
daili
dose
recombin
factor
ix
patient
two
year
old
male
sever
fixd
famili
histori
anaphylaxi
factor
caus
earli
death
male
rel
diseas
never
receiv
factor
ix
detect
inhibitor
prior
desensit
success
underw
desensit
recombin
factor
ix
rituximab
icu
return
clinic
weekli
infus
x
experienc
advers
reaction
concern
anaphylaxi
continu
toler
factor
ix
product
without
evid
intoler
develop
inhibitor
continu
prophylact
dose
recombin
factor
ix
everi
day
experi
singl
institut
prove
cyclophosphamid
novel
agent
induc
fixd
anaphylaxi
also
provid
evid
rituximab
desensit
patient
sever
fixd
differ
includ
longer
durat
cyclophosphamid
therapi
month
vs
month
background
cartilagehair
hypoplasia
chh
autosom
recess
chondrodysplasia
associ
defect
cellmedi
immun
caus
mutat
ribonucleas
mitochondri
rna
process
rmrp
gene
cancer
incid
higher
patient
chh
gener
popul
especi
nonhodgkin
lymphoma
use
rituximab
anti
antibodi
result
decreas
host
bcell
number
impair
humor
function
month
safeti
rituximab
pediatr
patient
cancer
immunodefici
well
document
diagnosi
underli
immunodefici
may
discourag
physician
use
rituximab
due
risk
sever
bacteri
infect
viral
reactiv
object
report
case
burkitt
lymphoma
young
adult
femal
chh
defect
cellular
immun
success
treat
rituximab
result
old
amish
femal
disproportion
short
statur
present
center
manag
stage
iv
biopsi
proven
burkitt
lymphoma
myc
rearrang
present
week
earlier
cervic
occipit
submandibular
lymphadenopathi
splenomegali
fever
night
sweat
weight
loss
week
exam
height
three
feet
associ
brachydactyli
mild
bow
leg
normal
size
head
without
frontal
boss
fine
spars
hair
normal
intellig
pattern
dysmorph
suggest
chh
genet
test
perform
time
diagnosi
petct
scan
show
stage
iv
diseas
involv
cervic
lymph
node
spleen
iliac
bone
bone
marrow
treatment
standardintens
fablmb
therapi
group
c
addit
rituximab
initi
incomplet
respons
cop
reduct
tumor
mass
achiev
complet
remiss
cours
complic
sever
varicella
zoster
complet
therapi
remain
complet
diseas
remiss
month
treatment
complet
genet
test
subsequ
perform
prove
homozygos
chh
g
variant
opportunist
infect
therapi
conclus
use
rituximab
safe
benefici
patient
despit
defect
cell
mediat
immun
secondari
chh
suggest
rituximab
may
safe
use
patient
cellular
immun
defici
background
hemophilia
b
bleed
disord
character
defici
factor
viii
ix
respect
spontan
provok
hemarthrosi
known
complic
hemophilia
repetit
episod
hemarthrosi
lead
debilit
hemophil
arthropathi
lyme
diseas
tickborn
infect
endem
increas
part
unit
state
chronic
lyme
diseas
phase
lyme
arthriti
typic
develop
occur
month
year
initi
infect
character
swell
one
larg
joint
gener
absenc
system
symptom
object
review
case
hemophilia
b
patient
episod
provok
hemarthrosi
refractori
intens
recombin
factor
replac
therapi
found
concurr
lyme
arthriti
designmethod
report
two
clinic
case
review
relev
literatur
result
first
report
yearold
male
moder
hemophilia
provok
knee
hemarthrosi
fail
improv
despit
month
intens
factor
replac
therapi
requir
multipl
hospit
factor
replac
regimen
includ
twice
daili
standard
halflif
recombin
factor
viii
product
daili
everi
day
extend
halflif
recombin
factor
viii
product
trough
level
aim
high
factor
viii
pk
studi
obtain
dose
confirm
adher
evalu
subclin
inhibitor
inhibitor
test
neg
given
protract
symptom
addit
workup
hemarthrosi
purs
lyme
titer
posit
igg
though
neg
igm
treat
day
doxycyclin
time
hemarthrosi
greatli
improv
examin
imag
abl
recov
function
physic
therapi
second
report
yearold
male
moder
hemophilia
b
requir
multipl
hospit
admiss
provok
knee
hemarthrosi
improv
symptom
despit
week
daili
twice
daili
factor
replac
standard
halflif
recombin
factor
ix
product
aim
correct
perform
inhibitor
test
neg
pk
studi
assess
nondetect
inhibitor
dose
adher
lyme
test
posit
igg
though
neg
igm
treat
amoxicillin
day
time
hemarthrosi
significantli
improv
examin
imag
diagnosi
followup
imag
studi
patient
includ
mri
serial
bedsid
ultrasound
perform
per
uc
san
diego
school
medicin
msku
guidelin
background
relapserefractori
aml
follow
allogen
hematopoiet
stem
cell
transplant
hsct
hold
high
mortal
rate
current
relapserefractori
therapi
modal
younger
patient
may
includ
reinduct
clofarabinebas
regimen
follow
second
allogen
hsct
even
patient
undergo
second
hsct
fiveyear
surviv
rate
dismal
new
therapi
includ
small
molecul
inhibitor
studi
posthsct
relaps
set
unfit
hsct
promis
result
venetoclax
small
molecul
inhibitor
receiv
breakthrough
design
aml
treatment
elderli
patient
object
report
young
adult
aml
patient
relaps
post
hsct
success
reinduc
topotecan
vinorelbin
thiotepa
clofarabin
tvtc
sustain
remiss
venetoclax
mainten
therapi
approach
appear
uniqu
term
report
literatur
result
patient
femal
note
mll
rearrang
aml
initi
diagnosi
year
old
underw
chemotherapi
consist
cytarabinedaunorubicin
accord
standard
due
persist
diseas
reinduc
gcsf
clofarabin
highdos
cytarabin
gclac
put
cr
cours
complic
sepsi
coliti
gastrointestin
bleed
deep
venou
thrombosi
transfusionassoci
circulatori
overload
given
comorbid
receiv
anoth
cycl
clofarabinecytarabin
proceed
reduc
intens
allogen
hsct
accord
bmt
ctn
patient
toler
hsct
well
experienc
transplantrel
complic
includ
acut
chronic
gvhd
unfortun
relaps
month
posthsct
initi
salvag
therapi
consist
anoth
cours
gclac
due
persist
diseas
decis
made
reinduc
topotecan
vinorelbin
thiotepa
clofarabin
tvtc
time
howev
found
extens
infect
fusarium
speci
requir
cours
antifung
therapi
bone
marrow
evalu
show
residu
diseas
mrd
absolut
neutrophil
count
recov
patient
start
singleag
venetoclax
mainten
therapi
welltoler
remain
morpholog
remiss
month
describ
herein
young
adult
multipli
relaps
aml
wherein
tvtc
reinduct
follow
mainten
venetoclax
safe
use
posthsct
set
venetoclax
therapi
relaps
aml
set
warrant
studi
background
vitamin
defici
uncommon
children
develop
countri
especi
absenc
risk
factor
like
malabsorpt
inadequ
dietari
intak
often
present
nonspecif
symptom
sign
elud
diagnosi
recognit
treatment
vitamin
defici
critic
lead
bone
marrow
failur
well
sever
neurolog
development
problem
children
increas
index
suspicion
vitamin
defici
anemia
children
report
rare
case
vitamin
defici
anemia
child
present
sever
macrocyt
anemia
sign
hemolysi
concern
malign
designmethod
almost
threeyearold
previous
healthi
girl
present
day
histori
fever
emesi
fatigu
pallor
dysmorph
featur
hepatosplenomegali
lymphadenopathi
exam
growth
develop
normal
laboratori
find
show
sever
macrocyt
anemia
hemoglobin
gramsdl
mcv
fl
reticulocytopenia
sign
intravascular
hemolysi
present
elev
lactat
dehydrogenas
unitsl
haptoglobin
assay
limit
immunemedi
hemolysi
rule
initi
pictur
hemolyt
anemia
compound
find
moder
neutropenia
mild
thrombocytopenia
peripher
smear
show
occasion
blast
workup
done
broad
differenti
diagnosi
includ
leukemia
hemolyt
anemia
bone
marrow
failur
syndrom
specif
defici
result
workup
reveal
abnorm
low
vitamin
level
along
significantli
elev
homocystein
methylmalon
acid
level
indic
function
vitamin
defici
bone
marrow
evalu
show
megaloblast
anemia
dyserythropoiesi
consist
vitamin
defici
rule
leukemia
vitamin
defici
caus
hemolyt
anemia
like
pictur
secondari
intramedullari
hemolysi
due
ineffect
erythropoiesi
myeloid
precursor
also
affect
lead
neutropenia
thrombocytopenia
abnorm
peripher
blood
cell
patient
initi
symptomat
anemia
treat
blood
transfus
follow
intramuscular
vitamin
inject
normal
lab
valu
far
workup
etiolog
vitamin
defici
neg
except
equivoc
rang
antipariet
cell
antibodi
rais
concern
pernici
anemia
howev
rare
age
group
anoth
rare
condit
inborn
error
cobalamin
transport
current
oral
vitamin
supplement
workup
plan
base
respons
conclus
case
highlight
import
earli
consider
thorough
evalu
vitamin
defici
children
unclear
etiolog
anemia
prompt
treatment
initi
memori
hospit
univers
miami
miami
florida
unit
state
background
despit
great
success
treatment
acut
lymphoblast
leukemia
outcom
patient
relaps
remain
poor
prognost
indic
includ
time
site
relaps
blinatumomab
first
agent
class
simultan
bind
cytotox
cell
b
cell
result
lysi
malign
cell
howev
mechan
leukemia
resist
blinatumomab
unclear
object
describ
case
multipl
site
extramedullari
em
relaps
blinatumomab
therapi
result
hispan
male
philadelphia
posit
bprecursor
cell
refractori
chemotherapi
fail
bone
marrow
bm
place
blinatumomab
imatinib
achiev
minim
residu
diseas
mrd
neg
system
remiss
fifth
cycl
develop
bilater
periorbit
mass
biopsi
confirm
isol
em
relaps
diseas
treat
radiat
therapi
rt
notabl
resolut
em
diseas
continu
system
therapi
subsequ
present
pain
left
scapular
swell
imag
show
muscl
lung
parenchym
em
relaps
confirm
histolog
continu
blinatumomab
local
rt
await
cart
cell
therapi
bm
mrd
remain
neg
develop
system
mrdposit
blast
follow
sixth
cycl
primari
resist
blinatumomab
poorli
understood
propos
expans
clone
downregul
follow
blinatumomab
may
play
role
observ
patient
periorbit
relaps
subsequ
em
system
relaps
consist
coexist
multipl
clone
relaps
also
postul
em
relaps
could
link
failur
blinatumomab
cell
migrat
em
site
diseas
drug
inactiv
microenviron
second
em
relaps
patient
diseas
suggest
possibl
mechan
relaps
report
patient
posit
nonhodgkin
lymphoma
nhl
higher
dose
blinatumomab
howev
shown
promis
result
popul
despit
blinatumomab
effect
induc
remiss
patient
refractoryrelaps
appear
limit
patient
em
diseas
may
aris
either
multiclon
associ
relaps
due
emerg
resist
blinatumomab
includ
failur
migrat
em
site
background
cyclic
neutropenia
rare
hereditari
disord
character
recurr
neutropenia
cycl
week
interv
variabl
associ
symptom
includ
oral
ulcer
fever
report
case
cyclic
neutropenia
associ
chronic
inflamm
lead
develop
reactiv
aa
amyloidosi
one
patient
also
present
amyloid
goiter
report
new
case
cyclic
neutropenia
associ
renal
thyroid
amyloid
designmethod
femal
present
month
histori
thyromegali
recurr
aphthou
ulcer
associ
fever
laboratori
workup
show
sever
neutropenia
anemia
azotemia
abnorm
thyroid
function
absolut
neutrophil
count
l
hemoglobin
gdl
serum
creatinin
mgdl
uric
acid
mgdl
thyroid
stimul
hormon
elev
iuml
normal
free
urinalysi
show
protein
blood
urin
red
blood
cellshpf
chest
radiograph
show
mild
narrow
trachea
thyroid
compress
bone
marrow
biopsi
show
hypocellular
marrow
trilineag
hematopoiesi
left
shift
myeloid
matur
rare
matur
neutrophil
renal
biopsi
thyroid
fine
needl
aspir
reveal
abund
amyloid
note
father
aa
amyloidosi
result
endstag
renal
diseas
esrd
requir
hemodialysi
recurr
aphthou
ulcer
famili
histori
suggest
famili
predisposit
genet
test
reveal
pathogen
elan
gene
mutat
autosom
domin
inherit
confirm
diagnosi
cyclic
neutropenia
treat
patient
daili
granulocyt
coloni
stimul
factor
reduc
burden
chronic
inflamm
induc
cyclic
neutropenia
preserv
renal
end
organ
function
affect
amyloid
deposit
result
proband
elan
gene
mutat
posit
cyclic
neutropenia
amyloidosi
thyroid
kidney
posit
patern
histori
aa
amyloidosi
result
esrd
cyclic
neutropenia
may
result
chronic
inflammatori
state
lead
secondari
amyloidosi
univers
kentucki
lexington
kentucki
unit
state
background
overal
surviv
burkitt
lymphoma
bl
regardless
stage
greater
pediatr
popul
treat
multiag
chemotherapi
adenoviru
common
usual
selflimit
infect
within
pediatr
popul
howev
find
vari
within
immunocompromis
host
hepat
rare
complic
report
radiolog
find
patient
popul
discuss
three
year
old
male
histori
bl
present
clinic
radiograph
evid
relaps
found
adenoviru
hepat
designmethod
case
report
patient
bl
complet
remiss
complet
standard
care
chemotherapi
present
return
high
fever
elev
ldh
transamin
hepat
lesion
describ
hepat
imag
patholog
consist
adenoviru
hepat
immunocompromis
host
patient
present
three
year
old
six
week
histori
worsen
abdomin
pain
fever
found
right
side
pleural
effus
multipl
lesion
liver
diffus
abdomin
lymphadenopathi
biopsi
lymph
tissu
consist
bl
complet
therapi
per
arm
b
complet
remiss
end
plan
therapi
one
month
complet
therapi
return
high
fever
abdomin
pain
transamin
similar
initi
present
ct
scan
show
multipl
hypodens
discret
lesion
throughout
liver
reaccumul
right
side
pleural
effus
ldh
peak
ul
uln
ul
uric
acid
remain
within
normal
limit
bilirubin
peak
mgdl
conjug
liver
biopsi
perform
show
smudgi
nuclei
immunohistochem
stain
posit
adenoviru
evid
lymphomat
involv
resolut
hepat
lesion
transamin
normal
ldh
fever
occur
symptomat
treatment
alon
adenoviru
known
caus
system
diseas
immunocompromis
patient
rare
hepat
pediatr
patient
discret
hepat
lesion
secondari
adenoviru
report
literatur
three
case
discret
hepat
lesion
report
adult
immunocompromis
patient
two
fatal
fulmin
liver
failur
one
requir
cidofovir
case
demonstr
common
pediatr
viral
infect
present
lesion
concern
metastat
diseas
pediatr
lymphoma
patient
prompt
diagnosi
vital
manag
patient
recurr
lymphoma
differenti
background
heparin
induc
thrombocytopenia
hit
immunolog
process
antibodi
bind
heparin
complex
caus
paradox
hypercoagul
state
ramif
process
may
includ
multitud
thrombot
event
bleed
complic
secondari
platelet
consumpt
patient
hit
manifest
increas
bruis
acut
decreas
platelet
count
continu
clot
crrt
circuit
hit
although
rare
pediatr
includ
differenti
children
thrombocytopenia
receiv
heparin
product
present
uniqu
case
report
critic
ill
pediatr
patient
develop
hit
presenc
multiorgan
system
failur
discuss
challeng
encount
identif
altern
anticoagul
result
obes
caucasian
femal
child
present
facil
bilater
pulmonari
emboli
unclear
etiolog
initi
start
continu
heparin
infus
transit
enoxaparin
within
day
without
issu
five
day
enoxaparin
initi
patient
develop
acut
kidney
injuri
evidenc
increas
creatinin
attribut
biventricular
heart
failur
due
need
continu
renal
replac
therapi
crrt
transit
back
continu
heparin
infus
wherea
initi
platelet
count
transit
normal
develop
sever
thrombocytopenia
within
hour
due
intermedi
risk
low
suspicion
hit
antibodi
sent
posit
much
discuss
transit
argatroban
infus
titrat
accord
ptt
level
within
hour
platelet
count
normal
discharg
prescrib
apixaban
anticoagul
manag
conclus
hit
uncommon
present
pediatr
popul
given
rariti
often
delay
diagnosi
increas
risk
complic
bleed
stroke
limb
ischemia
even
diagnosi
suspect
proven
may
challeng
initi
altern
agent
limit
data
exist
pediatr
option
argatroban
remain
treatment
choic
patient
hit
experi
pediatr
patient
limit
dose
recommend
extrapol
adult
studi
anecdot
data
exist
use
bivalirudin
children
although
studi
primarili
focu
use
specif
cardiac
case
patient
case
choic
complic
renal
failur
case
studi
highlight
need
research
regard
identif
secondari
anticoagul
agent
use
pediatr
patient
hit
background
subcutan
panniculitislik
tcell
lymphoma
sptl
rare
form
nonhodgkin
lymphoma
character
infiltr
cytotox
tcell
subcutan
tissu
sptl
occur
adult
children
present
patient
popul
either
alphabeta
gammadelta
subtyp
patient
gammadelta
phenotyp
overal
poorer
surviv
although
exact
etiolog
unclear
interestingli
subtyp
sptl
present
secondari
hemophagocyt
lymphohistiocytosi
hlh
associ
wors
prognosi
current
standard
treatment
protocol
sptl
clinic
manag
includ
watch
wait
corticosteroidsimmunosuppress
chemotherapi
stem
cell
transplant
primari
object
compar
two
patient
diagnosi
respond
acut
therapi
perform
retrospect
chart
review
two
pediatr
patient
institut
diagnos
alphabeta
sptl
secondari
hlh
examin
present
treatment
cours
outcom
complet
brief
review
current
literatur
describ
treatment
outcom
sptl
secondari
hlh
result
two
patient
present
similar
manner
sign
symptom
hlh
subsequ
diagnos
alphabeta
sptl
biopsi
cutan
nodul
diffus
diseas
measur
pet
howev
demonstr
vastli
differ
acut
respons
therapi
one
patient
pretreat
system
glucocorticoid
receiv
definit
chemotherapi
toler
therapi
well
outpati
patient
start
system
chemotherapi
without
steroid
pretreat
develop
sever
cytokin
storm
character
hypotens
cardiac
dysfunct
multiorgan
failur
cytokin
elev
patient
achiev
complet
remiss
cr
treatment
chop
chemotherapi
remain
diseasefre
month
therapi
patient
present
sptl
secondari
hlh
propos
initi
treatment
antiinflammatori
anticytokin
therapi
decreas
even
prevent
possibl
life
threaten
cytokin
releas
result
cytotox
chemotherapi
background
congenit
dyserythropoiet
anemia
type
ii
cda
ii
rare
autosom
recess
disord
rare
present
neonat
period
iron
overload
often
occur
late
sequela
ineffect
erythropoiesi
intramedullari
hemolysi
object
report
novel
use
iron
chelat
infant
cda
ii
associ
sever
iron
overload
patient
former
infant
prenat
nonimmun
hydrop
transfusiondepend
fetal
anemia
present
persist
anemia
reticulocytopenia
hyperbilirubinemia
liver
dysfunct
hyperferritinemia
initi
ferritin
ngml
tibc
ugdl
transferrin
mgdl
bone
marrow
biopsi
show
trilineag
hematopoiesi
erythroid
dyspoiesi
character
binucl
latestag
precursor
genet
test
reveal
compound
heterozyg
missens
mutat
splice
site
mutat
gene
confirm
diagnosi
cda
ii
initi
liver
biopsi
reveal
mild
portal
fibrou
expans
abund
hepat
iron
deposit
ferritin
continu
increas
peak
ngml
along
liver
enzym
peak
alanin
aminotransferas
alt
ul
aspart
aminotransferas
ast
ul
ferriscan
show
elev
estim
liver
concentr
mgg
dri
tissu
repeat
liver
biopsi
month
later
show
giant
cell
hepat
worsen
mild
portal
fibrosi
hemosiderosi
addit
tissu
liver
iron
concentr
mcgg
dri
weight
cardiac
mri
reveal
mild
cardiac
iron
deposit
given
signific
degre
iron
overload
deferoxamin
use
reduc
hemosiderosi
liver
morbid
prepar
bone
marrow
transplant
patient
receiv
deferoxamin
mgkgday
iv
x
daysweek
three
month
without
clinic
signific
advers
event
blood
count
hepat
renal
function
monitor
weekli
without
abnorm
growth
paramet
liver
enzym
significantli
improv
receiv
chelat
therapi
noninvas
costeffect
method
serum
ferritin
level
monitor
monthli
gaug
respons
treatment
despit
receiv
blood
transfus
everi
week
serum
ferritin
decreas
ngml
liver
enzym
decreas
alt
ul
ast
ul
prior
bone
marrow
transplant
report
use
deferoxamin
patient
cda
ii
less
year
age
treatment
iron
overload
patient
toler
deferoxamin
well
without
signific
advers
event
organ
toxic
deferoxamin
may
welltoler
method
reduc
iron
burden
young
patient
ironload
patholog
background
low
grade
glioma
fusion
typic
favor
prognosi
infrequ
rate
high
grade
transform
low
rate
metastasi
even
lower
rate
extra
cn
metastasi
highgrad
transform
report
tumor
braf
mutat
delet
previous
report
glioma
fusion
case
report
highgrad
cn
malign
metastas
ventriculoperiton
vp
shunt
lowgrad
glioma
metastas
manner
extrem
rare
object
describ
uniqu
case
periton
tumor
dissemin
braf
fusion
posit
high
grade
neuroepitheli
tumor
child
vp
shunt
place
multifoc
braf
fusion
posit
low
grade
astrocytoma
result
eightyearold
male
initi
diagnos
multifoc
lowgrad
astrocytoma
hypothalamu
spinal
cord
initi
test
reveal
fusion
braf
mutat
initi
surgic
manag
includ
vp
shunt
resect
cervic
spinal
lesion
receiv
vincristin
carboplatin
follow
transit
vinblastin
given
new
thorac
metastat
lesion
month
therapi
month
diagnosi
scan
concern
diffus
leptomening
progress
diseas
new
intracrani
lesion
necessit
craniospin
radiat
follow
near
cr
present
month
later
acut
onset
abdomin
pain
ct
scan
reveal
periren
perirect
soft
tissu
mass
confirm
exploratori
laparotomi
periton
tumor
dissemin
high
grade
neuroepitheli
tumor
fusion
note
confirm
rtpcr
ident
seen
origin
cn
tumor
addit
find
includ
delet
chromosom
without
loss
heterozyg
homozyg
delet
found
fish
brisk
mitot
activ
justifi
highgrad
design
salvag
chemotherapi
consist
cycl
ice
subsequ
resolut
petavid
diseas
minim
perinephr
tissu
remain
given
favor
respons
surgic
resect
multipl
tissu
biopsi
perform
document
residu
activ
diseas
shunt
revis
start
trametinib
mainten
present
uniqu
case
periton
dissemin
high
grade
neuroepithei
tumor
fusion
multifoc
low
grade
astrocytoma
child
vp
shunt
rais
suspicion
tumor
metastasi
transform
higher
grade
malign
versu
two
distinct
diseas
may
indic
underli
cancer
predisposit
texa
children
hospit
houston
texa
unit
state
background
polycythemia
common
referr
hematolog
import
evalu
high
oxygen
affin
hemoglobinopathi
ensur
appropri
test
perform
earli
diagnosi
avoid
addit
test
procedur
year
old
mexican
femal
present
elev
hemoglobin
hematocrit
symptom
plethora
hand
feet
chest
pain
palpit
fatigu
confound
pictur
also
signific
menorrhagia
iron
defici
diagnos
rare
high
oxygen
affin
hemoglobin
new
mexico
variant
previous
describ
literatur
year
old
black
boy
object
patient
initi
present
age
hemoglobin
hematocrit
initi
work
consist
hemoglobin
electrophoresi
diagnos
sickl
cell
trait
cooximetri
panel
normal
erythropoietin
level
also
normal
lost
follow
reref
age
competit
basketbal
athlet
time
present
hemoglobin
hematocrit
erythropoietin
level
continu
normal
designmethod
cardiolog
consult
regard
chest
pain
palpit
normal
evalu
chest
xray
also
normal
bone
marrow
aspir
biopsi
perform
result
signific
mild
erythroid
hyperplasia
mild
reticulin
fibrosi
jak
mutat
von
hippel
lindau
bpgm
hereditari
erythrocytosi
mutat
includ
epor
mutat
analysi
sent
normal
test
mayo
clinic
rbc
oxygen
dissoci
return
low
normal
rang
subsequ
hemoglobin
electrophoresi
identifi
hemoglobin
variant
lead
beta
globin
gene
sequenc
result
patient
found
heterozyg
hemoglobin
new
mexico
hb
new
mexico
hba
evid
hb
evalu
patient
polycythemia
maintain
high
index
suspicion
high
affin
hemoglobinopathi
may
elimin
unnecessari
invas
test
patient
caution
use
use
hemoglobin
electrophoresi
test
sinc
hb
new
mexico
known
migrat
similarli
hb
hplc
minim
chang
may
detect
regular
laboratori
high
affin
hemoglobinopathi
report
signific
symptom
case
patient
complain
fatigu
occasion
palpit
plethora
hand
feet
need
follow
patient
possibl
attribut
symptomatolog
divya
keerthi
simon
chang
warren
alperstein
patricia
delgado
claudia
roja
ofelia
alvarez
matteo
trucco
univers
miami
jackson
memori
hospit
miami
florida
unit
state
background
improv
technolog
enabl
detect
previous
unidentifi
transloc
mutat
otherwis
unclassifi
sarcoma
one
mutat
corepressor
intern
tandem
duplic
bcoritd
allow
new
classif
bcor
posit
undifferenti
round
cell
sarcoma
urc
sarcoma
similar
appear
clear
cell
sarcoma
kidney
ccsk
potenti
repres
extraren
manifest
tumor
clinic
patholog
featur
ident
object
case
highlight
recombin
polymeras
chain
reaction
rtpcr
bcor
immunohistochem
stain
eas
diagnosi
rare
sarcoma
result
monthold
femal
present
right
side
presept
cellul
tempor
subcutan
mass
detect
multipl
subcutan
nodul
exam
rais
concern
malign
admit
evalu
two
subcutan
mass
abdomen
cutan
mass
leg
back
shoulder
cheek
submandibular
area
lack
spontan
lower
limb
movement
bilater
clonu
imag
confirm
multipl
mass
throughout
bodi
includ
paravertebr
area
bilater
adren
gland
left
kidney
muscl
upper
lower
extrem
initi
differenti
includ
neuroblastoma
infantil
myofibromatosi
rhabdomyosarcoma
atyp
present
renal
tumor
howev
synaptophysin
chromogranin
stain
neg
standard
immunohistochemistri
tumor
could
broadli
classifi
undifferenti
sarcoma
maintain
diagnost
challeng
use
rtpcr
set
morpholog
primit
round
cell
neoplasm
strong
bcor
express
two
extern
institut
simultan
diagnos
tumor
bcorurc
primari
lesion
unknown
potenti
may
aros
kidney
bcorurc
heterogen
histolog
tumor
cell
appear
monomorph
nest
cell
separ
septa
uniform
nuclei
frequent
orphan
anni
eye
appear
spars
cytoplasm
cell
diagnosi
made
sole
evalu
nonspecif
histolog
rtpcr
use
genet
abnorm
undifferenti
sarcoma
narrow
differenti
bcor
immunohistochem
stain
provid
context
bcor
signific
diagnost
valu
given
sensit
specif
urc
anoth
potenti
marker
includ
fusion
occur
smaller
subset
case
requir
studi
rtpcr
help
classifi
tumor
lead
diagnosi
rare
undifferenti
sarcoma
bcor
overexpress
technolog
benefici
avail
limit
access
improv
earlier
identif
treatment
may
possibl
maxim
chanc
posit
outcom
background
hematohidrosi
rare
condit
mimic
bleed
disord
case
present
ooz
blood
ting
fluid
variou
site
like
eye
ear
nose
skin
etc
report
caus
condit
stress
fear
physic
activ
psycholog
disord
condit
selflimit
nt
affect
gener
condit
patient
may
contribut
psychosoci
problem
may
increas
stress
anxieti
condit
need
promptli
treat
test
respons
diseas
associ
headach
propranolol
treatment
designmethod
case
femal
patient
year
old
offspr
non
consanguin
marriag
admit
recurr
episod
ooz
blood
ting
fluid
eye
ear
nose
month
admiss
ml
orific
last
minut
subsid
spontan
could
involv
site
simultan
site
number
attack
time
per
day
gradual
increas
time
per
day
later
patient
develop
bleed
attack
umbilicu
attack
aggrav
stress
physic
activ
decreas
rest
sleep
condit
associ
sever
headach
involv
whole
head
throb
natur
gradual
onset
increas
physic
activ
reliev
analges
condit
associ
vomit
blur
diminut
vision
ocular
pain
eye
discolor
earach
tinnitu
diminut
hear
form
discharg
eye
ear
nose
histori
ecchymot
patch
bleed
orific
blood
product
transfus
histori
trauma
drug
intak
fever
rash
symptom
system
affect
past
histori
recurr
attack
epistaxi
two
oper
done
pass
without
remark
bleed
similar
condit
famili
physic
examin
free
evid
psycholog
problem
complet
blood
count
coagul
profil
platelet
function
factor
ct
brain
normal
ooz
fluid
patient
analyz
show
compon
blood
result
case
start
oral
propranolol
base
use
similar
case
literatur
frequenc
attack
headach
reduc
stop
month
treatment
nt
recur
stoppag
propranolol
propranolol
treat
condit
success
investig
need
determin
link
condit
sever
headach
case
suffer
background
wilm
tumor
common
renal
solid
tumor
childhood
deriv
primit
metanephr
cell
locat
kidney
primari
extraren
wilm
tumor
erwt
extrem
rare
estim
compris
wilm
tumor
despit
similar
histolog
appear
intraren
erwt
differ
embryolog
tissu
origin
erwt
aris
primit
mesonephr
pronephr
origin
therefor
develop
anywher
along
craniocaud
migrat
pathway
primit
tissu
often
retroperiton
inguinalgenit
lumbosacralpelv
mediastin
tumor
typic
stage
treat
per
nation
wilm
tumor
studi
nwt
guidelin
definit
stage
ii
greater
due
locat
beyond
kidney
border
base
case
report
literatur
outcom
erwt
compar
renal
wilm
tumor
local
recurr
rate
twoyear
eventfre
surviv
report
first
case
stage
iii
testicular
extraren
wilm
tumor
male
intrabdomin
undescend
testi
underw
complet
surgic
excis
follow
chemotherapi
inguin
radiat
result
full
term
old
male
underw
orchipexi
undescend
left
testicl
testicl
note
grossli
abnorm
peasiz
thicken
tissu
adher
upper
pole
separ
mass
outsid
scrotum
superior
epididymi
mass
remov
patholog
demonstr
wilm
tumor
favor
histolog
neg
margin
ct
imag
chest
abdomen
pelvi
neg
primari
renal
tumor
local
residu
diseas
patholog
lymph
node
enlarg
distant
metastas
tumor
classifi
per
nwt
stage
iii
due
tumor
remov
multipl
piec
patient
complet
treatment
vincristin
doxorubicin
dactinomycin
per
cgi
left
inguin
radiat
current
month
therapi
without
clinic
radiograph
evid
recurr
diseas
primari
erwt
extrem
rare
malign
neoplasm
associ
challeng
diagnosi
stage
treatment
base
case
report
literatur
outcom
similar
intraren
wilm
tumor
four
pediatr
paratesticular
wilm
tumor
report
literatur
best
knowledg
first
case
stage
iii
testicular
wilm
tumor
success
treat
chemotherapi
radiat
erwt
nwt
guidelin
stage
treatment
appli
evalu
kidney
exclud
intraren
primari
tumor
background
patient
yo
f
esrd
secondari
atyp
hu
versu
ttp
present
thrombot
microangiopathi
aki
thrombocytopenia
anemia
live
unrel
donor
kidney
transplant
patient
initi
downtrend
creatinin
postop
day
hematolog
consult
increas
ldh
drop
platelet
peripher
smear
notabl
absenc
schistocyt
yet
biopsi
kidney
reveal
microthrombi
patient
diagnos
thrombot
microangiopathi
plasmapharesi
initi
day
time
ms
r
note
significantli
elev
creatinin
plasmapharesi
yield
correct
lab
signific
bruis
develop
patient
start
eculizimab
plasmapharesi
stop
shortli
creatinin
anemia
thrombocytopenia
correct
level
discharg
overal
patient
found
progress
anemia
thrombocytopenia
increas
creatinin
ldh
concern
atyp
hu
despit
absenc
schistocyt
peripher
smear
respond
well
eculizimab
correct
hematolog
chang
induct
discharg
eculizimab
continu
respond
normal
platelet
count
hemoglobin
differenti
light
patient
thrombot
microangiopathi
thrombocytopenia
also
includ
ttp
yet
remain
normal
dic
unlik
given
normal
fibrinogen
level
ddimer
object
present
atyp
hu
vs
ttp
discuss
eculizumab
treatment
atyp
hu
highlight
atyp
present
ill
transplant
patient
result
despit
absenc
schistocyt
smear
pt
diagnos
atyp
hu
base
present
fail
plasmapharesi
respond
well
eculizumab
though
present
abnorm
respons
antibodi
block
complement
cascad
suggest
experienc
complementmedi
process
rare
document
case
literatur
atyp
hu
without
schistocyt
hemolyt
urem
syndrom
hu
character
hemolyt
anemia
thrombocytopenia
acut
kidney
injuri
atyp
hu
diagnosi
exclus
due
common
etiolog
shiga
toxin
among
atyp
caus
complementmedi
form
caus
antibodi
complement
factor
addit
plasmapharesi
renal
transplant
support
care
mainstay
treatment
atyp
hu
eculizumab
antibodi
block
complement
termin
cascad
case
describ
patient
uniqu
diagnos
atyp
hu
without
schistocyt
smear
secondli
respond
eculizumab
unremark
gene
studi
final
case
highlight
transplant
patient
often
uniqu
present
nicklau
children
hospit
miami
florida
unit
state
background
synovi
sarcoma
spindl
cell
tumor
categor
soft
tissu
sarcoma
chromosom
transloc
x
lead
fusion
protein
uniqu
sarcoma
slow
grow
tumor
common
recurr
often
present
evid
metastat
diseas
resect
feasibl
neoadjuv
adjuv
chemotherapi
recommend
metastasi
carri
unfavor
prognosi
given
synovi
sarcoma
histor
respond
well
chemotherapi
trabectedin
welltoler
alkyl
agent
current
indic
treatment
liposarcoma
leiomyosarcoma
present
male
metastat
synovi
sarcoma
lung
progress
refractori
chemotherapi
administ
trabectedin
form
palli
chemotherapi
signific
clinic
radiograph
respons
designmethod
pubm
search
done
search
terminolog
includ
synovi
sarcoma
trabectedin
paper
relev
case
select
literatur
review
male
patient
present
larg
right
axillari
mass
initi
imag
show
heterogen
multisept
mass
invad
subscapulari
tere
major
muscl
along
innumer
lung
nodul
biopsi
confirm
diagnosi
monophas
synovi
sarcoma
patient
start
protocol
arst
ifosfomid
mesna
doxorubicin
complet
cycl
follow
radic
resect
session
radiat
due
progress
diseas
multipl
chemotherapi
regimen
tri
includ
topotecan
cyclophosphamid
protocol
advl
lorvotuzumab
pazopanib
imag
chest
continu
show
signific
progress
metastasi
patient
clinic
statu
deterior
worsen
respiratori
statu
requir
oxygen
therapi
inabl
ambul
start
trabectedin
palli
care
cycl
treatment
patient
longer
requir
oxygen
ambul
without
assist
radiolog
imag
show
signific
reduct
number
size
lung
nodul
trabectedin
recent
approv
alkyl
agent
manag
sarcoma
resist
first
line
treatment
respons
synovi
sarcoma
scarc
document
pediatr
popul
epidemiolog
place
common
age
group
young
adult
children
case
open
door
consider
use
trabectedin
pediatr
patient
metastat
synovi
sarcoma
background
xlink
gene
play
critic
role
hematopoiesi
mutat
gene
associ
variou
blood
disord
includ
diamond
blackfan
anemia
cytopenia
congenit
dyserythropoietc
anemia
acut
megakaryoblast
leukemia
report
patient
macrocyt
anemia
platelet
dysfunct
carri
novel
mutat
report
result
male
complex
medic
histori
includ
prematur
week
dysmorph
featur
global
development
delay
hyperinsulin
hypogonadotrop
hypogonad
growth
hormon
defici
micropeni
failur
thrive
patent
ductu
arteriosu
statu
post
ligat
sever
hypotonia
refer
hematolog
month
old
resolv
transient
thrombocytopenia
macrocyt
anemia
sinc
month
age
chromosom
microarray
show
chromosom
delet
gene
nt
famili
histori
diamond
blackfan
anemia
dba
despit
mom
mutat
diagnos
dba
lab
workup
show
mild
macrocyt
anemia
hgb
gdl
mcv
normal
inappropri
low
reticulocyt
count
normal
white
blood
cell
platelet
count
hgf
erythroid
ada
eugm
hgb
elev
abnorm
prolong
closur
time
adp
epinephrin
low
von
willebrand
antigen
ristocetin
cofactor
activ
sever
pancreat
insuffici
bone
marrow
biopsi
show
normocellular
marrow
trilineag
hematopoiet
matur
without
ring
sideroblast
sinc
mother
gene
mutat
matern
lab
done
show
evid
macroytosi
anemia
diagnosi
dba
question
whole
exom
sequenc
identifi
pathogen
sequenc
chang
code
region
gene
detect
mutat
report
variant
uncertain
signific
mother
share
mutat
asymptomat
may
affect
sinc
ii
xlink
father
nt
harbor
mutat
conclus
gene
encod
zinc
finger
dna
bind
hematopoiet
transcript
factor
import
erythroid
differenti
mutat
report
literatur
novel
variant
mutat
might
contribut
patient
clinic
pictur
studi
warrant
confirm
mutat
pathogen
sequenc
chang
alexand
boucher
tomoyuki
mizuno
alexand
vink
greg
tiao
stuart
goldstein
jame
geller
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
hepatoblastoma
hb
common
pediatr
primari
hepat
malign
associ
specif
congenit
syndrom
recent
chronic
kidney
diseas
genitourinari
anomali
link
hb
cisplatin
key
chemotherapeut
agent
treat
hb
renal
clearanc
toxic
profil
limit
use
endstag
renal
diseas
esrd
object
use
institut
case
seri
present
data
use
cisplatin
hb
dialysisdepend
esrd
defin
recommend
dose
futur
use
designmethod
chart
review
patient
concurr
hb
esrd
dialysi
treat
cisplatin
institut
undertaken
demograph
data
diagnost
histori
tumor
patholog
alpha
fetoprotein
afp
hear
assess
dose
schema
treatment
outcom
therapyrel
toxic
review
total
cisplatin
level
collect
time
point
within
day
infus
free
cisplatin
level
also
collect
infus
dialys
cisplatin
level
pk
paramet
gener
use
bayesian
estim
publish
popul
pk
model
priori
inform
result
three
patient
meet
criteria
identifi
low
risk
nonmetastat
resect
diseas
present
underw
upfront
resect
congenit
renal
anomali
esrd
prior
hb
diagnosi
cisplatin
infus
given
hour
follow
hour
later
hemodialysi
patient
receiv
cisplatin
children
oncolog
group
weightbas
dose
mgkg
patient
receiv
bodi
surfac
areabas
dose
cycl
requir
second
dose
reduct
cycl
due
prolong
cisplatin
exposur
total
area
curv
averag
seven
evalu
cycl
earli
sensorineur
hear
loss
hz
hear
loss
patient
identifi
mild
toxic
also
includ
grade
emesi
grade
neutropenia
thrombocytopenia
median
rang
clearanc
volum
distribut
steadyst
elimin
halflif
termin
phase
total
platinum
kg
kg
hour
respect
patient
receiv
cycl
rapid
afp
normal
patient
requir
addit
cycl
like
second
primari
hb
year
initi
therapi
cisplatin
use
success
pediatr
patient
esrd
hemodialysi
treat
hb
minim
morbid
use
standard
mgkgbase
dose
mgkg
achiev
pharmacolog
appropri
cisplatin
exposur
background
treatment
immun
thrombocytopenia
itp
group
rescu
mainten
therapi
often
reserv
patient
bleed
sever
thrombocytopenia
improv
qualiti
life
splenectomi
consid
one
invas
definit
treatment
success
rate
treatment
itp
difficult
set
previou
treatment
immun
modul
patient
immunocompromis
candid
splenectomi
object
present
interest
case
patient
autoimmun
diseas
present
sever
thrombocytopenia
unrespons
rescu
therapi
requir
emerg
splenectomi
set
acut
intracrani
hemorrhag
ich
year
old
femal
histori
juvenil
dermatomyos
present
fine
purpur
rash
extrem
wet
purpura
platelet
count
l
bone
marrow
evalu
time
consist
itp
cyclosporin
plaquenil
dermatomyos
platelet
fail
increas
three
dose
intraven
immunoglobulin
high
dose
steroid
follow
two
week
cours
oral
prednison
eltrombopag
present
persist
sever
thrombocytopenia
l
anemia
gdl
lower
gi
bleed
start
amicar
novoseven
rituximab
given
platelet
transfus
improv
bleed
subsequ
develop
subdur
hematoma
midlin
shift
surgeri
perform
emerg
open
splenectomi
concurr
continu
platelet
transfus
result
monitor
close
post
oper
due
ich
transfus
maintain
platelet
greater
l
week
postop
normal
platelet
count
transfus
medic
stop
within
three
day
discharg
repres
eight
day
later
abdomin
pain
thrombocytosi
found
portal
vein
splenic
vein
mesenter
vein
thrombosi
start
lovenox
therapi
admit
monitor
due
histori
ich
unknown
whether
patient
underli
immun
dysregul
histori
treatment
immunosuppress
medic
may
contribut
unrespons
multipl
therapeut
agent
addit
signific
bleed
allow
us
fulli
evalu
respons
second
tier
therapi
add
scarciti
literatur
itp
respons
pediatr
patient
autoimmun
diseas
may
support
aggress
therapi
upfront
patient
background
multiviscer
organ
transplant
involv
concurr
transplant
stomach
pancrea
liver
intestin
splenectomi
classic
use
pediatr
popul
infant
intestin
failur
disord
affect
foregut
integr
data
demonstr
efficaci
adult
lowgrad
abdomin
malign
tradit
use
hepatocellular
carcinoma
treatment
describ
uniqu
pediatr
case
multiviscer
organ
transplant
definit
therapi
refractori
fibrolamellar
hepatocellular
carcinoma
adolesc
male
year
old
male
present
histori
fibrolamellar
hepatocellular
carcinoma
tumor
invas
portal
vein
sever
portal
hypertens
complic
bleed
esophag
varic
hypersplen
two
treatment
radioembol
without
signific
respons
complet
six
cycl
tradit
chemotherapi
combin
sorafenib
resolut
petavid
minim
decreas
tumor
size
continu
portal
hypertens
sinc
diseas
remain
rel
stabl
year
evalu
list
multiviscer
organ
transplant
approxim
year
month
diagnosi
underw
en
bloc
liver
pancrea
stomach
small
bowel
colon
transplant
splenectomi
singl
lymph
node
posit
malign
time
resect
addit
expect
posttranspl
complic
also
develop
skin
acut
graft
versu
host
diseas
week
transplant
treat
success
thymoglobulin
cours
clinic
improv
back
baselin
activ
level
full
oral
feed
within
month
posttransplant
three
six
month
posttransplant
concern
relaps
hepatocellular
carcinoma
comprehens
imag
evalu
maintain
protocol
immunosuppress
posttranspl
support
present
first
known
case
success
multiviscer
organ
transplant
treatment
refractori
pediatr
fibrolamellar
hepatocellular
carcinoma
background
hematohidrosi
rare
disord
present
spontan
excret
whole
blood
intact
skin
mucosa
diagnosi
base
clinic
observ
occurr
proven
presenc
erythrocyt
blood
compon
without
abnorm
account
phenomenon
exist
literatur
scarc
consist
primarili
case
studi
report
describ
bleed
facial
site
around
eye
ear
nose
avail
literatur
suggest
anxieti
physic
emot
stress
reaction
common
incit
event
littl
evid
exist
regard
ideal
therapeut
approach
howev
propranolol
use
success
reduc
bleed
frequenc
sever
multipl
case
report
specif
genet
etiolog
elucid
famili
case
previous
report
present
pair
halfsibl
present
spontan
cutan
mucos
bleed
two
year
age
report
preliminari
result
propranolol
therapi
tanzania
month
age
becam
ill
develop
spontan
bleed
ear
nose
scalp
continu
frequent
bleed
episod
usual
relat
ill
physic
distress
bleed
diathesi
workup
unremark
howev
episod
sever
enough
requir
transfus
patient
subsequ
diagnos
hiv
hepat
b
presum
acquir
via
unscreen
blood
product
transfus
patient
b
infant
femal
born
mother
patient
differ
father
healthi
two
month
age
develop
spontan
bleed
hairlin
eyelid
ear
genitalrect
area
bleed
episod
nearli
alway
associ
irrit
cri
extens
coagul
workup
unremark
result
propranolol
therapi
start
patient
titrat
goal
mgkgday
patient
frequenc
durat
bleed
episod
significantli
improv
patient
b
continu
milder
occasion
bleed
episod
eye
ear
scalp
significantli
less
discomfort
irrit
episod
conclus
knowledg
prior
report
involv
two
relat
patient
hematohidrosi
case
seri
suggest
may
genet
predisposit
yet
identifi
propranolol
shown
effect
reduc
symptom
frequenc
sever
background
glioma
common
central
nervou
system
tumor
children
classifi
differ
grade
base
genotyp
idh
braf
tsc
etc
lowgrad
glioma
oligodendroglioma
astrocytoma
mix
oligoastrocytoma
classifi
grade
ii
molecular
level
alter
case
report
focus
braf
mutat
braf
member
raf
famili
serinethreonin
protein
kinas
play
import
role
cell
surviv
prolifer
termin
differenti
object
discuss
two
case
dabrafenib
braf
kinas
inhibitor
util
manag
glioma
case
focu
use
dabrafenib
late
versu
earli
diseas
cours
designmethod
patient
jl
year
old
femal
diagnos
lowgrad
glioneuron
tumor
metastat
lesion
brain
jl
treat
chemotherapi
radiat
surgic
resect
despit
treatment
patient
diseas
progress
develop
lower
extrem
dysfunct
urinari
incontin
poor
truncal
control
hydrocephalu
dabrafenib
start
braf
mutat
confirm
patient
lg
year
old
femal
present
novemb
left
facial
upper
extrem
weak
ct
mri
scan
demonstr
mix
solid
cystic
lesion
extend
optic
chiasm
hypothalamu
right
thalamu
posterior
basal
ganglia
addit
involv
right
cerebr
peduncl
neurosurg
intervent
undertaken
dabrafenib
start
braf
mutat
confirm
result
patient
jl
mri
scan
demonstr
improv
spine
diminish
area
enhanc
along
thecal
margin
decreas
volum
enhanc
within
trigemin
plate
cistern
resolut
ependym
enhanc
within
right
ventricl
patient
recent
mri
exhibit
diseas
progress
head
spine
jl
shown
improv
clinic
sinc
start
dabrafenib
patient
lg
shown
improv
strength
recent
mri
brain
shown
resolut
enhanc
along
surgic
resect
margin
decreas
hyperintens
along
inferomedi
aspect
right
basal
ganglia
new
enhanc
conclus
low
grade
glioma
alter
person
qualiti
life
even
lead
life
threaten
complic
often
standard
chemotherapi
radiat
surgeri
nt
prevent
complic
genet
analysi
help
clinician
target
therapi
toward
certain
mutat
braf
dabrafenib
shown
decreas
tumor
burden
earli
util
therapi
help
prevent
morbid
mortal
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
copper
essenti
cofactor
enzymat
reaction
essenti
proper
hematolog
skelet
neurolog
vascular
function
copper
requir
children
age
mgday
readili
acquir
typic
diet
copper
defici
known
occur
patient
rare
xlink
mutat
older
individu
gastrointestin
bypass
surgeri
howev
rare
report
condit
object
highlight
individu
autism
spectrum
disord
development
delay
limit
dietari
repertoir
risk
copper
defici
thu
high
index
suspicion
must
exist
order
diagnos
disord
designmethod
yo
boy
prior
diagnosi
global
development
delay
oral
avers
present
slowli
progress
fatigu
weak
gait
instabl
weight
loss
longstand
feed
difficulti
refractori
intens
feed
program
daili
diet
consist
milk
individu
serv
butterscotch
pud
ironday
initi
complet
blood
count
demonstr
white
blood
cell
count
absolut
neutrophil
count
hemoglobin
mean
corpuscular
volum
reticulocyt
count
platelet
count
review
peripher
blood
smear
reveal
microcyt
hypochrom
red
cell
without
mark
fragment
anisopoikilocytosi
ring
sideroblast
morpholog
abnorm
leukocyt
platelet
iron
studi
demonstr
ferritin
total
iron
bind
capac
iron
satur
evid
folat
defici
blood
loss
addit
evalu
reveal
serum
copper
level
rang
cerulosplasmin
rang
result
diagnosi
copper
defici
made
patient
promptli
began
cours
parenter
copper
replet
receiv
iv
copper
x
day
weekli
intraven
infus
given
malnutrit
gtube
place
begin
oral
copper
replet
enter
nutrit
within
week
copper
level
improv
well
blood
count
unfortun
although
blood
count
copper
level
normal
neurolog
statu
remain
old
baselin
although
made
gain
gross
fine
motor
abil
conclus
acquir
copper
defici
pediatr
popul
rare
event
given
hematolog
neurolog
consequ
prompt
recognit
treatment
import
patient
clinic
cours
demonstr
need
high
index
suspicion
concomit
nutrit
defici
routin
evalu
iron
folat
background
lymphoepitheliomalik
thymic
carcinoma
lelc
rare
aggress
neoplasm
high
rate
invas
metastasi
recurr
known
cur
therapi
metastat
lelc
report
case
male
present
metastat
ebv
posit
lelc
site
diseas
includ
larg
primari
anterior
mediastin
mass
metastas
hilar
lymph
node
lung
liver
initi
treat
cisplatin
follow
mediastin
radiat
partial
respons
therapi
end
therapi
scan
show
diseas
progress
lung
liver
hilar
supraclavicular
axillari
lymph
node
object
molecularli
target
therapi
tailor
patient
genet
profil
offer
novel
approach
obtain
improv
surviv
outcom
designmethod
patient
enrol
precis
medicin
trial
molecularguid
therapi
treatment
patient
relaps
refractori
childhood
cancer
studi
tumornorm
whole
exom
sequenc
tumor
rna
sequenc
perform
molecular
report
detail
result
genom
gene
express
analysi
gener
treatment
plan
design
within
molecular
tumor
board
compris
oncologist
pharmacist
genomicist
molecular
biologist
domain
expertis
result
exom
sequenc
reveal
somat
code
point
mutat
structur
mutat
focal
copi
number
chang
transloc
candid
somat
driver
mutat
includ
well
kit
gene
previous
implic
thymic
carcinoma
rna
express
analysi
demonstr
aberr
activ
biolog
pathway
includ
overexpress
kit
tym
dhfr
molecular
tumor
board
select
combin
pemetrex
day
day
cycl
imatinib
mg
daili
vorinostat
mg
day
day
cycl
admit
herp
zoster
infect
imatinib
discontinu
order
reduc
risk
herp
zoster
recurr
imag
cycl
show
complet
metabol
respons
fdg
pet
partial
respons
ct
size
criteria
decemb
patient
receiv
cycl
pemetrex
vorinostat
scan
decemb
show
increas
size
metabol
activ
two
right
lower
lobe
pulmonari
nodul
new
site
diseas
imatinib
restart
background
system
lupu
erythematosu
sle
chronic
autoimmun
diseas
affect
multipl
organ
system
associ
mani
differ
autoantibodi
patient
present
vagu
constitut
symptom
includ
fever
rash
fatigu
weight
loss
variou
hematolog
manifest
sle
includ
anemia
chronic
diseas
leukopenia
autoimmun
hemolyt
anemia
aiha
idiopath
thrombocytopen
purpura
itp
present
sign
sle
evan
syndrom
es
diseas
character
itp
aiha
rare
hematolog
manifest
sle
neurofibromatosi
rel
common
neurocutan
disord
patient
risk
develop
benign
malign
tumor
associ
autoimmun
disord
includ
sle
remain
rare
object
case
literatur
patient
combin
sle
case
patient
sle
es
result
caucasian
femal
present
two
month
vagin
bleed
weight
loss
petechia
exam
remark
petechia
au
lait
macul
laboratori
find
show
sever
anemia
thrombocytopenia
receiv
blood
platelet
transfus
stabil
bone
marrow
aspir
perform
rule
malign
neg
base
presenc
thrombocytopenia
posit
coomb
test
autoimmun
process
es
consid
screen
test
sle
reveal
posit
antinuclear
antidoubl
strand
dna
antibodi
well
low
complement
receiv
intraven
immunoglobulin
methylprednisolon
eventu
vagin
bleed
slow
count
recov
begin
sle
therapi
hydroxychloroquin
azathioprin
due
presenc
au
lait
macul
exam
genet
evalu
perform
patient
also
diagnos
date
seven
case
sle
report
literatur
two
pediatr
case
report
combin
sle
es
conclus
es
rare
hematolog
manifest
sle
initi
present
diseas
one
larg
studi
estim
childhoodonset
sle
case
observ
es
screen
sle
consid
es
patient
even
absenc
typic
clinic
find
associ
sle
rare
describ
whether
associ
reflect
causal
relationship
coincident
need
investig
lube
ped
blood
cancer
univers
california
san
diego
la
jolla
california
unit
state
background
high
grade
glioma
hgg
poor
outcom
adult
children
extraneur
metastas
rare
hgg
poorli
character
small
case
seri
adult
isol
case
report
pediatr
genom
data
previous
publish
children
hgg
develop
extraneur
metastas
object
object
describ
natur
histori
two
children
hgg
boni
extraneur
metastas
compar
clinic
characterist
well
whole
exom
sequenc
data
tumor
inform
would
suggest
similar
patient
monitor
close
extraneur
metastasi
may
benefit
system
therapi
designmethod
present
case
seri
two
patient
present
hgg
develop
boni
metastas
less
six
month
initi
diagnosi
patient
molecular
profil
whole
exom
sequenc
we
first
patient
male
tumor
found
left
later
ventricl
invad
fornic
hypothalamu
left
midbrain
subtot
resect
boni
metastasi
found
month
diagnosi
die
month
diagnosi
initi
receiv
radiat
follow
nivolimuab
second
femal
tectalpin
tumor
multipl
spinal
cord
metastas
subtot
resect
develop
boni
metastasi
month
diagnosi
die
month
diagnosi
histolog
diagnosi
pineoblastoma
revis
hgg
whole
exom
sequenc
receiv
craniospin
radiat
follow
chemotherapi
per
cisplatin
vincristin
cyclophosphamid
cycl
fail
respond
satisfactorili
therapi
we
tumor
perform
find
consist
hgg
treatment
transit
temodar
lomustin
hgg
diagnosi
given
ongo
progress
diseas
despit
therapi
well
trial
nivolumab
everolimu
vorinostat
neither
patient
extraneur
metastasi
present
tumor
whole
exom
sequenc
identifi
mutat
tumor
also
addit
known
mutat
associ
hgg
overlap
mutat
case
seri
repres
first
descript
genet
alter
pediatr
hgg
patient
develop
extraneur
metastas
common
mutat
pediatr
midlin
hgg
especi
dipg
associ
aggress
diseas
associ
extraneur
metastasi
prior
seri
background
deferiproneinduc
agranulocytosi
well
known
albeit
rare
side
effect
drug
incid
agranulocytosi
vari
milder
neutropenia
report
patient
treat
deferipron
deferasirox
unknown
caus
complic
clinic
trial
post
market
side
effect
monitor
studi
possibl
correl
differ
risk
factor
develop
agranulocytosi
unfortun
studi
directli
address
special
risk
commun
background
ethnic
neutropenia
like
oman
object
report
incid
neutropenia
among
omani
children
b
thalassemia
use
differ
iron
chelat
designmethod
retrospect
studi
conduct
patient
yearold
b
thalassemia
treat
differ
iron
chelat
electron
patient
record
review
detect
episod
neutropenia
either
mild
anc
moder
anc
sever
agranulocytosi
anc
data
collect
includ
sex
age
person
famili
histori
ethnic
neutropenia
iron
chelat
agent
infect
complic
manag
outcom
detail
clinic
laboratori
radiolog
inform
report
patient
develop
lifethreaten
agranulocytosi
among
young
patient
b
thalassemia
treat
squh
neutropenia
report
patient
sever
neutropenia
encount
occas
patient
deferipron
includ
episod
agranulocytosi
defersirox
combin
chelat
chelat
moder
neutropenia
encount
patient
occas
deferipron
deferasirox
combin
chelat
episod
chelat
mild
neutropenia
preval
encount
patient
occas
deferipron
defersirox
combin
chelat
chelat
patient
expos
deferipron
patient
neutropenia
higher
previous
report
deferiproneinduc
agranulocytosi
encount
patient
three
life
threaten
complic
one
patient
develop
pneumonia
complic
ruptur
pulmonari
arteri
aneurysmmass
hemoptysi
recov
fulli
cathet
embol
second
facial
cellul
treatment
gcsf
complic
frequent
ventricular
extrasystol
third
sepsi
dissemin
herp
simplex
requir
admiss
icu
inotrop
support
commun
background
ethnic
neutropenia
neutropenia
common
encount
among
thalassem
patient
chelat
therapi
care
monitor
anc
ration
choicemodif
chelat
agent
requir
optim
manag
iron
overload
avoid
life
threaten
complic
object
case
control
studi
aim
evalu
systol
diastol
cardiac
function
group
children
ti
non
transfus
group
group
receiv
earli
regular
blood
transfus
compar
healthi
control
designmethod
thirteen
regularli
transfus
patient
ti
mean
age
year
compar
eight
patient
nontransfus
minim
transfus
rbc
transfusionyear
mean
age
year
healthi
control
mean
age
year
clinic
paramet
standard
echocardiograph
tissu
doppler
imag
tdi
compar
result
young
nontransfus
ti
patient
statist
signific
higher
peak
late
diastol
veloc
left
ventricular
inflow
doppler
mitral
valv
wave
durat
pulmonari
vein
wave
durat
ratio
pulmonari
vein
sd
veloc
ratio
compar
transfus
group
p
valu
respect
addit
lower
ea
ratio
mitral
valv
inflow
larger
left
atrial
aortic
diamet
ratio
compar
control
group
p
valu
respect
diamet
right
left
outflow
tract
significantli
larger
non
transfus
group
trend
higher
cardiac
index
compar
transfus
group
systol
function
similar
studi
group
none
patient
evid
pulmonari
hypertens
young
patient
ti
receiv
earli
regular
blood
transfus
normal
systol
function
diastol
function
assess
reveal
indic
abnorm
relax
left
ventricl
non
transfus
group
indic
diastol
dysfunct
abnorm
affect
multipl
diastol
function
paramet
give
indic
chang
clinic
signific
statist
signific
increas
diamet
outflow
tract
like
attribut
high
cardiac
output
statu
nontransfus
ti
patient
trend
higher
cardiac
index
find
support
earli
commenc
regular
blood
transfus
therapi
ti
patient
prevent
seriou
cardiac
complic
adult
life
background
sustain
studi
crizanlizumab
mgkg
significantli
reduc
frequenc
scpc
versu
placebo
vs
p
increas
time
first
ontreat
scpc
vs
month
p
patient
sickl
cell
diseas
scd
evalu
time
first
scpc
sustain
studi
subgroup
likelihood
experienc
scpc
durat
trial
use
post
hoc
analys
designmethod
sustain
random
doubleblind
placebocontrol
phase
studi
inclus
criteria
scd
patient
age
year
scpc
previou
month
concomit
hydroxyurea
use
permit
month
stabl
dose
month
patient
random
receiv
intraven
crizanlizumab
mgkg
mgkg
placebo
studi
treatment
administ
day
everi
week
week
final
assess
week
median
time
first
scpc
first
dose
summar
crizanlizumab
mgkg
placebo
subgroup
scpc
previou
month
scd
genotyp
hydroxyurea
use
baselin
hazard
ratio
hr
crizanlizumab
mgkg
versu
placebo
calcul
base
cox
regress
analysi
treatment
covari
descript
statist
use
summar
frequenc
patient
scpc
eventfre
durat
studi
prior
scpc
event
scd
genotyp
hydroxyurea
use
baselin
patient
receiv
crizanlizumab
mgkg
receiv
placebo
meaning
delay
time
first
scpc
crizanlizumab
mgkg
versu
placebo
observ
entir
studi
popul
effect
present
scpc
subgroup
largest
treatment
differ
observ
hbss
scd
versu
genotyp
vs
month
hr
patient
take
hydroxyurea
experienc
scpc
previou
year
time
first
onstudi
scpc
longer
crizanlizumab
mgkg
versu
placebo
vs
month
hr
greater
proport
patient
treat
crizanlizumab
mgkg
scpc
eventfre
versu
placebo
analyz
subgroup
one
third
patient
take
hydroxyurea
treat
crizanlizumab
mgkg
scpc
eventfre
studi
versu
placebo
possibl
suggest
addit
effect
crizanlizumab
mgkg
clinic
meaning
delay
time
first
scpc
increas
likelihood
scpcfree
versu
placebo
subgroup
investig
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
shwachmandiamond
syndrom
sd
inherit
marrow
failur
syndrom
associ
increas
risk
myelodysplasia
md
acut
myeloid
leukemia
aml
object
multiinstitut
retrospect
studi
investig
clinic
featur
treatment
outcom
sd
patient
develop
md
aml
central
patholog
review
designmethod
nine
individu
present
aml
male
femal
male
femal
md
male
femal
one
male
isol
persist
somat
mutat
one
md
patient
progress
aml
median
age
year
diagnosi
md
rang
rang
aml
rang
complex
cytogenet
note
aml
case
one
normal
cytogenet
complex
clonal
cytogenet
abnorm
note
patient
clonal
abnorm
md
patient
follow
avail
aml
patient
deceas
receiv
chemotherapi
intent
proceed
hematopoiet
stem
cell
transplant
hsct
four
fail
achiev
remiss
die
diseas
without
proceed
transplant
one
patient
proceed
hsct
without
prior
chemotherapi
four
six
transplant
subject
die
relaps
diseas
treatment
relat
mortal
larg
infecti
gvhd
sole
surviv
aml
patient
normal
cytogenet
achiev
remiss
chemotherapi
underw
hsct
separ
stem
cell
infus
due
two
primari
graft
failur
remain
aliv
remiss
year
diagnosi
patient
underw
ric
hsct
three
aliv
one
die
infect
fifth
patient
stabl
diseas
continu
decitabin
monotherapi
year
md
patient
treatment
data
upfront
hsct
therapi
upfront
chemotherapi
therapi
three
patient
requir
hsct
due
graft
failur
follow
avail
deceas
relaps
diseas
treatment
relat
mortal
larg
infecti
graft
failur
one
individu
die
hepat
failur
unrel
md
seven
md
patient
aliv
remiss
summari
prognosi
poor
patient
sd
develop
aml
due
resist
diseas
treatmentrel
complic
better
marker
risk
stratif
need
identifi
patient
would
benefit
earli
transplant
novel
therapeut
strategi
urgent
need
improv
outcom
sd
patient
md
aml
background
unlik
primari
myelofibrosi
pmf
adult
associ
somat
mutat
mpl
calr
myelofibrosi
children
rare
underli
genet
mechan
remain
elus
describ
famili
autosom
recess
congenit
macrothrombocytopenia
focal
myelofibrosi
cmtfm
due
germlin
mutat
megakaryocytespecif
immun
receptor
tyrosinebas
inhibitori
motif
itim
receptor
object
character
clinic
phenotyp
histolog
featur
identifi
caus
gene
cmtfm
perform
affymetrix
snp
genotyp
index
famili
identifi
share
region
homozygos
descent
whole
exom
sequenc
ws
perform
three
pedigre
identifi
potenti
caus
mutat
studi
affect
children
famili
macrothrombocytopenia
anemia
mild
leukocytosi
distinct
pattern
bone
marrow
bm
fibrosi
center
around
cluster
atyp
megakaryocyt
affect
children
mild
moder
bleed
symptom
requir
platelet
red
cell
transfus
none
show
evid
extramedullari
hematopoiesi
neg
mutat
mpl
calr
snp
genotyp
identifi
multipl
statist
nonsignific
genom
loci
includ
region
major
histocompat
locu
mhc
chromosom
lod
focus
region
affect
individu
two
famili
share
common
homozyg
human
leukocyt
antigen
hla
type
congenit
adren
hyperplasia
cah
due
mutat
hla
loci
locat
we
reveal
homozyg
frameshift
mutat
megakaryocyt
platelet
inhibitori
receptor
encod
within
candid
linkag
region
identifi
two
distinct
frameshift
mutat
individu
within
three
famili
mutat
segreg
phenotyp
identifi
valid
potenti
diseasecaus
gene
evalu
express
bm
biopsi
specimen
affect
patient
control
sampl
immunohistochem
stain
use
monoclon
antibodi
strongli
select
express
megakaryocyt
control
sampl
complet
absent
clinic
affect
individu
murin
knockout
lack
strikingli
similar
phenotyp
macrothrombocytopenia
myelofibrosi
aberr
platelet
product
function
affirm
causal
mutat
show
autosom
recess
lossoffunct
mutat
caus
cmtfm
uncov
molecular
basi
rare
diseas
loss
inhibit
megakaryocyt
activ
like
underli
distinct
focal
myelofibrot
phenotyp
might
import
form
marrow
fibrosi
cardin
glennon
saint
loui
missouri
unit
state
background
intrauterin
transfus
method
choic
manag
fetal
anemia
due
red
blood
cell
alloimmun
despit
decreas
preval
anemia
due
rhesu
alloimmun
prophylact
administr
antirhd
immunoglobulin
rh
neg
patient
matern
red
red
blood
cell
alloimmun
type
red
blood
cell
antigen
remain
import
caus
fetal
anemia
newborn
receiv
intrauterin
transfus
hemolyt
diseas
may
prolong
postnat
transfus
requir
object
evalu
clinic
outcom
fetus
newborn
receiv
intrauterin
transfus
determin
need
pack
red
blood
cell
transfus
month
age
conduct
retrospect
case
seri
studi
intrauterin
transfus
due
anemia
secondari
red
blood
cell
alloimmun
perform
region
center
ssm
st
loui
missouri
april
januari
evalu
indic
diagnosi
gestat
age
frequenc
intrauterin
transfus
along
infant
gestat
age
birth
durat
admiss
time
blood
transfus
monitor
hemoglobin
result
intrauterin
transfus
perform
patient
common
caus
alloimmun
due
antibodi
n
kell
antibodi
n
median
gestat
age
first
intrauterin
transfus
week
median
pretransfus
hemoglobin
gdl
gestat
age
first
intrauterin
transfus
found
significantli
correl
number
postnat
transfus
r
p
median
gestat
age
birth
found
week
week
hemoglobin
popul
patient
receiv
postnat
transfus
first
week
life
close
monitor
follow
hematologist
establish
patient
discharg
nurserynicu
one
neonat
death
occur
sever
morbid
due
sever
anemia
occur
one
infant
despit
continu
risk
factor
persist
anemia
patient
follow
hemoglobin
monitor
primari
care
provid
conclus
infant
anemia
due
red
blood
cell
alloimmun
treat
intrauterin
transfus
monitor
close
via
regular
complet
blood
count
persist
anemia
due
suppress
fetal
erythropoiesi
sebastian
hess
piotr
grabowski
juri
rappsilb
christoph
klein
dr
von
hauner
childen
hospit
lmu
univers
hospit
munich
munich
germani
background
neutrophil
granulocyt
abund
leukocyt
peripher
blood
valid
diagnost
option
cell
limit
leav
mani
patient
function
neutrophil
defect
without
defin
diagnosi
object
evalu
proteom
new
diagnost
tool
investig
defect
neutrophil
granulocyt
analyz
neutrophil
granulocyt
children
sever
congenit
neutropenia
scn
associ
elan
mutat
children
chronic
granulomat
diseas
cgd
cyba
cybb
mutat
children
leukocyt
adhes
defici
lad
due
mutat
addit
collect
sampl
children
genet
undetermin
neutrophil
defect
neutrophil
healthi
individu
serv
control
cell
isol
fresh
venou
blood
use
neg
select
puriti
whole
cell
proteom
analysi
done
dataindepend
acquisit
show
correl
coeffici
princip
compon
analysi
demonstr
unequivoc
separ
proteom
healthi
diseas
cell
differenti
express
analysi
show
minim
proteom
aberr
lad
defici
cell
surfac
receptor
upregul
alpl
total
downregul
protein
total
upregul
protein
analysi
neutrophil
cgd
patient
also
show
limit
proteom
aberr
cyba
cybb
diminish
independ
genotyp
wherea
protein
cluster
around
center
network
increas
total
neutrophil
elan
mutat
show
gravest
proteom
disturb
total
upregul
translat
apparatu
srpdepend
ribosom
protein
fold
complex
increas
mitochondri
protein
protein
granul
subset
dysregul
metabol
pathway
upregul
detail
analysi
proteom
patient
genet
undefin
diseas
current
ongo
one
patient
clinic
phenotyp
cgd
found
mutat
nadph
oxidas
member
whole
exom
sequenc
critic
low
level
protein
level
heterozygos
map
show
autozytoc
region
warrant
current
effort
sequenc
promot
intron
region
gene
mass
spectrometri
base
proteom
promis
excit
new
insight
monogen
diseas
neutrophil
granulocyt
may
offer
new
diagnost
option
particular
synergi
genom
sequenc
virtu
intern
careforrar
allianc
open
new
partner
hope
proteom
focu
may
lead
better
delin
yet
unknown
diseas
neutrophil
granulocyt
background
warm
autoimmun
hemolyt
anemia
aiha
igg
mediat
diseas
although
postvir
often
idiopath
also
form
frust
malign
autoimmun
diseas
initi
manag
includ
steroid
often
relaps
steroid
wean
refractori
use
second
line
treatment
rituximab
object
abatacept
fusion
protein
mimet
use
amelior
autoimmun
manifest
associ
haploinsuffici
use
abatacept
novel
therapeut
agent
manag
patient
refractori
aiha
designmethod
retrospect
case
seri
two
patient
phoenix
children
hospit
sever
refractori
aiha
result
patient
previous
healthi
year
old
femal
present
week
icteru
fatigu
hemoglobinuria
spleen
enlarg
costal
margin
laboratori
evalu
demonstr
hemoglobin
gdl
mild
leukopenia
platelet
reticulocytosi
posit
direct
coomb
test
mycoplasma
igm
igg
posit
bone
marrow
evalu
show
hypercellular
marrow
continu
need
pack
red
blood
cell
prbc
transfus
despit
receiv
high
dose
steroid
ivig
rituximab
mayjuli
august
start
sirolimu
decreas
transfus
requir
start
abatacept
bimonthli
three
dose
monthli
octob
maintain
hemoglobin
gdl
without
transfus
patient
previous
healthi
month
old
male
present
one
week
progress
fatigu
jaundic
poor
feed
splenomegali
absent
laboratori
evalu
reveal
hemoglobin
leukocytosi
platelet
reticulocytosi
neg
direct
coomb
test
nonspecif
reactiv
antibodi
screen
evalu
inherit
hemolyt
anemia
includ
next
gener
sequenc
panel
neg
evalu
blood
bank
show
posit
coomb
due
warm
antibodi
cold
agglutinin
diseas
rule
bone
marrow
evalu
normal
receiv
high
dose
ivig
steroid
spare
agent
continu
requir
prbc
transfus
weekli
prednison
seem
slow
hemolysi
treatment
abatacept
initi
requir
transfus
two
month
steroid
wean
present
success
treatment
two
refractori
aiha
case
abatacept
patient
steroid
transfus
free
continu
monthli
abatacept
sirolimu
patient
also
transfus
free
continu
steroid
taper
crucial
suppress
function
treg
cell
abatacept
bind
seem
enhanc
treg
activ
amelior
autoimmun
hemolysi
children
minnesota
minneapoli
minnesota
unit
state
background
transfusion
iron
overload
common
patient
receiv
chronic
red
cell
transfus
result
iron
chelat
requir
minim
toxic
iron
overload
chelat
singl
agent
inadequ
control
reduc
iron
burden
combin
therapi
requir
deferoxamin
may
ad
oral
chelat
deferoxamin
gener
given
subcutan
hour
day
week
mani
patient
struggl
remain
compliant
schedul
prompt
trial
intraven
highdos
hd
deferoxamin
prior
report
shortterm
hd
deferoxamin
shown
minim
side
effect
howev
prolong
use
hd
deferoxamin
known
toxic
complianc
concern
center
use
hd
deferoxamin
infus
x
everi
week
object
evalu
safeti
efficaci
hd
deferoxamin
institut
help
guid
futur
therapi
designmethod
retrospect
review
complet
patient
previous
treat
hd
deferoxamin
april
septemb
children
minnesota
final
sampl
includ
patient
age
year
underli
diagnosi
thalassemia
diamondblackfan
anemia
deferoxamin
infus
given
hour
everi
day
mean
length
treatment
day
result
patient
combin
therapi
deferasirox
howev
deferasirox
held
deferoxamin
infus
mean
predeferoxamin
liver
iron
concentr
lic
mean
post
lic
p
ferritin
mean
predeferoxamin
compar
mean
post
p
two
patient
possibl
allergi
lead
deferoxamin
discontinu
one
patient
develop
hive
eye
swell
cough
emesi
cough
anoth
patient
experienc
facial
nerv
palsi
unclear
etiolog
recur
resumpt
deferoxamin
respiratori
complic
seen
result
show
signific
decreas
iron
burden
follow
combin
therapi
high
dose
deferoxamin
deferasirox
signific
pulmonari
liver
renal
vision
hear
toxic
observ
three
patient
report
reaction
deferoxamin
infus
howev
one
abl
success
continu
deferoxamin
without
incid
shortterm
hd
deferoxamin
effect
reduc
lic
combin
oral
chelat
requir
evalu
assess
potenti
increas
risk
toxic
shortterm
hd
deferoxamin
may
consid
set
poor
complianc
subcutan
administr
inadequ
chelat
singl
agent
therapi
studi
need
clarifi
ideal
dose
time
risk
toxic
background
immun
thrombocytopenia
itp
common
caus
symptomat
thrombocytopenia
childhood
remain
diagnosi
exclus
warrant
evalu
atyp
find
present
two
male
children
month
year
old
newli
diagnos
immun
thrombocytopenia
itp
found
initi
evalu
persist
elev
lactat
dehydrogenas
ldh
alanin
aminotransferas
alt
aspart
aminotransferas
ast
serum
enzym
abnorm
attribut
itp
set
thrombocytopenia
elev
transaminas
ldh
creat
diagnost
complex
hematologyoncolog
provid
elev
rais
concern
malign
hemolyt
diseas
system
diseas
rais
awar
unexpect
pattern
duchenn
muscular
dystrophi
patient
undergo
evalu
itp
expand
differenti
hematologistoncologist
abnorm
lab
support
nonhematolog
diagnosi
designmethod
caseseri
two
patient
clinic
laboratori
find
discov
retrospect
chart
review
result
thorough
evalu
hemolyt
anemia
liver
diseas
infecti
etiolog
neg
bone
marrow
liver
biopsi
consid
eventu
children
found
sever
elev
serum
creatin
kinas
ck
skelet
muscl
highest
concentr
ck
tissu
thu
signific
ck
elev
almost
exclus
attribut
muscl
injuri
sensit
specif
enzym
diagnosi
muscl
diseas
referr
neuromuscular
specialist
genet
test
confirm
diagnosi
duchenn
muscular
dystrophi
children
allow
initi
appropri
intervent
date
clear
genet
predisposit
itp
patient
muscular
dystrophi
although
investig
may
need
hematologyoncolog
provid
consid
obtain
serum
ck
rule
muscl
diseas
male
child
unexplain
elev
serum
ldh
andor
aminotransferas
provid
easi
inexpens
noninvas
approach
screen
addit
clinic
histori
physic
examin
aid
diagnosi
muscular
dystrophi
gross
motor
delay
abnorm
muscl
bulk
gower
sign
proxim
muscl
weak
possibl
find
object
identifi
rang
cbc
patient
ds
without
infect
hematolog
immun
disord
creat
accur
refer
rang
total
white
blood
count
hemoglobin
hematocrit
mcv
platelet
count
absolut
neutrophil
anc
lymphocyt
monocyt
eosinophil
basophil
designmethod
retrospect
investig
healthi
pediatr
patient
ds
receiv
cbc
part
medic
care
singl
larg
pediatr
teach
hospit
studi
group
consist
children
ds
male
mean
age
year
sd
time
blood
draw
initi
children
review
possibl
particip
studi
howev
patient
exclud
due
meet
studi
inclus
criteria
descript
statist
perform
demograph
clinic
characterist
kruskalw
h
test
anova
ttest
run
determin
signific
associ
independ
mean
result
signific
differ
absolut
neutrophil
racial
group
f
p
observ
increas
anc
african
american
racial
group
caucasian
differ
also
found
anc
hispanicslatino
versu
nonhispaniclatino
result
higher
nonhispan
latino
signific
differ
ci
p
preliminari
kruskalw
h
test
run
determin
signific
differ
age
group
total
white
blood
cell
hemoglobin
hematocrit
platelet
lymphocyt
anc
studi
run
evalu
age
group
differ
lie
creat
refer
rang
age
race
sex
conclus
among
patient
ds
differ
racial
group
age
group
data
compar
previous
establish
refer
rang
cbc
current
establish
healthi
cbc
control
use
valid
refer
rang
rang
publish
help
guid
provid
workup
manag
patient
ds
background
transfus
critic
part
care
provid
neonat
intens
care
unit
without
risk
low
birth
weight
prematur
infant
becom
anaem
immatur
haematopoiet
system
frequent
phlebotomi
infant
often
receiv
multipl
red
blood
cell
transfus
identifi
infant
like
requir
intervent
import
ensur
appropri
usag
scarc
resourc
determin
whether
birth
weight
gestat
age
gender
length
stay
mode
deliveri
predict
red
cell
concentr
rcc
transfus
unit
requir
donor
exposur
time
exposur
designmethod
retrospect
chart
review
infant
born
week
gestat
andor
birth
weight
less
receiv
red
blood
cell
transfus
juli
juli
cork
univers
matern
hospit
neonat
unit
result
infant
met
inclus
criteria
receiv
rcc
transfus
studi
show
lower
gestat
age
p
lower
birth
weight
p
infant
like
transfus
donor
exposur
increas
lower
birth
weight
p
multivari
analysi
show
infant
lower
gestat
age
per
day
p
lower
birth
weight
per
p
longer
length
stay
per
day
p
like
receiv
higher
number
rcc
transfus
time
first
rcc
transfus
shorter
lower
birth
weight
per
p
lower
gestat
age
per
day
p
gender
mode
deliveri
found
predictor
red
blood
cell
transfus
studi
conclus
low
birth
weight
prematur
infant
like
receiv
rcc
transfus
admiss
neonat
unit
studi
highlight
predictor
rcc
transfus
donor
exposur
time
transfus
use
identifi
risk
infant
counsel
parent
anticip
transfus
requir
emili
southard
r
grant
row
david
william
akiko
shimamura
taizo
nakano
children
hospit
colorado
aurora
colorado
unit
state
background
mecom
locu
encod
transcript
factor
regul
hematopoiet
stem
cell
selfrenew
mainten
overexpress
mecom
note
acut
myeloid
leukemia
sever
solid
tumor
denot
poor
prognosi
mutat
reduc
mecom
express
disrupt
protein
function
howev
implic
develop
bone
marrow
failur
bmf
undefin
pathway
associ
mecom
mutat
radioulnar
synostosi
amegakaryocyt
thrombocytopenia
rusat
syndrom
report
howev
character
phenotyp
yet
explor
character
phenotyp
spectrum
cohort
pediatr
patient
novel
mecom
mutat
perform
retrospect
review
five
patient
mecom
mutat
refer
hematolog
children
hospit
colorado
boston
children
hospit
clinic
laboratori
genet
data
collect
subject
avail
famili
member
result
four
subject
identifi
infanc
present
congenit
cytopenia
physic
dysmorph
prompt
broad
genet
screen
platform
genet
detect
includ
microarray
target
genet
panel
whole
exom
sequenc
three
subject
cytopenia
present
congenit
thrombocytopenia
rapidli
progress
sever
aplast
anemia
four
subject
present
congenit
anomali
demonstr
radioulnar
synostosi
addit
dysmorph
featur
identifi
includ
craniofaci
low
set
ear
cardiac
pda
vsd
aortic
root
dilat
pulmonari
pulmonari
hypertens
arterioven
malform
development
delay
one
subject
present
age
year
acut
pancytopenia
hypocellular
marrow
dysmorph
mecom
variant
unknown
signific
identifi
mecom
mutat
includ
one
mb
delet
involv
sever
gene
includ
mecom
one
variant
affect
splice
acceptor
consensu
sequenc
predict
disrupt
splice
three
novel
missens
mutat
absent
public
databas
predict
silico
deleteri
describ
phenotyp
spectrum
patient
novel
mecom
variant
subset
patient
lack
radioulnar
synostosi
presenc
addit
system
anomali
demonstr
vari
clinic
phenotyp
isol
rusat
syndrom
central
public
access
databas
share
clinic
annot
mecom
variant
togeth
analysi
expert
mecom
function
would
advanc
understand
clinic
interpret
mecom
variant
mecom
consid
differenti
diagnosi
bone
marrow
failur
advoc
inclus
mecom
target
sequenc
panel
cairo
univers
cairo
egypt
background
beta
thalassemia
regard
seriou
public
health
problem
mediterranean
region
southeast
asia
middl
east
howev
studi
conduct
assess
qualiti
life
qol
among
thalassemia
major
patient
object
assess
qualiti
life
among
bthalassemia
major
patient
use
short
form
sf
questionnair
determin
factor
associ
qualiti
life
designmethod
crosssect
studi
conduct
among
thalassemia
major
patient
attend
hematolog
outpati
clinic
cairo
univers
hospit
studi
period
data
collect
octob
march
qualiti
life
assess
patient
age
year
mean
age
studi
group
year
major
one
monthli
blood
transfus
mean
total
score
gener
health
percept
domain
affect
domain
mean
score
vital
least
affect
one
statist
signific
differ
male
femal
regard
differ
qualiti
domain
except
vital
mean
score
significantli
higher
male
femal
p
age
onset
diseas
first
blood
transfus
document
factor
posit
correl
qualiti
life
among
enrol
thalassemia
patient
conclus
qualiti
life
thalassemia
major
patient
found
compromis
thalassemia
patient
undergo
assess
qualiti
life
intervent
focus
affect
domain
implement
background
intern
adopt
children
special
need
becom
preval
recent
year
lead
tremend
growth
number
us
thalassemia
patient
adopt
foreign
countri
current
thalassemia
patient
regist
cooley
anemia
foundat
caf
patient
databas
adopt
foreign
countri
primarili
china
popul
continu
grow
inform
need
order
provid
famili
best
support
care
primari
goal
studi
character
sociodemograph
health
status
adopt
children
thalassemia
famili
secondari
goal
describ
adopt
famili
motiv
experi
challeng
support
resourc
designmethod
redcap
survey
access
famili
adopt
children
thalassemia
caf
websit
caf
social
media
januari
august
follow
fourquest
screen
elig
subject
direct
complet
adopt
questionnair
famili
least
one
adopt
child
thalassemia
receiv
care
particip
thalassemia
treatment
center
hematolog
offic
us
consid
elig
descript
statist
analyz
use
sa
respond
inelig
provid
incomplet
data
remov
dataset
prior
analysi
survey
respond
qualifi
complet
survey
household
adopt
total
children
thalassemia
male
china
live
orphanag
legal
guardian
identifi
primarili
christian
major
complet
postsecondari
educ
report
household
incom
greater
adopt
famili
connect
adopt
group
commun
includ
onlin
group
local
support
group
adopt
network
commonli
cite
challeng
volum
frequent
medic
appoint
insuffici
support
local
care
center
financi
burden
realiti
care
popul
adopt
patient
thalassemia
us
seem
match
expect
set
provid
hope
data
use
assist
adopt
famili
navig
complex
thalassemia
care
find
suggest
popul
would
benefit
addit
outreach
educ
guidanc
advocaci
resourc
especi
earli
stage
adopt
initi
postadopt
medic
care
background
mani
higherincom
countri
thalassemia
major
becom
chronic
disord
mani
outcom
differ
emerg
countri
limit
resourc
analyz
healthrel
qualiti
life
qofl
thalassemia
conduct
highincom
set
object
assess
impact
health
statu
qofl
thalassemia
patient
emerg
countri
assess
qofl
randomlyselect
patient
thalassemia
major
hemoglobin
e
thalassemia
five
thalassemia
intermedia
nation
thalassemia
center
kurunegala
sri
lanka
approxim
patient
manag
treatment
free
compar
north
americaeurop
access
tertiari
staff
resourc
limit
overal
control
bodi
iron
estim
serum
ferritin
concentr
sem
gl
optim
mani
patient
understand
impact
health
statu
qofl
use
health
survey
analyz
score
physic
function
pain
gener
health
social
function
emot
mental
health
gener
overal
physic
mental
compon
score
result
compar
report
higherincom
countri
american
journal
hematolog
physic
function
score
similar
sri
lankan
patient
inde
three
categori
physic
role
social
function
emot
role
sri
lankan
score
slightli
higher
contrast
compar
score
higherincom
set
estim
bodili
pain
gener
health
mental
health
significantli
lower
result
overal
significantli
lower
physic
compon
score
sri
lankan
patient
male
sri
lankan
patient
report
higher
score
femal
somewhat
surprisingli
four
categori
physic
function
physic
role
social
function
emot
role
report
higher
score
obtain
higherincom
set
lower
score
physic
function
lead
overal
lower
physic
compon
score
record
femal
patient
hemoglobin
e
thalassemia
report
gener
poorer
qofl
thalassemia
major
lack
differ
qofl
patient
high
low
hemoglobin
like
relat
low
pretransfus
hb
gdl
nearli
patient
earli
data
small
cohort
thalassemia
patient
emerg
set
suggest
mani
patient
bodili
pain
reduc
mental
health
poorer
view
gener
health
affect
overal
qofl
prospect
studi
larger
cohort
includ
evalu
adequaci
transfus
chelat
therapi
complic
overal
access
care
may
guid
approach
improv
qofl
lowerincom
set
thalassemia
care
geetanjali
bora
anand
prakash
dubey
tarun
sekhri
mammen
puliyel
aparna
roy
maulana
azad
medic
colleg
new
delhi
delhi
india
background
last
two
decad
presenc
osteopenia
describ
optim
treat
patient
transfus
depend
thalassemia
pathogenesi
seem
differ
osteopenia
nontransfus
patient
preval
rate
low
bone
miner
densiti
bmd
pediatr
popul
highli
variabl
amongst
studi
done
worldwid
furthermor
role
metabol
endocrin
factor
determin
bone
mass
popul
well
understood
object
assess
bmd
subject
transfus
depend
beta
thalassemia
dualenergyx
rayabsorptiometri
find
corel
clinic
biochem
hematolog
paramet
designmethod
compar
crosssect
studi
includ
patient
transfus
depend
beta
thalassemia
age
year
enrol
thalassemia
day
care
center
year
time
enrol
age
sex
bmi
z
score
pubert
stage
durat
type
chelat
therapi
note
enrol
subject
scan
bmd
lumbar
spine
left
femor
neck
use
dexa
scan
bmd
express
mean
valu
z
score
age
bmi
ethnic
gender
match
histor
control
use
gener
z
score
ml
pre
transfus
fast
venou
blood
sampl
obtain
test
serum
calcium
phosphat
alkalin
phosphatas
pth
thyroid
function
panel
serum
ferritin
serum
level
mean
valu
pretransfus
hemoglobin
serum
ferritin
last
month
calcul
result
total
subject
median
age
year
male
femal
ethnic
asian
bmi
centil
pre
pubert
receiv
transfus
chelat
therapi
preval
low
z
score
sd
low
sd
bmd
respect
left
femor
neck
respect
trend
lower
bmd
z
score
advanc
age
statist
signific
corel
p
valu
found
low
bmd
low
mean
pretransfus
hemoglobin
serum
phosphat
igf
vitamin
level
conclus
sizabl
proport
children
adolesc
transfus
depend
thalassemia
suboptim
bone
miner
densiti
declin
may
start
earli
year
age
despit
transfus
regimen
highlight
import
yearli
dexa
screen
optim
pretransfus
hemoglobin
vitamin
igf
level
vanderbilt
univers
medic
center
nashvil
tennesse
unit
state
background
well
describ
iron
defici
anemia
ida
copres
thrombocytosi
thrombocytopenia
though
case
thrombocytopenia
less
frequent
thrombocytosi
prior
report
thrombocytopenia
includ
adult
pediatr
patient
menorrhagia
menorrhagia
due
uterin
fibroid
gynecolog
abnorm
case
highlight
pattern
ida
thrombocytopenia
menorrhagia
set
signific
menstrual
clot
without
observ
gynecolog
abnorm
africanamerican
adolesc
object
describ
clinic
cours
three
adolesc
femal
sever
ida
menorrhagia
thrombocytopenia
result
case
includ
three
femal
africanamerican
patient
age
present
sever
anemia
concurr
thrombocytopenia
set
menorrhagia
three
patient
report
heavi
prolong
menstrual
cycl
bleed
signific
clot
two
three
admit
transfus
present
note
signific
menstrual
bleed
continu
blood
loss
requir
addit
transfus
bleed
control
estrogen
therapi
two
patient
evalu
pelvic
ultrasound
reveal
promin
endometrium
patient
hyperecho
materi
consist
clot
one
patient
averag
hemoglobin
present
gmdl
averag
platelet
count
averag
mcv
sever
iron
defici
averag
ferritin
ngml
subsequ
treat
oral
iron
one
patient
prior
histori
ida
requir
transfus
subsequ
normal
complet
blood
count
two
patient
subsequ
thrombocytosi
normal
platelet
count
two
patient
receiv
platelet
transfus
one
due
recent
neurosurg
intervent
higher
goal
platelet
count
help
control
menstrual
bleed
nadir
platelet
count
review
clinic
histori
red
cell
indic
point
ida
ongo
blood
loss
menorrhagia
reason
bicytopenia
thrombocytopenia
case
may
exacerb
consumpt
platelet
signific
clot
three
patient
report
reason
treat
iron
supplement
support
care
may
includ
transfus
manag
menorrhagia
oral
contracept
hormon
method
background
sickl
cell
diseas
one
common
inherit
red
blood
cell
disord
yet
mani
awar
carrier
statu
american
colleg
obstetrician
gynecologist
guidelin
recommend
pregnant
women
african
mediterranean
southeast
asian
descent
screen
hemoglobinopathi
cbc
hemoglobin
howev
adher
practic
frequenc
improp
screen
sickledex
unknown
proper
screen
counsel
impact
famili
knowledg
allow
establish
relationship
pediatr
hematolog
provid
earlier
object
sought
assess
prenat
hemoglobinopathi
screen
practic
pattern
method
obstetr
gynecolog
obgyn
famili
medicin
provid
nyc
region
area
designmethod
crosssect
electron
survey
administ
obgyn
famili
medicin
practition
four
nyc
institut
question
focus
prenat
hemoglobinopathi
screen
practic
use
case
scenario
variat
parent
trait
statu
ethnic
chisquar
analys
use
compar
two
provid
group
categor
variabl
total
respons
survey
complet
obgyn
famili
medicin
provid
respond
mainli
academ
medic
center
major
faculti
obgyn
famili
medicin
signific
differ
found
frequenc
screen
patient
posit
famili
histori
hemoglobinopathi
ask
screen
practic
patient
without
personalfamili
histori
hemoglobinopathi
obgyn
versu
famili
medicin
provid
alway
screen
hemoglobinpathi
p
analyz
ethnic
background
signific
differ
group
screen
patient
white
vs
black
vs
mediterranean
vs
asian
descent
vs
howev
case
hemoglobinopathi
carrier
statu
parent
known
differ
screen
hemoglobin
electrophoresi
furthermor
respond
use
sickledex
screen
case
scenario
conclus
pilot
survey
highlight
differ
method
likelihood
prenat
hemoglobinopathi
screen
base
type
prenat
care
provid
screen
differ
lead
variat
prenat
guidanc
diagnost
procedur
inform
decisionmak
knowledg
famili
refer
pediatr
hematolog
clinic
first
studi
analyz
prenat
screen
hemoglobinopathi
obgyn
famili
medicin
improv
prenat
screen
practic
collabor
hematologist
may
decreas
health
care
dispar
allow
earlier
relationship
build
pediatr
hematolog
acog
opinion
poster
hermanskypudlak
syndrom
spectrum
oman
background
hermanskypudlak
syndrom
hp
rare
autosom
recess
disord
character
triad
oculocutan
albin
hemorrhag
diathesi
result
storag
pooldefici
platelet
accumul
ceroidlipofuscinlik
materi
variou
tissu
nine
differ
type
hermanskypudlak
syndrom
identifi
distinguish
sign
symptom
underli
genet
caus
tenth
type
defin
base
mutat
gene
hp
type
character
addit
sever
neutropenia
recurr
sinopulmonari
infect
diseas
common
puerto
rico
first
report
oman
describ
clinic
laboratori
genet
characterist
hp
subtyp
oman
includ
first
case
hp
type
designmethod
retrospect
studi
includ
case
hp
suspect
clinic
confirm
genet
mutat
analysi
clinic
data
includ
sex
age
present
initi
clinic
present
skin
eye
develop
neurolog
involv
bleed
tendenc
recurr
infect
cours
diseas
laboratori
data
complet
blood
count
platelet
absolut
neutrophil
count
coagul
screen
platelet
function
test
platelet
function
analyz
platelet
aggreg
studi
use
differ
agonist
record
pcr
next
gener
sequenc
genet
confirm
test
mutat
gene
done
result
seven
omani
case
hp
identifi
male
femal
age
rang
birth
year
two
patient
hp
type
patient
type
case
hp
type
subtyp
encount
oman
patient
product
consanguin
marriag
one
patient
adren
hge
other
mild
hemorrhag
phenotyp
character
recurr
bruis
mild
epistaxi
laboratori
test
confirm
variabl
platelet
aggreg
defect
differ
platelet
agonist
patient
characterist
hypopigment
iri
transillumin
nystagmu
foveal
hypoplasia
patient
hp
type
homozyg
mutat
gene
present
sever
neutropenia
earli
diagnosi
initi
gcsf
one
improv
outcom
prevent
develop
complic
late
diagnosi
patient
result
develop
bronchiectasi
result
recurr
sinopulmonari
infect
background
sickl
cell
diseas
scd
genet
disord
character
defect
sickl
hemoglobin
hb
trigger
red
blood
cell
sickl
hemolysi
vasoocclus
inflamm
ischem
injuri
scd
start
infanc
accumul
lifetim
caus
pain
fatigu
progress
endorgan
damag
culmin
earli
mortal
voxelotor
oral
oncedaili
therapi
modul
hemoglobin
oxygen
affin
therebi
inhibit
hemoglobin
polymer
object
assess
safeti
pharmacokinet
efficaci
voxelotor
pediatr
patient
scd
designmethod
ongo
studi
conduct
part
part
singl
dose
voxelotor
mg
pediatr
adolesc
patient
part
b
multipl
dose
voxelotor
mgd
mgd
week
adolesc
part
b
primari
object
assess
effect
voxelotor
modifi
anemia
secondari
object
includ
measur
marker
diseas
modif
hemolysi
daili
scd
symptom
use
patientreport
outcom
pro
measur
safeti
result
novemb
patient
femal
receiv
voxelotor
mg
patient
femal
receiv
voxelotor
week
median
age
patient
year
receiv
hydroxyurea
hu
pain
crise
past
year
data
hemolysi
measur
avail
patient
receiv
voxelotor
week
six
patient
achiev
hemoglobin
hb
respons
gdl
increas
laboratori
marker
hemolysi
improv
concordantli
median
reduct
reticulocyt
indirect
bilirubin
respect
ten
patient
show
reduct
total
symptom
score
tss
week
median
reduct
tss
baselin
treatmentrel
seriou
advers
event
ae
drug
discontinu
due
ae
voxelotor
mg
week
adolesc
scd
major
receiv
hu
demonstr
consist
sustain
efficaci
hb
level
measur
hemolysi
patient
show
gdl
improv
hb
improv
tss
mildli
symptomat
patient
suggest
pro
sensit
treatment
effect
support
use
ongo
hope
phase
studi
voxelotor
reassur
safeti
profil
consist
result
adult
interim
result
support
ongo
clinic
evalu
voxelotor
potenti
diseasemodifi
therapi
adult
children
scd
support
global
blood
therapeut
background
acut
kidney
injuri
aki
common
complic
sickl
cell
diseas
scd
potenti
risk
factor
sickl
nephropathi
aki
associ
acut
declin
hemoglobin
hb
vasoocclus
pain
crisi
acut
chest
syndrom
ac
unclear
patholog
factor
play
stronger
role
aki
develop
hb
drop
increas
free
heme
vasoocclus
event
secondari
hemolysi
hb
declin
object
investig
hb
declin
alon
associ
aki
test
renal
function
patient
scd
worsen
parvoviru
transient
aplast
crisi
tac
absenc
accentu
hemolysi
designmethod
irb
approv
retrospect
studi
patient
laboratori
confirm
conduct
serum
creatinin
scr
within
month
tac
event
collect
comparison
clinic
laboratori
characterist
analyz
use
wilcoxon
test
continu
variabl
aki
defin
increas
scr
mgdl
increas
scr
baselin
evalu
differ
chang
hb
aki
risk
chang
scr
tac
compar
pain
crisi
ac
admiss
fit
gener
linear
mix
model
binari
outcom
compar
sampl
ac
event
vasoocclus
pain
crisi
use
estim
rate
aki
accord
hb
level
result
three
patient
scd
develop
aki
tac
associ
identifi
chang
hb
baselin
tac
event
p
case
aki
identifi
hb
decreas
gdl
chang
hb
gdl
baselin
next
develop
model
evalu
impact
chang
hb
baselin
patient
admit
tac
pain
crisi
ac
aki
gdl
decreas
admiss
hb
baselin
patient
tac
probabl
develop
aki
acut
chest
syndrom
pain
crisi
would
probabl
respect
data
suggest
aki
still
preval
parvoviru
tac
howev
risk
aki
tac
event
time
lower
sever
anemia
induc
acut
chest
syndrom
vasoocclus
pain
event
respect
hemolysisinduc
anemia
scd
crisi
appear
signific
role
develop
aki
compar
agen
anemia
background
natur
histori
hemoglobin
e
beta
thalassemia
hbethal
commonest
form
sever
beta
thalassemia
worldwid
examin
longterm
studi
previous
report
find
hbethal
patient
sri
object
evalu
longterm
requir
transfus
splenectomi
complic
death
hbethal
patient
designmethod
avail
patient
review
time
annual
year
result
patient
die
age
mean
sem
year
known
caus
commonli
includ
iron
overload
infect
patient
surviv
patient
age
year
patient
origin
classifi
sever
group
mildest
group
sever
phenotyp
assess
mild
group
transfus
discontinu
ultim
resum
transfus
often
follow
shift
increasingli
sever
phenotyp
includ
increas
intoler
anemia
age
resumpt
transfus
follow
transfusionfre
interv
year
year
sever
group
regular
transfus
stop
patient
resum
younger
age
year
shorter
transfusionfre
period
year
milder
patient
midparent
height
mph
ultim
achiev
patient
splenectom
updat
analysi
respons
splenectomi
origin
group
patient
show
splenectomi
year
follow
extend
imperman
transfusionfre
interv
year
patient
resum
transfus
usual
relat
exercis
intoler
poor
growth
group
complic
anemia
ineffect
erythropoiesi
includ
leg
ulcer
gallston
frequent
group
fractur
observ
across
group
except
regularlytransfus
group
patient
pulmonari
arteri
pressur
mm
record
patient
evalu
patient
hbethal
requir
observ
year
without
definit
patient
mild
sever
may
mislead
mani
patient
transfus
may
withheld
reduc
frequenc
troublesom
complic
may
surfac
advanc
age
even
milder
patient
although
individu
consider
transfus
requir
critic
avail
effect
chelat
provid
without
prohibit
cost
may
alter
balanc
risk
benefit
regular
transfus
hbethal
premawardhena
lancet
background
social
determin
health
sdh
environment
socioeconom
factor
access
food
hous
affect
health
outcom
pediatrician
increasingli
screen
sdh
part
primari
care
visit
howev
less
known
screen
sdh
pediatr
hematolog
evid
suggest
sdh
play
role
diseas
sever
children
scd
face
signific
socioeconom
racial
dispar
goal
qualiti
improv
qi
project
increas
percentag
patient
scd
connect
commun
resourc
unmet
social
need
designmethod
base
intervent
success
implement
wecar
institut
pediatr
primari
care
clinic
elig
patient
identifi
start
clinic
session
arriv
parent
given
selfreport
screen
tool
six
sdh
childcar
educ
employ
food
util
hous
result
enter
electron
health
record
physician
social
worker
print
preexist
resourc
list
patient
posit
screen
use
seri
plandostudyact
pdsa
cycl
studi
test
chang
track
process
measur
percentag
patient
screen
percentag
patient
unmet
social
need
receiv
resourc
sheet
outcom
measur
percentag
patient
unmet
social
need
connect
commun
resourc
balanc
measur
staff
patient
provid
satisfact
run
chart
review
weekli
monthli
inform
test
chang
exampl
pdsa
cycl
includ
gave
paper
survey
patient
social
worker
physician
versu
medic
assist
length
time
survey
month
result
august
decemb
screen
rate
improv
patient
screen
report
least
one
unmet
social
need
receiv
target
list
commun
resourc
first
month
project
fifth
month
final
patient
reach
phone
connect
commun
resourc
within
week
clinic
visit
success
implement
univers
screen
sdh
patient
scd
urban
pediatr
hematolog
clinic
without
requir
extra
staff
next
step
includ
pdsa
cycl
connect
patient
appropri
resourc
track
improv
health
care
util
outcom
address
sdh
vulner
patient
popul
background
clinic
manifest
sickl
cell
diseas
scd
chronic
hemolyt
anemia
vasoocclus
occur
direct
result
sickl
hemoglobin
hb
polymer
voxelotor
firstinclass
oral
oncedaili
investig
agent
design
modul
hemoglobin
oxygen
affin
target
approach
inhibit
hb
polymer
object
examin
pharmacokinet
pk
safeti
dose
voxelotor
children
age
year
adolesc
age
year
scd
part
studi
designmethod
ongo
openlabel
phase
studi
patient
age
year
scd
sickl
cell
anemia
sickl
beta
zero
thalassemia
part
studi
focu
abstract
examin
pk
singledos
mg
voxelotor
pk
sampl
measur
whole
blood
plasma
voxelotor
concentr
collect
day
follow
singledos
administr
separ
popul
pk
ppk
model
develop
describ
concentr
versu
time
profil
voxelotor
whole
blood
plasma
use
nonlinear
mix
effect
model
nonmem
version
ppk
model
physiolog
base
pk
pbpk
model
use
simul
voxelotor
pk
paramet
support
dose
select
futur
evalu
younger
children
part
includ
adolesc
femal
median
age
year
rang
children
femal
median
age
year
rang
mean
weight
kg
rang
kg
kg
rang
kg
adolesc
children
respect
voxelotor
well
toler
drugrel
grade
advers
event
ae
seriou
ae
model
firstord
absorpt
best
describ
pk
voxelotor
model
structur
use
adult
scd
voxelotor
pk
exposur
adolesc
compar
observ
adult
higher
exposur
observ
children
ppk
pbpk
model
support
use
weightbas
dose
strategi
younger
children
age
year
futur
trial
adult
voxelotor
dose
use
adolesc
howev
base
higher
pk
exposur
lower
weightbas
dose
strategi
recommend
children
ppk
pbpk
model
provid
innov
approach
minim
experiment
dose
children
acceler
dose
select
voxelotor
ongo
futur
clinic
studi
abstract
support
global
blood
therapeut
background
hydroxyurea
hu
reduc
rate
acut
complic
improv
long
term
outcom
patient
sickl
cell
diseas
scd
fda
approv
children
previou
work
increas
number
elig
patient
hu
clinic
howev
access
compound
pharmaci
remain
signific
barrier
hu
adher
infant
children
swallow
capsul
object
object
qualiti
improv
project
improv
adher
hu
among
pediatr
patient
scd
urban
safeti
net
hospit
address
barrier
obtain
liquid
hu
designmethod
begin
met
leadership
outpati
pharmaci
offer
mail
order
deliveri
howev
like
retail
pharmaci
necessari
protect
equip
compound
liquid
hu
seri
discuss
began
uniqu
partnership
institut
inpati
chemotherapi
pharmaci
compound
liquid
hu
deliv
outpati
pharmaci
dispens
liquid
hu
famili
use
seri
plandostudyact
pdsa
cycl
track
adher
calcul
medic
possess
ratio
mpr
defin
percentag
day
given
period
time
patient
medic
hand
mpr
liquid
hu
mpr
among
enrol
patient
track
pharmaci
staff
review
monthli
addit
pdsa
cycl
includ
ad
automat
refil
remind
call
pharmaci
staff
improv
commun
deliveri
also
track
patient
satisfact
result
march
decemb
total
thirti
pediatr
patient
enrol
program
onsit
compound
free
mail
order
deliveri
liquid
hu
mpr
liquid
hu
current
among
enrol
patient
significantli
higher
mpr
report
literatur
risen
steadili
sinc
begin
project
famili
highli
satisfi
program
specif
appreci
conveni
mail
order
deliveri
save
deliveri
fee
remind
call
refil
due
compound
dispens
liquid
hu
directli
institut
outpati
pharmaci
significantli
improv
adher
hu
therapi
highrisk
popul
next
step
includ
analysi
chang
clinic
outcom
patient
enrol
program
adher
hydroxyurea
associ
decreas
acut
care
util
cost
program
could
play
crucial
role
reduc
excess
cost
ed
util
among
patient
popul
background
experi
ironchel
deferasirox
report
wide
higherincom
set
contrast
reallif
experi
emerg
countri
infrequ
report
object
evalu
nontrial
set
reallif
respons
deferasirox
emerg
countri
designmethod
sri
lanka
nation
thalassemia
center
manag
patient
without
tertiari
staff
quantit
evalu
bodi
iron
estim
extrahepat
iron
record
patient
began
deferasirox
retrospect
review
result
baselin
assess
indic
substanti
iron
load
serum
ferritin
sf
ugl
serum
alt
ul
normal
ul
deferasirox
introduc
low
dose
mgkgday
mani
patient
start
mgkg
month
dose
remain
mgkgday
patient
month
sf
patient
remain
ugl
month
mean
sf
declin
ugl
p
similarli
mean
alt
normal
ul
month
death
complic
systemat
record
staff
charg
without
provis
addit
resourc
introduct
new
drug
hundr
patient
result
contrast
sri
lanka
tertiari
thalassemia
center
patient
follow
introduct
deferasirox
sf
declin
rapidli
even
rel
less
ironload
patient
gl
month
p
find
underscor
import
implement
new
drug
regimen
lowerincom
center
margin
resourc
invest
method
quantit
bodi
iron
burden
handson
educ
initi
guid
daytoday
manag
compet
nonexpert
staff
data
system
record
efficaci
effect
toxic
complianc
invest
critic
optimis
therapi
improv
complic
thalassemia
patient
worldwid
even
sri
lanka
resourc
direct
thalassemia
manag
greater
asia
result
oldest
live
cohort
born
indic
undertreat
elev
iron
burden
sf
ugl
high
preval
diabet
hypothyroid
even
younger
cohort
born
benefit
improv
treatment
preval
mani
complic
exce
report
highincom
set
next
decad
two
decad
declar
impact
thalassemia
global
mortal
morbid
underrecogn
increas
invest
government
nongovernment
sourc
necessari
improv
outcom
asian
patient
thalassemia
background
major
barrier
success
hydroxyurea
hu
treatment
patient
sickl
cell
diseas
scd
nonadher
object
optim
hu
adher
patient
scd
designmethod
care
model
design
sickl
cell
qi
team
children
hospit
improv
hu
adher
among
scd
patient
origin
model
includ
bimonthli
famili
phone
contact
monthli
dispens
pharmaci
phone
contact
lab
monitor
adher
measur
includ
obtain
hu
pharmaci
monthli
complet
monthli
lab
hb
f
percentag
mcv
mtd
achiev
sever
pdsa
cycl
refin
care
model
oneyear
followup
survey
gather
feedback
care
model
firstyear
data
involv
patient
biggest
improv
result
make
pharmaci
call
patientfamili
call
ship
liquid
hu
outli
patient
track
call
timecont
qi
goal
hu
adher
baselin
adher
rate
increas
remain
rang
complet
rate
patientpar
phone
call
increas
first
month
six
month
pharmaci
prescript
pickup
increas
per
month
lack
liquid
hu
avail
overcom
ship
medic
patient
home
parent
hesit
share
inform
phone
especi
qi
team
member
establish
relationship
overcom
longtim
sickl
cell
nurs
mani
earli
call
howev
survey
feedback
show
famili
becam
comfort
sever
clinic
personnel
call
call
gave
famili
opportun
ask
question
child
andor
get
addit
inform
scd
call
also
provid
opportun
season
flu
shot
tcd
test
remind
survey
gave
inform
optim
time
day
reach
famili
provid
individu
increas
percentag
complet
call
two
famili
survey
said
longer
need
two
call
month
abl
rememb
pick
hu
administ
get
lab
qi
project
improv
hu
adher
also
foster
health
educationcounsel
increas
patientpar
satisfact
enhanc
servic
util
medic
team
member
patientfamili
comment
demonstr
help
build
relationship
trust
famili
medic
care
system
base
survey
feedback
individu
care
increas
adher
rate
sustain
improv
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
thalassemia
heterogen
group
genet
blood
disord
caus
mutat
decreas
elimin
synthesi
andor
globin
subunit
hemoglobin
phenotyp
thalassemia
depend
interact
globin
gene
cluster
loci
determin
chain
balanc
exampl
thalassemia
phenotyp
sever
expect
coinherit
globin
gene
triplic
copi
number
gain
exacerb
globin
imbal
object
describ
four
individu
incorrect
diagnosi
thalassemia
trait
later
properli
diagnos
comprehens
genet
test
thalassemia
intermedia
caus
heterozyg
thalassemia
mutat
coinherit
triplic
globin
loci
designmethod
sequenc
analysi
globin
globin
hbb
gene
copi
number
variat
analysi
globin
gene
cluster
multiplex
liganddepend
probe
amplif
result
four
unrel
individu
northern
european
ancestri
evalu
sign
symptom
explain
diagnosi
thalassemia
trait
previous
made
pediatr
hematologist
includ
growth
delay
splenomegali
moder
anemia
mark
elev
hemoglobin
f
thalassem
faci
reticulocytosi
andor
indirect
hyperbilirubinemia
genet
test
reveal
heterozyg
singl
globin
mutat
also
heterozyg
globin
triplic
previou
diagnos
thalassemia
trait
made
complet
blood
count
hemoglobin
electrophoresi
andor
sequenc
analysi
globin
gene
individu
phenotyp
rang
moder
anemia
multipl
stigmata
thalassemia
demonstr
phenotyp
variat
thalassemia
genotyp
correct
diagnosi
made
averag
age
year
trial
chronic
transfus
initi
one
patient
growth
failur
educ
potenti
exacerb
anemia
gallston
osteoporosi
iron
overload
even
without
transfus
parent
genet
test
recommend
assess
reproduct
risk
inherit
complex
genotyp
appar
autosom
domin
conclus
heterozygos
thalassemia
mutat
necessarili
indic
thalassemia
minor
trait
coinherit
globin
gene
triplic
symptomat
form
thalassemia
occur
correct
time
diagnosi
thalassemia
requir
care
consider
degre
anemia
examin
organomegali
boni
chang
jaundic
sequenc
analysi
copi
number
variat
analysi
globin
gene
cluster
key
hematologist
need
awar
diagnost
possibl
test
prevent
inaccur
delay
diagnosi
background
burden
healthcar
cost
sickl
cell
diseas
scd
nation
estim
billion
major
compon
cost
inpati
emerg
center
ec
visit
mani
potenti
avoid
sever
chronic
condit
subset
patient
account
avoid
encount
identifi
patient
first
step
target
care
deliveri
object
measur
analyz
scd
patient
util
pattern
ec
inpati
texa
children
hospit
tch
identifi
individu
year
old
encount
tch
associ
intern
classif
diseas
icd
code
scd
includ
hgb
ss
hgb
sc
hgb
sbeta
thalassemia
patient
identifi
inpati
ec
encount
day
prior
recent
encount
final
encount
classifi
associ
pain
acut
chest
syndrom
ac
use
algorithm
discharg
diagnosi
code
pharmaceut
deliveri
total
number
scdassoci
ec
inpati
encount
prior
year
calcul
patient
stratifi
patient
accord
util
pattern
low
encount
intermedi
encount
high
encount
identifi
uniqu
patient
scd
least
one
encount
juli
june
scdrelat
encount
day
prior
recent
encount
n
patient
exhibit
lowutil
pattern
n
intermedi
final
small
subset
n
demonstr
highutil
pattern
account
encount
highutil
associ
older
age
public
payment
mechan
pain
encount
predominantli
preadolesc
teenag
highand
intermediateutil
pattern
ac
frequent
preteen
younger
teen
intermediateutil
group
final
youngestag
high
intermedi
user
present
reason
febril
episod
splenic
sequestr
find
reflect
nation
trend
signific
portion
encount
attribut
small
subset
patient
exhibit
highor
super
util
pattern
institut
scd
superutil
associ
older
age
pain
also
identifi
group
infant
toddler
frequent
encount
fever
comprehens
address
burden
import
design
intervent
target
toward
age
specif
medic
need
background
background
rariti
diamond
blackfan
anemia
dba
hinder
describ
spectrum
diseas
identifi
predict
correl
guid
datadriven
recommend
longterm
toxic
steroid
transfus
therapi
start
childhood
remain
major
clinic
problem
patient
dba
receiv
stem
cell
transplant
object
object
defin
dba
patient
popul
st
jude
children
research
hospit
includ
treatment
respons
toxic
help
inform
recommend
treatment
monitor
designmethod
method
medic
record
review
patient
dba
treat
st
jude
diagnost
test
treatment
type
regimen
outcom
twosampl
ttest
wilcoxon
rank
sum
test
use
compar
continu
variabl
two
group
depend
normal
data
test
shapirowilk
test
result
total
patient
dba
identifi
median
age
year
rang
month
year
last
follow
ribosom
protein
gene
mutat
identifi
patient
mutat
thirteen
differ
congenit
malform
describ
patient
fourteen
twenti
patient
treat
corticosteroid
initi
respons
achiev
full
remiss
three
patient
becam
steroidrefractori
unabl
wean
accept
dose
five
twenti
patient
continu
lowerdos
steroid
five
patient
current
requir
therapi
univari
analysi
reveal
statist
signific
genet
predictor
respons
remiss
howev
patient
respond
steroid
longterm
remiss
ten
patient
maintain
chronic
transfus
undergon
success
hematopoiet
stem
cell
transplant
nineteen
treat
patient
treatmentrel
toxic
patient
steroid
like
short
statur
patient
transfus
remiss
p
sever
bone
miner
densiti
deficit
occur
patient
age
year
eight
patient
hepat
iron
overload
one
document
age
year
sever
toxic
includ
restrict
cardiomyopathi
iron
overload
patholog
fractur
diabet
mellitu
prematur
ovarian
failur
one
patient
genotyp
phenotyp
heterogen
dba
cohort
high
rate
treatmentrel
toxic
notabl
growth
retard
bone
densiti
loss
hepat
iron
overload
even
young
children
find
underscor
need
earli
standard
monitor
background
patient
sickl
cell
diseas
scd
face
worsen
morbid
mortal
age
must
transit
pediatr
adult
healthcar
effect
curriculum
address
diseas
knowledg
educ
vocat
skill
selfefficaci
social
support
critic
success
transit
tradit
didact
approach
led
durabl
knowledg
retent
technologybas
method
attempt
best
educ
approach
remain
unknown
object
understand
adolesc
young
adult
aya
patient
scd
view
exist
transit
educ
includ
patient
prefer
improv
transit
curriculum
develop
qualit
survey
assess
patient
view
exist
approach
learn
scd
opinion
prefer
transit
topic
thirti
patient
scd
age
year
old
recruit
januari
decemb
respons
manag
use
redcap
electron
data
tool
host
univers
rochest
qualit
quantit
data
analys
perform
includ
independ
ttest
compar
respons
age
group
result
approxim
subject
year
age
older
seventyon
percent
comput
cell
phone
report
daili
use
subject
report
greatest
satisfact
learn
doctor
clinic
visit
agre
strongli
agre
websit
cell
phone
agre
strongli
agre
least
popular
method
onlin
chat
room
powerpoint
present
satisfact
similar
across
age
group
recommend
transit
topic
view
posit
subject
rank
highest
understand
bloodwork
agre
strongli
agre
understand
law
protect
student
chronic
diseas
agre
strongli
agre
older
subject
year
old
agre
strongli
learn
opioid
addict
understand
differ
adult
pediatr
doctor
younger
subject
year
old
p
pilot
studi
success
help
us
understand
educ
need
aya
patient
scd
preliminari
data
underscor
import
educ
provid
pediatr
hematologist
result
also
suggest
optim
use
technologybas
method
requir
investig
tailor
transit
educ
age
group
may
use
background
similar
patient
transfusiondepend
betathalassemia
tdtbeta
survivor
hemoglobin
bart
hydrop
fetali
homozyg
tdtalpha
requir
lifelong
transfus
erythrocyt
previous
shown
transfus
strategi
base
guidelin
develop
tdtbeta
convent
transfus
suboptim
patient
owe
differ
pathophysiolog
anemia
two
condit
tdtalpha
convent
transfus
strategi
lead
gradual
increas
nonfunct
hbh
subsequ
tissu
hypoxia
hemolysi
aggress
transfus
strategi
base
reduct
hbh
increas
function
hemoglobin
level
result
improv
tissu
oxygen
reduct
hemolysi
associ
signific
increas
transfusion
iron
burden
amid
et
al
blood
object
defin
optim
chronic
blood
transfus
target
hbh
function
hemoglobin
patient
tdtalpha
designmethod
follow
research
ethic
board
approv
longitudin
data
patient
tdtalpha
male
median
age
retrospect
collect
variabl
interest
includ
total
pretransfus
hemoglobin
hbh
function
hemoglobin
measur
total
hemoglobin
x
outcom
variabl
lactat
dehydrogenas
ldh
marker
hemolysi
solubl
transferrin
receptor
str
marker
erythropoiesi
hemoglobin
analysi
done
use
highperform
liquid
chromatographi
capillari
zone
electrophoresi
examin
associ
function
hemoglobin
str
hbh
ldh
use
repeatedmeasur
anova
adjust
effect
multipl
test
construct
receiv
oper
characterist
curv
calcul
area
curv
defin
best
cutoff
valu
variabl
interest
strong
associ
function
hb
str
well
hbh
ldh
optim
cutoff
function
hemoglobin
associ
str
mgl
gl
auc
sensit
specif
respect
optim
cutoff
hbh
supress
ldh
ul
auc
sensit
specif
respect
optim
pretransfus
hbh
reduct
hemolysi
optim
function
hemoglobin
adequ
supress
erythropoiesi
gl
meet
hbh
function
hb
target
simpl
blood
transfus
patient
tdtalpha
would
requir
hypertransfus
regimen
minimum
pretransfus
total
hb
gl
consequ
high
transfusion
iron
burden
altern
approach
use
exchang
transfus
reduc
hbh
improv
function
hemoglobin
would
associ
less
volum
transfus
potenti
better
longterm
outcom
hospit
sacr
coeur
milot
haiti
background
initi
result
work
develop
pediatr
sickl
cell
diseas
scd
clinic
coeur
hsc
milot
northern
haiti
present
aspho
purpos
clinic
pediatrician
special
interest
scd
provid
scd
care
advis
trait
manag
diseas
penicillin
prophylaxi
pcn
hydroxyurea
therapi
hu
select
patient
clinic
start
collabor
us
base
hematologist
support
yalenew
hospit
object
describ
success
challeng
provid
pcn
hu
scd
clinic
hsc
review
patient
record
designmethod
sinc
clinic
incept
databas
patient
basic
clinic
inform
kept
made
access
dropbox
us
hematologist
record
present
clinic
review
hemoglobin
diagnosi
made
either
clinic
histori
sickl
cell
prep
hemoglobin
electrophoresi
alpha
laboratori
portauprinc
haiti
result
ninetynin
individu
seen
first
year
program
fiftysix
underw
hemoglobin
electrophoresi
year
old
thirtytwo
start
pcn
vk
year
old
eleven
patient
start
hu
therapi
patient
hu
shown
progress
increas
hemoglobin
clinic
complic
hu
therapi
none
patient
take
hu
requir
hospit
transfus
three
patient
hu
hospit
complic
scd
osteomyel
pain
less
half
number
program
admiss
sever
anemia
pain
stroke
splenic
sequestr
ongo
extern
support
local
reput
excel
sickl
cell
care
clinic
hsc
abl
expand
servic
improv
health
grow
number
patient
scd
earli
data
suggest
pcn
hu
therapi
help
reduc
complic
improv
qualiti
life
challeng
date
includ
lack
fund
transport
clinic
hospit
cover
cost
electrophores
time
continu
provid
excel
care
gather
data
crucial
explor
opportun
collabor
cooper
way
assur
clinic
becom
independ
sustain
continu
improv
qualiti
life
individu
serv
background
inflammatori
glycoprotein
express
infiltr
macrophag
variou
inflammatori
condit
found
elev
patient
differ
patholog
condit
like
acut
chronic
inflamm
increas
remodel
extracellular
matrix
ecm
develop
fibrosi
cancer
sever
studi
found
elev
concentr
sera
patient
liver
diseas
hepat
fibrosi
hepat
c
viru
suggest
concentr
reflect
degre
liver
fibrosi
evalu
serum
level
patient
thalassemia
relat
viral
hepat
liver
stiff
assess
transient
elastographi
fibroscan
fs
hepat
iron
concentr
designmethod
prospect
studi
includ
patient
tm
male
femal
mean
age
year
rang
year
serum
ferritin
level
liver
enzym
alt
ast
hb
ag
anti
hcv
ab
serum
use
elisa
kit
evalu
patient
subject
liver
mri
detect
liver
iron
content
sequenc
transient
elastographi
fibroscan
fs
assess
degre
liver
stiff
result
mean
fibroscan
valu
kpa
median
rang
kpa
patient
categor
stage
patient
sever
fibrosi
median
serum
ferritin
patient
valu
exceed
gl
median
cardiac
patient
valu
ms
median
lic
mgg
dw
patient
show
read
mgg
dw
evalu
marker
inflamm
liver
fibrosi
show
mean
valu
pgml
rang
pgml
mean
significantli
higher
among
male
p
patient
chelat
therapi
p
patient
df
abnorm
liver
enzym
splenectomis
patient
patient
hbv
seroposit
moder
elev
patient
high
grade
liver
fibrosi
p
show
posit
correl
rate
transfus
lic
ferritin
alt
ast
neg
correl
weight
height
roc
curv
analysi
reveal
cutoff
valu
pgml
could
differenti
tm
patient
without
viral
hepat
sensit
specif
area
curv
auc
posit
predict
valu
neg
predict
valu
p
roc
curv
analysi
reveal
cutoff
valu
pgml
could
detect
tm
patient
liver
cirrhosi
sensit
specif
area
curv
auc
posit
predict
valu
neg
predict
valu
p
conclus
serum
level
elev
patient
thalassemia
detect
patient
activ
viral
hepat
liver
stiff
background
common
splenic
complic
pediatr
patient
sickl
cell
diseas
scd
acut
splenic
sequestr
ass
often
manag
splenectomi
although
splenectomi
treatment
choic
year
longterm
vascular
complic
thoroughli
evalu
pulmonari
hypertens
phtn
sever
complic
scd
adult
scd
phtn
associ
mortal
rate
approxim
report
splenectom
patient
hemolyt
disord
even
greater
risk
phtn
sever
medic
exist
treat
phtn
studi
efficaci
toxic
patient
scd
addit
patient
often
treat
either
chronic
prbc
transfus
hydroxyurea
hu
rais
hemoglobin
reduc
hemolysi
prevent
vasoocclus
event
object
evalu
effect
chronic
prbc
hu
vs
intervent
tricuspid
regurgit
jet
veloc
trv
pediatr
patient
scd
histori
splenectomi
designmethod
retrospect
chart
review
splenectom
patient
hbss
follow
marian
anderson
center
st
christoph
hospit
children
philadelphia
analyz
trv
hu
prbc
control
group
receiv
neither
treatment
patient
hu
prbc
neither
mean
age
echo
data
analyz
linear
correl
analysi
varianc
anova
includ
post
hoc
test
least
signific
differ
lsd
pair
treatment
group
result
trv
significantli
correl
age
time
assess
time
splenectomi
trv
univari
anova
among
group
yield
trv
mean
cm
hu
prbc
neither
found
notabl
differ
mean
hu
group
almost
cm
lower
other
overal
statist
signific
associ
group
exist
howev
perform
post
hoc
test
adjust
multipl
comparison
look
pair
within
anova
found
lsd
hu
prbc
group
statist
signific
p
trend
exist
hu
group
neither
treatment
group
p
data
suggest
treatment
hu
correl
reduct
trv
pediatr
patient
scd
underw
splenectomi
given
promis
result
believ
data
warrant
studi
larger
treatment
group
nanci
olivieri
gaurav
sharma
susmita
nath
rajib
de
tuphan
kanti
dolai
praka
kumar
mandal
abhijit
phukan
amir
sabouhanian
robert
yamashita
angela
allen
david
weatheral
prantar
chakrabarti
background
hemoglobin
e
thalassemia
hbethal
account
sever
beta
thalassemia
worldwid
estim
preval
west
bengal
littl
inform
clinic
find
report
object
document
clinic
laboratori
find
patient
hbethal
ultim
improv
resourc
clinic
manag
designmethod
review
record
databas
record
patient
name
clinic
chart
special
chart
contain
addit
detail
transfus
patient
transfus
daycar
record
addit
india
public
hospit
origin
labimag
report
commonli
retain
home
famili
interview
provid
addit
inform
exclud
record
patient
age
year
patient
age
year
review
sinc
result
least
one
visit
record
hbethal
patient
nr
hospit
patient
regularli
review
examin
chart
age
year
age
year
male
repres
approxim
regularlyreview
patient
famili
report
monthli
incom
indian
rupe
monthli
cost
live
rupe
kolkata
mean
hemoglobin
gdl
patient
receiv
eight
transfus
per
year
treat
deferasirox
mgkgday
iron
control
estim
serum
ferritin
concentr
gl
highli
variabl
total
patient
splenectom
substanti
obstacl
document
complic
lack
record
five
sourc
mani
relev
paramet
exampl
statu
sexual
matur
normal
delay
absent
document
less
measur
fast
blood
glucos
less
record
record
complic
rate
high
delayedabnorm
sexual
matur
record
patient
age
year
patient
age
year
age
year
respect
hypothyroid
record
elev
serum
alt
evalu
patient
year
height
measur
percentil
cardiac
find
rare
document
includ
pulmonari
hypertens
reduc
left
ventricular
eject
fraction
patient
despit
dedic
attent
mani
aspect
thalassemia
care
insuffici
document
limit
clear
understand
current
morbid
hbethal
patient
invest
personnel
technolog
critic
record
relev
inform
ultim
improv
clinic
manag
next
decad
children
hospit
richmond
vcu
health
richmond
virginia
unit
state
background
sepsi
common
caus
death
children
sickl
cell
diseas
scd
recommend
care
fever
children
scd
includ
immedi
medic
evalu
includ
blood
cultur
initi
broadspectrum
antibiot
therapi
increas
avail
pcrbase
respiratori
pathogen
panel
rpp
provid
opportun
rapidli
identifi
viral
caus
fever
role
rpp
identifi
sourc
fever
children
scd
affect
provid
practic
well
studi
determin
epidemiolog
respiratori
virusassoci
fever
children
scd
determin
whether
posit
rpp
associ
reduc
risk
bacteremia
popul
singlecent
retrospect
cohort
studi
identifi
review
medic
record
children
scd
seen
emerg
depart
ed
temperatur
home
ed
januari
septemb
well
febril
children
rpp
sent
sinc
introduct
rpp
april
review
result
blood
cultur
rpp
chest
radiograph
ed
note
discharg
summari
identifi
sourc
infect
independ
test
chisquar
analysi
use
appropri
compar
result
use
overal
rate
bacteremia
case
bacteremia
among
children
posit
rpp
children
neg
rpp
true
bacteremia
posit
rpp
reduc
likelihood
bacteremia
p
patient
bacteremia
higher
present
temperatur
without
bacteremia
vs
p
common
rpp
find
rhinovirusenteroviru
human
metapneumoviru
influenza
send
rpp
affect
admiss
rate
respect
p
howev
likelihood
admiss
lower
patient
posit
rpp
vs
p
length
stay
lo
shorter
patient
rpp
sent
vs
day
p
previous
report
bacteremia
febril
children
scd
low
remain
seriou
concern
particularli
set
high
fever
posit
rpp
reduc
odd
bacteremia
statist
signific
impact
admiss
rate
lo
work
need
understand
rpp
result
impact
provid
decisionmak
care
children
scd
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
diffus
myocardi
fibrosi
common
defin
featur
heart
sickl
cell
anemia
sca
strongli
associ
diastol
dysfunct
found
diffus
myocardi
fibrosi
everi
patient
sca
cohort
n
rang
age
year
niss
treatment
prevent
complic
sca
studi
object
diffus
myocardi
fibrosi
must
begin
earli
childhood
hypothes
earli
initi
uninterrupt
use
diseasemodifi
therapi
sca
prevent
designmethod
use
cardiac
magnet
reson
imag
cmr
measur
myocardi
extracellular
volum
fraction
ecv
quantifi
diffus
myocardi
fibrosi
individu
sca
treat
uninterrupt
hydroxyurea
chronic
transfus
therapi
sinc
year
age
two
comparison
group
use
individu
sca
treat
diseasemodifi
therapi
sinc
year
age
n
control
without
sca
n
result
studi
individu
mean
age
year
rang
mean
age
start
diseasemodifi
therapi
year
rang
evid
mild
diffus
myocardi
fibrosi
ecv
detect
diffus
fibrosi
ecv
upper
limit
normal
mean
ecv
significantli
lower
ecv
individu
sca
receiv
earli
uninterrupt
therapi
p
statist
differ
normal
control
p
none
macroscop
fibrosi
late
gadolinium
enhanc
evid
myocardi
hemosiderosi
imag
patient
diastol
dysfunct
echocardiograph
classif
right
heart
catheter
diseasemodifi
therapi
sca
prevent
diffus
myocardi
fibrosi
possibl
diastol
dysfunct
start
earli
childhood
prospect
trial
diseasemodifi
antifibrot
therapi
plan
prevent
diffus
myocardi
fibrosi
monitor
noninvas
cmr
improv
outcom
sca
niss
blood
background
statewid
sickl
cell
surveil
system
sscss
develop
goal
determin
preval
sickl
cell
diseas
scd
indiana
level
care
patient
receiv
throughout
state
person
scd
high
risk
infect
especi
encapsul
organ
well
increas
complic
influenza
util
sscss
data
relationship
vaccin
statu
mortal
explor
determin
vaccin
statu
associ
mortal
person
scd
project
grant
waiver
consent
st
vincent
irb
death
certif
obtain
identifi
caus
death
deceas
patient
case
match
age
gender
sickl
genotyp
live
patient
control
vaccin
data
collect
medic
record
children
hoosier
immun
registri
program
chirp
date
death
case
case
control
assign
point
complet
pneumococcu
meningococcu
haemophilu
influenza
type
b
hib
vaccin
seri
one
point
influenza
vaccin
given
within
year
prior
death
case
max
vaccin
statu
score
vss
total
point
compar
case
control
two
tail
ttest
compar
mean
continu
data
wilcoxon
signedrank
test
compar
ordin
data
one
thousand
fortyeight
individu
includ
sscss
six
hundr
seven
seen
one
institut
includ
analysi
mean
age
year
thirtythre
deceas
time
analysi
six
point
one
control
case
receiv
vss
mean
vss
case
control
thirti
point
three
control
vss
one
compar
case
p
patient
die
infect
streptococcu
n
pseudomona
n
unidentifi
organ
n
date
vaccin
encapsul
organ
two
receiv
influenza
vaccin
year
prior
death
sampl
mortal
occur
exclus
among
adult
patient
consist
current
pattern
develop
countri
among
adult
vss
mortal
rate
relat
limit
studi
includ
small
sampl
size
potenti
incomplet
vaccin
record
vaccin
rate
standard
care
indic
explor
larger
cohort
patient
determin
associ
mortal
background
sickl
cell
diseas
scd
genet
disord
result
acut
chronic
complic
includ
delay
puberti
delay
puberti
advers
physic
psychosoci
effect
affect
children
famili
publish
report
ghana
pubert
time
children
scd
aim
crosssect
studi
describ
pubert
chang
children
scd
korl
bu
teach
hospit
kbth
accra
compar
find
control
group
without
scd
designmethod
children
scd
children
hb
aa
age
year
consecut
recruit
match
age
sex
socioeconom
statu
investigatoradminist
questionnair
use
obtain
demograph
data
particip
inform
menarch
girl
pubert
statu
assess
physic
examin
use
tanner
stage
testicular
volum
determin
boy
use
prader
orchidomet
bodi
mass
index
bmi
socioeconom
statu
se
particip
analyz
determin
associ
tanner
stage
scd
hb
ss
hb
sc
femal
compris
case
control
mean
age
onset
breast
develop
significantli
delay
girl
scd
year
compar
control
year
signific
age
differ
onset
pubic
hair
develop
mean
age
menarch
significantli
delay
girl
hb
ss
year
hb
sc
year
compar
hb
aa
year
boy
mean
age
onset
puberti
significantli
delay
scd
year
genit
develop
year
pubic
hair
develop
compar
without
scd
year
year
respect
mean
testicular
volum
significantli
lower
case
compar
control
across
age
rang
p
mean
bmi
case
control
similar
onset
breast
develop
girl
howev
boy
without
scd
mean
bmi
valu
significantli
differ
pubert
onset
univari
analysi
se
associ
tanner
stage
genit
breast
develop
mean
age
pubert
onset
significantli
delay
children
scd
longitudin
studi
need
character
associ
bmi
determin
potenti
modifi
risk
factor
affect
pubert
onset
scd
background
sicklecel
diseas
scd
lifethreaten
genet
disord
associ
multipl
chronic
acut
complic
specif
monitor
treatment
children
major
part
medic
focu
remain
lack
realworld
evid
diseas
burden
practic
pattern
among
pediatr
scd
popul
object
examin
clinic
burden
manag
scd
among
pediatr
patient
designmethod
retrospect
claim
studi
conduct
use
medicaid
analyt
extract
databas
pediatr
patient
age
year
scd
identifi
use
diagnosi
code
first
observ
scd
diagnosi
identif
period
design
index
date
patient
requir
continu
medic
pharmaci
benefit
least
month
preand
month
postindex
period
patient
data
assess
earliest
occurr
follow
event
disenrol
death
end
studi
period
patient
demograph
baselin
clinic
characterist
clinic
outcom
mortal
incid
pain
crisi
complic
scd
manag
healthcar
util
examin
variabl
analyz
descript
result
total
patient
met
studi
inclus
criteria
mean
age
year
patient
black
charlson
comorbid
index
score
mortal
followup
personyear
event
rate
pain
crisi
inpati
set
personyear
three
common
complic
pain
crisi
highest
rate
personyear
fever
infecti
parasit
diseas
asthma
rate
lifethreaten
complic
also
examin
personyear
includ
acut
chest
syndrom
stroke
splenic
sequestr
pulmonari
hypertens
pulmonari
embol
patient
prescrib
antibiot
oneyear
postindex
period
frequent
medic
util
among
children
folic
acid
nonsteroid
antiinflammatori
drug
opioid
hydroxyurea
patient
blood
transfus
within
one
year
postindex
date
patient
frequent
health
care
util
inpati
visit
emerg
room
visit
offic
visit
pharmaci
visit
set
oneyear
followup
period
pediatr
scd
patient
burden
high
rate
complic
includ
pain
crisi
addit
patient
util
substanti
amount
health
care
resourc
includ
outpati
offic
care
acut
care
visit
background
novel
use
hydroxyurea
african
region
malaria
noharm
random
control
trial
hydroxyurea
young
children
sickl
cell
anemia
live
uganda
year
studi
particip
receiv
blind
studi
treatment
hydroxyurea
placebo
receiv
hydroxyurea
increas
risk
malaria
laboratori
clinic
benefit
year
studi
particip
receiv
openlabel
hydroxyurea
treatment
assess
effect
openlabel
hydroxyurea
treatment
young
popul
children
sickl
cell
anemia
live
uganda
studi
endpoint
includ
rate
sever
malaria
infect
clinic
sicklerel
event
laboratori
effect
designmethod
children
noharm
trial
enrol
mulago
hospit
sickl
cell
clinic
kampala
uganda
year
children
receiv
openlabel
fixeddos
hydroxyurea
mgkgday
month
previous
receiv
either
hydroxyurea
placebo
month
result
total
children
enter
year
noharm
trial
receiv
fixeddos
hydroxyurea
includ
male
femal
averag
age
year
among
children
previous
placebo
malaria
event
children
includ
sever
grade
three
death
two
acut
chest
syndrom
one
sepsi
clinic
advers
event
rate
drop
per
patient
year
hospit
reduc
expect
hematolog
benefit
increas
hemoglobin
mcv
fetal
hemoglobin
along
decreas
neutrophil
reticulocyt
rapidli
achiev
laboratori
advers
event
infrequ
event
per
patientyear
half
doselimit
hematolog
toxic
among
children
previous
hydroxyurea
malaria
event
children
includ
sever
grade
two
death
one
acut
chest
syndrom
one
sepsi
clinic
advers
event
rate
hospit
maintain
low
rate
hematolog
benefit
hydroxyurea
continu
throughout
extend
treatment
period
doselimit
toxic
remain
infrequ
fixeddos
hydroxyurea
treatment
young
children
sickl
cell
anemia
live
uganda
associ
increas
risk
malaria
clinic
laboratori
benefit
occur
includ
children
previous
placebo
crossedov
hydroxyurea
treatment
futur
studi
focu
optim
dose
monitor
strategi
effort
determin
overal
feasibl
safeti
introduc
hydroxyurea
therapi
across
subsaharan
africa
background
acut
chest
syndrom
ac
second
common
caus
hospit
patient
sickl
cell
diseas
lead
caus
morbid
mortal
algorithm
implement
cohen
children
medic
center
initi
transfus
within
four
hour
diagnosi
ac
order
improv
patient
outcom
object
aim
project
analyz
effect
earli
blood
transfus
outcom
patient
ac
focus
number
total
transfus
need
exchang
transfus
need
intens
care
unit
icu
stay
length
hospit
designmethod
retrospect
chart
review
complet
patient
admit
ccmc
primari
diagnosi
sickl
cell
diseas
secondari
diagnosi
either
ac
pneumonia
year
data
three
year
directli
prior
implement
algorithm
compar
data
three
year
directli
implement
algorithm
total
patient
analyz
belong
prealgorithm
group
postalgorithm
group
patient
postalgorithm
group
higher
incid
transfus
mean
transfus
number
pre
versu
mean
post
well
exchang
transfus
pre
versu
post
postalgorithm
group
shorter
overal
length
stay
mean
day
pre
versu
day
post
overal
percentag
patient
requir
icu
admiss
similar
group
pre
versu
post
postprotocol
group
lower
likelihood
requir
icu
admiss
reason
outsid
line
placement
exchang
transfus
commonli
iculevel
respiratori
support
pre
versu
post
despit
higher
total
number
transfus
earli
recognit
transfus
ac
lead
decreas
length
hospit
well
decreas
need
iculevel
respiratori
support
studi
compar
differ
center
clinic
practic
guidelin
necessari
improv
standard
care
background
novel
use
hydroxyurea
african
region
malaria
noharm
first
placebocontrol
random
clinic
trial
hydroxyurea
subsaharan
africa
noharm
young
children
sca
receiv
either
hydroxyurea
placebo
year
follow
openlabel
hydroxyurea
studi
particip
year
ancillari
noharm
project
design
determin
hydroxyurea
treatment
lower
transcrani
doppler
tcd
veloc
possibl
reduc
stroke
risk
young
cohort
object
perform
tcd
screen
noharm
cohort
measur
timeaverag
mean
veloc
tamv
end
year
year
hypothes
maximum
tamv
would
lower
noharm
studi
particip
receiv
hydroxyurea
compar
receiv
placebo
key
clinic
laboratori
paramet
would
also
influenc
tcd
veloc
designmethod
children
enrol
noharm
elig
undergo
tcd
examin
two
studi
time
point
month
complet
blind
treatment
phase
month
end
openlabel
treatment
phase
tcd
measur
includ
tamv
read
main
intracrani
arteri
middl
cerebr
arteri
distal
intern
carotid
arteri
bifurc
tcd
tcd
examin
score
classifi
normal
less
cmsec
condit
cmsec
abnorm
greater
equal
cmsec
higher
score
correl
greater
risk
stroke
result
end
year
tcd
exam
conduct
suitabl
analysi
hydroxyurea
placebo
base
maximum
tamv
median
veloc
cmsec
iqr
children
hydroxyurea
cmsec
iqr
placebo
p
maximum
tamv
valu
neg
correl
hemoglobin
concentr
fetal
hemoglobin
oxygen
satur
posit
correl
note
age
absolut
neutrophil
count
end
year
tcd
exam
conduct
suitabl
analysi
median
veloc
cmsec
openlabel
hydroxyurea
treatment
regardless
previou
blind
treatment
correl
tamv
maintain
except
age
conclus
compar
placebo
hydroxyurea
treatment
young
children
sca
live
uganda
associ
lower
tcd
veloc
correl
studi
lower
risk
primari
stroke
tcd
veloc
correl
hematolog
clinic
paramet
improv
hydroxyurea
therapi
children
hospit
richmond
virginia
commonwealth
univers
richmond
virginia
unit
state
background
acut
chest
syndrom
ac
defin
respiratori
symptom
new
pulmonari
infiltr
seriou
complic
sickl
cell
diseas
scd
ac
occur
hospit
nonpulmonari
condit
vasoocclus
crisi
surgeri
nih
clinic
practic
guidelin
encourag
incent
spirometri
decreas
incid
ac
addit
wide
accept
earli
frequent
ambul
postop
pneumonia
patient
decreas
length
stay
lo
decreas
ac
event
children
scd
children
hospit
aim
use
ageappropri
pediatr
sickl
cell
admiss
designmethod
multidisciplinari
team
examin
inpati
ac
prevent
practic
includ
children
hospit
richmond
key
driver
identifi
includ
educ
awar
patient
healthcar
staff
order
placement
document
aim
scd
patient
month
age
hospit
admiss
diagnosi
particip
use
tradit
incent
spiromet
similar
ageand
abilityappropri
devic
eg
posit
expiratori
pressur
devic
bubbl
pinwheel
secondarili
aim
increas
activ
event
specif
ambul
bed
time
educ
outreach
tool
includ
patient
inform
brochur
incent
program
staff
inform
session
refer
materi
workstat
diseasespecif
order
set
implement
includ
desir
activ
order
data
collect
prospect
may
novemb
pdsa
cycl
conduct
admiss
correspond
month
previou
year
review
comparison
independ
ttest
analysi
perform
use
graftpad
prism
statist
analysi
softwar
result
improv
reach
statist
signific
includ
increas
order
placement
admiss
p
admiss
document
use
increas
p
lo
decreas
mean
day
day
p
postadmiss
develop
ac
also
decreas
admiss
reach
statist
signific
p
addit
increas
appropri
activ
order
placement
document
activ
event
conclus
improv
educ
outreach
patient
staff
includ
implement
diseasespecif
order
set
improv
use
activ
event
declin
seen
incid
ac
develop
hospit
though
statist
signific
decreas
lo
encourag
effort
continu
improv
trend
background
pain
vasoocclus
crise
voc
frequent
debilit
complic
sickl
cell
diseas
scd
thought
occur
due
progress
blockag
microvasculatur
rigid
sickl
shape
red
blood
cell
trigger
decreas
microvascular
blood
flow
mbf
promot
entrap
sickl
cell
microvasculatur
progress
voc
exposur
cold
wind
chang
weather
common
trigger
voc
associ
increas
frequenc
hospit
pain
patient
scd
limit
experiment
data
physiolog
effect
factor
peripher
perfus
scd
studi
effect
grade
thermal
stimuli
peripher
mbf
scd
designmethod
scd
control
healthi
sickl
trait
subject
age
year
expos
individu
threshold
temperatur
heat
cold
detect
heat
cold
pain
via
tsaii
thermod
place
thenar
emin
mbf
measur
contralater
thumb
use
photoplethysmographi
ppg
vasoconstrict
respons
within
complex
ppg
signal
detect
use
crosscorrel
techniqu
mean
mbf
deriv
ppg
amplitud
stimuli
compar
baselin
mbf
cross
correl
analysi
show
cold
pain
caus
signific
vasoconstrict
respons
subject
follow
heat
pain
cold
detect
heat
detect
signific
drop
mbf
cold
pain
p
heat
pain
p
heat
detect
p
cold
detect
p
compar
baselin
mbf
cold
pain
caus
greatest
drop
mbf
thermal
sensit
mbf
respons
compar
scd
control
conclus
exposur
grade
thermal
stimuli
caus
progress
drop
mbf
exposur
cold
pain
elicit
strongest
vasoconstrict
respons
vasoconstrict
occur
contralater
hand
averag
second
stimuli
suggest
neural
mediat
mechan
although
signific
differ
vasoconstrict
respons
scd
control
drop
mbf
patient
sickl
cell
diseas
increas
likelihood
entrap
sickl
red
blood
cell
lead
vasoocclus
find
consist
extens
report
literatur
exposur
cold
weather
associ
higher
frequenc
voc
suggest
neural
mediat
vasoconstrict
like
import
factor
pathophysiolog
behind
cold
exposur
lead
voc
scd
background
vasoocclus
crisi
voc
major
caus
hospit
admiss
children
sickl
cell
diseas
scd
although
use
clinic
biomark
voc
studi
especi
regard
acut
chest
syndrom
ac
less
data
regard
overal
voc
sever
predict
addit
new
biomark
platelet
lymphocyt
ratio
plr
neutrophil
lymphocyt
ratio
nlr
lymphocyt
monocyt
ratio
lmr
littl
studi
regard
scd
object
identifi
whether
admiss
laboratori
valu
chang
well
baselin
laboratori
valu
new
biomark
plr
nlr
lmr
could
predict
sever
vasoocclus
crisi
children
sickl
cell
diseas
admit
voc
designmethod
retrospect
singl
center
observ
studi
admiss
voc
children
age
year
hbss
septemb
novemb
exclud
hypertransfus
protocol
admiss
diagnosi
ac
univari
analysi
done
use
student
ttest
mannwhitney
non
parametr
test
fischer
exact
test
appropri
depend
distribut
admiss
laboratori
data
complet
blood
count
cbc
reticulocyt
count
comprehens
metabol
panel
lactat
dehydrogenas
ldh
chang
well
baselin
cbc
valu
within
month
previous
plr
nlr
lmr
develop
complic
voc
complic
voc
defin
develop
secondari
acut
chest
syndrom
prolong
admiss
durat
day
hour
requir
blood
transfus
readmiss
within
day
result
total
admiss
studi
fiftynin
femal
complic
signific
differ
sex
p
age
p
univari
analysi
reveal
signific
elev
total
bilirubin
p
ldh
p
platelet
count
p
complic
voc
also
signific
differ
percentag
chang
platelet
count
baselin
greater
declin
uncompl
voc
p
signific
differ
plr
p
nlr
p
lmr
p
conclus
elev
total
bilirubin
ldh
platelet
count
admiss
laboratori
valu
associ
develop
complic
voc
addit
complic
voc
present
significantli
less
declin
platelet
count
baselin
well
cbc
plr
nlr
lmr
seem
use
predict
biomark
sever
voc
background
sickl
cell
diseas
scd
caus
health
problem
vari
frequenc
sever
valid
biomark
children
scd
transcrani
doppler
reliabl
predictor
exist
scd
sever
children
scd
could
treat
accord
risk
categori
mani
patient
scd
face
psychosoci
econom
hardship
factor
evalu
risk
marker
medic
function
sever
scd
object
goal
project
develop
stratifi
preliminari
list
psychosoci
risk
factor
health
outcom
could
use
scd
sever
predictor
st
vincent
institut
review
board
list
potenti
psychosoci
risk
factor
advers
health
outcom
compil
base
assess
materi
util
sickl
safe
program
indiana
hemoglobinopathi
newborn
screen
followup
program
list
item
distribut
child
abus
prevent
scd
expert
rank
item
likert
scale
least
import
import
mean
score
calcul
use
spss
version
assess
retrospect
analyz
determin
psychosoci
risk
factor
frequenc
risk
factor
occur
home
consid
high
frequenc
event
overal
high
agreement
among
expert
risk
factor
consid
import
predictor
sever
scd
outcom
risk
factor
highest
frequenc
elig
public
assist
program
fifteen
risk
factor
rate
expert
four
high
frequenc
event
occur
home
child
hbss
hb
take
hydroxyurea
parent
report
treat
fever
home
past
month
tobacco
use
someon
household
famili
report
signific
psychosoci
stressor
past
year
tobacco
use
home
significantli
correl
sever
risk
factor
smoke
pregnanc
r
health
concern
child
r
child
health
insur
r
suggest
part
constel
health
risk
gener
risk
factor
rate
import
health
outcom
occur
less
frequent
sampl
studi
repres
import
progress
toward
identifi
group
psychosoci
risk
factor
scd
sever
necessari
first
step
futur
investig
empir
relationship
candid
risk
factor
scd
outcom
unitvers
cartagena
cartagena
bolivar
colombia
background
sickl
cell
diseas
autosom
recess
disord
character
mutat
globin
chain
produc
hb
acut
chronic
complic
aplast
crisi
acut
chest
syndrom
priapism
stroke
leg
ulcer
primarysecondari
prevent
stroke
treat
simpl
transfus
exchang
transfus
latter
offer
advantag
lower
iron
overload
posttreat
hb
goal
control
lower
viscos
improv
microvascular
circul
widelyus
option
associ
technic
difficulti
object
standard
new
partial
exchang
transfus
protocol
group
patient
sickl
cell
diseas
within
framework
chronic
transfus
program
designmethod
prospect
descript
studi
includ
patient
year
sickl
cell
diseas
hbss
hbstal
indic
partial
exchang
transfus
chronic
transfus
program
accord
institut
protocol
patient
fulfil
inclus
criteria
enrol
studi
februari
decemb
registri
medic
technic
complic
made
procedur
databas
construct
excel
graphpad
version
oc
softwar
use
statist
analysi
sequenc
follow
isovolem
phlebotomi
transfus
pack
red
cell
depend
recent
hemoglobin
level
hr
phlebotomi
cckg
hb
cckg
hb
cckg
isovolem
solut
ns
cckg
hb
cckg
hb
cckg
pack
red
cell
transfus
cckg
hb
cckg
hb
cckg
safeti
exchang
transfus
protocol
analyz
patient
sickl
cell
diseas
procedur
differ
sex
distribut
median
age
year
popul
homozyg
indic
transfus
primari
stroke
prevent
secondari
stroke
prevent
reason
low
percentag
complic
found
medic
origin
hypotens
nauseavomit
present
total
procedur
standard
protocol
safe
use
could
extend
lowincom
center
treat
patient
sickl
cell
diseas
need
chronic
transfus
program
includ
patient
hemoglobin
level
suggest
studi
measur
secur
efficaci
protocol
patient
acut
complic
background
clinic
trial
aim
achiev
pain
reduct
challeng
achiev
clinic
endpoint
pain
quantifi
biomark
may
unrel
scd
furthermor
threshold
seek
medic
care
differ
patient
voc
occur
home
miss
present
nonintervent
longitudin
studi
identifi
voc
patient
scd
object
examin
longitudin
relationship
pro
biomark
subject
scd
selfreport
voc
event
order
build
model
inhom
clinic
voc
collect
longitudin
pro
biomark
data
subject
span
voc
event
home
clinic
hospit
designmethod
longitudin
measur
pain
fatigu
function
activ
biomark
scd
patient
steadi
state
voc
studi
six
month
period
patient
selfreport
pain
fatigu
function
medic
use
use
novel
epro
tool
voc
report
realtim
trigger
mobil
phlebotomi
team
blood
collect
sequenti
selfreport
voc
home
hospit
blood
sampl
drawn
two
day
resolut
voc
report
patient
nonvoc
period
blood
drawn
everi
week
establish
baselin
biomark
includ
leukocyteplatelet
aggreg
circul
microparticl
cell
solubl
adhes
molecul
cytokin
inflammatori
mediat
coagul
factor
patient
wore
actigraphi
devic
track
sleep
activ
rest
result
twentyseven
thirtyf
patient
experienc
total
day
voc
hr
day
result
healthcar
util
voc
day
significantli
higher
pain
fatigu
score
voc
day
associ
significantli
decreas
function
score
significantli
greater
decreas
voc
requir
medic
contact
compar
athom
voc
differ
activ
profil
identifi
nonvoc
athom
voc
medic
contact
voc
day
actigraphi
monitor
athom
voc
day
exhibit
increas
daytim
rest
compar
nonvoc
day
medic
contact
voc
decreas
averag
peak
activ
increas
daytim
rest
compar
nonvoc
day
sleep
fragment
index
trend
athom
medic
contact
voc
day
signific
chang
voc
day
observ
creactiv
protein
increas
nucleat
rbc
increas
monocyteplatelet
aggreg
increas
neutrophilplatelet
aggreg
increas
increas
increas
tnfalpha
increas
identif
assess
athom
voc
use
epro
actigraphi
biomark
feasibl
demonstr
innov
athom
studi
design
background
riskstratifi
sickl
cell
diseas
scd
patient
demonstr
respons
diseasemodifi
therapi
challeng
due
phenotyp
heterogen
scd
pathogen
role
procoagul
von
willebrand
factor
vwf
via
excess
vwf
high
molecular
weight
multim
hmwm
propos
variabl
report
increas
vwf
hmwm
crisi
vs
steadyst
adult
less
vwf
children
scd
moreov
vwf
multim
studi
sickl
trait
object
pilot
studi
evalu
potenti
vwf
antigen
vwf
ag
hmwm
densitometr
trace
serv
biomark
diseas
sever
treatment
respons
children
young
adult
scd
compar
sickl
trait
hba
sibl
designmethod
evalu
vwf
ag
vwf
multim
retrospect
clinic
data
hbss
hbsc
hba
subject
steadi
state
one
hbsc
subject
also
crisi
sampl
median
scd
age
year
year
femal
scd
sever
judg
annual
vasoocclus
acut
chest
event
strokeelev
tcd
eight
hbss
hbsc
took
hydroxyurea
four
hbss
subject
sever
scd
chronic
transfus
result
mean
vwf
ag
normal
iudl
higher
hbss
sever
hbss
compar
hbsc
p
respect
howev
lack
statist
signific
compar
hba
p
respect
vwf
ag
elev
steadyst
includ
sever
diseas
chronic
transfus
take
hydroxyurea
hbsc
crisi
hbsc
baselin
vwf
ag
high
hba
sibl
four
increas
hmwm
baselin
hbsssever
diseasechron
transfus
hbsshydroxyurea
hbsc
untreat
hmwm
increas
vasoocclus
crisi
hydroxyureatr
hbsc
subject
ultralarg
hmwm
observ
preliminari
studi
young
scd
subject
vwf
ag
trend
higher
hbss
vs
hbsc
sever
hbss
particip
singl
timepoint
serial
evalu
baselin
crisi
optim
diseasemodifi
therapi
need
determin
potenti
vwf
ag
hmwm
biomark
sever
treatment
respons
surprisingli
vwf
ag
high
sickl
trait
subject
sinc
hba
associ
health
challeng
increas
thrombosi
risk
examin
vwf
endotheli
dysfunct
sickl
trait
may
provid
novel
insight
role
biomark
background
nation
heart
lung
blood
institut
nhlbi
guidelin
acut
manag
voe
recommend
rapid
evalu
treatment
pain
includ
administr
parenter
opioid
within
triag
registr
pain
reassess
repeat
opioid
deliveri
within
inf
use
increas
ped
due
rapid
onset
eas
administr
object
evalu
ped
util
inf
effect
intraven
iv
opioid
administr
pain
control
treatment
voe
designmethod
retrospect
review
emr
perform
children
present
ped
voe
pain
score
scale
janjun
variabl
studi
median
time
ci
ped
arriv
firstparenteralopioidadministr
timetofirstivopioid
first
final
pain
score
disposit
readmiss
rate
timetofirstivopioid
also
compar
histor
data
n
prior
inf
protocol
initi
addit
patient
receiv
iv
opioid
within
minut
ed
arriv
infiv
opioid
vs
iv
opioid
alon
group
p
differ
found
group
includ
inf
alon
group
conclus
use
inf
ped
voe
excel
strategi
shorten
timetofirstparenteralopioidadministr
improv
pain
score
improv
adher
nhlbi
guidelin
howev
distinct
unexpect
find
delay
iv
opioid
deliveri
inf
use
inf
alon
appear
provid
suffici
pain
control
without
iv
opioid
disposit
home
voe
patient
whether
latter
reflect
insuffici
pain
manag
milder
subgroup
inf
alon
suffici
requir
investig
studi
illustr
experi
pedbas
inf
protocol
term
unanticip
delay
iv
opioid
also
discharg
inf
alon
effort
underway
improv
use
inf
voe
manag
st
christoph
hospit
children
philadelphia
pennsylvania
unit
state
background
folat
supplement
commonli
includ
standard
manag
patient
sickl
cell
diseas
howev
clear
evid
support
clinic
benefit
practic
lack
singl
studi
demonstr
improv
occurr
repeat
dactyl
higher
dose
folic
acid
compar
clinic
outcom
pediatr
patient
sickl
cell
diseas
treat
folat
supplement
versu
designmethod
studi
retrospect
chart
review
includ
patient
year
old
sickl
cell
diseas
type
ss
follow
st
christoph
hospit
children
data
collect
includ
inform
folat
supplement
red
cell
indic
presenc
absenc
clinic
outcom
includ
vasoocclus
crisi
requir
hospit
last
six
month
acut
chest
syndrom
infect
asthma
sleep
apnea
nephropathi
cerebr
vascular
diseas
stroke
avascular
necrosi
analysi
varianc
anova
use
evalu
mean
differ
age
number
infect
number
voc
event
hemoglobin
reticulocyt
count
mean
corpuscular
volum
addit
chi
squar
analysi
implement
evalu
differ
folat
nonfol
group
left
ventricular
remodel
lvr
sickl
cell
nephropathi
asthma
obstruct
sleep
apnea
osa
nocturn
hypoxia
avascular
necrosi
avn
mean
differ
folat
nonfol
group
compar
patient
hydroxyurea
therapi
one
hundr
seven
patient
met
inclus
criteria
follow
review
clinic
data
patient
includ
studi
patient
found
take
folat
patient
statist
analysi
show
signific
differ
incid
clinic
outcom
patient
folat
versu
folat
patient
hydroxyurea
hemoglobin
level
significantli
higher
patient
folat
versu
p
significantli
differ
patient
hydroxyurea
studi
suggest
folat
supplement
make
signific
impact
red
blood
cell
indic
anemia
incid
advers
clinic
outcom
children
sickl
cell
diseas
howev
larger
prospect
studi
need
guid
futur
consider
folat
supplement
sickl
cell
patient
clinic
set
background
tanzania
rank
global
number
infant
born
annual
sickl
cell
diseas
scd
lack
nation
newborn
screen
program
preval
sickl
cell
trait
sct
scd
highest
northwestern
region
around
lake
victoria
serv
bugando
medic
centr
bmc
teach
consult
hospit
mwanza
bmc
also
hous
hiv
earli
infant
diagnosi
eid
laboratori
test
dri
blood
spot
db
hivexpos
infant
db
test
hiv
retest
sickl
cell
trait
diseas
determin
preval
sickl
trait
diseas
region
district
northwestern
tanzania
use
exist
public
health
infrastructur
secondari
object
explor
associ
sct
scd
malaria
hiv
designmethod
tanzania
sickl
surveil
studi
prospect
yearlong
crosssect
studi
hivexpos
infant
born
northwestern
tanzania
whose
db
collect
eid
program
test
bmc
avail
test
sct
scd
sampl
children
month
age
test
isoelectr
focus
ief
score
independ
two
tanzanian
staff
normal
sct
scd
variant
uninterpret
db
sampl
score
diseas
variant
repeat
cours
month
ief
gel
run
total
db
sampl
score
includ
children
less
old
overal
preval
sct
preval
scd
along
hemoglobin
variant
qualiti
laboratori
result
extrem
high
db
sampl
yield
uninterpret
result
geospati
map
first
sampl
reveal
region
scd
preval
rang
among
region
serv
bmc
preval
sct
scd
high
northwestern
tanzania
geospati
map
identifi
high
preval
area
target
newborn
screen
start
use
exist
public
health
infrastructur
minim
startup
cost
train
data
enhanc
accuraci
map
district
level
background
pediatr
patient
sickl
cell
diseas
scd
could
develop
obstruct
restrict
mix
abnorm
pulmonari
function
pf
sever
public
report
progress
worsen
pf
time
could
lead
sever
morbid
adult
patient
sickl
cell
diseas
adult
sickl
cell
anemia
mortal
relat
lung
diseas
earli
intervent
aim
improv
lung
function
could
significantli
decreas
morbid
possibl
improv
life
expect
among
diseas
modifi
approach
commonli
use
scd
hydroxyurea
hu
chronic
prbc
transfus
intervent
lead
increas
hemoglobin
decreas
hb
fraction
lead
decreas
hemolysi
report
effect
hu
pulmonari
function
conflict
suggest
effect
other
propos
slower
declin
pulmonari
function
goal
studi
evalu
effect
diseas
modifi
therapi
like
hu
chronic
prbc
chang
pulmonari
function
pediatr
patient
sickl
cell
diseas
designmethod
studi
util
retrospect
chart
review
children
scd
multipl
pft
analyz
pft
patient
done
clinic
visit
scd
patient
divid
three
treatment
group
hydroxyurea
chronic
transfus
neither
data
analyz
linear
correl
analysi
varianc
anova
comparison
made
three
group
specif
observ
chang
absolut
number
pft
time
use
first
last
pft
patient
result
total
patient
multipl
pft
rang
control
hydroxyurea
chronic
transfus
mean
chang
control
hydroxyurea
pft
paramet
chronic
transfus
group
demonstr
small
improv
pft
time
fvc
howev
declin
howev
statist
signific
pvalu
differ
pft
paramet
group
children
scd
declin
pf
paramet
time
although
signific
differ
seen
three
group
appear
chronic
transfus
may
improv
limit
declin
pft
larger
studi
need
done
evalu
differ
pf
declin
patient
scd
patient
background
use
mobil
technolog
health
care
grow
trend
patient
chronic
diseas
sickl
cell
diseas
scd
requir
close
monitor
provid
appropri
treatment
recommend
avoid
complic
conduct
feasibl
studi
patient
scd
hospit
pain
use
selfdevelop
mobil
applic
trupain
technolog
resourc
better
understand
pain
wearabl
activ
tracker
subject
symptom
pain
object
data
heart
rate
hr
measur
aim
correl
nurs
record
mobil
technolog
record
get
feedback
patient
usabl
designmethod
enrol
patient
scd
year
old
hour
admiss
uncompl
vasoocclus
crisi
exclud
patient
admit
icu
patient
given
ipad
wearabl
devic
instruct
record
applic
least
per
day
keep
wearabl
remov
charg
prior
discharg
patient
complet
feasibl
questionnair
enrol
patient
femal
median
age
rang
admit
median
day
rang
uncompl
pain
crisi
patient
use
applic
throughout
hospit
made
one
entryday
rang
pain
score
record
via
trupain
correl
well
r
p
pain
score
record
emr
averag
data
point
record
per
day
wearabl
maximum
data
pointsday
median
amount
hour
wearabl
data
per
day
maximum
hr
record
via
wearabl
correl
significantli
hr
record
emr
r
pvalu
usabl
patient
indic
never
problem
technolog
found
trupain
easi
somewhat
easi
use
satisfi
particip
studi
indic
help
track
pain
pilot
studi
hospit
show
strong
potenti
use
trupain
patient
scd
pain
data
applic
hr
wearabl
correl
well
emr
data
accord
feedback
receiv
applic
easi
use
help
patient
track
pain
despit
limit
batteri
life
use
wearabl
technolog
feasibl
provid
addit
data
activ
optimist
continu
improv
trupain
system
help
improv
care
patient
scd
background
hydroxyurea
chronic
blood
transfus
bone
marrow
transplant
reduc
complic
improv
surviv
sickl
cell
diseas
scd
associ
signific
decision
dilemma
inher
riskbenefit
tradeoff
lack
compar
studi
treatment
underutil
lead
avoid
morbid
prematur
mortal
need
tool
provid
patient
highqual
inform
treatment
option
associ
risk
benefit
help
clarifi
valu
allow
share
process
inform
medic
decis
make
object
develop
health
literaci
sensit
webbas
decis
aid
ptda
help
patient
scd
make
inform
choic
treatment
estim
random
clinic
trial
accept
effect
ptda
improv
patient
knowledg
involv
decisionmak
decisionmak
qualiti
designmethod
conduct
qualit
interview
scd
patient
caregiv
stakehold
healthcar
provid
decision
need
assess
identifi
decision
conflict
knowledg
expect
valu
support
resourc
decis
type
time
stage
learn
person
clinic
characterist
guid
develop
ptda
transcript
code
use
qsr
nvivo
stakehold
complet
alpha
beta
test
ptda
conduct
random
clinic
trial
adult
caregiv
pediatr
patient
evalu
compar
efficaci
ptda
vs
standard
care
result
ptda
wwwsickleoptionsorg
develop
per
decision
need
describ
stakehold
final
follow
alpha
test
beta
test
stakehold
respect
random
trial
subject
consid
variou
treatment
option
qualit
interview
reveal
high
level
usabl
accept
util
educ
valu
clarif
prepared
decis
make
ptda
median
rate
accept
ptda
good
excel
provid
narr
comment
endors
accept
eas
use
util
prepar
decis
make
ptda
met
intern
standard
content
develop
process
efficaci
except
full
rang
posit
neg
experi
patient
stori
compar
baselin
ptda
group
statist
signific
improv
prepared
decis
make
p
inform
subscal
decision
conflict
p
decision
selfefficaci
knowledg
choic
predisposit
stage
decisionmak
ptda
patient
scd
develop
follow
extens
engag
key
stakehold
found
accept
use
easi
use
improv
prepared
decis
make
decreas
decision
conflict
background
pain
vasoocclus
crisi
voc
account
major
emerg
depart
ed
visit
hospit
sickl
cell
diseas
scd
interest
studi
mental
stress
associ
autonom
nervou
system
an
imbal
caus
vasoconstrict
possibl
trigger
scd
pain
end
develop
mobil
phone
applic
app
record
daili
pain
frequenc
intens
clinic
endpoint
might
predict
an
paramet
measur
laboratori
particular
think
aura
may
repres
an
instabl
preced
even
trigger
chang
blood
flow
voc
object
assess
feasibl
use
app
evalu
frequenc
sever
voc
potenti
associ
mental
stress
presenc
aura
designmethod
app
develop
io
android
system
allow
patient
track
pain
stress
aura
idea
creat
app
easi
use
intent
captur
pain
episod
rather
detail
descript
pain
scd
patient
elig
parent
version
avail
younger
children
deidentifi
data
automat
transfer
hipaa
compliant
databas
via
cloudbas
server
interfac
main
research
project
databas
feedback
questionnair
implement
least
month
util
assess
usabl
scd
patient
enrol
particip
util
app
particip
provid
feedback
indic
app
easi
navig
mean
pain
scale
standard
deviat
enter
pain
day
although
mean
stress
level
statist
signific
correl
increas
stress
level
increas
pain
score
p
aura
report
patient
patient
report
episod
moreov
day
aura
present
greater
incid
pain
present
well
p
howev
statist
signific
associ
pain
intens
presenc
aura
p
conclus
consist
prior
research
report
pain
intens
significantli
associ
report
stress
intens
although
associ
presenc
aura
pain
seem
correl
pain
intens
uniqu
design
app
monitor
scd
pain
clinic
help
understand
role
sickl
dysautonomia
genesi
scd
pain
univers
florida
colleg
medicin
gainesvil
florida
unit
state
background
evidencedbas
guidelin
recommend
emerg
evalu
fever
children
sickl
cell
diseas
scd
preval
bacteremia
decreas
outpati
manag
becom
common
howev
fever
sometim
herald
complic
scd
acut
chest
syndrom
vasoocclus
pain
crisi
splenic
sequestr
aplast
crisi
institut
practic
regard
fever
manag
scd
remain
variabl
littl
known
clinic
outcom
children
hospit
uncompl
fever
object
primari
object
determin
rate
bacteremia
scdrelat
complic
per
febril
episod
children
scd
admit
singl
institut
januari
june
uncompl
fever
retrospect
cohort
studi
febril
patient
year
age
scd
genotyp
admit
univers
florida
defin
studi
period
elig
patient
identifi
databas
search
use
admit
diagnosi
code
scd
fever
base
intern
classif
diseas
revis
encount
manual
review
confirm
elig
patient
exclud
indic
hospit
appar
time
admiss
acut
vasoocclus
episod
requir
parent
narcot
asthma
exacerb
addit
complic
scd
databas
search
identifi
encount
exclud
base
confound
indic
hospit
sixtythre
elig
patient
account
hospit
median
age
year
rang
year
male
mean
durat
hospit
day
rang
day
eight
posit
blood
cultur
identifi
six
classifi
contamin
bacteremia
develop
scdrelat
complic
identifi
admiss
includ
acut
chest
syndrom
n
bacteremia
n
splenic
sequestr
n
red
cell
transfus
n
exploratori
analys
potenti
predictor
bacteremia
scdrelat
complic
show
associ
present
white
blood
cell
count
degre
fever
p
patient
classifi
scdrelat
complic
hemoglobin
ss
diseas
least
one
prior
document
complic
patient
transfus
least
one
prior
transfus
conclus
improv
prevent
care
substanti
lower
rate
bacteremia
children
scd
fever
warrant
care
evalu
acut
scdrelat
complic
provid
consid
inpati
observ
select
case
addit
studi
warrant
defin
subset
patient
suitabl
outpati
fever
manag
background
children
sickl
cell
diseas
scd
exhibit
lower
neurocognit
function
healthi
peer
even
absenc
stroke
among
domain
commonli
affect
work
memori
wm
seem
particularli
affect
diseas
process
wm
deficit
signific
implic
academ
achiev
diseas
selfmanag
intervent
improv
work
memori
pediatr
scd
evalu
determin
effect
cogm
homebas
computer
wm
train
intervent
children
scd
use
random
control
trial
design
designmethod
particip
age
scd
complet
baselin
neuropsycholog
assess
wm
deficit
random
either
begin
cogm
immedi
enter
waitlist
cogm
homebas
intervent
complet
ipad
consist
increasingli
challeng
exercis
target
visualspati
verbal
wm
practic
session
end
train
particip
complet
postintervent
neuropsycholog
assess
includ
test
visualspati
verbal
wm
wechsler
intellig
scale
childrenfifth
edit
wiscv
result
ninetyon
particip
age
sd
femal
hbss
enrol
studi
n
exhibit
wm
deficit
random
either
begin
cogm
immedi
wait
week
start
cogm
among
receiv
intervent
reach
end
train
period
n
particip
complet
least
cogm
session
finish
least
session
finish
least
session
mean
number
complet
cogm
session
sd
pair
sampl
ttest
reveal
signific
improv
work
memori
index
p
digit
span
p
spatial
spanbackward
p
subtest
improv
especi
pronounc
particip
complet
least
session
partial
correl
control
respect
baselin
score
indic
number
cogm
session
complet
posit
correl
posttest
score
digit
span
r
p
spatial
spanbackward
r
p
subtest
among
particip
complet
least
cogm
session
score
averag
rang
higher
work
memori
index
postintervent
assess
compar
baselin
result
support
efficaci
cogm
produc
signific
improv
wm
doseeffect
observ
particip
complet
cogm
session
greater
improv
wm
homebas
cognit
train
program
may
amelior
scdrelat
wm
deficit
method
motiv
support
patient
complet
homebas
intervent
need
enhanc
adher
effect
background
sickl
cell
diseas
associ
myriad
complic
lead
signific
morbid
earli
mortal
hydroxyurea
use
success
reduc
incid
complic
led
signific
improv
qualiti
durat
life
children
minnesota
recommend
hydroxyurea
patient
hb
sss
thalassemia
earli
month
age
goal
start
patient
month
age
object
purpos
studi
evalu
use
hydroxyurea
therapi
young
patient
sickl
cell
diseas
particular
attent
children
less
one
year
age
designmethod
retrospect
chart
review
conduct
patient
less
year
age
sickl
cell
diseas
began
hydroxyurea
therapi
januari
decemb
studi
popul
divid
three
cohort
base
upon
age
hydroxyurea
initi
cohort
year
cohort
year
cohort
year
outcom
includ
laboratori
data
clinic
event
hospit
dactyl
pain
crisi
transfus
splenic
sequestr
acut
chest
syndrom
toxic
occur
first
year
life
result
total
patient
includ
cohort
n
mean
age
month
n
mean
age
month
n
mean
age
month
patient
cohort
higher
hemoglobin
p
mcv
p
lower
absolut
reticulocyt
count
p
compar
cohort
wbc
p
anc
p
significantli
lower
compar
older
cohort
howev
patient
therapi
held
neutropenia
mean
baselin
hemoglobin
f
cohort
compar
cohort
respect
p
p
mean
durat
therapi
cohort
month
compar
month
cohort
p
month
cohort
p
time
hb
f
level
remain
higher
cohort
mean
compar
cohort
mean
p
mean
p
patient
cohort
experienc
fewer
hospit
p
pain
crise
p
transfus
p
differ
toxic
group
hydroxyurea
use
safe
infant
month
age
result
robust
hematolog
respons
decreas
sicklerel
complic
compar
patient
start
hydroxyurea
later
life
children
nation
health
system
washington
district
columbia
unit
state
background
children
sickl
cell
diseas
scd
significantli
greater
risk
silent
overt
cerebr
infarct
gener
popul
infarct
associ
declin
cognit
function
academ
achiev
infarct
reliabl
identifi
use
mri
scan
expens
occasion
necessit
sedat
moreov
mri
recommend
routin
monitor
cerebr
infarct
addit
tool
need
discrimin
presenc
cerebr
infarct
brief
noninvas
inexpens
repeat
object
evalu
differ
perform
cogstat
computer
neurocognit
assess
patient
scd
without
histori
cerebr
infarct
designmethod
particip
includ
children
scd
age
sd
femal
hbss
enrol
cognit
intervent
trial
particip
complet
cogstat
pediatr
batteri
measur
process
speed
sustain
attent
verbal
learn
work
memori
execut
function
histori
silent
overt
infarct
determin
via
health
record
review
particip
also
complet
measur
intellig
iq
math
fluenci
result
particip
standard
score
across
neurocognit
measur
lower
expect
compar
standard
sampl
mean
iq
sd
thirti
percent
particip
n
document
histori
cerebr
infarct
particip
histori
cerebr
infarct
score
lower
cogstat
task
measur
sustain
attent
p
execut
function
p
well
measur
math
fluenci
p
receiv
oper
characterist
roc
analys
demonstr
cogstat
task
measur
sustain
attent
fair
discrimin
patient
without
histori
infarct
auc
p
wherea
iq
score
auc
p
cogstat
process
speed
sustain
attent
task
fairli
discrimin
patient
least
averag
averag
intellig
auc
p
auc
p
respect
final
cogstat
process
speed
task
good
discrimin
least
averag
averag
math
fluenci
auc
p
multipl
task
cogstat
pediatr
batteri
appear
adequ
identifi
patient
histori
cerebr
infarct
addit
cogstat
task
appear
fair
predictor
impair
iq
academ
achiev
outcom
cogstat
inexpens
easili
administ
medic
set
minim
train
approxim
minut
result
support
potenti
cogstat
use
screen
tool
medic
neuropsycholog
abnorm
children
scd
st
christoph
hospit
children
philadelphia
pennsylvania
unit
state
background
cardiovascular
diseas
contribut
morbid
mortal
patient
sickl
cell
diseas
scd
hydroxyurea
therapi
scd
known
clinic
efficaci
includ
improv
anemia
decreas
episod
vasoocclus
crisi
acut
chest
syndrom
decreas
mortal
effect
hydroxyurea
cardiac
function
children
scd
well
studi
earlier
studi
suggest
protect
effect
hydroxyurea
left
ventricular
lv
hypertrophi
scd
hypothes
hydroxyurea
use
would
associ
decreas
lv
remodel
improv
cardiac
function
aim
evalu
associ
hydroxyurea
use
lv
remodel
cardiac
dysfunct
children
scd
designmethod
complet
retrospect
studi
patient
scd
year
old
follow
st
christoph
hospit
children
echocardiogram
complet
past
month
data
collect
includ
gender
bmi
scd
genotyp
hydroxyurea
use
chronic
transfus
use
doppler
echocardiograph
paramet
cardiac
structur
geometri
systol
function
diastol
function
echocardiogram
paramet
includ
analysi
varianc
anova
test
perform
assess
statist
signific
differ
cardiac
paramet
patient
without
hydroxyurea
use
analysi
covari
ancova
test
perform
control
age
result
demograph
echocardiogram
data
collect
patient
met
inclus
criteria
patient
includ
hydroxyurea
therapi
patient
hydroxyurea
significantli
lower
mean
rel
wall
thick
p
significantli
higher
mean
peak
earli
lv
fill
veloc
p
peak
earli
lv
fillingsept
annuli
earli
peak
eea
veloc
p
howev
eea
veloc
remain
signific
control
age
p
mean
peak
earli
lv
fill
veloc
approach
signific
control
age
p
hydroxyurea
therapi
result
significantli
higher
eea
veloc
suggest
patient
wors
diastol
function
possibl
patient
initi
hydroxyurea
alreadi
wors
diseas
manifest
hydroxyurea
possibl
account
decreas
diastol
function
control
age
hydroxyurea
use
result
signific
differ
cardiac
structur
paramet
systol
function
paramet
cardiac
geometri
prospect
studi
larger
sampl
size
need
valid
find
examin
addit
statist
signific
differ
develop
prevent
strategi
cardiovascular
diseas
children
scd
background
acut
chest
syndrom
ac
lead
caus
death
children
sickl
cell
diseas
mortal
us
report
mostli
due
respiratori
failur
earli
transfus
improv
clinic
outcom
although
patient
concurr
asthma
consid
increas
risk
poor
outcom
risk
factor
respiratori
failur
pediatr
ac
welldefin
determin
whether
specif
epidemiolog
clinic
featur
children
hospit
ac
predict
need
mechan
ventil
designmethod
data
kid
inpati
databas
review
identifi
patient
age
year
discharg
diagnosi
ac
year
outcom
defin
intern
classif
diseas
ninth
revis
clinic
modif
code
data
weight
estim
total
annual
hospit
accord
hospit
characterist
unit
state
trend
healthcar
cost
length
hospit
stay
transfus
mechan
ventil
use
analyz
use
multivari
linear
regress
addit
multivari
logist
regress
use
ascertain
specif
clinic
epidemiolog
factor
associ
mechan
ventil
use
adjust
patient
hospit
characterist
total
hospit
ac
report
use
mechan
ventil
rang
associ
nonblack
compar
black
children
ci
fall
season
ci
age
preexist
asthma
hbgenotyp
comorbid
obes
ci
obstruct
sleep
apnea
ci
heart
diseas
ci
associ
mechan
ventil
use
use
simpl
exchang
transfus
ac
admiss
rang
respect
among
pediatr
ac
patient
obes
obstruct
sleep
apnea
heart
diseas
increas
risk
respiratori
failur
might
benefit
earli
intervent
eg
transfus
surprisingli
asthma
children
ac
appear
distinct
risk
factor
respiratori
failur
studi
need
clarifi
whether
differ
treatment
approach
eg
addit
corticosteroid
bronchodil
might
impact
ac
progress
andor
sever
even
high
risk
patient
without
asthma
object
compar
pulmonari
function
aa
k
children
scd
assess
high
hb
f
level
contribut
better
function
designmethod
cross
section
studi
done
children
scd
hb
ss
diseas
follow
comprehens
sickl
cell
program
aa
patient
follow
brookdal
hospit
ny
k
patient
follow
mubarak
hospit
kuwait
children
age
year
pulmonari
function
test
pft
done
routin
screen
enrol
pft
done
use
spiromet
plethysmographi
patient
congenit
anatom
lung
abnorm
heart
diseas
pulmonari
diseas
acut
chest
syndrom
acut
asthma
pneumonia
within
week
exclud
result
children
group
scd
restrict
pattern
pft
seen
aa
vs
k
p
obstruct
pattern
seen
aa
vs
k
group
p
group
children
normal
pft
aa
group
hb
f
compar
k
group
p
abnorm
pft
note
children
group
hbf
aa
group
vs
k
group
p
patient
abnorm
pft
mean
hbf
aa
group
compar
k
group
p
conclus
abnorm
pft
highli
preval
among
children
scd
group
aa
children
like
restrict
diseas
k
obstruct
pattern
level
hbf
seem
protect
k
patient
abnorm
pft
find
emphas
import
perform
pft
part
initi
evalu
children
scd
background
sickl
cell
diseas
scd
lifethreaten
diseas
vari
clinic
spectrum
sever
lead
prematur
death
lack
valid
prognost
marker
scd
recent
evid
suggest
inflamm
platelet
adhes
play
critic
role
pathophysiolog
vasoocclus
scd
elev
mean
platelet
volum
mpv
valu
associ
higher
degre
inflamm
mani
diseas
state
effect
sickl
cell
diseas
sever
unknown
object
analyz
role
mpv
predict
diseas
severitymort
pediatr
patient
scd
designmethod
singl
center
retrospect
studi
includ
patient
sickl
cell
diseas
month
year
age
period
demograph
inform
lab
data
clinic
inform
includ
acut
chest
syndrom
ac
priapism
transfus
sepsi
pain
crisi
avascular
necrosi
collect
laboratori
data
collect
steadi
state
crisi
recent
past
month
diseas
sever
scoreprob
death
calcul
use
valid
model
predict
risk
death
sickl
cell
diseas
sebastiani
et
al
blood
pearson
test
use
analyz
correl
mpv
probabl
death
result
total
patient
male
femal
median
age
year
patient
africanamerican
origin
diseas
sever
hb
ss
hb
sc
sicklebeta
thalassemia
patient
hydroxyurea
significantli
lower
mpv
p
independ
hb
f
level
mpv
signific
posit
correl
probabl
death
p
correl
coeffici
r
subgroup
analysi
correl
even
signific
age
group
year
p
r
use
linear
regress
model
probabl
death
depend
variabl
hydroxyurea
mpv
independ
variabl
mpv
maintain
signific
associ
probabl
death
p
conclus
mpv
independ
biomark
predict
diseas
sever
probabl
death
pediatr
patient
sickl
cell
diseas
hydroxyurea
known
diseas
amelior
agent
associ
lower
mpv
valu
effect
independ
level
fetal
hemoglobin
may
due
antiinflammatori
effect
hydroxyurea
effect
platelet
background
major
success
initi
qi
project
sickl
cell
care
team
children
hospit
precipit
ongo
inclus
qi
approach
mani
aspect
patient
care
object
optim
scd
patient
care
util
qi
process
designmethod
success
scd
qi
team
initi
project
transcrani
doppler
studi
tcd
second
complex
project
hydroxyurea
hu
adher
led
addit
project
complet
key
immun
rbc
phenotyp
vitamin
level
test
use
similar
process
principl
hu
adher
project
plandostudyact
pdsa
cycl
use
conduct
smallscal
test
chang
patient
chart
prep
sheet
creat
bimonthli
preappoint
chart
prep
meet
significantli
modifi
includ
focus
care
qi
object
difficulti
emr
databas
capabl
data
collect
emr
track
excel
spreadsheet
uniqu
track
vehicl
variou
paramet
exampl
due
clinic
diffus
geograph
scatter
popul
mani
separ
nonshar
primari
care
emr
lack
mandatori
state
immun
registri
immun
record
need
retriev
pcp
outli
hospit
public
health
depart
fqhc
ad
emr
excel
databas
start
data
collect
updat
monthli
one
year
time
averag
immun
complet
rate
seven
key
immun
pcv
pcv
hepat
hepat
b
meningococc
meningococc
b
hpv
increas
biggest
improv
increas
complet
meningococc
meningococc
b
respect
complet
rate
rbc
phenotyp
rose
patient
least
one
vitamin
lab
test
increas
sinc
start
tcd
project
percent
patient
complet
annual
tcd
gone
baselin
sustain
valu
conclus
qi
project
increas
adher
nation
recommend
care
scd
patient
help
establish
scd
clinic
methodolog
creat
implement
sustain
process
focus
care
initi
promin
display
patient
chart
prep
sheet
serv
remind
medic
team
member
check
statu
item
methodolog
current
use
formul
addit
qi
project
annual
renal
function
paramet
specialti
visit
annual
eye
dental
exam
background
dominican
republ
high
burden
sickl
cell
diseas
children
homozyg
hbss
sickl
cell
anemia
sca
develop
primari
stroke
transcrani
doppler
tcd
ultrasonographi
effect
screen
tool
primari
stroke
risk
routin
avail
dominican
republ
hydroxyurea
blood
transfus
avail
prospect
screen
treatment
program
stroke
prevent
implement
date
screen
larg
cohort
children
sca
live
dominican
republ
use
tcd
identifi
elev
stroke
risk
determin
effect
treatment
stroke
prevent
hydroxyurea
condit
veloc
transfus
abnorm
veloc
hypothes
hydroxyurea
blood
transfus
decreas
elev
tcd
veloc
help
prevent
primari
stroke
designmethod
stroke
avoid
children
dominicana
sacr
featur
research
partnership
cincinnati
children
hospit
robert
reid
cabral
children
hospit
dominican
republ
protocol
consent
form
redcap
databas
prepar
collabor
translat
spanish
irb
approv
obtain
institut
initi
prospect
phase
children
receiv
tcd
screen
period
condit
tcd
veloc
maximum
timeaverag
veloc
cmsec
receiv
fixeddos
hydroxyurea
mgkgday
follow
dose
escal
maximum
toler
dose
abnorm
tcd
veloc
cmsec
receiv
monthli
transfus
stroke
prevent
result
total
children
enrol
sacr
averag
age
year
initi
tcd
screen
reveal
normal
condit
abnorm
inadequ
veloc
among
children
male
femal
averag
age
year
initi
hydroxyurea
mgkgday
condit
tcd
veloc
complet
six
month
treatment
expect
hematolog
benefit
includ
signific
increas
hemoglobin
concentr
gdl
fetal
hemoglobin
clinic
stroke
occur
treatment
group
repeat
tcd
examin
hydroxyurea
treatment
reveal
previou
condit
veloc
normal
tcd
veloc
preval
condit
tcd
veloc
dominican
republ
high
indic
elev
stroke
risk
among
children
sca
hydroxyurea
treatment
associ
improv
hematolog
paramet
lower
tcd
veloc
probabl
decreas
stroke
risk
sacr
import
prospect
collabor
research
trial
provid
epidemiolog
data
regard
tcd
screen
stroke
risk
hydroxyurea
effect
among
children
sca
background
red
blood
cell
aggreg
rheolog
properti
explain
shearthin
behavior
blood
lower
shear
rate
blood
flow
red
cell
tend
aggreg
wherea
higher
shear
rate
blood
flow
aggreg
dispers
properti
especi
import
venou
system
low
shear
rate
blood
flow
predomin
inconsist
data
literatur
concern
aggreg
aggreg
sickl
cell
diseas
scd
object
lorrca
myrenn
instrument
shown
similarli
effect
methodolog
red
cell
aggreg
measur
aim
determin
whether
measur
aggreg
indic
scd
myrenn
lorrca
consist
lab
designmethod
measur
aggreg
blood
sampl
correct
hematocrit
aggreg
measur
use
dextran
myrenn
lorrca
aggreg
index
use
lorrca
measur
patient
scd
healthi
subject
enrol
studi
blood
flow
aggreg
aggreg
use
myrenn
measur
patient
scd
healthi
subject
enrol
separ
studi
blood
flow
result
use
lorrca
found
aggreg
index
patient
scd
less
healthi
subject
p
myrenn
aggreg
stasi
slightli
higher
patient
scd
compar
healthi
subject
p
aggreg
low
shear
rotat
differ
aggreg
higher
patient
scd
compar
healthi
subject
stasi
low
shear
rotat
p
red
cell
aggreg
import
determin
low
shear
blood
flow
deoxygen
venou
blood
particularli
import
low
shear
blood
flow
patient
sickl
cell
diseas
found
two
differ
aggregomet
predict
differ
aggreg
result
scd
unclear
systemat
differ
two
method
possibl
first
syllectogram
lorrca
gener
backscatt
light
laser
myrenn
measur
transmit
light
second
distanc
bob
cup
lorrca
micron
gap
plate
myrenn
micron
might
affect
disaggreg
red
cell
work
need
understand
differ
red
cell
aggreg
aggreg
use
instrument
particularli
use
aggreg
predictor
blood
flow
tissu
perfus
background
children
sickl
cell
diseas
scd
risk
acut
splenic
sequestr
crisi
assc
assc
lifethreaten
complic
character
splenomegali
pain
sever
anemia
assc
often
occur
young
children
sever
form
scd
onethird
patient
one
episod
treatment
base
primarili
expert
opinion
includ
blood
transfus
surgic
splenectomi
object
plan
assess
clinic
practic
pattern
physician
treat
children
assc
designmethod
survey
studi
perform
survey
includ
six
scenario
sever
scd
variat
age
hydroxyureaus
episod
number
assc
question
focus
acut
chronic
manag
assc
survey
dissemin
three
occas
sixmonth
period
use
onlin
survey
tool
surveymonkey
pediatr
hematologistoncologist
particip
american
societi
pediatr
hematologyoncolog
hemoglobinopathi
special
interest
group
survey
respons
rate
respond
recent
graduat
practic
academ
urban
center
greater
sicklecel
patient
seventynin
percent
recommend
hydroxyurea
initi
mo
sever
scd
prophylact
penicillin
surgic
splenectomi
continu
year
acut
manag
assc
result
vari
despit
patient
age
hydroxyurea
use
number
previou
assc
episod
simpl
transfus
prefer
recommend
slow
transfus
recommend
routin
simpl
transfus
chronic
manag
assc
result
vari
base
patient
age
number
previou
assc
episod
mo
first
episod
recommend
observ
hydroxyurea
initi
mo
prior
episod
assc
recommend
chronic
transfus
therapi
surgic
referr
splenectomi
yo
first
episod
recommend
surgic
splenectomi
increas
hydroxyurea
dose
yo
prior
assc
episod
recommend
referr
surgic
splenectomi
survey
found
provid
continu
recommend
simpl
transfus
assc
surgic
splenectomi
two
episod
major
provid
continu
delay
referr
surgic
splenectomi
age
two
earlier
referr
children
two
use
chronic
transfus
therapi
also
report
variabl
chronic
manag
highlight
need
research
splenic
sequestr
background
develop
therapi
sickl
cell
diseas
scd
challeng
part
accept
endpoint
vasoocclus
crisi
voc
occur
infrequ
measur
full
diseas
burden
measur
healthcar
util
phase
studi
patient
scd
voxelotor
demonstr
increas
hemoglobin
hb
level
reduc
hemolysi
safe
welltoler
voxelotor
evalu
ongo
hope
phase
trial
object
report
innov
phase
hope
trial
design
novel
primari
secondari
outcom
acceler
drug
develop
designmethod
hope
phase
random
placebocontrol
multicent
studi
oral
voxelotor
patient
scd
age
year
baselin
hb
gdl
episod
voc
prior
year
acceler
clinic
trial
support
drug
develop
studi
combin
phase
exploratori
doseselect
phase
group
pivot
phase
group
patient
group
random
voxelotor
mgday
placebo
analysi
dose
select
occur
final
patient
receiv
week
treatment
group
continu
enrol
random
dose
select
base
analysi
group
cohort
group
allow
seamless
transit
group
random
patient
select
dose
placebo
final
data
analysi
set
includ
group
patient
receiv
placebo
select
dose
group
patient
primari
endpoint
object
laboratori
measur
surrog
clinic
benefit
increas
hb
gdl
baselin
week
base
voxelotor
mechan
action
inhibit
hb
polymer
trial
first
use
patientreport
outcom
pro
sickl
cell
diseas
sever
measur
secondari
endpoint
novel
electron
pro
develop
specif
hope
studi
follow
fda
guidanc
evalu
chang
scd
symptom
exacerb
total
symptom
score
baselin
week
addit
secondari
endpoint
includ
measur
hemolysi
rate
voc
transfus
opioid
use
studi
design
enabl
select
prodefin
symptom
exacerb
tradit
defin
voc
key
secondari
endpoint
group
analysi
result
studi
ongo
hope
trial
expect
complet
enrol
late
evalu
efficaci
safeti
voxelotor
compar
placebo
patient
scd
support
global
blood
therapeut
background
inflamm
coagul
activ
oxid
stress
blood
cell
adhes
element
sickl
cell
diseas
scd
pathophysiolog
patient
scd
low
level
fatti
docosahexaeno
acid
dha
eicosatetraeno
acid
epa
plasma
blood
cell
membran
dha
bioactiv
fatti
acid
antiinflammatori
antiblood
cell
adhes
antioxid
properti
altemiatm
novel
dha
ethyl
ester
formul
proprietari
deliveri
platform
advanc
lipid
enhanc
oral
dha
bioavail
scot
trial
investig
effect
altemiatm
children
scd
object
demonstr
effect
altemiatm
blood
cell
membran
index
select
biomark
inflamm
coagul
adhes
haemolysi
associ
scd
designmethod
children
scd
age
year
n
enrol
subject
random
receiv
either
placebo
one
three
daili
oral
dose
altemiatm
mgkgday
dha
two
month
effect
altemiatm
red
blood
cell
rbc
white
blood
cell
platelet
membran
fatti
acid
index
total
dha
epa
level
assess
four
week
treatment
effect
altemiatm
marker
inflamm
adhes
coagul
hemolysi
assess
eight
week
treatment
cell
membran
dha
epa
concentr
determin
use
lcmsm
method
percent
chang
baselin
blood
cell
membran
index
select
scd
biomark
compar
three
dose
group
placebo
use
mixedmodel
repeatedmeasur
mmrm
analysi
baselin
blood
cell
membran
index
hydroxyurea
use
treatment
fix
effect
patient
random
effect
four
week
treatment
blood
cell
membran
dha
epa
level
significantli
increas
altemiatm
dose
p
eight
week
treatment
signific
reduct
observ
seselectin
p
ddimer
p
patient
expos
altemiatm
dose
level
vs
placebo
hemoglobin
significantli
increas
altemiatm
dose
level
versu
placebo
plasma
highsensit
creactiv
protein
lactat
dehydrogenas
solubl
vascular
cell
adhes
white
blood
cell
count
show
improv
week
treatment
three
altemiatm
dose
level
reach
signific
conclus
treatment
altemiatm
enrich
dha
epa
blood
cell
membran
patient
scd
improv
select
sickl
cell
diseas
biomark
blood
cell
adhes
thrombin
gener
find
provid
insight
mechan
action
altemiatm
sickl
cell
diseas
brown
univers
hasbro
children
hospit
provid
rhode
island
unit
state
background
despit
clinic
advanc
treatment
sickl
cell
diseas
scd
pediatr
young
adult
patient
pain
remain
signific
sourc
diseaserel
morbid
physic
therapi
shown
use
treatment
pain
children
young
adult
variou
chronic
ill
pain
signific
compon
howev
data
exist
regard
potenti
benefit
physic
therapi
pediatr
young
adult
patient
scd
object
queri
healthcar
provid
other
involv
care
pediatr
young
adult
scd
patient
regard
possibl
benefit
barrier
physic
therapi
potenti
treatment
modal
designmethod
conduct
webbas
survey
healthcar
provid
within
new
england
pediatr
sickl
cell
consortium
nepscc
attempt
identifi
potenti
benefit
barrier
outpati
physic
therapi
patient
popul
result
nearli
survey
particip
felt
physic
therapi
potenti
somewhat
benefici
benefici
pediatr
young
adult
patient
scd
major
physician
report
refer
patient
scd
physic
therapi
past
frequent
identifi
perceiv
potenti
benefit
includ
improv
function
mobil
improv
chronic
pain
symptom
decreas
use
opiat
improv
mood
symptom
improv
acut
pain
symptom
improv
adher
medic
clinic
visit
signific
perceiv
barrier
identifi
includ
lack
transport
time
constraint
patient
lack
understand
difficulti
insur
coverag
studi
indic
healthcar
provid
overwhelmingli
posit
view
use
physic
therapi
manag
pediatr
young
adult
patient
scd
signific
barrier
exist
need
address
futur
research
focu
patient
parent
perspect
regard
physic
therapi
well
random
control
trial
physic
therapi
intervent
patient
popul
background
vitamind
defici
fast
becom
increasingli
recogn
patient
sickl
cell
diseas
scd
estim
patient
five
time
like
develop
vitamind
defici
exact
clinic
signific
larg
unknown
given
defici
inexpens
easili
treat
studi
sought
establish
preval
vitamind
defici
patient
popul
relationship
diseas
sever
object
estim
preval
vitamind
defici
patient
scd
institut
analyz
diseas
sever
relat
vitamind
level
designmethod
retrospect
chart
review
analyz
subject
repres
cohort
patient
follow
adult
pediatr
hematolog
servic
univers
miami
known
diagnosi
scd
vitamind
level
drawn
januari
august
conduct
crosssect
studi
record
first
vitamind
level
period
patient
demograph
medic
social
histori
inform
collect
along
laboratori
data
number
admiss
vasoocclus
crisi
voc
acut
chest
syndrom
within
one
year
preced
collect
vitamind
level
also
record
result
total
chart
review
adult
chart
pediatr
chart
exclus
patient
enrol
subclin
vitamind
defici
evid
laboratori
blood
test
vitamind
accord
laboratori
result
patient
classifi
suffici
ngml
insuffici
ngml
defici
ngml
case
defici
insuffici
optim
statist
analysi
two
neg
correl
identifi
increas
vitamind
level
decreas
white
blood
cell
count
ci
decreas
incid
voc
ci
conclus
studi
confirm
signific
preval
vitamind
defici
patient
scd
furthermor
result
investig
prove
vitamind
defici
associ
acut
pain
leukocytosi
patient
scd
given
multitud
confound
factor
affect
vitamind
absorpt
intak
multivari
analys
requir
truli
investig
relationship
texa
children
hospit
houston
texa
unit
state
background
hemophagocyt
lymphohistiocytosi
hlh
rare
lifethreaten
condit
hyperinflamm
character
splenomegali
cytopenia
hyperferritinemia
hypertriglyceridemia
hemophagocytosi
coagulopathi
although
time
diagnosi
imper
often
challeng
individu
sign
symptom
may
occur
varieti
clinic
condit
report
case
undiagnos
sickl
cell
anemia
present
sever
ebv
viremia
associ
hemophagocyt
lymphohistiocytosi
result
previous
healthi
male
present
respiratori
distress
increas
fatigu
focal
seizur
follow
twoweek
histori
cough
lowgrad
fever
physic
exam
consist
hypovolem
shock
reveal
signific
splenomegali
laboratori
test
reveal
sever
hypoglycemia
acidosi
electrolyt
disturb
includ
hyperkalemia
hyperphosphatemia
hyperuricemia
lab
show
leukocytosi
wbc
sever
low
hemoglobin
platelet
coagul
test
reveal
prolong
ptinr
ptt
hypofibrinogenemia
highli
elev
ddimer
addit
workup
complet
determin
etiolog
acut
present
given
broad
differenti
diagnosi
infecti
studi
consist
acut
ebv
infect
plasma
ebv
pcr
elev
level
solubl
ferritin
complet
criteria
diagnosi
hlh
bone
marrow
evalu
show
trilineag
hematopoiesi
abnorm
blast
popul
hemophagocytosi
result
hemoglobin
electrophoresi
sent
initi
cbc
sampl
notabl
hb
hbf
hba
confirm
diagnosi
sickl
cell
diseas
patient
start
hydroxyurea
penicillin
splenomegali
resolv
support
care
demonstr
gradual
improv
symptom
laboratori
abnorm
includ
normal
solubl
ferritin
level
immunoglobulin
declin
ebv
titer
nk
cell
function
remain
abnorm
low
elimin
possibl
acquir
hlh
despit
spontan
improv
conclus
splenic
sequestr
associ
sickl
cell
diseas
combin
acut
infecti
mononucleosi
could
explain
mani
present
symptom
includ
anemia
thrombocytopenia
splenomegali
howev
explain
unusu
high
ebv
titer
degre
inflamm
meet
diagnost
criteria
hlh
rais
concern
underli
immunolog
abnorm
xlink
lymphoprolif
disord
xlp
although
test
xlp
neg
requir
continu
monitor
futur
sign
relaps
case
illustr
complex
diagnos
lymphohistiocyt
disord
signific
overlap
present
disord
medic
condit
background
vasoocclus
crisi
voc
one
distress
occurr
patient
sickl
cell
diseas
scd
patient
control
analgesia
pca
recommend
nih
expert
opinion
favor
earli
use
aim
review
use
pca
patient
voc
evalu
earli
use
associ
faster
pain
control
reduc
length
stay
lo
designmethod
retrospect
singl
center
studi
includ
pediatr
patient
admit
treat
pca
sever
voc
earli
use
defin
start
pca
within
hour
arriv
emerg
depart
ed
late
use
hour
time
reach
adequ
analgesia
defin
oucher
verbal
scale
face
pain
scale
obtain
twice
consecut
interv
time
reach
adequ
analgesia
lo
compar
earlypca
latepca
group
result
total
patient
present
episod
voc
treat
pca
studi
sixtyon
episod
treat
earlypca
latepca
group
compar
term
age
vs
year
old
gender
femal
vs
hemoglobin
phenotyp
hbss
vs
median
pain
score
admiss
higher
earlypca
latepca
vs
median
differ
ci
earlypca
associ
median
reduct
lo
day
ci
median
earlypca
lo
vs
latepca
day
time
reach
analgesia
could
evalu
subset
patient
earlypca
latepca
group
although
time
reach
adequ
analgesia
tend
shorter
earlypca
group
statist
differ
hour
vs
hour
differ
ci
side
effect
observ
pca
treatment
episod
earlypca
latepca
group
among
signific
advers
event
observ
patient
requir
intervent
desatur
requir
oxygen
without
intub
neurolog
abnorm
hallucin
visual
abnorm
stroke
urinari
retent
conclus
earli
use
pca
sever
voc
associ
reduc
length
hospit
stay
despit
patient
higher
pain
score
admiss
prospect
studi
need
support
posit
outcom
background
acut
chest
syndrom
one
lead
caus
death
children
sickl
cell
caus
acut
chest
syndrom
commonli
identifi
fat
embol
infecti
caus
believ
common
extrem
high
mortal
rate
rapid
identif
initi
therapi
essenti
surviv
case
present
describ
case
femal
sickl
cell
sc
diseas
admit
vasoocclus
pain
crisi
quickli
progress
multisystem
organ
failur
due
fat
embol
syndrom
parvoviru
infect
object
case
highlight
present
diagnosi
provid
optim
outcom
underrecogn
syndrom
designmethod
parvoviru
studi
return
day
show
parvoviru
dna
pcr
detect
parvo
igg
posit
igm
posit
patient
experienc
approxim
gdl
drop
hemoglobin
hr
progress
thrombocytopenia
peripher
smear
show
microcyt
normochrom
red
cell
nucleat
rbc
occasion
nuclear
bud
slight
polychromasia
schistocyt
polymorph
cell
toxic
granul
suggest
leukoerythroblastosi
emerg
transfer
region
quaternari
care
hospit
ongo
ecmo
therapi
experienc
chang
pupillari
exam
prompt
stat
ct
scan
show
sever
diffus
cerebr
edema
transtentori
herniat
decis
made
withdraw
lifesustain
therapi
famili
refus
postmortem
autopsi
examin
fat
embol
syndrom
sever
uncommonli
recogn
complic
sickl
cell
diseas
seen
commonli
nonss
phenotyp
previou
mild
diseas
cours
present
sever
unrel
vasoocclus
pain
episod
andor
acut
chest
syndrom
progress
respiratori
distress
alter
mental
statu
cutan
chang
rapid
identif
initi
exchang
transfus
therapi
initi
clinic
suspicion
extrem
high
mortal
rate
although
previous
consid
rare
need
consid
differenti
diagnosi
commonli
encount
complic
sickl
cell
diseas
background
patient
sickl
cell
diseas
scd
experi
vasoocclus
crisi
voc
result
extrem
pain
often
requir
opioid
admiss
genet
environment
factor
affect
frequenc
sever
episod
previou
research
born
conflict
evid
whether
environment
temperatur
contributori
edmonton
alberta
northern
citi
popul
million
north
america
increas
sickl
cell
popul
expos
extrem
winter
condit
provid
suitabl
popul
atmospher
studi
influenc
cold
extern
temperatur
scd
studi
sought
identifi
pediatr
patient
scd
experi
greater
morbid
cold
extern
temperatur
board
approv
retrospect
case
control
seri
patient
identifi
clinic
databas
emerg
visit
phone
call
admiss
data
collect
fiveyear
period
averag
minimum
chang
temperatur
day
present
hour
prior
collect
govern
alberta
statist
analyz
use
descript
statist
determin
relat
vasoocclus
event
result
onehundr
eighteen
patient
identifi
voc
event
review
mean
patient
age
year
age
rang
year
old
femal
male
ratio
equival
femal
male
voc
event
eight
record
document
cold
exposur
analysi
temperatur
frequenc
event
yield
signific
correl
averag
minimum
temperatur
day
admiss
largest
percentag
voc
event
occur
mild
temperatur
c
respect
chang
temperatur
day
admiss
hour
largest
percentag
voc
event
mild
moder
chang
temperatur
degre
data
hour
prior
admiss
show
similar
result
secondari
data
analysi
account
lower
proport
extrem
weather
day
comparison
moder
temper
day
show
signific
impact
correl
averag
minimum
chang
temperatur
day
admiss
hour
prior
multipl
cofound
factor
like
contribut
result
retrospect
studi
mani
confound
precipit
factor
may
record
identifi
prospect
studi
better
record
specif
cold
exposur
warrant
children
nation
health
system
washington
district
columbia
unit
state
background
achiev
optim
anticoagul
unfraction
heparin
ufh
pediatr
patient
receiv
extracorpor
membran
oxygen
ecmo
often
challeng
due
antithrombin
mediat
heparin
resist
hr
intermitt
dose
pediatr
ecmo
support
maintain
adequ
level
continu
infus
cati
present
altern
strategi
achiev
consist
goal
level
optim
heparin
howev
cati
pediatr
ecmo
adequ
studi
object
describ
center
experi
ecmo
cati
protocol
designmethod
modifi
ecmo
anticoagul
protocol
includ
ufh
titrat
accord
antifactor
xa
antifxa
level
cati
patient
atmedi
hr
cati
rate
calcul
use
baselin
goal
level
account
circuit
volum
cati
administ
ufh
circuit
via
yinfus
set
antifxa
level
monitor
everi
hour
recombin
rat
concentr
use
center
subsequ
transit
plasmaderiv
pdat
concentr
due
longer
halflif
pdat
concentr
protocol
modifi
cati
stop
target
antifxa
level
achiev
conduct
retrospect
studi
patient
receiv
cati
ecmo
support
center
data
report
median
interquartil
rang
compar
use
mannwhitney
u
test
twotail
pvalu
consid
statist
signific
sinc
patient
male
age
month
ecmo
support
receiv
cati
rat
pdat
per
protocol
patient
receiv
pdat
infus
one
ecmo
run
durat
cati
hour
cati
administr
led
signific
increas
antifxa
level
baselin
unitsml
first
level
within
goal
unitsml
respect
p
respect
time
achiev
goal
antifxa
level
hour
hour
respect
peak
antifxa
level
unitsml
cati
patient
requir
circuit
chang
patient
develop
cannula
thrombosi
patient
experienc
nonfat
major
bleed
conclus
cati
pediatr
patient
receiv
ecmo
support
close
monitor
antifxa
level
associ
signific
rapid
increas
optim
heparin
effect
reduct
thrombot
complic
without
increas
major
bleed
compar
prior
report
prospect
studi
dose
strategi
warrant
children
hospit
orang
counti
orang
california
unit
state
background
inherit
factor
xiii
defici
rare
bleed
disord
wide
heterogen
clinic
manifest
rang
mild
bruis
mucos
umbil
stump
bleed
spontan
sever
intracrani
bleed
bleed
phenotyp
influenc
zygos
fxiii
mutat
alon
also
coinherit
variant
clot
protein
gene
also
play
major
role
clot
format
stabil
present
seri
three
sibl
found
gene
variant
platelet
dysfunct
link
bleed
phenotyp
designmethod
retrospect
chart
review
index
case
coagul
studi
whole
gene
sequenc
index
patient
present
two
year
age
subdur
hematoma
fall
requir
emerg
craniotomi
week
initi
evacu
rebl
prompt
extens
workup
potenti
bleed
disord
includ
activ
von
willebrand
profil
comprehens
fibrinolysi
panel
antigen
level
platelet
map
thromboelastogram
pltteg
genet
analysi
patient
ident
twin
older
sibl
symptom
bruis
underw
similar
evalu
index
patient
demonstr
consist
low
activ
platelet
function
test
reveal
decreas
respons
adp
agonist
twin
older
sibl
normal
level
slightli
decreas
respons
adp
platelet
studi
whole
gene
analysi
gene
next
gener
panel
reveal
sever
intron
delet
index
patient
share
sibl
like
account
decreas
circul
level
symptom
respond
well
monthli
treatment
factor
concentr
three
children
share
variant
previous
describ
risk
factor
intracrani
hemorrhag
mutat
associ
intracrani
hemorrhag
young
women
presenc
variant
alon
may
enough
caus
sever
bleed
phenotyp
famili
studi
identifi
novel
delet
index
patient
may
account
decreas
level
would
overlook
standard
sequenc
futur
studi
includ
evalu
platelet
level
perform
platelet
dysfunct
detect
laboratori
clinic
evalu
requir
delin
long
term
implic
interact
even
mild
defici
present
addit
clot
disord
platelet
function
defect
sibl
background
acquir
hemolyt
anemia
occur
due
mechan
shear
red
blood
cell
classic
seen
patient
prosthet
heart
valv
report
traumat
effect
repair
includ
annuloplasti
follow
valvular
procedur
flow
disturb
exist
across
valv
lead
shear
stress
hemolysi
although
von
willebrand
diseas
vwd
typic
seen
due
inherit
disord
pediatr
popul
flow
disturb
set
valv
abnorm
lead
acquir
von
willebrand
syndrom
avw
von
willebrand
factor
multim
becom
unfold
elong
set
shear
stress
result
increas
suscept
cleavag
specif
loss
high
molecular
weight
multim
hmwm
lead
syndrom
akin
type
vwd
object
describ
case
mechan
hemolysi
acquir
type
vwd
designmethod
girl
histori
hypoplast
left
heart
syndrom
sever
tricuspid
valv
insuffici
underw
norwood
procedur
blaloktaussig
shunt
placement
subsequ
bidirect
glenn
tricuspid
valv
annuloplasti
follow
month
requir
weekli
red
blood
cell
rbc
transfus
due
intermitt
anemia
also
experienc
bloodi
stool
dark
urin
laboratori
evalu
notabl
normocyt
anemia
reticulocytosi
elev
lactat
dehydrogenas
low
haptoglobin
consist
hemolyt
process
immunemedi
hemolysi
transfus
reaction
presenc
autoimmun
alloimmun
antibodi
test
neg
investig
gi
bleed
work
vwd
reveal
normal
vw
activ
antigen
loss
high
molecular
weight
multim
consist
acquir
type
vwd
consult
cardiolog
felt
tricuspid
valv
insuffici
jet
could
lead
mechan
hemolysi
avw
repeat
echo
show
persist
moder
tricuspid
insuffici
signific
chang
due
patient
continu
need
weekli
rbc
transfus
subsequ
trial
pentoxifyllin
use
adult
patient
decreas
blood
viscos
increas
erythrocyt
flexibl
patient
mechan
hemolysi
transfus
need
remain
medic
discontinu
two
week
requir
one
transfus
week
later
transfus
sinc
time
although
commonli
seen
pediatr
patient
diagnosi
mechan
hemolysi
accompani
avw
pursu
patient
congenit
heart
diseas
signific
anemia
andor
bleed
work
patient
difficult
echocardiogram
inconclus
thu
extens
hematolog
evalu
usual
necessari
object
aim
assess
incid
potenti
risk
factor
central
linerel
dvt
institut
addit
goal
analyz
incid
differ
three
central
line
type
identif
linespecif
risk
designmethod
retrospect
chart
review
central
line
placement
pediatr
patient
cleveland
clinic
conduct
data
includ
demograph
potenti
risk
factor
line
characterist
relat
thrombot
event
studi
cohort
consist
line
pediatr
patient
age
year
age
thrombi
ci
per
line
day
statist
signific
risk
factor
thrombu
includ
diagnosi
group
liquid
tumor
highest
rate
solid
tumor
lowest
type
line
picc
broviac
mediport
locat
line
greater
number
line
per
patient
peg
asparaginas
vs
sepsi
histori
procoagul
state
line
characterist
lumen
size
number
lumen
identifi
signific
risk
significantli
higher
rate
thrombu
previou
year
pool
vs
p
incid
dvt
pediatr
patient
institut
highest
broviac
line
signific
risk
factor
patient
popul
includ
liquid
tumor
femor
vein
locat
peg
asparaginas
sepsi
histori
procoagul
state
incid
thrombi
highest
therefor
highlight
urgent
need
improv
nationwid
hospit
practic
minim
risk
thrombi
format
earli
detect
higherrisk
popul
still
much
learn
regard
characterist
specif
differ
central
line
would
influenc
thrombi
format
nyu
winthrop
hospit
mineola
new
york
unit
state
background
pediatr
immun
thrombocytopen
purpura
itp
autoimmun
disord
platelet
count
caus
increas
risk
signific
hemorrhag
increas
immunolog
platelet
destruct
due
product
specif
autoantibodi
along
inhibit
platelet
product
random
trial
exist
guid
manag
ultim
patient
requir
individu
treatment
plan
itp
may
acut
diagnosi
chronic
month
one
treatment
chronic
itp
laparoscop
splenectomi
ls
well
toler
rare
complic
ls
splenosi
autotransplant
implant
ectop
splenic
tissu
within
abdomin
caviti
unusu
bodi
compart
splenosi
sometim
associ
relaps
itp
due
preserv
immun
activ
usual
manag
symptomat
splenosi
surgic
resect
object
describ
medic
manag
young
patient
itp
relaps
due
extens
unresect
splenosi
follow
ls
designmethod
patient
origin
diagnos
year
itp
treat
ls
year
age
chronic
sever
thrombocytopenia
persist
bleed
respond
first
line
therapi
toler
well
complet
respons
cr
defin
platelet
count
measur
occas
day
apart
absenc
bleed
maintain
normal
platelet
count
twelv
year
relaps
loss
respons
cr
sever
thrombocytopenia
hematuria
necessit
high
dose
steroid
ct
scan
show
multipl
wellcircumscrib
soft
tissu
mass
left
lower
quadrant
adjac
uteru
left
ovari
involv
left
omentum
anterior
abdomin
wall
partli
find
confirm
damag
rbc
nuclear
scan
splenosi
laparoscopi
splenosi
lesion
deem
extens
resect
complet
avoid
postop
morbid
start
sirolimu
around
time
treatment
relaps
itp
steroid
wean
result
eight
month
sinc
begin
sirolimu
therapeut
level
remain
cr
bleed
requir
steroid
immunoglobulin
anti
immunoglobulin
conclus
sirolimu
safe
effect
steroidspar
agent
treatment
chronic
itp
first
instanc
patient
poorli
resect
splenosi
respond
well
medic
itp
data
need
regard
longterm
efficaci
intervent
whether
elimin
need
second
surgeri
relaps
itp
patient
extens
splenosi
background
storag
pool
disord
affect
platelet
result
bleed
symptom
relat
defici
defect
alpha
granul
delta
granul
deltastorag
pool
disord
dspd
defici
delta
granul
constitu
result
inabl
platelet
properli
activ
well
lack
proper
constrict
blood
vessel
bleed
episod
amongst
patient
dspd
femal
commonli
present
menorrhagia
male
tend
present
epistaxi
easi
bruis
intern
societi
thrombosi
hemostasi
isth
develop
screen
bleed
assess
tool
bat
mild
bleed
disord
shown
valid
tool
children
diagnosi
dspd
classic
made
platelet
electron
microscopi
pem
valu
delta
granul
per
platelet
dgpl
recent
lower
diagnost
threshold
dgpl
even
dgpl
suggest
object
evalu
correl
pem
bleed
score
also
examin
variou
cutoff
valu
use
diagnos
risk
stratifi
patient
dspd
designmethod
retrospect
chart
review
pediatr
patient
follow
hematolog
diagnosi
dspd
perform
clinician
obtain
bleed
score
patient
standard
care
hemostasi
clinic
quartil
rang
establish
appropri
three
stage
sever
base
upon
bleed
score
statist
analysi
perform
use
softwar
r
exploratori
data
analysi
evalu
correl
result
amongst
patient
averag
bat
score
pem
dgpl
averag
bleed
score
pem
dgpl
dgpl
averag
bleed
score
pem
dgpl
correl
coeffici
pem
bleed
score
use
threshold
dgpl
patient
would
met
diagnost
criteria
quartil
rang
bleed
score
follow
quartil
quartil
quartil
conclus
patient
mark
granul
defici
exhibit
sever
bleed
phenotyp
suggest
proper
platelet
function
sole
determin
granul
quantiti
patient
bleed
sever
may
appropri
assess
bleed
score
rather
pem
valu
use
quartil
rang
may
aid
risk
stratif
therapeut
intervent
dspd
patient
work
remain
determin
optim
diagnost
threshold
pem
dspd
pediatr
popul
texa
children
hospit
houston
texa
unit
state
background
warfarin
manag
mani
challeng
aspect
includ
pharmacogenom
food
drug
interact
lack
standard
dose
patient
complianc
track
lab
result
multipl
lab
locat
potenti
signific
bleed
thrombot
complic
literatur
review
reveal
limit
data
highlight
anticoagul
monitor
workflow
emr
document
specif
data
pediatr
popul
histor
texa
children
hospit
cardiolog
hematolog
center
document
anticoagul
data
within
epic
tm
system
differ
epic
tm
origin
design
anticoagul
document
result
necess
duplic
document
order
see
atagl
critic
anticoagul
monitor
inform
object
object
project
standard
inr
document
across
depart
reduc
risk
patient
safeti
event
improv
workflow
designmethod
workgroup
assembl
consist
nurs
cardiolog
hematolog
depart
along
staff
member
epic
tm
support
group
workgroup
identifi
current
document
practic
avail
epic
tm
tool
brainstorm
idea
streamlin
improv
document
current
epic
tm
tool
physician
partner
identifi
cardiolog
hematolog
coagul
laboratori
gain
input
new
anticoag
ac
encount
develop
first
made
avail
epic
tm
practic
environ
approv
epic
tm
written
educ
train
session
complet
depart
staff
result
survey
sent
health
care
provid
cardiolog
hematolog
center
prior
new
ac
encount
also
health
care
provid
six
month
implement
ac
encount
six
respons
receiv
survey
preimplement
survey
show
problemat
part
document
system
anticoagul
singl
place
emr
find
complet
anticoagul
pictur
post
ac
encount
implement
survey
result
reveal
health
care
provid
use
epic
tm
inr
remind
pool
less
time
need
compil
report
three
month
anticoagul
inform
less
time
need
document
individu
encount
less
locat
need
document
ac
inform
decreas
amount
type
document
use
standard
ac
encount
improv
workflow
less
time
need
document
compil
inform
less
type
document
util
easier
access
patient
ac
inform
next
step
includ
retrospect
review
patient
inr
time
therapeut
rang
determin
impact
patient
complianc
continu
evalu
modifi
ac
encount
enhanc
user
friendli
caitlin
tyde
jennif
meldau
christin
guelcher
carol
hennessey
eena
kapoor
michael
guerrera
yaser
diab
children
nation
health
system
washington
district
columbia
unit
state
background
venou
anatom
abnorm
vaa
consid
risk
factor
develop
deep
vein
thrombos
dvt
occur
result
signific
alter
venou
blood
flow
identif
predispos
vaa
challeng
henc
diagnosi
delay
overlook
especi
pediatr
patient
dvt
children
adolesc
predispos
vaa
describ
sporad
case
report
small
case
seri
object
describ
characterist
outcom
dvt
pediatr
patient
underli
vaa
treat
center
designmethod
conduct
retrospect
chart
review
pediatr
patient
object
confirm
extrem
dvt
treat
institut
period
identifi
patient
underli
vaa
patient
manag
accord
standard
institut
protocol
base
publish
guidelin
postthrombot
syndrom
pt
assess
center
use
mancojohnson
instrument
relev
data
collect
summar
use
descript
statist
studi
period
pediatr
patient
femal
median
age
year
rang
diagnos
extrem
dvt
center
found
underli
vaa
vaa
includ
maythurn
anomali
patient
venou
thorac
outlet
obstruct
patient
inferior
vena
cava
ivc
atresia
patient
addit
provok
factor
identifi
patient
time
present
dvt
locat
includ
upper
extrem
vein
patient
lower
extrem
vein
patient
lower
extrem
vein
ivc
patient
major
dvt
patient
complet
occlus
high
risk
thrombophilia
defin
inherit
defici
antithrombin
protein
c
protein
antiphospholipid
antibodi
syndrom
present
patient
patient
treat
therapeut
anticoagul
patient
continu
indefinit
anticoagul
endovascular
intervent
perform
patient
includ
percutan
pharmacomechan
thrombectomi
andor
catheterdirect
thrombolysi
patient
balloon
angioplasti
patient
stent
angioplasti
patient
surgic
intervent
includ
thorac
decompress
surgeri
patient
surgic
thrombectomi
patient
vva
repres
import
risk
factor
develop
extens
extrem
dvt
adolesc
special
popul
risk
shortterm
longterm
complic
earli
identif
correct
vaa
may
improv
outcom
howev
multicent
prospect
studi
need
develop
optim
evidencebas
treatment
approach
alexand
glaro
roland
chu
sureyya
savasan
meera
chitlur
madhvi
rajpurkar
yaddanapudi
ravindranath
children
hospit
michigan
detroit
michigan
unit
state
background
acut
buddchiari
syndrom
bc
rare
thrombot
emerg
children
etiologiestreat
less
welldefin
adult
adult
systemat
approach
includ
anticoagul
relief
venou
obstruct
treatment
underli
caus
proven
success
recent
treatment
tilt
toward
aggress
surgic
intervent
carri
signific
risk
often
feasibl
object
review
experi
three
differ
patient
bc
suggest
mechanist
base
approach
treatment
record
three
patient
bc
review
present
etiolog
treatment
outcom
report
result
patient
femal
paroxysm
nocturn
hemoglobinuria
present
recurr
worsen
abdomin
pain
sever
month
narrow
inferior
vena
cava
ivc
hepat
vein
note
imag
liver
transplant
consid
surgic
feasibl
treat
eculizumab
steroid
anticoagul
restor
hepat
venou
flow
week
patient
b
male
sever
week
right
upper
quadrant
pain
fatigu
presyncop
episod
histori
blunt
abdomin
trauma
footbal
scrimmag
week
earlier
found
near
complet
occlus
ivc
hepat
vein
liver
transplant
consid
feasibl
success
treat
anticoagul
alon
patient
c
male
acut
myeloid
leukemia
induct
cycl
develop
sever
pancytopenia
typhliti
diagnos
manag
medic
day
later
acut
decompens
arrest
place
extra
corpor
membran
oxygen
imag
show
complet
occlus
portal
vein
hepat
vein
ivc
level
atrium
bilater
pulmonari
emboli
emerg
liver
transplant
cathet
base
intervent
deem
feasibl
treatment
eculizumab
consid
presum
inflamm
induc
complement
activ
normal
normal
trigger
thrombosi
patient
progress
quickli
die
could
initi
experi
bc
show
invas
intervent
option
liver
transplant
may
feasibl
patient
multipl
reason
rapid
diagnosi
aggress
etiologybas
medic
manag
paramount
success
treatment
rare
complic
eculizumab
may
consid
treat
bc
complement
activ
due
innat
disord
also
secondari
acut
inflamm
proper
laboratori
evid
present
background
platelet
aggreg
studi
gold
standard
diagnosi
platelet
function
defect
evalu
patient
bleed
problem
platelet
aggreg
test
measur
well
platelet
clot
respons
differ
concentr
epinephrin
adenosin
diphosph
adp
collagen
arachidon
acid
ristocetin
platelet
function
defect
often
underrecogn
underdiagnos
pediatr
patient
true
incid
unknown
report
experi
diagnosi
platelet
defect
institut
period
order
add
clariti
limit
pediatr
data
avail
object
primari
object
document
correlationstrend
less
wellknown
platelet
function
abnorm
clinic
signific
bleed
institut
period
designmethod
appropri
irb
approv
obtain
perform
retrospect
chart
review
children
platelet
aggreg
test
done
data
collect
includ
demograph
age
sex
race
person
famili
histori
bleed
screen
coagul
defect
platelet
aggreg
test
result
symptom
examin
data
limit
epistaxi
heavi
menstrual
period
symptom
result
analyz
abnorm
respons
adp
epinephrin
patient
exist
bleed
diagnos
incomplet
medic
record
exclud
identifi
patient
patient
epistaxi
abnorm
platelet
aggreg
test
heavi
menstrual
period
abnorm
result
within
popul
abnorm
platelet
function
assay
result
race
appear
correl
abnorm
platelet
aggreg
test
case
epistaxi
sex
also
noncontributori
preliminari
result
suggest
platelet
aggreg
test
use
predict
platelet
defect
clinic
bleed
histori
epistaxi
oppos
heavi
menstrual
period
present
symptom
platelet
aggreg
test
offer
diagnost
benefit
abnorm
respons
adp
platelet
aggreg
test
common
find
popul
clinic
signific
well
understood
go
forward
plan
document
whether
abnorm
result
correl
significantli
subsequ
final
diagnos
patient
background
decis
make
sever
hemophilia
previous
untreat
patient
pup
recent
becom
signific
ethic
debat
recombin
factor
viii
rfviii
product
previous
recommend
avoid
transmiss
blood
born
pathogen
associ
plasmaderiv
fviii
pdfviii
product
howev
increas
incid
fviii
alloantibodi
inhibitor
rfviii
product
compar
pdfviii
product
challeng
former
standard
care
despit
support
medic
scientif
advisori
council
recommend
consid
pdfviii
product
pup
remain
controversi
designmethod
use
modifi
utilitarian
approach
involv
clinic
public
health
research
ethic
share
decis
make
permeat
framework
maxim
understand
minim
bia
respect
inform
consent
dissent
provid
care
align
patient
famili
valu
medic
practic
feasibl
framework
three
tier
first
evalu
whether
resourc
scarc
abund
equit
resourc
alloc
fviii
product
scarc
recommend
develop
central
suppli
emerg
use
evalu
need
sever
hemophilia
patient
priorit
receiv
factor
product
would
decid
design
team
base
avail
factor
product
clinic
scenario
prefer
given
research
trial
howev
resourc
abund
treatment
acut
bleed
standard
care
prophylaxi
measur
includ
primari
prophylaxi
could
continu
second
tier
account
whether
new
infecti
epidem
concern
pathogen
elimin
healthcar
public
health
worker
may
limit
use
pdfviii
product
pdfviii
rfviii
product
equal
consid
third
tier
evalu
whether
clinic
scenario
emerg
acut
emerg
bleed
immedi
avail
resourc
use
along
bypass
andor
adjuv
resourc
need
bleed
resolv
improv
align
patient
famili
prefer
attempt
pdfviii
rfviii
product
avail
similar
cost
institut
would
ideal
ethic
framework
endeavor
balanc
autonomi
benefic
nonmalefic
justic
help
guid
discuss
among
provid
pup
sever
hemophilia
famili
disclaim
find
conclus
author
necessarili
repres
offici
posit
center
diseas
control
prevent
emori
univers
children
healthcar
atlanta
background
von
willebrand
diseas
vwd
common
bleed
disord
affect
popul
without
gender
predilect
bleed
associ
condit
result
defici
abnorm
von
willebrand
factor
interf
format
primari
hemostasi
ehlersdanlo
syndrom
ed
group
rare
inherit
connect
tissu
disord
may
associ
bleed
manifest
without
abnorm
coagul
test
bleed
symptom
report
ed
result
capillari
tissu
fragil
joint
hypermobl
syndrom
jh
inherit
condit
nearli
indistinguish
ed
iii
report
coinherit
vwd
ed
jh
infrequ
object
retrospect
studi
review
patient
coexist
vwd
ed
jh
indiana
hemophilia
thrombosi
center
order
describ
type
sever
bleed
symptom
physic
examin
find
pertin
laboratori
data
designmethod
electron
medic
record
databas
indiana
hemophilia
thrombosi
center
queri
patient
diagnosi
vwd
one
follow
descriptor
hypermobl
syndrom
hypermobl
hypermobil
joint
ehlersdanlo
syndrom
record
identifi
patient
review
demograph
type
sever
bleed
symptom
beighton
score
bs
vwd
antigen
ristocetin
cofactor
factor
viii
level
vwd
multim
pattern
vwd
subtyp
genet
test
ed
famili
histori
ed
result
total
patient
dual
diagnos
vwd
ed
patient
vwd
hypermobl
identifi
queri
two
patient
complet
genet
test
ed
one
gene
mutat
identifi
signific
bleed
symptom
vwd
ed
group
includ
hematuria
postop
hemorrhag
two
patient
delay
wound
heal
postop
seven
patient
identifi
type
vwd
jh
moder
sever
somewhat
unusu
bleed
episod
report
includ
hematuria
hematemesi
hemoptysi
patient
signific
periop
bleed
femal
compos
vwd
ed
group
vwd
jh
group
conclus
coinherit
vwd
ed
uncommon
phenomenon
patient
vwd
ed
jh
may
atyp
moder
sever
bleed
especi
procedur
intervent
incorpor
bs
assess
patient
bleed
disord
use
identifi
potenti
inherit
collagen
disord
diagnosi
condit
may
impact
clinic
manag
yearlong
phase
ii
studi
khe
patient
respond
patient
follow
year
studi
complet
collect
data
growth
develop
complic
therapi
unexpect
toxic
need
continu
sirolimu
object
studi
therapi
treatment
one
year
object
includ
assess
long
term
toxic
year
period
studi
therapi
complet
assess
unexpect
toxic
assess
overal
condit
patient
assess
need
restart
continu
sirolimu
therapi
designmethod
prospect
followup
patient
diagnosi
khe
institut
inclus
criteria
followup
year
poststudi
result
followup
includ
data
year
n
year
n
time
point
averag
age
start
treatment
month
patient
avail
follow
four
patient
longer
sirolimu
one
patient
complet
studi
therapi
remain
treatment
ot
year
requir
year
treatment
year
ot
requir
addit
treatment
cours
prior
success
discontinu
month
ot
patient
still
sirolimu
restart
medic
symptom
pain
swell
andor
edema
interf
qualiti
life
made
averag
attempt
discontinu
sirolimu
patient
reoccurr
kmp
patient
improv
clinic
radiolog
appear
khe
residu
lesion
note
imag
andor
clinic
exam
unexpect
toxic
growth
delay
development
issu
long
term
toxic
sirolimu
note
conclus
first
prospect
data
longterm
follow
khe
patient
treat
sirolimu
although
number
small
sirolimu
well
toler
howev
half
patient
still
medic
year
follow
stress
need
continu
long
term
follow
young
patient
investig
mechan
sirolimu
effect
nationwid
children
hospit
columbu
ohio
unit
state
background
recent
studi
identifi
adult
person
hemophilia
pwh
higher
preval
hypertens
renal
diseas
gener
popul
hematuria
known
complic
hemophilia
b
ha
hb
longterm
impact
pwh
current
known
annual
screen
patient
urinalysi
pediatr
center
identifi
half
patient
demonstr
hematuria
fouryear
period
motiv
desir
identifi
earli
marker
hypertens
renal
diseas
sought
determin
find
reflect
pediatr
hemophilia
popul
whole
object
establish
populationwid
preval
hematuria
pediatr
pwh
designmethod
use
pediatr
health
inform
system
phi
databas
contain
clinic
resourc
util
data
inpati
hospit
nationwid
analyz
preval
hematuria
hypertens
renal
diseas
relat
diagnosi
code
pediatr
pwh
admit
januari
septemb
result
fiveyear
period
uniqu
pediatr
pwh
account
admiss
major
admiss
bleed
infecti
concern
patient
affili
admiss
code
hematuria
admiss
whole
median
age
year
admit
infant
toddler
children
adolesc
older
identifi
admiss
ha
remain
hb
admit
bypass
agent
administ
median
length
stay
person
hematuria
day
compar
day
nonhematuriaoth
bleed
admiss
hypertens
report
though
patient
receiv
antihypertens
medic
admiss
addit
admiss
report
diagnosi
code
renal
diseas
studi
demonstr
pediatr
pwh
experienc
hematuria
gener
patient
persist
hematuria
requir
hospit
admiss
suspect
data
underrepres
number
pwh
experienc
hematuria
manag
outpati
set
also
suspect
hypertens
grossli
underreport
undertr
pediatr
pwh
addit
low
number
patient
experienc
renal
diseas
requir
hospit
admiss
among
cohort
given
littl
research
longterm
impact
hematuria
hemophilia
feel
find
support
need
vigil
pediatr
pwh
background
gla
gsd
aggress
destroy
bone
signific
impact
morbid
mortal
mtor
inhibitor
sirolimu
shown
effect
treatment
diseas
base
addit
mtor
inhibit
bisphosphon
therapi
metastat
cancer
therapi
regimen
use
refractori
high
risk
gla
gsd
heterogen
diagnosi
variabl
drug
regimen
assess
effect
object
assess
variabl
clinic
featur
gla
gsd
assess
heterogen
diagnosi
assess
drug
regimen
respons
assess
across
multipl
institut
designmethod
conduct
retrospect
review
institut
case
gla
gsd
treat
sirolimu
bisphosphon
least
month
assess
clinic
featur
treatment
protocol
respons
regimen
side
effect
result
patient
includ
gla
n
gsd
n
averag
age
diagnosi
year
clinic
featur
includ
effus
gla
n
soft
tissu
lymphat
malform
gla
n
gsd
n
multipl
splenic
lesion
gla
n
soft
tissu
swell
site
boni
lesion
gsd
n
present
symptom
patient
pain
patient
gla
present
short
breath
fractur
note
patient
gla
gsd
diagnost
andor
respons
imag
includ
mri
ct
bone
scan
skelet
survey
dexa
scan
treatment
consist
initi
sirolimu
use
addit
bisphosphon
secondari
worsen
diseas
n
initi
therapi
agent
interferon
chemotherapeut
agent
radiat
chang
sirolimu
bisphosphon
secondari
toxic
n
sirolimu
bisphosphon
n
sirolimu
bisphosphon
interferon
n
seventeen
patient
stabl
diseas
patient
improv
diseas
sirolimu
protocol
standard
howev
bisphosphon
protocol
vari
dose
frequenc
side
effect
toler
expect
grade
iii
iv
toxic
sirolimu
bisphosphon
safe
effect
therapi
gsd
gla
consist
medic
regimen
redefin
respons
improv
radiolog
classif
import
develop
prospect
clinic
trial
background
hemophilia
bleed
disord
defici
clot
factor
viii
signific
sequela
hemophilia
tendenc
develop
hemarthrosi
incit
joint
destruct
preval
overweight
obes
increas
gener
hemophilia
popul
lead
sever
morbid
includ
arthropathi
particular
concern
hemophilia
arthropathi
consequ
joint
bleed
object
purpos
studi
detect
relat
bodi
mass
index
bmi
joint
health
endpoint
pediatr
hemophilia
popul
designmethod
particip
studi
includ
patient
hemostasi
thrombosi
center
children
hospit
lo
angel
particip
prescreen
approach
studi
routin
followup
appoint
patient
age
year
old
diagnos
hemophilia
includ
mild
moder
sever
qualifi
studi
inform
consent
obtain
patient
parent
enrol
joint
health
object
measur
physic
therapist
children
hospit
lo
angel
use
hemophilia
joint
health
score
hjh
hjh
total
score
calcul
assess
swell
durat
swell
muscl
atrophi
crepitu
motion
flexion
loss
extens
loss
joint
pain
muscl
strength
major
joint
subject
data
also
obtain
patient
record
annual
bleed
rate
within
past
year
patient
normal
weight
overweight
obes
use
chisquar
analysi
compar
joint
score
across
bmi
classif
chi
squar
df
pvalu
although
approach
statist
signific
averag
hjh
score
patient
hjh
show
increas
trend
among
bmi
classif
normal
bmi
patient
overweight
bmi
patient
obes
bmi
patient
averag
number
annual
bleed
posit
valu
show
normal
bmi
patient
overweight
bmi
patient
obes
bmi
patient
although
posit
effect
adipos
found
joint
hemophilia
pediatr
patient
effect
show
enough
evid
conclud
differ
futur
studi
need
address
whether
obes
effect
hemophilia
determin
whether
overweightobes
lead
complic
hemophil
joint
background
stagnant
blood
flow
slowflow
vascular
malform
vm
particularli
venou
compon
lead
local
intravascular
coagul
lic
character
elev
ddimer
level
low
fibrinogen
decreas
platelet
count
coagul
derang
lead
local
thrombosi
bleed
result
pain
function
limit
possibl
progress
dissemin
intravascular
coagulopathi
dic
treatment
vm
associ
coagulopathi
proven
difficult
patient
complex
vm
frequent
manag
sirolimu
mtor
inhibitor
clinic
benefit
includ
reduct
pain
improv
function
impair
possibl
improv
sirolimu
could
secondari
improv
coexist
lic
object
studi
assess
use
sirolimu
manag
coagulopathi
seen
slowflow
vm
designmethod
review
chart
patient
vm
follow
vascular
anomali
center
arkansa
children
hospit
start
sirolimu
efficaci
object
assess
improv
ddimer
fibrinogen
platelet
count
three
set
lab
valu
presirolimu
month
postsirolimu
recent
obtain
patient
avail
identifi
total
patient
prescrib
sirolimu
eighteen
exclud
base
underli
condit
slowflow
vascular
malform
inadequ
medic
record
total
patient
combin
vascular
venou
includ
studi
elev
ddimer
level
mean
mcgml
feu
median
mcgml
feu
rang
prior
treatment
two
patient
associ
low
fibrinogen
mgdl
indic
sever
lic
treatment
patient
show
overal
decreas
ddimer
level
averag
decreas
mcgml
feu
preand
postsirolimu
lab
averag
decreas
mcgml
feu
presirolimu
recent
valu
two
patient
low
fibrinogen
prior
treatment
show
decreas
ddimer
level
mean
decreas
mcgml
feu
increas
normal
fibrinogen
mean
increas
mgdl
begin
sirolimu
patient
thrombocytopenia
report
treatment
sirolimu
effect
improv
coagulopathi
associ
slowflow
vm
evidenc
decreas
ddimer
level
increas
fibrinogen
andor
platelet
longterm
use
medic
popul
may
decreas
bleed
thrombot
complic
patient
experi
especi
follow
invas
vascular
procedur
background
safeti
efficaci
bay
sitespecif
pegyl
bdomaindelet
recombin
factor
viii
previous
treat
adolesc
adult
age
year
sever
hemophilia
demonstr
phase
protect
viii
studi
ongo
extens
object
subanalysi
examin
efficaci
safeti
bay
adolesc
protect
viii
ongo
extens
studi
data
cutoff
januari
designmethod
protect
viii
patient
includ
adolesc
receiv
bay
demand
prophylaxi
week
prophylaxi
regimen
week
twiceweekli
iukg
iukg
onceweekli
iukg
infus
base
bleed
runin
period
iukg
twiceweekli
prophylaxi
patient
continu
prophylaxi
regimen
extens
chang
regimen
time
result
twelv
patient
age
year
includ
protect
viii
intenttotreat
popul
addit
patient
discontinu
dose
includ
safeti
popul
patient
receiv
prophylaxi
studi
enrol
median
rang
number
total
joint
bleed
month
studi
entri
respect
ten
patient
target
joint
baselin
median
rang
per
patient
week
protect
viii
entir
time
patient
remain
design
prophylaxi
dose
frequenc
median
quartil
q
annual
bleed
rate
abr
patient
receiv
twiceweekli
n
n
onceweekli
prophylaxi
n
respect
overal
prophylaxi
n
two
patient
switch
onceweekli
twiceweekli
n
prophylaxi
n
number
bleed
decreas
one
patient
patient
main
studi
continu
extens
mean
abr
extens
vari
dose
regimen
twice
weekli
n
everi
day
n
weekli
n
two
patient
chang
onceweekli
prophylaxi
extens
mean
abr
one
patient
nonneutr
antibodi
bay
baselin
endofstudi
titer
neg
patient
develop
antipeg
antibodi
factor
viii
inhibitor
experienc
seriou
advers
event
relat
bay
main
studi
extens
previous
treat
adolesc
sever
hemophilia
bay
prophylaxi
effect
prevent
bleed
less
bleed
overal
versu
prestudi
gener
well
toler
fund
bayer
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
vascular
malform
vm
consist
heterogen
group
congenit
disord
character
abnorm
develop
blood
andor
lymphat
vessel
caus
broad
spectrum
clinic
manifest
although
consid
benign
vm
frequent
associ
cutan
complic
caus
signific
morbid
nodular
overgrowth
skin
thicken
pruritu
ooz
bleed
lymphat
bleb
secondari
infect
oral
sirolimu
shown
effect
treatment
complic
vascular
malform
known
side
effect
need
frequent
laboratori
monitor
current
limit
studi
use
topic
sirolimu
treatment
cutan
manifest
vascular
malform
object
evalu
efficaci
safeti
topic
sirolimu
vm
cutan
complic
propos
indic
use
designmethod
retrospect
review
medic
record
patient
vascular
malform
treat
topic
sirolimu
januari
decemb
respons
determin
subject
object
improv
result
twentyfour
patient
femal
male
vascular
malform
cutan
manifest
treat
topic
sirolimu
age
rang
year
indic
treatment
bleb
n
caus
either
leak
bleed
pain
pruritu
swell
recurr
infect
nodular
overgrowth
n
pyogen
granuloma
n
bleed
n
cosmet
n
treatment
cours
rang
month
major
side
effect
report
one
patient
report
burn
itch
sensat
regard
clinic
respons
n
patient
improv
cutan
lesion
n
stabl
lesion
n
stop
treatment
due
side
effect
priorconcomit
treatment
n
prior
surgeri
laser
sclerotherapi
n
concomit
oral
sirolimu
patient
receiv
concomit
system
sirolimu
n
oral
sirolimu
patient
n
good
respons
topic
treatment
topic
sirolimu
appear
benefici
welltoler
minim
side
effect
profil
treatment
cutan
manifest
vascular
malform
singl
agent
adjuv
therapi
system
sirolimu
symptom
adequ
control
studi
need
prospect
analyz
efficaci
safeti
topic
sirolimu
patient
popul
object
evalu
safeti
efficaci
longterm
romiplostim
children
itp
designmethod
patient
receiv
weekli
sc
romiplostim
gkg
target
platelet
count
l
median
minmax
treatment
patient
week
total
patientyear
year
per
patient
baselin
median
minmax
age
year
femal
prior
splenectomi
median
minmax
averag
weekli
dose
gkg
includ
escal
stabl
dose
patient
start
gkg
reason
discontinu
romiplostim
n
includ
consent
withdrawn
n
requir
therapi
n
ae
n
asthenia
headach
dehydr
vomit
one
patient
anxieti
none
treatment
relat
fifti
four
seriou
ae
occur
patient
treatment
relat
one
concurr
grade
thrombocytopenia
grade
epistaxi
grade
anemia
antiromiplostim
neutral
antibodi
detect
one
patient
discontinu
receiv
therapi
antibodi
absent
retest
week
median
platelet
count
remain
l
median
platelet
count
l
week
nearli
patient
platelet
respons
platelet
count
l
exclud
week
rescu
medic
patient
platelet
respons
time
time
sixti
patient
caregiv
selfadminist
romiplostim
fifteen
patient
treatmentfre
period
platelet
count
l
week
ie
remiss
patient
girl
boy
itp
median
minmax
year
none
prior
splenectomi
receiv
romiplostim
year
platelet
count
l
month
month
median
minmax
durat
l
week
baselin
characterist
sex
platelet
count
itp
durat
number
past
itp
treatment
age
year
predict
develop
treatmentfre
period
week
p
sevenyear
openlabel
extens
children
itp
achiev
platelet
respons
romiplostim
well
toler
importantli
patient
abl
discontinu
itp
medic
month
fund
amgen
inc
background
sirolimu
immunosuppress
drug
wide
use
solid
organ
bone
marrow
transplant
recent
treatment
vascular
lymphat
anomali
sirolimu
associ
decreas
immun
transplant
set
patient
receiv
immunosuppress
drug
immunosuppress
previou
chemotherapi
effect
sirolimu
immun
system
chemotherapi
children
receiv
immunosuppress
agent
well
understood
variabl
approach
fever
pcp
prophylaxi
understand
effect
sirolimu
immun
system
patient
noncompl
vascular
lymphat
anomali
evalu
anc
alc
prior
sirolimu
therapi
designmethod
multiinstitut
retrospect
review
done
includ
patient
noncompl
vascular
lymphat
anomali
effusionsascit
multiorgan
involv
histori
vascularanomalyrel
infect
prior
treatment
exclud
result
twenti
patient
kaposiform
hemangioendothelioma
n
gener
lymphat
anomali
n
clove
syndrom
simpl
vascular
malform
n
includ
age
initi
sirolimu
treatment
rang
year
male
femal
ratio
sirolimu
initi
due
extens
diseas
lack
respons
steroid
bisphosphon
pain
dment
lymphat
drainag
prevent
ongo
overgrowth
prior
start
sirolimu
mean
anc
alc
target
level
sirolimu
vari
indic
patient
rang
steadi
state
level
month
sirolimu
mean
anc
decreas
alc
month
sirolimu
mean
anc
alc
first
sirolimu
level
mean
level
nine
patient
place
pcp
prophylaxi
start
sirolimu
none
patient
infecti
complic
sirolimu
median
fu
month
one
patient
mild
neutropenia
anc
normal
discontinu
pjp
prophylaxi
conclus
small
cohort
patient
found
anc
alc
level
patient
noncompl
vascular
lymphat
anomali
differ
prospect
studi
specif
track
anc
alc
igg
lymphocyt
function
conduct
better
understand
effect
sirolimu
immun
system
data
allow
uniform
recommend
regard
prophylaxi
manag
febril
episod
background
acut
infect
associ
system
inflamm
increas
risk
venou
thromboembol
vte
certain
welldefin
clinic
scenario
may
primari
trigger
vte
pediatr
patient
pediatr
data
vte
set
acut
infect
spars
object
describ
characterist
outcom
vte
pediatr
patient
acut
infect
conduct
retrospect
chart
review
pediatr
patient
object
confirm
vte
treat
institut
sinc
identifi
patient
acut
infect
identifi
vte
trigger
patient
manag
accord
standard
institut
protocol
base
publish
guidelin
relev
demograph
clinic
laboratori
data
collect
summar
use
descript
statist
sinc
acut
infect
identifi
trigger
vte
diagnos
center
median
age
time
vte
diagnosi
group
year
interquartil
rang
male
commonli
affect
femal
repres
case
neonat
vte
event
account
case
sepsi
common
acut
infect
identifi
vte
trigger
case
vte
event
associ
acut
infect
consid
hospitalassoci
vte
time
vte
diagnosi
patient
critic
ill
extens
vte
defin
complet
occlus
thrombosi
involv
venou
segment
occur
patient
acut
infect
deem
primari
trigger
vte
patient
infectionassoci
vte
cohort
includ
cerebr
sinu
venou
thrombosi
due
sinu
cn
infect
patient
septic
thrombophleb
patient
lemierr
lemierreslik
syndrom
patient
osteomyelitisassoci
deep
vein
thrombosi
patient
system
anticoagul
prescrib
patient
anticoagulationrel
major
bleed
occur
patient
vte
complic
includ
vte
recurr
patient
vte
progress
patient
acut
pulmonari
embol
patient
arteri
ischem
stroke
patient
studi
indic
acut
infect
common
risk
factor
pediatr
vte
especi
critic
ill
children
primari
trigger
signific
proport
vte
case
associ
acut
infect
anticoagul
appear
overal
safe
popul
associ
low
rate
seriou
vterel
acut
complic
howev
studi
also
suggest
popul
may
increas
risk
vte
recurr
anticoagulationrel
major
bleed
background
epithelioid
hemangioma
eh
rare
benign
vascular
tumor
occur
soft
tissu
bone
present
third
sixth
decad
life
subset
eh
harbor
fo
rearrang
eh
describ
children
littl
known
longterm
outcom
pediatr
eh
main
object
obtain
data
use
improv
understand
rare
diseas
order
provid
standard
care
develop
futur
research
studi
boardapprov
retrospect
review
clinic
patholog
radiograph
characterist
treatment
outcom
patient
diagnos
eh
result
eight
patient
male
mean
age
diagnosi
year
rang
lesion
involv
lower
extrem
n
cranium
n
pelvi
n
spine
n
multifoc
diseas
identifi
five
patient
common
present
involv
signific
local
pain
neurolog
symptom
headach
cranial
nerv
injuri
loss
conscious
radiograph
studi
identifi
variabl
featur
multifoc
lytic
boni
lesion
sclerot
margin
enhanc
soft
tissu
compon
surround
inflammatori
edema
histolog
specimen
compos
vascular
channel
line
epithelioid
endotheli
cell
without
signific
cytolog
atypia
solid
cellular
area
n
endotheli
cell
posit
egr
neg
fo
rearrang
assess
one
specimen
detect
mean
followup
time
day
rang
patient
treat
surgic
resect
intravascular
embol
bisphosphon
propranolol
interferon
sirolimu
one
patient
treat
interferon
one
sirolimu
exhibit
partial
respons
mean
followup
day
although
eh
benign
neoplasm
difficult
manag
without
standard
protocol
portend
consider
morbid
find
suggest
medic
manag
particularli
sirolimu
may
benefit
patient
howev
longterm
followup
need
treat
children
novel
fo
inhibitor
develop
may
benefit
patient
fo
rearrang
penn
state
health
children
hospit
hershey
pennsylvania
unit
state
background
central
venou
cathet
cvc
often
requir
critic
care
set
order
provid
secur
point
access
life
sustain
care
clinic
studi
identifi
cvc
presenc
singl
import
risk
factor
deep
vein
thrombosi
dvt
children
venou
thromboembol
event
vte
incid
rate
critic
ill
children
cvc
rang
per
cathet
day
depend
popul
studi
per
institut
protocol
penn
state
health
children
hospit
picu
hershey
pa
util
low
dose
continu
infus
unfraction
heparin
ldufh
unitskghr
prophylaxi
cvcrelat
vte
maintain
line
patenc
efficaci
approach
never
evalu
determin
ldufh
prophylaxi
result
lower
incid
cvcrelat
vte
cathet
dysfunct
central
line
associ
blood
stream
infect
clabsi
without
increas
morbid
determin
incid
cathet
relat
vte
lower
histor
publish
data
retrospect
chart
review
conduct
util
institut
electron
medic
record
patient
age
year
cvc
picu
admiss
secondari
object
incid
cathet
dysfunct
clabsi
associ
bleed
complic
also
analyz
result
interim
data
analysi
reveal
cvc
nontunnel
cvc
total
implant
devic
tunnel
line
peripher
insert
central
cathet
picc
total
patient
median
age
year
overal
vte
incid
vte
associ
nontunnel
cvc
picc
sixti
one
percent
nontunnel
cvc
receiv
ldufh
patient
vte
associ
nontunnel
cvc
receiv
ldufh
prophylaxi
vte
incid
rate
nontunnel
cvc
ldufh
per
picu
cathet
day
vte
event
identifi
within
studi
cohort
picc
group
two
patient
experienc
vte
one
receiv
ldufh
clabsi
incid
nontunnel
cvc
tunnel
cvc
picc
major
bleed
complic
associ
ldufh
preliminari
data
demonstr
ldufh
efficaci
prevent
cvcrelat
vte
comparison
publish
report
analysi
compar
anoth
similar
size
acuiti
level
picu
practic
method
background
fibroadipos
vascular
anomali
fava
rare
challeng
disord
associ
mutat
fava
often
caus
pain
replac
muscl
soft
tissu
fibrot
adipos
tissu
associ
ectat
drain
vein
treatment
focal
lesion
surgic
excis
cryoablat
sclerotherapi
role
medic
therapi
unclear
fava
lesion
extens
directli
involv
neurovascular
structur
result
refractori
pain
object
retrospect
evalu
efficaci
sirolimu
patient
residu
symptom
procedur
therapi
fava
designmethod
retrospect
review
individu
case
institut
fava
refractori
therapi
treat
sirolimu
least
month
case
identifi
poll
member
aspho
vascular
anomali
special
interest
group
result
seven
patient
report
improv
sirolimu
therapi
patient
receiv
prior
procedur
includ
sclerotherapi
patient
cryoablat
patient
andor
resect
patient
mean
age
sirolimu
initi
rang
mean
length
therapi
month
rang
month
six
patient
treat
bid
dose
one
adult
receiv
daili
dose
goal
sirolimu
improv
pain
musculoskelet
dysfunct
pain
function
improv
patient
includ
discontinu
narcot
use
resumpt
particip
sport
time
symptom
improv
rang
week
four
patient
dose
lower
pain
recur
four
respond
restart
increas
sirolimu
dose
patient
preand
postsirolimu
imag
decreas
fava
lesion
size
seen
case
avail
imag
sirolimu
side
effect
similar
prior
report
commonli
mouth
sore
elev
lipid
acn
report
first
known
data
support
role
sirolimu
refractori
fava
case
sirolimu
welltoler
initi
improv
rapid
within
week
initi
whether
sirolimu
role
upfront
therapi
reduc
lesion
size
prior
procedur
deserv
studi
object
assess
platelet
respons
children
itp
receiv
romiplostim
designmethod
elig
children
itp
month
prior
therapi
screen
platelet
count
l
uncontrol
bleed
weekli
dose
gkg
target
platelet
count
l
bone
marrow
biopsi
evalu
europ
baselin
year
cohort
mar
patient
receiv
dose
baselin
median
minmax
age
year
itp
durat
year
platelet
count
l
patient
prior
splenectomi
median
time
platelet
respons
platelet
count
l
rescu
medic
past
week
month
primari
endpoint
cours
studi
patient
platelet
respons
four
patient
maintain
platelet
count
l
itp
medic
week
median
minmax
treatment
durat
week
patientyear
total
median
minmax
averag
weekli
romiplostim
dose
cours
studi
gkg
median
dose
gkg
year
n
gkg
year
n
patient
initi
selfadministr
sixtyfour
patient
discontinu
treatment
frequent
lack
efficaci
n
patient
request
n
advers
event
ae
n
fortyon
patient
seriou
ae
sae
includ
epistaxi
decreas
platelet
count
five
patient
treatmentrel
sae
headach
abdomin
pain
presyncop
neutral
antibodi
ab
case
neutral
ab
romiplostim
patient
test
none
tpo
continu
elev
platelet
count
case
ab
found
retest
cohort
patient
baselin
bone
marrow
biopsi
evalu
onstudi
biopsi
schedul
year
patient
increas
grade
find
collagen
abnorm
interim
datacut
romiplostim
openlabel
studi
children
itp
children
platelet
respons
overal
median
dose
gkg
median
romiplostim
dose
time
reach
gkg
new
safeti
signal
observ
patientyear
fund
amgen
inc
background
hepat
hemangioma
benign
vascular
tumor
without
medic
home
manag
multipl
specialti
diagnosi
assign
histor
variou
vascular
lesion
affect
liver
complet
differ
clinic
present
result
difficult
standard
manag
object
consensu
steer
committe
identifi
acut
need
clear
definit
evalu
guidelin
use
updat
intern
societi
studi
vascular
anomali
issva
classif
goal
formul
recommend
adopt
specialti
involv
care
children
hepat
hemangioma
designmethod
use
rigor
transpar
consensu
protocol
input
multipl
pediatr
expert
vascular
anomali
hematologyoncolog
surgeri
patholog
radiolog
gastroenterolog
first
section
precis
defin
subtyp
hepat
hemangioma
seen
children
congenit
infantil
use
clinic
cours
histolog
radiolog
characterist
inclus
exclus
limit
diagnosi
note
follow
two
section
describ
subtyp
detail
includ
complic
consid
monitor
respect
recommend
screen
evalu
conclus
institut
variat
may
exist
specif
clinic
detail
clear
understand
diagnosi
hepat
hemangioma
affect
pediatr
popul
possibl
complic
requir
screen
monitor
period
standard
patient
hepat
hemangioma
manag
differ
medic
surgic
specialti
multidisciplinari
consensu
base
current
literatur
data
extract
liver
hemangioma
registri
expert
opinion
requir
accomplish
manuscript
object
investig
associ
routin
prophylaxi
bay
bleed
outcom
adjust
key
patient
pharmacokinet
pk
characterist
designmethod
leopold
kid
studi
evalu
safeti
efficaci
bay
prophylaxi
previous
treat
boy
age
year
sever
hemophilia
patient
receiv
bay
iukg
n
n
follow
month
prophylaxi
dose
frequenc
assign
investig
pk
paramet
includ
area
curv
auc
halflif
clearanc
deriv
popul
pk
model
reflect
predict
pk
valu
dose
patient
characterist
compar
group
use
wilcoxon
rank
sum
chisquar
test
neg
binomi
regress
use
model
associ
prophylaxi
frequenc
annual
bleed
rate
abr
total
bleed
first
without
adjust
adjust
age
pk
paramet
bleed
histori
result
mean
sd
age
patient
analysi
year
patient
receiv
prophylaxi
bleed
episod
month
studi
entri
mean
sd
median
vs
p
like
treat
demand
vs
p
pk
paramet
similar
group
without
adjust
abr
studi
higher
group
compar
group
rate
ratio
rr
ci
p
abr
lower
group
rr
ci
p
adjust
age
auc
number
bleed
prior
month
conclus
abr
numer
lower
significantli
differ
group
adjust
age
pk
paramet
find
suggest
even
among
patient
group
homogen
respect
age
pk
bleed
histori
individu
bay
prophylaxi
base
characterist
may
help
reduc
bleed
episod
even
lower
treatment
frequenc
larger
realworld
studi
need
verifi
find
fund
bayer
stanford
palo
alto
california
unit
state
background
vascular
malform
may
lymphat
arteri
venou
capillari
endotheli
origin
may
simpl
complex
complex
malform
combin
soft
tissu
skelet
overgrowth
although
like
present
birth
malform
often
becom
symptomat
puberti
infect
rang
littl
clinic
impact
life
threaten
symptom
malform
primarili
venou
origin
pain
may
signific
hypothes
caus
phlebolith
develop
intramalform
thrombi
inflamm
consumpt
coagulopathi
vascular
engorg
endotheli
prolifer
antiangiogen
antiplatelet
therapi
report
reliev
pain
howev
use
anticoagul
pain
well
describ
object
report
clinic
featur
outcom
patient
vascular
malform
venou
origin
treat
anticoagul
pain
perform
retrospect
review
patient
vascular
malform
follow
hematolog
servic
januari
decemb
treat
pain
anticoagul
pain
relief
determin
wongbak
pain
scale
patient
report
clinic
data
extract
electron
medic
record
identifi
five
patient
venou
malform
vm
receiv
anticoagul
pain
four
patient
femal
median
age
year
old
rang
year
old
time
initi
anticoagul
five
patient
vm
extrem
two
vm
lower
extrem
three
patient
vm
upper
extrem
two
patient
concomit
coagulopathi
demonstr
decreas
ddimer
initi
anticoagul
four
patient
receiv
enoxaparin
one
adult
patient
receiv
rivaroxaban
patient
report
improv
pain
administr
anticoagul
one
patient
exhibit
mild
epistaxi
bruis
inject
site
signific
bleed
complic
pain
signific
complic
patient
venou
malform
case
seri
suggest
anticoagul
safe
effect
therapi
pain
relief
popul
investig
indic
compar
effect
anticoagul
therapeut
intervent
sclerotherapi
surgeri
sirolimu
treatment
pain
associ
venou
malform
maria
ahmadnabi
christin
knoll
sanjay
shah
lucia
mirea
phoenix
children
hospit
phoenix
arizona
unit
state
background
estim
incid
dvt
patient
osteomyel
rang
wide
howev
risk
factor
outcom
dvt
cohort
thoroughli
establish
object
studi
aim
estim
incid
dvt
patient
osteomyel
assess
risk
factor
outcom
dvt
cohort
designmethod
irb
approv
retrospect
chart
review
conduct
patient
age
year
seen
phoenix
children
hospit
icd
code
osteomyel
exclus
criteria
includ
chronic
recurr
multifoc
osteomyel
chronic
dvt
demograph
clinic
factor
outcom
compar
osteomyel
patient
without
dvt
use
fisherexact
wilcoxonrank
sum
test
appropri
data
distribut
result
total
studi
subject
osteomyel
mean
standard
deviat
age
year
dvt
present
patient
patient
receiv
anticoagul
week
respect
patient
vs
without
dvt
like
male
vs
pvalu
significantli
higher
rate
bacteremia
vs
pvalu
rate
central
line
compar
dvt
nondvt
patient
vs
pvalu
howev
patient
dvt
vs
without
dvt
significantli
longer
mean
length
stay
vs
day
pvalu
higher
rate
icu
admiss
vs
pvalu
incid
dvt
among
osteomyel
pediatr
patient
estim
risk
increas
male
sex
bacteremia
patient
dvt
significantli
higher
rate
icu
admiss
longer
length
hospit
stay
mani
patient
standard
practic
manag
dvt
week
anticoagul
data
highlight
need
recognit
high
risk
patient
need
futur
effort
target
dvt
prophylaxi
baylor
colleg
medicin
houston
texa
unit
state
background
lymphat
malform
lm
frequent
occur
head
neck
often
disfigur
even
lifethreaten
manag
option
includ
observ
surgeri
sclerotherapi
sirolimu
optim
sequenc
therapeut
intervent
determin
due
lack
compar
clinic
trial
establish
guidelin
thu
prenat
plan
multidisciplinari
team
benefici
present
case
seri
ten
children
head
neck
lm
evalu
multidisciplinari
vascular
anomali
center
chart
review
perform
assess
treatment
modal
recent
trend
result
seven
patient
head
neck
lm
diagnos
prenat
six
patient
requir
ex
utero
intrapartum
treatment
procedur
patient
start
sirolimu
median
age
month
rang
day
year
four
patient
recent
start
sirolimu
less
month
age
time
initi
six
patient
underw
partial
excis
lm
first
year
life
none
receiv
sirolimu
prior
surgeri
sirolimu
discontinu
one
patient
given
chronic
clostridium
difficil
infect
noncompli
anoth
patient
five
patient
receiv
sclerotherapi
tracheostomi
necessari
six
patient
one
patient
decannul
month
sirolimu
patient
radiograph
clinic
improv
lm
vari
treatment
modal
current
clinic
observ
show
improv
respons
sirolimu
demonstr
toler
sirolimu
young
age
conclus
treatment
pediatr
head
neck
lm
challeng
multidisciplinari
approach
necessari
major
patient
diagnos
prenat
prenat
plan
discuss
potenti
use
sirolimu
benefici
avail
vascular
anomali
expert
prenatalneonat
period
offer
best
manag
result
earli
initi
sirolimu
consid
complex
lesion
longterm
follow
warrant
investig
efficaci
time
treatment
option
yale
school
medicin
new
connecticut
unit
state
background
mitig
transfus
pathogencontamin
platelet
amotosalen
synthet
psoralen
compound
ad
sdp
compon
exposur
uva
light
activ
amotosalen
crosslink
dnarna
base
pair
prevent
replic
broad
spectrum
viral
bacteri
pathogen
may
contamin
platelet
prsdp
fda
approv
clinic
use
age
restrict
initi
use
prsdp
novemb
patient
retrospect
analyz
usag
prsdp
vs
convent
nonpr
platelet
cp
neonat
pediatr
patient
thrombocytopenia
compar
hemostat
efficaci
incid
transfus
reaction
tr
product
one
year
dual
platelet
inventori
designmethod
sinc
prsdp
fdalicens
irb
approv
requir
prsdp
cp
consid
standard
care
evalu
transfus
pediatr
patient
age
year
receiv
platelet
transfus
novemb
novemb
determin
volum
mean
ml
type
platelet
compon
transfus
number
platelet
transfus
episod
report
tr
base
cdc
hemovigil
guidelin
subgroup
analysi
perform
thrombocytopen
neonat
month
result
patient
year
receiv
cp
n
receiv
total
ml
platelet
mlpatient
transfus
episodespati
comparison
patient
receiv
prsdp
total
ml
platelet
mlpatient
p
infus
transfus
episodespati
p
neonat
month
n
receiv
cp
ml
cp
ml
patient
transfus
episod
episodespati
comparison
receiv
prsdp
n
receiv
ml
prsdp
mlpatient
p
transfus
episod
episodespati
p
recipi
year
n
includ
addit
patient
receiv
cp
prsdp
three
report
allerg
tr
transfus
episod
allerg
reaction
report
prsdp
transfus
one
febril
tr
report
cp
transfus
three
report
prsdp
conclus
prsdp
pediatr
popul
age
year
compar
cp
product
regard
volum
episod
platelet
transfus
incidencetyp
transfus
reaction
prsdp
safe
effect
use
pediatr
patient
popul
background
vascular
anomali
classifi
either
vascular
tumor
vascular
malform
fibroadipos
vascular
anomali
fava
newli
describ
entiti
present
distinct
clinic
radiograph
histopatholog
find
present
case
diagnosi
fava
complic
persist
low
platelet
count
secondari
immun
thrombocytopenia
itp
describ
challeng
diagnosi
novel
vascular
anomali
fava
complic
sever
thrombocytopenia
year
old
male
present
hospit
bruis
left
thigh
pain
relat
remot
sport
injuri
blood
work
reveal
platelet
count
otherwis
normal
complet
blood
count
follow
also
normal
aptt
fibrinogen
dimer
level
slightli
increas
treat
one
dose
ivig
mgkg
presum
itp
respond
well
platelet
count
increas
return
hospit
week
later
recurr
thrombocytopenia
worsen
leg
pain
ultrasound
left
thigh
reveal
x
x
lesion
within
vastu
mediali
diagnosi
intramuscular
hematoma
secondari
persist
thrombocytopenia
made
patient
present
multipl
episod
thrombocytopenia
next
sever
month
itp
respond
oral
prednison
mgday
day
continu
shortliv
respons
ivig
requir
infus
everi
week
platelet
count
would
fall
leg
pain
progress
restrict
wheelchair
imag
mri
brought
question
diagnosi
hematoma
biopsi
thigh
lesion
perform
result
consist
diagnosi
fava
subsequ
excis
conclus
uniqu
case
vascular
anomali
misdiagnos
hematoma
due
patient
persist
thrombocytopenia
histori
injuri
fava
newer
entiti
unlik
vascular
anomali
link
thrombocytopenia
local
consumpt
coagulopathi
excis
fava
patient
chronic
pain
mobil
resolv
though
itp
persist
object
preliminari
exploratori
analysi
realworld
administr
data
conduct
determin
unit
dispens
factor
replac
productrel
direct
expenditur
associ
current
market
shl
ehl
rfix
product
designmethod
deidentifi
claim
data
commerci
avail
truven
health
research
us
claim
databas
use
identifi
direct
expenditur
number
intern
unit
iu
dispens
patient
age
year
diagnosi
code
use
nonacog
alfa
eftrenonacog
alfa
studi
period
june
juli
refer
weight
measur
center
diseas
control
prevent
nation
center
health
statist
cdc
nch
anthropometr
data
use
estim
product
dispens
iu
per
kg
basi
nonacog
alfa
eftrenonacog
group
compris
patient
respect
median
iqr
age
two
group
year
respect
patient
eftrenonacog
alfa
group
calendar
quarter
avail
data
patient
nonacog
alfa
group
avail
quarter
median
rfix
product
dispens
per
quarter
iqr
iu
nonacog
alfa
group
iqr
iu
eftrenonacog
alfa
group
incorpor
attribut
weight
valu
median
rfix
product
iu
dispens
per
kg
per
week
iukgwk
iqr
iukgwk
nonacog
alfa
group
iukgwk
iqr
iukgwk
eftrenonacog
alfa
group
appli
wac
price
eftrenonacog
alfa
nonacog
alfa
calcul
estim
kgweek
nonacog
alfa
eftranonacog
alfa
group
respect
conclus
preliminari
realworld
data
deriv
larg
us
claim
databas
reveal
differ
product
dispens
factor
productrel
expenditur
among
pediatr
patient
sever
hemophilia
b
shl
ehl
rfix
product
prescrib
refin
data
potenti
exclud
instanc
sporad
usag
may
shed
light
realworld
dispens
rfix
product
among
pediatr
hemophilia
b
patient
background
vascular
malform
classifi
simpl
includ
capillari
venou
lymphat
arterioven
combin
malform
major
name
vessel
associ
anomali
multipl
modal
includ
laser
treatment
sclerotherapi
embol
surgeri
pharmacolog
intervent
mtor
inhibitor
like
sirolimu
use
treatment
vascular
malform
intervent
use
alon
combin
vari
outcom
present
institut
experi
multimod
approach
simpl
combin
vascular
malform
designmethod
perform
retrospect
chart
review
patient
vascular
malform
refer
center
intervent
radiolog
evalu
june
juli
includ
patient
age
month
year
refer
initi
intervent
radiolog
procedur
irp
vascular
malform
patient
symptom
pain
andor
swellingdeform
diagnosi
base
vascular
imag
doppler
ultrasound
mriav
nine
patient
venou
malform
vm
five
macrocyst
lymphat
malform
lm
six
lymphaticven
malform
lvm
two
arterioven
malform
avm
patient
initi
underw
intervent
radiolog
procedur
vm
patient
respond
sclerotherapi
alon
three
patient
lm
respond
sclerotherapi
alon
remaind
requir
surgic
intervent
one
avm
patient
respond
well
embol
need
surgic
resect
embol
four
lvm
patient
underw
irp
minim
improv
symptom
procedur
attempt
surgic
resect
attempt
patient
poor
respons
patient
start
sirolimu
twice
day
lvm
patient
start
sirolimu
respond
well
decreas
pain
swell
time
initi
symptom
respons
rang
week
month
start
medic
case
seri
patient
simpl
vm
respond
well
sclerotherapi
alon
avm
lm
patient
need
irp
andor
surgeri
complet
respons
complex
lvm
respond
well
surgeri
irp
improv
clinic
symptom
addit
sirolimu
treatment
regimen
respons
variou
modal
treatment
vari
base
type
vascular
malform
multidisciplinari
approach
manag
vascular
malform
essenti
provid
multimod
therapeut
option
rapid
symptom
relief
improv
qualiti
life
fragil
patient
especi
complex
malform
background
von
willebrand
diseas
vwd
common
bleed
disord
human
affect
unit
state
popul
desmopressin
ddavp
longact
vasopressin
analog
induc
vasoconstrict
releas
vwf
ddavp
use
patient
vwd
surgic
prophylaxi
carri
antidiuret
properti
avoid
electrolyt
imbal
hyponatremia
fluid
restrict
recommend
hour
postddavp
administr
object
studi
sought
examin
periop
practic
outcom
follow
ddavp
administr
fluid
restrict
protocol
popul
pediatr
patient
von
willebrand
diseas
designmethod
retrospect
chart
review
conduct
patient
von
willebrand
diseas
underw
surgic
procedur
children
hospit
pittsburgh
upmc
januari
decemb
patient
age
sex
weight
diagnosi
surgic
procedur
total
fluid
administ
postop
sodium
level
record
primari
outcom
note
proport
patient
exceed
recommend
fluid
consumpt
period
postddavp
administr
defin
local
guidelin
secondari
outcom
presenc
bleed
requir
er
visit
readmiss
hyponatrem
seizur
within
hour
ddavp
administr
result
data
compil
patient
femal
male
mean
age
year
sd
year
median
age
year
rang
year
procedur
includ
dental
otolaryngolog
orthoped
gastrointestin
plastic
neurosurgeri
ophthalmolog
dermatolog
gener
surgeri
gynecolog
patient
exceed
fluid
volum
recommend
first
period
postddavp
administr
still
surgic
set
patient
exceed
fluid
volum
recommend
total
period
postddavp
administr
postop
sodium
level
obtain
patient
patient
return
er
admit
bleed
hour
postddavp
administr
patient
return
er
admit
hyponatremia
seizur
hour
postddavp
administr
mainten
fluid
restrict
protocol
effect
deter
neg
outcom
cohort
howev
signific
fluid
volum
administ
nearli
third
patient
despit
restrict
given
risk
hyponatremia
limit
complianc
fluid
restrict
postop
sodium
level
record
follow
ddavp
administr
assess
possibl
hyponatremia
reinforc
import
fluid
restrict
commun
result
male
fetu
requir
utero
insert
pleuroamniot
shunt
bilater
pleural
effus
diagnos
antenat
ultrasound
shortli
deliveri
term
develop
respiratori
distress
found
reaccumul
pleural
effus
blood
work
day
life
show
platelet
count
l
decreas
precipit
demonstr
schistocyt
bloodsmear
sign
consumpt
coagulopathi
hypofibrinogenemia
high
ddimer
compensatori
reticulocytosi
requir
multipl
transfus
admiss
intens
care
unit
respiratori
support
investig
rule
congenit
ttp
neonat
alloimmun
thrombocytopenia
noonan
syndrom
given
high
clinic
suspicion
underli
vascular
lesion
caus
kmp
full
bodi
mri
without
contrast
undertaken
show
focal
area
suspici
signal
intens
upper
paraspin
musculatur
ultrasound
mri
contrast
demonstr
extens
infiltr
vascular
lesion
involv
paraspin
musculatur
prevertebr
space
posterior
extrapleur
space
mediastinum
neck
child
commenc
prednison
rapamycin
twiceday
clinic
laboratori
improv
one
month
biopsi
perform
confirm
khe
second
month
rapamycin
therapi
platelet
count
gradual
normal
patient
discharg
hospit
life
prednison
wean
month
life
repeat
mri
month
show
signific
reduct
khe
almost
year
therapi
well
conclus
uniqu
case
khe
kmp
initi
present
extens
recurr
pleural
pericardi
effus
case
demonstr
import
suspect
underli
vascular
malform
presenc
kmp
patient
delay
overal
good
respons
rapamycin
studi
investig
durat
rapamycin
therapi
key
optim
manag
patient
rosa
diaz
donald
mahoney
lakshmi
srivath
donald
yee
texa
children
hospit
houston
texa
unit
state
background
sinc
von
willebrand
diseas
vwd
common
inherit
bleed
disord
must
coexist
less
common
bleed
disord
dualli
affect
patient
howev
report
combin
defici
factor
viii
fviii
von
willebrand
factor
vwf
rare
object
studi
preval
bleed
phenotyp
combin
defici
fviii
vwf
male
hemophilia
hemophilia
treatment
center
designmethod
retrospect
review
electron
medic
record
male
hemophilia
follow
institut
past
year
primari
secondari
outcom
studi
preval
combin
fviii
vwf
defici
bleed
phenotyp
patient
identifi
vwf
defici
n
patient
hemophilia
n
patient
test
vwf
defici
part
initi
hemostat
evalu
onethird
test
due
clinic
concern
inadequ
respons
fviii
concentr
median
durat
follow
year
rang
patient
refer
clinic
median
age
month
rang
year
evalu
easi
bruis
n
mucos
n
surgic
bleed
n
primari
diagnos
includ
sever
moder
mild
discrep
hemophilia
secondari
diagnos
includ
low
vwf
activ
type
vwd
type
unclassifi
patient
experienc
episod
musculoskelet
n
mucocutan
n
cn
bleed
n
total
patient
receiv
factor
prophylaxi
half
patient
initi
treat
fviii
concentr
subsequ
chang
combin
fviiivwf
product
due
frequenc
breakthrough
bleed
despit
good
complianc
patient
combin
fviiivwf
product
time
review
total
cohort
develop
chronic
joint
diseas
manifest
decreas
rang
motion
andor
abnorm
mri
find
combin
defici
fviii
vwf
present
center
hemophilia
patient
patient
exhibit
sever
bleed
phenotyp
evidenc
high
frequenc
hemarthrosi
need
prophylaxi
high
preval
chronic
joint
diseas
optim
treatment
strategi
remain
elucid
earli
recognit
combin
defici
may
import
clinic
implic
particularli
patient
demonstr
suboptim
respons
fviii
concentr
alon
background
childhood
neutropenia
heterogen
may
congenit
acquir
cerebr
cavern
malform
neurovascular
malform
disord
lesion
consist
low
flow
dilat
capillari
endotheli
channel
increas
permeabl
predispos
hemorrhag
thrombosi
program
cell
death
protein
activ
implic
glia
neuron
migrat
recent
link
dysregul
actin
microtubul
cytoskeleton
therebi
affect
cellular
morpholog
migrat
variant
encod
associ
caus
greater
earlier
diseas
burden
ccm
present
younger
year
patient
associ
extraneuron
manifest
suggest
play
role
tissu
describ
patient
signific
blood
cytopenia
associ
designmethod
retrospect
chart
review
obtain
patient
data
result
old
femal
present
seizur
found
multipl
intracrani
cystic
lesion
abscess
due
pneumonia
serotyp
treatment
develop
anemia
hemoglobin
gdl
thrombocytopenia
platelet
cellsl
profound
neutropenia
absolut
neutrophil
count
zero
initi
bone
marrow
evalu
reveal
normocellular
marrow
mark
granulocyt
hypoplasia
hematogon
flow
cytometri
floresc
situ
hybrid
exclud
cytogenet
chang
characterist
myelodysplast
syndrom
evalu
includ
test
neutrophil
antibodi
chromosom
breakag
telomer
length
result
normal
whole
exom
sequenc
exclud
mutat
affect
congenit
neutropenia
gene
detect
de
novo
variant
therebi
diagnos
neutropenia
respond
well
granulocyt
coloni
stimul
factor
gcsf
still
need
month
age
moreov
thrombocytopenia
progress
requir
period
platelet
transfus
time
bone
marrow
hematogon
popul
decreas
month
age
though
granulocyt
hypoplasia
persist
conclus
case
describ
first
patient
neutropenia
thrombocytopenia
associ
hypothes
variant
etiolog
bone
marrow
dysfunct
due
role
actin
microtubul
cytoskeleton
format
akin
pathophysiolog
xlink
neutropenia
support
featur
underli
genet
caus
marrow
dysfunct
includ
persist
cytopenia
beyond
infect
resolut
well
presenc
hematogon
hematogon
previous
report
occur
patient
congenit
neutropenia
disord
indic
could
featur
congenit
neutropenia
may
reactiv
surround
cell
apoptosi
test
role
hematopoiesi
explor
background
adult
women
suffer
heavi
menstrual
bleed
hmb
lifetim
women
inherit
bleed
disord
suffer
hmb
pauciti
data
hmb
among
adolesc
young
adult
aya
popul
hmb
may
larg
social
educ
effect
object
studi
social
academ
implic
hmb
aya
popul
designmethod
questionnair
base
survey
conduct
mediums
citi
california
recruit
femal
year
age
one
high
school
local
univers
questionnair
set
research
electron
data
captur
redcap
institut
allow
us
obtain
object
data
respond
menstrual
cycl
link
sent
high
school
student
via
onlin
portal
schoolloop
univers
student
via
social
media
word
mouth
data
collect
week
may
august
receiv
repli
complet
use
regress
analysi
data
analyz
respond
age
group
mean
age
year
develop
composit
score
hmb
base
factor
includ
satur
level
number
pad
durat
bleed
soak
pad
within
two
hour
passag
clot
size
number
clot
gush
sensat
conduct
statist
analysi
driver
implic
hmb
base
composit
score
result
indic
rel
hmb
bleed
problem
anemia
driver
higher
hmb
score
result
also
indic
hmb
advers
affect
qualiti
life
measur
particip
sport
social
activ
afterschool
activ
tired
absente
gpa
hmb
also
associ
increas
rate
anemia
use
antidepress
hmbdriven
anemia
advers
affect
gpa
underrepres
minor
like
higher
hmb
score
well
increas
advers
effect
hmb
gpa
result
suggest
social
cost
hmb
pervas
aya
popul
especi
pronounc
among
minor
rel
hmb
signific
driver
heavi
menstrual
bleed
hemostat
screen
includ
assess
aya
popul
hmb
john
hopkin
children
hospit
st
petersburg
florida
unit
state
background
propranolol
noncardioselect
beta
blocker
medic
frequent
prescrib
hemangioma
hyperthyroid
propranolol
inhibit
type
ii
iodothyronin
deiodinas
enzym
convert
bioinact
thyroxin
bioactiv
triiodothyronin
hypothyroid
wellrecogn
complic
diffus
hepat
hemangioma
produc
type
iii
deiodinas
enzym
convert
bioinact
revers
diiodothyronin
thyroxin
typic
select
replac
popul
even
though
dose
physiolog
may
necessari
hypothes
low
dose
nearli
physiolog
would
safer
equal
effect
bypass
propranolol
impact
pituitarythyroid
axi
report
infant
diffus
hepat
hemangiomatosi
acquir
hypothyroid
success
treat
propranolol
prednison
triiodothyronin
designmethod
healthi
femal
present
abdomin
distens
poor
oral
intak
hepatomegali
mri
confirm
diffus
hepat
hemangiomatosi
largest
lesion
measur
cm
cm
thyrotropin
tsh
elev
refer
rang
mcgiuml
total
rr
ngdl
total
rr
mcgdl
treatment
start
prednison
mgkgday
three
week
propranolol
mgkgday
dose
slowli
titrat
maximum
mcgkgday
thyroid
hormon
level
rapidli
improv
replac
two
week
tsh
eight
month
tsh
twelv
month
tsh
drop
suggest
decreas
tumor
product
type
iii
iodothyronin
deiodinas
liver
mri
confirm
fewer
hemangioma
largest
cm
cm
patient
dose
reduc
propranolol
discontinu
twentyfour
month
treatment
one
year
therapi
child
normal
growth
develop
two
hepat
hemangioma
evid
hypothyroid
tsh
conclus
near
physiolog
dose
correct
consumpt
hypothyroid
associ
diffus
hepat
hemangioma
replac
prefer
thyroxin
due
lower
risk
rebound
hyperthyroid
hemangioma
involut
type
iii
deiodinas
product
declin
two
prior
case
report
describ
use
without
one
employ
propranolol
util
steroid
hemangioma
manag
first
case
report
long
term
followup
child
treat
multimod
therapi
includ
propranolol
prednison
triiodothyronin
rr
refer
rang
total
total
background
multifoc
lymphangioendotheliomatosi
thrombocytopenia
mlt
rare
congenit
disord
first
describ
character
multipl
vascular
abnorm
commonli
involv
skin
gastrointestin
tract
well
consumpt
coagulopathi
often
result
gi
bleed
infanc
describ
unusu
present
success
manag
mlt
neonat
designmethod
babi
h
born
full
term
pregnanc
complic
matern
sinu
venou
thrombosi
requir
anticoagul
begin
week
birth
diagnos
multipl
hemangioma
base
clinic
exam
two
week
age
develop
melena
hematemesi
cbc
reveal
platelet
count
refer
ed
abdomin
ultrasound
concern
abnorm
hepat
waveform
cxr
show
multipl
pulmonari
nodul
workup
reveal
lesion
hematolog
abnorm
biopsi
presum
hemangioma
ultim
reveal
smooth
musclelin
vascular
prolifer
without
immunoreact
consist
mlt
earli
cours
complic
acut
hemodynam
signific
gi
bleed
esophagogastroduodenoscopi
identifi
six
bleed
vascular
malform
within
stomach
inject
epinephrin
scleros
success
hemostasi
receiv
multipl
prbc
platelet
transfus
central
access
obtain
start
oral
sirolimu
base
previou
report
success
use
manag
vascular
malform
given
antiangiogen
immunosuppress
effect
toler
well
evid
toxic
achiev
partial
respons
stabl
hemoglobin
platelet
count
cutan
lesion
diminish
intens
sign
gi
bleed
receiv
pentamidin
pcp
prophylaxi
continu
appropri
growth
develop
describ
unusu
present
alreadi
rare
diseas
cutan
gi
lesion
typic
mlt
pulmonari
involv
welldescrib
literatur
earli
identif
tissuebas
diagnosi
enabl
time
stabil
treatment
patient
five
month
later
continu
toler
sirolimu
shown
signific
respons
diminish
color
cutan
lesion
stabl
blood
count
bleed
mlt
rel
newlyrecogn
disord
signific
phenotyp
variabl
given
bleed
secondari
kasabachmerritttyp
consumpt
thrombocytopenia
major
caus
morbid
mortal
first
year
life
children
mlt
essenti
recogn
diagnosi
initi
appropri
treatment
earli
possibl
arch
background
patient
gener
joint
hypermobl
jhm
may
experi
easi
bruis
bleed
given
associ
symptom
abnorm
collagen
requir
compon
primari
hemostasi
heavi
menstrual
bleed
hmb
common
initi
present
femal
underli
hemostat
defect
may
sole
manifest
bleed
disord
howev
limit
report
describ
jhm
caus
hmb
lead
recognit
object
describ
clinic
characterist
manag
young
women
present
hmb
set
jhm
designmethod
studi
util
hmb
research
registri
includ
subject
year
seen
nationwid
children
young
women
hematolog
clinic
februari
novemb
hmb
jhm
medic
record
retrospect
review
histori
present
menorrhagia
impact
questionnair
miq
valid
qualityoflif
tool
femal
hmb
medic
profil
relev
laboratori
studi
result
twentyf
patient
met
inclus
criteria
median
age
year
rang
averag
beighton
score
rang
particip
present
averag
year
rang
month
year
menarch
despit
patient
report
heavi
heavi
mens
sinc
menarch
accord
miq
respons
particip
express
hmbassoci
limit
physic
activ
social
activ
work
school
activ
particip
report
bleed
symptom
addit
hmb
commonli
easi
bruis
epistaxi
cutan
bleed
forti
percent
young
women
present
anemia
due
chronic
blood
loss
result
hemostat
test
unremark
except
one
patient
also
found
type
von
willebrand
diseas
addit
femal
report
arthralgia
knee
ankl
commonli
affect
joint
time
present
particip
report
failur
initi
therapi
patient
manag
longterm
oral
hormon
therapi
small
popul
young
women
found
jhm
initi
present
hmb
patient
like
prior
bleed
symptom
well
substanti
delay
menarch
time
present
young
women
hematolog
clinic
despit
limit
activ
daili
life
greater
awar
associ
bleed
symptom
jhm
despit
typic
normal
hemostat
laboratori
result
necessari
patient
easili
identifi
receiv
appropri
therapi
object
determin
impact
cl
care
practic
involv
home
environ
ambulatori
clabsi
rate
designmethod
inform
pi
collect
comprehens
survey
complet
annual
ccbdn
member
hospit
respons
question
cl
care
practic
involv
home
environ
select
pi
ambulatori
clabsi
rate
ambulatori
total
bloodstream
infect
bsi
rate
obtain
anoth
ccbdn
databas
proport
hospit
employ
particular
cl
care
practic
talli
mean
ambulatori
clabsi
rate
mean
ambulatori
total
bsi
rate
hospit
employ
particular
cl
care
practic
compar
use
gener
linear
model
techniqu
assum
underli
neg
binomi
distribut
result
twentyf
hospit
submit
respons
question
cl
care
practic
involv
home
environ
one
hospit
exclud
lack
bsi
data
sixtythre
percent
hospit
programmat
educ
parent
aspect
cl
care
bundl
mean
ambulatori
clabsi
rate
hospit
educ
parent
significantli
lower
hospit
cl
day
vs
cl
day
p
mean
ambulatori
total
bsi
rate
also
significantli
lower
cl
day
vs
cl
day
p
mean
ambulatori
clabsi
rate
mean
ambulatori
total
bsi
rate
significantli
differ
cl
care
practic
conclus
analysi
cl
care
practic
involv
home
environ
reveal
parent
educ
aspect
cl
care
bundl
associ
lower
ambulatori
clabsi
rate
lower
ambulatori
total
bsi
rate
find
highlight
import
systemat
teach
famili
member
proper
method
handl
cl
background
children
undergo
chemotherapi
high
risk
develop
nausea
dr
ami
baxter
collabor
pediatr
oncolog
patient
nurs
develop
valid
pictori
nausea
rate
scale
children
age
year
call
baxter
retch
face
barf
nausea
scale
staff
nurs
larg
academ
pediatr
hospit
locat
within
washington
dc
identifi
variabl
nurs
assess
document
chemotherapi
induc
nausea
vomit
cinv
pediatr
oncolog
patient
purpos
qualiti
improv
project
util
barf
scale
standard
assess
document
nausea
pediatr
oncolog
patient
receiv
chemotherapi
primari
aim
project
assess
feasibl
barf
scale
clinic
practic
increas
nurs
knowledg
cinv
educ
session
increas
document
nausea
assess
use
scale
secondari
aim
project
increas
recognit
nausea
use
standard
assess
tool
designmethod
pdsa
model
use
guid
design
implement
plan
first
phase
project
data
collect
identifi
preval
nausea
patient
admit
chemotherapi
prior
three
month
educ
session
discuss
cinv
util
barf
scale
conduct
pre
post
assess
nurs
knowledg
cinv
document
assess
second
phase
barf
scale
implement
practic
nurs
ask
util
barf
scale
assess
document
nausea
score
patient
age
year
receiv
chemotherapi
end
implement
period
nurs
survey
feasibl
scale
post
data
collect
identifi
preval
nausea
document
electron
health
record
project
undertaken
qualiti
improv
initi
children
nation
constitut
human
subject
research
oversight
institut
review
board
result
data
collect
howev
complet
data
analysi
conduct
upcom
week
background
sickl
cell
diseas
scd
common
inherit
blood
disord
unit
state
us
howev
qualiti
measur
evalu
scd
practic
nhlbi
publish
guidelin
includ
two
key
intervent
children
sickl
cell
anemia
sca
use
transcrani
doppler
tcd
screen
stroke
prevent
hydroxyurea
hu
prevent
scd
pain
crisi
conduct
nation
survey
scd
manag
sent
provid
institut
us
better
assess
knowledg
guidelin
barrier
hu
counsel
tcd
screen
guidelin
implement
hypothes
barrier
tcd
screen
differ
barrier
hu
counsel
prescrib
anonym
survey
sent
provid
mail
followup
email
survey
theme
includ
nhlbi
guidelin
knowledg
comfort
understand
implement
tcd
screen
hu
use
respons
rate
howev
one
survey
incomplet
thu
analyz
final
data
set
respond
activ
practic
academ
care
children
scd
major
provid
felt
extrem
confid
knowledg
tcd
screen
interpret
similarli
provid
felt
extrem
familiar
hu
dose
manag
tcd
screen
provid
estim
screen
rate
provid
felt
annual
screen
rate
two
biggest
barrier
tcd
screen
note
provid
moder
extrem
signific
includ
lack
support
staff
lack
time
patient
visit
regard
hu
prescrib
practic
provid
offer
hu
least
children
sca
nine
month
age
biggest
barrier
hu
prescrib
note
provid
concern
patient
adher
access
medic
provid
felt
lack
support
staff
moder
signific
barrier
hu
prescrib
pediatr
scd
provid
survey
access
nhlbi
guidelin
despit
widespread
guidelin
knowledg
differ
barrier
tcd
screen
versu
hu
prescrib
prevent
optim
implement
result
although
recommend
nhlbi
guidelin
like
requir
differ
implement
strategi
systemsbas
intervent
tcd
screen
intervent
improv
patient
adher
hu
counsel
improv
outcom
background
invas
fungal
diseas
ifd
major
caus
mortal
morbid
among
pediatr
immunocompromis
patient
receiv
chemotherapi
hematopoiet
stem
cell
transplant
current
diagnost
gold
standard
ifd
remain
cultur
infect
tissu
obtain
biopsi
noninvas
biomark
test
galactomannan
bg
low
sensit
provid
specieslevel
identif
nextgener
sequenc
ng
cellfre
plasma
promis
noninvas
approach
provid
specieslevel
identif
ifd
via
blood
test
guid
specif
treatment
object
describ
incid
posit
fungal
specif
pathogen
ng
analysi
highrisk
immunocompromis
pediatr
popul
correl
result
standard
infecti
studi
perform
designmethod
immunocompromis
pediatr
patient
suspect
ifd
enrol
plasma
collect
time
enrol
ng
perform
extract
dna
cellfre
plasma
kariu
redwood
citi
ca
remov
human
read
remain
sequenc
align
curat
databas
includ
pathogen
organ
present
significancelevel
predefin
threshold
report
result
twentyseven
sampl
enrol
patient
process
thu
far
subject
enrol
prolong
febril
neutropenia
hour
despit
broadspectrum
antibiot
recrudesc
febril
neutropenia
abnorm
imag
find
evalu
routin
studi
perform
patient
met
criteria
proven
ifd
probabl
ifd
possibl
ifd
use
eortcmsg
guidelin
ng
plasma
test
identifi
pathogen
cultur
infect
tissu
blood
proven
case
probabl
case
pneumocysti
jirovecii
identifi
patient
posit
bg
pgml
pneumonia
among
possibl
case
toxoplasma
gondii
detect
patient
prolong
febril
neutropenia
lung
imag
suggest
ifd
addit
candida
glabrata
isol
patient
prolong
febril
neutropenia
criteria
ifd
numer
pathogen
also
identifi
could
explain
clinic
paramet
includ
cmv
vzv
ebv
bk
polyoma
viru
ureaplasma
parvum
cellfre
plasma
ng
test
detect
invas
fungal
infect
blood
test
identifi
fungi
proven
ifd
detect
pathogen
probabl
possibl
ifd
case
use
diagnost
tool
evalu
ifd
suppli
sampl
shipment
process
support
kariu
inc
baylor
colleg
medicin
texa
children
hospit
houston
texa
unit
state
background
practic
medicin
lifelong
learn
process
note
institut
medicin
semin
report
err
human
advers
outcom
typic
result
individu
reckless
rather
result
faulti
system
process
condit
provid
environ
conduc
make
mistak
fail
prevent
one
learn
systemat
review
error
translat
lesson
learn
qualiti
improv
qi
initi
critic
compon
practicebas
learn
improv
practition
career
level
object
develop
method
selfreflect
nonthreaten
approach
incid
analysi
translat
lesson
learn
qi
initi
designmethod
use
valid
structur
case
audit
approach
modifi
szostek
et
al
review
document
relat
case
identifi
health
care
provid
involv
interview
stakehold
includ
directli
provid
support
care
use
qi
tool
conduct
rootcaus
analysi
identifi
system
issu
contribut
outcom
propos
systemslevel
intervent
priorit
initi
base
effortyield
project
result
pdsa
cycl
plan
establish
committe
identifi
potenti
case
triag
case
confer
present
determin
time
frequenc
confer
develop
train
manual
record
identifi
qi
initi
establish
quarterli
sectionwid
meet
member
pediatr
hematologyoncolog
servic
invit
includ
administr
nurs
leadership
develop
train
manual
structur
present
templat
priorit
case
discuss
advanc
multidisciplinari
case
review
session
present
senior
fellow
instruct
focu
discuss
potenti
opportun
qi
studi
identifi
case
meet
criteria
mmi
present
qi
initi
identifi
confer
result
number
system
practic
chang
howev
encount
challeng
sustain
chang
time
act
object
next
pdsa
cycl
establish
method
track
adher
recommend
chang
practic
maxim
sustain
integr
qi
initi
institut
qi
leadership
practic
standard
committe
success
implement
mmi
confer
meet
institut
medicin
qualiti
domain
safeti
effect
patientcentered
timeli
effici
standard
consist
approach
mmi
present
includ
identif
contribut
factor
specif
qi
implic
potenti
improv
provid
educ
patient
caresafeti
john
hopkin
univers
baltimor
maryland
unit
state
background
receiv
cancer
diagnosi
lifechang
event
patient
caregiv
although
littl
known
experi
oncologist
receiv
dedic
train
deliv
bad
news
initi
convers
often
primari
pediatrician
provid
often
feel
receiv
adequ
train
commun
cancer
diagnosi
object
object
twofold
first
better
defin
experi
caregiverspati
told
cancer
diagnosi
queri
caregiverspati
believ
provid
improv
disclosur
bad
news
secondli
assess
train
primari
pediatrician
receiv
skill
assess
comfort
provid
variou
set
stage
train
commun
cancer
diagnos
designmethod
novemb
semistructur
indepth
interview
conduct
pediatr
oncolog
patient
caregiv
patient
n
diagnos
past
year
regard
experi
receiv
diagnosi
institut
addit
pediatr
resid
n
outpati
pediatr
primari
care
physician
pediatr
emerg
medicin
physician
n
interview
regard
experi
deliv
cancer
diagnos
interview
analyz
follow
principl
themat
analysi
interview
patient
caregiv
two
common
theme
emphas
wish
direct
thorough
inform
patient
caregiv
emphas
gratitud
felt
physician
gave
hope
emphas
good
prognosi
child
cancer
lack
train
area
well
lack
comfort
deliv
news
common
provid
addit
provid
report
variabl
approach
give
bad
news
includ
whether
tell
caregiv
separ
tell
child
parent
togeth
whether
give
favor
prognost
inform
addit
attend
physician
also
differ
significantli
approach
teach
resid
believ
resid
give
news
gain
experi
other
felt
appropri
resid
inexperienc
one
resid
report
ever
receiv
feedback
commun
skill
type
discuss
conclus
plan
build
interview
develop
nation
survey
patient
caregiv
provid
better
understand
issu
surround
discuss
use
find
develop
commun
curriculum
pediatr
resid
focus
discuss
occur
outpati
set
primari
pediatrician
background
human
papilloma
viru
hpv
common
femal
male
respons
patholog
rang
benign
genit
wart
cervic
penil
cancer
hpv
strain
respons
malign
year
unit
state
one
third
aris
men
pharmaceut
compani
develop
vaccin
help
prevent
virusassoci
malign
cdc
initi
recommend
femal
age
year
receiv
vaccin
seri
start
expand
elig
male
age
year
despit
wide
avail
highli
public
elig
femal
receiv
full
vaccin
seri
object
studi
aim
assess
knowledg
hpv
attitud
toward
hpv
vaccin
identifi
barrier
prevent
full
util
identifi
aim
overcom
barrier
order
improv
vaccin
rate
elig
adolesc
distribut
standard
questionnair
parent
elig
femal
male
patient
pediatr
hematologyoncolog
clinic
assess
parent
knowledg
hpv
vaccin
view
vaccin
reason
may
oppos
result
approxim
parent
claim
educ
hpv
mostli
primari
care
physician
howev
know
disord
hpv
caus
felt
vaccin
ad
typic
vaccin
schedul
parent
intend
vaccin
child
oppos
vaccin
onethird
concern
potenti
side
effect
nearli
feel
enough
inform
addit
parent
awar
vaccin
avail
child
doctor
parent
discuss
hpv
vaccin
child
doctor
largest
barrier
util
hpv
vaccin
identifi
appear
lack
educ
result
begun
distribut
cdc
hpv
vaccin
patient
guid
patient
famili
intervent
current
process
readminist
survey
famili
implement
intervent
assess
success
increas
knowledg
util
hpv
vaccin
cancer
institut
chennai
chennai
tamilnadu
india
background
rasburicas
recombin
urat
oxidas
enzym
approv
use
tumor
lysi
syndrom
tl
act
reduc
serum
uric
acid
level
use
rasburicas
recommend
dose
day
expens
known
whether
extend
schedul
clinic
benefici
compar
singl
fix
dose
mg
aim
present
studi
evalu
efficaci
singl
dose
rasburicas
mg
prevent
manag
tl
designmethod
rasburicas
avail
singl
use
mg
vial
institut
singl
dose
rasburicas
mg
irrespect
bodyweight
use
adult
children
dose
mgkg
maximum
mg
use
sinc
prevent
manag
tl
subsequ
dose
given
base
biochem
respons
clinic
condit
retrospect
analys
case
record
patient
receiv
rasburicas
januari
januari
studi
includ
patient
hematolog
malign
receiv
rasburicas
children
account
n
patient
male
compris
n
rasburicas
use
prophylact
patient
laboratori
tl
patient
clinic
tl
patient
singl
fix
dose
rasburicas
prevent
laboratoryclin
tl
prophylact
group
prevent
clinic
tl
laboratori
tl
group
none
patient
prophylact
laboratori
tl
group
develop
clinic
tl
howev
major
patient
clinic
tl
requir
one
dose
rasburicas
singl
dose
mg
vial
rasburicas
effici
prevent
manag
laboratori
tl
econom
viabl
resourc
constrain
set
nicol
wood
lauren
amo
nichola
clark
chri
klockau
karen
lew
alan
gami
children
merci
kansa
citi
kansa
citi
missouri
unit
state
background
medic
reconcili
newli
diagnos
oncolog
patient
complic
cumbersom
patient
often
admit
medic
leav
multipl
chemotherapi
support
medic
crucial
despit
numer
individu
overse
process
prescrib
error
omiss
still
occur
review
literatur
improv
occur
interprofession
standard
process
medic
reconcili
object
project
aim
improv
accuraci
discharg
medic
reconcili
process
februari
process
measur
percentag
patient
discharg
accur
checklist
addit
time
staff
spent
complet
checklist
avoid
increas
error
rate
chang
prescrib
process
follow
balanc
measur
creat
discharg
medic
checklist
includ
list
requir
home
medic
prescrib
resid
ideal
hour
prior
discharg
requir
fellow
attend
review
pharmaci
review
list
educ
famili
checklist
collect
monthli
review
electron
medic
record
emr
accuraci
result
six
pdsa
cycl
complet
error
data
collect
time
frame
pdsa
cycl
patient
receiv
acetaminophen
pain
control
avoid
home
addit
patient
receiv
diphenhydramin
instead
ondansetron
prefer
antiemet
pdsa
cycl
patient
pend
diagnosi
sent
home
acetaminophen
note
patient
checklist
complet
upon
discharg
project
provid
novel
import
method
standard
discharg
medic
reconcili
process
complex
patient
popul
clarifi
type
medic
patient
need
provid
pharmaci
teach
famili
done
previous
prescrib
discharg
medic
famili
sooner
first
medic
reconcili
error
checklist
revis
error
made
follow
revis
except
one
patient
without
complet
checklist
discharg
accuraci
rate
increas
baselin
follow
implement
process
make
checklist
electron
access
emr
interim
end
data
collect
implement
emr
leukemia
patient
sent
home
without
epinephrin
pen
demonstr
import
standard
discharg
process
reason
reinstitut
checklist
electron
version
avail
background
survivor
pediatr
cancer
risk
lose
preexist
protect
antibodi
vaccin
prevent
diseas
prior
studi
children
year
lost
humor
immun
measl
result
chemotherapi
induc
alter
immun
system
measl
recipi
immunosuppress
chemotherapi
mortal
rate
volit
vaccin
refus
dramat
increas
measl
infect
case
includ
sever
statewid
outbreak
small
pediatr
oncolog
practic
frequent
share
floorclin
space
gener
pediatr
patient
put
risk
measl
sinc
virul
start
hour
prior
symptom
standard
protocol
revaccin
postchemotherapi
patient
assess
measl
risk
base
serial
humor
immun
statu
cohort
pediatr
oncolog
patient
receiv
intens
chemotherapi
designmethod
patient
year
age
known
vaccin
statu
receiv
intens
chemotherapi
juli
institut
pediatr
oncolog
practic
includ
prospect
studi
serial
measl
igg
antibodi
measur
diagnosi
month
month
initi
chemotherapi
use
elisa
measl
immun
defin
per
lab
standard
comparison
prechemotherapi
serial
postchemotherapi
immun
titer
made
patient
diagnosi
studi
popul
consist
children
male
patient
nonhodgkin
lymphoma
sarcoma
solid
tumor
two
patient
unvaccin
nonprotect
measl
antibodi
level
baselin
remain
patient
patient
leukemia
lymphoma
sarcoma
lost
protect
antibodi
titer
month
initi
chemotherapi
leukemia
lymphoma
sarcoma
month
initi
therapi
remain
patient
retain
measl
antibodi
titer
within
protect
rang
month
also
demonstr
steadi
declin
antibodi
titer
month
therapi
initi
loss
protect
measl
humor
immun
occur
significantli
often
patient
leukemia
compar
malign
oncolog
patient
practic
undergo
intens
chemotherapi
demonstr
progress
wane
protect
measl
igg
titer
data
suggest
standard
practic
check
patient
measl
humor
immun
prior
start
chemotherapi
complet
larger
studi
need
perform
establish
guidelin
revaccin
postchemotherapi
pediatr
patient
intervent
easili
applic
low
cost
background
accur
determin
glomerular
filtrat
rate
gfr
import
screen
acut
kidney
injuri
dose
chemotherapi
identifi
risk
chronic
kidney
diseaseb
correl
inulin
clearanc
measur
gfr
iohexol
plasma
disappear
igfr
new
gold
standard
measur
gfr
pediatr
cohort
studi
igfr
base
clearanc
exogen
marker
unaffect
endogen
compound
patient
muscl
mass
compar
igfr
urin
creatinin
clearanc
gfr
estim
equat
use
serum
creatinin
scr
serum
cystatin
c
cystc
pediatr
patient
cancer
recruit
particip
age
yr
contin
urin
diagnos
malign
past
year
elig
subject
stabl
kidney
function
least
two
week
prior
assess
igfr
consent
subject
baselin
assess
includ
height
weight
vital
sign
blood
sampl
obtain
serum
chemistri
time
zero
iohexol
igfr
determin
iohexol
solut
infus
minut
follow
steril
salin
blood
drawn
minutesat
time
igfr
collect
igfr
calcul
use
twocompart
model
area
curv
compar
igfr
publish
gfr
equat
schwartz
et
al
kidney
int
result
ten
subject
agre
particip
distribut
diagnos
subject
lymphoma
brain
tumor
hepatocellular
carcinoma
six
patient
therapi
lower
gfr
note
patient
malign
leukemia
like
due
use
cisplatin
base
therapi
averag
igfr
wherea
demonstr
overestim
gfr
compar
igfr
compar
igfr
univari
equat
use
scr
cystc
multivari
equat
univari
cystc
equat
correl
well
igfr
other
overestim
igfr
found
overestim
igfr
univari
cystc
equat
better
correl
igfr
equat
scr
poor
perform
scr
base
method
assess
gfr
might
due
decreas
muscl
mass
inadequ
nutrit
statu
creatininebas
determin
gfr
alon
may
accur
popul
studi
need
determin
igfr
standard
care
assess
gfr
children
cancer
particularli
receiv
nephrotox
medic
incontin
urin
background
pediatr
oncolog
patient
undergo
chemotherapi
indwel
venou
cathet
increas
risk
sever
sepsi
especi
neutropen
due
chemotherapi
rapid
triag
earli
recognit
essenti
delay
initi
antibiot
fluid
patient
delay
transfer
higher
level
care
initi
stabil
associ
poor
clinic
outcom
pediatr
oncolog
outpati
clinic
design
articl
unit
wherebi
provid
initi
give
treatment
intraven
fluid
antibiot
chemotherapi
blood
product
object
global
aimoptim
manag
earli
sepsi
decreas
morbid
mortal
hospit
length
stay
high
risk
pediatr
oncolog
patient
smart
aimimprov
time
manag
initi
fluid
antibiot
transfer
septic
patient
higher
level
care
month
patient
designmethod
multidisciplinari
team
physician
nurs
creat
retropect
chart
review
sepsi
patient
treat
clinic
april
octob
done
use
audit
sheet
identifi
barrier
deliveri
care
three
patient
identifi
data
analyz
prior
intervent
two
analyz
post
intervent
key
driver
diagram
creat
group
drive
intervent
process
map
design
identifi
differ
step
care
patient
pinpoint
area
need
improv
differ
time
data
point
use
start
time
arriv
clinic
time
antibiot
fluid
time
transfer
higher
level
care
rapid
pdsa
cycl
done
improv
process
deliveri
care
run
chart
creat
improv
close
goal
data
point
use
pdsa
cycl
improv
includ
conduct
frequent
mock
code
appropri
feedback
real
time
coach
process
plan
nurs
staff
partner
pharmaci
close
loop
commun
clinic
staff
improv
commun
physican
differ
level
conclus
sepsi
neutropen
pediatr
oncolog
patient
deadli
revers
time
manag
differ
level
given
promis
result
project
want
reinforc
process
part
daili
practic
first
line
clinic
staff
eventu
extend
principl
learnt
manag
triag
sepsi
outpati
emerg
chemotherapi
relat
anaphylaxi
background
chemotherapyinduc
nausea
vomit
cinv
common
side
effect
children
receiv
antineoplast
chemotherapi
recommend
prophylact
antiemet
medic
base
classif
chemotherapi
emetogen
howev
despit
appropri
use
antiemet
agent
patient
still
experi
nausea
andor
vomit
children
oncolog
group
clinic
practic
guidelin
recommend
addit
olanzapin
prophylact
regimen
manag
breakthrough
cinv
object
pediatr
hematolog
oncolog
center
implement
qualiti
improv
qi
project
aim
increas
use
olanzapin
pediatr
cancer
patient
year
age
older
receiv
moder
highli
emetogen
chemotherapi
experienc
breakthrough
cinv
month
period
designmethod
qi
project
conduct
util
plandostudyact
pdsa
cycl
first
pdsa
cycl
baselin
data
collect
chart
review
determin
rate
olanzapin
use
breakthrough
cinv
month
period
juli
decemb
breakthrough
cinv
defin
use
dose
antiemet
agent
given
cinv
prophylaxi
guidelin
treatment
breakthrough
cinv
review
pediatr
hematologyoncolog
attend
physician
fellow
flyer
creat
list
chemotherapi
regimen
consid
moder
highli
emetogen
patient
experienc
breakthrough
cinv
flyer
place
patient
roadmap
binder
signal
olanzapin
ad
next
chemotherapi
block
data
collect
month
period
septemb
follow
first
intervent
second
pdsa
cycl
consist
didact
educ
train
pediatr
oncolog
nurs
well
pediatr
resid
regard
addit
olanzapin
breakthrough
cinv
rate
olanzapin
use
collect
octob
novemb
result
olanzapin
use
increas
baselin
first
pdsa
cycl
p
second
pdsa
cycl
olanzapin
use
increas
anoth
p
administr
olanzapin
success
increas
modifi
patient
roadmap
patient
experienc
breakthrough
cinv
well
educ
train
pediatr
oncolog
staff
fellow
resid
nurs
background
venou
thromboembol
vte
increasingli
affect
children
accord
administr
databas
studi
increas
incid
vte
among
children
admit
freestand
children
hospit
unit
state
risk
factor
hospitalacquir
vte
wellknown
wellstudi
adult
evidencebas
prevent
measur
avail
similar
guidelin
lack
children
object
ongo
nationalin
develop
institut
method
screen
prevent
hospitalacquir
vte
children
nationwid
children
hospit
institut
electron
screen
form
requir
patient
admit
hour
patient
score
riskstratifi
base
eight
riskcategori
summat
score
use
determin
vte
risk
level
use
make
prophylaxi
recommend
patient
year
well
patient
year
admit
intens
care
icu
surgic
trauma
unit
purpos
irb
exempt
qualiti
improv
initi
retrospect
review
experi
riskstratif
tool
result
hospitalacquir
vte
event
occur
uniqu
subject
median
age
vte
diagnosi
year
vte
occur
children
year
age
vte
deep
vein
thrombosi
dvt
involv
pulmonari
embol
vte
common
subspecialti
unit
includ
pediatr
cardiac
icu
neonat
icu
hematologyoncolog
vte
associ
central
venou
cathet
cvc
event
associ
alter
mobil
congenit
heart
diseaseheart
failur
common
chronic
medic
condit
associ
vte
event
wherea
infect
traumasurgeri
common
acut
medic
condit
associ
vte
event
respect
event
subject
score
summat
score
summari
singl
institut
prospect
maintain
databas
cvc
remain
common
risk
factor
vte
follow
cardiac
diseas
infect
traumasurgeri
subject
develop
vte
score
high
score
screen
tool
small
proport
vte
occur
patient
older
year
thu
elig
thromboprophylaxi
result
indic
futur
vte
prevent
endeavor
includ
age
group
addit
explor
aggress
prophylact
modal
includ
pharmacolog
prophylaxi
background
pediatr
fellow
requir
activ
engag
qualiti
improv
qi
activ
yet
nation
acgm
review
found
traine
limit
knowledg
qi
method
limit
particip
interprofession
qi
team
twenti
fellow
pediatr
hematologyoncolog
train
program
identifi
blood
cultur
util
qi
prioriti
institut
recent
introduc
hospitalwid
decis
algorithm
guid
provid
regard
obtain
blood
cultur
often
low
threshold
obtain
blood
cultur
immunocompromis
pediatr
oncolog
patient
often
lowyield
result
falseposit
fellow
spearhead
project
implement
algorithm
inpati
pediatr
oncolog
popul
improv
proport
appropri
drawn
blood
cultur
investig
appropri
algorithm
util
inpati
pediatr
oncolog
floor
prior
sever
educ
step
aim
dissemin
algorithm
member
care
team
primari
endpoint
quantifi
proport
cultur
episod
drawn
inappropri
goal
reduc
inappropri
episod
algorithm
initi
introduc
nurs
staff
resid
cover
twentyb
inpati
unit
septemb
qi
project
plan
took
place
upper
level
fellow
januari
fellow
faculti
receiv
intens
train
algorithm
julyaugust
conduct
retrospect
chart
review
blood
cultur
episod
drawn
august
novemb
upper
level
fellow
score
cultur
episod
whether
decis
cultur
number
cultur
drawn
appropri
inappropri
catalogu
indic
cultur
episod
applic
episod
found
inappropri
addit
fellow
discuss
inappropri
cultur
episod
team
onservic
provid
direct
feedback
algorithm
fail
result
august
decemb
averag
patientday
drawn
fortynin
percent
cultur
episod
inappropri
januari
octob
follow
target
educ
algorithm
rate
blood
cultur
drawn
decreas
patientday
averag
proport
inappropri
cultur
episod
fell
repres
decreas
inappropri
cultur
util
correct
applic
decis
algorithm
blood
cultur
util
reduc
total
cultur
drawn
inpati
pediatr
oncolog
unit
fellowl
educ
multidisciplinari
team
decreas
rate
inappropri
cultur
episod
well
provid
activ
engag
qi
background
inadequ
understand
sickl
cell
diseas
scd
common
affect
patient
complianc
therefor
morbid
mortal
especi
transit
adult
care
optim
clinic
care
scd
includ
diseas
educ
difficult
given
breadth
possibl
topic
limit
time
clinic
unclear
best
provid
person
effici
educ
adolesc
scd
qualiti
improv
qi
studi
aim
implement
questionnairebas
system
improv
patient
knowledg
scd
document
educ
nurs
physician
studi
object
improv
provid
document
patient
knowledg
scd
identifi
patient
gap
comprehens
januari
studi
aim
increas
educ
document
april
studi
aim
increas
use
smart
phrase
educ
document
june
studi
aim
increas
patient
knowledg
diseas
designmethod
twentyon
scd
patient
enrol
irb
approv
qi
studi
twenti
activ
patient
comprehens
team
gener
questionnair
knowledgebas
question
two
age
group
year
old
comprehens
visit
questionnair
distribut
least
interv
provid
score
questionnair
review
two
educ
topic
wrong
answer
take
prioriti
plandostudyact
pdsa
cycl
includ
pdsa
patient
complet
questionnair
pdsa
smart
phrase
address
questionnair
topic
creat
share
provid
pdsa
patient
receiv
educ
handout
clinic
educ
document
clinic
note
process
measur
questionnair
score
outcom
measur
result
pdsa
complet
pdsa
four
patient
remain
pdsa
ongo
due
variabl
visit
frequenc
multipl
concurr
cycl
pdsa
free
text
document
complet
averag
cours
month
pdsa
document
increas
within
month
questionnair
score
increas
averag
question
patient
got
wrong
first
visit
significantli
like
improv
retest
topic
taught
address
vs
p
current
complet
pdsa
collect
post
pdsa
data
questionnairebas
scd
educ
coupl
standard
smart
phrase
improv
patient
scd
knowledg
document
provid
improv
knowledg
expect
addit
handout
background
exposur
suffer
profound
impact
well
caregiv
often
refer
cost
care
cost
especi
high
pediatr
hematologyoncolog
repeat
exposur
suffer
potenti
neg
impact
resili
increas
risk
burnout
thu
impact
qualiti
care
patient
satisfact
develop
peer
support
team
util
critic
incid
stress
manag
cism
model
model
success
use
profess
frequent
face
traumat
event
fire
fighter
polic
emerg
medic
technician
hope
team
help
peer
endur
stress
consist
volunt
multidisciplinari
staff
member
receiv
train
provid
group
peer
support
follow
critic
incid
may
impact
one
staff
member
hypothes
implement
hope
team
improv
staff
resili
decreas
overal
rate
burnout
improv
compass
satisfact
designmethod
use
empir
metric
anecdot
report
assess
impact
hope
team
prior
activ
team
pediatr
hematologyoncolog
clinic
staff
member
survey
use
valid
tool
assess
level
resili
burnout
secondari
trauma
compass
satisfact
brief
resili
scale
also
ask
rate
number
time
experienc
critic
incid
well
perceiv
level
distress
deal
traumat
event
hope
team
function
month
send
survey
staff
member
measur
chang
pay
special
attent
resili
rate
burnout
compass
satisfact
result
enthusiasm
develop
team
high
peopl
approach
volunt
time
particip
multidisciplinari
team
agre
includ
attend
physician
fellow
nurs
nurs
practition
child
life
specialist
social
worker
clergi
psychologist
volunt
particip
train
conduct
instructor
intern
critic
incid
stress
foundat
engag
first
staff
survey
high
respond
date
data
collect
ongo
clinic
staff
pediatr
hematologyoncolog
may
particularli
vulner
burnout
decreas
resili
repeatedli
wit
suffer
trauma
peer
support
intervent
follow
critic
incid
may
lead
increas
resili
compass
satisfact
decreas
rate
burnout
enthusiasm
develop
peer
support
team
high
background
monthli
blood
transfus
indic
therapi
pediatr
patient
sickl
cell
diseas
certain
complic
maxim
transfus
effici
busi
infus
clinic
requir
ensur
appropri
blood
unit
avail
hospit
blood
bank
laboratori
specimen
obtain
patient
advanc
coordin
clinic
appoint
nurs
avail
sought
improv
clinic
effici
identifi
way
better
commun
patientsfamili
regard
upcom
laboratori
transfus
appoint
assess
efficaci
implement
webbas
person
text
remind
pingercom
measur
baselin
frequenc
transfus
appoint
miss
famili
move
later
within
week
delay
due
late
lab
conveni
sampl
patient
receiv
monthli
transfus
receiv
questionnair
patientpar
prefer
appoint
remind
barrier
keep
appoint
patientspar
optout
addit
text
remind
receiv
person
text
care
team
remind
lab
transfus
appoint
rate
missedmoveddelay
appoint
compar
group
receiv
addit
text
messag
group
receiv
standard
hospitalgener
appoint
remind
telephon
call
result
fortyon
famili
patient
respond
survey
captur
inform
patient
receiv
chronic
transfus
therapi
thirteen
famili
declin
addit
text
remind
famili
report
prefer
text
remind
often
email
telephon
famili
want
receiv
remind
transfus
laboratori
appoint
major
famili
report
compet
worklif
prioriti
reason
missedl
appoint
famili
note
transportationtravel
fearillnesspain
lack
remind
reason
miss
appoint
baselin
twelv
week
appoint
miss
weekli
basi
rang
avail
per
week
move
appoint
delay
intervent
period
twelv
week
miss
move
delay
combin
group
differ
miss
text
vs
standard
move
text
vs
standard
delay
text
vs
standard
appoint
though
famili
center
report
prefer
textbas
remind
person
text
remind
appoint
improv
clinic
effici
measur
miss
move
delay
transfus
appoint
improv
appoint
adher
group
receiv
person
text
addit
standard
hospit
remind
univers
utah
salt
lake
citi
utah
unit
state
background
childhood
cancer
outcom
improv
significantli
larg
part
due
multiinstitut
collabor
clinic
trial
run
children
oncolog
group
cog
approxim
half
elig
children
cancer
enrol
therapeut
trial
littl
known
factor
affect
caregiv
decisionmak
regard
enrol
well
requir
element
inform
consent
convey
consent
process
object
assess
coverag
ten
requir
element
inform
consent
cog
therapeut
trial
describ
factor
affect
caregiv
decisionmak
regard
therapeut
trial
enrol
survey
famili
children
offer
enrol
onto
phase
cog
therapeut
studi
initi
cancer
diagnosi
previou
month
fisher
exact
wilcoxon
ranksum
test
util
compar
demograph
motiv
factor
relat
enrol
decisionmak
result
seventi
particip
survey
regard
basic
requir
element
inform
consent
knew
trial
involv
research
knew
consent
requir
knew
enrol
length
trial
knew
could
continu
care
independ
enrol
knew
contact
question
knew
option
besid
enrol
knew
could
withdraw
time
knew
inform
confidenti
knew
risk
associ
trial
knew
benefit
particip
n
enrol
onto
therapeut
studi
among
enrolle
n
primari
caregiv
complet
colleg
compar
n
enrol
p
ask
factor
impact
decis
n
enrol
said
felt
risk
know
risk
associ
studi
compar
n
choos
enrol
p
enrol
n
report
physician
recommend
somewhat
strongli
affect
decis
enrol
compar
n
enrol
p
enrol
n
report
feel
pressur
enrol
n
enrol
report
pressur
p
enrolle
n
report
enough
time
decid
compar
n
enrol
p
failur
convey
requir
element
inform
consent
highlight
possibl
defici
consent
process
cog
therapeut
trial
caregiv
percept
pressur
lack
time
make
inform
decis
may
impact
clinic
trial
enrol
background
abnorm
uterin
bleed
aub
frequent
adolesc
gynecolog
complaint
howev
limit
research
exist
guid
manag
acut
care
vari
sought
improv
emerg
care
adolesc
aub
develop
clinic
effect
guidelin
ceg
assess
impact
qualiti
care
designmethod
stakehold
engag
group
consist
member
depart
hematologyoncolog
adolesc
medicin
gener
pediatr
emerg
medicin
design
ceg
algorithm
emerg
aub
manag
pediatr
resid
receiv
ceg
train
knowledg
attitud
assess
use
pre
post
intervent
survey
code
identifi
electron
health
record
data
patient
present
pediatr
emerg
depart
ed
aub
month
ceg
implement
prepubert
patient
vagin
bleed
trauma
exclud
weight
score
system
consist
priorit
aspect
histori
laboratori
studi
manag
develop
quantifi
qualiti
care
provid
ttest
chi
squar
test
wilcoxon
rank
sum
test
run
chart
use
analysi
patient
identifi
met
inclus
criteria
patient
current
use
form
contracept
bleed
relat
current
recent
pregnanc
median
aub
qualiti
care
score
preand
postintervent
p
run
chart
data
show
shift
trend
overal
median
score
pre
postimplement
point
deduct
frequent
assess
personalfamili
clot
disord
histori
inappropri
usedos
oral
contracept
success
design
implement
ceg
educ
intervent
aub
manag
pediatr
ed
data
suggest
ceg
may
effect
tool
improv
emerg
aub
care
adolesc
though
addit
cycl
need
background
highdos
methotrex
hdmtx
common
chemotherapi
administ
inpati
center
administr
particularli
suscept
error
due
need
frequent
drug
level
result
chang
support
care
error
prolong
patient
stay
caus
patient
harm
object
global
aimto
reduc
length
stay
lo
hdmtx
admiss
smart
aimsto
increas
percentag
patient
whose
prehydr
fluid
start
increas
percentag
patient
receiv
hdmtx
use
rapid
process
improv
method
target
earlier
methotrex
administr
key
driver
prolong
lo
hypothes
drug
level
return
overnight
rather
day
time
due
delay
hdmtx
start
chang
implement
includ
schedul
hdmtx
patient
first
patient
day
exam
clinic
schedul
lab
pass
hdmtx
day
prior
admiss
ongo
pdsa
cycl
chang
locat
prehydr
start
inpati
room
clinic
exam
room
order
meet
hdmtx
administr
time
goal
pilot
two
differ
educ
materi
improv
patient
experi
one
explain
hdmtx
level
redyellowgreen
stoplight
format
remind
patient
prepar
admiss
intervent
regard
test
urin
ph
safeti
check
order
process
histori
delay
clearanc
plan
stage
project
ongo
start
methotrex
time
improv
baselin
project
start
prehydr
never
start
fluid
start
time
pdsa
cycl
ongo
yet
sustain
reduct
lo
month
shown
decreas
lo
much
hour
baselin
measur
rapid
cycl
improv
util
decreas
lo
hdmtx
admiss
import
financi
implic
well
potenti
reduc
secondari
harm
unnecessari
time
hospit
pediatr
cancer
center
schedul
hdmtx
admiss
first
thing
morn
data
regard
kidney
injuri
drug
clearanc
interpret
day
team
children
clear
discharg
middl
night
background
educ
train
interdisciplinari
pediatr
oncolog
provid
requir
train
principl
palli
endoflif
eol
care
experi
bereav
parent
inform
enhanc
palli
care
educ
curricula
uniqu
power
valuabl
way
object
studi
present
innov
palli
care
educ
program
oncolog
provid
facilit
train
bereav
parent
serv
volunt
educ
local
nation
palli
care
educ
forum
describ
incorpor
bereav
parent
educ
forum
affect
particip
comfort
commun
manag
children
eol
designmethod
survey
tool
adapt
determin
bereav
parent
educ
affect
particip
experi
differ
educ
forum
institut
seminar
pediatr
palli
eol
care
roleplay
base
commun
train
session
intern
symposium
pediatr
palli
oncolog
preand
postsess
survey
incorpor
retrospect
preprogram
assess
item
control
respons
shift
use
evalu
institut
seminar
commun
train
session
result
feedback
survey
sent
attende
use
apprais
particip
experi
intern
oncolog
symposium
result
involv
train
parent
educ
across
divers
interdisciplinari
educ
forum
improv
attende
comfort
commun
care
patient
famili
seriou
ill
importantli
parent
educ
also
deriv
benefit
educ
interdisciplinari
clinician
integr
bereav
parent
palli
eol
care
educ
innov
effect
model
benefit
interdisciplinari
clinician
bereav
parent
background
poorli
control
chemotherapyinduc
nausea
vomit
cinv
significantli
impair
patient
qualiti
life
contribut
ongo
medic
cost
increas
length
stay
hospit
readmiss
outpati
visit
control
nausea
vomit
dehydr
lack
adher
nation
evidencedbas
guidelin
dictat
antiemet
prescrib
variabl
emetogen
chemotherapi
leav
patient
vulner
increas
cinv
ensu
complic
object
review
institut
antiemet
prescrib
practic
consist
antiemesi
guidelin
nation
comprehens
cancer
network
nccn
children
oncolog
group
cog
endors
support
care
guidelin
develop
tool
increas
adher
nationalbas
guidelin
improv
control
cinv
perform
retrospect
chart
review
inpati
chemotherapi
encount
evalu
emetogenicti
chemotherapi
high
medium
low
initi
antiemet
regimen
order
number
need
medic
requir
adher
nation
evidenc
base
guidelin
tailor
level
emetogen
prescript
antiemet
result
fiftyf
total
inpati
chemotherapi
encount
review
month
eighteen
encount
consid
highli
emetogen
chemotherapi
hec
remain
consid
moder
emetogen
hec
encount
complet
includ
guidelinerecommend
agent
demonstr
lack
consist
across
provid
dose
aprepit
need
medic
signific
variat
order
first
second
third
line
antiemet
order
lorazepam
promethazin
use
frequent
aim
improv
antiemet
prescrib
practic
patient
current
rebuild
chemotherapi
treatment
plan
electron
medic
record
incorpor
antiemet
drug
order
set
follow
evidencedbas
guidelin
variabl
emetogen
chemotherapi
use
conjunct
educ
initi
best
practic
support
care
prescrib
antiemet
review
depart
recent
inpati
chemotherapi
encount
show
fall
short
follow
nation
recommend
standard
appropri
antiemet
coverag
chemotherapi
identif
defici
allow
implement
qualiti
initi
improv
prescrib
adher
evidencedbas
guidelin
better
control
cinv
background
current
consensu
guidelin
manag
pediatr
oncolog
patient
present
fever
without
neutropenia
histor
patient
treat
similarli
neutropen
patient
empir
antibiot
shift
toward
reduc
unnecessari
empir
treatment
limit
research
outcom
associ
withhold
empir
iv
antibiot
patient
popul
assess
safeti
efficaci
institut
current
protocol
observ
wellappear
patient
present
fever
without
neutropenia
compar
outcom
patient
receiv
empir
iv
antibiot
designmethod
prospect
singleinstitut
cohort
studi
patient
includ
current
undergo
chemotherapi
oncolog
diagnosi
present
initi
outpati
fever
nonneutropenia
defin
anc
episod
record
lab
blood
cultur
result
sign
symptom
initi
present
clinic
outcom
includ
antibiot
administr
hospit
admiss
result
total
episod
wellappear
patient
fever
without
neutropenia
identifi
complianc
institut
protocol
high
patient
observ
without
receiv
empir
iv
antibiot
major
patient
discharg
home
seriou
complic
infecti
death
incid
posit
blood
cultur
low
includ
sever
like
contamin
despit
presenc
central
venou
cathet
major
patient
signific
differ
age
oncolog
diagnosi
central
line
access
anc
valu
incid
bacteremia
patient
receiv
empir
iv
antibiot
patient
admit
hospit
significantli
like
receiv
iv
antibiot
p
despit
document
reassur
exam
howev
admit
patient
initi
receiv
iv
antibiot
like
discharg
within
hour
compar
patient
observ
propos
empir
iv
antibiot
administr
febril
nonneutropen
otherwis
wellappear
patient
unnecessari
studi
demonstr
advers
consequ
observ
signific
differ
clinic
outcom
patient
receiv
iv
antibiot
asid
rate
hospit
support
practic
observ
without
empir
antibiot
patient
background
children
hepatoblastoma
hb
undergo
repetit
comput
tomographi
ct
scan
determin
respons
treatment
assess
relaps
imag
expos
children
radiat
anesthesia
impos
financi
emot
burden
object
review
institut
experi
determin
afp
measur
suffici
assess
respons
treatment
detect
relaps
conduct
retrospect
chart
review
patient
diagnos
hb
institut
data
collect
includ
serum
afp
total
number
type
imag
studi
post
treatment
relaps
progress
diseas
detect
result
thirtyon
patient
diagnos
afp
posit
hb
therapi
ct
scan
perform
assess
respons
therapi
surgic
plan
averag
scanspati
due
concern
progress
rise
afp
therapi
surveil
ct
scan
perform
averag
scanspati
includ
chest
patient
lung
metastasi
diagnosi
relaps
patient
averag
surveil
scan
done
relaps
note
imag
case
radiograph
evid
relaps
without
prior
increas
afp
treatment
respons
therapi
base
imag
correl
declin
afp
patient
argu
repetit
scan
need
set
unless
requir
surgic
plan
scan
perform
therapi
surveil
display
evid
relaps
preced
rise
afp
studi
repres
largest
cohort
hb
patient
prior
studi
suggest
similar
result
includ
fewer
patient
lower
stage
diseas
less
year
surveil
monitor
institut
cost
ct
cap
reimburs
vari
comparison
cost
afp
measur
mani
scan
also
requir
anesthesia
result
emot
toil
famili
concern
procedur
well
result
thu
afp
demonstr
greater
sensit
signific
cost
save
decreas
emot
burden
use
monitor
therapi
replac
routin
serial
imag
background
observ
practic
draw
daili
blood
cultur
hospit
patient
fever
neutropenia
wast
result
excess
neg
cultur
add
patient
care
smart
aim
qualiti
improv
project
reduc
number
neg
blood
cultur
drawn
hospit
patient
fever
neutropenia
month
designmethod
review
publish
evid
suggest
draw
daili
blood
cultur
febril
neutropen
patient
unnecessari
new
blood
cultur
guidelin
implement
cultur
drawn
present
fever
neutropenia
neg
hour
repeat
cultur
drawn
except
clinic
chang
new
fever
afebril
hour
antimicrobi
changedbroaden
impact
key
driver
educ
staff
chang
blood
cultur
order
set
requir
provid
select
reason
order
cultur
elimin
nurs
order
draw
daili
cultur
fever
compar
number
blood
cultur
drawn
per
central
lineday
proport
posit
versu
neg
cultur
preguidelin
juli
postguidelin
june
calcul
cost
save
reduc
cultur
assess
patient
safeti
potenti
septic
event
without
correspond
posit
blood
cultur
review
data
analyz
servic
oncolog
stem
cell
transplant
chisquar
test
use
compar
rate
stem
cell
transplant
patient
pre
vs
postguidelin
vs
total
cultur
vs
posit
decreas
p
vs
neg
decreas
p
oncolog
patient
pre
vs
postguidelin
vs
total
cultur
vs
posit
decreas
p
vs
neg
decreas
p
decreas
posit
cultur
rate
among
oncolog
patient
may
due
decreas
cultur
contamin
andor
effect
concurr
initi
decreas
clabsi
group
safeti
concern
howev
chart
review
conclud
guidelin
lead
miss
infect
patient
first
month
guidelin
total
cost
save
blood
cultur
implement
new
blood
cultur
guidelin
success
led
substanti
reduct
collect
neg
cultur
cost
save
without
compromis
detect
bacteremia
hospit
pediatr
patient
fever
neutropenia
background
variou
evidencebas
guidelin
treatment
adult
cancer
nccn
guidelin
previous
care
standard
new
diagnosi
pediatr
cancer
patient
enrol
clinic
trial
decreas
clinic
trial
avail
enrol
evidencebas
guidelin
pediatr
cancer
care
standard
challeng
pediatr
cancer
object
assess
consist
care
determin
plan
treatment
diagnosi
pediatr
patient
receiv
chemotherapi
newli
diagnos
cancer
singl
center
designmethod
patient
new
cancer
diagnosi
larg
tertiari
care
pediatr
oncolog
center
calendar
year
identifi
report
chemotherapi
order
entri
coe
system
report
includ
diagnosi
record
standard
option
plan
treatment
chart
review
use
exclud
patient
start
treatment
elsewher
patient
treat
relaps
clarifi
diagnosi
standard
option
coe
unclear
clarifi
treatment
plan
need
data
enter
analyz
redcap
databas
specif
diagnos
cluster
higher
level
diseas
group
distribut
treatment
plan
patient
within
determin
project
deem
exempt
irb
approv
human
subject
research
qualifi
qualiti
improv
project
patient
first
chemotherapi
order
exclud
due
one
reason
stem
cell
transplant
transfer
care
relaps
addit
patient
exclud
patientsyeardiagnosi
cn
tumor
diseas
group
patient
thu
patient
hematolog
malign
noncn
solid
tumor
focu
analysi
patient
intermedi
risk
rhabdomyosarcoma
plan
treatment
standard
arm
cog
protocol
patient
arst
subsequ
patient
protocol
activ
diseas
includ
lymphoblast
leukemialymphoma
exclud
infant
classic
hodgkin
lymphoma
aml
exclud
trisomi
apml
stage
iiiiv
burkitt
lymphomadiffus
larg
bcell
lymphoma
posttranspl
lymphoprolif
diseas
wilm
tumor
rhabdomyosarcoma
ewe
sarcoma
osteosarcoma
neuroblastoma
retinoblastoma
one
treatment
plan
per
risk
categori
use
conclus
analysi
demonstr
highli
consist
chemotherapi
treatment
singl
center
patient
hematolog
malign
noncn
solid
tumor
next
step
includ
explor
strategi
group
diagnos
cn
tumor
assess
qualiti
evid
support
treatment
given
background
rapid
initi
empir
antibiot
patient
fever
neutropenia
shown
reduc
morbid
mortal
current
practic
guidelin
call
initi
antibiot
patient
within
sixti
minut
timetoantibiot
tta
suggest
qualityofcar
measur
mani
institut
includ
face
barrier
meet
time
limit
object
util
qualiti
improv
model
determin
barrier
implement
intervent
reduc
timetoantibiot
pediatr
febril
patient
suspect
neutropenia
present
emerg
depart
ed
institut
identifi
implement
intervent
util
plandostudyact
model
qualiti
improv
twelvemonth
retrospect
review
conduct
evalu
efficaci
current
practic
algorithm
larg
academ
tertiarycar
hospit
subject
identifi
pediatr
oncolog
patient
undergo
activ
chemotherapi
present
ed
febril
neutropenia
identifi
two
specif
barrier
triag
level
assign
delay
order
antibiot
address
barrier
creat
wallet
size
fever
card
patient
instruct
show
upon
arriv
ed
collabor
ed
staff
effort
also
made
educ
pediatr
staff
use
fever
card
postintervent
data
collect
current
underway
preand
postintervent
antibiot
deliveri
time
compar
preintervent
cohort
consist
thirtythre
encount
mean
timetoantibiot
deliveri
minut
seventyf
minut
greater
accept
standard
care
one
patient
receiv
antibiot
within
sixti
minut
arriv
postintervent
data
collect
current
underway
sinc
identifi
two
barrier
meet
standard
care
institut
implement
qualiti
improv
measur
empow
patient
famili
direct
appropri
triag
ed
well
simplifi
treatment
protocol
ed
provid
expect
identifi
improv
timetoantibiot
preintervent
postintervent
period
background
sickl
cell
diseas
scd
genet
disord
sickl
hemoglobin
hb
trigger
multipl
downstream
effect
includ
red
cell
sickl
hemolysi
vasoocclus
inflamm
scd
lifelong
diseas
initi
birth
injuri
accumul
time
caus
signific
endorgan
damag
clinic
complic
undertr
associ
earli
death
homozyg
mutat
hbss
caus
sever
form
scd
individu
scd
increas
risk
infect
stroke
retinopathi
clinic
guidelin
pediatr
patient
scd
recommend
prophylact
penicillin
use
age
annual
screen
stroke
transcrani
doppler
tcd
imag
age
annual
ophthalmolog
exam
assess
retinopathi
age
limit
realworld
data
implement
nhlbibas
recommend
object
describ
util
penicillin
tcd
screen
ophthalmolog
care
children
hbss
diseas
medicaid
administr
claim
databas
use
identifi
us
patient
age
year
first
indic
hbss
record
calendar
year
patient
requir
medic
pharmaci
benefit
calendar
year
identifi
month
prior
first
record
hbss
indic
prior
year
util
penicillin
tcd
ophthalmologist
visit
measur
annual
cohort
annual
cohort
includ
commerci
mean
age
year
femal
medicaid
mean
age
year
femal
patient
hbss
diseas
fewer
half
patient
receiv
tcd
scan
previou
year
similar
rate
seen
across
age
group
payer
ophthalmologist
visit
increas
patient
age
patient
age
year
highest
proport
ophthalmologist
visit
payer
popul
overal
implement
remain
low
contrast
low
use
tcd
ophthalmolog
visit
penicillin
use
highest
year
age
group
use
given
year
payer
conclus
although
data
demonstr
high
penicillin
use
year
age
group
consist
guidelin
opportun
improv
implement
guidelinesbas
recommend
screen
exampl
tcd
screen
identifi
children
risk
scdrelat
stroke
order
initi
prevent
therapi
research
understand
potenti
barrier
proper
screen
evalu
strategi
improv
awar
adher
implement
recommend
screen
children
scd
warrant
support
global
blood
therapeut
background
childhood
cancer
therapi
improv
mani
longterm
survivor
psychosoci
difficulti
pediatr
cancer
survivor
recogn
preval
problem
initi
survivorship
present
unclear
object
examin
preval
overal
intern
symptom
eg
depressionanxieti
pediatr
cancer
survivor
present
survivorship
clinic
examin
mitig
receiv
psycholog
servic
evid
parent
depressionanxieti
designmethod
pediatr
cancer
survivor
attend
first
visit
reach
survivorship
clinic
vanderbilt
age
includ
survivor
parent
femal
complet
child
behavior
checklist
cbcl
beck
depress
inventoryii
beck
anxieti
inventori
survivor
year
complet
selfreport
wilcoxon
ranksum
pearson
test
use
univari
analys
effect
size
confid
interv
ci
estim
multivari
linear
regress
report
result
childhood
cancer
survivor
median
year
old
year
therapi
includ
thirti
one
survivor
show
least
borderlin
clinic
intern
problem
score
cbcl
patient
report
receiv
psycholog
servic
nine
survivor
normal
score
also
report
receiv
psycholog
servic
parent
depress
anxieti
symptom
correl
parent
report
survivor
overal
intern
symptom
spearman
p
p
respect
howev
correl
survivor
selfreport
furthermor
parent
mild
sever
depress
symptom
mild
sever
anxieti
symptom
like
rate
child
higher
overal
intern
symptom
p
p
respect
multivari
linear
regress
show
adjust
age
gender
cancer
diagnosi
time
treatment
report
util
psycholog
servic
ci
p
parent
depress
symptom
p
significantli
associ
child
overal
intern
symptom
otherwis
ident
altern
model
substitut
parent
anxieti
parent
depress
parent
anxieti
also
signific
risk
factor
p
altern
parent
anxietydepress
symptom
significantli
associ
child
selfreport
intern
symptom
childhood
cancer
survivor
elev
preval
experienc
intern
symptom
seldom
report
receiv
psycholog
servic
childhood
cancer
survivor
parent
anxiousdepress
symptom
like
rate
children
intern
problem
compar
patient
selfreport
ongo
longitudin
analys
help
clarifi
best
time
potenti
intervent
background
life
expect
adult
sickl
cell
diseas
scd
remain
unchang
past
year
despit
improv
pediatr
scd
surviv
greatest
risk
adolesc
young
adult
aya
transit
pediatr
adult
care
allen
counti
rank
scd
incid
among
counti
indiana
board
certifi
pediatr
hematologistoncologist
children
age
pediatr
system
provid
knowledg
manag
adult
scd
region
novel
partnership
hematologist
famili
medicin
resid
program
allen
counti
initi
educ
famili
medicin
resid
fp
scd
hydroxyurea
hu
manag
scdrelat
complic
goal
increas
number
knowledg
provid
care
adult
scd
determin
effect
onlin
learn
modul
educ
fp
hu
best
practic
aya
scd
care
transit
three
onlin
learn
modul
scd
comprehens
care
aya
scd
hu
best
practic
aya
transit
develop
cmeaccredit
electron
preand
posttest
distribut
fp
five
question
modul
cover
contracept
screen
test
hu
indic
dose
monitor
development
mileston
scd
knowledg
assess
st
vincent
irb
review
protocol
grant
waiver
consent
result
twentysix
fp
complet
preand
posttest
twothird
correctli
identifi
clinic
benefit
hu
assess
knowledg
rational
hu
therapi
increas
complet
hu
modul
correct
pretest
vs
posttest
p
proport
correct
respons
increas
comprehens
aya
scd
care
posttest
question
lead
caus
death
priapismrel
question
reach
statist
signific
vs
p
vs
p
respect
proport
correct
respons
transitionfocus
question
unchang
proport
correct
posttest
respons
selfcar
assess
question
significantli
increas
vs
p
modul
complet
fp
abl
correctli
identifi
common
scd
complic
hu
effect
treatment
individu
scd
best
practic
transit
clinic
modul
may
need
modif
improv
physician
understand
intricaci
establish
maintain
scd
transit
clinic
overal
onlin
train
effect
educ
fp
could
use
increas
number
provid
knowledg
scd
care
background
surviv
rate
pediatr
hodgkin
lymphoma
hl
exceed
contemporari
therapi
studi
pediatr
hl
survivor
treat
shown
increas
risk
treatmentrel
chronic
health
condit
riskadapt
therapi
includ
tailor
radiotherapi
develop
reduc
longterm
morbid
maintain
excel
surviv
littl
known
chronic
condit
associ
contemporari
therapi
present
first
year
therapi
complet
earli
outcom
object
analyz
surviv
earli
outcom
pediatr
hl
patient
treat
contemporari
therapi
conduct
retrospect
review
hl
patient
diagnos
year
age
institut
threeyear
overal
os
eventfre
ef
surviv
calcul
kaplan
meier
statist
use
sa
result
standard
screen
target
toxic
develop
year
therapi
complet
identifi
grade
per
ctcae
criteria
censor
occur
date
death
year
therapi
complet
decemb
data
last
collect
point
use
preval
calcul
case
multipl
evalu
identifi
patient
male
nonhispan
white
mean
age
diagnosi
year
median
time
sinc
therapi
complet
year
rang
initi
treatment
includ
chemotherapi
multimod
treatment
patient
receiv
anthracyclin
median
dose
receiv
alkyl
agent
median
cyclophosphamid
equival
dose
ced
os
ef
chemotherapi
multimod
treatment
p
patient
relapsedrefractori
diseas
receiv
salvag
treatment
includ
chemotherapi
n
multimod
therapi
n
multimod
treatment
includ
stem
cell
transplant
autolog
n
autologousallogen
n
patient
develop
thyroid
dysfunct
cardiac
dysfunct
subsequ
neoplasm
male
gonad
dysfunct
studi
period
pulmonari
dysfunct
limit
ctcae
grade
antimullerian
hormon
amh
normal
rang
found
pubert
femal
receiv
ced
compar
femal
receiv
ced
two
femal
low
amh
also
follicl
stimul
hormon
studi
first
evalu
earli
outcom
pediatr
hl
survivor
result
indic
contemporari
chemotherapi
lower
rate
radiotherapi
util
lead
excel
surviv
rate
minim
earli
toxic
femal
expos
ced
increas
risk
gonad
dysfunct
priorit
fertil
preserv
approach
prior
initi
cancer
therapi
background
cancer
one
lead
diseaserel
caus
death
among
individu
age
year
unit
state
recent
evalu
nation
trend
pediatr
cancer
use
data
cover
us
popul
object
studi
describ
pediatr
cancer
incid
rate
trend
use
recent
comprehens
cancer
registri
data
avail
us
designmethod
data
us
cancer
statist
use
evalu
cancer
incid
rate
trend
among
individu
age
year
data
state
cover
us
popul
assess
trend
calcul
averag
annual
percent
chang
aapc
rate
use
joinpoint
regress
rate
trend
stratifi
sex
age
raceethn
us
censu
region
countybas
econom
statu
countybas
ruralurban
classif
cancer
type
group
intern
classif
childhood
cancer
iccc
identifi
case
pediatr
cancer
overal
cancer
incid
rate
per
million
incid
rate
highest
leukemia
brain
tumor
lymphoma
rate
highest
among
male
age
year
nonhispan
white
northeast
us
censu
region
top
counti
econom
statu
metropolitan
counti
overal
pediatr
cancer
incid
rate
increas
aapc
ci
contain
joinpoint
rate
increas
stratum
sex
age
raceethn
except
nonhispan
american
indianalaska
nativ
region
econom
statu
ruralurban
classif
rate
stabl
individu
cancer
type
increas
nonhodgkin
lymphoma
except
burkitt
lymphoma
iccc
group
ii
b
aapc
ci
central
nervou
system
neoplasm
group
iii
aapc
ci
renal
tumor
group
vi
aapc
ci
hepat
tumor
group
vii
aapc
ci
thyroid
carcinoma
group
xi
b
aapc
ci
rate
malign
melanoma
decreas
group
xi
aapc
ci
studi
document
increas
rate
pediatr
cancer
demograph
variabl
examin
increas
overal
rate
hepat
cancer
decreas
rate
melanoma
novel
find
use
data
sinc
next
step
address
chang
rate
could
includ
investig
diagnost
report
standard
host
biolog
factor
environment
exposur
potenti
intervent
reduc
cancer
risk
increas
pediatr
cancer
incid
rate
may
necessit
chang
relat
treatment
survivorship
care
capac
background
childhood
cancer
treatment
modal
improv
delay
effect
cancer
treatment
continu
compromis
qualiti
life
survivor
metabol
syndrom
ms
diagnos
base
presenc
three
follow
find
obes
dyslipidemia
hypertens
insulin
resist
per
world
health
organ
criteria
increas
risk
ms
among
childhood
cancer
survivor
first
report
known
increas
incid
cardiovascular
diseas
individu
object
assess
frequenc
ms
childhood
cancer
survivor
institut
conduct
retrospect
chart
review
pediatr
cancer
survivor
year
age
treat
sri
ramachandra
medic
institut
research
foundat
august
august
patient
receiv
least
one
year
treatment
chemotherapi
andor
radiat
surgeri
includ
medic
histori
famili
histori
diabet
cardiovascular
diseas
hypercholesterolemia
tanner
stage
weight
height
per
criteria
bmi
per
indian
academi
pediatr
iap
blood
pressur
nhlbi
criteria
fast
blood
sugar
level
lipid
profil
obtain
chart
statist
analysi
data
done
use
ibm
spss
statist
softwar
version
result
patient
studi
male
year
age
year
year
leukemia
survivor
compris
sampl
nonleukem
treat
chemotherapi
alon
radiotherapi
chemotherapi
underw
surgeri
radiotherapi
chemotherapi
hypertens
found
studi
group
dyslipidemia
impair
fast
blood
glucos
found
obes
studi
group
diagnos
ms
base
criteria
conclus
studi
popul
found
ms
per
criteria
individu
metabol
complic
detect
popul
acut
lymphoblast
leukemia
survivor
appear
high
risk
popul
ms
known
increas
cardiovascular
complic
cancer
survivor
multidisciplinari
team
approach
manag
patient
import
close
monitor
manag
longterm
complic
relat
ms
type
diabet
atherosclerosi
approach
essenti
decreas
long
term
morbid
mortal
ms
vulner
popul
background
surviv
rate
childhood
cancer
exce
howev
children
requir
admiss
pediatr
intens
care
unit
picu
within
three
year
diagnosi
children
account
approxim
picu
death
mortal
higher
posthematopoiet
stem
cell
transplant
hsct
nation
guidelin
recommend
provid
share
inform
regard
prognosi
treatment
option
within
first
hour
icu
admiss
prognost
goal
care
convers
pgocc
critic
care
children
malign
subpopul
risk
increas
mortal
determin
frequenc
pgocc
well
describ
differ
patient
characterist
critic
care
therapi
pgocc
statu
designmethod
retrospect
cohort
studi
conduct
use
univers
michigan
virtual
picu
system
databas
picu
admiss
last
longer
hour
patient
age
year
juli
june
oncolog
diagnosi
andor
hsct
identifi
data
pgocc
patient
demograph
diagnos
picu
intervent
outcom
record
compar
children
pgocc
without
use
chi
squar
test
categor
variabl
kruskalw
test
continu
data
picu
admiss
male
mean
age
year
lead
diagnos
acut
lymphoblast
leukemia
acut
myeloid
leukemia
lymphoma
neuroblastoma
brain
tumor
patient
posthsct
pgocc
document
patient
comparison
patient
pgocc
children
pgocc
like
readmit
picu
vs
p
like
relaps
diseas
vs
p
patient
pgocc
higher
sever
ill
score
p
higher
use
noninvas
vs
p
invas
convent
ventil
vs
p
high
frequenc
ventil
vs
p
also
patient
pgocc
like
receiv
continu
renal
replac
therapi
vs
p
arteri
catheter
vs
p
cardiopulmonari
resuscit
p
critic
ill
children
hematologiconcolog
diseas
pgocc
held
children
pgocc
sicker
receiv
critic
care
intervent
futur
research
need
evalu
content
pgocc
background
central
nervou
system
cn
tumor
autism
spectrum
disord
asd
repres
signific
diseas
cohort
pediatr
popul
asd
diagnos
children
preval
everi
children
unit
state
addit
cn
tumor
report
children
age
year
unit
state
brain
tumor
common
solid
tumor
lead
caus
death
among
childhood
cancer
genet
etiolog
autism
cn
tumor
complex
specif
gene
alter
present
certain
cancer
similarli
describ
suspect
play
role
asd
subtyp
target
therapi
panel
like
foundat
one
fo
benefici
guid
treatment
cancer
base
distinct
gene
alter
given
genet
overlap
potenti
therapeut
benefit
crossov
action
gene
target
panel
merit
explor
asd
cn
tumor
aim
identifi
describ
genet
alter
known
action
target
cancer
therapi
fo
potenti
diagnost
therapeut
research
target
neurodevelopment
diseas
plan
discuss
common
genet
alter
cancer
neurodevelopment
diseas
describ
literatur
fo
data
extract
compar
literatur
report
gene
alter
fo
plu
keyword
autism
psych
use
pubm
search
suspect
associ
neurodevelopment
disord
result
twentyon
patient
repres
cohort
six
uniqu
astrocytomaf
ependymomasix
gbmfour
gliomathre
nerv
sheath
tumoron
etmrtwo
cn
tumor
investig
fo
produc
eighti
total
sixti
uniqu
gene
alter
thirtyon
yield
least
one
publish
suspect
associ
neurodevelopment
disord
common
gene
alter
braffour
main
function
categori
cellular
prolifer
structur
differenti
degrad
chromatin
model
histon
transcript
modif
dna
methyl
repair
strna
neural
signal
sixti
uniqu
gene
alter
found
cn
tumor
set
use
foundat
one
thirtyon
discret
alter
pair
least
one
descript
literatur
similarli
alter
asd
subtyp
mani
alter
action
target
therapi
present
foundat
one
cn
tumor
may
relev
guid
futur
target
therapi
research
asd
subtyp
monoclon
antibodi
therapi
usag
associ
significantli
improv
surviv
bcell
nhl
aya
patient
although
usag
increas
aya
popul
magnitud
increas
low
factor
affect
use
mab
includ
race
insur
type
research
warrant
identifi
privat
insur
patient
less
like
receiv
drug
background
prevent
chemotherapyinduc
nausea
vomit
cinv
remain
challeng
despit
advanc
pharmacotherapi
develop
cinv
clinic
practic
guidelin
pediatr
oncolog
group
ontario
pogo
endors
children
oncolog
group
achiev
control
cinv
pediatr
complic
difficulti
young
children
vocal
symptom
use
valid
nauseaassess
tool
conjunct
improv
adher
evidencebas
guidelin
may
result
better
quantif
symptom
reduct
nausea
sever
vomit
frequenc
pediatr
patient
undergo
chemotherapi
pediatr
nausea
assess
tool
penat
valid
children
age
integr
clinic
practic
may
help
optim
cinv
control
object
singleinstitut
studi
sought
improv
control
cinv
patient
admit
chemotherapi
standard
antiemet
regimen
prescrib
provid
accord
institut
cinv
algorithm
develop
pogo
guidelin
hypothes
treatment
use
standard
guidelin
would
improv
cinv
control
patient
admit
chemotherapi
baselin
cohort
admiss
chemotherapi
complet
penat
assess
cinv
diari
prior
receiv
chemotherapi
four
time
daili
admiss
daili
day
follow
complet
chemotherapi
may
januari
provid
provid
institut
cinv
treatment
algorithm
base
pogo
guidelin
receiv
educ
department
meet
appropri
implement
algorithm
second
cohort
admiss
complet
penat
assess
cinv
diari
similar
fashion
juli
decemb
result
complet
control
vomit
markedli
improv
follow
cinv
guidelin
implement
vs
p
treatment
failur
also
significantli
reduc
vs
p
control
degre
emetogen
chemotherapi
receiv
patient
time
like
vomit
prior
guidelin
implement
ci
differ
nausea
control
even
adjust
emetogen
chemotherapi
conclus
control
chemotherapyinduc
vomit
civ
improv
follow
widespread
implement
institut
cinv
treatment
algorithm
singl
institut
sever
nausea
report
remain
unchang
may
reflect
difficulti
assess
nausea
inadequ
sampl
size
futur
research
may
focu
cinv
treatment
manag
use
guidelin
specif
breakthrough
cinv
delay
cinv
background
aspho
profession
develop
committe
pdc
recogn
pediatr
hematologistsoncologist
pho
serv
unit
state
us
militari
uniqu
profession
develop
need
may
address
aspho
similar
profession
societi
individu
may
also
encount
challeng
transit
civilian
career
howev
barrier
profession
develop
systemat
character
object
character
number
pho
current
prior
militari
servic
mpho
identifi
unmet
profession
develop
need
designmethod
work
group
consist
pdc
member
senior
earli
career
mpho
form
initi
comment
solicit
email
known
mpho
regard
potenti
gap
profession
develop
interest
work
aspho
improv
support
mpho
survey
develop
pilot
four
member
advisori
group
question
revis
base
feedback
final
version
distribut
via
aspho
websit
onlin
commun
forum
target
email
sent
mpho
identifi
aspho
militari
databas
elig
complet
survey
includ
complet
fellowship
pediatr
hematologyoncolog
current
prior
servic
activ
duti
militari
provid
quantit
qualit
inform
collect
includ
demograph
data
perceiv
barrier
profession
develop
respons
summar
use
descript
statist
result
sixtyf
mpho
identifi
survey
complet
respons
rate
respond
engag
varieti
profession
activ
male
serv
activ
duti
commit
felt
profession
develop
gap
area
concern
categor
nine
theme
concern
limit
civilian
knowledg
mpho
practic
particip
inabl
attend
profession
societi
meet
possibl
deploy
particip
express
desir
educ
product
meet
specif
need
network
opportun
civilian
colleagu
qualit
analys
identifi
concern
low
patient
number
practic
size
subset
mpho
perceiv
signific
gap
profession
develop
addit
research
need
better
defin
area
intervent
mani
concern
align
similarli
size
civilian
program
may
address
profession
societi
network
opportun
aspho
special
interest
group
background
infertil
establish
caus
distress
neg
impact
qualiti
life
among
childhood
cancer
survivor
american
societi
clinic
oncolog
establish
guidelin
fertil
counsel
individu
reproduct
age
diagnos
cancer
goal
improv
reproduct
psychosoci
outcom
studi
shown
institut
fertil
team
provid
counsel
discuss
fertil
preserv
fp
option
result
improv
patient
satisfact
patient
cancer
object
goal
studi
examin
predictor
referr
multidisciplinari
fertil
team
document
fp
intervent
among
patient
designmethod
irbapprov
retrospect
medic
record
review
perform
larg
pediatr
academ
center
patient
new
cancer
diagnos
receiv
chemotherapi
includ
januari
fertil
team
establish
present
standard
abstract
form
use
collect
inform
age
diagnosi
gender
cancer
type
whether
fertil
consult
place
document
fp
intervent
data
summar
descript
comparison
made
use
nonparametr
statist
method
result
patient
met
inclus
criteria
male
cancer
type
follow
leukemialymphoma
cn
tumor
sarcoma
embryon
tumor
langerhan
cell
histiocytosi
lch
mean
age
year
rang
year
overal
patient
consult
fertil
team
patient
significantli
less
like
fertil
consult
younger
p
differ
consult
rate
diagnos
sarcoma
patient
complet
consult
compar
cn
tumor
embryon
tumor
leukemialymphoma
none
patient
lch
find
show
mani
children
adolesc
young
adult
newli
diagnos
cancer
still
receiv
fertil
counsel
despit
expand
bodi
literatur
support
need
provid
counsel
guidelin
publish
sever
organ
recommend
discuss
infertil
risk
fp
option
presenc
multidisciplinari
fertil
team
specif
strategi
need
develop
improv
access
younger
children
diseas
group
fertil
consult
underutil
youth
cn
tumor
embryon
tumor
leukemialymphoma
background
socioeconom
statu
se
impact
overal
surviv
pediatr
oncolog
popul
unfortun
data
insuffici
detail
explain
mechan
behind
phenomenon
parent
handl
health
manag
demand
place
time
child
cancer
diagnosi
may
repres
point
differenti
health
outcom
object
determin
associ
socioeconom
factor
cancer
literaci
parent
understand
home
emerg
manag
respons
instanc
pain
nausea
fever
prospect
observ
studi
parent
whose
children
newli
diagnos
cancer
obtain
demograph
inform
use
valid
instrument
dumenc
evalu
cancer
literaci
test
understand
educ
parent
receiv
home
emerg
manag
multiplechoic
vignettebas
questionnair
focus
action
need
home
scenario
follow
parent
actual
behavior
period
phone
call
assess
instanc
nausea
pain
fever
respons
episod
result
preliminari
analysi
particip
show
averag
score
parent
understand
questionnair
rang
variabl
associ
increas
score
collegelevel
educ
point
ci
privat
insur
point
adequ
cancer
literaci
point
actual
behavior
report
famili
indic
marri
parent
incom
less
like
treat
instanc
pain
ci
respect
white
parent
collegelevel
educ
adequ
cancer
literaci
less
like
treat
instanc
nausea
respect
associ
found
socioeconom
marker
parent
respons
instanc
fever
find
suggest
associ
demograph
socioeconom
marker
improv
parent
understand
home
emerg
manag
paradox
marker
show
decreas
treatment
respons
pain
nausea
larger
prospect
studi
need
link
behavior
pattern
health
outcom
help
inform
extent
se
impact
home
emerg
manag
emori
universitychildren
heathcar
atlanta
atlanta
georgia
unit
state
background
cardiovascular
diseas
lead
caus
morbid
mortal
childhood
cancer
survivor
cc
previou
research
show
wide
practic
variat
referr
pattern
cardiolog
survivor
clinic
recommend
cardiologist
need
test
exercis
restrict
develop
cardiooncolog
algorithm
order
standard
referr
cardiolog
provid
guidelin
cardiologist
evalu
pediatr
cc
designmethod
survivorship
cardiolog
expert
develop
weight
score
system
pediatr
cc
receiv
cardiotox
therapi
base
time
sinc
treatment
risk
factor
identifi
children
oncolog
group
cog
american
heart
associ
aha
cardiooncolog
algorithm
assign
score
score
rang
categor
guid
cardiolog
referr
screen
echo
consid
cardiolog
referr
recommend
cardiolog
referr
regular
cardiolog
followup
algorithm
also
provid
recommend
cardiologist
screen
exercis
modif
base
score
establish
algorithm
conveni
sampl
institut
survivor
clinic
patient
chart
retrospect
review
first
month
quarter
april
valid
algorithm
evalu
referr
pattern
cardiolog
assess
cardiolog
recommend
retrospect
chart
review
evalu
patient
male
nonhispan
white
leukemia
survivor
median
age
diagnosi
year
rang
median
time
offtherapi
year
rang
patient
receiv
anthracyclin
median
dose
rang
receiv
cardiac
radiat
assign
cardiooncolog
score
result
echo
consid
cardiolog
referr
recommend
cardiolog
referr
regular
cardiolog
followup
evalu
detect
rate
late
effect
cardiooncolog
score
survivor
abnorm
echo
echo
consid
referr
recommend
referr
regular
cardiolog
followup
assess
referr
pattern
prior
initi
algorithm
reveal
fortytwo
survivor
refer
cardiolog
echo
consid
referr
recommend
referr
regular
cardiolog
followup
patient
seen
cardiologist
institut
diagnost
test
order
ie
stress
test
receiv
exercis
restrict
cardiooncolog
algorithm
guidelin
standard
cardiac
care
survivor
assign
score
guid
referr
cardiolog
practic
referr
prospect
clinic
use
begun
review
occur
one
year
determin
chang
detect
rate
cardiac
late
effect
referr
recommend
cardiologist
oregon
health
scienc
univers
portland
oregon
unit
state
background
delirium
affect
patient
pt
pediatr
intens
care
unit
picu
associ
increas
length
stay
decreas
attent
school
posttraumat
stress
disord
diagnost
statist
manual
mental
disord
dsm
v
defin
delirium
disturb
conscious
reduc
abil
focu
sustain
shift
attent
due
underli
medic
condit
despit
medic
complex
hospit
pho
popul
publish
prospect
studi
look
delirium
pt
hypothes
delirium
recogn
pho
popul
design
yearlong
prospect
studi
use
valid
screen
tool
determin
frequenc
delirium
hospit
pho
pt
identifi
associ
clinic
factor
designmethod
baselin
frequenc
pt
symptom
suggest
delirium
determin
retrospect
chart
review
use
data
mine
program
electron
medic
record
emr
prospect
studi
pho
picu
nurs
train
use
cornel
assess
pediatr
delirium
record
score
within
emr
pho
pt
everi
shift
predetermin
demograph
clinic
variabl
enter
daili
redcap
databas
hospit
pho
pt
result
baselin
frequenc
delirium
without
activ
screen
determin
hospit
pho
pt
first
month
prospect
studi
consecut
admiss
occur
among
uniqu
pho
pt
oncolog
hematolog
stem
cell
transplant
pt
pt
least
posit
delirium
screen
preval
per
admiss
statist
signific
variabl
associ
delirium
p
univari
logist
regress
includ
prolong
length
stay
pt
locat
picu
vs
pho
unit
fever
adjust
length
stay
administr
benzodiazepin
opiat
also
significantli
associ
delirium
p
respect
averag
nurs
complet
delirium
screen
pt
shift
studi
accrual
end
jan
final
data
analys
report
abstract
present
conclus
delirium
occur
pho
hospit
popul
screen
train
nurs
staff
feasibl
pt
highest
risk
appear
pt
prolong
hospit
stay
picu
admiss
frequent
use
benzodiazepinesopioid
routin
screen
improv
recognit
delirium
allow
us
promptli
interven
prevent
delirium
effort
avoid
potenti
acut
long
term
consequ
background
high
surviv
rate
children
adolesc
hodgkin
lymphoma
hl
treatment
regimen
design
maxim
cure
decreas
risk
longterm
health
outcom
associ
chemotherapi
radiat
therapi
within
contemporari
treatment
regimen
comparison
toxic
experienc
patient
receiv
chemotherapi
plu
radiotherapi
crt
versu
chemotherapi
co
studi
extens
object
studi
examin
select
selfreport
advers
health
outcom
survivor
contemporarilytr
pediatr
hl
better
understand
balanc
efficaci
toxic
associ
chemotherapi
radiat
therapi
cog
evalu
responsebas
treatment
paradigm
pediatr
hl
patient
receiv
initi
chemotherapi
random
base
earli
respons
continu
chemotherapi
chemotherapi
plu
radiotherapi
augment
chemotherapi
plu
radiotherapi
patient
complet
selfreport
questionnair
health
problem
year
follow
therapi
examin
select
patientreport
pulmonari
gastrointestin
gi
cardiac
endocrin
outcom
kaplanmei
surviv
curv
use
determin
probabl
surviv
without
select
advers
health
outcom
logrank
test
use
compar
co
versu
crt
group
result
total
enrol
patient
patient
co
group
patient
crt
group
complet
questionnair
median
year
complet
therapi
analyz
cumul
incid
endocrin
dysfunct
significantli
greater
crt
group
versu
co
group
versu
p
driven
incid
hypothyroid
versu
p
signific
differ
cardiac
versu
p
pulmonari
versu
p
gastrointestin
dysfunct
versu
p
co
crt
patient
conclus
studi
demonstr
low
cumul
incid
overal
organ
dysfunct
earli
post
complet
contemporari
therapi
hl
addit
radiat
therapi
significantli
increas
risk
hypothyroid
higher
risk
note
cardiac
pulmonari
gi
dysfunct
limit
includ
selfreport
statu
potenti
select
bia
rel
short
latenc
period
follow
end
therapi
longer
followup
need
determin
delay
risk
organ
dysfunct
order
best
defin
balanc
therapeut
efficaci
longterm
advers
health
outcom
relat
chemotherapi
andor
radiat
therapi
background
identif
organ
via
bronchoalveolar
lavag
bal
respiratori
tract
biopsi
rtb
histor
consid
gold
standard
diagnosi
invas
fungal
infect
ifi
howev
data
previous
publish
group
show
procedur
infrequ
lead
chang
manag
children
oncolog
diagnosi
undergo
hematopoiet
stem
cell
transplant
hsct
also
pauciti
data
cost
ifi
popul
compar
cost
workup
manag
pulmonari
ifi
diagnos
base
ct
scan
alon
versu
ct
scan
chest
xray
prompt
bal
rtb
designmethod
collect
cost
data
patient
ann
robert
h
luri
children
hospit
chicago
undergo
chemotherapi
within
month
hsct
suspect
ifi
order
includ
suffici
time
account
postprocedur
complic
avoid
includ
cost
unrel
ifi
data
includ
day
day
diagnost
scan
procedur
cost
data
avail
patient
previous
studi
thirtysix
patient
diagnos
suspect
ifi
base
ct
patient
underw
bal
rtb
evalu
specif
cost
inpati
bed
cost
higher
bal
rtb
group
median
versu
p
yet
trend
toward
higher
cost
antifung
agent
median
versu
p
respiratori
support
median
versu
p
mani
initi
ct
scan
captur
evalu
period
bal
rtb
group
base
studi
design
howev
even
account
ct
scan
week
prior
procedur
total
cost
ct
scan
higher
ct
group
median
versu
p
scan
despit
total
cost
significantli
higher
patient
underw
bal
rtb
versu
ct
scan
median
versu
p
combin
previou
data
bal
rtb
infrequ
lead
chang
manag
children
oncolog
diagnosi
undergo
hsct
suspect
ifi
significantli
higher
cost
associ
procedur
make
invas
diagnost
techniqu
even
less
desir
batra
pediatr
blood
cancer
background
infant
month
age
acut
lymphoblast
leukemia
poor
prognosi
infant
acut
myeloid
leukemia
aml
fare
better
despit
intens
therapi
limit
data
differ
particularli
differ
support
care
requir
induct
therapi
infant
object
compar
induct
mortal
resourc
util
infant
rel
noninf
age
year
separ
aml
designmethod
use
previous
establish
cohort
children
treat
new
onset
aml
children
hospit
us
contribut
pediatr
health
inform
system
patient
syndrom
exclud
followup
start
first
day
induct
chemotherapi
continu
earliest
day
commenc
chemotherapi
start
subsequ
cours
death
high
acuiti
present
defin
icu
requir
involv
organ
system
within
first
hour
follow
initi
admiss
compar
use
log
binomi
regress
inpati
mortal
compar
use
cox
regress
resourc
util
rate
day
use
per
inpati
day
compar
use
poisson
regress
result
total
infant
noninf
aml
infant
noninf
includ
analys
infant
like
present
high
acuiti
compar
noninf
rr
p
aml
vs
rr
ci
p
infant
higher
inpati
mortal
compar
noninf
even
account
differ
acuiti
present
vs
adjust
hr
ci
p
contrast
inpati
mortal
similar
infant
noninf
aml
vs
adjust
hr
ci
p
compar
rate
among
infant
infant
aml
higher
rate
util
fresh
frozen
plasma
cryoprecipit
diuret
supplement
oxygen
ventil
rel
noninf
infant
also
higher
rate
total
parenter
nutrit
ecmo
patient
control
analges
compar
noninf
infant
experienc
significantli
higher
induct
mortal
compar
noninf
differ
entir
explain
acuiti
present
differ
ru
among
infant
may
reflect
higher
present
acuiti
greater
treatment
relat
toxic
work
need
elucid
contribut
treatment
relat
toxic
earli
mortal
infant
background
fever
child
cancer
medic
emerg
due
signific
risk
seriou
bacteri
infect
mani
attempt
made
risk
stratifi
patient
respiratori
pathogen
panel
rpp
panel
polymeras
chain
reaction
test
identifi
seventeen
common
respiratori
virus
three
bacteri
infect
sampl
taken
via
nasopharyng
swab
rpp
frequent
sent
data
determin
whether
posit
result
lead
stratif
lower
risk
bacteri
infect
determin
epidemiolog
respiratori
virusassoci
fever
pediatr
oncolog
patient
determin
whether
posit
rpp
associ
reduc
risk
bacteremia
popul
singlecent
retrospect
cohort
studi
identifi
review
medic
record
pediatr
oncolog
patient
seen
emerg
depart
ed
fever
introduct
rpp
april
septemb
review
result
blood
cultur
rpp
chest
radiograph
discharg
summari
identifi
sourc
infect
also
identifi
patient
cancer
diagnosi
age
absolut
neutrophil
count
anc
absolut
lymphocyt
count
alc
result
posit
rpp
found
among
pediatr
oncolog
patient
present
ed
fever
common
posit
rpp
find
rhinovirusenteroviru
rev
parainfluenza
influenza
coronaviru
polyvir
among
patient
posit
rpp
bacteremia
compar
bacteremia
among
pediatr
oncolog
patient
fever
p
case
bacteremia
associ
rev
bacteremia
identifi
patient
rpp
posit
virus
p
rev
posit
confer
lower
risk
bacteremia
rpp
neg
patient
p
anc
p
alc
p
less
number
patient
sever
neutropenia
p
statist
differ
rev
nonrev
posit
rpp
group
rpp
posit
virus
rev
reduc
likelihood
bacteremia
febril
pediatr
oncolog
patient
ed
set
patient
bacteremia
may
concurr
infect
rev
larger
studi
warrant
determin
posit
rpp
result
inform
clinic
manag
child
febril
neutropenia
emili
mueller
ann
cochran
seethal
jacob
aaron
carrol
background
usag
mobil
health
mhealth
refer
applic
mobil
wireless
commun
technolog
health
healthcar
grown
exponenti
recent
year
mhealth
tool
use
caregiv
vulner
popul
littl
focus
caregiv
children
cancer
object
conduct
survey
understand
mobil
technolog
usag
barrier
desir
mhealth
tool
caregiv
children
cancer
conduct
mail
crosssect
paper
survey
caregiv
children
diagnos
cancer
riley
hospit
children
june
june
survey
contain
question
fix
openend
english
spanish
three
round
survey
sent
respond
respond
primarili
parent
median
age
year
rang
white
nonhispaniclatino
top
three
annual
household
incom
bracket
includ
major
educ
colleg
graduat
graduat
degre
high
school
educ
ged
nearli
respond
own
smart
phone
own
tablet
major
use
io
oper
system
report
use
devic
android
oper
system
caregiv
report
use
least
one
mobil
websiteapp
regularli
person
use
respond
report
barrier
mobil
technolog
use
top
barrier
select
data
limit
overal
want
least
one
medic
managementrel
websiteapp
medic
knowledg
healthcar
symptom
trackingmanag
medic
remind
healthcar
systemrel
desir
high
want
access
child
medic
record
want
websiteapp
facilit
better
commun
medic
provid
signific
associ
socioeconom
statu
incom
educ
barrier
type
websitesapp
desir
caregiv
sinc
vast
major
caregiv
use
mobil
technolog
minim
barrier
futur
research
focu
design
mhealth
tool
address
medic
manag
need
caregiv
children
cancer
support
caregiv
type
mhealth
tool
could
posit
impact
patient
clinic
outcom
greater
adher
medic
treatment
protocol
background
children
fever
neutropenia
earli
initi
target
antibiot
therapi
improv
outcom
yet
standard
choic
empir
antibiot
institut
implement
earli
empir
ceftriaxon
eec
protocol
reduc
time
antibiot
administr
febril
hematologyoncolog
patient
potenti
neutropen
absolut
neutrophil
count
yet
know
ceftriaxon
given
immedi
obtain
blood
cultur
lab
studi
patient
found
neutropen
ceftriaxon
discontinu
cefepim
initi
purpos
retrospect
studi
evalu
eec
protocol
neutropen
patient
assess
ceftriaxon
sensit
posit
blood
cultur
compar
rate
advers
outcom
cohort
patient
treat
prior
implement
protocol
conduct
prospect
studi
thoroughli
investig
antibiot
sensit
organ
isol
blood
cultur
neutropen
patient
designmethod
hematologyoncolog
patient
least
one
posit
blood
cultur
januari
decemb
identifi
patient
demograph
neutrophil
count
antibiot
treatment
isol
organ
sensit
advers
outcom
increas
respiratori
support
hypotens
requir
intervent
icu
admiss
obtain
retrospect
chart
review
fisher
exact
test
use
compar
dichotom
variabl
patient
group
prospect
identifi
febril
neutropen
patient
posit
blood
cultur
perform
antibiot
sensit
test
sever
antibiot
commonli
use
empir
therapi
febril
neutropenia
result
retrospect
identifi
neutropen
patient
total
bacteri
isol
blood
cultur
organ
isol
test
sensit
ceftriaxon
sensit
gramposit
cultur
gramneg
cultur
ten
eec
patient
advers
outcom
versu
noneec
patient
p
notabl
eec
patient
requir
icu
admiss
versu
noneec
patient
p
thu
far
data
obtain
prospect
reveal
similar
rate
ceftriaxon
resist
cultur
sensit
ceftriaxon
ci
retrospect
studi
statist
signific
differ
seen
overal
advers
outcom
rate
two
cohort
though
icu
admiss
rate
significantli
higher
eec
patient
ceftriaxon
resist
rate
high
test
isol
support
preliminari
data
ongo
prospect
studi
given
data
eec
may
effect
improv
outcom
febril
neutropen
pediatr
hematologyoncolog
patient
background
approxim
children
diagnos
cancer
die
diseas
despit
advanc
treatment
result
two
focu
group
six
parent
met
june
parent
predominantli
femal
femal
male
lost
children
averag
year
prior
rang
year
two
parent
famili
nearli
patient
offer
palli
care
offer
hospic
die
home
home
icu
parent
discuss
uncov
six
broad
theme
benefici
provid
qualiti
optim
commun
help
systemat
support
struggl
feel
like
good
parent
struggl
loss
control
unmet
need
parent
appreci
provid
consist
reliabl
honest
parent
desir
commun
sensit
need
patient
famili
balanc
hope
realism
parent
appreci
tangibl
support
provid
social
work
emot
support
child
life
patient
sibl
parent
struggl
defin
advoc
child
qualiti
life
especi
led
disagre
medic
team
sever
parent
express
frustrat
unfamiliar
caregiv
hospit
especi
traine
express
strong
desir
anticipatori
guidanc
end
life
includ
discuss
children
also
wish
cancerspecif
support
group
bereav
parent
conclus
bereav
parent
pediatr
oncolog
patient
focu
group
appreci
consist
reliabl
provid
commun
balanc
realism
hope
appreci
tangibl
emot
support
receiv
want
anticipatori
guidanc
end
child
life
result
help
guid
clinic
care
especi
commun
without
strong
palli
care
support
research
need
develop
intervent
improv
end
life
care
background
clinic
trial
involv
human
subject
depend
inform
consent
ic
ensur
ethic
protect
particip
parent
children
cancer
often
lack
full
understand
basic
element
ic
clinic
trial
addit
stress
child
cancer
diagnosi
may
affect
decisionmak
capabl
especi
problemat
children
reli
parent
fulli
comprehend
clinic
trial
weigh
benefit
risk
physician
commun
critic
effect
familycent
care
acgm
mandat
train
program
teach
assess
traine
commun
skill
howev
current
publish
curricula
aim
train
pediatr
hematologyoncolog
fellow
deliv
ic
effect
cancer
clinic
trial
develop
pilottest
simulationbas
curriculum
enhanc
commun
skill
pediatr
hematologyoncolog
fellow
deliveri
ic
cancer
clinic
trial
develop
test
implement
curriculum
two
phase
review
literatur
simulationbas
curricula
complet
need
assess
creat
clinic
scenario
full
curriculum
use
standard
patient
use
miller
pyramid
model
fellow
assess
includ
immedi
debrief
survey
assess
prepost
confid
knowledg
basic
ic
element
know
know
summ
assess
compil
fellow
selfassess
faculti
standard
patient
show
initi
test
refin
done
fellow
implement
curriculum
fellow
likert
scale
strongli
strongli
agre
basic
p
valu
report
result
fellow
gave
high
mean
rate
train
relev
standard
patient
prepared
almost
report
use
knowledg
gain
clinic
practic
increas
selfreport
confid
prepost
note
domain
gener
describ
possibl
benefit
clinic
trial
p
risk
potenti
side
effect
p
explain
altern
p
research
discuss
purpos
clinic
trial
p
random
p
familycent
address
emot
ic
p
deliv
bad
news
p
summ
evalu
mean
rate
fellow
rang
novel
simulatedbas
ic
curriculum
significantli
increas
fellow
selfreport
confid
skill
ic
deliveri
importantli
ic
curriculum
address
researchrel
content
also
manag
parent
emot
need
ic
discuss
next
phase
includ
kirkpatrick
model
program
evalu
dissemin
across
train
program
institut
nation
kaohsiung
normal
univers
kaohsiung
taiwan
provinc
china
background
taiwan
childhood
cancer
foundat
report
surviv
rate
childhood
cancer
result
mani
childhood
cancer
survivor
back
school
treatment
howev
childhood
cancer
survivor
educ
outcom
suffer
longterm
absenc
school
late
effect
cancer
cancer
treatment
school
reentri
protocol
develop
nurs
profession
taiwan
facilit
student
return
school
remain
experiment
natur
hardli
access
parent
student
teacher
left
devic
make
individu
school
reentri
plan
object
studi
aim
examin
uncov
common
among
three
middl
school
student
success
school
reentri
experi
teacher
perspect
analyz
factor
contribut
success
designmethod
qualit
interview
studi
indepth
semistructur
interview
conduct
three
middl
school
teacher
decemb
percept
observ
experi
work
adolesc
childhood
cancer
survivor
student
two
boy
leukemia
one
girl
bone
cancer
diagnos
first
year
middl
school
year
old
return
school
third
final
year
student
met
follow
criteria
success
school
reentri
regular
school
attend
averageabov
averag
academ
perform
friendship
mainten
high
school
diploma
theme
bring
class
hospit
found
key
adolesc
success
return
school
without
prescrib
school
reentri
protocol
face
limit
bedsid
educ
servic
homeroom
teacher
link
school
home
hospit
brought
class
hospit
student
doubl
bedsid
teacher
conduct
lesson
hospit
student
home
becam
friend
parent
wit
firsthand
student
pain
triumph
treatment
brought
student
back
school
visit
celebr
deliv
classmat
wish
news
student
encourag
welcom
classmat
visit
hospit
togeth
parent
teacher
develop
flexibl
school
reentri
schedul
student
ongo
studi
demonstr
critic
role
function
homeroom
teacher
success
bring
student
back
school
andor
cancer
treatment
analysi
focus
three
homeroom
teacher
abl
carri
unexpect
task
top
alreadi
full
workload
jennif
kesselheim
shicheng
weng
victoria
allen
collabor
group
fellowship
program
director
danafarberboston
children
cancer
blood
disord
center
boston
massachusett
unit
state
background
novel
casebas
curriculum
entitl
human
profession
pediatr
hematologyoncolog
hppho
aim
foster
pho
fellow
reflect
grief
loss
compet
demand
fellowship
difficult
relationship
patient
famili
physician
wellb
burnout
small
group
facilit
session
fellow
work
identifi
cope
strategi
explor
challeng
fellowship
influenc
doctor
patient
experi
object
administ
hppho
curriculum
prospect
clusterrandom
trial
measur
whether
exposur
educ
intervent
compar
standard
condit
foster
human
profession
improv
satisfact
train
designmethod
pho
fellowship
program
n
clusterrandom
deliv
usual
train
human
profession
control
novel
curriculum
intervent
academ
year
primari
outcom
measur
pediatr
hematologyoncolog
selfassess
human
phosah
secondari
measur
includ
satisfact
scale
maslach
burnout
inventori
mbi
patientprovid
orient
scale
empower
work
scale
particip
fellow
pretest
summer
posttest
spring
chang
score
calcul
studi
instrument
compar
outcom
arm
use
mix
effect
model
adjust
pretest
score
fix
effect
site
random
effect
result
random
yield
intervent
control
fellow
two
arm
significantli
differ
distribut
fellow
age
gender
postgradu
year
intervent
site
success
administ
modul
chang
score
phosah
significantli
differ
control
intervent
arm
adjust
mean
differ
confid
interv
ci
p
compar
control
arm
fellow
expos
curriculum
gave
significantli
higher
rate
sever
item
within
satisfact
scale
includ
satisfact
train
physician
burnout
adjust
mean
differ
ci
p
physician
depress
adjust
mean
differ
ci
p
balanc
profession
duti
person
life
adjust
mean
differ
ci
p
human
overal
adjust
mean
differ
ci
p
chang
score
secondari
measur
significantli
differ
studi
arm
conclus
exposur
hppho
curriculum
alter
fellow
selfassess
human
profession
howev
curriculum
prove
feasibl
administ
intervent
fellow
express
higher
level
satisfact
human
train
indic
curriculum
posit
impact
fellow
learn
environ
background
recent
work
document
signific
level
unmet
need
among
adolesc
young
adult
cancer
particularli
psychosoci
challeng
transit
adulthood
eg
abrupt
disrupt
school
social
life
social
isol
given
adolesc
young
adult
drive
mobil
app
use
mobilephon
may
ideal
way
deliv
psychosoci
intervent
adolesc
young
adult
cancer
use
patientcent
approach
inform
mobilebas
mind
social
support
intervent
adolesc
young
adult
patient
cancer
designmethod
particip
ten
aya
sarcoma
femal
adolesc
parent
five
adolesc
six
healthcar
provid
n
form
research
involv
three
step
indepth
interview
conduct
ten
aya
sarcoma
parent
five
adolesc
six
healthcar
provid
n
adapt
made
exist
mind
app
offer
program
youth
modif
includ
creat
mind
resili
ill
program
relax
exercis
addit
video
featur
two
sarcoma
survivor
program
host
content
inform
mind
curriculum
adolesc
learn
breath
privat
facebook
usabl
group
organ
elicit
belief
mind
app
potenti
futur
enhanc
ii
promot
social
support
result
indepth
interview
reveal
theme
around
adolesc
function
cope
includ
bodi
imag
concern
recurrencerel
anxieti
anger
loss
overwhelm
medic
inform
theme
interview
incorpor
demonstr
version
mobil
app
patientcent
approach
wide
recommend
develop
mobilebas
health
behavior
chang
intervent
may
use
way
inform
develop
mobilebas
mind
social
support
intervent
adolesc
young
adult
cancer
background
medic
traine
consist
report
suboptim
instruct
poor
selfconfid
commun
skill
despit
deficit
train
program
provid
comprehens
pediatricspecif
commun
educ
particularli
provis
bad
news
indepth
survey
examin
histor
experi
commun
need
pediatr
fellow
conduct
larg
academ
pediatr
center
first
step
toward
develop
comprehens
commun
curriculum
determin
previou
educ
clinic
experi
pediatr
subspecialti
fellow
assess
level
comfort
context
variou
commun
topic
queri
potenti
modal
topic
futur
commun
train
designmethod
need
assess
survey
develop
use
previous
develop
valid
question
review
literatur
survey
review
intern
extern
pediatr
oncolog
palli
expert
pretest
subset
traine
enhanc
content
valid
result
thirtytwo
total
fellow
complet
survey
complet
rate
pediatr
hematologyoncolog
subspecialti
fellow
fellow
particip
previou
teach
session
includ
involv
role
play
simul
howev
fellow
receiv
feedback
senior
clinician
commun
skill
fellow
receiv
feedback
scale
indic
well
prepar
mean
score
commun
item
fellow
felt
least
prepar
lead
discuss
around
inform
consent
experiment
therapi
end
life
care
autopsi
fellow
indic
didact
educ
session
addit
coursework
less
use
strategi
improv
commun
skill
wherea
small
group
role
play
session
faculti
andor
bereav
parent
educ
use
fellow
overal
commun
prepared
score
correl
postgradu
year
posit
associ
number
time
previous
deliv
bad
news
patient
famili
fellow
request
addit
train
mani
topic
greatest
interest
learn
skill
optim
commun
angri
patient
famili
addit
topic
request
includ
place
limit
resuscit
withdrawingwithhold
therapi
ageappropri
inclus
patient
difficult
discuss
despit
selfreport
prior
commun
skill
train
pediatr
subspecialti
fellow
felt
underprepar
particip
difficult
discuss
patient
famili
learner
identifi
roleplay
coach
realtim
feedback
physician
bereav
parent
use
train
strategi
compar
didact
session
background
children
die
cancer
parent
must
adjust
child
absenc
amidst
linger
turmoil
preced
death
wit
child
undergo
pain
treatment
make
difficult
decis
anticip
devast
loss
hope
recoveri
adjust
child
death
depict
current
bereav
literatur
necessit
make
mean
one
loss
profession
care
staff
help
parent
make
sens
child
ill
turn
parent
experi
treatment
howev
extent
relationship
profession
care
team
member
influenc
parent
abil
make
sens
success
cope
loss
examin
object
examin
bereav
parent
interact
deceas
child
pediatr
oncolog
profession
care
team
impact
grief
symptom
designmethod
better
understand
interact
profession
care
staff
relat
parent
grief
outcom
conduct
mixedmethod
studi
examin
staff
impact
parent
grief
thirti
particip
whose
children
die
cancer
one
three
year
ago
complet
indepth
interview
psychometr
valid
survey
measur
meaningmak
depress
grief
symptom
result
correl
analys
measur
found
increas
mean
make
associ
lower
depress
grief
symptom
content
analysi
interview
found
mani
particip
regard
staff
like
famili
ongo
relationship
staff
child
die
describ
variou
way
staff
interact
treatment
child
death
help
make
sens
loss
particular
particip
describ
interact
staff
help
find
benefit
loss
learn
creat
new
relationship
child
despit
physic
absenc
quantifi
interview
data
statist
analyz
along
measur
found
particip
increas
frequenc
describ
staff
posit
impact
grief
correl
higher
meaningmak
score
lower
grief
symptom
score
studi
found
bereav
parent
lost
children
cancer
articul
share
experi
staff
engag
commun
treatment
offer
numer
exampl
staff
aid
make
mean
loss
reliabl
associ
subsequ
grief
hope
result
mix
method
research
encourag
studi
import
staff
interact
famili
critic
period
children
care
last
impact
regardless
treatment
outcom
memori
sloan
ketter
cancer
center
new
york
new
york
unit
state
background
although
resili
recogn
necessari
healthcar
profession
traine
feel
unprepar
emot
challeng
inher
care
sick
die
patient
compound
long
hour
challeng
work
environ
lack
formal
train
handl
emot
difficult
situat
mani
institut
recogn
need
intervent
reduc
traine
distress
goal
fellowl
qualiti
improv
initi
determin
whether
need
emot
support
amongst
pediatr
hematolog
oncolog
fellow
provid
formal
resili
debrief
session
measur
feasibl
accept
effect
implement
curriculum
designmethod
anonym
survey
determin
need
resili
debrief
session
follow
traumat
event
distribut
activ
pediatr
hematolog
oncolog
fellow
memori
sloan
ketter
cancer
center
januari
need
establish
intervent
consist
formal
curriculum
develop
initi
june
involv
schedul
ad
hoc
debrief
session
respons
traumat
event
includ
patient
death
code
interperson
conflict
endoflif
care
led
psychiatrist
social
worker
fellow
pediatr
oncologist
mentor
attend
resili
didact
curriculum
led
palli
medicin
specialist
focus
skill
contest
cognit
distort
mind
effect
session
measur
use
followup
anonym
survey
month
current
underway
month
postiniti
intervent
initi
survey
demonstr
traine
present
death
train
less
half
respond
attend
postev
debrief
session
respond
felt
suffici
emot
support
institut
physician
care
die
patient
separ
preintervent
survey
found
respond
express
need
regular
debrief
nearli
anticip
would
benefit
debrief
concern
identifi
traine
would
preclud
particip
curriculum
includ
prefer
deal
emot
situat
privat
time
constraint
traine
identifi
need
formal
debrief
resili
skill
develop
program
easili
implement
feasibl
accept
good
attend
feedback
receiv
mark
determin
deficit
possibl
improv
curriculum
survey
measur
effect
program
whether
continu
background
acut
kidney
injuri
aki
common
underrecogn
complic
among
patient
leukemia
associ
prolong
hospit
stay
increas
mortal
progress
chronic
kidney
diseas
delay
chang
cancer
therapi
may
affect
patient
prognosi
howev
data
aki
pediatr
patient
cancer
still
lack
overal
investig
incid
aki
patient
newli
diagnos
center
januari
septemb
perform
retrospect
chart
review
patient
newli
diagnos
neonat
year
facil
determin
incid
aki
popul
use
kidney
diseas
improv
global
outcom
kdigo
diagnost
criteria
also
assess
nephrotox
exposur
nci
risk
stratif
risk
aki
tumor
lysi
syndrom
tl
identifi
patient
diagnos
studi
period
met
inclus
criteria
median
followup
time
month
rang
cohort
predominantli
male
hispan
analysi
show
aki
kdigo
criteria
grade
grade
grade
aki
present
multipl
aki
episod
studi
period
older
age
longer
length
hospit
associ
aki
p
p
respect
associ
aki
nci
risk
classif
contrast
exposur
hyponatremia
elev
white
blood
cell
count
uric
acid
level
antimicrobi
therapi
diuret
use
studi
conclus
aki
common
find
studi
popul
major
grade
aki
kdigo
criteria
howev
aki
associ
older
age
longer
length
stay
studi
need
determin
shortand
longterm
impact
aki
pediatr
patient
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
region
avail
train
pediatr
oncologist
limit
barrier
care
children
cancer
unidad
nacion
de
unop
universidad
francisco
school
medicin
guatemala
establish
pediatr
hematologyoncolog
fellowship
program
sponsor
st
jude
children
research
hospit
provid
central
america
caribbean
welltrain
specialist
systemat
analysi
impact
fellowship
program
pediatr
oncolog
never
done
especi
context
region
educ
program
object
studi
sought
analyz
impact
unop
fellowship
program
base
region
number
provid
pediatr
cancer
center
patient
volum
addit
sought
character
job
scientif
output
graduat
impact
evalu
context
cost
analysi
defin
volum
provid
pediatr
cancer
center
patient
director
pediatr
cancer
center
central
america
sent
onlin
survey
obtain
data
center
contact
maintain
updat
hospitalbas
patient
registri
addit
graduat
fellowship
program
also
sent
onlin
survey
ask
job
graduat
current
role
scientif
product
cost
analysi
includ
assess
direct
cost
includ
salari
stipend
away
rotat
well
indirect
cost
faculti
time
spent
teach
sinc
establish
unop
fellowship
program
region
provid
pediatr
cancer
p
center
treat
larger
volum
patient
p
two
new
center
open
graduat
program
one
graduat
practic
pediatr
oncolog
major
countri
origin
graduat
practic
outsid
region
almost
half
graduat
hold
leadership
role
institut
major
time
spent
public
sector
major
graduat
particip
clinic
research
particip
creation
implement
therapeut
protocol
averag
graduat
publish
peerreview
articl
sinc
complet
train
unop
fellowship
program
favor
impact
pediatr
cancer
care
region
contribut
capac
treat
larger
volum
patient
graduat
practic
pediatr
oncolog
region
public
sector
frequent
hold
leadership
role
scientif
product
background
abandon
treatment
major
caus
treatment
failur
poor
surviv
children
cancer
lowand
middleincom
countri
incid
abandon
peru
report
object
aim
studi
examin
preval
associ
factor
treatment
abandon
pediatr
patient
cancer
peru
retrospect
review
sociodemograph
clinic
data
children
refer
januari
decemb
two
main
tertiari
center
childhood
cancer
locat
lima
peru
definit
treatment
abandon
use
siop
intern
societi
paediatr
oncolog
podc
paediatr
oncolog
develop
countri
abandon
treatment
work
group
recommend
result
data
children
diagnos
malign
solid
tumor
lymphoma
analyz
abandon
treatment
univari
logist
regress
analysi
show
signific
higher
abandon
rate
children
live
outsid
capit
citi
lima
p
prolong
travel
time
tertiari
center
hour
p
live
rural
set
p
lack
parent
formal
job
p
accord
cancer
diagnosi
children
retinoblastoma
like
abandon
compar
solid
tumor
multivari
regress
analys
rural
origin
lack
formal
parent
employ
independ
predict
abandon
conclus
treatment
abandon
preval
countri
high
close
relat
sociodemograph
factor
treatment
outcom
could
substanti
improv
strategi
help
prevent
abandon
therapi
base
result
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
improv
qualiti
pediatr
hematologyoncolog
fellowship
program
systemat
assess
must
perform
evalu
current
state
identifi
area
opportun
well
modif
time
unfortun
wide
agreedupon
metric
qualiti
pediatr
hematologyoncolog
fellowship
program
current
exist
particularli
import
field
due
global
shortag
specialist
reason
assess
instrument
applic
throughout
world
must
creat
object
st
jude
global
educ
program
assess
tool
epat
novel
instrument
seek
evalu
pediatr
hematologyoncolog
fellowship
program
around
world
systemat
object
way
epat
help
determin
key
perform
index
relev
qualiti
educ
pediatr
hematologyoncolog
fellowship
program
establish
framework
improv
designmethod
firstli
key
domain
evalu
program
assess
identifi
priori
base
continuum
pediatr
hematologyoncolog
fellowship
program
context
geographi
educ
structur
subsequ
question
formul
evalu
key
domain
seek
assess
element
involv
ensur
compet
clinic
practic
academ
product
region
impact
due
novelti
tool
lack
defin
metric
qualiti
epat
reli
expert
opinion
twostep
process
intern
depart
global
pediatr
medicin
st
jude
children
research
hospit
subsequ
panel
expert
global
pediatr
oncolog
medic
educ
around
world
ten
key
domain
identifi
evalu
aspect
relev
train
program
around
world
regardless
educ
geograph
context
question
creat
assess
domain
make
epat
quantit
assign
weight
valu
reflect
rel
import
grade
system
allow
score
key
domain
permit
monitor
chang
time
epat
current
stage
extern
expert
review
subsequ
pilot
five
fellowship
program
around
world
provid
differ
geograph
patient
care
context
valid
epat
final
distribut
pediatr
hematologyoncolog
fellowship
program
around
world
appli
epat
propos
novel
strategi
assess
train
program
systemat
way
includ
aspect
relev
train
program
global
context
tool
help
guid
improv
pediatr
hematologyoncolog
fellowship
program
assur
welltrain
workforc
background
improv
pediatr
oncolog
patient
surviv
outcom
past
sever
decad
monitor
recurr
longterm
effect
therapi
becom
even
import
util
person
treatment
summari
survivorship
care
plan
scp
one
way
commun
inform
patient
famili
american
colleg
surgeon
commiss
cancer
coc
creat
standard
regard
provis
scp
elig
patient
decemb
metric
accredit
cancer
center
standard
appli
patient
stage
ii
iii
cancer
diagnos
requir
creation
scp
within
one
year
diagnosi
six
month
complet
treatment
implement
pediatr
cancer
center
identifi
barrier
use
guidelin
childhood
cancer
set
object
defin
elig
scp
pediatr
oncolog
patient
includ
patient
cur
intent
deliv
scp
within
six
month
finish
therapi
designmethod
use
chart
review
cancer
center
registri
queri
identifi
childhood
cancer
patient
potenti
elig
scp
collect
stage
goal
therapi
date
treatment
patient
cur
intent
deem
elig
scp
regardless
stage
iiv
patient
follow
oncolog
clinic
posttreat
surveil
care
includ
even
receiv
scp
survivorship
program
greater
six
month
therapi
time
implement
expect
pediatr
oncolog
popul
acut
lymphoblast
leukemia
common
diagnosi
compris
patient
stratifi
risk
group
instead
surgic
stage
categori
treatment
durat
greater
one
year
unlik
mani
adultonset
malign
differ
requir
interpret
guidelin
appli
pediatr
popul
pediatr
diagnos
nonsurg
base
stage
pediatr
oncolog
clinic
date
provid
scp
elig
patient
adapt
guidelin
focu
patient
cur
intent
receiv
scp
six
month
therapi
cancer
stage
guidelin
goal
cur
intent
well
length
treatment
vari
pediatr
adult
popul
coc
guidelin
requir
adapt
optim
applic
pediatr
oncolog
popul
background
educ
commun
fellow
field
requir
difficult
discuss
famili
natur
adult
learn
pedagogi
role
play
underutil
medic
educ
shown
effect
tradit
teach
method
lectur
cours
fellow
hematologyoncolog
hospic
palli
medicin
radiat
oncolog
pediatr
hematologyoncolog
implement
januaryfebruari
fellow
particip
program
topic
cover
includ
fundament
commun
cope
spiritu
deliveri
bad
news
commun
famili
sexual
dysfunct
treatment
palli
caredeath
die
burnout
object
overal
goal
cours
foster
holist
physician
view
patient
peopl
cancer
cancer
patient
physician
commun
effect
patient
throughout
diseas
continuum
end
cours
learner
abl
practic
fundament
principl
good
commun
designmethod
fellow
initi
particip
precours
osc
establish
baselin
skill
osc
facilit
center
learn
innov
northwel
includ
actor
portray
pediatr
patient
famili
member
fellow
break
bad
news
two
month
later
cours
carri
span
eight
week
includ
didact
session
follow
minut
role
play
scenario
five
eight
modul
includ
role
play
faculti
member
serv
simul
patient
cours
second
break
bad
news
osc
held
osc
film
feedback
given
onsit
actor
addit
faculti
member
given
access
video
onlin
format
given
evalu
tool
assess
fellow
perform
preand
postintervent
fellow
given
subject
survey
preand
postcours
well
result
subject
data
particip
show
notic
increas
comfort
level
area
preand
postcours
survey
data
obtain
osc
video
show
improv
commun
skill
assess
sp
faculti
member
use
new
evalu
tool
develop
faculti
initi
firstrun
data
show
cours
success
improv
commun
skill
well
increas
fellow
comfort
level
across
sever
domain
commun
futur
direct
cours
includ
improv
valid
assess
tool
expand
topic
base
includ
aya
pediatr
scenario
faculti
develop
improv
role
play
investig
impact
practic
cours
complet
background
acut
lymphoblast
leukemia
common
form
childhood
cancer
approxim
children
diagnos
year
surviv
rate
improv
significantli
past
sever
year
children
risk
develop
musculoskelet
complic
complet
treatment
contribut
impair
activ
elev
bodi
mass
index
bmi
risk
complic
intervent
involv
physic
activ
could
improv
musculoskelet
strength
well
overal
health
children
aim
studi
examin
feasibl
direct
physic
activ
program
children
newli
diagnos
initi
intens
phase
therapi
evalu
overal
health
qualiti
life
children
particip
direct
physic
activ
program
designmethod
subject
receiv
educ
materi
import
safeti
physic
activ
nutrit
handout
subject
also
particip
direct
physic
activ
program
supervis
train
physic
therapist
least
minut
everi
week
week
program
entail
four
station
includ
cardiovascular
balancepropriocept
strength
flexibl
coordin
cardio
feasibl
assess
track
particip
rate
throughout
studi
period
assess
made
studi
entri
end
week
physic
activ
initi
month
complet
intervent
assess
includ
overal
strength
flexibl
weight
height
bmi
blood
pressur
perform
score
descript
statist
use
studi
result
total
patient
male
femal
enrol
studi
month
period
patient
age
rang
year
half
patient
enrol
complet
week
program
patient
stabil
improv
physic
function
score
data
collect
analysi
ongo
patient
earli
intens
phase
therapi
risk
complic
affect
physic
function
direct
physic
activ
protocol
may
improv
overal
physic
function
patient
may
need
specif
physic
therapi
howev
direct
physic
activ
program
appear
benefici
patient
main
roadblock
success
complet
program
difficulti
schedul
strain
parent
patient
treatment
unplan
admiss
fever
well
nausea
fatigu
time
visit
albani
medic
center
albani
new
york
unit
state
background
commun
skill
core
compet
highlight
acgm
increas
resid
confid
deliv
difficult
news
shown
lead
effect
commun
current
major
resid
program
lack
formal
train
commun
skill
object
demonstr
feasibl
efficaci
integr
standardizedpati
base
train
program
commun
skill
curriculum
pediatr
resid
designmethod
date
pediatr
medicinepediatr
resid
particip
program
intern
year
program
consist
three
twohour
long
session
resid
given
sever
opportun
act
case
scenario
standard
patient
scenario
includ
inform
parent
child
new
cancer
diagnosi
disclosur
posit
hiv
test
teenag
resid
receiv
post
hoc
peer
peer
preceptor
learner
feedback
pre
postprogram
survey
complet
resid
result
follow
cours
complet
resid
report
increas
confid
multipl
area
commun
includ
give
difficult
diagnosi
p
discuss
poor
prognosi
p
respond
differ
patientfamili
member
emot
respons
ie
cri
anger
p
organ
vital
inform
relay
p
conclus
commun
skill
train
pediatr
resid
feasibl
provid
platform
develop
valuabl
skill
taught
elsewher
within
curriculum
background
children
cancer
transit
back
school
treatment
challeng
literatur
support
need
school
reentri
program
eas
transit
howev
program
vari
wide
among
pediatr
cancer
institut
littl
data
address
program
compon
data
studi
provid
inform
current
school
reentri
program
across
institut
object
one
object
studi
assess
correl
presenc
school
reentri
program
factor
geograph
locat
institut
size
second
object
establish
list
differ
institut
school
reentri
program
compon
final
aim
describ
current
school
reentri
practic
well
program
benefit
perceiv
area
improv
state
membership
children
oncolog
group
offer
enrol
studi
member
institut
invit
particip
survey
establish
research
team
person
close
associ
institut
school
reentri
practic
interview
queri
institut
demograph
well
program
compon
eg
particip
target
audienc
resourc
comment
also
collect
program
benefit
potenti
improv
analysi
transcript
perform
use
pearson
correl
assess
relationship
institut
size
geograph
locat
program
presenc
ground
theori
use
analysi
benefit
improv
result
thirtynin
fortyon
pediatr
institut
offer
enrol
particip
studi
twentynin
institut
indic
presenc
school
reentri
program
ten
state
none
correl
found
institut
size
presenc
school
reentri
program
p
ns
also
correl
found
institut
locat
presenc
school
reentri
program
p
ns
major
theme
surround
benefit
program
includ
educ
return
student
peer
program
perceiv
improv
includ
increas
staf
abil
offer
servic
result
support
hypothesi
presenc
school
reentri
program
influenc
size
geograph
locat
treat
institut
howev
data
seem
suggest
avail
staf
may
influenc
presenc
program
futur
studi
need
address
potenti
influenc
well
take
evidencebas
approach
determin
effect
intervent
present
program
cohen
children
medic
center
zucker
school
medicin
hofstranorthwel
new
hyde
park
new
york
unit
state
background
geneticsgenom
evolv
extrem
rapid
pace
current
advanc
lead
individu
algorithm
toward
diseas
treatment
diseas
multipl
branch
point
fellow
learn
fraction
knowledg
formal
approach
teach
critic
analysi
inform
applic
algorithm
toward
diseas
addit
knowledg
evolv
extrem
rapidli
approach
must
teach
selfacquisit
applic
evolv
discoveri
object
creat
implement
evalu
novel
curriculum
geneticsgenom
target
toward
pediatr
hematologyoncolog
fellow
designmethod
curriculum
includ
four
compon
genet
genom
medic
knowledg
one
initi
teambas
learn
session
weekli
onlin
multipl
choic
question
essenti
pathway
teach
molecular
pathway
common
oncogenesi
relev
target
therapi
microteach
session
use
auditori
visual
tactil
learn
knowledg
acquisit
clinic
judgment
allow
learner
gain
experi
research
data
avail
develop
priorit
potenti
treatment
plan
use
problembas
learn
session
stage
patient
research
treatment
option
priorit
present
find
synthesi
demonstr
independ
abil
research
recommend
therapi
independ
project
learner
given
case
present
case
research
find
geneticsgenom
molecular
pathway
make
recommend
therapi
molecular
tumor
board
faculti
fellow
evalu
plan
recruit
institut
match
size
program
implement
half
evalu
year
fellow
group
mcq
exam
satisfact
survey
creation
multimodul
adultlearn
base
curriculum
genet
genom
pediatr
oncolog
feasibl
implement
evalu
necessari
demonstr
efficaci
background
neuroblastoma
common
extracrani
solid
tumor
children
chimer
antibodi
dinutuximab
therapi
improv
surviv
children
newli
diagnos
highrisk
neuroblastoma
patient
well
time
first
relapseprogress
acut
neuropath
pain
welldocu
side
effect
dinutuximab
administr
howev
addit
advers
effect
includ
sensorimotor
neuropathi
ocular
symptom
behavior
chang
describ
incid
sever
effect
current
welldocu
pediatr
patient
improv
long
term
surviv
patient
receiv
modal
import
look
potenti
late
effect
dinutuximab
object
determin
incid
sever
neurolog
ophthalmolog
behavior
chang
dinutuximab
administr
institut
perform
retrospect
chart
review
use
electron
medic
record
includ
patient
highrisk
neuroblastoma
age
year
institut
diagnos
receiv
dinutuximab
patient
histori
opsoclonusmyoclonu
syndrom
gross
sensorimotor
neuropathi
prior
receiv
dinutuximab
exclud
examin
clinic
document
subject
report
object
exam
find
neurolog
ophthalmolog
behavior
chang
also
look
referr
made
neurolog
ophthalmolog
physic
medicin
rehabilit
pm
r
psycholog
twentytwo
patient
met
inclus
criteria
time
chart
review
patient
aliv
deceas
eighteen
patient
receiv
dinutuximab
per
patient
receiv
dinutuximab
per
patient
patient
report
symptom
interest
report
multipl
symptom
six
patient
report
symptom
began
least
month
complet
dinutuximab
nine
patient
object
find
exam
includ
decreas
deep
tendon
reflex
abnorm
pupil
nearsighted
patient
referr
made
ophthalmolog
pm
r
neuropsycholog
test
neurolog
two
patient
report
symptom
interest
refer
specialist
conclus
neurolog
ophthalmolog
behavior
symptom
commonli
report
demonstr
exam
among
pediatr
patient
highrisk
neuroblastoma
receiv
dinutuximab
import
identifi
effect
appropri
specialist
referr
place
adequ
manag
chang
recogn
symptom
may
sole
due
dinutuximab
patient
receiv
agent
includ
opioid
prospect
trial
need
evalu
longterm
effect
dinutuximab
determin
best
screen
effect
akron
children
hospit
akron
ohio
unit
state
background
pediatr
cancer
lead
caus
diseaserel
death
children
unit
state
us
fifteen
thousand
children
diagnos
cancer
us
popul
high
risk
malnutrit
due
multimod
therapi
receiv
surgeri
chemotherapi
radiat
therapi
antibodi
therapi
andor
bone
marrow
transplant
advers
effect
therapi
includ
tast
chang
loss
appetit
diarrhea
vomit
andor
mucos
make
difficult
children
abl
consum
adequ
amount
nutrit
therapi
gold
standard
measur
tool
identifi
patient
risk
malnutrit
nutrit
statu
frequent
evalu
compon
clinic
trial
assess
anthropometr
measur
weight
height
zscore
diagnosi
well
durat
treatment
assist
earli
identif
malnutrit
incid
preval
malnutrit
popul
unknown
akron
children
hospit
purpos
studi
describ
nutrit
statu
provis
nutrit
support
therapi
pediatr
patient
first
year
post
new
oncolog
diagnosi
object
identifi
incid
preval
malnutrit
across
oncolog
diagnost
categori
first
twelv
month
post
diagnosi
perform
retrospect
record
review
patient
newli
diagnos
cancer
akron
children
hospit
demograph
anthropometr
data
collect
time
diagnosi
nutrit
statu
categor
z
score
anthropometr
nutrit
support
data
collect
everi
two
month
first
year
diagnosi
along
incid
unplan
inpati
admiss
result
total
patient
includ
analysi
malnourish
time
diagnosi
develop
malnutrit
first
year
patient
solid
tumor
repres
patient
preexist
acquir
malnutrit
overal
patient
receiv
least
one
nutrit
support
modal
patient
preexist
acquir
malnutrit
nonsignific
increas
unplan
admiss
p
studi
demonstr
patient
solid
tumor
found
increas
risk
preexist
acquir
malnutrit
follow
leukemia
experienc
higher
incid
unplan
admiss
time
period
observ
prospect
multicent
replic
studi
includ
detail
collect
nutrit
therapi
recommend
guid
develop
diagnosi
specif
nutrit
support
guidelin
background
pediatr
young
adult
oncolog
patient
treat
intens
chemotherapi
high
incid
transfusion
iron
overload
iron
deposit
lead
heart
failurearrhythmia
liver
abnorm
endocrin
dysfunct
ineffect
erythropoiesi
increas
cancer
mortal
risk
howev
pauciti
data
regard
recommend
manag
transfusion
iron
overload
cancer
survivor
consequ
longterm
complic
transfusion
iron
overload
specif
patient
assess
object
assess
screen
phlebotomybas
treatment
algorithm
popul
designmethod
retrospect
chart
review
pediatr
young
adult
complet
oncolog
manag
iron
overload
initi
phlebotomi
treatment
conduct
tier
screen
occur
patient
receiv
least
pack
red
blood
cell
prbc
transfus
patient
recommend
evalu
possibl
phlebotomi
liver
iron
concentr
lic
mg
irongram
dri
weight
liver
tissu
ferriscan
andor
cardiac
mri
ms
phlebotomi
iron
statu
assess
quarterli
phlebotomi
discontinu
lic
normal
ferritinimag
lic
verif
descript
statist
employ
report
characterist
studi
popul
spearman
correl
util
describ
associ
transfus
lic
ferritin
iron
satur
number
phlebotomi
session
result
twenti
five
survivor
underw
phlebotomi
mean
age
year
sd
femal
oncolog
diagnos
aml
nhl
ewe
sarcoma
osteosarcoma
neuroblastoma
cn
patient
receiv
median
iqr
transfus
median
number
phlebotomi
session
iqr
year
iqr
prior
phlebotomi
median
lic
mgg
iqr
ferritin
ngml
iqr
patient
demonstr
abnorm
cardiac
mri
n
patient
complet
phlebotomi
one
discontinu
due
poor
vascular
access
patient
develop
iron
defici
lic
reduc
median
mgg
iqr
ferritin
ngml
correl
number
transfus
phlebotomi
session
poor
conclus
manag
guidelin
lack
transfusion
iron
overload
pediatr
young
adult
survivor
cancer
demonstr
phlebotomi
algorithm
effect
toler
correl
number
transfus
receiv
phlebotomi
treatment
poor
necessit
serial
assess
use
manag
algorithm
prospect
studi
evalu
effect
iron
remov
iron
overload
complic
patient
popul
penn
state
children
hospit
hershey
pennsylvania
unit
state
background
cancer
therapi
lead
impair
immun
system
take
time
recov
import
ensur
survivor
adequ
immun
prevent
common
yet
potenti
sever
childhood
ill
valid
guidelin
current
exist
surveil
test
reimmun
popul
retrospect
analysi
involv
small
cohort
pediatr
cancer
patient
treat
penn
state
children
hospit
show
patient
screen
varicella
immun
therapi
complet
adequ
diseas
titer
determin
proport
pediatr
cancer
survivor
lost
humor
immun
previous
receiv
vaccin
determin
rate
respons
singl
dose
booster
full
vaccin
seri
seroneg
subject
one
booster
designmethod
pediatr
cancer
survivor
treat
children
hospit
least
month
complet
cancer
therapi
prospect
test
antibodi
level
hepat
b
tetanu
varicella
measl
strain
pneumococcu
sampl
analyz
cdc
measl
varicella
avid
seroneg
subject
commerci
studi
elig
receiv
booster
vaccin
titer
recheck
least
week
booster
reevalu
immun
still
seroneg
subject
receiv
entir
vaccin
seri
titer
final
test
least
week
final
dose
vaccin
seri
immun
analyz
therapi
booster
vaccin
seri
result
pediatr
cancer
survivor
complet
therapi
nonimmun
hepat
b
nonimmun
pneumococc
strain
test
nonimmun
measl
nonimmun
varicella
nonimmun
tetanu
subject
receiv
mmr
vaccin
therapi
prior
studi
enrol
protect
antibodi
measl
subject
receiv
varicella
vaccin
end
therapi
prior
studi
enrol
maintain
protect
antibodi
level
cdc
result
measl
varicella
pend
well
repeat
studi
vaccin
booster
seri
conclus
signific
percentag
pediatr
cancer
survivor
retain
immun
hepat
b
pneumococcu
measl
varicella
one
booster
high
percentag
subject
develop
protect
immun
varicella
subject
immun
tetanu
consist
high
immunogen
tetanu
toxoid
formal
guidelin
need
protect
popul
vaccineprevent
ill
posttherapi
children
hospit
richmond
virginia
commonwealth
univers
health
system
richmond
virginia
unit
state
background
childhood
cancer
survivor
risk
overweight
diet
physic
exercis
import
maintain
healthi
lifestyl
weight
howev
report
cancer
survivor
less
activ
peer
one
reason
may
clearli
establish
riskbas
exercis
recommend
cancer
survivor
anoth
reason
may
provid
tend
focu
recommend
exercis
toward
patient
overweight
object
describ
chang
physic
fit
childhood
cancer
survivor
exercis
designmethod
move
forward
well
physic
fit
program
center
care
beyond
cure
chor
offer
partnership
ask
childhood
cancer
foundat
ymca
program
avail
childhood
cancer
survivor
age
seen
center
survivor
defin
fit
well
goal
work
trainer
week
least
min
session
throughout
year
achiev
goal
baselin
ongo
measur
core
strength
endur
overal
strength
balanc
collect
averag
paramet
particip
compar
begin
end
program
year
increas
endur
measur
averag
mile
walk
minut
increas
core
strength
measur
averag
number
situp
sec
increas
overal
strength
measur
averag
weight
lift
leg
press
averag
weight
lift
chest
press
increas
balanc
measur
averag
number
second
balanc
singl
leg
addit
child
actual
gain
weight
process
approxim
increas
averag
weight
children
benefit
regular
exercis
beyond
weight
control
improv
physic
fit
seen
even
without
weight
loss
regular
physic
exercis
result
improv
physic
fit
univers
advoc
patient
determin
insulin
resist
measur
chang
fatigu
well
percept
follow
exercis
futur
direct
intend
explor
danafarb
cancer
institut
boston
massachusett
unit
state
background
improv
adolesc
young
adult
cancer
patient
aya
surviv
rate
qualiti
life
outcom
lag
behind
children
older
adult
highlight
need
research
target
uniqu
popul
current
literatur
support
valu
strong
ayaclinician
commun
notabl
facilit
therapeut
allianc
howev
littl
known
aya
commun
prioriti
cancer
care
barrier
optim
ayaclinician
commun
object
explor
aya
oncolog
clinician
commun
prioriti
identifi
barrier
facilit
ayaoncolog
clinician
commun
designmethod
semistructur
interview
held
aya
cancer
patient
survivor
age
year
singl
larg
academ
institut
oncolog
clinician
physician
nurs
practition
academ
institut
northeastern
unit
state
interview
conduct
english
phone
person
interview
audiorecord
transcrib
verbatim
analys
aid
softwar
aya
identifi
wide
rang
topic
import
discuss
clinician
frequent
identifi
topic
side
effect
treatment
emphasi
physic
appear
function
n
social
issu
includ
friendship
famili
school
n
look
ahead
futur
n
sexual
reproduct
health
includ
futur
fertil
contracept
romant
relationship
n
clinician
priorit
cancer
treatment
side
effect
n
emot
psycholog
health
n
sexual
reproduct
health
focu
fertil
risk
fertil
preserv
n
aya
report
facilit
good
commun
includ
open
longestablish
relationship
clinician
n
clinician
engag
ageappropri
patientdirect
convers
n
barrier
includ
parent
presenc
visit
n
clinician
report
barrier
includ
clinician
discomfort
feel
wellequip
discuss
psychosoci
topic
sexual
health
spiritu
relationship
peer
n
presenc
parentsfamili
n
perceiv
patient
discomfort
discuss
specif
topic
sexual
health
n
clinician
acknowledg
need
collabor
effort
addit
team
member
ie
nurs
psychosoci
provid
assist
meet
aya
commun
need
conclus
aya
clinicianreport
commun
prioriti
larg
align
howev
aya
emphas
topic
social
function
appear
sexual
health
highli
priorit
clinician
may
result
gap
care
aya
treatment
survivorship
data
identifi
opportun
intervent
includ
clinician
educ
patient
famili
educ
clinicbas
intervent
systemsbas
chang
develop
test
background
primari
care
physician
pcp
cite
lack
knowledg
inadequ
commun
oncolog
team
major
barrier
provid
recommend
surveil
late
effect
treatment
childhood
cancer
survivor
standard
telephon
handoff
pcp
posttherapi
potenti
strategi
increas
survivorship
care
pcp
interact
commun
determin
feasibl
structur
telephon
commun
use
situat
background
assess
recommend
sbar
commun
tool
deliv
train
oncolog
nurs
increas
pcp
knowledg
willing
provid
survivorship
care
designmethod
regist
nurs
expert
childhood
cancer
survivorship
attempt
contact
telephon
pcp
recent
patient
attend
yale
childhood
cancer
survivorship
clinic
year
old
englishspeak
year
posttreat
pcp
previous
sent
individu
survivorship
care
plan
scp
list
patient
previou
treatment
histori
recommend
surveil
test
upon
success
contact
confirm
receipt
scp
nurs
explain
definit
late
effect
descript
patient
diagnosi
treatment
histori
associ
potenti
late
complic
schedul
recommend
surveil
test
pcp
also
ask
hisher
abil
willing
provid
need
surveil
late
effect
futur
overal
pcp
success
contact
median
phone
call
rang
last
median
minut
rang
median
busi
day
rang
pcp
end
call
midconvers
pcp
recept
express
appreci
call
twentyf
pcp
express
understand
materi
discuss
endors
belief
abil
willing
provid
late
effect
surveil
patient
pcp
question
discuss
patient
care
nurs
versu
physician
interact
structur
commun
nurs
pcp
telephon
feasibl
associ
highlevel
pcp
confid
provid
survivorship
care
background
childhood
cancer
cc
admiss
account
nonnewborn
pediatr
hospit
hospit
longer
expens
hospit
admiss
payer
medicaid
commerci
reflect
health
polici
sociodemograph
statu
object
studi
determin
length
stay
lo
cost
cc
admiss
differ
payer
use
kid
inpati
databas
sampl
pediatr
hospit
discharg
unit
state
analysi
studi
limit
admiss
contain
cancer
diagnosi
discharg
code
admiss
subcategor
discharg
code
accord
diagnosi
leukemia
lymphoma
solid
tumor
brain
tumor
reason
admiss
chemotherapi
procedur
infect
noninfecti
toxic
charg
convert
cost
use
costtocharg
ratio
multivari
linear
regress
model
perform
control
age
gender
race
reason
admiss
diagnosi
result
weight
admiss
children
cancer
diagnosi
admiss
medicaid
commerci
insur
less
payer
mean
lo
medicaid
admiss
day
ci
compar
day
ci
commerci
insur
surgic
admiss
account
largest
differ
length
stay
medicaid
admiss
day
longer
cover
commerci
insur
day
vs
day
howev
differ
significantli
differ
reason
admiss
multivari
analysi
admiss
associ
commerci
insur
shorter
p
account
approxim
one
hospit
day
admiss
associ
medicaid
control
variabl
includ
race
mean
overal
cost
medicaid
admiss
ci
compar
ci
commerci
insur
multivari
model
cost
collinear
race
conclus
lo
cost
admiss
associ
medicaid
differ
associ
commerci
payer
medicaid
admiss
longer
averag
commerci
insur
account
differ
length
stay
approxim
one
day
although
differ
vari
reason
hospit
chemotherapi
surgic
procedur
infect
toxic
cost
admiss
independ
race
investig
potenti
explan
differ
includ
differenti
access
home
care
need
outpati
reimburs
differ
social
indic
prolong
hospit
provid
bias
warrant
background
pediatr
cancer
major
caus
morbid
mortal
among
children
surpass
accid
despit
improv
outcom
high
incom
countri
hic
surviv
rate
remain
poor
develop
word
variou
diagnost
therapeut
limit
contribut
significantli
surviv
gap
main
object
studi
evalu
outcom
pediatr
cancer
armenia
identifi
diagnost
therapeut
limit
countri
conduct
retrospect
studi
among
year
old
children
cancer
solid
tumor
hematolog
malign
diagnos
treat
clinic
chemotherapi
muratsan
hospit
complex
yerevan
state
medic
univers
patient
nt
receiv
chemotherapi
reason
includ
studi
cohort
epidemiolog
social
medic
inform
collect
patient
chart
review
includ
patient
age
diagnosi
sex
place
resid
citi
vs
villag
educ
level
employ
statu
parent
type
cancer
stage
present
symptom
first
medic
specialti
consult
time
consult
initi
workup
type
treatment
receiv
inform
diagnosistreat
receiv
abroad
result
clinic
mention
period
time
major
patient
present
hematolog
patient
inform
diagnosi
delay
averag
delay
diagnosi
day
case
first
contact
healthcar
system
pediatrician
surgeon
relaps
patient
receiv
salvag
treatment
armenia
abroad
stay
treatment
armenia
patient
surviv
major
relaps
patient
acut
lymphoblast
leukemia
leukemia
patient
immunophenotyp
cytogenet
avail
patient
major
miss
case
diagnost
modal
avail
afford
countri
patient
receiv
part
diagnosi
andor
treatment
abroad
frequent
reason
go
abroad
bone
marrow
transplant
otherwis
none
avail
armenia
patient
lost
followup
patient
fatal
outcom
patient
remiss
median
follow
year
conclus
unavail
cancer
registri
sever
essenti
diagnostictreat
modal
luck
multidisciplinari
care
palli
support
high
rate
outofpocket
expens
among
main
challeng
pediatr
cancer
care
armenia
background
advers
drug
reaction
adr
increasingli
recogn
import
sometim
irrevers
complic
cancer
treatment
anthracyclin
cisplatin
effect
chemotherapeut
agent
use
limit
cardiotox
anthracyclin
ototox
cisplatin
patient
genet
variant
use
predict
risk
develop
adr
discov
replic
object
creat
pharmacogenet
risk
predict
model
anthracyclin
cisplatin
toxic
discuss
result
oncologist
facilit
incorpor
treatment
decisionmak
appropri
designmethod
risk
predict
model
develop
linear
regress
stronglypredict
genom
variant
odd
ratio
discov
replic
least
three
patient
popul
model
use
assess
individu
patient
genom
risk
develop
cardiotox
anthracyclin
hear
loss
cisplatin
risk
result
return
oncologist
show
specif
patient
genet
risk
toxic
lie
continuum
lowest
highest
risk
group
across
studi
patient
use
multigen
model
interview
conduct
patient
famili
oncologist
determin
result
valu
util
result
patient
genotyp
genet
risk
result
return
oncologist
first
patient
character
determin
impact
test
result
clinic
care
result
describ
use
decisionmak
patient
andor
oncologist
case
addit
patient
extrem
risk
group
highest
lowest
risk
chang
treatment
plan
order
time
cisplatin
patient
time
anthracyclin
patient
includ
increas
cardiac
audiolog
monitor
addit
protect
agent
choos
altern
treatment
protocol
risk
outweigh
benefit
remain
current
treatment
plan
interview
patient
indic
felt
involv
decis
make
felt
reassur
understand
genet
risk
toxic
genet
risk
predict
model
anthracyclin
cardiotox
cisplatin
ototox
highli
util
patient
oncologist
decisionmak
result
found
import
tool
inform
patient
risk
adr
cancer
treatment
result
patient
famili
feel
involv
decisionmak
background
childhood
cancer
survivor
increas
risk
develop
execut
dysfunct
low
socioeconom
statu
se
identifi
one
mediat
execut
function
previou
studi
use
tradit
measur
se
parent
educ
level
famili
annual
incom
occup
recent
area
base
socioeconom
measur
like
block
group
poverti
statu
deem
use
monitor
social
inequ
health
unit
state
block
group
statist
divis
censu
tract
gener
contain
peopl
current
studi
aim
understand
associ
block
group
poverti
statu
percentag
household
famili
block
group
resid
live
feder
poverti
level
execut
function
among
cancer
survivor
children
designmethod
use
retrospect
cohort
childhood
cancer
survivor
relev
inform
collect
medic
record
administr
data
set
parentfil
survey
address
inform
geocod
use
arcgi
obtain
data
block
group
poverti
statu
priori
cutpoint
set
repres
block
group
famili
live
poverti
level
execut
function
assess
parentr
instrument
behavior
rate
inventori
execut
function
brief
multipl
linear
regress
use
determin
relationship
block
group
poverti
statu
brief
score
result
data
examin
famili
childhood
cancer
survivor
rang
age
year
sampl
famili
report
annual
incom
report
incom
report
annual
incom
primari
care
giver
cancer
survivor
high
school
educ
famili
live
block
group
poor
household
respect
block
group
poverti
level
significantli
associ
annual
incom
level
spearman
rho
p
parent
educ
level
spearman
rho
p
stepwis
multipl
linear
regress
statist
signific
associ
seen
block
group
poverti
statu
execut
function
adjust
covari
final
model
futur
prospect
studi
bigger
sampl
size
longer
follow
period
robust
measur
execut
function
like
clinician
administ
test
need
understand
effect
block
group
poverti
statu
execut
function
complet
day
rang
parent
strongli
agreedagre
help
would
recommend
particip
anoth
famili
ten
parent
report
time
spent
right
parent
felt
worri
due
intervent
though
parent
found
particip
stress
interim
analysi
suggest
parent
favor
experi
recommend
intervent
date
enrol
parent
fail
particip
show
promis
accept
interdisciplinari
commun
intervent
target
earli
treatment
period
childhood
cancer
children
hospit
research
center
oakland
oakland
california
unit
state
background
screen
echocardiogram
recommend
children
oncolog
group
cog
guidelin
assess
anthracyclineinduc
left
ventricular
lv
systol
dysfunct
yield
screen
echocardiogram
chemotherapi
immedi
posttherapi
period
uncertain
object
assess
incid
lv
dysfunct
detect
screen
echocardiogram
chemotherapi
immedi
posttherapi
period
defin
month
offtherapi
designmethod
children
diagnos
cancer
januari
receiv
anthracyclin
chemotherapi
identifi
echocardiogram
perform
per
protocol
institut
cog
guidelin
review
retrospect
lv
dysfunct
defin
fraction
shorten
fs
eject
fraction
ef
result
cohort
n
median
age
year
common
diagnosi
follow
aml
echocardiogram
perform
treatment
immedi
posttreat
period
thirtyeight
patient
decreas
fs
compar
pretreat
echocardiogram
none
patient
requir
treatment
modif
cardiac
medic
patient
echocardiogramproven
lv
dysfunct
discov
screen
echocardiogram
treatment
cours
eventu
die
due
multiorgan
failur
follow
septic
shock
patient
receiv
treatment
aml
receiv
doxorubicinequival
anthracyclin
time
abnorm
echocardiogram
one
patient
metastat
ewe
sarcoma
borderlin
lv
dysfunct
fs
detect
month
complet
therapi
receiv
doxorubicin
equival
anthracyclin
time
abnorm
echocardiogram
requir
therapi
modif
addit
cardiac
medic
serial
echocardiogram
done
patient
shown
stabl
ventricular
function
offtherapi
screen
echocardiogram
identifi
lv
dysfunct
experi
yield
echocardiogram
detect
anthracyclinerel
cardiac
dysfunct
treatment
immedi
posttherapi
period
low
one
patient
develop
lv
dysfunct
treatment
one
borderlin
fs
lv
dysfunct
identifi
within
month
complet
chemotherapi
though
fs
decreas
patient
none
requir
intervent
studi
need
optim
use
echocardiographi
screen
children
treat
anthracyclin
refer
landier
w
et
al
jco
background
platinumbas
chemotherapi
increas
risk
sensorineur
hear
loss
children
cancer
littl
known
impact
hear
loss
cognit
emot
function
survivor
determin
associ
severeprofound
hear
loss
platinumbas
chemotherapi
cognit
impair
emot
distress
ie
anxieti
andor
depress
crosssect
studi
patient
attend
yale
childhood
cancer
survivorship
clinic
year
therapi
cancer
diagnos
year
treat
cisplatin
andor
carboplatin
histori
cn
tumor
cranial
radiat
congenit
hear
loss
development
delay
hear
loss
sever
hear
aid
data
abstract
audiogram
detail
clinic
histori
cognit
impair
defin
behavior
rate
inventori
execut
function
score
assess
neuropsychologist
andor
histori
special
educ
emot
distress
determin
brief
symptom
inventori
score
global
two
subscal
behavior
emot
screen
system
score
psychologist
interview
andor
histori
psychotrop
medicationpsychotherapi
recent
avail
patient
data
use
logist
regress
sa
softwar
version
perform
result
overal
patient
femal
white
met
elig
criteria
median
age
year
iqr
diagnosi
year
evalu
iqr
diagnosi
sarcoma
neuroblastoma
receiv
cisplatin
receiv
carboplatin
fifteen
patient
severeprofound
hear
loss
least
one
ear
patient
severeprofound
hear
loss
significantli
increas
risk
cognit
impair
ci
emot
distress
compar
patient
without
severeprofound
hear
loss
signific
associ
age
diagnosi
current
age
time
sinc
diagnosi
sex
race
ethnic
diagnosi
either
cognit
impair
emot
distress
similarli
signific
interact
age
diagnosi
hear
loss
sex
hear
loss
either
cognit
impair
emot
distress
ten
patient
severeprofound
hear
loss
least
one
ear
recommend
hear
aid
report
complianc
time
conclud
severeprofound
hear
loss
significantli
associ
cognit
impair
emot
distress
childhood
cancer
survivor
data
support
need
intervent
improv
hear
patient
includ
complianc
hear
aid
background
grade
anaplast
astrocytoma
high
grade
glioma
depend
vascular
endotheli
growth
factor
vegf
mediat
angiogenesi
growth
infiltr
bevacizumab
recombin
human
monoclon
antibodi
bind
vegfa
inhibit
angiogenesi
common
advers
effect
bevacizumab
hypertens
proteinuria
thrombosi
bleed
anim
model
base
studi
shown
bevacizumab
may
impair
ovarian
function
effect
bevacizumab
therapi
human
fertil
clear
sinc
physiolog
pregnanc
involv
neovascularizationangiogenesi
recommend
concept
avoid
least
month
follow
exposur
bevacizumab
describ
cours
young
adult
becam
pregnant
receiv
bevacizumab
radiat
therapi
treatment
anaplast
astrocytoma
year
old
woman
diagnos
local
hemispher
anaplast
astrocytoma
treat
chemotherapi
radiat
gy
follow
cycl
biweekli
bevacizumabtemozolomid
patient
opt
pursu
fertil
preserv
prior
initi
treatment
experienc
bevacizumabassoci
proteinuria
hypertens
treatment
receiv
protocol
mandat
dose
cumul
dose
bevacizumab
mgkg
temozolomid
spontan
unassist
pregnanc
month
complet
treatment
pregnanc
unev
normotens
throughout
fetal
ultrasonographi
week
reveal
abnorm
brain
heart
great
vessel
kidney
extrem
placenta
umbil
cord
week
deliv
femal
infant
via
cesarean
section
birth
weight
gram
apgar
excess
postpartum
hemorrhag
report
placenta
bilob
weigh
g
histolog
analysi
reveal
normal
placent
villou
develop
matur
two
small
infarct
conclus
exposur
bevacizumab
patient
detriment
effect
fertil
placentalfet
vascular
develop
hope
report
add
exist
data
effect
bevacizumab
therapi
fertil
children
healthcar
atlanta
emori
univers
school
medicin
atlanta
georgia
unit
state
background
report
malnutrit
incid
preval
young
cancer
patient
variabl
well
establish
previou
research
suggest
children
especi
less
year
old
treat
intens
cancerdirect
therapi
higher
risk
malnutrit
howev
standard
assess
use
evalu
risk
popul
object
aim
assess
trend
weightforag
patient
follow
cancer
diagnosi
studi
first
use
standard
measur
treatment
intens
intens
treatment
rate
scale
assist
target
intervent
identif
treatment
malnutrit
designmethod
observ
retrospect
studi
obtain
data
center
pediatr
cancer
registri
electron
medic
record
patient
classifi
tumor
type
brain
nonbrain
tumor
treatment
intens
incorpor
diagnosi
chemotherapi
radiat
surgeri
begin
lowest
intens
highest
intens
inclus
criteria
includ
new
cancer
diagnosi
less
year
old
weight
obtain
avail
within
day
therapi
start
date
incomplet
data
altern
growth
chart
treatment
intens
exclud
weight
obtain
start
therapi
year
treatment
initi
approxim
day
convert
zscore
adjust
age
sex
weight
trajectori
model
use
gener
linear
mix
model
subjectspecif
random
intercept
spline
function
separ
function
construct
subgroup
interest
tumor
type
itr
result
patient
includ
patient
brain
tumor
nonbrain
tumor
includ
patient
treatment
intens
observ
period
valid
weight
record
initi
treatment
differ
exist
zscore
tumor
type
p
intens
vs
p
vs
p
vs
p
tumor
type
affect
zscore
follow
period
zscore
higher
intens
rate
vs
vs
p
p
respect
day
start
treatment
persist
day
p
p
respect
higher
treatment
intens
associ
declin
zscore
failur
return
baselin
futur
direct
includ
analysi
specif
risk
factor
time
weight
loss
longerterm
followup
weight
trend
target
intervent
identif
prevent
treatment
malnutrit
object
ass
pt
requir
bleed
episod
prospect
cohort
pcp
use
threshold
compar
threshold
histor
cohort
collect
pt
data
pcp
treat
center
diagnosi
prescript
pt
prophylaxi
vs
bleed
disord
plt
count
transfus
unit
assess
pt
pcp
treat
june
receiv
prophylact
pt
threshold
cohort
pt
treat
receiv
prophylact
pt
threshold
pt
done
procedur
pt
concomit
hemorrhag
patholog
exclud
compar
number
pt
prescrib
prophylaxi
vs
bleed
episod
cohort
data
analyz
graphpad
prim
statist
analysi
percentag
confid
interv
ci
tstudent
test
parametr
variabl
mannwhitney
test
nonparametr
variabl
statist
signific
p
review
pt
cohort
cohort
b
patient
acut
leukemia
receiv
auto
allo
hsct
diagnos
proport
patient
undergo
hsct
compar
cohort
averag
number
pt
per
patient
cohort
cohort
b
p
ns
signific
differ
found
hsct
patient
exclud
comparison
pt
per
patient
cohort
vs
cohort
b
p
result
estim
reduct
pt
prescript
furthermor
pt
prescrib
bleed
episod
cohort
versu
cohort
b
p
ns
patient
receiv
hsct
entir
group
versu
receiv
hsct
similar
pt
requir
bleed
episod
vs
p
ns
conclus
plt
count
threshold
prophylact
pt
safe
pcp
chemotherapi
hsct
result
signific
reduct
pt
usag
key
word
platelet
transfus
prophylaxi
cancer
childhood
ucsf
benioff
children
hospit
oakland
oakland
california
unit
state
background
transit
care
adolesc
young
adult
aya
survivor
childhood
cancer
pediatr
adultori
longterm
followup
ltfu
complex
loss
followup
common
littl
known
success
rate
among
differ
model
survivor
childhood
cancer
program
sccp
ucsf
benioff
children
hospit
oakland
employ
communitybas
model
transit
care
multidisciplinari
team
provid
aya
survivor
comprehens
treatment
summari
recommend
facilit
transit
primari
care
adult
oncolog
ltfu
program
evalu
success
rate
transit
care
among
aya
survivor
childhood
cancer
ltfu
program
identifi
barrier
success
transit
designmethod
aya
patient
seen
novemb
august
sccp
intent
transit
ask
email
telephon
follow
design
provid
primari
outcom
success
transit
defin
establish
care
within
month
visit
patient
also
ask
barrier
transit
rate
new
provid
familiar
cancer
histori
ltfu
need
result
transit
intend
patient
eightyseven
contact
respond
success
transit
lost
followup
age
rang
year
year
sinc
complet
therapi
ten
transit
primari
care
provid
adult
oncolog
ltfu
program
pediatrician
patient
rate
new
provid
knowledg
averag
scale
poor
excel
survivor
lost
follow
indic
follow
barrier
transit
losschang
insur
inabl
find
provid
busyforgot
problem
transport
concern
costcopay
twelv
patient
request
assist
transit
conclus
twothird
respond
patient
success
transit
work
need
overcom
variou
barrier
transit
one
third
aya
survivor
albani
medic
center
albani
new
york
unit
state
background
transit
activ
treatment
offtherapi
followup
stress
event
parent
children
cancer
psychosoci
need
parent
therapi
receiv
limit
attent
unit
state
publish
quantit
studi
largest
parent
secur
fund
recruit
transit
care
coordin
tcc
investig
object
object
assess
screen
parent
end
child
treatment
develop
intervent
support
parent
time
thereaft
designmethod
inform
consent
standard
questionnair
psychosoci
assess
tool
pat
administ
parent
end
therapi
month
later
year
later
tcc
provid
univers
intervent
famili
end
therapi
binder
contain
treatment
summari
followup
roadmap
inform
late
effect
survivor
scholarship
base
score
parent
provid
intervent
specif
symptom
target
intervent
score
refer
behavior
health
specialist
clinic
social
worker
counsel
score
result
analysi
data
show
parent
n
score
target
clinic
rang
parent
score
rang
signific
gender
differ
reveal
mean
score
men
women
confirm
show
statist
signific
p
analysi
conduct
subgroup
data
compos
coupl
n
analysi
data
coupl
n
show
mean
score
men
women
p
gender
differ
appar
caregiv
stress
reaction
question
focus
ptsd
symptom
subgroup
coupl
score
n
caregiv
stress
reaction
analyz
signific
differ
p
caregiv
stress
reaction
mean
men
versu
women
note
subcategori
score
rang
studi
initi
octob
use
tcc
screen
tool
result
suggest
greater
stress
mother
therapi
substanti
proport
parent
symptom
ptsd
therapi
background
hodgkin
lymphoma
hl
common
childhood
cancer
character
inflammatori
microenviron
chemotherapi
radiat
may
exacerb
inflamm
contribut
develop
late
effect
pneumon
pulmonari
fibrosi
heterogen
cohort
childhood
cancer
survivor
expos
pulmonarytox
therapi
associ
proinflammatori
cytokin
late
pulmonari
dysfunct
observ
object
test
associ
rel
uniform
cohort
survivor
hl
given
wellrecogn
proinflammatori
background
diseas
object
character
offtherapi
pulmonari
function
survivor
hl
treat
contemporari
therapi
investig
associ
persist
system
inflamm
designmethod
blood
sampl
clinic
data
pulmonari
function
test
obtain
survivor
hl
month
therapi
lung
function
score
lf
valid
method
assess
degre
pulmonari
dysfunct
scale
iv
determin
diffus
capac
forc
expiratori
volum
one
second
control
group
blood
sampl
patient
benign
noninflammatori
hematolog
condit
use
plasma
concentr
inflammatori
cytokin
measur
luminex
platform
emd
millipor
associ
clinic
featur
cytokin
level
lf
normal
vs
iiiv
evalu
use
logist
regress
wilcoxon
rank
sum
test
respect
result
survivor
mean
age
diagnosi
year
rang
mean
time
therapi
year
rang
categor
lf
ii
mild
dysfunct
lf
iii
moder
dysfunct
survivor
lf
iv
sever
dysfunct
higher
lf
associ
femal
sex
p
demograph
diseas
treatment
factor
fortyeight
survivor
blood
sampl
collect
mean
age
year
rang
mean
time
sinc
treatment
complet
year
rang
control
mean
age
time
blood
collect
year
rang
survivor
significantli
elev
cytokin
level
compar
control
femal
survivor
hl
month
therapi
increas
risk
pulmonari
dysfunct
neither
evid
pulmonari
dysfunct
measur
lf
durat
time
therapi
relat
system
inflamm
studi
pulmonari
function
deterior
clinic
pulmonari
symptom
rare
observ
immedi
follow
therapi
increas
time
futur
studi
may
consid
explor
contribut
system
inflamm
pulmonari
late
effect
survivor
farther
therapi
risk
late
effect
greater
background
thyroid
carcinoma
rare
tumor
pediatr
account
childhood
carcinoma
unit
state
europ
aim
detect
risk
second
malign
among
pediatr
thyroid
cancer
survivor
cohort
analysi
consist
pediatr
cancer
patient
age
less
year
diagnos
primari
thyroid
cancer
identifi
site
code
report
seer
databas
follow
death
end
studi
period
decemb
patient
diagnos
primarili
thyroid
carcinoma
patient
incid
subsequ
malign
mean
age
patient
initi
diagnosi
thyroid
cancer
year
femal
significantli
higher
incid
second
malign
sm
male
overal
standard
incid
ratio
sir
sm
thyroid
pediatr
patient
higher
expect
sir
specif
site
show
significantli
higher
incid
salivari
gland
sir
gum
mouth
sir
kidney
sir
overal
risk
sm
patient
receiv
radioact
iodin
higher
expect
sir
cumul
incid
sm
initi
diagnosi
thyroid
cancer
calcul
surviv
methodolog
compet
risk
death
treat
compet
event
cumul
incid
sm
ci
year
substanti
expand
year
reach
ci
year
cumul
incid
tumor
type
year
ci
breast
cancer
ci
salivari
gland
ci
one
kidney
cervix
uteri
ci
one
ovari
melanoma
skin
cumul
incid
sm
stratifi
base
race
gender
radiotherapi
exposur
statist
differ
conclus
race
gender
histolog
subtyp
radioact
iodin
may
play
import
role
prognost
factor
develop
sm
among
pediatr
thyroid
cancer
survivor
identif
underli
mechan
rais
risk
sm
import
treatment
followup
strategi
background
ethic
practic
inform
consent
requir
voluntari
understood
research
particip
pediatr
oncolog
parent
must
undergo
inform
consent
enrol
child
cancer
clinic
trial
often
difficult
understand
especi
parent
low
english
profici
previou
research
shown
parent
children
cancer
difficulti
understand
voluntari
parent
satisfact
inform
consent
alway
correl
adequ
comprehens
object
examin
sociodemograph
contextu
correl
comprehens
inform
consent
voluntari
satisfact
parent
consent
particip
child
cancer
clinic
trial
focus
character
differ
nonhispan
hispan
fastest
grow
ethnic
group
us
designmethod
parentsguardian
n
children
age
year
newli
diagnos
cancer
consent
particip
child
clinic
trial
cancer
treatment
radi
children
hospitalsan
diego
prospect
recruit
parent
complet
questionnair
assess
comprehens
voluntari
satisfact
health
literaci
sociodemograph
accultur
level
hispan
comprehens
survey
baselin
longitudin
month
comprehens
voluntari
satisfact
outcom
analyz
sociodemograph
health
literaci
accultur
level
use
logist
regress
result
particip
survey
hispan
nonhispan
found
higher
health
literaci
associ
greater
object
comprehens
p
voluntari
p
socioeconom
statu
p
accultur
p
hispan
report
lower
object
comprehens
p
voluntari
p
health
literaci
p
se
p
compar
nonhispan
spanishspeak
report
lower
voluntari
p
health
literaci
p
accultur
p
compar
englishspeak
followup
comprehens
hispan
significantli
improv
p
compar
baselin
comprehens
satisfact
moder
high
across
subgroup
significantli
impact
sociodemograph
health
literaci
accultur
studi
equival
number
hispan
nonhispan
particip
found
hispan
spanishspeak
parent
children
newli
diagnos
cancer
inadequ
inform
consent
comprehens
voluntari
health
literaci
despit
high
satisfact
studi
suggest
hispan
individu
limit
english
profici
make
truli
inform
decis
child
cancer
ensur
ethic
practic
research
pediatr
oncolog
inform
consent
decisionmak
process
must
improv
cultur
linguist
intervent
underserv
popul
memori
sloan
ketter
cancer
center
new
york
new
york
unit
state
background
pediatr
oncolog
patient
undergo
repeat
bone
marrow
aspir
biopsi
bmabx
potenti
pain
procedur
exacerb
anxieti
distress
standard
practic
memori
sloan
ketter
msk
depart
pediatr
use
propofol
amnest
analges
properti
sought
evalu
whether
addit
local
anesthet
would
improv
patient
experi
bmabx
purpos
reppair
reduc
procedur
pain
improv
recoveri
qualiti
life
qol
evalu
efficaci
local
anesthesia
ropivacain
reduc
procedur
pain
improv
postprocedur
qol
pediatr
neuroblastoma
patient
undergo
bmabx
gener
anesthesia
reppair
prospect
random
crossov
clinic
trial
open
enrol
octob
elig
patient
year
old
neuroblastoma
particip
observ
trial
two
sequenti
bm
procedur
one
procedur
intervent
propofol
alon
pa
intervent
b
propofol
plu
ropivacain
pr
particip
random
intervent
sequenc
ab
ba
blind
order
intervent
particip
recoveri
room
rr
nurs
also
blind
follow
standard
postprocedur
pain
manag
algorithm
primari
endpoint
percentag
particip
requir
opioid
analgesia
hour
postprocedur
secondari
endpoint
includ
total
opioid
hour
nonopioid
analgesia
use
pain
score
time
first
opioid
shortterm
qol
qol
assess
parentproxi
metric
evalu
pain
interfer
sleep
physic
emot
social
recoveri
januari
patient
assess
elig
patient
random
complet
procedur
primari
endpoint
slightli
higher
proport
particip
requir
opioid
pa
pr
versu
p
pain
score
rr
significantli
higher
pa
pr
median
percentil
versu
p
statist
signific
differ
total
opioid
nonopioid
analgesia
pain
score
median
time
first
opioid
pain
interfer
score
advers
event
conclus
preliminari
find
reppair
trial
suggest
local
anesthesia
reduc
need
opioid
analgesia
improv
shortterm
qol
pediatr
patient
undergo
bmabx
gener
anesthesia
local
anesthesia
improv
pain
score
immedi
recoveri
period
final
result
studi
help
establish
evidencebas
guidelin
optim
experi
pediatr
patient
bone
marrow
procedur
center
background
children
advanc
cancer
experi
rang
symptom
throughout
treatment
end
life
poorli
control
minim
suffer
includ
effect
symptom
manag
children
advanc
cancer
central
valu
pediatr
oncolog
clinician
patientreport
outcom
use
symptomrel
research
pediatr
oncolog
patient
howev
major
literatur
specif
symptom
palli
care
end
life
children
adolesc
advanc
cancer
base
primarili
upon
medic
record
review
lesser
extent
patient
selfreport
purpos
studi
prospect
describ
symptom
frequenc
sever
level
distress
childrenadolesc
advanc
cancer
use
patient
selfreport
parent
proxi
designmethod
prospect
cohort
design
use
studi
five
pediatr
oncolog
institut
across
unit
state
particip
children
adolesc
elig
particip
year
age
englishspeak
diagnosi
advanc
cancer
defin
histori
progress
recurr
nonrespons
diseas
decis
pursu
curativefocus
therapi
modifi
version
memori
symptom
assess
scale
msa
use
measur
symptom
frequenc
sever
level
distress
administ
childpar
dyad
electron
via
smartphon
everi
two
week
inform
regard
diseas
statu
cancer
treatment
collect
concurr
data
analyz
use
descript
statist
univari
logist
regress
analysi
result
total
children
adolesc
parent
particip
studi
median
age
child
particip
year
half
male
median
age
parent
year
child
particip
varieti
primari
diagnosi
includ
leukemialymphoma
n
solid
tumor
n
brain
tumor
n
frequent
report
symptom
children
advanc
cancer
parent
pain
n
lack
energi
n
nausea
n
presenc
diseas
p
recent
diseas
progress
p
receiv
cancer
therapi
p
signific
factor
presenc
pain
high
intens
cancer
therapi
signific
factor
pain
frequenc
p
level
distress
p
feasibl
collect
data
prospect
children
advanc
cancer
regard
symptom
frequenc
sever
level
distress
clinician
increas
understand
symptom
experi
may
promot
commun
children
adolesc
time
intervent
research
need
understand
symptom
cluster
children
advanc
cancer
vanderbilt
children
hospit
nashvil
tennesse
unit
state
background
febril
neutropenia
fn
frequent
occurr
children
undergo
chemotherapi
though
guidelin
recommend
ad
second
antibiot
broadspectrum
antipseudomon
coverag
specif
scenario
augment
empir
therapi
second
antibiot
common
practic
addit
empir
antibiot
aea
use
increas
risk
antibiot
toxic
futur
antimicrobi
resist
data
clarifi
indic
aea
limit
pediatr
patient
object
identifi
risk
factor
gramposit
gp
gramneg
gn
bacteremia
patient
present
fn
determin
situat
aea
use
warrant
designmethod
retrospect
chart
review
conduct
pediatr
sever
fn
absolut
neutrophil
count
l
occur
singl
institut
potenti
priori
risk
factor
base
clinic
reason
antibiot
expans
chill
hypotens
mucos
skin
soft
tissu
infect
ssti
recent
administr
highdos
cytarabin
hdac
diagnosi
acut
myeloid
leukemia
aml
potenti
factor
gn
bacteremia
chill
hypotens
mucos
abdomin
pain
associ
potenti
risk
factor
gp
gn
bacteremia
identifi
logist
regress
use
multivari
analysi
review
yield
episod
gp
bacteremia
isol
case
gn
bacteremia
episod
multivari
analysi
hypotens
ci
p
ssti
p
independ
associ
increas
risk
gp
bacteremia
mucos
p
recent
administr
hdac
p
chill
p
ten
patient
aml
nt
receiv
hdac
thu
associ
aml
gp
bacteremia
could
reliabl
estim
hypotens
p
chill
p
independ
associ
higher
risk
gn
bacteremia
mucos
p
abdomin
pain
p
gn
infect
resist
cefepim
empir
agent
choic
institut
patient
fn
ssti
hypotens
recent
hdac
increas
risk
gp
bacteremia
indic
potenti
benefit
empir
vancomycin
set
mucos
chill
associ
gp
bacteremia
hypotens
chill
associ
gn
bacteremia
potenti
warrant
empir
antibiot
expans
mucos
abdomin
pain
identifi
specif
indic
aea
use
pediatr
sever
fn
use
may
improv
antimicrobi
util
decreas
unnecessari
antibiot
use
improv
patient
outcom
background
childrenyoung
adult
incur
high
grade
glioma
hgg
like
diffus
intrins
pontin
glioma
dipg
glioblastoma
multiform
gbm
oncologist
endeavor
align
therapi
patientfamili
goal
care
may
influenc
provid
prefer
limit
resourc
ethic
challeng
aris
around
perceiv
purpos
risk
benefit
therapi
option
provid
conflict
interest
access
care
decid
decision
prioriti
patient
famili
conflict
around
endoflif
care
object
evalu
factor
play
longitudin
decis
make
children
young
adult
hgg
famili
oncologist
use
qualit
approach
ethnograph
element
designmethod
elig
patient
age
dipg
gbm
secondari
hgg
patient
exclus
includ
nonenglish
speak
state
custodi
death
prior
diagnosi
seen
oncolog
oncologist
declin
particip
key
decis
make
visit
eg
mri
review
serial
audiorecord
along
subsequ
semistructur
interview
patient
andor
parent
decis
make
process
field
note
clinician
meet
chart
note
oncologist
questionnair
obtain
discuss
interview
transcrib
independ
code
three
investig
interrat
reliabl
assess
code
book
develop
discrep
discuss
consensu
met
constant
comparison
analysi
maxqda
softwar
continu
themat
satur
result
twentytwo
elig
patient
approach
agre
particip
one
withdrew
upon
transfer
care
mean
age
year
sd
male
caucasian
african
american
hispan
asian
four
encount
hour
record
averag
per
patient
parentpati
interview
theme
includ
hope
cure
prolong
life
qualiti
life
import
physician
recommend
import
support
system
famili
commun
social
media
food
cancer
etiolog
intervent
financ
person
research
fund
commun
medic
provid
famili
commun
death
god
belief
prayer
existenti
question
oncologist
desir
prolong
qualiti
life
patientsfamili
transit
hope
hope
cure
decis
made
set
hgg
multifactori
ultim
reflect
compet
valu
decis
maker
optim
treatment
efficaci
held
tension
poor
prognosi
allow
function
hope
acknowledg
patient
famili
shift
hope
allow
chang
goal
care
share
decis
make
futur
work
need
develop
prefer
tool
pediatr
patient
famili
inform
medic
provid
provid
train
commun
share
decis
make
oncologist
emori
univers
atlanta
georgia
unit
state
background
bone
marrow
transplant
bmt
potenti
cur
underutil
treatment
scd
previou
work
shown
variat
physician
philosophi
practic
consid
bmt
treatment
option
patient
scd
physician
may
discuss
patient
famili
potenti
treatment
option
random
clinic
trial
test
effect
decis
aid
diseas
modifi
therapi
sickl
cell
diseas
adult
patient
scd
well
caregiv
adultpediatr
patient
interview
seek
sought
inform
relat
scd
made
decis
treatment
scd
identifi
treatment
option
interest
learn
use
decis
aid
tool
perform
secondari
analysi
baselin
data
understand
patient
inform
need
attitud
regard
bmt
treatment
option
scd
goal
analys
understand
patient
caregiv
attitud
perceiv
inform
need
regard
bmt
treatment
option
scd
perform
analysi
baselin
interview
caregiv
patient
scd
adult
patient
random
control
trial
decis
aid
tool
scd
interview
belong
caregiv
patient
scd
addit
review
interview
discuss
bmt
interrog
mention
term
bone
marrow
transplant
cure
stem
cell
transplant
interview
code
use
analyz
emerg
theme
result
baselin
interview
interview
met
select
criteria
thirteen
interview
caregiv
pediatr
patient
remaind
adult
patient
includ
young
adult
patient
scd
major
particip
want
learn
bmt
cur
option
mani
particip
express
despit
knowledg
like
candid
transplant
desir
inform
bmt
includ
elig
benefit
risk
longterm
effect
qualiti
life
financi
aspect
relat
bmt
patient
discuss
learnt
bmt
approxim
half
mention
healthcar
provid
previous
mention
examin
knowledg
bmt
attitud
demograph
clinic
variabl
patient
caregiv
pediatr
patient
scd
want
learn
bmt
treatment
option
healthcar
provid
consid
discuss
bmt
patient
scd
natasha
frederick
anna
revett
alexi
michaud
jennif
mack
sharon
bober
danafarb
cancer
institut
boston
massachusett
unit
state
background
adolesc
young
adult
aya
consist
identifi
need
improv
patientclinician
commun
sexual
reproduct
health
srh
issu
howev
oncolog
clinician
routin
integr
srh
convers
aya
diseas
treatment
survivorship
littl
known
convers
take
place
object
explor
aya
percept
recept
srh
commun
oncolog
clinician
identifi
barrier
facilit
convers
designmethod
semistructur
interview
held
aya
cancer
patient
survivor
age
year
men
women
twelv
particip
activ
treatment
within
year
treatment
complet
interview
conduct
english
phone
person
interview
transcript
underw
pretest
aya
interview
audiorecord
transcrib
verbatim
transcript
analyz
summar
two
train
qualit
research
accord
standard
comprehens
themat
qualit
analysi
method
analys
aid
softwar
result
aya
perceiv
exist
srh
commun
aya
oncolog
provid
inadequ
aya
report
need
improv
srh
commun
oncolog
provid
three
key
area
need
emerg
gener
educ
address
specif
srh
issu
experienc
treatment
survivorship
understand
longterm
impact
cancer
treatment
srh
aya
felt
current
srh
discuss
limit
narrow
scope
scale
aya
report
srh
convers
focu
exclus
fertil
n
usual
take
place
start
treatment
addit
yet
limit
commun
report
sexual
activ
n
contracept
n
sexual
function
n
aya
report
convers
potenti
treatment
complic
relat
sexual
infertil
key
barrier
srh
convers
includ
patient
discomfort
initi
convers
n
presenc
famili
member
n
addit
report
barrier
includ
perceiv
provid
discomfort
n
lack
rapport
provid
n
agegend
differ
n
aya
felt
commun
tool
handout
brochur
websit
would
help
facilit
direct
commun
oncolog
clinician
want
convers
start
treatment
initi
continu
treatment
survivorship
conclus
aya
identifi
key
role
pediatr
oncolog
provid
srh
care
diagnosi
survivorship
howev
multipl
barrier
interfer
discuss
srh
regular
basi
identifi
barrier
suggest
futur
effort
focu
provid
educ
train
srh
srhrelat
commun
order
optim
care
provid
uniqu
patient
popul
background
peripher
insert
central
venou
cathet
picc
provid
secur
vascular
access
pediatr
patient
deliveri
necessari
therapi
eas
placement
inpati
outpati
set
expand
util
howev
recent
data
analys
show
signific
increas
venou
thromboembol
vte
risk
use
picc
line
rise
use
modifi
risk
factor
need
understood
prevent
measur
object
studi
aim
understand
patient
cathet
specif
characterist
relat
develop
vte
designmethod
irb
approv
retrospect
interrog
electron
medic
record
picc
databas
rainbow
babi
children
hospit
complet
studi
cohort
contain
patient
year
age
picc
line
place
januari
decemb
data
collect
includ
indic
line
placement
line
dwell
time
locat
insert
includ
blood
vessel
extrem
number
attempt
line
placement
lumen
size
indwel
line
length
addit
collect
number
day
vte
format
associ
symptom
locat
vte
chisquar
analys
fischer
exact
test
use
appropri
statist
analysi
analyz
neonat
newli
place
picc
line
fifti
lineassoci
vte
event
found
incid
vte
occur
placement
first
picc
line
intraven
therapi
common
reason
line
placement
statist
signific
found
variou
indic
placement
common
symptom
vte
manifest
extrem
swell
follow
extrem
pain
right
extrem
picc
found
higher
incid
vte
larger
cathet
lumen
size
french
higher
incid
vte
found
mean
time
day
vte
detect
unabl
find
clinic
patient
line
specif
factor
lead
increas
vte
format
statist
analysi
special
consider
given
durat
picc
line
use
may
reduc
incid
comorb
associ
vte
still
much
understood
cathet
associ
vte
format
analys
indic
need
prospect
data
collect
larger
scale
hope
creat
guidelin
relat
cathet
use
pediatr
background
decis
transfus
patient
complex
one
never
base
sole
number
howev
certain
hemoglobin
platelet
count
threshold
propos
aid
physician
make
transfus
decis
hospit
threshold
pack
red
blood
cell
prbc
platelet
transfus
pediatr
oncolog
patient
hemoglobin
level
gdl
platelet
count
brain
tumor
respect
recent
threshold
question
ask
whether
could
safe
lower
threshold
gdl
hemoglobin
platelet
count
object
investig
platelet
hemoglobin
transfus
threshold
oncolog
patient
children
hospit
michigan
designmethod
retrospect
chart
review
period
examin
platelet
hemoglobin
pretransfus
level
prbc
platelet
transfus
given
oncolog
patient
result
cours
month
elig
oncolog
patient
median
age
year
receiv
transfus
prbc
transfus
platelet
transfus
mean
pretransfus
hemoglobin
level
gdl
rang
n
total
prbc
transfus
differ
among
diseas
categori
p
patient
anemia
symptom
sign
n
slightli
lower
hemoglobin
level
compar
n
vs
gdl
p
mean
pretransfus
platelet
count
rang
total
platelet
transfus
n
patient
brain
tumor
n
patient
leukemia
n
patient
solid
tumor
n
mean
pretransfus
platelet
count
significantli
higher
transfus
brain
tumor
compar
diseas
group
p
mean
pretransfus
platelet
count
differ
among
patient
bleedingbruis
symptom
n
versu
n
p
bleedingbruis
rate
slightli
insignificantli
higher
platelet
count
vs
vs
p
sinc
patient
develop
symptom
anemia
hemoglobin
gdl
patient
develop
bleedingbruis
symptom
platelet
count
current
polici
far
reflect
safe
threshold
transfus
lower
threshold
investig
prospect
studi
background
renal
impair
import
complic
childhood
cancer
treatment
serum
creatinin
level
frequent
use
screen
test
monitor
renal
function
howev
patient
significantli
decreas
glomerular
filtrat
rate
gfr
normal
serum
creatinin
determin
preval
chronic
kidney
diseas
ckd
among
children
cancer
diagnosi
base
calcul
gfr
compar
differ
use
serum
creatinin
valu
alon
versu
gfr
detect
ckd
designmethod
retrospect
review
medic
record
patient
age
year
diagnos
solid
tumor
analyz
serum
creatinin
calcul
gfr
use
schwartz
formula
record
ckd
classifi
foundat
kidney
diseas
outcom
qualiti
initi
use
ckd
stage
gfr
mlmin
per
ckd
stage
gfr
mlmin
per
statist
analysi
use
spss
softwar
chisquar
test
proport
within
group
pearson
chisquar
fisher
exact
test
statist
differ
group
pvalu
consid
indic
signific
result
record
review
male
femal
mean
age
year
patient
receiv
one
nephrotox
chemotherapi
drug
cisplatinum
carboplatinum
ifosphamid
mainli
nonwilm
solid
tumor
group
compar
wilm
tumor
wt
group
base
calcul
gfr
schwartz
formula
ckd
stage
diagnos
patient
overwhelm
major
mild
stage
ckd
patient
abnorm
high
serum
creatinin
level
p
patient
receiv
nephrotox
chemotherapi
develop
ckd
compar
receiv
p
despit
wt
group
patient
receiv
nephrotox
chemotherapi
yet
group
higher
percentag
ckd
compar
nonwt
group
p
significantli
lower
mean
gfr
notic
wt
group
compar
nonwt
group
p
conclus
high
preval
mild
ckd
found
among
solid
tumor
patient
use
serum
creatinin
alon
measur
renal
function
significantli
estim
renal
impair
patient
earli
identif
ckd
easili
achiev
use
calcul
gfr
help
provid
care
giver
avoid
potenti
nephrotox
antibiot
contrast
media
nsaid
dehydr
may
deterior
renal
function
univers
texa
southwestern
medic
center
dalla
texa
unit
state
background
children
syndrom
ds
increas
risk
develop
leukemia
pediatr
patient
dsassoci
acut
lymphoblast
leukemia
dsall
known
signific
toxic
reinduct
chemotherapi
histor
poor
outcom
stem
cell
transplant
sct
chimer
antigen
receptor
car
tcell
therapi
tisagenlecleucel
demonstr
high
rate
durabl
complet
remiss
cr
manag
safeti
profil
children
rr
bcell
acut
lymphoblast
leukemia
ball
object
character
efficaci
safeti
tisagenlecleucel
pediatricyoung
adult
dsall
designmethod
pool
data
singlearm
multicent
phase
trial
tisagenlecleucel
pediatricyoungadult
patient
rr
ball
eliana
ensign
analyz
eight
patient
dsall
enrol
data
cutoff
eliana
novemb
ensign
februari
seven
infus
tisagenlecleucel
patient
die
progress
intracrani
hemorrhag
infus
manufactur
issu
occur
product
infus
patient
male
prior
sct
age
rang
year
patient
achiev
cr
cr
incomplet
blood
count
recoveri
cri
day
crcri
die
evalu
analysi
minim
residu
diseas
neg
bone
marrow
respond
patient
two
patient
relaps
month
ongo
remiss
patient
without
relaps
rang
month
safeti
profil
n
appear
similar
patient
without
ds
trial
n
grade
g
cytokin
releas
syndrom
occur
patient
ds
without
ds
rate
advers
event
special
interest
appear
favor
consist
trend
patient
withwithout
ds
febril
neutropenia
vs
neurolog
event
vs
tumor
lysi
syndrom
vs
infect
observ
patient
ds
vs
one
patient
die
infus
due
intracrani
parenchym
hemorrhag
associ
ongo
coagulopathi
time
extent
tisagenlecleucel
expans
longterm
persist
similar
group
conclus
first
analysi
car
tcell
therapi
pediatr
patient
rr
ball
ds
data
suggest
toxic
appear
similar
patient
ball
without
ds
remiss
rate
dsall
high
longterm
outcom
sustain
persist
appear
promis
explor
tisagenlecleucel
altern
sct
children
rr
dsall
warrant
sponsor
novarti
background
hispan
adolesc
young
adult
twice
like
develop
acut
lymphoblast
leukemia
high
risk
featur
nonhispan
white
also
poor
prognosi
higher
death
rate
ball
overexpress
caus
genet
alter
cytokin
receptor
five
time
common
subgroup
approxim
ball
case
also
genet
alter
ikaro
involv
transcript
regul
sever
import
gene
involv
leukemogenesi
overexpress
casein
kinas
ii
impair
function
ikaro
object
understand
molecular
mechan
regul
express
ball
present
evid
ikarosmedi
repress
transcript
ball
hispan
children
regul
designmethod
primari
ball
patient
sampl
hispan
children
use
ikaro
retrovir
transduct
ikaro
shrna
transfect
real
timepcr
luciferac
assay
quantit
chromatin
immunoprecipit
qchip
coupl
nextgener
sequenc
chipseq
cytotox
assay
western
blot
result
ikaro
bind
promot
confirm
use
quantit
chip
function
experi
overexpress
ikaro
ball
primari
cell
result
transcript
repress
wherea
ikaro
silenc
use
shrna
result
increas
transcript
result
suggest
ikaro
neg
regul
express
molecular
inhibit
shrna
target
catalyt
subunit
well
pharmacolog
target
result
transcript
repress
inhibit
associ
increas
ikaro
dnabind
promot
howev
abil
repress
lost
sever
reduc
cell
shrna
silenc
ikaro
compar
cell
intact
ikaro
moreov
similar
result
note
follow
treatment
leukemia
cell
obtain
high
risk
ball
patient
delet
one
allel
ikaro
bind
poorli
promot
gene
cell
treatment
restor
ikaro
dnabind
promot
associ
strong
repress
serial
qchip
analysi
epigenet
signatur
promot
show
increas
ikaro
bind
promot
follow
inhibit
associ
enrich
histon
modif
marker
repress
chromatin
result
demonstr
express
epigenet
regul
axi
show
antileukem
effect
via
restor
ikaro
tumor
suppressor
function
result
repress
suggest
advantag
use
inhibitor
potenti
therapeut
approach
alter
ball
result
hypodiploid
modal
chromosom
number
andor
di
identifi
patient
patient
nci
standard
risk
sr
nci
high
risk
hr
remov
frontlin
protocol
therapi
postinduct
overal
ef
os
transplant
statu
retrospect
avail
underw
hsct
fiveyear
ef
hsct
vs
without
p
os
without
hsct
vs
p
correct
median
time
hsct
day
signific
differ
ef
os
rate
without
hsct
vs
nci
risk
group
mrd
subset
benefit
significantli
hsct
sr
patient
n
ef
os
hsct
n
vs
without
hr
patient
n
ef
os
hsct
n
vs
without
endinduct
mrd
n
ef
os
hsct
n
vs
without
endinduct
mrdposit
patient
n
fare
poorli
ef
os
hsct
n
vs
without
multivari
regress
analysi
includ
nci
risk
group
mrd
hsct
show
mrd
neg
significantli
associ
ef
hr
p
os
hr
p
patient
hypodiploid
fare
poorli
particularli
endinduct
mrd
hsct
standard
treatment
approach
confer
signific
benefit
unabl
assess
bridg
therapi
prior
hsct
compar
group
small
taken
togeth
howev
new
strategi
urgent
need
patient
background
raspathway
mutat
known
play
pivot
role
signific
proport
myeloid
malign
includ
upward
pediatr
aml
case
raspathway
mutat
myeloid
malign
commonli
cooccur
mutat
epigenet
regul
suggest
cooper
leukemogenesi
among
epigenet
modifi
frequent
mutat
myeloid
malign
regul
dna
methyl
indic
alter
dna
methyl
contribut
leukemogenesi
teneleven
transloc
epigenet
regul
play
import
role
regul
dna
methyl
action
hydroxyl
ultim
lead
passiv
demethyl
dna
cytosin
myeloid
malign
loss
function
mutat
one
frequent
cooccur
lesion
ra
mutat
malign
specif
alter
methyl
pattern
raspathway
driven
diseas
promot
leukemogenesi
unclear
object
hypothes
mice
raspathway
mutat
epigenet
modifi
cooccur
loss
function
prime
stem
cell
andor
earli
differenti
progenitor
transform
prevent
repress
stem
cell
selfrenew
gene
inhibit
differenti
enhanc
ra
signal
lead
leukemogenesi
gener
novel
murin
model
constitut
delet
combin
induc
activ
mutat
mice
track
evid
hematolog
malign
compar
mice
correspond
singl
genet
lesion
cooper
leukemogenesi
demonstr
decreas
latenc
diseas
onset
impact
malign
lineag
addit
investig
mechanist
pathway
leukemogenesi
may
promot
result
demonstr
statist
signific
differ
peripher
white
blood
cell
count
hemoglobin
platelet
level
earli
post
raspathway
activ
peripher
cell
lineag
analysi
demonstr
earli
skew
toward
myeloid
differenti
mark
splenomegali
mice
harbor
genet
lesion
compar
wild
type
mice
singl
genet
lesion
phosphoflow
cytometr
analysi
reveal
increas
perk
activ
enrich
bone
marrow
cell
compar
either
genet
lesion
alon
studi
util
murin
model
examin
raspathway
mutat
addit
cooccur
epigenet
lesion
demonstr
lesion
appear
cooper
promot
earli
myeloid
differenti
attend
chang
signal
pathway
explor
elucid
mechan
raspathway
mediat
diseas
lay
foundat
identif
patient
may
benefit
exist
therapi
dmti
identifi
new
signal
target
therapeut
explor
background
humor
immunogen
chimer
antigen
receptor
car
murin
scfv
domain
develop
treatment
tisagenlecleucel
relapsedrefractori
rr
pediatricyoungadult
acut
lymphoblast
leukemia
evalu
studi
littl
known
presenceimpact
preexistingtreatmentinduc
antimurin
antibodi
patient
treat
car
therapi
object
patient
eliana
n
ensign
n
evalu
tisagenlecleucel
infus
determin
impact
antibodi
cellular
kinet
efficaci
safeti
designmethod
antibodi
determin
flow
cytometri
report
median
fluoresc
intens
assay
valid
includ
evalu
interfer
intraven
immunoglobulin
ivig
treatment
antibodi
assay
impact
preexist
treatmentinduc
immunogen
cellular
kinet
efficaci
safeti
determin
treatmentinduc
immunogen
defin
posit
increas
antibodi
level
baselin
assess
calcul
foldchang
preexist
ie
baselin
postinfus
level
result
patient
display
preexist
antibodi
similar
incid
detect
healthi
volunt
sampl
method
valid
patient
develop
treatmentinduc
antibodi
relationship
identifi
tisagenlecleucel
expans
preexistingtreatmentinduc
antibodi
respect
similar
result
seen
cmax
presenc
treatmentinduc
antibodi
appear
impact
transgen
persist
respons
kaplanmei
estim
show
preexistingtreatmentinduc
antibodi
appear
impact
durat
respons
eventfre
surviv
strip
plot
show
consist
level
preexistingtreatmentinduc
antibodi
across
patient
safeti
event
includ
cytokin
releas
syndrom
neutropenia
thrombocytopenia
neurolog
event
appar
relationship
treatmentinduc
antibodi
bcell
recoveri
categori
ongo
sustain
aplasia
associ
exist
time
bcell
recoveri
presenc
treatmentinduc
antibodi
bcell
aplasia
requir
ivig
occur
follow
tisagenlecleucel
major
patient
tisagenlecleucel
concentrationtim
profil
patient
treatmentinduc
antibodi
categor
time
follow
ivig
administr
time
ivig
administr
impact
vivo
transgen
expans
persist
report
first
comprehens
assess
impact
antibodi
clinic
endpoint
car
therapi
pediatricyoungadult
patient
rr
high
frequenc
baselin
antibodi
preexistingtreatmentinduc
antibodi
impact
cellular
kinet
safeti
efficaci
tisagenlecleucel
cellmedi
immun
studi
ongo
sponsor
novarti
background
adopt
immunotherapi
use
engag
tcell
shown
success
preclin
studi
recogn
kill
acut
myeloid
leukemia
aml
blast
vitro
vivo
tcell
secret
bispecif
molecul
recogn
tcell
aml
blast
abl
direct
transduc
tcell
recruit
bystand
tcell
kill
blast
howev
provid
costimul
shown
capabl
sequenti
kill
target
vitro
seek
improv
expans
persist
sequenti
kill
capabl
genet
modifi
cell
induc
costimulatori
molecul
activ
chemic
induc
dimer
cid
gener
retrovir
vector
encod
induc
costimulatori
molecul
link
sequenc
tcell
gener
retrovir
transduct
effector
function
compar
without
cid
use
flow
cytometr
analysi
assess
transduct
effici
chromium
releas
assay
evalu
cytolyt
activ
elisa
determin
cytokin
product
success
gener
tcell
achiev
mean
initi
transduct
effici
maintain
throughout
studi
period
tcell
cid
tcell
readili
kill
aml
blast
cytotox
assay
compar
control
cocultur
assay
tcell
secret
increas
ifngamma
presenc
cid
target
compar
cocultur
target
absenc
cid
addit
tcell
display
enhanc
sequenti
kill
capabl
ifngamma
secret
stimul
weekli
cid
tumor
cell
ratio
compar
tcell
conclus
tcell
abl
recogn
kill
aml
blast
antigen
depend
manner
tcell
improv
effector
function
presenc
cid
judg
cytokin
product
abil
sequenti
kill
target
cell
thu
induc
costimul
promis
strategi
improv
effector
function
tcell
warrant
activ
explor
preclin
studi
background
eliana
n
pivot
multicent
studi
test
efficaci
tisagenlecleucel
cart
childrenyoung
adult
rr
ball
tocilizumab
toci
use
manag
moderatesever
grade
cr
patient
treat
tisagenlecleucel
equival
dose
use
approv
nononcolog
pediatr
indic
receiv
receiv
max
dose
cr
onset
grade
penn
grade
scale
gener
occur
median
day
rang
infus
requir
administr
toci
dose
patient
via
protocolspecif
treatment
algorithm
toci
human
monoclon
antibodi
inhibit
receptor
signal
pharmacokinet
pk
pharmacodynam
pd
toci
pediatr
patient
ball
carassoci
cr
previous
describ
object
character
toci
pkpd
cr
manag
follow
tisagenlecleucel
infus
describ
impact
cellular
kinet
designmethod
toci
pk
level
solubl
determin
serum
quantifi
use
valid
assay
maximum
toci
concentr
cmax
deriv
use
noncompartment
method
proinflammatori
cytokin
cr
resolut
time
character
describ
toci
pd
summari
statist
graphic
analys
tisagenlecleucel
exposur
number
dose
perform
describ
impact
toci
tisagenlecleucel
kinet
patient
respond
tisagenlecleucel
infus
patient
cr
receiv
first
toci
dose
median
day
rang
cr
onset
seventeen
patient
receiv
dose
rang
mgkg
receiv
dose
mgkg
receiv
dose
mgkg
per
cr
treatment
algorithm
firstdos
mean
cmax
sd
gml
second
dose
gml
individu
patient
pd
concentrationtim
profil
show
increas
level
first
toci
dose
remain
elev
follow
second
dose
follow
toci
administr
median
time
cr
resolut
includ
fever
resolut
day
rang
cr
onset
coincid
tisagenlecleucel
expans
follow
peak
serum
cytokin
includ
geometr
mean
cmax
tisagenlecleucel
transgen
pcr
higher
tisagenlecleucelrespond
tocitr
patient
conclus
cr
symptom
resolv
within
median
day
toci
administr
toci
level
achiev
patient
ball
similar
report
pediatr
nononcolog
indic
tocilizumab
label
result
concentrationtimedepend
increas
transgen
continu
expand
persist
follow
toci
administr
data
support
treatment
toci
cr
manag
buechner
eha
sponsor
novarti
background
acut
myeloid
leukemia
aml
mesenchym
stem
stromal
cell
msc
bone
marrow
microenviron
contribut
extrins
mediat
chemoresist
therefor
import
potenti
therapeut
target
studi
patientderiv
msc
competit
disadvantag
howev
tradit
mean
isol
msc
bone
marrow
aspir
interfer
isol
highli
priorit
leukem
cell
mani
opportun
studi
msc
therefor
miss
object
develop
novel
method
isol
msc
use
otherwis
discard
portion
bone
marrow
aspir
therebi
decoupl
isol
primari
msc
isol
leukemia
cell
designmethod
aml
patient
bone
marrow
aspir
obtain
prospect
children
oncolog
group
healthi
patient
marrow
purchas
experiment
msc
isol
bottommost
layer
rbclayer
produc
densitygradi
separ
bone
marrow
aspir
typic
discard
control
msc
isol
buffi
coat
mnc
layer
nonadher
cell
remov
hour
adher
cell
cultur
memalpha
contain
fb
growth
curv
obtain
seed
plate
cell
per
well
cell
stain
use
oil
red
observ
adipocyt
differenti
result
rbclayer
msc
grow
success
follow
overnight
shipment
aspir
ident
mnclayer
msc
rbclayer
msc
exhibit
fibroblast
morpholog
adher
plastic
rbclayer
msc
persist
cultur
passag
senesc
exhibit
slower
growth
curv
rel
mnclayer
msc
overal
doubl
time
similar
approxim
hour
surprisingli
msc
rbclayer
exhibit
adipocyt
differenti
stimul
reveal
stemcel
like
qualiti
present
method
isol
msc
discard
portion
bone
marrow
aspir
interfer
isol
leukemia
cell
patient
portion
aspir
ship
sit
least
hour
without
sacrif
msc
rbclayer
msc
nearli
ident
msc
obtain
convent
perhap
importantli
rbclayer
msc
retain
stemcel
like
capac
show
highli
valuabl
cell
popul
aml
research
futur
plan
includ
investig
potenti
select
enrich
stemcel
msc
rbclayer
could
explain
unexpect
differ
growth
kinet
aml
research
opportun
studi
excit
compon
bone
marrow
microenviron
without
sacrif
valuabl
leukem
cell
process
background
neutropenia
one
frequent
side
effect
chemotherapi
associ
increas
risk
infect
especi
case
depth
durat
neutropenia
extend
gene
variat
darc
gsdma
known
influenc
white
blood
cell
neutrophil
count
previou
studi
conduct
children
acut
lymphoblast
leukemia
show
polymorph
gene
might
play
role
onset
chemotherapi
complic
consolid
mainten
treatment
object
order
support
previou
find
expand
studi
induct
period
cohort
children
treat
saintejustin
univers
health
center
juli
juli
designmethod
previou
associ
singl
nucleotid
polymorph
snp
darc
gsdma
gene
analyz
associ
complic
occur
induct
includ
durat
low
neutrophil
count
pnn
low
absolut
phagocyt
count
apc
proven
infect
delay
induct
consolid
phase
result
signific
effect
found
studi
polymorphim
minor
allel
darc
gsdma
associ
higher
risk
complic
induct
treatment
wherea
darc
particularli
gg
genotyp
protect
effect
gg
genotyp
associ
lower
risk
postinduct
delay
p
ci
less
frequent
febril
episod
p
lower
number
day
apcpnn
count
reduct
p
apc
p
pnn
contrast
minor
allel
anoth
darc
polymorph
rs
associ
longer
apcpnn
count
reduct
p
apc
p
pnn
tt
genotyp
gsdma
p
apc
p
pnn
patient
gsdma
also
higher
risk
document
febril
episod
p
ci
aa
genotyp
associ
higher
risk
postinduct
delay
due
infect
p
ci
conclus
complementari
studi
confirm
previou
result
show
overal
variat
darc
gsdma
gene
influenc
onset
chemotherapi
complic
pediatr
regardless
treatment
phase
polymorph
might
use
pharmacogenet
marker
possibl
guid
adjust
chemotherapi
intens
background
pediatr
acut
myeloid
leukemia
aml
poor
surviv
rate
urgent
need
newer
target
therapi
car
tcell
base
therapi
effect
similar
therapi
aml
still
develop
recent
clinic
trial
highlight
concern
toxic
therapi
relat
death
car
tcell
antigen
select
key
factor
determin
specif
efficaci
toxic
car
tcell
contemporari
adopt
tcell
therapi
use
monoclon
antibodi
tumor
associ
antigen
employ
natur
occur
ligand
fl
target
aml
cell
express
receptor
receptor
express
multipot
myelomonocyt
progenitor
well
myeloid
leukemia
cell
gener
fl
contain
chimer
tlymphocyt
design
flcar
tcell
evalu
efficaci
aml
cell
designmethod
flcar
construct
fuse
code
sequenc
human
fl
costimulatori
domain
chain
intracellular
region
seri
clone
phivegfp
lentivir
vector
express
cell
line
primari
cell
obtain
healthi
donor
empti
phivegfp
vector
use
neg
control
flcar
express
tlymphocyt
confirm
western
blot
cell
cytox
evalu
cocultur
flcar
tcell
aml
cell
follow
flow
cytometr
analys
cytokin
product
assess
analyz
express
use
quantit
rtpcr
result
flcar
tcell
gener
jurkat
cell
line
lentivir
transduct
effici
effici
primari
cell
lower
flcar
express
kda
protein
cell
partial
phosphoryl
tyrosin
express
flcar
lymphocyt
lead
increas
basal
express
cell
augment
fold
upon
coincub
flcar
tcell
target
cell
jurkat
cell
cell
primari
human
cell
express
flcar
suppress
growth
aml
cell
line
primari
aml
cell
vitro
notabl
flcar
tcell
gener
healthi
donor
caus
strong
inhibit
aml
cell
even
lower
transduct
effici
vivo
experi
use
nsgsgm
mice
xenograft
human
aml
cell
underway
data
demonstr
flcar
effect
express
tlymphocyt
mediat
potent
cytotox
aml
cell
vitro
complet
human
deriv
chimer
protein
repres
promis
candid
therapeut
develop
holli
pacenta
kelli
sullivan
ahwan
pandey
kelli
maloney
joaquin
espinosa
children
hospit
colorado
denver
colorado
unit
state
background
individu
syndrom
ds
higher
risk
develop
acut
lymphoblast
leukemia
typic
popul
sever
import
differ
individu
ds
dsall
individu
without
ds
ndsall
first
patient
dsall
lower
percentag
favor
cytogenet
featur
compar
ndsall
second
patient
dsall
like
activ
mutat
overexpress
delet
despit
clear
genotyp
differ
knowledg
yet
exploit
therapeut
purpos
dsall
outcom
dsall
compar
ndsall
similar
cytogenet
featur
surviv
rate
similar
howev
individu
dsall
increas
risk
treatmentrel
mortal
trm
current
therapi
dsall
similar
ndsall
except
small
chang
decreas
toxic
preval
dsall
recent
identifi
interferon
signal
constitut
activ
healthi
individu
hypothes
aberr
interferon
signal
could
play
role
uniqu
leukemia
observ
ds
patient
object
identifi
differ
gene
express
intracellular
signal
cascad
uniqu
individu
dsall
rel
ndsall
healthi
individu
ds
exploit
therapeut
use
designmethod
bone
marrow
sampl
obtain
dsall
patient
match
ndsall
patient
base
clinic
characterist
genet
featur
rna
sequenc
sampl
perform
total
sampl
use
transcriptom
analysi
dsall
vs
ndsall
differenti
express
data
gener
analyz
use
ingenu
pathway
analysi
analysi
reveal
chromosom
gene
implic
leukemogenesi
differenti
express
dsall
sampl
rel
ndsall
inflammatori
signatur
identifi
includ
interferon
gamma
upstream
regul
predict
activ
dsall
find
consist
prior
observ
healthi
individu
ds
exampl
result
potenti
action
target
includ
upregul
sever
gene
ra
pathway
gene
involv
histon
methyl
increas
interferon
signal
seen
healthi
individu
ds
also
identifi
dsall
may
contribut
develop
mutat
inflammatori
pathway
dsall
target
common
pathway
small
molecul
inhibitor
may
therapeut
benefit
dsall
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
nextgener
sequenc
ng
guid
precis
medicin
approach
oncolog
use
therapi
target
molecular
alter
found
within
individu
cancer
increas
avail
ng
coupl
prolifer
target
drug
develop
heighten
need
reliabl
preclin
anim
model
report
patientderiv
xenograft
pdx
system
integr
molecular
profil
preclin
test
convent
cytotox
novel
target
agent
object
util
ng
patient
pediatr
leukemia
guid
ration
preclin
trial
pdx
leukemia
avatar
determin
pdx
mice
toler
respons
cytotox
target
therapi
pediatr
acut
lymphoblast
leukemia
sampl
obtain
adher
irbapprov
protocol
xenograft
rg
nrg
mice
ng
perform
clinic
use
heme
panel
de
novo
sampl
bear
mutat
involv
use
preclin
test
thirtyseven
nrg
mice
transplant
million
patient
cellsmous
via
iv
inject
standard
induct
chemotherapi
administ
consist
vincristin
dexamethason
pegaspargas
daunorubicin
vxpd
n
mice
comparison
vehicl
control
n
parallel
pdx
cohort
treat
singl
agent
target
therapi
base
ng
find
includ
ruxolitinib
n
crizotinib
n
n
fourweek
treatment
period
began
day
transplant
confirm
engraft
follow
complet
therapi
residu
diseas
burden
analyz
flow
cytometri
bone
marrow
bm
date
pdx
model
establish
use
thirti
ngsprofil
pediatr
sampl
includ
six
sampl
bear
philadelphia
ph
chromosom
phlike
mutat
preclin
test
perform
repr
conclus
ng
reveal
concomit
mutat
phlike
may
repres
addit
target
therapi
predict
tyrosin
kinas
inhibitor
tki
resist
show
xenograft
nrg
mice
toler
multiag
cytotox
chemotherapi
induct
regimen
well
ration
target
agent
serv
robust
preclin
model
precis
medicin
trial
background
osteonecrosi
wellcharacter
therapeut
toxic
attribut
glucocorticoid
asparaginas
methotrex
disproportion
affect
adolesc
alternateweek
dexamethason
doubl
delay
intensif
di
reduc
osteonecrosi
vs
continu
dexamethason
singl
di
rapid
earli
respond
rer
compar
ef
os
hrall
patient
vs
without
osteonecrosi
designmethod
hrall
patient
receiv
cog
augment
therapi
random
induct
dexamethason
vs
prednison
interim
mainten
im
highdos
methotrex
hdm
vs
escalatingdos
methotrexatepegaspargas
ema
rer
receiv
singl
slow
earli
respond
ser
doubl
imdi
initi
receiv
monthli
dexamethason
mainten
puls
patient
receiv
di
alternateweek
dexamethason
patient
receiv
di
continu
dexamethason
osteonecrosisrel
amend
patient
receiv
di
alternateweek
dexamethason
patient
assign
induct
prednison
patient
receiv
di
alternateweek
dexamethason
mainten
prednison
puls
result
osteonecrosi
confirm
patient
cumul
incid
ci
overal
increas
age
alternateweek
dexamethason
vs
continu
dexamethason
p
p
among
random
rer
patient
ci
differ
glucocorticoid
dexamethason
vs
prednison
p
methotrex
assign
hdm
vs
ema
p
among
random
ser
patient
ci
differ
regimen
result
similar
patient
entir
studi
popul
patient
osteonecrosi
superior
ef
vs
p
os
vs
p
without
osteonecrosi
ef
significantli
higher
among
random
patient
vs
without
osteonecrosi
vs
p
find
present
differ
age
rang
rerser
subset
within
especi
rer
vs
p
ser
vs
p
cohort
across
group
asparaginas
allergi
significantli
associ
reduc
osteonecrosi
risk
hr
p
patient
develop
osteonecrosi
significantli
increas
ef
os
suggest
host
differ
increas
sensit
develop
osteonecrosi
render
cell
chemorespons
pennsylvania
state
univers
hershey
pennsylvania
unit
state
background
cell
divis
cycl
protein
belong
rho
famili
small
gtpase
rasoncogen
superfamili
prooncogen
role
overexpress
ra
driven
solid
tumor
well
known
howev
role
leukemia
yet
establish
encod
ikaro
protein
import
role
regul
lymphoid
develop
tumor
suppress
leukemia
casein
kinas
ii
oncogen
overexpress
leukemia
impair
ikaro
function
restor
use
inhibitor
object
investig
role
leukemia
regul
ikaro
bcell
acut
lymphoblast
leukemia
ball
shrna
transfect
real
timepcr
luciferac
assay
quantit
chromatin
immunoprecipit
qchip
coupl
nextgener
sequenc
chipseq
cytotox
assay
western
blot
result
identifi
one
ikaro
target
gene
analysi
genomewid
dna
bind
ikaro
use
chipseq
qchip
ball
primari
cell
express
also
note
higher
patient
sampl
compar
normal
bone
marrow
function
experi
show
ikaro
overexpress
via
retrovir
transduct
result
transcript
repress
ikaro
silenc
use
shrna
result
increas
express
data
suggest
ikaro
neg
regul
transcript
express
directli
phosphoryl
ikaro
impair
function
transcript
factor
note
molecular
inhibit
via
sirna
well
treatment
specif
inhibitor
also
decreas
express
treatment
primari
ball
ikaro
haploinsuffici
restor
ikaro
bind
promot
repress
express
howev
effect
evid
presenc
ikaro
treatment
ikaro
silenc
ikaro
shrna
cell
show
chang
express
result
emphas
import
ikaro
regul
express
furthermor
analyz
chang
epigenet
signatur
promot
follow
treatment
result
show
loss
histon
marker
open
chromatin
increas
histon
marker
repress
chromatin
promot
data
suggest
ikaro
transcript
repress
via
chromatin
remodel
specif
inhibitor
show
cytotox
effect
primari
ball
cell
conclus
may
import
role
hematolog
malign
express
b
cell
regul
ikaro
result
suggest
target
could
potenti
therapeut
strategi
leukemia
caitlyn
duffi
laura
hall
justin
godown
koyama
tatsuki
scott
borinstein
monro
carel
jr
children
hospit
vanderbilt
nashvil
tennesse
unit
state
background
system
corticosteroid
wide
use
treatment
acut
lymphoblast
leukemia
lymphoblast
lymphoma
anecdot
report
bradycardia
pediatr
patient
receiv
corticosteroid
extens
analysi
effect
need
object
aim
studi
describ
incid
sever
time
steroidinduc
bradycardia
document
advers
event
associ
bradycardia
designmethod
perform
retrospect
review
newli
diagnos
patient
center
alllymphoblast
lymphoma
receiv
corticosteroid
dexamethason
dose
prednison
dose
induct
chemotherapi
patient
exclud
preexist
cardiac
abnorm
receiv
prior
corticosteroid
averag
hour
heart
rate
hr
assess
period
prior
initi
steroid
therapi
hour
period
surround
nadir
follow
steroid
administr
degre
time
steroid
induc
bradycardia
assess
advers
patient
event
concomit
medic
use
document
identifi
contribut
factor
bradycardia
total
children
femal
male
year
includ
analysi
demonstr
decreas
mean
hr
follow
steroid
administr
median
hr
decreas
beat
per
minut
quartil
prior
initi
steroid
surround
nadir
sixti
one
percent
develop
bradycardia
less
equal
percentil
age
rang
nadir
occur
dose
rang
treatment
correspond
hour
initi
therapi
patient
experienc
bradycardia
associ
dexamethason
rather
prednison
hr
nadir
associ
vital
sign
abnorm
complet
induct
chemotherapi
patient
document
resolut
bradycardia
hr
greater
percentil
age
observ
children
continu
rel
low
hr
often
younger
year
old
examin
nadir
hr
subsequ
hospit
steroid
administ
exclud
hr
procedur
sedat
demonstr
signific
incid
bradycardia
concomit
opioid
betablock
medic
exposur
contribut
incid
bradycardia
corticosteroidinduc
bradycardia
extrem
common
children
teenag
young
adult
receiv
induct
chemotherapi
bradycardia
associ
clinic
advers
event
resolv
complet
corticosteroid
treatment
therefor
cardiac
assess
may
warrant
presenc
bradycardia
suspect
secondari
steroid
administr
baylor
colleg
medicin
houston
texa
unit
state
background
surviv
newli
diagnos
pediatr
acut
myeloid
leukemia
aml
approxim
howev
surviv
fall
dramat
patient
relaps
current
approxim
onethird
patient
pediatr
aml
relaps
standard
chemotherapi
regimen
aml
cell
expos
proteotox
stress
baselin
due
rapid
ineffici
metabol
proteotox
stress
increas
chemotherapi
due
accumul
reactiv
oxygen
speci
result
misfold
protein
lead
activ
cell
stress
pathway
unfold
protein
respons
upr
endoplasm
reticulum
activ
upr
make
cell
sensit
proteotox
stress
hypothes
upr
activ
correl
respons
chemotherapi
object
determin
statu
upr
pediatr
aml
correl
chemosensit
designmethod
peripher
blood
sampl
pediatr
patient
aml
collect
start
induct
chemotherapi
hour
h
h
post
initi
system
chemotherapi
tumor
cell
sort
peripher
blood
mononuclear
cell
express
upr
protein
determin
chemiluminesc
use
autom
capillari
electrophoresi
system
clinic
correl
perform
use
annot
databas
measur
five
upr
protein
glucos
regul
protein
inositolrequir
enzym
activ
transcript
factor
patient
aml
time
higher
express
upr
protein
except
baselin
normal
control
key
upr
driverhad
highest
level
protein
express
myeloid
blast
wide
variabl
level
baselin
upr
express
eight
sampl
express
fold
increas
lowest
level
similarli
patient
respect
fold
increas
compar
patient
low
basal
express
upr
protein
limit
sampl
set
trend
toward
lower
overal
surviv
os
eventfre
surviv
patient
low
baselin
conclus
upr
variabl
express
baselin
pediatr
aml
trend
toward
lower
os
patient
low
basal
low
express
suggest
less
chemosensit
subgroup
convers
possibl
blast
upregul
upr
prior
chemotherapi
manag
proteotox
stress
less
effect
faster
apoptosi
henc
better
respons
chemotherapi
patient
high
basal
upr
current
expand
find
larger
cohort
patient
enrol
children
oncolog
group
protocol
background
children
newli
diagnos
acut
lymphoblast
leukemia
undergo
chest
xray
cxr
evalu
initi
diagnost
workup
ensur
safe
airway
manag
howev
knowledg
systemat
assess
cxr
find
report
object
evalu
cxr
find
diagnosi
associ
clinic
characterist
review
cxr
find
diagnosi
patient
treat
total
xv
xvi
protocol
st
jude
children
research
hospit
find
evalu
associ
clinic
characterist
present
clinic
manag
mediastin
mass
review
mediastin
mass
seen
patient
evalu
common
older
patient
mean
age
year
younger
patient
mean
age
year
p
male
femal
p
patient
tall
ball
p
also
associ
mediastin
mass
higher
white
blood
cell
count
wbc
diagnosi
mean
vs
lower
wbc
mean
p
cn
involv
vs
involv
p
standardhighrisk
diseas
vs
lowrisk
diseas
p
cxr
find
includ
pulmonari
opac
patient
bronchialperihilar
thicken
patient
cardiomegali
patient
osteopeniafractureperiost
lesion
patient
pulmonari
opac
common
younger
patient
mean
age
year
older
patient
mean
age
year
p
tall
vs
ball
p
bronchialperihilar
thicken
cardiomegali
osteopeniafractureperiost
lesion
also
common
younger
patient
older
one
p
p
p
respect
lowrisk
diseas
versu
standardhighrisk
diseas
p
p
p
respect
patient
mediastin
mass
cxr
underw
confirmatori
chest
ct
scan
confirm
mediastin
mass
notabl
patient
airway
compress
compress
venou
structur
identifi
patient
receiv
iv
contrast
clinic
cours
evalu
patient
mediastin
mass
detect
cxr
fifti
patient
requir
icu
admiss
mean
stay
day
gener
anesthesia
use
patient
patient
less
invas
peripher
insert
central
cathet
death
occur
acut
phase
conclus
cxr
time
diagnosi
detect
variou
intrathorac
lesion
help
plan
initi
diagnost
workup
manag
background
mertk
receptor
tyrosin
kinas
aberrantli
express
pediatr
primari
aml
sampl
mertk
inhibit
small
molecul
tyrosin
kinas
inhibitor
tki
decreas
tumor
burden
prolong
surviv
aml
xenograft
treatment
reduc
leukemia
peripher
blood
less
effect
bone
marrow
suggest
role
marrow
microenviron
therapeut
resist
jakstat
pathway
implic
mediat
bone
marrow
deriv
resist
tki
inhibitor
pathway
clinic
develop
treatment
aml
determin
role
bone
marrow
stromal
nich
mediat
resist
mertk
inhibit
evalu
efficaci
combin
mertk
jakstat
inhibit
designmethod
aml
cell
line
cultur
without
stromal
cell
line
condit
medium
treat
jakstat
inhibitor
ruxolitinib
control
induct
apoptosi
cell
cycl
arrest
aml
cell
measur
flow
cytometri
express
total
phosphoryl
determin
immunoblot
result
cocultur
stromal
cell
significantli
reduc
aml
cell
death
phase
arrest
respons
treatment
compar
cocultur
cell
death
versu
p
arrest
versu
p
arrest
accompani
increas
express
similarli
abrog
cocultur
condit
medium
provid
protect
induc
apoptosi
arrest
induct
inhibit
phosphoryl
direct
cocultur
condit
medium
potent
increas
basal
phosphoryl
inhibit
determin
whether
observ
induct
phosphoryl
function
relev
cocultur
treat
ruxolitinib
ruxolitinib
potent
inhibit
phosphoryl
presenc
cocultur
combin
treatment
overcom
stromal
mediat
protect
induc
apoptosi
similarli
addit
exogen
gmcsf
induc
phosphoryl
yield
protect
function
effect
absenc
cocultur
togeth
data
support
model
wherebi
direct
cellcel
contact
stromal
cell
bone
marrow
nich
protect
leukemia
cell
induc
apoptosi
cell
cycl
alter
dna
damag
cocultur
potent
induc
phosphoryl
leukemia
cell
neither
necessari
suffici
stromalcel
mediat
protect
mertk
inhibit
combin
treatment
jakstat
inhibitor
unlik
therapeut
efficaci
background
mercaptopurin
immunosuppress
thiopurin
drug
key
compon
acut
lymphoblast
leukemia
treatment
metabol
respons
antileukem
effect
well
nucleotid
associ
hepatotox
patient
preferenti
metabol
increas
risk
hepatotox
potenti
reduc
antileukem
effect
hepatotox
caus
interrupt
delay
therapi
may
jeopard
cure
rate
allopurinol
increasingli
use
patient
inflammatori
bowel
diseas
ibd
shunt
metabol
toward
away
minim
hepatotox
preserv
therapeut
effect
object
retrospect
chart
review
expand
upon
previous
publish
case
seri
three
patient
allopurinol
success
use
redirect
metabol
twelv
addit
patient
subsequ
receiv
allopurinol
combin
therapi
texa
children
hospit
data
larger
patient
sampl
longer
follow
analyz
increas
knowledg
effect
longitudin
effect
ad
allopurinol
reduc
risk
hepatotox
designmethod
data
abstract
electron
medic
record
patient
treat
texa
children
hospit
present
found
evid
alter
metabol
allopurinol
ad
therapi
due
concern
risk
recurr
hepatotox
metabolit
level
dose
alanin
transaminas
alt
prior
initi
allopurinol
approxim
week
later
compar
wilcoxon
signedrank
test
appli
statist
analysi
addit
allopurinol
patient
experienc
signific
decreas
mean
level
p
correl
signific
decreas
mean
alt
p
initi
allopurinol
mean
dose
decreas
period
mean
level
increas
p
follow
beyond
week
patient
hold
due
hepatotox
addit
allopurinol
appear
shift
metabol
toward
increas
mean
level
despit
decreas
mean
dose
may
limit
neg
side
effect
thu
result
fewer
gap
therapi
possibl
improv
outcom
analysi
dose
titrat
effect
anc
time
well
effect
overal
surviv
ongo
prospect
background
alter
epigenet
pattern
fundament
featur
acut
myeloid
leukemia
aml
treatment
dna
methyltransferas
inhibitor
dnmti
yield
respons
aml
molecular
mechan
underli
effect
poorli
understood
prior
work
demonstr
induct
gene
involv
pirna
rna
piwi
silenc
pathway
common
gene
featur
aml
cell
line
treat
decitabin
piwi
pathway
rna
silenc
system
distinct
classic
small
rna
transcript
silenc
respons
transposonsilenc
gametogenesi
emerg
data
suggest
role
system
somat
cell
base
data
postul
piwi
induct
play
crucial
role
aml
recoveri
follow
demethyl
disrupt
pathway
would
modul
respons
andor
recoveri
decitabin
treatment
assess
effect
contribut
pirna
pathway
respons
follow
dnmti
treatment
aml
designmethod
choos
target
gene
pirna
pathway
disrupt
cell
first
treat
escal
dose
decitabin
use
quantit
rtpcr
dosedepend
express
sever
pirnaassoci
gene
analyz
two
gene
mael
select
disrupt
experi
base
preliminari
data
suggest
decitabin
dosedepend
respons
cell
transduc
shrna
target
gene
use
lentiviru
deliveri
system
select
puromycin
knockdown
effici
assess
rtqpcr
determin
gene
disrupt
affect
cell
growth
knockdown
cell
treat
decitabin
prolifer
assess
celltit
glo
assay
follow
decitabin
treatment
clonogen
potenti
assess
coloni
form
assay
transduc
cell
treatment
decitabin
result
follow
decitabin
exposur
markedli
increas
express
mael
compar
untreat
cell
respect
thu
candid
gene
chosen
disrupt
mael
shrna
construct
two
result
rel
express
mael
compar
control
shrna
construct
best
knockdown
show
rel
express
signific
differ
prolifer
clonogen
stabli
select
mael
knockdown
cell
follow
decitabin
treatment
use
gene
knockdown
procedur
mael
appear
mark
effect
growth
respons
decitabin
treatment
howev
result
may
limit
ineffici
knockdown
use
shrna
target
method
work
use
base
inactiv
gene
ongo
children
cancer
hospit
cairo
egypt
background
hypodiploidi
chromosom
uncommon
particularli
poor
outcom
childhood
acut
lymphoblast
leukemia
subdivid
nearhaploid
lowhypodiploid
highhypodiploid
determin
minim
residu
diseas
mrd
identifi
group
patient
better
prognosi
hypodploid
popul
treat
intens
chemotherapi
alon
designmethod
retrospect
studi
includ
patient
age
diagnos
hypodiploid
bprecursor
period
januari
treat
children
cancer
hospit
egypt
sjcrh
total
studyxv
irhr
sixteen
patient
chromosom
nearhaploid
lowhypodiploid
constitut
pediatr
patient
bprecursor
studi
period
patient
nearhaploid
median
age
year
rang
initi
leukocyt
count
wbc
median
rang
male
hrnci
criteria
four
patient
aliv
complet
remiss
cr
rang
month
median
one
die
induct
hematolog
relaps
rang
month
median
patient
lowhypodiploid
significantli
older
age
median
year
rang
median
wbc
rang
male
one
patient
aliv
cr
one
die
induct
one
fail
achiev
cr
postinduct
patient
hematolog
relaps
rang
month
median
mrd
flowcytometri
end
induct
achiev
patient
nearhaploid
compar
patient
lowhypodiploid
respect
p
p
respect
allogen
transplant
perform
initi
remiss
mrd
neg
patient
one
relaps
one
cr
patient
induct
failur
relaps
posttranspl
five
total
six
patient
neg
mrd
end
induct
aliv
cr
chemotherapi
alon
patient
neg
mrd
end
induct
mrd
rang
relaps
well
patient
detect
mrd
end
induct
differ
relaps
statist
signific
relat
negativemrd
p
end
induct
p
conclus
children
hypodiploid
neg
mrd
induct
highli
curabl
intens
chemotherapi
alon
patient
neg
mrd
end
induct
detect
mrd
dismal
outcom
background
overal
surviv
pediatr
acut
myeloid
leukemia
aml
plateau
death
induct
chemotherapi
seen
patient
respiratori
complic
contribut
morbid
mortal
pediatr
aml
induct
howev
incid
pattern
predictor
respiratori
advers
event
ae
period
unknown
estim
incid
respiratori
ae
induct
therapi
de
novo
pediatr
aml
character
grade
respiratori
ae
identifi
predictor
respiratori
ae
develop
conduct
retrospect
longitudin
studi
present
day
institut
de
novo
pediatr
aml
patient
year
march
decemb
outcom
includ
nci
ctcae
grade
respiratori
ae
death
anoth
caus
demograph
diseas
treatmentrel
data
abstract
specif
bestfit
ctcae
categori
grade
ae
determin
descript
statist
surviv
analysi
multivari
logist
regress
analysi
timetoev
distribut
perform
sa
cari
nc
among
elig
patient
n
experienc
discret
respiratori
ae
incid
grade
ae
n
bimod
timetoev
distribut
demonstr
peak
treatment
day
induct
death
occur
n
includ
death
respiratori
failur
associ
dissemin
fungal
diseas
univari
analysi
experienc
ae
differ
significantli
regard
older
age
diagnosi
p
higher
initi
wbc
p
higher
initi
peripher
blast
percentag
p
coagulopathi
diagnosi
pt
p
ddimer
p
fluid
overload
statu
p
occurr
infect
p
occurr
tumor
lysi
syndrom
tl
p
patient
hyperleukocytosi
p
fluid
overload
p
fab
morpholog
p
significantli
decreas
probabl
complet
follow
period
without
experienc
respiratori
ae
multivari
analysi
fluid
overload
aor
ci
older
age
aor
ci
significantli
associ
ae
occurr
gender
hyperleukocytosi
tl
infect
statu
held
constant
describ
high
incid
respiratori
ae
pediatr
aml
induct
fluid
overload
older
age
diagnosi
independ
associ
ae
develop
control
propos
risk
factor
intervent
focus
conserv
fluid
manag
offset
fluid
overload
explor
newli
diagnos
pediatr
aml
effort
reduc
respiratori
complic
induct
overal
surviv
rate
outstand
continu
improv
riskadapt
therapi
strike
improv
occur
tall
os
rate
exceed
parallel
ball
surviv
improv
howev
observ
uniformli
across
subgroup
gap
outcom
differ
narrow
among
black
outcom
hispan
remain
static
improv
surviv
observ
infant
aya
new
treatment
approach
implement
popul
background
acut
myeloid
leukemia
aml
account
approxim
new
childhood
leukemia
case
chest
xray
cxr
perform
newli
diagnos
aml
case
evalu
safeti
airway
manag
anesthesia
diagnost
procedur
howev
cxr
result
pediatr
patient
aml
describ
object
primari
object
evalu
cxr
find
diagnosi
patient
aml
secondari
object
includ
assess
associ
cxr
find
clinic
characterist
overal
goal
aid
evalu
use
cxr
initi
diagnost
studi
pediatr
patient
aml
designmethod
cxr
find
clinic
characterist
evalu
patient
newli
diagnos
aml
enrol
one
three
protocol
st
jude
children
research
hospit
find
categor
base
radiolog
report
associ
find
clinic
characterist
evalu
evalu
cxr
find
total
patient
common
cxr
find
pulmonari
opac
n
bronchialperihilar
thicken
n
splenomegali
n
mediastin
mass
lymph
node
n
pleural
effusionthicken
n
demineralizationfractureperiost
lesion
n
scoliosi
n
granulomat
diseas
n
three
cxr
find
associ
younger
age
diagnosi
pulmonari
opac
median
age
year
patient
posit
find
vs
year
neg
find
p
bronchialperihilar
thicken
median
age
year
vs
year
p
demineralizationfractureperiost
lesion
median
age
year
vs
year
p
two
cxr
find
associ
older
age
diagnosi
scoliosi
median
age
year
vs
year
p
granulomat
diseas
median
age
year
vs
year
p
higher
white
blood
cell
count
wbc
diagnosi
associ
cxr
show
pulmonari
opac
median
wbc
vs
p
splenomegali
median
wbc
vs
p
frenchamericanbritish
fab
subtyp
frequent
associ
pulmonari
opac
compar
other
p
find
signific
differ
femal
male
patient
conclus
cxr
patient
newli
diagnos
aml
show
varieti
thorac
abdomin
boni
lesion
import
initi
evalu
manag
pulmonari
opac
common
find
frequent
seen
patient
younger
higher
wbc
diagnosi
fab
background
children
diagnos
acut
lymphoblast
leukemia
requir
central
venou
cathet
cvc
administ
chemotherapi
safe
extern
intern
cvc
carri
risk
complic
includ
thrombosi
infect
possibl
replac
intern
cathet
port
gener
use
major
patient
durat
treatment
sinc
therapi
last
sever
year
mani
institut
place
port
time
diagnosi
institut
prefer
start
induct
therapi
via
placement
peripher
insert
central
cathet
picc
defer
port
placement
complet
induct
therapi
due
concern
increas
risk
infecti
complic
port
placement
object
compar
rate
common
cvc
associ
complic
type
cvc
place
start
induct
therapi
children
treat
newli
diagnos
jimmi
everest
center
jec
univers
oklahoma
health
scienc
center
designmethod
retrospect
chart
review
analyz
data
newli
diagnos
patient
treat
jec
data
collect
complic
includ
thrombosi
bacteremia
insert
site
infect
cvc
malfunct
need
remov
data
collect
began
start
induct
complet
end
induct
therapi
statist
analysi
use
univari
multivari
logist
regress
model
compar
complic
rate
port
versu
picc
place
start
induct
result
data
collect
patient
fiftysix
patient
port
place
start
therapi
picc
place
fourteen
percent
patient
cvc
associ
complic
univari
analysi
show
statist
signific
differ
rate
cvc
associ
complic
group
port
picc
p
rate
hospit
cvc
associ
complic
similar
group
port
picc
p
rate
cvc
remov
also
similar
group
port
picc
p
multivari
model
includ
baselin
patient
characterist
includ
type
patient
bodi
surfac
area
gender
ethnic
age
continu
demonstr
signific
differ
cvc
associ
complic
group
conclus
singl
institut
studi
show
signific
differ
cvc
associ
complic
port
picc
line
placement
start
childhood
induct
therapi
port
placement
consid
safe
option
start
induct
therapi
complet
remiss
cr
cr
incomplet
blood
count
recoveri
cri
within
treatment
cycl
interim
data
report
result
seventeen
patient
enrol
receiv
dose
lenalidomid
median
age
year
rang
patient
femal
patient
receiv
median
prior
regimen
rang
nine
patient
previous
undergon
bone
marrow
transplant
bmt
four
patient
relaps
aml
refractori
immedi
prior
treatment
median
durat
studi
treatment
week
rang
patient
complet
median
treatment
cycl
rang
patient
evalu
primari
outcom
achiev
morpholog
cri
cycl
patient
achiev
cr
respond
male
histori
rr
aml
firstand
secondlin
treatment
bmt
salvag
chemotherapi
baselin
complex
cytogenet
karyotyp
monoallel
identifi
molecular
mutat
also
posit
del
posttreat
karyotyp
show
abnorm
sixteen
patient
experienc
treatment
failur
due
resist
diseas
indetermin
caus
treatment
failur
postbaselin
assess
perform
patient
experienc
grade
treatmentemerg
advers
event
teae
commonli
report
thrombocytopenia
n
anemia
n
febril
neutropenia
n
hypokalemia
n
fifteen
patient
experienc
teae
relat
lenalidomid
patient
discontinu
treatment
remain
followup
studi
close
enrol
ten
patient
die
studi
treatment
followup
death
attribut
aml
complic
due
aml
conclus
thirdlin
lenalidomid
monotherapi
associ
clinic
respons
pediatr
patient
rr
aml
howev
treatment
exposur
limit
safeti
data
consist
known
profil
lenalidomid
lenalidomid
efficaci
treatment
rr
pediatr
aml
fund
celgen
corpor
summit
nj
usa
cook
children
medic
center
fort
worth
texa
unit
state
background
well
document
pediatr
patient
acut
lymphoblast
leukemia
often
experi
signific
weight
gain
induct
therapi
later
struggl
obes
howev
patient
experi
unintend
weight
loss
induct
therapi
sinc
issu
well
report
often
goe
undertr
although
malnutrit
report
associ
decreas
surviv
increas
risk
infect
loss
lean
bodi
mass
remain
scarciti
indepth
analysi
preval
risk
factor
contribut
problem
studi
attempt
address
critic
yet
unmet
need
object
aim
identifi
clinic
risk
factor
outcom
associ
weight
loss
induct
therapi
pediatr
designmethod
retrospect
chart
review
patient
year
age
diagnos
cook
children
medic
center
patient
collect
height
weight
age
bodi
mass
index
bmi
zscore
diagnosi
end
induct
therapi
risk
stratif
whether
consolid
delay
patient
bmi
percentil
diagnosi
categor
overweight
obes
use
logist
regress
analys
examin
variabl
predict
whether
patient
increas
decreas
bmi
zscore
throughout
induct
critic
alpha
level
indic
statist
signific
result
ninetysix
patient
met
inclus
criteria
experienc
decreas
bmi
induct
therapi
compar
patient
whose
bmi
increas
induct
patient
decreas
bmi
like
overweight
obes
diagnosi
vs
p
year
age
vs
p
highor
veryhighrisk
stratif
vs
p
experi
delay
start
consolid
therapi
vs
p
conclus
research
highlight
risk
previous
identifi
literatur
may
impact
outcom
patient
treat
highor
veryhighrisk
protocol
overweight
obes
diagnosi
year
age
diagnosi
monitor
close
weight
loss
induct
therapi
patient
experi
weight
loss
receiv
prompt
intervent
hope
inform
use
futur
prospect
studi
help
develop
evidencebas
guidelin
background
abnorm
observ
patient
hematolog
malign
loss
function
tumor
suppressor
gene
chromosom
play
import
role
develop
leukemia
patient
usual
poor
outcom
due
chemotherapi
associ
poor
prognosi
object
studi
aim
identifi
frequenc
abnorm
iranian
children
adult
patient
aml
acut
myeloid
leukemia
malign
designmethod
abnorm
analyz
via
bone
marrow
karyotyp
fish
method
acut
myeloid
leukemia
patient
studi
abnorm
observ
patient
diagnos
case
signific
strong
correl
abnorm
high
risk
factor
poor
risk
cytogenet
observ
patient
aml
malign
abnorm
patient
complex
karyotyp
patient
monosom
karyotyp
patient
monosom
karyotyp
accompani
complex
karyotyp
overal
abnorm
independ
risk
factor
acut
myeloid
leukemia
evalu
abnorm
fish
complementari
techniqu
prior
treatment
might
help
better
risk
stratif
high
risk
aml
patient
background
hepatotox
treatment
acut
lymphoblast
leukemia
well
studi
transient
affect
patient
receiv
antimetabolit
therapi
rare
patient
develop
liver
injuri
sever
prolong
enough
undergo
liver
biopsi
littl
known
patient
differ
patient
develop
transient
hepatotox
sought
describ
diseas
treatment
characterist
patient
develop
hepatotox
sever
enough
undergo
liver
biopsi
also
look
predict
factor
liver
biopsi
includ
sign
earli
hepat
injuri
initi
treatment
protocol
designmethod
patholog
report
patient
liver
biopsi
databas
children
healthcar
atlanta
collect
control
match
age
subtyp
treatment
protocol
demograph
treatment
protocol
overal
outcom
collect
electron
health
record
hepat
lab
result
transaminas
coagul
albumin
collect
induct
consolid
interim
mainten
delay
intensif
mainten
result
sixteen
patient
diagnos
median
age
diagnosi
year
rang
male
preb
includ
case
seri
median
time
diagnosi
liver
biopsi
year
rang
eight
patient
mainten
time
biopsi
none
activ
diseas
eight
postbon
marrow
transplant
biopsi
result
includ
steatosi
acut
inflammatoryinfecti
liver
infiltr
fibrosi
graftvshost
diseas
gvhd
six
patient
deceas
allcaus
mortal
diagnosi
thiopurin
methyltransferas
tpmt
statu
known
case
control
case
intermedi
wildtyp
statu
differ
control
p
patient
requir
liver
biopsi
evid
acut
hepatotox
astalt
normal
valu
initi
treatment
protocol
hepatotox
requir
liver
biopsi
rare
outcom
treatment
patient
elev
rate
relaps
bmt
allcaus
mortal
suggest
sever
diseas
process
howev
difficult
sort
tempor
relaps
bmt
hepatox
requir
biopsi
limit
sampl
addit
patient
bmt
preced
liver
biopsi
confound
factor
make
difficult
includ
analysi
final
limit
descript
data
show
notabl
correl
earli
hepatotox
later
indic
liver
biopsi
futur
cohort
casecontrol
studi
larger
sampl
size
requir
explor
earli
predict
factor
sever
hepatotox
requir
liver
biopsi
nathan
gossai
joanna
perkin
michael
richard
yoav
messing
bruce
bostrom
background
major
chemotherapeut
agent
use
treat
hodgkin
lymphoma
teratogen
pregnanc
screen
prior
start
chemotherapi
support
clinic
guidelin
baselin
test
standard
compon
therapeut
trial
limit
data
avail
incid
pregnanc
screen
prior
start
hodgkin
therapi
previou
studi
suggest
pregnanc
screen
especi
pediatr
institut
consist
complet
object
object
studi
evalu
incid
pregnanc
screen
contracept
counsel
prior
start
therapi
femal
diagnos
hodgkin
lymphoma
designmethod
retrospect
chart
review
perform
femal
patient
newli
diagnos
hodgkin
lymphoma
hospit
sick
children
toronto
ontario
patient
intend
receiv
multiag
chemotherapi
includ
regardless
age
data
collect
includ
demograph
diseas
inform
chemotherapi
regimen
enrol
clinic
trial
pregnanc
test
within
two
week
prior
start
therapi
captur
well
type
pregnanc
test
perform
document
menstrual
statu
contracept
counsel
contracept
provis
univari
multivari
analys
use
describ
factor
influenc
incid
pregnanc
test
result
total
femal
patient
newli
diagnos
hodgkin
lymphoma
age
year
identifi
sixti
patient
pregnanc
test
done
prior
start
therapi
test
modal
includ
serum
urin
screen
well
quantit
betahcg
measur
older
age
p
document
menstrual
statu
diagnosi
p
diagnosi
p
associ
higher
incid
screen
enrol
therapeut
trial
associ
higher
incid
screen
p
contracept
counsel
document
patient
patient
prescrib
contracept
medic
therapi
prechemotherapi
pregnanc
test
complet
femal
newli
diagnos
hodgkin
lymphoma
improv
requir
intervent
includ
clarif
institut
standard
modif
chemotherapi
order
set
staff
educ
plan
rao
et
al
cancer
univers
louisvil
louisvil
kentucki
unit
state
background
granulocyt
sarcoma
also
known
chloroma
leukemia
cuti
first
describ
burn
solid
tumor
compris
immatur
granulocyt
cell
repres
extramedullari
manifest
underli
leukemia
chloroma
commonli
associ
acut
myeloid
leukemia
may
aris
myeloprolif
disord
rare
seen
b
cell
acut
lymphoblast
leukemia
object
although
patient
rare
chloroma
remain
differenti
patient
unusu
swell
mass
designmethod
present
case
seri
two
patient
institut
diagnos
b
cell
chloroma
present
symptom
first
patient
present
primari
provid
nasal
congest
oneweek
histori
bilater
eye
swell
refer
allergist
symptom
resolv
antihistamin
review
system
otherwis
neg
refer
urgent
ent
two
month
later
mass
palpat
along
medial
border
left
eye
mri
show
left
facial
mass
surround
zygoma
extend
anterior
inferior
left
orbit
biopsi
reveal
b
cell
acut
lymphoblast
lymphoma
bone
marrow
aspir
biopsi
confirm
diagnosi
b
cell
second
patient
present
primari
doctor
rapid
growth
scalp
nodul
present
month
refer
dermatolog
treat
suppos
kerion
tinea
capiti
lesion
continu
grow
becam
irrit
treatment
punch
biopsi
reveal
complic
phenotyp
lymphoblast
lymphoma
howev
lymph
node
biopsi
bone
marrow
aspir
biopsi
diagnosi
confirm
b
posit
point
review
system
question
patholog
weight
loss
area
mat
cervic
lymph
node
patient
chloroma
complet
disappear
induct
therapi
worth
note
patient
present
chloroma
symptom
underli
leukemia
led
initi
misdiagnosi
delay
identifi
leukemia
therefor
rare
patient
b
present
chloroma
experi
show
differenti
patient
present
unusu
swell
mass
background
hodgkin
lymphoma
hl
lymphoprolif
neoplasm
commonli
present
histori
adenopathi
predict
pattern
diseas
involv
without
system
symptom
fever
andor
weight
loss
hand
experienc
oncologist
diagnosi
hl
usual
challeng
occasion
diagnost
challeng
present
patient
atyp
present
suggest
altern
diagnosi
describ
case
seri
patient
diagnos
hl
whose
initi
clinic
present
lead
diagnosi
differ
form
hl
hondura
nicaragua
unit
state
result
six
pediatr
oncolog
center
american
contin
conduct
retrospect
review
patient
diagnos
hl
sinc
patient
initi
present
suggest
hl
initi
diagnos
diseas
hl
includ
total
patient
argentina
n
guatemala
n
hondura
n
nicaragua
n
unit
state
n
five
patient
femal
male
patient
age
rang
year
patient
n
older
year
three
patient
present
nonimmun
cytopenia
without
overt
lymphadenopathi
one
activ
hemophagocyt
syndrom
five
patient
suspect
local
solid
tumor
ewe
sarcoma
n
rhabdomyosarcoma
n
hepatocellular
carcinoma
n
soft
tissu
tumor
cheek
n
two
metastat
solid
malign
present
dissemin
pulmonari
nodul
five
autoimmun
disord
hashimoto
thyroid
n
autoimmun
hemolyt
anemia
n
nephrot
syndrom
n
ten
chronic
infecti
process
brucella
n
tonsillar
abscess
n
splenic
abscess
n
tuberculosi
tb
n
patient
suspect
tuberculosi
diagnos
outsid
unit
state
six
patient
ultim
diagnos
tb
hl
seventeen
patient
annarbor
stage
iii
iv
seven
patient
stage
ii
either
b
symptom
bulki
diseas
patient
treat
variou
chemotherapi
regimen
accord
treat
center
abvd
abvepc
oepacopdac
avpc
beacopp
two
patient
recurr
diseas
one
die
diseas
progress
one
die
caus
relat
hl
conclus
small
proport
hl
patient
atyp
unusu
present
hl
includ
differenti
diagnosi
solid
tumor
autoimmun
disord
infect
cytopenia
common
atyp
present
infecti
process
background
acut
lymphoblast
leukemia
repres
largest
group
pediatr
malign
high
cure
rate
childhood
repres
one
remark
success
stori
war
cancer
lower
middl
incom
countri
lmic
like
philippin
review
five
year
surviv
tertiari
referr
center
object
retrospect
cohort
studi
aim
determin
surviv
children
year
old
treat
tertiari
referr
center
childhood
cancer
philippin
januari
decemb
designmethod
retrospect
cohort
studi
review
medic
chart
newli
diagnos
age
year
old
januari
decemb
total
subject
includ
studi
year
overal
surviv
os
event
free
surviv
ef
respect
year
os
standard
risk
high
risk
patient
year
os
patient
remiss
relaps
univari
multivari
cox
proport
hazard
regress
reveal
wbc
count
diagnosi
risk
classif
immunophenotyp
develop
relaps
show
signific
prognost
impact
mortal
age
gender
report
prognost
signific
os
ef
lower
compar
develop
countri
compar
lmic
prognost
factor
relaps
mortal
compat
literatur
overal
adopt
treatment
protocol
childhood
institut
show
accept
result
relaps
signific
prognost
impact
mortal
develop
access
care
increas
awar
earli
detect
resourc
hand
achiev
improv
follow
protocol
prevent
delay
treatment
patient
educ
prevent
noncompli
psychosoci
support
develop
better
support
care
expand
facil
given
emphasi
improv
surviv
prevent
relaps
object
seek
character
entiti
describ
patholog
clinic
featur
pediatr
case
burkittlik
lymphoma
aberr
collect
patholog
clinic
data
medic
record
pediatr
high
grade
bcell
lymphoma
hgbcl
case
diagnos
institut
period
case
classifi
neither
burkitt
lymphoma
diffus
larg
bcell
lymphoma
dlbcl
fish
myc
well
array
compar
genom
hybrid
acgh
perform
identifi
case
hgbcl
includ
case
burkitt
lymphoma
present
pure
leukem
phase
hgbcl
case
burkitt
lymphoma
defin
myc
rearrang
dlbcl
collect
major
patient
primari
diseas
outsid
headneck
patient
present
advanc
stage
iiiiv
diseas
remain
case
aberr
identifi
case
use
acgh
case
histolog
immunophenotyp
resembl
burkitt
lymphoma
lack
myc
rearrang
instead
show
proxim
gain
telomer
loss
case
involv
primari
diseas
cervic
lymph
node
andor
tonsil
three
case
local
stage
ii
fourth
case
involv
metabol
activ
nonenlarg
lymph
node
chest
abdomen
stage
iii
patient
achiev
complet
remiss
standard
therapi
matur
bcell
lymphoma
aliv
clinic
evid
diseas
median
followup
month
although
number
small
result
suggest
major
nonburkitt
nondlbcl
case
pediatr
hgbcl
carri
aberr
addit
patient
aberr
appear
like
present
lower
stage
diseas
thu
requir
less
intens
therapi
also
tend
primari
diseas
headneck
find
support
classif
burkittlik
lymphoma
aberr
distinct
patholog
clinic
entiti
propos
pediatr
nonburkitt
nondlbcl
case
hgbcl
regularli
undergo
workup
possibl
aberr
mari
clair
miladi
august
joseph
bernard
st
damien
hospit
portauprinc
portauprinc
haiti
background
hodgkin
lymphoma
hl
nonhodgkin
lymphoma
nhl
account
cancer
unit
state
pediatr
popul
central
america
caribbean
second
posit
among
type
pediatr
cancer
previou
studi
pediatr
cancer
haiti
show
lymphoma
fifth
place
leukemia
wilm
tumor
retinoblastoma
sarcoma
main
object
studi
present
epidemiolog
profil
lymphoma
manag
haitian
pediatr
hospit
designmethod
retrospect
studi
conduct
case
lymphoma
diagnos
manag
st
damien
hospit
januari
decemb
key
variabl
age
gender
stage
diagnosi
histopatholog
type
outcom
collect
present
characterist
retrospect
cohort
case
cancer
diagnos
studi
period
diagnosi
lymphoma
sex
ratio
male
femal
averag
age
year
year
case
hl
case
nhl
patient
diagnos
stage
iii
iv
among
hl
case
nodular
sclerosi
lymphoma
mix
cellular
lymphocyt
predomin
nhl
case
burkitt
lymphoma
lymphoblast
tcell
lymphoma
among
patient
immunohistochemistri
found
case
hl
case
nhl
patient
hivposit
patient
confirm
exposur
epsteinbarr
viru
patient
lost
followup
remiss
relaps
still
treatment
deceas
univers
chicago
chicago
illinoi
unit
state
background
due
adopt
riskadapt
therapi
pediatr
adolesc
acut
lymphoblast
leukemia
associ
high
cure
rate
despit
excel
outcom
children
patient
certain
blast
cytogenet
featur
fare
well
furthermor
african
american
nativ
american
hispan
patient
wors
outcom
caucasian
patient
outcom
discrep
certainli
multifactori
blast
cytogenet
relat
age
remain
unclear
whether
ethnic
blast
cytogenet
correl
divers
patient
popul
univers
chicago
provid
opportun
evalu
correl
object
describ
cytogenet
find
racial
ethnic
divers
popul
patient
age
group
diagnos
univers
chicago
determin
correl
raceethn
blast
cytogenet
result
total
newli
diagnos
patient
age
includ
studi
patient
ball
tall
one
earli
tcell
precursor
one
mix
phenotyp
bt
caucasian
account
patient
african
american
aa
hispan
asian
race
age
distribut
bimod
pattern
peak
incid
anoth
year
age
consist
publish
data
cytogenet
categori
includ
rearrang
hypodiploidi
hyperdiploidi
doubl
trisomi
chromosom
aa
hispan
patient
ball
present
frequent
age
year
compar
caucasian
p
respect
aa
patient
overrepres
p
compar
caucasian
mainli
observ
patient
year
caucasian
patient
like
noncaucasian
hyperdiploidi
p
especi
patient
age
year
rate
significantli
higher
aa
patient
cohort
particular
patient
age
year
hyperdiploidi
like
caucasian
age
year
find
may
suggest
vari
blast
cytogenet
could
contribut
outcom
differ
race
ahm
elgamm
yasser
elborai
moham
fawzi
asmaa
salama
eman
eldesouki
lobna
shalabi
nation
cancer
institut
cairo
cairo
egypt
background
hodgkin
lymphoma
hl
children
one
malign
high
chanc
cure
stage
iv
hl
remain
challeng
get
good
clinic
outcom
stage
mani
treatment
protocol
use
give
combin
chemotherapi
combin
modal
treatment
mainstay
treatment
protocol
object
aim
assess
outcom
use
consolid
radiotherapi
chemotherapi
combin
modal
treatment
versu
combin
chemotherapi
alon
treatment
stage
iv
hl
designmethod
includ
patient
stage
iv
hl
whose
data
retriev
medic
record
pediatr
oncolog
depart
nation
cancer
institut
cairo
univers
egypt
till
june
follow
till
august
treatment
either
give
cycl
abvd
adriamycin
bleomycin
vinblastin
dacarbazin
give
cycl
abvd
follow
consolid
radiotherapi
studi
includ
case
male
femal
mean
age
year
rang
year
histopatholog
subtyp
nodular
sclerosi
major
case
case
follow
mix
cellular
case
one
case
lymphocyt
rich
nine
case
initi
bulki
case
constitut
manifest
present
case
absent
case
bone
marrow
involv
case
radiotherapi
given
complet
chemotherapi
case
case
receiv
chemotherapi
overal
surviv
patient
receiv
radiotherapi
superior
receiv
chemotherapi
alon
versu
respect
statist
signific
p
progress
free
surviv
also
higher
radiotherapi
other
versu
p
patient
stage
iv
hl
receiv
consolid
radiotherapi
appar
better
outcom
receiv
chemotherapi
suggest
radiotherapi
contribut
significantli
chemotherapi
cure
rate
patient
feinstein
institut
medic
research
manhasset
new
york
unit
state
background
microrna
mirna
short
noncod
rna
play
decis
role
cancer
biolog
includ
leukemia
exosom
microvesicl
nm
produc
cell
biolog
fluid
exosom
repres
fingerprint
parent
tumor
load
bioactiv
marker
mirna
may
regul
tumor
growth
exosom
cargo
transfer
target
cell
chang
biolog
properti
studi
investig
function
role
exosom
pediatr
acut
lymphoid
leukemia
pall
object
demonstr
pall
exosom
induc
cell
confirm
exosomeinduc
cell
prolifer
diseasestag
specif
analyz
exosom
express
profil
authent
inhibit
exosom
reduc
leukemia
prolifer
designmethod
exosom
isol
ultracentrifug
healthi
donor
hd
pall
serum
condit
medium
cm
control
human
cell
line
cell
line
expos
differ
sourc
leukemiaderiv
exosom
paracrin
autocrin
fashion
triplic
prolifer
assess
microscop
cell
count
confirm
gene
express
prolifer
prosurviv
proapoptot
gene
mirna
profil
perform
human
cancer
pathway
finder
microarray
qiagen
silenc
exosom
carri
inhibitor
qiagen
util
exofecttm
exosom
transfect
reagent
sbi
system
bioscienc
exosom
silenc
confirm
qpcr
cellular
uptak
texredsirna
sbi
system
bioscienc
confirm
flow
cytometri
transfer
exosom
target
cell
evalu
qpcr
elucid
cmderiv
exosom
cell
line
induc
cell
prolifer
autocrin
paracrin
cell
paracrin
p
serum
pall
exosom
promot
paracrin
cell
prolifer
cell
line
compar
hdderiv
exosom
p
heatmap
analysi
mirna
profil
leukemia
exosom
cell
line
pall
identifi
significantli
upregul
leukemia
exosom
compar
control
also
upregul
cell
line
exposur
leukemia
exosom
induc
prolifer
moreov
exosom
inhibit
reduc
leukem
prolifer
pediatr
data
suggest
exosom
induc
cell
prolifer
leukem
cell
line
paracrin
autocrin
fashion
exosom
regul
phenomena
highli
orchestr
way
transfer
function
exosom
mirna
result
studi
suggest
exosom
inhibit
act
novel
way
growthsuppress
pediatr
leukemia
result
total
diseas
site
detect
petct
site
detect
contrastenhanc
ct
bone
marrow
biopsi
bmb
petct
show
improv
detect
nodal
lesion
p
kappa
valu
extranod
lesion
p
kappa
valu
bone
marrow
p
kappa
valu
compar
contrast
enhanc
ct
bmb
petct
upstag
case
downstag
case
p
kappa
valu
among
upstag
case
patient
upstag
stage
ii
iii
base
residu
petct
seen
contrast
enhanc
ct
abdomin
mass
excis
four
patient
upstag
stage
iii
iv
base
bone
marrow
uptak
fdgpet
without
posit
bma
bmbregard
respons
assess
sensit
pet
contrastenhanc
ct
p
specif
pet
ct
p
posit
predict
valu
pet
ct
scan
p
neg
predict
valu
pet
ct
p
five
patient
biopsi
confirm
viabil
residu
lesion
lesion
neg
patholog
examin
metabol
neg
petct
deauvil
score
one
lesion
posit
patholog
examin
posit
petct
deauvil
score
conclus
petct
detect
addit
site
compar
contrastenhanc
ct
result
chang
stage
diseas
pet
scan
significantli
specif
ct
manag
children
burkitt
lymphoma
background
deep
sequenc
immunoglobulin
heavi
chain
igh
locu
indic
b
compos
innumer
subclon
mani
case
subclon
exhibit
differ
phenotyp
qualiti
howev
remain
unclear
whether
subclon
demonstr
distinct
tissu
distribut
within
patient
object
quantifi
extent
clonal
heterogen
diagnost
b
specimen
identifi
variabl
clonal
composit
bone
marrow
bm
peripher
blood
pb
diseas
site
designmethod
igh
sequenc
perform
purifi
dna
pair
match
bm
pb
patient
specimen
multiplex
pcr
use
global
amplifi
igh
locu
next
gener
sequenc
ng
perform
use
miseq
index
clone
defin
sequenc
read
specimen
subclon
progeni
defin
share
nucleotid
base
immedi
upstream
common
jh
identifi
use
igblastdetermin
vh
jh
align
http
wwwncbinlmnihgovigblast
establish
inhous
comput
pipelin
result
index
clone
per
specimen
discov
sampl
remain
bmpb
pair
pair
reveal
clonal
igh
elimin
analysi
clone
frequenc
reach
index
threshold
predomin
clonal
precursor
infer
preval
subclon
progeni
subclon
count
rang
per
index
clone
combin
subclon
deriv
pb
index
clone
observ
contrast
bm
index
clone
gave
rise
subclon
subclon
heterogen
observ
pair
specimen
bmpb
pair
index
clone
exist
equival
proport
diseas
site
contrast
bmpb
pair
demonstr
highfrequ
index
clone
bm
limit
represent
clone
pb
respect
case
preval
clone
pb
match
least
frequent
index
clone
bm
similarli
anoth
pair
show
predomin
index
clone
pb
index
threshold
bm
pair
patient
specimen
index
clone
predomin
discov
overtli
distinct
bm
pb
among
pair
extent
subclon
progeni
deriv
index
clone
show
mark
variabl
far
higher
subclon
frequenc
pb
bm
data
indic
b
clonal
composit
differ
diseas
site
valley
children
healthcar
madera
california
unit
state
background
tuberculosi
tb
present
hodgkin
lymphoma
hl
rare
coexist
could
lead
delay
diagnosi
tb
hodgkin
lymphoma
due
similar
sign
symptom
present
case
report
adult
literatur
describ
case
seri
children
suspect
tb
found
coexist
tb
hl
result
retrospect
review
hl
patient
guatemala
argentina
six
year
uncov
patient
simultan
diagnosi
tb
hl
eight
patient
guatemala
incid
argentina
incid
femal
male
age
rang
year
mean
year
media
year
nine
patient
suspect
tb
present
refer
physician
two
patient
found
tb
time
relaps
routin
tissu
cultur
initi
system
symptom
includ
fever
n
weight
loss
n
night
sweat
n
six
patient
second
system
symptom
addit
fever
time
referr
oncolog
center
rang
week
month
nine
patient
diagnos
tb
hl
tissu
cultur
serum
quantiferon
one
patient
found
hl
without
tb
two
patient
system
symptom
diagnosi
tb
came
light
routin
tissu
cultur
five
patient
stage
iiib
ivb
two
stage
iia
one
iib
diagnosi
hl
treatment
given
accord
institut
standard
depend
stage
risk
abvd
oepacopdac
radiat
therapi
ice
relaps
five
patient
start
anti
tb
treatment
isoniazid
rifampin
pyrazinamid
ethambutol
month
follow
isoniazid
rifampin
week
simultan
chemotherapi
three
other
complet
cycl
two
relaps
patient
start
tb
treatment
cycl
chemotherapi
seven
patient
aliv
follow
month
year
one
patient
die
therapi
anoth
die
caus
relat
tb
hl
one
current
receiv
treatment
conclus
tuberculosi
coexist
hl
area
preval
tb
high
microbiolog
investig
biopsi
specimen
strongli
consid
therapi
tb
given
simultan
chemotherapi
coexist
tb
hl
appear
affect
outcom
children
hospit
affili
capit
institut
pediatr
unit
state
background
signal
pathway
play
central
role
cell
growth
prolifer
surviv
physiolog
condit
signal
pathway
consid
innov
target
therapi
cancer
abnorm
activ
prove
relat
tcell
acut
lymphoblast
leukemia
tall
despit
improv
treatment
strategi
multidrug
combin
highdos
chemotherapi
kind
applic
popular
hematopoiet
stem
cell
transplant
children
drug
resist
relaps
tall
still
rather
wors
overal
outcom
prognosi
much
poorer
common
blineag
object
explor
relationship
pathway
pediatr
tall
probe
exact
molecular
mechan
tall
provid
direct
treatment
designmethod
case
new
recurr
acut
lymphocyt
leukemia
children
clinic
inform
collect
children
hospit
affili
capit
institut
pediatr
age
gender
match
healti
children
control
inform
consent
express
key
gene
pathway
analyz
western
blot
rtpcr
analysi
enzym
activ
detect
elisa
ccrf
cem
prolifer
apoptosi
test
mtt
flow
cytometri
technolog
tall
cell
line
ccrfcem
differ
treatment
group
result
tall
children
clinic
show
protein
gene
express
level
higher
appar
control
group
p
enzym
activ
increas
well
p
inhibitor
made
signific
inhibit
cell
prolifer
promot
cell
apoptosi
also
enhanc
effect
clinic
commonli
use
chemotherapeut
drug
dnr
combin
dnr
treatment
group
cell
viabil
dramat
declin
apoptosi
apoptosi
relat
protein
express
tall
patient
obvious
higher
control
singl
drug
group
signal
pathway
relat
protein
gene
express
level
akt
transcript
ccrfcem
significantli
higher
control
p
pten
transcript
significantli
lower
control
p
abnorm
activ
signal
pathway
might
play
import
role
pediatr
tall
patient
especi
cell
prolifer
apoptosi
result
might
provid
new
train
thought
direct
target
suppress
signal
pathway
combin
chemotherapi
drug
therapi
look
effect
less
cytotox
treatment
pediatr
tall
cleveland
clinic
children
hospit
cleveland
ohio
unit
state
background
nonhodgkin
lymphoma
nhl
heterogen
group
lymphoprolif
diseas
compris
childhood
malign
nhl
divid
b
cell
lymphoma
cellnatur
killer
nk
cell
lymphoma
depend
immunophenotyp
molecular
biolog
clinic
respons
treatment
although
nkt
cell
lymphoma
occur
childhood
adolesc
compris
small
portion
lymphoma
present
mani
diagnost
therapeut
challeng
role
angiogenesi
lymphoma
pathogenesi
becom
evid
high
molecular
weight
kininogen
hk
central
compon
kallikreinkinin
system
previous
report
cleav
hk
hka
induc
apoptosi
prolifer
endotheli
cell
inhibit
angiogenesi
matrigel
plug
corneal
angiogenesi
model
howev
role
endogen
kininogen
regul
angiogenesi
tumor
microenviron
unknown
object
elabor
role
hk
lymphoma
angiogenesi
use
murin
tcell
lymphoma
model
compar
angiogenesi
tumor
growth
wildtyp
kininogen
defici
mice
also
evalu
effect
hka
lymphoma
cell
prolifer
designmethod
murin
tcell
lymphoma
cell
implant
wildtyp
tumor
size
measur
use
calip
tumor
volum
calcul
use
formula
volum
length
seventeen
day
cell
implant
tumor
harvest
process
immunoblot
immunofluoresc
stain
cell
prolifer
assay
mt
perform
investig
possibl
inhibitori
effect
hka
cell
growth
human
umbil
vein
endotheli
cell
huvec
use
posit
control
result
lymphoma
grew
rapidli
larger
size
compar
wildtyp
mice
signific
differ
appar
day
tumor
implant
p
day
volum
tumor
approxim
larger
wildtyp
mice
mean
volum
standard
deviat
vs
respect
p
mt
assay
show
hka
directli
inhibit
prolifer
cell
vitro
though
significantli
impair
viabil
ec
studi
simultan
conclus
find
suggest
hk
import
endogen
regul
angiogenesi
tumor
growth
tcell
lymphoma
model
suggest
hka
specif
modul
endotheli
prolifer
tumor
microenviron
work
need
understand
mechan
underli
find
provid
futur
antiangiogen
approach
increas
therapeut
option
patient
nhl
bruce
bostrom
jack
knudson
nathan
gossai
joanna
perkin
michael
richard
jawhar
rawwa
susan
sencer
juli
chu
nanci
mcallist
yoav
messing
children
minnesota
minneapoli
minnesota
unit
state
background
osteonecrosi
caus
signific
pain
morbid
older
patient
treat
acut
lymphoblast
leukemia
besid
alter
schedul
dexamethason
delay
intensif
intervent
known
reduc
incid
symptomat
osteonecrosi
pamidron
shown
reduc
bone
pain
osteonecrosi
prevent
joint
collaps
advanc
object
compar
incid
symptomat
osteonecrosi
patient
receiv
prophylact
pamidron
compar
concurr
control
describ
increas
side
effect
use
pamidron
designmethod
patient
age
year
time
diagnosi
given
intraven
pamidron
monthli
one
year
discret
primari
oncologist
start
first
year
therapi
concurr
control
patient
age
receiv
pamidron
patient
treat
accord
concurr
cog
protocol
receiv
intermitt
dexamethason
delay
intensif
patient
bcrabl
exclud
use
imatinib
may
increas
risk
osteonecrosi
imag
done
osteonecrosi
suspect
base
clinic
symptom
patient
censor
time
relaps
data
analyz
retrospect
studi
approv
children
minnesota
irb
patient
evalu
male
femal
bcell
tcell
median
followup
year
rang
year
pamidron
given
patient
develop
symptomat
osteonecrosi
concurr
control
develop
osteonecrosi
signific
differ
leukemia
lineag
gender
distribut
bodi
mass
index
bmi
diagnosi
group
patient
median
bmi
rang
age
diagnosi
significantli
higher
pamidron
group
median
year
vs
control
p
kaplanmei
analys
incid
symptomat
osteonecrosi
significantli
lower
pamidron
group
vs
control
logrank
pvalu
breslow
pvalu
sensit
earli
event
untoward
sideeffect
pamidron
pamidron
infus
significantli
reduc
incid
symptomat
osteonecrosi
patient
age
compar
concurr
control
receiv
pamidron
arahana
awasthi
dina
edani
janet
ayello
christian
klein
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
matur
bnhl
includ
bl
pmbl
express
excel
prognosi
howev
subset
patient
relaps
secondari
chemoimmunotherapi
resist
diseas
dismal
prognosi
yr
ef
cairo
et
al
blood
gerrardcairo
et
al
blood
goldmancairo
et
al
leukemia
pv
demonstr
possess
signific
preclin
activ
indol
polson
et
al
previous
observ
obinutuzumab
mab
significantli
enhanc
cell
death
increas
overal
surviv
bl
awasthicairo
et
al
bjh
xenograft
nsg
mice
howev
additivesynergist
effect
pv
obinutuzumab
matur
pmblbl
unknown
determin
efficaci
pv
obinutuzumabrtx
alon
combin
pmbl
rituximab
rtx
sensitiveresist
bl
cell
line
designmethod
provid
barth
md
roswel
park
cancer
institut
raji
atcc
usa
cultur
rpmi
tumor
cell
incub
pv
andor
mmae
gener
suppli
genentech
inc
obinutuzumab
rituximab
hr
nk
cell
e
ratio
cytotox
determin
delfia
cytotox
assay
six
week
old
femal
nsg
nodcgprkdcscid
divid
group
pb
isotyp
control
pv
mab
mmae
mice
xenograft
intraven
inject
luc
bl
pmbl
cell
tumor
burden
monitor
ivi
spectrum
system
result
os
mice
receiv
pv
alon
significantli
increas
compar
ab
isotyp
control
raji
preliminari
data
indic
pv
significantli
increas
surviv
bl
pmbl
nsg
xenograft
compar
ab
alon
furthermor
pv
combin
obinutuzumab
significantli
enhanc
invitro
cytotox
bl
pmbl
compar
obinutuzumab
pv
alon
result
maxim
grade
g
cr
occur
patient
respect
median
lowest
fibrinogen
level
patient
maxim
cr
respect
patient
maxim
cr
lowest
report
fibrinogen
level
eight
patient
cr
low
fibrinogen
level
occur
n
n
maxim
cr
grade
time
improv
n
patient
maxim
cr
fibrinogen
level
onset
fibrinogen
level
patient
concurr
increas
intern
normal
ratio
activ
partial
thromboplastin
cryoprecipit
primari
treatment
us
fibrinogen
concentr
fc
guidelin
tisagenlecleucelassoci
coagulopathi
develop
countri
administr
fresh
frozen
plasma
problemat
fc
avail
site
infus
patient
cr
cr
cryoprecipit
avail
site
infus
patient
cr
cr
cr
risk
bleed
increas
pediatr
patient
comorbid
thrombocytopenia
anticoagul
treatment
patient
decreas
platelet
within
day
fibrinogen
level
fatal
case
intraparenchym
cranial
hemorrhag
occur
resolv
cr
hypofibrinogenemia
ongo
thrombocytopenia
continu
venoven
hemofiltr
citrat
hypofibrinogenemia
observ
frequent
patient
higher
cr
grade
duringwhen
cr
improv
resolv
fc
cryoprecipit
treatment
guidelin
develop
frequent
monitor
fibrinogen
replac
need
patient
cr
sponsor
novarti
prolong
cn
halflif
may
allow
reduct
number
intrathec
inject
object
safe
reduc
burden
therapi
reduc
number
inject
reduc
total
dose
doxorubicin
addit
liposom
cytarabin
rituximab
designmethod
patient
year
bnhl
fab
group
b
good
risk
stage
iii
stage
iii
ldh
fab
group
b
intermedi
risk
stage
iii
ldh
stage
iv
bm
blast
fab
group
c
high
risk
elig
patient
receiv
fab
backbon
therapi
addit
six
rituximab
dose
two
dose
prior
two
induct
cours
one
dose
prior
two
consolid
cours
cumul
doxorubicin
reduc
gr
patient
system
methotrex
clearanc
patient
receiv
age
base
dose
liposom
cytarabin
inject
reduc
nine
five
primari
outcom
safeti
toxic
death
among
evalu
patient
estim
surviv
monitor
independ
dsmb
result
date
evalu
patient
fab
group
b
group
c
cn
posit
median
age
year
rang
male
dlbcl
gr
ir
hr
enrol
one
grade
anaphylact
reaction
rituximab
one
grade
facial
nerv
palsi
seriou
advers
event
attribut
protocol
therapi
death
progress
diseas
relaps
median
follow
month
ef
os
respect
initi
result
show
excel
ef
os
consist
publish
standard
care
outcom
addit
rituximab
intrathec
liposom
cytarabin
despit
reduct
therapi
enrol
ongo
continu
long
term
outcom
need
confirm
earli
result
futur
random
studi
need
examin
short
term
mucos
infect
hospit
day
long
term
late
cardiac
toxic
endpoint
goldman
etal
leukemia
cairo
etal
jco
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
bereav
parent
identifi
signific
spiritu
need
around
time
death
throughout
bereav
journey
spiritu
identifi
primari
mean
bereav
parent
find
mean
loss
abil
find
mean
associ
lower
maladapt
grief
symptom
use
spiritu
cope
strategi
associ
improv
cope
mental
health
outcom
among
bereav
parent
object
better
understand
bereav
parent
experi
spiritu
throughout
bereav
effect
object
measur
grief
depress
meaningmak
designmethod
thirti
particip
whose
children
die
progress
cancer
relat
complic
one
three
year
prior
particip
complet
indepth
semistructur
telephon
interview
experi
grief
particip
prompt
describ
impact
spiritu
bereav
process
addit
particip
complet
survey
relat
grief
prolong
grief
disord
questionnair
depress
beck
depress
inventori
bdi
meaningmak
integr
stress
life
experi
scale
isl
result
analyz
use
mix
method
approach
includ
semant
content
analysi
qualit
content
kruskalw
h
test
posthoc
analys
quantit
data
result
correl
analys
demonstr
signific
differ
particip
posit
neg
spiritu
experi
bereav
particip
neg
experi
bereav
statist
signific
increas
score
compar
posit
spiritu
experi
signifi
greater
symptom
prolong
grief
particip
neg
spiritu
experi
grief
significantli
lower
score
isl
suggest
lesser
degre
adapt
integr
loss
signific
differ
depress
score
group
conclus
bereav
parent
neg
spiritu
experi
bereav
increas
risk
prolong
grief
symptom
less
like
find
mean
children
death
bereav
parent
describ
posit
spiritu
experi
bereav
provid
consid
explor
spiritu
belief
provis
spiritu
care
parent
children
face
lifelimit
ill
treatment
bereav
background
langerhan
cell
histiocytosi
lch
inflammatori
myeloid
neoplasia
character
frequent
relaps
treatment
failur
associ
higher
risk
death
neurodegen
diseas
lchnd
activ
somat
mutat
mapk
pathway
gene
identifi
almost
case
approxim
lesion
target
therapi
success
treat
refractori
cancer
braf
mutat
melanoma
given
central
role
mapk
pathway
activ
lch
mapk
pathway
inhibit
may
effect
therapeut
strategi
children
lch
object
purpos
studi
report
efficaci
toxic
profil
retrospect
cohort
patient
lch
treat
mapk
pathway
inhibitor
designmethod
medic
record
pediatr
patient
lch
system
andor
lchassoci
neurodegener
treat
mapk
pathway
inhibitor
retrospect
review
five
institut
patient
fail
least
one
prior
system
therapi
proven
mapk
pathway
mutat
result
patient
seri
less
year
old
median
year
rang
year
median
three
prior
treatment
rang
time
initi
mapk
inhibitor
use
nine
patient
lchnd
diagnos
clinic
andor
radiograph
imag
remain
three
patient
system
diseas
patient
treat
median
month
rang
month
variou
reason
discontinu
three
patient
receiv
combin
mapk
inhibitor
therapi
three
patient
receiv
concurr
lchdirect
therapi
four
twelv
patient
grade
toxic
report
three
patient
requir
dose
reduct
order
abl
success
resum
therapi
overal
surviv
median
month
followup
rang
month
one
patient
achiev
transient
complet
respons
remain
ten
patient
partial
respons
stabl
diseas
four
patient
develop
progress
diseas
therapi
conclus
mapk
pathway
inhibitor
may
rel
safe
salvag
therapi
refractori
system
lch
lchnd
efficaci
durabl
strategi
remain
defin
combin
cytotox
chemotherapi
may
requir
order
erad
diseasecaus
cell
futur
prospect
trial
mapk
pathway
inhibitor
patient
refractori
lch
need
order
directli
compar
efficaci
toxic
rel
current
salvag
strategi
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
medic
adher
mainten
therapi
shown
direct
relationship
diseas
relaps
pediatr
leukemia
previou
research
determin
patient
adher
greater
risk
relaps
primari
aim
present
studi
examin
relationship
metabolit
profil
behavior
adher
rate
obtain
via
electron
monitor
day
hypothes
patient
demonstr
low
level
thioguanin
tgn
methyl
mercaptopurin
mmp
lower
behavior
adher
rate
prior
blood
draw
designmethod
multisit
prospect
studi
patient
age
year
diagnos
acut
lymphoblast
leukemia
lymphoblast
lymphoma
lbl
adher
measur
across
month
mainten
therapi
use
behavior
adher
electron
monitor
pharmacolog
metabolit
measur
metabol
mmp
tgn
cluster
analysi
use
gener
three
mutuallyexclus
profil
adher
behavior
adher
rate
calcul
day
prior
blood
draw
result
studi
identifi
three
metabolit
profil
across
month
previou
research
indic
low
level
metabolit
suggest
nonadher
medic
low
level
one
metabolit
high
level
anoth
metabolit
indic
adher
studi
low
tgnlow
mmp
group
behavior
adher
rate
mean
adher
rate
mean
high
tgnlow
mmp
group
mean
adher
adher
rate
mean
low
tgnhigh
mmp
group
patient
mean
adher
level
adher
rate
patient
low
tgnlow
mmp
group
adher
rate
conclus
find
suggest
electron
monitor
metabolit
concentr
use
monitor
medic
adher
mainten
therapi
notabl
subsampl
pediatr
patient
identifi
nonadher
base
electron
monitor
howev
metabolit
level
indic
adher
similarli
subsampl
patient
identifi
adher
base
electron
monitor
metabolit
profil
indic
subtherapeut
level
find
underscor
clinic
signific
use
object
measur
medic
adher
inform
clinic
decis
make
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
hemophagocyt
lymphohistiocytosi
hlh
lifethreaten
hyperinflammatori
syndrom
character
nonremit
fever
rash
hepatosplenomegali
cytopenia
liver
dysfunct
coagulopathi
includ
central
nervou
system
involv
sever
genet
diseas
caus
hlh
impair
normal
lymphocyt
macrophag
function
hlh
panel
cincinnati
children
genet
laboratori
includ
gene
associ
hlh
lymphoprolif
diseas
includ
gene
caus
primari
hlh
xlink
lymphoprolif
diseas
xiap
itk
defici
itk
hermanskypudlak
syndrom
type
chediakhigashi
syndrom
lyst
defici
xmen
syndrom
lysinur
protein
intoler
deletiondupl
analysi
avail
reflex
test
gene
copi
number
variat
cnv
directli
assess
sequenc
object
preval
cnv
among
larg
group
patient
hlh
north
america
unknown
assess
frequenc
cnv
gene
hlh
panel
retrospect
review
order
deletiondupl
analysi
perform
nextgener
sanger
sequenc
order
gene
panel
order
gene
panel
deletiondupl
analysi
perform
custom
microarray
annot
ncbi
build
ucsc
march
deletiondupl
analysi
result
confirmatori
diagnosi
case
pathogen
like
pathogen
cnv
common
three
xlink
gene
delet
xiap
delet
duplic
delet
hemizyg
delet
xlink
gene
male
patient
typic
suspect
amplif
failur
previou
sequenc
autosom
recess
gene
pathogen
cnv
observ
three
gene
heterozyg
lyst
heterozyg
homozyg
two
heterozyg
case
second
chang
identifi
sequenc
deletiondupl
analysi
offer
confirmatori
diagnosi
patient
deletiondupl
analysi
perform
pathogen
like
pathogen
variant
identifi
autosom
recess
gene
sequenc
howev
case
second
mutat
uncov
cnv
analysi
recommend
deletiondupl
analysi
routin
perform
male
patient
hlh
lack
genet
diagnosi
sequenc
hlhassoci
gene
especi
region
fail
amplifi
deletiondupl
analysi
may
perform
femal
patient
sequenc
genet
form
hlh
highli
suspect
yield
expect
low
cleveland
clinic
children
hospit
cleveland
ohio
unit
state
background
develop
posttranspl
neoplasia
typic
lymphoprolif
diseas
ptld
sever
complic
transplant
recipi
affect
approxim
pediatr
solid
organ
recipi
rate
lymphoma
adult
heart
transplant
patient
compar
low
less
two
percent
ten
year
publish
report
longterm
outcom
neoplasia
pediatr
heart
transplant
aim
identifi
subsequ
malign
occur
pediatr
heart
transplant
patient
larg
singl
institut
describ
treatment
subsequ
clinic
cours
perform
retrospect
chart
review
pediatr
heart
transplant
recipi
follow
cleveland
clinic
children
hospit
januari
octob
exclud
patient
die
within
day
heart
transplant
review
depth
histori
clinic
cours
subject
develop
neoplasm
result
patient
underw
heart
transplant
surviv
least
day
post
transplant
nine
patient
develop
subsequ
malign
case
seri
median
age
heart
transplant
year
old
median
time
develop
neoplasia
month
primari
neoplasia
includ
monomorph
ptld
polymorph
ptld
burkitt
lymphoma
hodgkin
lymphoma
plasmacytomalik
lymphoma
epsteinbarr
virusassoci
smooth
muscl
tumor
ebvsmt
one
patient
hodgkin
lymphoma
subsequ
develop
monomorph
ptld
one
patient
polymorph
ptld
subsequ
develop
ebvsmt
later
undifferenti
gastric
cancer
one
patient
monomorph
ptld
develop
ebvsmt
evid
epsteinbarr
viru
present
six
nine
patient
diagnosi
first
malign
four
nine
patient
receiv
reduct
immunosuppress
primari
intervent
initi
malign
two
complet
respons
cr
one
partial
respons
one
progress
diseas
five
patient
treat
chemotherapi
four
cr
one
progress
diseas
three
patient
die
malign
recurr
ebvsmt
undifferenti
gastric
cancer
monomorph
ptld
posthodgkin
diseas
two
patient
die
transplant
relat
complic
conclus
secondari
malign
repres
signific
diseas
burden
survivor
cardiac
transplant
expect
much
malign
burden
driven
ebv
despit
aggress
histolog
mani
malign
success
cure
set
multidisciplinari
approach
stanford
univers
school
medicin
palo
alto
california
unit
state
background
current
treatment
langerhan
cell
histiocytosi
lch
base
extent
organ
system
involv
high
risk
system
affect
gastrointestin
gi
involv
diagnos
lch
patient
classic
present
children
year
age
malabsorpt
failur
thrive
bloodi
diarrhea
anemia
although
gi
system
consid
standard
risk
mortal
rate
occur
within
year
diagnosi
report
studi
perform
due
discrep
limit
number
publish
case
object
review
clinic
cours
outcom
patient
diagnos
gi
lch
designmethod
retrospect
chart
review
patient
histolog
confirm
gi
lch
diagnos
last
year
identifi
bass
center
histiocytosi
clinic
databas
perform
two
pediatr
hematologyoncolog
center
ucsf
benioff
children
hospit
oakland
san
francisco
queri
addit
case
result
four
patient
biopsi
proven
gi
lch
subject
databas
record
l
center
queri
identifi
failur
thrive
hypoalbuminemia
bloodi
diarrhea
rash
common
present
symptom
lch
skin
found
patient
risk
organ
system
involv
patient
note
subject
african
racial
background
median
age
diagnosi
month
month
year
mean
albumin
gdl
gdl
mean
esr
mmhr
mmhr
patient
initi
receiv
combin
therapi
per
lchiii
protocol
vinblastin
prednison
mercaptopurin
two
patient
recurr
diseas
receiv
second
line
therapi
cytarabin
local
radiat
therapi
patient
aliv
without
activ
diseas
last
followup
month
complet
therapi
systemat
approach
evalu
gi
involv
perform
children
diagnos
lch
experi
combin
chemotherapi
patient
lch
involv
gi
tract
effect
intervent
activ
diseas
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
bhatia
indic
rate
adher
better
clinic
outcom
adher
rate
increas
risk
diseas
relaps
present
studi
investig
pattern
medic
adher
use
groupbas
trajectori
model
larg
sampl
pediatr
patient
describ
pattern
behavior
adher
mainten
phase
therapi
cohort
pediatr
patient
age
year
diagnos
acut
lymphoblast
leukemia
lymphoblast
lymphoma
n
previou
research
document
relationship
optim
level
medic
adher
posit
health
outcom
hypothes
three
group
would
identifi
optim
adher
deterior
adher
chronic
nonadher
hypothes
patient
optim
adher
group
would
adher
rate
poor
adher
would
adher
rate
designmethod
present
studi
longitudin
multisit
studi
investig
adher
pediatr
cohort
patient
use
electron
monitor
devic
daili
adher
rate
electron
monitor
examin
across
health
outcom
measur
quarterli
interv
medic
chart
review
result
uncondit
growth
curv
model
indic
mean
percentag
behavior
adher
baselin
declin
three
trajectori
behavior
adher
identifi
optim
adher
patient
averag
behavior
adher
across
month
moder
adher
rel
stabl
nonadher
rate
across
month
chronic
nonadher
adher
decreas
respect
pattern
medic
adher
relationship
clinicallyrelev
health
outcom
signific
differ
health
outcom
patient
adher
versu
nonadher
trajectori
includ
mean
absolut
neutrophil
count
anc
risk
infect
measur
anc
healthcar
util
risk
diseas
relaps
although
longitudin
pattern
behavior
adher
relat
health
outcom
notabl
current
sampl
adher
rate
fact
current
sampl
demonstr
adher
rate
find
import
develop
futur
adher
promot
studi
pediatr
cancer
find
underscor
rel
signific
tailor
adher
promot
intervent
subgroup
patient
includ
problemat
pattern
adher
patient
demonstr
adequ
level
adher
could
still
benefit
less
intens
prevent
intervent
sustain
improv
adher
sophi
gatineausailli
pascal
grimard
marieclaud
miron
guy
grimard
annesophi
carret
jeanmari
leclerc
chu
saintejustin
montreal
quebec
canada
background
vertebr
involv
langerhan
cell
histiocytosi
lch
still
subject
interest
due
low
frequenc
absenc
manag
guidelin
object
provid
addit
inform
present
treatment
morbid
pediatr
lch
vertebr
lesion
report
case
children
vertebr
lesion
biopsyproven
lch
januari
decemb
saintejustin
univers
health
center
montreal
quebec
canada
conduct
retrospect
studi
review
chart
imag
vertebr
lch
popul
children
median
age
year
lch
diagnosi
follow
median
durat
month
symptom
present
treatment
modal
morbid
collect
result
vertebr
lesion
present
lch
diagnosi
case
usual
diagnos
secondari
back
pain
case
asymptomat
one
case
despit
epidur
extens
case
child
develop
neurolog
symptom
lesion
frequent
involv
vertebr
bodi
case
rare
unstabl
case
vertebr
lesion
dorsal
local
lesion
patient
lch
multipl
vertebra
diagnosi
median
vertebr
height
loss
compar
last
imag
control
use
imag
modal
petscan
plain
xray
treatment
divers
consist
chemotherapi
children
three
bisphosphon
case
radiat
therapi
use
patient
six
patient
benefit
orthosi
lch
recurr
observ
patient
involv
vertebra
case
one
patient
treatmentresist
lch
diseas
relaps
requir
multipl
line
treatment
children
aliv
diseasefre
last
followup
patient
radiolog
vertebr
sequela
clinic
sequela
studi
consist
epidemiolog
data
describ
larger
cohort
children
vertebr
lesion
lch
favor
prognosi
associ
lesion
nevertheless
aggress
treatment
long
term
followup
seem
essenti
recurr
rare
spontan
bone
regener
often
incomplet
plain
xray
appear
good
followup
tool
vertebr
lesion
allow
reliabl
measur
less
exposur
radiat
lower
cost
nation
cancer
institu
giza
giza
egypt
background
acut
lymphoblast
leukemia
common
type
childhood
cancer
also
complic
treatment
requir
mani
intervent
treatment
allevi
suffer
form
side
effect
pancreat
one
toxic
common
appear
patient
occur
mani
drug
combin
induc
prepancreat
even
direct
destruct
pancreat
tissu
pancreat
induc
mani
drug
use
treatment
chemotherapeut
agent
support
treatment
lasparaginas
backbon
drug
treatment
dose
requir
achiev
complet
remiss
statu
induct
phase
treatment
dose
mainten
phaseit
enzym
destruct
lasparagin
amino
acid
aspart
acid
ammonia
thu
deplet
asparagin
extracellular
matrix
mani
drug
investig
effect
treatment
induc
pancreat
nsaid
antiinflammatori
glycerin
tri
nitrat
improv
microcircul
tnfalpha
antibodi
paf
inhibitor
specif
antiinflammatori
low
molecular
weight
heparin
none
drug
investig
abil
prevent
occurr
pancreat
object
studi
design
evalu
protect
effect
enoxaparin
diclofenac
lasparaginas
induc
pancreat
designmethod
acut
pancreat
induc
rat
intramuscular
inject
lasparaginas
iukg
given
daili
five
day
enoxaparin
given
subcutan
iukg
diclofenac
given
intraperiton
mgkg
daili
five
day
marker
pancreat
injuri
lipid
immun
cell
infiltr
oxid
stress
analyz
histopatholog
examin
pancreat
tissu
result
acut
pancreat
oxid
stress
marker
significantli
chang
indic
reduc
tissu
glutathion
increas
malondialdehyd
level
accompani
signific
increas
immun
cell
infiltr
indic
high
level
myeloperoxidas
proinflammatori
cytokin
tnfalpha
triglycerid
show
increas
level
treatment
enoxaparin
andor
diclofenac
restor
level
biochem
marker
includ
serum
alphaamylas
reduc
glutathion
malondialdehyd
proinflammatori
cytokin
tnfalpha
myeloperoxidas
triglycerid
histolog
injuri
pancreat
tissu
vacuol
necrosi
epitheli
line
pancreat
acini
inflammatori
cell
infiltr
focal
pancreat
hemorrhag
also
reduc
treatment
enoxaparin
andor
diclofenac
present
studi
emphas
potenti
protect
effect
enoxaparin
diclofenac
lasparaginas
induc
pancreat
background
rosai
dorfman
diseas
rdd
sinu
histiocytosi
massiv
lymphadenopathi
shml
rare
condit
immun
dysregul
unknown
etiolog
aris
massiv
accumul
nonlangerhan
type
histiocyt
cell
insid
lymph
node
diseas
classic
present
bulki
painless
lymphadenopathi
often
associ
infect
show
distens
lymph
node
sinus
abund
histiocyt
cell
case
diseas
selflimit
case
prolong
chronic
cours
exacerb
remiss
extranod
involv
diseas
threaten
vital
structur
treatment
may
necessari
treatment
consensu
describ
case
lifethreaten
unresect
recurr
rdd
success
treat
langerhan
cell
histiocytosi
lch
therapi
designmethod
compar
case
current
literatur
chemotherapeut
treatment
rdd
search
pubm
ovid
googl
scholar
similar
case
believ
first
report
case
use
lch
therapi
success
treat
rdd
male
present
outsid
hospit
two
year
massiv
neck
swell
caus
torticolli
biopsi
confirm
rdd
intermitt
treat
cours
antibiot
partial
respons
surgic
remov
affect
lymph
node
unsuccess
due
proxim
spinal
cord
two
year
later
patient
present
institut
initi
treat
prednison
fast
taper
dose
second
relaps
decis
made
tri
chemotherapi
follow
protocol
weekli
vinblastin
high
dose
steroid
burst
experienc
two
addit
relaps
therapi
age
year
old
includ
cmv
associ
septic
shock
cytokin
storm
requir
rapid
respons
picu
admiss
ionotrop
support
last
episod
treat
prolong
induct
mainten
therapi
extend
slowli
taper
mainten
therapi
regimen
year
daili
monthli
vinblastin
steroid
slowli
taper
dose
fourth
remiss
result
continu
complet
remissionth
longest
stretch
life
similar
case
found
literatur
search
demonstr
consensu
regard
effect
treatment
rdd
previou
case
success
treat
follow
lch
chemotherapi
protocol
hypothes
multiag
rel
mild
therapi
mitig
immun
dysregul
rdd
case
suggest
therapi
use
treat
case
rdd
amend
surgeri
observ
nicklau
children
hospit
miami
florida
unit
state
background
central
venou
cathet
cvc
necessari
manag
patient
malign
especi
children
patient
acut
leukemia
al
higher
rate
central
line
associ
complic
bloodstream
infect
compar
malign
object
examin
choic
placement
cvc
differ
outcom
peripher
insert
central
cathet
picc
port
patient
leukemia
induct
designmethod
retrospect
chart
review
patient
newli
diagnos
leukemia
nicklau
children
hospit
result
nineti
four
patient
new
diagnosi
leukemia
undergo
induct
chemotherapi
identifi
averag
age
year
overal
patient
port
place
picc
place
decis
picc
port
subject
physician
base
main
outcom
measur
local
inflammationinfect
bacteremia
thrombophleb
block
cathet
prematur
remov
common
complic
bacteremia
multipl
logist
regress
analysi
predict
whether
patient
least
one
complic
result
show
least
one
complic
time
odd
patient
aml
compar
patient
p
compar
picc
vs
port
patient
picc
frequent
episod
block
cathet
prematur
remov
compar
patient
port
p
p
respect
induct
local
inflamm
bacteremia
thrombophleb
statist
differ
p
p
p
respect
common
place
port
placement
right
subclavian
vein
signific
associ
port
locat
least
one
complic
p
acut
lymphocyt
leukemia
subgroup
analysi
fourteen
patient
picc
group
least
one
complic
port
group
statist
signific
p
seri
show
higher
incid
block
cathet
prematur
remov
picc
compar
port
patient
leukemia
induct
choic
placement
picc
vs
port
subject
physician
base
patient
despit
receiv
steroid
asparaginas
induct
show
statist
signific
increas
risk
thrombosi
infect
larger
number
may
need
futur
studi
univers
california
san
francisco
san
francisco
california
unit
state
background
hemophagocyt
lymphohistiocytosi
hlh
classic
disord
young
children
meet
system
hyperinflamm
criteria
present
late
adolesc
uncommon
furthermor
though
cn
sign
occur
case
initi
isol
neurolog
present
rare
frequent
resembl
enceph
demyelin
disord
cn
sign
isol
preced
system
diseas
delay
hlh
diagnosi
hlh
declar
adolesc
predomin
psychiatr
featur
well
document
object
describ
case
cn
hlh
present
neuropsychiatr
featur
absenc
classic
hlh
criteria
designmethod
retrospect
review
clinic
radiolog
histolog
immunophenotyp
molecular
featur
patient
cn
hlh
femal
present
acuteonset
headach
follow
nine
month
progress
anxieti
shortterm
memori
loss
emot
labil
perceptu
disturb
hypomania
brain
mri
demonstr
numer
enhanc
hyperintens
supratentori
infratentori
white
matter
lesion
left
thalamu
caudat
head
brain
biopsi
show
histiocyterich
inflamm
associ
demyelin
extens
evalu
includ
univers
microbi
pcr
fail
reveal
underli
infect
malign
past
medic
histori
notabl
presumpt
pulmonari
sarcoidosi
diagnos
month
prior
progress
respiratori
failur
associ
granulomat
pulmonari
nodul
respond
system
immunosuppress
present
neuropsychiatr
symptom
normal
ferritin
fibrinogen
triglycerid
pancytopenia
coagulopathi
bone
marrow
hemophagocytosi
fever
splenomegali
given
possibl
partial
immun
suppress
system
symptom
promin
neurolog
symptom
hlh
screen
lab
sent
notabl
decreas
natur
killer
cytotox
lymphocyt
function
normal
granzym
express
mobil
absent
perforin
express
genet
test
confirm
compound
heterozyg
mutat
c
famili
hlh
type
treat
lowdos
dexamethason
intrathec
chemotherapi
per
due
lack
evid
system
inflamm
highdos
steroid
held
within
one
week
initi
therapi
decreas
anxieti
improv
cognit
sustain
increment
neuropsychiatr
improv
addit
intrathec
treatment
toler
dexamethason
taper
without
symptom
flare
mri
also
demonstr
parenchym
lesion
improv
definit
treatment
underw
unrel
allogen
hematopoiet
cell
transplant
remain
neurolog
baselin
eight
month
posttranspl
ongo
imag
improv
conclus
case
famili
hlh
compound
heterozyg
perforin
mutat
adolesc
isol
neuropsychiatr
symptom
illustr
cn
hlh
may
underrecogn
phenomenon
absenc
system
sign
standard
hlh
therapi
may
effect
revers
symptom
associ
radiolog
respons
rush
univers
children
hospit
chicago
illinoi
unit
state
background
posterior
revers
encephalopathi
syndrom
pre
recogn
complic
pediatr
leukemia
treatment
report
patient
variou
seri
hypertens
chemotherapi
cortic
spread
depress
implic
pathophysiolog
due
combin
use
difficult
identifi
offend
drug
sever
implic
sinc
delay
chemotherapeut
treatment
children
high
risk
leukemia
unfavor
import
recogn
characterist
radiolog
find
manag
appropri
reintroduc
treatment
soon
possibl
pharmacoethn
recogn
import
factor
variat
neurotox
children
ethnic
differ
report
pre
event
pediatr
patient
well
describ
literatur
describ
factor
associ
pre
cohort
high
risk
pediatr
patient
singl
institut
designmethod
total
children
averag
age
year
year
diagnos
retrospect
review
occurr
pre
variou
demograph
factor
therapi
receiv
clinic
featur
radiolog
relat
find
manag
review
search
publish
articl
pre
leukemia
conduct
use
pubm
databas
result
five
children
averag
age
year
develop
pre
day
induct
patient
develop
develop
pre
hispan
patient
develop
pre
diagnos
high
risk
patient
receiv
vincristin
receiv
daunomycin
intrathec
methotrex
receiv
asparaginas
week
prior
event
mri
find
confirm
pre
patient
evid
methotrex
relat
leukoencephalopathi
leukemia
time
pre
patient
remiss
base
mrd
spinal
fluid
cytolog
twothird
patient
seizur
hypertens
time
event
prior
histori
either
patient
complet
recoveri
normal
mental
statu
resolut
pre
higher
incid
pre
previous
report
note
seri
hispan
ethnic
highrisk
exposur
vincristin
daunomycin
intrathec
methotrex
induct
associ
pre
cohort
new
associ
emerg
hispan
ethnic
pre
larger
studi
understand
import
pharmacoethn
pre
may
help
individu
chemotherapi
base
ethnic
differ
children
hospit
illinoi
peoria
illinoi
unit
state
background
hyper
ige
syndrom
primari
immunodefici
character
suscept
skin
lung
infect
well
increas
propens
malign
hemophagocyt
lymphohistiocytosi
hlh
syndrom
character
overwhelm
activ
lymphocyt
macrophag
occur
either
primari
hlh
caus
genet
abnorm
secondari
hlh
associ
infecti
malign
metabol
immunodefici
caus
describ
first
case
knowledg
hlh
patient
hyper
ige
syndrom
describ
case
hlh
pediatr
patient
hyper
ige
syndrom
result
old
caucasian
male
known
autosom
domin
hyper
ige
syndrom
mutat
transfer
pediatr
intens
care
unit
secondari
concern
septic
shock
patient
persist
slow
bleed
oral
lesion
central
cathet
site
despit
addit
aminocapro
acid
recombin
factor
viia
also
requir
numer
blood
product
transfus
secondari
anemia
thrombocytopenia
clinic
suspicion
high
hlh
patient
met
criteria
diagnosi
hlh
follow
ferritin
ngml
triglycerid
mgdl
decreas
nk
cell
function
sampl
contain
nk
cell
elev
solubl
receptor
uml
splenomegali
fever
infecti
workup
remark
posit
ebv
qpcr
copiesml
suggest
ebv
driven
secondari
hlh
famili
hlh
test
unabl
complet
therapi
initi
base
upon
studi
addit
ruxolitinib
anakinra
consid
patient
declin
rapidli
prior
treatment
ct
head
concern
stroke
sign
edema
increas
intracrani
pressur
like
lead
develop
symptom
consist
brain
stem
herniat
decis
made
withdraw
care
conclus
knowledg
first
report
hlh
patient
hyper
ige
syndrom
diagnos
hlh
requir
high
index
suspicion
critic
ill
patient
prompt
initi
therapi
essenti
challeng
case
hlh
patient
hyper
ige
syndrom
highlight
diagnost
challeng
variabl
present
need
effect
therapi
vulner
patient
popul
background
adolesc
young
adult
aya
cancer
risk
psychosoci
well
physic
symptom
burden
cancer
therapi
purpos
studi
explor
psycholog
physic
symptom
endors
aya
receiv
therapi
cancer
designmethod
survey
given
inpati
outpati
set
cancer
therapi
symptom
screen
pediatr
tool
sspedi
memori
symptom
assess
scale
msa
symptom
sever
rate
teen
point
likert
scale
spss
use
statist
analysi
result
total
aya
cancer
therapi
age
rang
year
femal
male
acut
leukemia
solid
tumor
diagnosi
report
aya
cancer
therapi
report
least
symptom
report
symptom
cluster
physic
symptom
report
distress
teen
mouth
sore
headach
top
caus
physic
symptom
frequent
endors
fatigu
top
follow
chang
appetit
vomit
pain
least
bowel
habit
chang
aya
rate
sad
frequent
psycholog
symptom
follow
feel
angri
scare
statist
signific
differ
notic
base
gender
differ
femal
report
symptom
p
type
cancer
acut
leukemia
versu
solid
tumor
statist
differ
conclus
aya
cancer
report
multipl
physic
psycholog
symptom
signific
distress
femal
seem
report
symptom
compar
male
screen
aya
cancer
therapi
relat
symptom
feasibl
routin
visit
add
import
inform
aya
wellb
background
sinu
histiocytosi
massiv
lymphadenopathi
shml
also
known
rosaidorfman
diseas
rare
histiocyt
prolif
disord
unknown
etiolog
mani
treatment
modal
employ
howev
uniform
guidelin
exist
object
literatur
review
treatment
option
shml
designmethod
chart
review
perform
pediatr
patient
diagnos
shml
children
hospit
montefior
irb
approv
inclus
criteria
includ
children
age
year
shml
exclus
criteria
includ
children
cutan
shml
four
case
shml
seen
montefior
describ
comprehens
review
literatur
identifi
addit
case
publish
manuscript
includ
treatment
modal
outcom
exclud
result
mani
patient
shml
respond
observ
alon
patient
patient
observ
resolut
diseas
five
stabl
diseas
five
lost
followup
one
patient
receiv
subsequ
system
therapi
surgic
manag
conduct
upfront
patient
resolut
diseas
one
stabl
diseas
one
recurr
therapi
note
remain
nine
patient
success
treat
system
therapi
consist
either
steroid
steroid
chemotherapi
system
therapi
use
firstlin
therapi
patient
steroid
alon
conjunct
chemotherapi
result
resolut
diseas
patient
respect
four
patient
stabl
three
progress
diseas
chemotherapi
without
steroid
result
resolut
stabl
diseas
patient
radiat
ineffect
conclus
shml
rare
diseas
publish
guidelin
treatment
result
case
detail
review
literatur
suggest
observ
may
consid
first
line
manag
patient
provid
signific
symptom
patient
symptomat
signific
progress
surgeri
may
consid
patient
recurr
refractori
diseas
steroid
andor
chemotherapi
may
use
presenc
nodal
extranod
diseas
seem
signific
impact
cours
treatment
given
rariti
diseas
difficult
conduct
random
control
trial
work
involv
collabor
center
cooper
intern
rare
histiocyt
disord
registri
would
help
boston
children
hospit
boston
massechusett
unit
state
background
increas
censu
intensifi
work
compress
inpati
oncolog
servic
institut
identifi
lead
resid
dissatisfact
impair
resid
learn
decreas
perceiv
qualiti
patient
care
object
evalu
impact
redesign
pediatr
inpati
hematolog
malign
ihm
servic
resid
percept
educ
valu
rotat
safeti
patient
care
designmethod
academ
year
initi
bundl
intervent
ihm
servic
modif
includ
decreas
patient
volum
ihm
servic
divid
two
team
util
extra
attend
teach
servic
consist
resid
fellow
team
compris
nurs
practition
intent
patient
team
assign
patient
deliber
assign
care
team
base
educ
opportun
provid
skill
set
intent
attend
faculti
select
attend
faculti
deeper
clinic
teach
experi
select
supervis
teach
team
increas
weekend
staf
complet
servic
junior
resid
complet
electron
survey
evalu
percept
educ
valu
rotat
well
abil
deliv
safe
care
rotat
fisher
exact
test
use
compar
respons
resid
experienc
redesign
resid
whose
experi
result
survey
complet
rate
intervent
resid
significantli
like
comparison
group
resid
choos
answer
good
excel
describ
overal
qualiti
rotat
intervent
vs
comparison
p
educ
experi
round
intervent
vs
comparison
p
intervent
resid
also
report
care
fewer
averag
primari
patient
daili
weekday
compar
comparison
resid
vs
patient
p
ci
furthermor
intervent
resid
like
comparison
resid
agre
strongli
agre
could
provid
safe
patient
care
weekend
day
intervent
vs
comparison
p
night
intervent
vs
comparison
p
oncolog
servic
redesign
initi
oncolog
servic
develop
new
teach
servic
led
improv
resid
percept
educ
valu
rotat
abil
provid
safe
care
patient
approach
could
use
servic
institut
promot
similar
outcom
resid
educ
patient
care
background
alkposit
histiocytosi
rare
histiocyt
prolif
disord
report
three
infant
present
primarili
hepatosplenomegali
anemia
thrombocytopenia
given
rariti
diseas
standard
treatment
algorithm
diagnosi
diseas
cours
outcom
remain
larg
unknown
publish
seri
describ
treatment
rang
monitor
alon
multidrug
chemotherapi
regimen
ultim
resolut
present
symptom
three
case
despit
vari
treatment
strategi
object
report
newli
diagnos
case
alkposit
histiocytosi
treat
novel
approach
use
cytarabin
monotherapi
result
full
term
male
infant
present
birth
difficulti
feed
hyperbilirubinemia
first
week
life
subsequ
develop
thrombocytopenia
transamin
profound
hypoalbuminemia
six
week
life
experienc
signific
abdomin
ascit
requir
repeat
paracentes
massiv
hepatosplenomegali
respiratori
distress
secondari
abdomin
distens
anemia
coagulopathi
underw
numer
diagnost
test
includ
liver
biopsi
follow
bone
marrow
biopsi
show
alkposit
histiocyt
infiltr
site
treatment
initi
cytarabin
mgkgday
x
day
repeat
everi
week
throughout
cours
five
cycl
treatment
experienc
intermitt
fever
mild
nausea
advers
event
end
five
cycl
hepatosplenomegali
resolv
blood
count
normal
demonstr
weight
gain
oral
feed
liver
enzym
normal
current
month
post
complet
therapi
remain
well
normal
physic
exam
laboratori
valu
conclus
treatment
alkposit
histiocytosi
lose
dose
cytarabin
result
complet
resolut
patient
symptom
minim
treatment
relat
advers
effect
longterm
treatment
relat
risk
given
rariti
diagnosi
report
effect
novel
treatment
option
import
futur
patient
care
background
adult
patient
melanoma
lung
cancer
harbor
braf
benefit
develop
subsequ
approv
specif
braf
inhibitor
delin
subset
similarli
target
pediatr
oncolog
patient
may
spur
develop
ration
use
inhibitor
children
importantli
point
mutat
fusion
braf
may
also
target
children
analog
recent
emerg
data
adult
cancer
patient
object
defin
genom
landscap
known
novel
braf
alter
fusion
pediatr
malign
report
index
case
clinic
respons
braf
mek
inhibitor
designmethod
dna
extract
micron
ffpe
section
tumor
pediatr
year
age
oncolog
patient
cgp
perform
hybridizationcaptur
adaptor
ligat
base
librari
mean
coverag
depth
cancerrel
gene
plu
intron
gene
frequent
rearrang
cancer
genom
alter
ga
includ
base
substitut
indel
copi
number
alter
fusionsrearrang
total
brafalt
pediatr
malign
identifi
harbor
singl
kinaseactiv
braf
short
variant
indel
fusion
alter
result
reduc
braf
kinas
activ
identifi
tumor
tumor
harbor
multipl
braf
alter
contain
least
singl
activ
short
variant
remain
tumor
contain
function
uncharacter
variant
kinaseactiv
braf
alter
identifi
divers
tumor
spectra
compris
brain
tumor
subtyp
carcinoma
subtyp
melanoma
constitut
case
hematolog
malign
subtyp
sarcoma
subtyp
extracrani
embryon
tumor
subtyp
seventytwo
brafalt
case
braf
fusion
identifi
involv
novel
fusion
partner
seven
fusionposit
case
predominantli
brain
tumor
identifi
involv
novel
fusion
partner
index
case
respons
therapi
intracrani
tumor
present
describ
popul
pediatr
patient
target
braf
alter
predominantli
enrich
primari
intracrani
tumor
span
divers
solid
tumor
type
hematolog
malign
addit
report
cohort
fusionposit
patient
index
case
multipl
previou
report
suggest
raf
mek
inhibitor
may
benefit
pediatr
patient
either
intracrani
extracrani
diseas
develop
drug
pediatr
indic
strongli
warrant
background
diffus
midlin
glioma
dmg
mutat
includ
diffus
intrins
pontin
glioma
dipg
lead
caus
brain
tumorrel
death
children
effect
therapeut
strategi
median
surviv
remain
dismal
genom
studi
identifi
recurr
mutat
major
dmg
involv
lysin
methionin
substitut
histon
result
chang
epigenet
landscap
dysregul
gene
express
promot
gliomagenesi
panobinostat
multipl
histon
deacetylas
hdac
inhibitor
found
one
effect
agent
dipg
patientderiv
cell
cultur
xenograft
model
previou
studi
present
clinic
trial
dipg
hdac
inhibit
panobinostat
may
also
exhibit
activ
diffus
midlin
glioma
thalamu
spinal
cord
evalu
effect
panobinostat
singl
agent
patientderiv
thalam
spinal
cord
diffus
midlin
glioma
cell
cultur
orthotop
xenograft
murin
model
spinal
cord
glioma
designmethod
patientderiv
thalam
spinal
cord
diffus
midlin
glioma
cell
cultur
treat
singl
agent
panobinostat
rang
concentr
cell
viabil
evalu
use
celltiterglo
assay
panobinostat
system
administ
orthotop
xenograft
murin
model
luciferaseexpress
spinal
cord
diffus
midlin
glioma
respons
panobinostat
evalu
ivi
vivo
imag
result
hdac
inhibit
panobinostat
significantli
decreas
cell
prolifer
nm
nm
spinal
cord
thalam
glioma
patientderiv
cell
cultur
respect
panobinostat
slow
tumor
growth
murin
model
spinal
cord
glioma
brain
p
n
spinal
cord
p
n
compar
vehicl
control
week
administr
panobinostat
clinic
trial
dipg
studi
suggest
hdac
inhibit
panobinostat
may
also
benefici
patient
thalam
spinal
cord
diffus
midlin
glioma
mutant
background
brain
tumor
common
solid
tumor
childhood
lead
caus
childhood
cancer
death
medulloblastoma
common
malign
brain
tumor
childhood
surviv
children
highgrad
glioma
hgg
glioblastoma
multiform
gbm
fare
much
wors
surviv
implic
poor
outcom
presenc
treatment
resist
brain
tumor
stemlik
cell
gbm
stemlik
cell
gsc
implic
tumor
growth
treatment
resist
patient
relaps
make
key
therapeut
prioriti
antipsychot
drug
apd
use
decad
variou
psychiatr
clinic
set
associ
lower
incid
cancer
includ
malign
brain
tumor
current
atyp
apd
evalu
potenti
allevi
cancer
treatment
induc
side
effect
furthermor
drug
may
direct
antitumor
effect
potenti
via
inhibit
dopamin
receptor
object
determin
anticanc
effect
atyp
apd
gbm
stemlik
cell
designmethod
anticanc
effect
apd
quetiapin
risperidon
evalu
gbm
stemlik
cell
line
develop
laboratori
glio
group
medulloblastoma
cell
line
cell
proliferationvi
determin
use
trypan
blue
exclus
mt
assay
effect
apd
cancer
stem
cell
selfrenew
determin
neurospher
assay
receptor
express
apd
effect
cell
cycl
protein
examin
western
blot
analysi
result
western
blot
analysi
gsc
demonstr
robust
express
indic
viabl
therapeut
target
apd
induc
dose
depend
cell
death
cell
line
test
treatment
either
apd
day
significantli
reduc
cell
prolifer
gsc
consist
find
observ
increas
cell
cycl
inhibitor
furthermor
day
apd
induc
robust
increas
gsc
death
approxim
compar
nontreat
control
lastli
apd
significantli
reduc
gsc
neurospher
format
compar
untreat
control
suggest
inhibit
gbm
stem
cell
selfrenew
data
indic
clinic
relev
concentr
low
micromolar
apd
induc
anticanc
effect
gsc
enrich
tumor
initiationpropag
properti
group
myc
amplifi
medulloblastoma
cell
line
apd
repres
strong
candid
potenti
adjuv
therapi
treatment
brain
tumor
background
poor
prognosi
high
risk
neuroblastoma
hrnb
underscor
need
new
treatment
strategi
elucid
specif
biolog
subset
neuroblastoma
suggest
way
improv
diseas
manag
identif
agent
target
specif
molecular
pathway
associ
develop
progress
diseas
hold
promis
dfmo
inhibitor
odc
shown
decreas
mycn
target
cancer
stem
cell
preclin
studi
current
patient
undergo
immunotherapi
relaps
dfmo
studi
prevent
relaps
immunotherapi
may
help
immunotherapi
well
hypothes
studi
incorpor
target
therapi
select
base
upon
upfront
tumor
genom
interrog
standard
induct
chemotherapi
hrnb
safe
feasibl
may
increas
prcrvgpr
respons
rate
end
induct
therapi
addit
dfmo
mainten
immunotherapi
safe
feasibl
may
decreas
relaps
rate
hrnb
multicent
feasibl
pilot
trial
subject
newli
diagnos
hrnb
within
beat
childhood
cancer
consortium
diagnosi
patient
tumor
underw
dna
exom
rna
sequenc
analyz
within
molecular
tumor
board
identifi
singl
best
drug
target
agent
ad
cycl
induct
chemotherapi
consolid
asct
radiat
patient
receiv
dfmo
along
standard
dinutuximab
retino
acid
dfmo
year
immunotherapi
patient
evalu
addit
toxic
addit
target
agent
dfmo
addit
induct
respons
result
pilot
studi
elig
patient
shown
process
feasibl
patient
complet
induct
portion
studi
combin
target
agent
chemotherapi
shown
safe
without
unexpect
toxic
delay
induct
cycl
week
relat
surgeri
infect
thrombocytopenia
induct
respons
demonstr
crvgprpr
rate
suggest
improv
histor
addit
patient
elig
combin
dfmo
dinutuximab
retino
acid
well
toler
safe
without
addit
toxic
due
dfmo
pilot
studi
patient
shown
process
genom
sequenc
addit
target
agent
upfront
chemotherapi
addit
dfmo
dinutuximab
retino
acid
mainten
therapi
newli
diagnos
hrnb
patient
feasibl
safe
without
unexpect
toxic
background
identifi
subpopul
medulloblastoma
tumor
stem
celllik
properti
hold
promis
reduc
diseas
recurr
known
unifi
marker
medulloblastoma
cancer
stem
cell
granulocyt
stimul
factor
receptor
gcsfr
well
understood
context
hematopoiesi
role
solid
tumor
pathogenesi
less
clear
neuroblastoma
melanoma
subpopul
express
gcsfr
cancer
stem
cell
properti
chemoresist
increas
tumorigen
enrich
tumor
chemotherapi
gcsfr
activ
lead
signal
jakstat
pathway
suggest
potenti
therapeut
target
hypothes
subpopul
medulloblastoma
cell
would
express
gcsfr
subpopul
would
demonstr
chemoresist
respons
inhibitor
jakstat
pathway
object
object
identifi
subpopul
medulloblastoma
cell
express
gcsfr
determin
rel
growth
rate
tumorigen
respons
chemotherapi
jakstat
inhibit
designmethod
medulloblastoma
cell
line
sort
via
flow
cytometri
gcsfr
surfac
express
subpopul
gcsfrposit
neg
medulloblastoma
cell
monitor
growth
continu
live
cell
imag
respons
chemotherapi
measur
subpopul
gcsfrposit
neg
medulloblastoma
cell
use
continu
live
cell
imag
measur
percent
cell
confluenc
cell
viabil
assay
valu
calcul
cell
line
agent
parent
medulloblastoma
cell
line
isol
gcsfrposit
neg
subpopul
also
treat
inhibitor
ruxolitinib
growth
rate
viabil
valu
calcul
result
gcsfr
surfac
express
identifi
medulloblastoma
cell
line
isol
gcsfr
posit
cell
demonstr
slower
growth
rate
compar
gcsfrneg
parent
unsort
medulloblastoma
cell
gcsfr
posit
cell
resist
vitro
vincristin
etoposid
carboplatin
compar
gcsfr
neg
popul
unsort
popul
cell
line
ruxolitinib
cytotox
medulloblastoma
cell
vitro
higher
valu
note
gcsfr
posit
cell
compar
unsort
gcsfr
neg
cell
show
subpopul
gcsfr
posit
cell
present
multipl
medulloblastoma
cell
line
via
flow
cytometri
isol
gcsfrposit
cell
slower
growth
rate
gcsfrneg
unsort
popul
also
show
ruxolitinib
vitro
activ
medulloblastoma
cell
line
propos
jak
inhibit
may
repres
adjunct
therapi
target
overal
tumor
burden
specif
target
gcsfrposit
subpopul
medulloblastoma
cell
may
drive
tumor
recurr
investig
efficaci
intensifi
adjuv
chemotherapi
osteosarcoma
patient
designmethod
retrospect
analyz
medic
record
children
osteosarcoma
treat
asan
medic
center
patient
receiv
induct
consist
cycl
cisplatin
doxorubicin
along
cycl
methotrex
map
proceed
surgic
resect
adjuv
ct
map
map
addit
ifosfamid
etoposid
mapi
mapi
mainli
consid
poor
respond
tumor
necrosi
patient
metastas
result
among
patient
patient
metastas
diagnosi
surgeri
conduct
patient
respond
induct
ct
show
tumor
necrosi
among
patient
proceed
adjuv
ct
patient
receiv
map
mapi
protocol
median
followup
month
overal
surviv
os
eventfre
surviv
ef
rate
patient
patient
patient
recur
die
diseas
progress
relaps
patient
receiv
salvag
ct
andor
surgeri
rescu
autolog
stem
cell
transplant
sct
three
patient
develop
treatmentrel
acut
myeloid
leukemia
aliv
allogen
sct
accord
respons
neoadjuv
ct
os
rate
good
respond
n
poor
respond
n
p
ef
rate
p
poor
respond
patient
receiv
map
adjuv
ct
receiv
mapi
os
rate
map
mapi
group
p
ef
rate
p
respect
patient
classifi
three
group
local
diseas
necrosi
n
local
diseas
necrosi
n
metastat
diseas
n
surviv
rate
order
group
os
ef
group
intensifi
adjuv
ct
mapi
improv
surviv
outcom
conclus
initi
metastat
diseas
poor
histolog
respons
neoadjuv
ct
major
risk
factor
poor
surviv
osteosarcoma
patient
found
ad
ifosfamid
etoposid
map
improv
surviv
outcom
patient
advers
risk
factor
effect
adjuv
therapi
patient
need
background
circul
cellfre
dna
cfdna
shed
tumor
circul
use
noninvas
molecular
profil
adult
cancer
littl
known
util
pediatr
cancer
pediatr
patient
metastat
refractori
solid
tumor
known
poor
surviv
rate
key
challeng
manag
obtain
biopsi
sampl
especi
time
diseas
wide
spread
patient
physic
unfit
sampl
develop
noninvas
profil
strategi
critic
optim
molecularli
guid
therapi
assess
respons
treatment
studi
want
determin
util
cfdna
noninvas
analyz
molecular
profil
pediatr
solid
tumor
neuroblastoma
nb
osteosarcoma
os
wilm
tumor
wt
designmethod
tumor
plasma
match
control
collect
patient
nb
wt
os
diagnosi
time
diseas
progress
cfdna
extract
plasma
analyz
multipl
methodolog
includ
target
next
gener
sequenc
panel
shallow
whole
genom
sequenc
swg
result
fifteen
nb
patient
os
patient
wt
patient
tumor
molecular
profil
known
differ
target
nextgener
sequenc
platform
cfdna
nb
patient
somat
mutat
copi
number
alter
previous
report
tumor
detect
includ
recurr
nb
driver
mycn
amplif
alk
atrx
mutat
mutat
detect
origin
tumor
also
found
nb
patient
includ
nra
potenti
action
os
mutat
known
tumor
found
cfdna
patient
includ
atrx
mutat
well
copi
number
alter
amplif
target
therapeut
avail
two
wt
patient
analyz
cfdna
reveal
mutat
tumor
one
patient
howev
cohort
patient
tumor
avail
cfdna
reveal
recurr
driver
mutat
feasibl
noninvas
identifi
somat
mutat
copi
number
alter
cfdna
patient
pediatr
solid
tumor
establish
platform
use
cfdna
identifi
molecular
profil
tumor
serv
power
tool
guid
treatment
monitor
respons
treatment
background
despit
multimod
therapi
prognosi
patient
metastat
osteosarcoma
remain
poor
necessit
develop
novel
target
therapi
immunotherapi
exploit
target
osteosarcoma
exquisit
specif
remain
limit
insuffici
tumor
specif
target
object
overcom
dearth
tumor
specif
antigen
explor
use
tumor
deriv
mrna
repres
tumor
specif
transcriptom
develop
person
nanoparticl
vaccin
designmethod
rnananoparticl
rnanp
amplifi
limit
amount
biopsi
tissu
induct
tumor
specif
cell
osteosarcoma
sinc
local
vaccin
strategi
mire
poor
overal
immunogen
assess
feasibl
immunogen
antitumor
activ
intraven
administ
rnanp
tumor
mrna
complex
dotap
nanoliposom
preclin
murin
canin
tumor
model
identifi
clinic
translat
np
formul
deliveri
rna
antigen
present
cell
apc
induc
vivo
gene
express
preserv
rna
stabil
time
tumor
deriv
rnanp
induc
antigen
specif
cell
immun
mediat
antitumor
efficaci
sever
preclin
solid
tumor
model
ie
administ
intraven
rnanp
increas
express
costimulatori
molecul
ie
cell
throughout
reticuloendotheli
organ
ie
spleen
liver
bone
marrow
within
tumor
microenviron
phenotyp
strictli
depend
type
interferon
target
inhibit
type
interferon
signal
via
mab
abrog
antitumor
efficaci
mediat
rnanp
enhanc
immunogen
platform
simpli
combin
mrna
encod
immunomodulatori
molecul
ie
hcvpamp
gmcsf
combin
rnanp
immun
checkpoint
inhibitor
addit
checkpoint
inhibitor
mab
rnanp
increas
tumor
infiltr
lymphocyt
intratumor
mhc
class
iii
express
mediat
synergist
antitumor
activ
set
inhibit
alon
confer
therapeut
benefit
explor
feasibl
rnanp
larg
anim
osteosarcoma
model
ongo
studi
canin
osteosarcoma
shown
suffici
amount
rna
extract
amplifi
manufactur
person
rnanp
vaccin
conclus
rnanp
reprogram
system
immun
mediat
antitumor
activ
provid
near
immedi
immun
induct
without
complex
cellular
immunotherapi
immun
correl
preclin
respons
rnanp
hallmark
interferon
depend
express
activ
apc
mhcii
cell
base
find
explor
preclin
safeti
efficaci
immunolog
effect
rnanp
target
canin
osteosarcoma
first
inhuman
evalu
background
ewe
sarcoma
aggress
bone
tumor
affect
mainli
adolesc
young
adult
treatment
base
compress
schedul
chemotherapi
combin
local
control
surgeri
andor
radiat
prognosi
poorer
patient
metastat
diseas
older
age
central
primari
surviv
diseas
recur
within
two
year
diagnosi
fusion
gene
well
character
domin
ew
drivergen
common
variat
ew
exon
exon
fusion
posit
patient
design
novel
pbishrna
tm
type
lpx
demonstr
safeti
efficaci
anim
model
rao
et
pbishrna
strategi
silenc
target
gene
express
concurr
induc
translat
repress
pbodi
sequestr
well
posttranscript
mrna
cleavag
determin
safeti
maximum
toler
dose
intraven
administr
pbishrna
tm
type
lipoplex
patient
advanc
ew
designmethod
phase
studi
escal
cohort
test
pbishrna
tm
type
lpx
start
iv
dose
mgkg
patient
age
advanc
ewe
sarcoma
type
transloc
intraven
infus
given
twice
week
week
follow
escal
schema
requir
kp
adequ
organ
function
cytokin
induct
pre
postinfus
analyz
tnfalpha
first
cohort
patient
enrol
age
year
three
relaps
patient
line
therapi
patient
refractori
diseas
patient
receiv
complet
cycl
pbishrna
tm
type
lpx
twice
week
infus
total
dose
given
promin
relat
toxic
hematolog
patient
develop
transient
neutropenia
anoth
patient
develop
anemia
requir
prbc
transfus
note
patient
signific
bone
bone
marrow
involv
one
patient
receiv
two
lpx
infus
develop
fatal
rsv
pneumonia
report
grade
toxic
includ
fatigu
headach
evalu
patient
stabl
diseas
month
progress
one
patient
sustain
respons
month
progress
two
patient
still
aliv
preliminari
experi
support
safeti
potenti
efficaci
pbishrna
tm
type
lpx
novel
treatment
advanc
ew
limit
toxic
increas
correl
higher
bishrnai
lpx
infus
rate
clinic
symptom
clinic
test
indic
background
children
cn
malign
bt
surviv
late
effect
therapi
receiv
better
describ
studi
show
radiat
therapi
particularli
harm
neurocognit
function
specif
process
speed
work
memori
attent
span
deficit
neg
effect
qualiti
life
especi
academ
profession
set
larg
proport
adult
survivor
bt
unabl
reach
adult
mileston
live
hold
steadi
job
get
marri
proton
beam
radiat
therapi
pbrt
tout
potenti
fewer
less
sever
side
effect
tradit
photon
radiat
therapi
xrt
properti
proton
amount
damag
energi
releas
nontarget
healthi
tissu
reduc
compar
xrt
although
studi
compar
iq
test
pbrt
xrt
found
differ
two
therapi
studi
compar
specif
neurocognit
domain
would
valuabl
evalu
full
neurocognit
test
score
nct
sinc
specif
domain
particularli
process
speed
psi
appear
vulner
radiat
therapi
object
primari
aim
assess
differ
psi
patient
bt
underw
pbrt
versu
xrt
secondari
aim
assess
differ
iq
fsiq
work
memori
wmi
retrospect
evalu
patient
treat
bt
jimmi
everest
cancer
center
within
past
year
receiv
rt
nct
post
radiat
examin
full
nct
result
subset
particip
evalu
differ
specif
domain
process
speed
work
memori
iq
measur
percentil
score
domain
object
report
experi
imag
children
mm
treat
uniformli
institut
melanoma
trial
retrospect
review
clinic
imag
find
patient
ajcc
stage
iiciv
cutan
mm
treat
institut
protocol
brain
mrict
petct
ct
chest
abdomen
pelvi
ctcap
perform
diagnosi
patient
treatment
stratum
patient
peginterferon
ajcc
iic
iiia
iiib
n
imag
repeat
everi
month
stratum
peginterferon
temozolomid
unresect
measur
diseas
metastat
recurr
n
pet
scan
everi
month
brain
imag
everi
month
stratum
peginterferon
temozolomid
unresect
nonmeasur
metastat
recurr
n
imag
perform
everi
month
therapi
patient
continu
imag
everi
month
year
result
patient
femal
median
age
year
eleven
spitzoid
convent
melanoma
primari
site
includ
headneck
n
trunk
n
extrem
n
patient
spitzoid
melanoma
imag
studi
pet
ctcap
ct
chest
ct
brain
mri
brain
median
studiespati
respect
median
cost
per
patient
thirteen
studi
show
suspici
lesion
addit
scan
diagnost
biopsi
one
posit
stratum
tert
promot
mutat
die
diseas
convent
mm
studi
pet
ctcap
ct
chest
ct
brain
mri
brain
perform
median
studiespati
respect
median
cost
per
patient
twenti
show
suspici
lesion
addit
scan
diagnost
biopsi
four
posit
two
diagnosi
die
diseas
two
recur
locoregion
detect
clinic
aliv
diseas
free
one
patient
diffus
metastas
die
shortli
enrol
median
follow
year
rang
patient
aliv
diseas
free
children
spitzoid
melanoma
minim
imag
diagnosi
followup
given
low
risk
recurr
low
yield
high
cost
aggress
imag
protocol
patient
convent
mm
imag
accord
adult
guidelin
nationwid
children
hospit
columbu
ohio
unit
state
background
role
infect
long
term
outcom
patient
bone
tumor
controversi
two
retrospect
studi
shown
increas
surviv
osteosarcoma
patient
postop
wound
infect
anoth
show
chang
overal
surviv
determin
relationship
wound
infect
andor
bloodstream
infect
bsi
surviv
pediatr
young
adult
patient
osteosarcoma
ewe
sarcoma
treat
tertiari
children
hospit
designmethod
retrospect
chart
review
perform
patient
diagnosi
osteosarcoma
ewe
sarcoma
patient
receiv
standard
chemotherapi
regimen
diseas
type
stage
local
control
includ
surgic
resect
andor
radiat
therapi
presenc
infect
determin
bsi
wound
cultur
receiv
treatment
primari
tumor
median
age
patient
rang
year
diagnosi
diagnosi
osteosarcoma
ewe
sarcoma
patient
develop
infect
treatment
bsi
wound
infect
patient
bsi
year
os
compar
without
bsi
p
bsi
wound
infect
poorest
overal
surviv
compar
patient
without
infect
patient
wound
infect
alon
year
os
compar
patient
without
wound
infect
analysi
reveal
decreas
os
patient
bsi
howev
could
due
confound
factor
presenc
bsi
bsi
bsi
wound
infect
poorest
surviv
wound
infect
without
bsi
associ
slight
increas
surviv
howev
studi
limit
number
patient
local
wound
infect
use
newer
surgic
techniqu
avail
antimicrobi
routin
use
prophylact
antibiot
incid
infect
undergo
treatment
low
howev
import
clinic
observ
indic
like
enhanc
immun
system
associ
infect
support
role
immunotherapi
treatment
aggress
tumor
background
hypoalbuminemia
wellrecogn
effect
cancer
chronic
ill
often
regard
marker
malnutrit
adult
hypoalbuminemia
associ
advers
outcom
patient
cancer
lung
pelvi
head
neck
gastrointestin
tract
bone
marrow
well
pediatr
patient
ewe
sarcoma
hodgkin
lymphoma
hypoalbuminemia
well
studi
children
cancer
determin
incid
hypoalbuminemia
use
agespecif
refer
children
cancer
receiv
chemotherapi
baselin
prior
start
chemotherapi
determin
whether
hypoalbuminemia
associ
inferior
overal
surviv
designmethod
perform
singl
institut
irbapprov
retrospect
review
pediatr
oncolog
patient
diagnos
fiveyear
surviv
estim
use
kaplanmei
method
group
compar
use
cox
regress
identifi
pediatr
patient
first
diagnosi
cancer
brain
tumor
condit
possibl
requir
chemotherapi
patient
exclud
reason
includ
receiv
chemotherapi
miss
data
leav
patient
serum
albumin
level
within
day
prior
start
chemotherapi
mean
age
year
sd
year
male
nonhispan
common
diagnosi
acut
lymphoblast
leukemia
one
hundr
thirti
nine
hypoalbuminemia
prior
start
chemotherapi
statist
signific
differ
overal
surviv
without
hypoalbuminemia
vs
respect
hazard
ratio
ci
conclus
hypoalbuminemia
baselin
pediatr
oncolog
patient
requir
chemotherapi
common
one
five
associ
inferior
overal
surviv
cohort
leptomening
metastas
diagnosi
standard
treatment
complet
resect
nonanaplast
supratentori
ependymoma
close
observ
treatment
anaplast
incomplet
resect
nonanaplast
ependymoma
maxim
safe
surgic
resect
follow
focal
radiat
howev
local
ependymoma
recur
role
chemotherapi
treat
ependymoma
investig
extraneur
metastas
anaplast
ependymoma
rare
report
outcom
dismal
object
report
extraneur
cervic
node
metastas
nonanaplast
ependymoma
success
treatment
surgic
resect
radiat
system
chemotherapi
designmethod
retrospect
review
patient
medic
record
includ
radiograph
imag
tumor
tissu
patholog
comprehens
literatur
review
result
previous
healthi
girl
underw
gross
total
resect
gtr
isol
right
pariet
lobe
ependymoma
grade
ii
age
year
magnet
reson
imag
mri
reveal
isol
local
recurr
underw
gtr
follow
observ
age
year
experienc
isol
local
recurr
underw
gtr
follow
gy
focal
conform
photon
radiat
recurr
patholog
reveal
nonanaplast
ependymoma
cerebr
spinal
fluid
csf
cytopatholog
spine
mri
neg
age
year
develop
enlarg
right
posterior
cervic
chain
lymph
node
subsequ
mri
reveal
larg
rimenhanc
hyperintens
lymph
node
multipl
abnorm
enhanc
region
node
consist
metastas
biopsi
reveal
nonanaplast
ependymoma
mri
brain
spine
comput
tomographi
chest
abdomen
pelvi
csf
marrow
evalu
unremark
chemotherapi
accord
initi
mri
cours
demonstr
signific
node
size
reduct
underw
right
neck
node
dissect
one
right
level
ii
lymph
node
show
metastas
treat
gy
irradi
neck
addit
cours
chemotherapi
remain
remiss
month
month
diagnosi
metastat
diseas
end
therapi
respect
literatur
review
reveal
rare
report
extraneur
metastat
diseas
anaplast
ependymoma
bone
lung
liver
involv
lymph
node
associ
poor
outcom
despit
multimod
therapi
knowledg
first
report
extraneur
metastas
nonanaplast
ependymoma
extraneur
metastas
consid
children
previous
treat
nonanaplast
ependymoma
experi
system
symptom
even
absenc
cn
relaps
multimod
treatment
offer
potenti
longterm
diseas
control
accept
toxic
arun
gurunathan
joel
sorger
andrew
trout
joseph
pressey
rajaram
nagarajan
brian
turpin
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
pigment
villonodular
synov
pvn
benign
neoplasm
synovium
standard
treatment
surgeri
postop
recurr
rate
high
radiat
therapi
use
local
control
associ
late
effect
pvn
rare
fatal
aggress
diseas
andor
extens
surgeri
result
substanti
function
impair
coloni
stimul
overexpress
often
due
chromosom
transloc
involv
drive
pvn
recruit
synoviallik
mononuclear
cell
express
tyrosin
kinas
inhibitor
imatinib
activ
shown
benefit
postsurg
relaps
set
howev
question
remain
regard
broader
applic
imatinib
regard
optim
respons
assess
present
three
patient
pvn
differ
clinic
scenario
demonstr
clinic
respons
imatinib
monitor
chang
metabol
activ
maximum
suv
petct
result
three
patient
pvn
demonstr
petct
respons
imatinib
guid
manag
challeng
clinic
scenario
patient
yearold
femal
left
hip
pvn
high
grade
articular
cartilag
loss
decreas
metabol
activ
suvmax
month
neoadjuv
imatinib
enabl
total
hip
replac
surgeri
plan
patient
yearold
femal
left
knee
pvn
recurr
synovectomi
spare
subsequ
surgic
control
attempt
clinic
improv
correl
petct
respons
imatinib
suvmax
month
patient
yearold
male
right
knee
pvn
recur
total
knee
replac
clinic
improv
correl
petct
respons
imatinib
suvmax
month
patient
would
character
stabl
diseas
respons
evalu
criteria
solid
tumor
recist
patient
imatinib
toler
well
therapi
interrupt
absent
easili
manag
side
effect
one
patient
take
dronabinol
decreas
appetit
one
patient
take
prn
immodium
diarrhea
patient
current
still
take
imatinib
therapi
length
rang
five
eleven
month
seri
three
patient
pvn
imatinib
show
promis
diseas
manag
neoadjuv
adjuv
set
toler
side
effect
profil
imatinib
consid
treatment
pvn
spare
surgic
radiotherapi
relat
morbid
treatment
effect
monitor
petct
background
metastat
rhabdomyosarcoma
rm
carri
poor
prognosi
threeyear
event
free
surviv
rate
rang
depend
oberlin
risk
factor
due
lack
significantli
effect
breakthrough
recent
past
urgent
unmet
need
new
treatment
strategi
diseas
metastat
rm
cell
line
exhibit
increas
express
erm
famili
membranecytoskeleton
linker
protein
ezrin
knockdown
ezrin
express
use
sirna
decreas
metastat
potenti
cell
wherea
forc
express
ezrin
result
increas
degre
metastasi
activ
ezrin
control
phosphoryl
threonin
residu
cterminu
protein
suggest
alter
ezrin
phosphoryl
may
control
rm
growth
metastasi
goal
determin
pharmacolog
inhibit
phosphoryl
ezrin
affect
growth
surviv
metastasi
rm
vitro
well
vivo
designmethod
rm
cell
line
repres
alveolar
embryon
histolog
subtyp
use
rm
cell
treat
small
molecul
inhibitor
ezrin
specif
dephosphoryl
ezrin
residu
baselin
express
ezrin
perm
level
well
effect
perm
level
rm
cell
line
determin
western
blot
cell
lysat
viabil
cell
assess
trypan
blue
exclus
morpholog
visual
bright
field
microscopi
extent
apoptosi
detect
imag
caspas
activ
use
fluoresc
microscopi
motil
rm
cell
examin
perform
woundheal
assay
subcutan
orthotop
xenograft
establish
nsg
mice
use
rd
cell
embryon
rm
mice
harbor
xenograft
treat
intraperiton
inject
dmso
result
ezrin
constitut
phosphoryl
residu
major
rm
cell
line
examin
dephosphoryl
ezrin
residu
cell
line
treatment
inhibit
growth
induc
apoptosi
inhibit
migrat
rm
cell
line
vitro
treatment
nsg
mice
bear
subcutan
orthotop
embryon
rhabdomyosarcoma
xenograft
significantli
imped
tumor
progress
without
obviou
advers
effect
find
suggest
dephosphoryl
ezrin
threonin
residu
may
potenti
novel
therapeut
strategi
rm
patient
india
institut
medic
scienc
new
delhi
new
delhi
delhi
india
background
role
laparoscopi
manag
pediatr
intraabdomin
solid
tumor
yet
establish
safeti
laparoscop
manag
pediatr
intraabdomin
tumor
still
question
studi
result
initi
case
seri
pediatr
intraabdomin
tumor
manag
laparoscop
institut
juli
onward
designmethod
total
children
femal
present
us
pediatr
intraabdomin
tumor
includ
tumor
includ
wilm
tumor
n
neuroblastoma
n
adren
cortic
tumor
n
ovarian
teratoma
n
children
receiv
neoadjuv
chemotherapi
laparoscop
nephrectomi
lymph
node
sampl
wilm
tumor
adrenalectomi
adren
tumor
perform
tumor
remov
intoto
ruptur
except
one
specimen
retriev
lumbar
incis
n
inguin
incis
n
children
regular
follow
two
children
wilm
tumor
recurr
neuroblastoma
child
underw
open
surgeri
recurr
later
conclus
laparoscopylaparoscop
assist
remov
pediatr
intra
abdomin
tumor
feasibl
safe
option
advantag
less
postop
pain
shorter
hospit
stay
better
cosmet
result
proper
patient
select
port
placement
laparoscop
experi
contributori
background
target
protein
cell
surfac
antigen
specif
cancer
cell
monoclon
antibodi
proven
effect
form
treatment
mani
form
cancer
cell
surfac
disialogangliosid
express
cell
surfac
normal
tissu
includ
nerv
cell
melanocyt
mesenchym
stromal
cell
overexpress
pediatr
cancer
like
neuroblastoma
osteosarcoma
dinutuiximab
chimer
monoclon
antibodi
fda
approv
treatment
patient
high
risk
neuroblastoma
investig
treatment
relaps
osteosarcoma
littl
known
pattern
express
pediatr
malign
object
sought
describ
pattern
express
follow
pediatr
sarcoma
synovi
sarcoma
rhabdomyosarcoma
ewe
sarcoma
designmethod
synovi
sarcoma
n
rhabdomyosarcoma
n
ewe
sarcoma
n
formalin
fix
paraffin
embed
core
obtain
seattl
children
research
institut
tissu
microarray
tma
biorepositori
tma
block
consist
melanoma
core
stain
without
antibodi
use
posit
neg
control
respect
slide
incub
antigangliosid
antibodi
clone
abcam
dilut
normal
goat
serum
bsa
tb
overnight
neg
control
human
melanoma
section
incub
normal
goat
serum
bsa
tb
without
primari
antibodi
express
indic
characterist
brown
diaminobenzidin
stain
intens
locat
tissu
stain
assess
compar
posit
neg
control
stain
consid
posit
intens
stain
consist
posit
control
cell
stain
posit
classif
intermedi
express
assign
slide
cell
stain
posit
slide
classifi
sporad
stain
cell
stain
posit
tissu
consid
complet
absenc
stain
similar
neg
control
object
evalu
clinic
present
manag
treatment
outcom
children
malign
germ
cell
tumor
institut
designmethod
prospect
studi
conduct
june
dec
depart
pediatr
surgeri
tertiari
care
institut
develop
countri
patient
evalu
local
diseas
metastat
diseas
imag
tumor
marker
risk
stratifi
chemotherapi
use
low
risk
tumor
receiv
chemotherapi
intermedi
risk
cours
peb
chemotherapi
high
risk
cours
peb
cours
pe
upfront
resect
primari
residu
diseas
neoadjuv
chemotherapi
feasibl
perform
follow
done
monthli
tumor
marker
month
imag
studi
everi
month
initi
year
five
year
overal
surviv
diseas
free
surviv
calcul
result
studi
treat
children
form
studi
group
gonad
testicular
ovarian
remain
extragonad
sacrococcyg
sct
common
site
one
hundr
thirteen
children
present
us
primarili
remain
receiv
treatment
elsewher
stage
stage
diseas
present
present
children
recurr
note
patient
respect
patient
testicular
mgct
children
age
year
male
significantli
poor
rf
rate
conclus
patient
mgct
stage
correctli
adjuv
chemotherapi
advis
patient
except
stage
enderm
sinu
tumor
testi
awar
regard
still
lack
countri
meticul
follow
need
recur
cure
rate
dismal
children
recurr
mgct
especi
chemotherapi
nemour
children
specialti
care
jacksonvil
florida
unit
state
background
radiotherapi
pediatr
head
neck
tumor
often
result
mucos
limit
oral
intak
compromis
patient
nutrit
statu
may
reduc
improv
conform
offer
proton
therapi
despit
widespread
use
enter
tube
feed
percutan
gastrostomi
peg
nasogastr
tube
ngt
littl
data
avail
regard
overal
incid
ngtpeg
placement
perspect
pediatr
patient
caregiv
object
estim
need
ngtpeg
support
b
character
patient
caregiv
percept
surround
enter
feed
children
head
neck
tumor
undergo
proton
therapi
designmethod
depend
develop
stage
patient
n
parent
n
fill
seri
custom
survey
accord
prospect
irb
approv
studi
seventythre
percent
patient
also
receiv
concurr
chemotherapi
question
address
current
feed
rout
percept
exampl
aspect
tube
feed
benefici
aspect
tube
feed
worri
scare
fiftyf
survey
distribut
radiat
chang
feed
rout
result
start
proton
therapi
patient
ngt
patient
peg
patient
ngtpeg
place
exclus
administr
medic
patient
need
ngtpeg
nutrit
patient
without
ngtpeg
would
consid
enter
feed
patient
without
ngtpeg
commonli
cite
benefit
maxim
nutrit
common
neg
aspect
fear
tube
placement
patient
subpopul
patient
cite
chang
appear
neg
aspect
patient
without
ngtpeg
start
proton
therapi
patientscaregiv
felt
enter
feed
unnecessari
patient
would
consid
ngtpeg
even
physician
advis
cours
proton
therapi
patientscaregiv
deem
enter
feed
unnecessari
decreas
complet
treatment
patient
use
ngtpeg
tube
nutrit
support
one
patient
reli
exclus
enter
feed
two
patient
without
ngtpeg
requir
parenter
support
data
support
prophylact
placement
ngtpeg
children
head
neck
tumor
undergo
proton
therapi
ongo
research
need
identifi
patient
need
ngt
peg
supplement
diet
cohort
anticipatori
counsel
focu
pain
cosmesi
util
children
nation
medic
center
washington
district
columbia
unit
state
background
ovarian
sex
cordstrom
tumor
osct
rare
neoplasm
typic
present
signssymptom
adnex
mass
sign
hormon
approxim
ovarian
sex
cordstrom
tumor
children
sertolileydig
cell
tumor
slct
median
age
present
year
knowledg
youngest
report
case
literatur
describ
old
femal
china
slct
treat
oophorectomi
studi
found
associ
famili
pleuopulmonari
blastoma
osct
germlin
mutat
lead
syndrom
associ
younger
age
object
describ
unusu
case
present
slct
infant
result
old
twin
femal
week
prematur
infant
present
emerg
depart
multipl
occas
abdomin
distent
feed
intoler
initi
thought
relat
previou
omphalocel
repair
umbil
hernia
ultrasound
demonstr
cm
mass
aris
right
ovari
larg
volum
ascit
requir
admiss
intens
care
unit
due
respiratori
distress
signific
ascit
serum
tumor
marker
includ
hcg
afp
ldh
neg
patient
underw
right
oophorectomi
tumor
capsul
note
open
time
surgeri
imag
post
oper
demonstr
site
diseas
patient
classifi
figo
stage
ic
due
presenc
signific
abdomin
ascit
presum
malign
preoper
tumor
patholog
diagnosi
challeng
eventu
result
mix
germ
cell
sex
cord
stromal
tumor
pattern
sertoli
cell
tumor
neuroendocrin
differenti
base
stage
figo
ic
preoper
ruptur
decis
made
treat
standard
platinum
base
regimen
higher
incid
relaps
stage
ic
patient
compar
ia
treat
observ
patient
toler
four
cycl
chemotherapi
well
end
therapi
scan
show
evid
diseas
interestingli
dicer
mutat
genet
perform
ion
torrent
tm
next
gener
sequenc
neg
germlin
tumor
studi
knowledg
patient
youngest
describ
slct
continu
follow
serial
imag
alon
evid
elev
tumor
marker
due
young
age
unusu
diagnosi
refer
cancer
genet
team
background
approxim
patient
wilm
tumor
wt
metastat
diseas
diagnosi
often
grave
prognosi
limit
cell
line
avail
studi
metastat
wt
longterm
passag
cell
line
alway
recapitul
human
condit
focal
adhes
kinas
fak
nonreceptor
tyrosin
kinas
control
cellular
pathway
involv
tumorigenesi
pediatr
renal
tumor
use
novel
patientderiv
xenograft
pdx
model
patient
primari
wt
coa
match
isogen
metastat
wt
coa
previous
demonstr
fak
express
inhibit
led
decreas
tumorigen
primari
metastat
pdx
kinom
profil
innov
highthroughput
method
use
investig
kinas
signal
identifi
potenti
therapeut
target
date
kinom
profil
primari
metastat
wt
examin
object
investig
baselin
kinom
differ
primari
metastat
wt
evalu
kinas
upstream
downstream
fak
potenti
target
therapi
designmethod
cell
coa
coa
treat
pf
small
molecul
fak
inhibitor
protein
cell
lysat
treat
untreat
coa
coa
combin
kinas
buffer
atp
fluoresc
label
antibodi
load
phosphotyrosin
kinas
serinethreonin
kinas
per
uab
kinom
core
protocol
phosphopeptid
substrat
analysi
kinom
workstat
intern
protocol
use
softwar
bionavig
v
use
analyz
kinas
upstream
downstream
fak
primari
wt
increas
decreas
pdgfrb
rel
pair
metastat
wt
baselin
treatment
pf
increas
ron
pdgfrb
mak
vacamkl
primari
wt
treatment
pf
decreas
increas
pair
metastat
wt
primari
wt
display
differ
kinom
profil
compar
metastat
wt
match
isogen
pdx
model
data
reveal
altern
therapi
specif
target
metastas
need
furthermor
fak
inhibit
result
divers
kinom
alter
primari
metastat
wt
inhibitor
target
mani
pathway
pdgfrb
inhibitor
current
avail
potenti
could
combin
fak
inhibitor
treatment
wt
result
current
studi
indic
kinas
upstream
downstream
fak
primari
metastat
wt
warrant
investig
background
use
highdos
methotrex
hdmtx
mainstay
standard
therapi
pediatr
osteosarcoma
os
north
america
pediatr
os
narrow
therapeut
window
hdmtx
decreas
tumor
respons
rate
mtx
concentr
decreas
surviv
due
sever
toxic
concentr
risk
factor
hdmtx
toxic
defin
adult
includ
bodi
mass
index
bmi
male
gender
studi
conduct
children
sought
examin
relationship
mtx
level
toxic
hdmtx
infus
pediatr
os
therebi
identifi
risk
factor
increas
toxic
provid
framework
therapeut
drug
monitor
designmethod
retrospect
chart
review
includ
patient
treat
texa
children
hospit
hdmtx
firstlin
therapi
os
data
abstract
electron
record
includ
patient
characterist
bmi
bodi
surfac
area
bsa
baselin
posttreat
laboratori
valu
mtx
level
hour
dose
given
hour
mtx
clear
mtx
um
grade
mucos
myleosuppress
persist
lft
elev
ctace
tumor
necrosi
correl
mtx
level
covari
summar
use
descript
statist
review
hdmtx
infus
correspond
patient
bmi
found
significantli
impact
mtx
level
p
femal
gender
also
significantli
associ
higher
mtx
level
p
percent
necrosi
avail
patient
associ
mtx
level
nearstatist
signific
p
mtx
level
found
contribut
toxic
associ
significantli
mtx
clearanc
analysi
larger
cohort
ongo
identifi
least
one
patient
factor
bmi
significantli
impact
mtx
level
potenti
use
futur
model
current
model
incorpor
bsa
find
concord
studi
adult
os
bmi
significantli
impact
mtx
level
diverg
femal
gender
associ
higher
level
importantli
data
support
target
mtx
level
ensur
minimum
concentr
adequ
tumor
necrosi
reach
result
suggest
monitor
level
would
prevent
toxic
thu
necessit
character
intrins
patient
factor
associ
toxic
overal
definit
clinic
factor
associ
mtx
level
contribut
framework
therapeut
drug
monitor
pediatr
os
children
merci
hospit
kansa
citi
kansa
citi
missouri
unit
state
background
post
consolid
immunotherapi
dinutuximab
aldesleukin
granulocyt
macrophag
coloni
stimul
factor
gmcsf
isotretinoin
standard
care
children
high
risk
neuroblastoma
dinutuximab
combin
altern
cycl
gmcsf
follow
cycl
isotretinoin
alon
administ
continu
infus
day
follow
higher
infus
dose
combin
dinutuximab
day
cycl
dose
may
administ
inpati
ambulatori
set
object
retrospect
compar
incid
inpati
outpati
side
effect
complic
associ
low
dose
provid
toler
data
necessari
evalu
venu
futur
administr
option
designmethod
studi
descript
singlecent
definit
studi
util
retrospect
conveni
sampl
popul
children
high
risk
neuroblastoma
receiv
low
dose
either
inpati
outpati
without
exclus
may
june
subject
identifi
tumor
registri
queri
post
irb
approv
electron
paper
medic
record
review
date
locat
infus
home
health
compani
use
applic
document
regard
clinic
statu
side
effect
toxic
demograph
limit
age
gender
result
infus
venu
chosen
provid
prefer
twentysix
infus
inpati
outpati
via
separ
home
health
compani
administ
entireti
without
interrupt
male
femal
rang
year
age
two
children
receiv
singl
outpati
infus
due
intoler
combin
dinutuximab
receiv
therapi
set
fever
inpati
outpati
common
side
effect
sourc
infect
ever
identifi
one
incid
diarrhea
one
patient
pruritu
outpati
inpati
set
respect
plan
outpati
infus
requir
subsequ
admiss
howev
outpati
fever
necessit
er
evalu
conclus
low
dose
il
success
administ
outpati
medic
minim
side
effect
fever
occur
none
associ
infect
outpati
infus
requir
subsequ
admiss
patient
receiv
cycl
infus
outpati
opt
receiv
next
cycl
inpati
baylor
colleg
medicin
houston
texa
unit
state
background
metastat
ewe
sarcoma
es
extrem
poor
overal
surviv
necessit
investig
molecular
mechan
identifi
novel
target
develop
new
therapi
previous
perform
vivo
studi
use
mous
model
design
provid
insight
transcriptom
proteom
signatur
metastat
es
identifi
potenti
therapeut
target
compar
profil
primari
tumor
correspond
metastat
lesion
identifi
aberr
express
integrin
downstream
activ
integrinlink
kinas
ilk
metastat
lesion
compar
primari
tumor
implic
pathway
key
regul
abil
es
establish
enhanc
metastasi
hypothesi
upregul
downstream
signal
event
play
key
role
es
metastasi
viabl
therapeut
target
object
investig
role
downstream
signal
pathway
drive
establish
enhanc
metastasi
es
investig
pathway
potenti
therapeut
target
investig
role
ilk
es
metastasi
use
sirna
knock
ilk
express
establish
es
cell
line
perform
function
assay
vitro
includ
cell
prolifer
invasionmigr
assay
also
test
inhibit
signal
pathway
use
avail
small
molecul
inhibitor
target
ilk
downstream
target
use
cilengitid
compound
respect
current
use
small
molecul
inhibitor
treatment
vivo
assess
rate
metastat
tumor
format
gener
stabl
ilk
overexpress
knockdown
cell
line
use
similar
vitro
vivo
investig
knockdown
ilk
sirna
cell
line
result
decreas
cell
prolifer
decreas
invas
migrat
compar
control
also
found
significantli
decreas
cell
prolifer
use
small
molecul
inhibitor
vitro
preliminari
studi
use
compound
vivo
establish
safeti
profil
dose
escal
underway
assess
effect
inhibit
es
metastasi
result
support
hypothesi
downstream
signal
event
play
key
role
abil
es
establish
metastat
foci
may
serv
potenti
therapeut
target
continu
investig
pathway
vitro
also
use
small
molecul
inhibitor
ilk
overexpress
knockdown
approach
studi
effect
metastat
tumor
develop
vivo
use
mous
model
background
neuroblastoma
nbl
character
phenotyp
heterogen
outcom
excel
patient
low
lr
intermediaterisk
ir
diseas
wherea
highrisk
hr
patient
surviv
epigenet
marker
activ
gene
transcript
profil
prognost
mani
type
adult
cancer
hypothes
profil
serv
robust
biomark
children
nbl
tumor
refin
current
risk
stratif
object
analyz
genomewid
nbl
tumor
correl
deposit
chromosom
copi
number
gene
express
designmethod
quantifi
nanohmcsealseq
dna
extract
hr
ir
lr
nbl
tumor
read
count
clinic
data
analyz
deseq
identifi
gene
differenti
pattern
risk
group
chromosom
copi
number
assess
chromosom
microarray
analysi
cma
subset
sampl
express
gene
locat
chromosom
evalu
use
public
avail
microarray
hr
nbl
tumor
known
loh
statu
result
global
lr
tumor
peak
ir
p
tumor
hr
tumor
p
gene
differ
pattern
deposit
hr
versu
lr
tumor
gene
map
chromosom
decreas
hr
versu
lr
tumor
padj
cma
analysi
delet
detect
tumor
test
tumor
loss
gene
map
show
decreas
deposit
compar
hr
tumor
without
loss
p
compar
tumor
without
loss
express
gene
decreas
p
includ
known
propos
tumor
suppressor
gene
nbl
conclus
differ
pattern
accumul
associ
neuroblastoma
risk
classif
nanohmcsealseq
sensit
copi
number
variat
potenti
identifi
chang
patient
tumor
result
suggest
deposit
contribut
silenc
tumor
suppressor
gene
may
also
regul
transcript
gene
drive
tumor
phenotyp
background
metastat
osteosarcoma
surviv
rate
pulmonari
metastas
remain
major
treatment
challeng
osteosarcoma
current
treatment
convent
chemotherapi
show
inadequ
activ
toward
metastas
toxic
system
side
effect
chloroquin
wide
use
antimalari
drug
shown
promis
anticanc
antimetastat
activ
polymer
drug
shown
multipl
advantag
small
molecular
parent
drug
includ
enhanc
therapeut
efficaci
improv
pharmacokinet
profil
decreas
system
toxic
hypothes
develop
chloroquin
polymer
drug
combin
convent
chemotherapi
improv
treatment
metastat
osteosarcoma
object
identifi
optim
combin
polymer
chloroquin
pcq
convent
chemotherapi
activ
osteosarcoma
new
mean
treat
metastat
diseas
murin
osteosarcoma
model
synthes
develop
pcq
evalu
antiinvas
activ
use
osteosarcoma
cell
migrat
invas
assay
evalu
efficaci
cell
kill
use
combin
drug
therapi
pcq
panel
convent
chemotherapi
agent
doxorubicin
docetaxel
cisplatin
paclitaxel
use
celltit
blue
cell
viabil
assay
develop
murin
osteosarcoma
model
intraven
inject
luciferaseexpress
human
osteosarcoma
cell
nsg
mice
administ
drug
combin
show
strongest
vitro
synergi
mice
evalu
anticanc
antimetastat
effect
vivo
tumor
growth
suppress
evalu
use
whole
bodi
bioluminesc
imag
result
success
synthes
pcq
contain
chloroquin
molecular
weight
kd
pcq
also
found
decreas
toxic
parent
chloroquin
pcq
show
strong
inhibit
osteosarcoma
cell
migrat
inhibit
compar
chloroquin
screen
combin
drug
therapi
found
combin
pcq
doxorubicin
show
strongest
synerg
pcqdoxorubicin
combin
current
evalu
murin
model
combin
drug
therapi
use
pcq
doxorubicin
show
synergist
cell
kill
inhibit
cell
migrat
vitro
combin
repres
promis
treatment
strategi
pulmonari
metastat
osteosarcoma
emori
universitychildren
healthcar
atlanta
atlanta
georgia
unit
state
background
surviv
relaps
highrisk
neuroblastoma
rnb
underscor
critic
need
novel
therapi
rnb
increas
rasrafmapk
mutat
increas
yesassoci
protein
yap
transcript
activ
yap
transcript
coactiv
bind
teadomain
tead
transcript
factor
regul
cellular
prolifer
selfrenew
surviv
found
shrna
inhibit
yap
decreas
nb
cell
prolifer
sensit
rasmut
nb
mek
inhibitor
support
yap
tractabl
therapeut
target
verteporfin
vp
photodynam
drug
use
macular
degener
drug
found
inhibit
yap
express
yap
tead
bind
kill
tumorderiv
cell
peptid
yap
peptidomimet
also
disrupt
yap
tead
interact
sought
determin
whether
compound
potent
nb
via
yap
direct
effect
designmethod
yap
express
nlf
skna
yap
null
ngp
sknasshyap
humanderiv
nb
incub
vp
without
direct
light
exposur
peptid
celltiterglo
immunoblot
use
assess
cell
death
yapdownstream
protein
express
respect
result
without
direct
light
exposur
vp
inhibit
yap
express
nm
dose
yet
nb
cell
death
observ
equal
higher
concentr
egfr
inhibit
along
yap
confirm
yapra
pathway
coregul
vp
expos
direct
incandesc
light
minut
nb
cell
death
occur
nb
test
even
lack
yap
peptid
caus
cell
death
yap
inhibit
um
neuroblastoma
resist
vp
dose
suffici
inhibit
yap
express
macular
degener
lightactiv
vp
produc
reactiv
oxygen
speci
hypothes
target
mechan
kill
nb
independ
yap
given
target
effect
need
light
activ
vp
ideal
preclin
clinic
yap
inhibitor
accordingli
peptid
poor
cell
permeabl
low
tead
affin
lead
lack
efficaci
given
relev
yap
rnb
cancer
chemic
optim
yap
peptidomimet
enhanc
permeabl
nuclear
local
tead
affin
creat
bonafid
yap
inhibitor
preclin
clinic
applic
kayeleigh
higgerson
aaron
sugalski
rajiv
rajani
josefin
heimhal
jaclyn
hung
annemari
langevin
ut
health
san
antonio
san
antonio
texa
unit
state
background
osteosarcoma
common
bone
malign
children
adolesc
young
adult
studi
cohort
hispan
patient
encompass
mani
differ
hispan
background
univers
texa
health
scienc
center
san
antonio
uthscsa
sarcoma
team
serv
latino
popul
predominantli
mexican
american
thu
provid
uniqu
opportun
evalu
popul
studi
expand
previou
data
collect
januari
decemb
institut
provid
increas
insight
outcom
mexican
american
children
adolesc
young
adult
osteosarcoma
object
understand
osteosarcoma
latino
children
adolesc
young
adult
designmethod
retrospect
analysi
demograph
tumor
characterist
respons
treatment
surviv
outcom
local
osteosarcoma
extrem
patient
year
age
diagnos
treat
uthscsa
sarcoma
team
januari
june
perform
result
origin
cohort
januari
decemb
observ
significantli
decreas
eventfre
surviv
ef
patient
diagnos
age
preadolesc
rel
patient
diagnos
age
vs
p
patient
overal
surviv
os
eventfre
surviv
respect
expand
cohort
januari
june
evalu
sixtysix
patient
median
age
rang
local
highgrad
osteosarcoma
extrem
expand
cohort
mexican
american
median
followup
month
rang
analysi
expand
cohort
ongo
postul
find
hold
true
increas
cohort
size
length
followup
conclus
analysi
previou
cohort
predominantli
mexican
american
ethnic
show
preadolesc
patient
increas
rate
relaps
compar
previou
larg
studi
also
show
trend
toward
decreas
ef
entir
cohort
hypothes
valid
find
expand
cohort
support
investig
potenti
caus
poor
outcom
vulner
latino
popul
background
neuroblastoma
infant
potenti
regress
matur
spontan
grow
literatur
show
case
subject
initi
observ
nt
show
inferior
outcom
compar
activ
treat
similar
categori
object
investig
whether
earli
activ
treatment
safe
avoideddef
select
favor
case
children
cancer
hospitalegypt
cche
designmethod
patient
enrol
watch
see
strategi
w
cche
small
primari
tumor
inss
stage
uncompl
stage
stage
infant
day
tissu
biopsi
mandatori
infant
month
age
local
adren
mass
stage
progress
immedi
intervent
took
place
accord
stage
risk
diseas
biolog
character
result
thirti
four
nbl
patient
enrol
w
strategi
eighteen
patient
stage
diseas
patient
stage
stage
primari
adren
site
report
patient
patient
small
mass
measur
cm
largest
diamet
os
ef
respect
month
median
followup
rang
month
spontan
totalnear
total
resolut
mass
occur
patient
median
time
elicit
regress
month
rang
month
month
rang
month
till
complet
resolut
patient
wit
progress
local
distant
combin
local
distant
progress
median
time
progress
month
rang
month
death
start
chemotherapi
watch
see
strategi
safe
approach
local
uncompl
stage
neuroblastoma
progress
case
could
rescu
baylor
colleg
medicin
houston
texa
unit
state
background
dotat
bind
somatostatin
receptor
express
neuroendocrin
tumor
net
approv
fda
use
petct
scan
local
somatostatin
receptor
posit
net
adult
pediatr
patient
pediatr
approv
base
mainli
extrapol
data
adult
object
describ
use
dotat
petct
scan
children
neuroendocrin
tumor
compar
imag
modal
designmethod
patient
net
enrol
texa
children
rare
tumor
registri
februari
octob
review
patient
underw
scan
includ
result
four
patient
net
underw
scan
without
advers
reaction
first
patient
femal
small
bowel
net
multipl
liver
metastas
mri
abdomen
fdg
pet
diagnosi
show
multipl
liver
metastas
could
identifi
primari
lesion
scan
abl
accur
identifi
enlarg
lymph
node
small
bowel
better
fdg
pet
delin
liver
metastas
second
patient
femal
recurr
small
bowel
net
liver
lung
paraspin
metastas
lesion
initi
detect
ct
scan
octreotid
scan
fail
show
uptak
identifi
lesion
taken
liver
lesion
lung
lesion
cm
size
paraspin
lesion
third
patient
male
pancreat
net
peripancreat
lymphadenopathi
multipl
liver
metastas
cardiophren
lymph
node
involv
primari
lesion
pancrea
could
identifi
ct
scan
ct
angiogram
mibg
scan
octreotid
scan
addit
uncertainti
involv
enlarg
cardiophren
lymph
node
addit
clearli
identifi
primari
lesion
scan
abl
detect
multipl
peripancreat
lymph
node
detect
scan
reveal
uptak
cardiophren
lymph
node
confirm
involv
tumor
fourth
patient
femal
malign
abdomin
paraganglioma
solitari
lung
metastasi
mibg
scan
scan
abl
identifi
primari
lesion
scan
perform
lung
metastasi
remov
thu
abil
detect
could
confirm
background
neuroblastoma
common
extracrani
solid
tumor
childhood
overal
surviv
highrisk
patient
hrnbl
near
outcom
hrnbl
improv
high
dose
chemotherapi
follow
autolog
stem
cell
rescu
abmt
data
factor
influenc
rate
hematopoiet
recoveri
follow
abmt
hrnbl
lack
literatur
object
identifi
factor
influenc
rate
hematopoiet
recoveri
follow
abmt
hrnbl
designmethod
retrospect
chart
review
patient
hrnbl
treat
texa
children
hospit
neutrophil
engraft
consid
first
three
consecut
day
posttranspl
neutrophil
count
greater
cellsul
red
blood
cell
platelet
engraft
consid
hemoglobin
greater
platelet
greater
three
day
last
transfus
race
condit
regimen
analyz
use
oneway
anova
amount
infus
cell
analyz
use
pearson
correl
coeffici
chemotherapi
delay
bone
marrow
bm
involv
cycl
induct
chemotherapi
analyz
use
independ
sampl
ttest
studi
includ
male
femal
median
age
diagnosi
year
thirtyeight
patient
caucasian
africanamerican
hispan
asian
race
document
mean
dose
infus
cell
cellskg
fortyf
patient
receiv
condit
therapi
carboplatinetoposidemelphalan
cem
receiv
busulfanmelphalan
bumel
receiv
thiotepacyclophosphamid
thiotepacpm
condit
regimen
administ
signific
p
time
engraft
neutrophil
bumel
day
cem
day
thiotepacpm
day
delay
chemotherapi
induct
n
signific
p
time
platelet
engraft
greater
trend
toward
signific
p
time
neutrophil
engraft
bm
involv
diagnosi
cycl
induct
signific
time
engraft
dose
stem
cell
infus
variabl
signific
hemoglobin
engraft
background
osteosarcoma
os
preval
aggress
primari
malign
bone
affect
children
young
adult
approxim
patient
metastat
diseas
initi
present
patient
isol
pulmonari
metastas
although
overal
surviv
patient
os
improv
advanc
therapi
signific
improv
surviv
outcom
patient
metastat
diseas
recent
studi
suggest
tumorassoci
vascular
cell
adhes
molecul
play
critic
role
metastat
progress
variou
tumor
indirect
evid
studi
suggest
integrin
signal
promot
tumor
surviv
metastat
progress
chang
tumor
nich
associ
immun
respons
determin
interf
signal
pulmonari
metastat
osteosarcoma
po
macrophag
mac
downregul
deplet
mac
block
signal
reduc
po
improv
overal
diseasefre
surviv
designmethod
use
pair
spontan
highgrad
murin
os
cell
line
balbc
mous
deriv
vivo
metastasi
use
lentivir
shrna
knockdown
mrna
protein
express
introduc
luciferas
variou
shrna
cell
line
follow
lung
metastasi
bioluminesc
bli
deplet
mac
intranas
administr
liposom
clodron
formul
test
abil
supernat
polar
mac
phenotyp
vitro
also
administ
monoclon
antibodi
mab
intranas
assess
outcom
function
blockad
signal
result
overexpress
compar
mac
deplet
anim
exhibit
reduc
po
weekli
administr
mab
result
tumorfre
rescu
among
mice
establish
po
interestingli
supernat
preferenti
induc
mac
suggest
novel
integrinmedi
mechan
differenti
valid
data
addit
os
cell
line
present
despit
aggress
multimod
therapi
overal
outcom
patient
po
remain
dismal
reason
novel
direct
therapi
approach
desper
need
molecular
target
approach
therapi
challeng
due
complex
genet
heterogen
os
immunemodifi
therapi
promis
new
altern
approach
po
univers
chicago
chicago
illinoi
unit
state
background
half
patient
diagnos
highrisk
neuroblastoma
achiev
longterm
surviv
mibg
scan
routin
use
evalu
diseas
diagnosi
follow
treatment
extent
diseas
quantifi
use
curi
score
system
previou
studi
yanik
et
al
shown
highrisk
patient
mycn
nonampliifi
tumor
score
less
versu
greater
follow
cycl
chemotherapi
associ
superior
surviv
wherea
score
less
versu
greater
prognost
patient
mycnamplifi
tumor
howev
prognost
signific
specif
site
metastat
diseas
diagnosi
known
determin
site
metastat
diseas
determin
mibg
imag
highrisk
patient
time
diagnosi
associ
outcom
designmethod
perform
retrospect
chart
review
highrisk
neuroblastoma
patient
treat
comer
children
hospit
luri
children
hospit
chicago
posit
mibg
scan
time
diagnosi
collect
imag
data
well
clinic
data
includ
bone
marrow
statu
site
diseas
defin
curi
region
posit
valu
kaplanmei
analysi
perform
evalu
associ
diseas
site
surviv
pearson
correl
coeffici
calcul
compar
bone
marrow
diseas
site
posit
mibg
scan
cohort
consist
highrisk
patient
skull
diseas
pelvic
diseas
presenc
mibg
posit
diseas
skull
pelvi
trend
toward
wors
ef
ef
year
patient
diseas
skull
diagnosi
patient
without
skull
diseas
p
ef
year
patient
without
pelvic
diseas
p
consist
prior
data
found
presenc
bone
marrow
diseas
associ
wors
surviv
year
ef
without
marrow
diseas
diagnosi
p
highest
correl
pelvic
diseas
mibg
scan
bone
marrow
diseas
pearson
coeffici
pelvic
diseas
note
mibg
scan
like
reflect
underli
bone
marrow
diseas
patient
highrisk
neuroblastoma
skull
diseas
pelvic
diseas
mibg
scan
diagnosi
may
predict
wors
event
free
surviv
background
osteosarcoma
one
deadliest
cancer
pediatr
popul
littl
progress
morbid
recurr
rate
sinc
oncolyt
herp
viru
ohsv
attenu
viru
shown
encourag
result
certain
solid
tumor
program
cell
death
protein
pd
cell
suppress
via
engag
ligand
also
particular
interest
due
recent
success
select
cancer
especi
high
genet
mutat
load
pediatr
cancer
wide
varieti
mutat
howev
osteosarcoma
chaotic
genom
prone
genet
mutat
shown
numer
studi
inhibit
alon
suffici
result
statist
signific
tumor
growth
delay
osteosarcoma
model
patient
hypothes
addit
ohsv
therapi
immunolog
stimulu
inhibit
efficaci
osteosarcoma
determin
whether
ohsv
therapi
enhanc
respons
inhibit
immunocompet
murin
model
osteosarcoma
quantifi
character
antitumor
tcell
infiltr
treatment
ohsv
inhibit
individu
combin
util
immunocompet
transplant
murin
model
use
cell
line
deriv
spontan
metastat
osteosarcoma
balbc
background
transplant
establish
tumor
wedg
subcutan
monitor
tumor
volum
calip
measur
tumor
reach
administ
intratumor
inject
plaqueform
unit
everi
day
total
inject
gave
intraperiton
inject
control
antibodi
twice
weekli
week
start
last
dose
viru
treatment
monitor
tumor
growth
via
calip
twice
weekli
tumor
reach
diamet
quantifi
character
innat
adapt
immun
cell
infiltr
tumor
use
flow
analysi
found
significantli
prolong
surviv
combin
therapi
group
compar
group
found
littl
impact
cell
recruit
combin
group
higher
influx
cell
reduc
amount
tregulatori
cell
also
found
increas
effector
memori
cell
osteosarcoma
deadli
cancer
therapeut
remain
unchang
last
year
describ
prolong
murin
surviv
treatment
combin
inhibit
ohsv
inject
combin
treatment
chang
microenviron
inflammatori
data
support
preclin
clinic
studi
background
neuroblastoma
second
common
caus
cancer
relat
death
children
treatment
highrisk
neuroblastoma
improv
significantli
past
twenti
year
howev
cure
rate
remain
immunotherapi
emerg
effect
therapi
neuroblastoma
howev
new
modal
target
need
improv
outcom
object
lab
develop
chimer
antigen
receptor
car
target
immun
checkpoint
molecul
overexpress
mani
cancer
includ
neuroblastoma
hypothes
would
good
target
car
base
immunotherapi
neuroblastoma
designmethod
neuroblastoma
tissu
microarray
primari
patient
sampl
screen
express
immunohistochemistri
cell
line
screen
use
flow
cytometri
car
cell
test
vitro
measur
tumor
cell
kill
cytokin
product
cocultur
tumor
cell
line
vivo
orthotop
model
neuroblastoma
result
express
detect
ihc
screen
neuroblastoma
patient
sampl
express
high
level
half
sampl
almost
cell
line
screen
homogen
posit
flow
cytometri
retrovir
transduc
car
cell
cocultur
three
posit
neuroblastoma
cell
line
kcnr
robust
tumor
cell
kill
demonstr
use
incucyt
assay
supernat
cocultur
harvest
hour
interferon
gamma
product
detect
elisain
orthotop
subren
capsul
xenograft
model
neuroblastoma
mice
treat
car
cell
show
signific
reduct
tumor
growth
prolong
surviv
compar
treat
untransduc
control
cell
howev
treatment
alway
car
cell
express
high
level
exhaust
marker
compar
car
control
order
overcom
inhibit
exhaust
car
cell
cocultur
neuroblastoma
cell
line
block
antibodi
nivolumab
significantli
increas
product
interferongamma
car
cell
studi
underway
determin
car
cell
activ
enhanc
vivo
treat
anim
blockad
along
car
cell
conclus
express
major
neuroblastoma
sampl
appear
promis
candid
car
cell
therapi
car
cell
demonstr
activ
neuroblastoma
xenograft
may
enhanc
addit
inhibitor
helen
devo
children
hospit
michigan
state
univers
grand
rapid
michigan
unit
state
background
osteosarcoma
common
bone
tumor
children
often
metastat
diagnosi
scenario
less
children
surviv
polyamin
small
molecul
found
cell
involv
mani
cell
process
includ
cell
cycl
regul
immun
modul
cell
signal
apoptosi
also
involv
tumor
develop
invas
metastasi
neuroblastoma
inhibit
polyamin
biosynthesi
pathway
odc
inhibitor
alphadifluoromethylornithin
dfmo
result
decreas
cell
prolifer
differenti
find
led
multipl
phase
phase
ii
multicent
clinic
trial
pediatr
neuroblastoma
patient
dfmo
attract
drug
oral
welltoler
given
prolong
period
alreadi
use
pediatr
patient
polyamin
pathway
evalu
osteosarcoma
object
evalu
effect
inhibit
polyamin
biosynthesi
dfmo
osteosarcoma
prolifer
cell
differenti
designmethod
three
osteosarcoma
cell
line
use
os
cell
expos
mm
dfmo
day
replac
media
dfmo
day
intracellular
polyamin
level
measur
high
perform
liquid
chromatographi
hplc
cell
number
obtain
hemocytomet
use
trypan
blue
flow
cytometri
cell
cycl
distribut
fac
propidium
iodid
use
evalu
cell
cycl
arrest
protein
express
sever
osteosarcoma
differenti
marker
measur
sdspage
western
blot
use
differenti
specif
antibodi
bioluminesc
cell
viabil
assay
use
measur
cell
recoveri
sever
day
dfmo
remov
replac
standard
media
result
dfmo
exposur
result
significantli
decreas
cell
prolifer
cell
line
treatment
intracellular
spermidin
level
nearli
elimin
cell
cell
cycl
arrest
observ
os
cell
differenti
pronounc
os
cell
determin
increas
osteopontin
level
remark
cell
prolifer
continu
suppress
sever
day
remov
dfmo
conclus
base
find
dfmo
promis
new
adjunct
current
osteosarcoma
therapi
high
risk
patient
welltoler
oral
drug
current
phase
ii
clinic
trial
pediatr
neuroblastoma
patient
mainten
therapi
type
regimen
may
also
improv
outcom
metastat
recurr
osteosarcoma
patient
essenti
medic
advanc
last
year
background
recent
studi
demonstr
lower
level
fusion
oncoprotein
associ
enhanc
metastat
capabl
ewe
sarcoma
nfkb
transcript
factor
critic
mediat
driven
metastasi
multipl
cancer
increas
express
associ
increas
metastasi
poor
prognosi
ewe
sarcoma
thu
sought
investig
impact
nfkb
signal
ewe
sarcoma
object
goal
studi
determin
impact
signal
metastasisassoci
nfkb
target
gene
express
ewe
sarcoma
investig
fusion
oncoprotein
modul
respons
designmethod
util
multipl
ewe
sarcoma
cell
line
includ
cell
surfac
express
determin
flow
cytometri
level
modul
use
sirna
express
level
confirm
western
blot
rtpcr
dna
bind
measur
via
elisa
nfkb
target
gene
express
assess
via
rtpcr
result
consist
ihc
analysi
primari
metastat
patient
tumor
sampl
pair
primari
metastat
ewe
sarcoma
cell
line
show
dramat
differ
express
metastat
line
demonstr
much
higher
express
receptor
cell
line
nonpair
show
variabl
express
genet
knockout
lead
signific
decreas
express
two
nfkb
transcript
target
known
play
key
role
tumor
metastasi
knockout
alter
endogen
mrna
level
convers
lower
level
use
sirna
lead
enhanc
nfkb
signal
indic
increas
dna
bind
consist
observ
treat
ewe
cell
line
sirna
also
result
significantli
increas
nfkb
target
gene
express
compar
control
cell
target
gene
express
enhanc
upon
receptor
stimul
receptor
ligand
find
indic
oncoprotein
neg
modul
nfkb
signal
suggest
low
high
cell
associ
enhanc
metastasi
poor
prognosi
would
anticip
exhibit
enhanc
express
key
nfkb
target
gene
importantli
nfkb
pathway
druggabl
target
could
potenti
serv
achil
heel
subset
high
risk
tumor
current
work
evalu
nfkb
inhibit
approach
treat
metastat
refractori
ewe
sarcoma
background
acut
graft
versu
host
diseas
agvhd
major
caus
morbid
mortal
follow
allogen
bone
marrow
transplant
bmt
pediatr
patient
gastrointestin
gi
agvhd
seriou
manifest
recent
decreas
paneth
cell
pc
predominantli
adult
cohort
shown
correl
agvhd
clinic
grade
respons
treatment
aim
demonstr
relationship
pc
count
gi
agvhd
stage
respons
therapi
designmethod
chart
patient
underw
endoscopi
follow
bmt
review
repeat
biopsi
cours
agvhd
first
includ
analysi
one
pathologist
retrospect
review
biopsi
count
pc
high
power
field
averag
pc
count
analyz
twentysix
percent
biopsi
review
second
blind
pathologist
statist
associ
pc
count
day
respons
agvhd
stage
studi
covari
interest
gaug
use
gener
linear
regress
agreement
pathologist
pc
count
quantifi
intraclass
correl
icc
research
approv
children
healthcar
atlanta
irb
result
seventyeight
biopsi
includ
analysi
mean
age
transplant
year
rang
month
year
patient
underw
transplant
hematolog
malign
major
transplant
use
match
unrel
donor
graft
includ
cord
myeloabl
condit
regimen
receiv
total
bodi
irradi
diagnos
clinic
gi
agvhd
stage
stage
stage
stage
icc
show
good
agreement
pathologist
mean
pc
patient
gut
agvhd
stage
stage
stage
stage
p
multivari
analysi
pc
strongli
associ
gi
agvhd
stage
p
control
age
prepar
regimen
intens
diagnosi
malign
vs
nonmalign
mean
pc
count
significantli
lower
patient
respons
steroid
therapi
complet
respons
mean
vs
persist
diseas
vs
partial
respons
p
patient
diagnos
gi
agvhd
pc
count
less
higher
risk
mortal
hr
ci
p
lower
pc
count
correl
stage
gi
agvhd
refractori
diseas
mortal
incorpor
pc
count
patholog
review
gi
agvhd
workup
may
help
agvhd
risk
stratif
background
increas
discuss
pressur
health
care
team
institut
potenti
bear
cost
clostridium
difficil
infect
cdi
health
careassoci
infect
recent
year
pediatr
oncolog
patient
popul
though
small
account
signific
portion
cdi
increas
risk
hematopoiet
stem
cell
transplant
hsct
recipi
constitut
uniqu
subset
distinct
risk
factor
sever
immun
defici
state
graft
versu
host
diseas
gvhd
although
ampl
data
cdi
adult
hsct
recipi
report
pediatr
experi
limit
object
evalu
incid
pattern
cdi
among
pediatr
hematolog
oncolog
hsct
inpati
institut
retrospect
review
clostridium
difficil
cd
stool
test
perform
use
toxin
enzym
immunoassay
later
polymeras
chain
reaction
target
toxin
gene
larg
urban
academ
children
hospit
perform
data
analyz
hematolog
oncolog
hsct
inpati
popul
case
separ
statist
comparison
perform
result
total
sampl
submit
microbiolog
laboratori
cd
test
studi
period
hematolog
patient
constitut
oncolog
hsct
other
case
cd
test
done
per
patient
averag
test
number
respect
cd
test
perform
posit
test
posit
higher
hsct
oncolog
case
test
compar
hematolog
case
statist
signific
p
overal
recurr
rate
hsct
patient
highest
recurr
rate
follow
oncolog
hematolog
case
reach
statist
signific
p
hsct
patient
highest
averag
number
recurr
follow
oncolog
gener
hematolog
group
season
variabl
incid
cdi
among
popul
analyz
prolong
hospit
stayantibiot
use
persist
diarrhea
due
gvhd
like
reason
higher
rate
cd
test
hsct
result
increas
monitor
thu
might
even
caus
underrepresent
posit
cd
test
frequenc
higher
incid
frequenc
recurr
underscor
inevit
natur
cdi
hsct
popul
consequ
current
therapi
may
lead
futur
radic
treatment
approach
like
fecal
implant
background
viral
infect
remain
challeng
treat
post
hct
children
significantli
contribut
morbid
mortal
viru
specif
cell
vst
shown
tremend
clinic
efficaci
treat
viral
infect
posthct
minim
toxic
long
term
efficaci
use
donorderiv
vst
individu
patient
howev
donor
agreeabl
process
numer
patient
may
benefit
vst
identifi
donorhav
diseas
indic
object
sought
activ
build
thirdparti
vst
bank
shelf
use
elig
patient
designmethod
vst
target
cmv
adenoviru
ebv
manufactur
use
one
techniqu
initi
ebv
transform
b
cell
genet
modifi
vector
use
antigen
present
cell
apc
stimul
expand
ebv
ad
specif
cell
recent
vst
expand
use
apc
puls
commerci
avail
peptid
pool
pepmix
expand
ebvcmvad
specif
cell
product
enter
bank
via
two
mechan
left
product
donorderiv
protocol
patient
longer
requir
vst
risk
develop
viral
infect
b
target
regular
blood
donor
base
hla
type
ensur
appropri
mix
high
frequenc
hla
type
optim
patient
match
antigen
present
base
current
knowledg
antigen
present
result
total
product
current
thirdparti
vst
bank
readi
use
twenti
seven
donor
deriv
protocol
three
target
donor
vst
product
met
safeti
vitro
efficaci
test
thirteen
vst
infus
given
patient
eleven
infus
given
cmv
two
adenoviru
five
seven
patient
respond
thirdparti
vst
infus
median
vst
infus
per
patient
rang
median
hla
match
per
patient
rang
patient
experienc
advers
reaction
gvhd
toxic
relat
vst
infus
thirdparti
vst
bank
feasibl
produc
clinic
appropri
vst
use
patient
viral
infect
hla
type
match
vst
product
essenti
reduc
toxic
promot
appropri
antigen
present
expans
vst
vivo
work
underway
character
vst
use
epitop
map
better
defin
hla
restrict
immunogen
vst
product
akron
children
hospit
akron
ohio
unit
state
background
acut
graftversushost
diseas
agvhd
wellknown
complic
hematopoiet
stem
cell
transplant
hsct
major
caus
posttranspl
relat
morbid
mortal
first
line
therapi
agvhd
involv
corticosteroid
calcineurin
inhibit
patient
sever
refractori
gvhd
mortal
reach
current
standard
care
treatment
steroid
refractori
agvhd
mani
center
look
use
antibodi
mediat
control
agvhd
competit
inhibit
inflammatori
cascad
basiliximab
chimer
monoclon
antibodi
tcell
receptor
use
adult
steroid
refractori
agvhd
patient
receiv
medic
demonstr
complet
partial
respons
therapi
minim
toxic
object
report
success
use
basiliximab
treatment
agvhd
follow
match
unrel
mud
hsct
designmethod
male
underw
mud
transplant
high
risk
aml
monosomi
condit
regimen
includ
busulfan
fludarabin
equin
atg
clinic
cours
complic
fever
mucos
agvhd
stage
skin
stage
gibiopsi
proven
gvhd
prophylaxi
includ
tacrolimu
methotrex
howev
progress
skin
rash
diarrhea
earli
satieti
gvhd
treatment
corticosteroid
initi
patient
continu
worsen
symptom
basiliximab
therapi
start
patient
receiv
dose
iv
basiliximab
two
consecut
day
receiv
weekli
therapi
total
dose
lead
initi
improv
patient
develop
acut
chronic
gvhd
day
subsequ
receiv
second
cours
basiliximab
initi
administr
basiliximab
patient
near
complet
resolut
symptom
howev
small
wean
tacrolimu
dose
patient
experienc
anoth
skin
gvhd
flare
prompt
second
basiliximab
cours
patient
subsequ
wean
immunosuppress
day
acut
complic
patient
experienc
receiv
basiliximab
right
toe
paronychia
asymptomat
low
ebv
titer
patient
current
immunosuppress
time
report
without
evid
cgvhd
conclus
singl
case
report
young
pediatr
patient
demonstr
use
basiliximab
may
safe
efficaci
treatment
pediatr
patient
agvhd
univers
california
san
diego
la
jolla
california
unit
state
background
clinic
outcom
allogen
hematopoiet
stem
cell
transplant
hsct
depend
restor
lymphocyt
popul
associ
recoveri
regulatori
cell
treg
protect
chronic
graft
versu
host
diseas
cgvhd
describ
adult
hsct
adult
cell
recoveri
driven
expans
donor
cell
treg
reconstitut
hypothes
result
peripher
convers
restor
cell
pediatr
patient
larger
contribut
thymopoiesi
howev
relationship
thymopoiesi
treg
recoveri
undefin
object
hypothes
effect
thymopoiesi
import
restor
treg
popul
protect
cgvhd
pediatr
hsct
patient
designmethod
perform
longitudin
flow
cytometri
peripher
blood
cell
pediatr
hsct
patient
agematch
healthi
donor
laboratori
data
correl
clinic
outcom
evalu
impact
recoveri
treg
occur
patient
posttranspl
day
day
treg
frequenc
patient
develop
cgvhd
cell
reduc
compar
cgvhdfree
patient
failur
restor
treg
cell
day
associ
increas
risk
cgvhd
first
year
posthsct
rr
p
major
treg
patient
recov
peripher
treg
compart
express
helio
marker
thymicderiv
treg
treg
express
helio
patient
fail
restor
adequ
treg
prompt
examin
relationship
defect
thymopoiesi
inabl
restor
treg
evalu
thymic
function
flow
cytometri
quantif
recent
thymic
emigr
rte
cell
confirm
qpcr
trec
content
hsct
patient
detect
rte
day
posthsct
thymic
product
rte
persist
absent
patient
develop
cgvhd
cell
patient
compar
cgvhdfree
patient
patient
cell
day
averag
cell
posthsct
thymic
activ
measur
rte
enumer
correl
treg
restor
rte
patient
restor
treg
compar
rtepati
conclus
failur
restor
treg
allogen
hsct
result
increas
risk
cgvhd
pediatr
patient
thymic
gener
new
cell
import
contributor
restor
treg
compart
data
support
investig
mechan
impair
posthsct
thymopoiesi
suggest
peripher
blood
treg
may
prognost
biomark
cgvhd
background
haploident
stem
cell
transplant
haplo
sct
riddl
uniqu
challeng
object
present
experi
use
haplo
sct
posttranspl
cyclophosphamid
ptci
adapt
requir
disord
optim
outcom
designmethod
perform
retrospect
studi
pediatr
blood
marrow
transplant
unit
apollo
cancer
institut
chennai
india
children
year
age
diagnos
benign
disord
underw
haplo
sct
ptci
juli
includ
result
ptci
use
ie
haplo
transplant
children
benign
disord
underli
condit
includ
fanconi
anemia
sever
aplast
anemia
md
jmml
hemoglobinopathi
prca
xld
primari
immunedefici
disord
pid
sourc
stem
cell
peripher
blood
bone
marrow
condit
includ
fludarabin
treosulphan
cyclophosphamid
pid
aplast
anemia
respect
neutrophil
engraft
durabl
graft
note
transplant
graft
versu
host
diseas
cmv
reactiv
mortal
rate
infant
less
month
age
develop
sever
fatal
cytokin
releas
syndrom
median
follow
year
year
longest
signific
late
effect
note
chronic
skin
gvhd
children
surviv
rate
superior
among
children
pid
surviv
group
haplo
sct
ptci
feasibl
costeffect
option
cure
children
lifethreaten
benign
disord
compat
famili
match
unrel
donor
care
patient
select
reduc
cyclophosphamid
relat
free
radic
toxic
use
n
acetylcystein
limit
cell
number
cap
posttranspl
viral
monitor
protocol
requir
reduc
morbid
mortal
work
univers
access
care
children
socioeconom
background
incorpor
innov
reduc
cost
hsct
without
compromis
outcom
haploident
hsct
use
tcr
deplet
cost
usd
compar
ptci
price
usd
children
sever
aplast
anemia
pid
transplant
use
reduc
intens
condit
ptci
hemoglobinopathi
pretranspl
immunosuppress
requir
prevent
graft
reject
graft
versu
host
diseas
remain
main
caus
mortal
children
fanconi
anemia
mortal
infant
less
month
ptci
high
tcr
deplet
would
superior
cohort
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
fanconi
anemia
fa
congenit
bone
marrow
failur
syndrom
hsct
cur
option
associ
bone
marrow
failur
patient
fa
undergo
hsct
may
experi
increas
toxic
relat
either
underli
diseas
effect
medic
result
inabl
toler
prophylact
medic
sideeffect
antimicrobi
therapi
object
postul
increas
cell
dose
would
associ
rapid
immun
reconstitut
therefor
earli
withdraw
antiinfect
prophylact
medic
designmethod
patient
fa
transplant
cchmc
unrel
donor
peripher
blood
stem
cell
graft
collect
select
perform
possibl
patient
serial
measur
immun
system
perform
vari
interv
post
hsct
defin
immun
reconstitut
normal
lymphocyt
cell
well
normal
respons
mitogen
stimul
includ
phytohemagglutinin
concanavalin
pokewe
first
measur
either
normal
cell
number
mitogen
respons
record
patient
result
total
patient
underw
hsct
fa
cchmc
patient
demograph
includ
median
age
year
hsct
vast
major
patient
fulli
match
one
antigen
mismatch
donor
major
patient
transplant
bone
marrow
failur
statist
significantli
decreas
time
posttranspl
immun
cell
recoveri
patient
receiv
cell
median
compar
receiv
cell
median
median
time
normal
count
day
count
versu
day
count
count
day
count
versu
day
count
count
day
count
versu
day
count
count
day
count
versu
day
count
time
normal
mitogen
respons
decreas
posttranspl
patient
receiv
increas
cell
dose
time
transplant
though
signific
reflect
low
number
patient
evalu
respons
patient
either
group
experienc
gvhd
graft
failur
patient
fa
transplant
higher
cell
dose
quicker
immun
reconstitut
receiv
lower
cell
dose
along
benefit
patient
includ
less
risk
infect
earli
termin
immuneprophylaxi
medic
support
use
high
dose
select
graft
vulner
popul
background
parvoviru
infect
transplant
first
report
sinc
numer
case
infect
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
report
report
anemia
predomin
clinic
manifest
howev
associ
pancytopenia
hepat
myocard
allograft
reject
present
patient
acut
lymphoblast
leukemia
develop
bone
pain
pancytopenia
follow
hsct
set
infect
describ
unusu
present
patient
acut
lymphoblast
leukemia
follow
hsct
designmethod
search
englishlanguag
medic
literatur
perform
use
pubm
medlin
databas
review
patient
medic
histori
perform
year
old
male
relaps
bcell
histori
fifth
diseas
infanc
present
four
month
hsct
focal
left
arm
pain
difficulti
fulli
extend
arm
bone
mri
show
enhanc
medullari
space
center
within
incomplet
transvers
cortic
fractur
interpret
patholog
fractur
due
neoplast
involv
ulna
histori
incit
injuri
subsequ
peripher
blood
count
decreas
low
normal
valu
wbc
kmicrol
anc
plt
hemoglobin
gdl
patient
chimer
remain
donor
bone
marrow
biopsi
aspir
perform
assess
recurr
leukemia
given
persist
bone
pain
develop
pancytopenia
marrow
find
includ
morpholog
cytopath
effect
erythroid
precursor
strong
parvoviru
stain
sign
red
cell
aplasia
recurr
bcell
diseas
morpholog
flow
cytometri
detect
blood
pcr
immunoglobulin
resolut
cytopenia
bone
pain
case
highlight
unusu
constel
symptom
follow
hsct
child
unexplain
bone
pain
medullari
infiltr
pancytopenia
suggest
recurr
leukemia
like
trigger
infect
question
remain
reactiv
primari
infect
new
strain
viru
aquir
stem
cell
bone
biopsi
could
justifi
light
clinic
improv
far
bone
lesion
describ
congenit
infect
appear
uncommon
hsct
review
literatur
yield
pediatr
case
howev
may
underestim
due
lack
routin
screen
patient
present
support
evalu
may
warrant
hsct
patient
present
symptom
suggest
relaps
leukemia
background
cardiac
injuri
may
occur
hematopoiet
stem
cell
transplant
hsct
pediatr
patient
asymptomat
mani
year
recommend
screen
avail
patient
receiv
anthracyclin
chest
irradi
guidelin
exist
unexpos
longterm
survivor
sought
defin
preval
echocardiograph
abnorm
longterm
survivor
pediatr
hsct
determin
need
screen
asymptomat
patient
designmethod
analyz
echocardiogram
perform
longterm
survivor
five
year
underw
hsct
cincinnati
children
hospit
analyz
echocardiogram
left
ventricular
eject
fraction
ef
enddiastol
dimens
lvedd
septal
thick
posterior
wall
thick
global
longitudin
strain
gl
normal
linear
measur
age
patient
bodi
surfac
area
includ
analysi
patient
echocardiogram
obtain
routin
surveil
result
total
patient
underw
hsct
aliv
year
transplant
echocardiogram
obtain
five
year
postinfus
echocardiogram
transplant
recent
median
vs
howev
differ
screen
unscreen
individu
note
age
transplant
sex
transplant
indic
anthracyclin
exposur
chest
irradi
cyclophosphamid
base
prepar
regimen
indic
echocardiogram
includ
cardiac
symptom
congenit
cardiac
anomali
hypertens
known
cardiac
pulmonari
diseas
routin
posthsct
surveil
unknown
mean
time
posthsct
year
among
routin
surveil
echocardiogram
mean
ef
zscore
mean
lvedd
zscore
mean
septal
thick
zscore
mean
posterior
wall
thick
zscore
mean
gl
patient
echocardiogram
perform
routin
surveil
patient
ef
measur
ef
zscore
abnorm
low
patient
expos
anthracyclin
mean
zscore
ef
vs
unexpos
patient
p
among
individu
receiv
neither
anthracyclin
tbi
found
abnorm
ef
zscore
gl
one
patient
normal
eject
fraction
zscore
ef
abnorm
gl
normal
longterm
survivor
pediatr
hsct
asymptomat
receiv
radiat
anthracyclin
like
requir
surveil
echocardiogram
unless
indic
clinic
symptom
patient
expos
anthracyclin
tbi
requir
close
echocardiograph
screen
clinic
monitor
develop
cardiac
complic
duke
children
hospit
durham
north
carolina
unit
state
background
children
undergo
pediatr
blood
marrow
transplant
pbmt
experi
signific
symptom
distress
mobil
health
mhealth
technolog
leverag
collect
monitor
patient
gener
health
data
subsequ
enhanc
understand
pbmt
symptom
cluster
pattern
trajectori
better
understand
symptom
complex
foster
develop
precis
health
strategi
improv
patient
outcom
howev
limit
research
exist
integr
mhealth
technolog
pbmt
manag
aim
explor
feasibl
accept
usabl
use
pbmt
specif
mobil
applic
collect
monitor
symptom
wearabl
technolog
appl
watch
measur
object
data
heart
rate
hr
activ
designmethod
exploratori
mix
method
design
began
octob
monitor
pbmt
symptom
patient
use
realtim
data
selfdevelop
mhealth
applic
app
collect
subject
symptom
data
appl
watch
collect
physiolog
measur
heart
rate
number
daili
step
data
collect
pretranspl
day
accept
assess
satisfact
survey
studi
complet
enrol
patient
date
current
use
app
watch
patient
averag
frequenc
daili
chart
app
wearabl
averag
daili
record
measur
hr
step
count
common
symptom
record
within
app
includ
fatigu
pain
note
trend
data
includ
decreas
activ
follow
transplant
gvhd
increas
follow
engraft
patient
state
app
help
keep
track
pain
day
day
tri
take
step
day
day
patient
often
remov
watch
charg
forget
put
back
consist
put
upon
remind
final
parent
often
requir
make
app
entri
patient
sick
record
continu
enrol
patient
enthusiasm
patient
parent
use
mhealth
pbmt
preliminari
find
suggest
feasibl
use
mhealth
devic
strongli
correl
patient
posttranspl
stage
facilit
caregiv
particip
devic
manag
charg
devic
remind
wear
watch
record
app
patient
report
satisfact
eas
use
devic
found
difficult
keep
charg
chart
find
indic
use
mobil
devic
may
use
method
collect
patient
gener
health
data
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
bacteri
bloodstream
infect
bsi
common
complic
follow
hematopoiet
stem
cell
transplant
hsct
pediatr
adult
popul
associ
poor
outcom
limit
data
describ
outcom
characterist
patient
develop
three
bsi
hsct
object
describ
characterist
outcom
pediatr
patient
develop
three
blood
stream
infect
firstyear
post
hsct
designmethod
perform
retrospect
chart
review
consecut
patient
underw
hsct
institut
compil
case
seri
data
collect
first
year
posthsct
includ
patient
demograph
underli
diseas
therapi
characterist
transplant
complic
thrombot
microangiopathi
tma
graft
versu
host
diseas
gvhd
overal
surviv
bsi
classifi
accord
current
center
diseas
control
guidelin
result
patient
develop
bsi
firstyear
post
transplant
total
bsi
case
includ
patient
case
major
underw
allogen
hsct
n
case
unrel
donor
n
half
patient
grade
gvhd
n
sixteen
tma
case
tma
preced
first
bsi
n
major
bsi
classifi
central
lineassoci
bloodstream
infect
clabsi
n
follow
mucos
barrier
injuri
laboratoryconfirm
bloodstream
infect
n
secondari
bsi
n
major
isol
organ
associ
mucos
barrier
injuri
pathogen
oneyear
overal
surviv
cohort
n
pediatr
patient
undergo
hsct
develop
bsi
firstyear
post
transplant
demonstr
increas
rate
tma
compar
overal
institut
incid
roughli
tma
diagnosi
preced
first
bsi
half
patient
suggest
tma
may
predispos
recurr
bsi
improv
strategi
earli
detect
treatment
tma
well
prevent
clabsi
may
help
reduc
number
bsi
ultim
lead
decreas
morbid
mortal
patient
popul
background
neutropen
pediatr
patient
infect
remain
signific
caus
morbid
mortal
granulocyt
transfus
util
decad
treat
infect
includ
pediatr
popul
efficaci
intervent
remain
poorli
describ
previou
guidelin
primarili
util
inform
adult
popul
furthermor
recruit
donor
typic
involv
friend
rel
patient
period
involv
commun
donor
use
readili
avail
local
donor
popul
improv
avail
yet
well
describ
immunocompromis
popul
particularli
suscept
worsen
infect
clinic
deterior
abil
rapidli
harvest
deliv
granulocyt
warrant
investig
investig
efficaci
safeti
outcom
sever
immunocompromis
patient
receiv
granulocyt
transfus
local
altruist
granulocyt
program
pediatr
tertiari
care
center
designmethod
retrospect
review
perform
evalu
context
receiv
transfus
well
primari
outcom
includ
infect
clearanc
surviv
discharg
overal
mortal
indiana
blood
bank
assist
time
interv
initi
order
placement
onset
first
granulocyt
infus
result
among
patient
popul
review
patient
receiv
separ
granulocyt
regimen
age
rang
year
mean
neutrophil
count
time
first
transfus
indic
transfus
includ
bacteremia
n
fungal
pneumonia
n
fungemia
n
primari
outcom
includ
clear
infect
surviv
discharg
median
time
initi
order
placement
infus
hour
although
signific
differ
respond
clear
infect
nonrespond
howev
addit
investig
found
ward
patient
chanc
surviv
discharg
patient
icu
time
initi
transfus
chanc
surviv
discharg
readili
avail
granulocyt
transfus
program
allow
patient
quickli
receiv
therapi
neutropen
set
benefici
patient
transfus
prior
clinic
decompens
correl
increas
likelihood
infect
clearanc
subsequ
improv
mortal
investig
need
like
prospect
studi
better
explor
circumst
benefici
granulocyt
transfus
background
donor
lymphocyt
infus
dli
compos
immun
cell
treat
relaps
hematopoiet
cell
transplant
hct
date
data
regard
efficaci
limit
pediatr
popul
furthermor
outcom
relat
content
character
knowledg
relationship
outcom
cellular
content
dli
never
report
object
determin
whether
primari
hematolog
malign
presenceabs
graftversushost
diseas
gvhd
uniqu
phenotyp
content
dli
impact
overal
surviv
os
pediatr
patient
hematolog
malign
designmethod
irbapprov
retrospect
studi
investig
consecut
dli
given
patient
children
hospit
wisconsin
analys
conduct
use
mannwhitney
fisher
exact
chisquar
patient
year
old
hematolog
malign
myeloid
aml
mdscmljmml
n
lymphoid
n
underw
dli
dli
median
time
hct
dli
rang
year
signific
differ
lymphoid
myeloid
group
respect
regard
median
age
hct
vs
yr
p
first
dli
vs
year
p
ultim
statist
signific
differ
gvhd
os
product
either
higher
lower
cellular
content
howev
median
content
doubl
patient
develop
gvhd
compar
patient
exhibit
gvhd
dli
vs
p
patient
receiv
one
dli
os
vs
receiv
dli
p
median
followup
rang
year
year
estim
os
patient
lymphoid
group
higher
vs
myeloid
group
although
signific
p
result
indic
surviv
benefit
use
dli
subset
patient
relaps
hct
unlik
adult
studi
demonstr
littl
effect
dli
lymphoid
diseas
mani
children
achiev
durabl
remiss
analysi
demonstr
dli
cellular
content
statist
signific
effect
gvhd
os
possibl
differ
could
found
larger
popul
target
cell
dose
studi
data
need
defin
relationship
identifi
patient
stand
benefit
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
mani
arab
speak
muslim
parent
children
requir
bone
marrow
transplant
bmt
receiv
medic
care
unit
state
provid
may
understand
impact
islam
parent
religi
belief
practic
health
care
experi
object
explor
islam
parent
use
religion
decis
make
understand
impact
religi
belief
practic
overal
health
care
experi
designmethod
use
ground
theori
induct
method
gather
data
interview
analyz
text
identifi
core
theme
ten
caregiv
bmt
children
middl
eastern
countri
interview
arabicspeak
provid
interview
code
interdisciplinari
team
identifi
key
theme
patienc
core
belief
islam
patienc
result
accept
allah
behavior
show
patienc
includ
pray
rather
question
cri
al
quran
provid
comfort
heal
protect
famili
listen
recit
al
quran
patient
room
feel
practic
comfort
promot
heal
well
certain
portion
quran
especi
meaning
surat
albaqara
explain
may
think
someth
bad
us
allah
know
good
us
religi
care
medic
center
help
famili
feel
respect
religi
care
medic
center
includ
interact
chaplain
understood
religion
expert
provis
space
prayer
religi
resourc
seek
religi
consult
religi
consult
imam
religi
scholar
mufti
sheikh
provid
interpret
quran
appli
famili
specif
situat
help
famili
make
difficult
decis
follow
allah
plan
muslim
belief
guid
decis
make
muslim
practic
brought
comfort
strength
peac
drawn
parent
understand
islam
parent
address
topic
said
would
islam
allow
indic
aspect
healthcar
understood
allow
within
islam
addit
muslim
practic
prayer
readinglisten
quran
give
alm
provid
comfort
strength
peac
identifi
sever
recur
theme
interview
allow
us
understand
famili
use
muslim
faith
deal
children
ill
influenc
decis
make
believ
better
understand
allow
inform
convers
patient
health
care
decis
make
show
respect
religi
belief
practic
nemoursdupont
hospit
children
wilmington
delawar
unit
state
background
virtual
children
infect
human
herpesviru
age
two
reactiv
stem
cell
transplant
caus
multiorgan
toxic
includ
enceph
inflamm
destruct
tempor
lobe
hippocampi
memori
loss
seizur
catatonia
character
postur
immobl
mutism
autonom
instabl
associ
variou
psychiatr
medic
condit
describ
patient
enceph
unusu
neurolog
sequela
includ
cognit
neurobehavior
dysfunct
catatonia
may
impact
understand
pathophysiolog
reactiv
enceph
object
describ
case
enceph
practic
implic
stem
cell
transplant
result
patient
diagnos
acut
myeloid
leukemia
age
within
year
relaps
receiv
two
stem
cell
transplant
day
second
transplant
develop
hyponatremia
refractori
seizur
brain
mri
show
edema
medial
right
tempor
lobe
linear
ischem
chang
eeg
show
diffus
encephalopathi
cerebrospin
fluid
csf
demonstr
white
blood
cell
red
blood
cell
pcr
prophylact
antivir
switch
foscarnet
ganciclovir
repeat
mri
show
abnorm
signal
bilater
medial
tempor
lobe
right
insula
three
month
later
develop
episod
diaphoresi
hypothermia
agit
mutism
unusu
postur
recur
almost
daili
recogn
catatonia
mri
show
improv
abnorm
bilater
medial
tempor
lobe
hippocampi
eeg
show
diffus
slow
month
antivir
therapi
csf
neg
ensu
year
numer
episod
diaphoresi
hypertens
hypothermia
pruriti
confus
agit
cogwheel
rigid
bizarr
postur
dopamin
block
agent
help
clonazepam
help
reduc
frequenc
hot
shower
help
break
acut
episod
mri
show
gener
cortic
volum
loss
suffer
depress
sever
impair
sleep
cognit
function
describ
novel
debilit
outcom
enceph
may
provid
diagnost
consider
continu
improv
understand
breadth
possibl
neurolog
sequela
transplant
patient
understood
infect
destroy
tempor
lobe
hippocampi
patient
autonom
dysfunct
indic
involv
hypothalamu
basal
ganglia
antidopaminerg
agent
may
worsen
catatonia
effect
patient
treatment
catatonia
includ
benzodiazepin
electroconvuls
therapi
attempt
case
may
also
use
background
epsteinbarr
viru
ebv
relat
posttranspl
lymphoprolif
disord
ptld
lifethreaten
complic
patient
follow
hematopoiet
stem
cell
transplant
frequenc
estim
cumul
incid
mortal
estim
high
studi
ebv
hypothes
tonsil
critic
propag
infect
tonsillar
epitheli
cell
shown
site
primari
viral
infect
continu
viral
shed
howev
date
studi
perform
assess
role
tonsillectomi
patient
ebv
ptld
object
identifi
patient
local
ebv
ptld
treat
tonsillectomi
identifi
prognost
factor
may
abl
help
guid
futur
treatment
decis
designmethod
patient
treat
memori
sloan
ketter
cancer
center
receiv
hematopoiet
stem
cell
transplant
bill
code
ebv
tonsillectomi
elig
inclus
studi
retrospect
chart
review
perform
assess
patient
demograph
transplant
characterist
laboratori
valu
tonsillar
patholog
clinic
cours
patient
unilater
bilater
tonsillectomi
perform
nonloc
diseas
defin
diseas
involv
outsid
oropharynx
neck
subsequ
immunodefici
n
fanconi
anemia
fa
n
hemoglobinopathi
n
nonfa
marrow
failur
n
metabol
disord
seventi
one
percent
n
normal
amh
age
pretranspl
n
low
amh
age
pretranspl
n
oncolog
diagnosi
n
fa
n
previous
treat
hlh
n
nonfa
marrow
failur
one
metabol
disord
one
hemoglobinopathi
patient
posttranspl
amh
measur
n
low
level
patient
previous
normal
pretranspl
amh
n
underw
myeloabl
condit
mac
regimen
n
low
amh
level
posttranspl
compar
n
underw
reduc
intens
condit
ric
regimen
n
low
amh
level
posttranspl
p
fifteen
percent
n
low
level
pretranspl
underw
mac
regimen
n
remain
low
patient
n
fa
nine
percent
n
low
level
underw
ric
regimen
n
amh
level
remain
low
n
patient
hlh
treat
prior
transplant
conclus
amh
level
use
detect
prematur
ovarian
failur
fertil
counsel
higher
risk
prematur
ovarian
failur
mac
regimen
prior
chemotherapi
vs
ric
regimen
follow
cohort
provid
inform
understand
effect
hsct
ovarian
function
use
amh
predictor
fertil
potenti
background
proven
strategi
prevent
blood
stream
infect
bsi
secondari
oral
mucos
barrier
injuri
hematopoiet
stem
cell
transplant
hsct
addit
recent
report
progress
gingiv
dental
plaqu
accumul
hsct
recipi
despit
current
oral
standard
care
three
time
daili
oral
rins
xylitol
nonferment
sugar
alcohol
reduc
dental
cari
plaqu
accumul
oral
diseas
progress
inhibit
bacteri
growth
hypothes
addit
xylitol
standard
oral
care
decreas
dental
plaqu
accumul
gingiv
bacteremia
oral
flora
object
identifi
clinic
effect
strategi
improv
oral
health
prevent
bsi
secondari
bacteri
transloc
oral
mucosa
patient
undergo
hsct
conduct
prospect
random
control
studi
test
hypothesi
intervent
arm
receiv
current
standard
care
three
time
daili
oral
rins
addit
daili
xylitol
wipe
control
receiv
oral
standard
care
alon
oral
exam
perform
baselin
weekli
first
day
post
hsct
metagenom
shotgun
sequenc
mss
gingiv
sampl
perform
time
point
evalu
microbiom
divers
pathogen
bacteri
load
final
perform
whole
genom
sequenc
pathogen
bacteri
isol
caus
bacteremia
assess
genet
related
correspond
strain
present
within
patient
oral
microbiom
preced
infect
preliminari
interim
analysi
patient
demonstr
improv
oral
health
patient
receiv
xylitol
n
receiv
standard
care
n
measur
oral
hygien
index
p
gingiv
index
p
nine
patient
complet
oral
mss
analysi
xylitol
appear
associ
decreas
streptococcu
mitisorali
domin
oral
microbiom
final
patient
receiv
xylitol
incid
streptococcu
mitisorali
bacteremia
first
day
compar
three
patient
standard
care
arm
interestingli
streptococcu
mitisorali
compris
oral
microbiom
one
child
subsequ
develop
streptococcu
mitisorali
bsi
expect
complet
studi
next
month
n
addit
xylitol
oral
standard
care
appear
decreas
dental
plaqu
gingiv
patient
undergo
hsct
xylitol
may
also
imped
streptococcu
mitisorali
domin
oral
microbiom
potenti
reduct
blood
stream
infect
day
twentyon
mdli
administ
lymphopenia
fourteen
patient
concomit
viralopportunist
infect
mix
chimerismgraft
failur
motiv
mdli
n
six
administ
acceler
immun
reconstitut
infus
well
toler
without
appear
worsen
gvhd
increas
tcell
count
observ
follow
six
mdli
although
transitori
respons
week
five
case
viralopportunist
infect
control
five
case
requir
median
mdli
achiev
respons
none
mdli
administ
case
mix
chimerismgraft
failur
effect
revert
situat
preliminari
data
suggest
mdli
safe
adopt
immunotherapi
strategi
even
high
dose
tcell
without
infus
side
effect
gvhd
complic
efficaci
observ
patient
lymphopenia
opportunist
infect
posit
result
patient
mix
chimerismgraft
failur
date
howev
determin
real
efficaci
strategi
prospect
studi
requir
jun
zhao
kristen
beeb
lucia
mirea
alexandra
walsh
shane
lipskind
alexand
ngwube
phoenix
children
hospit
phoenix
arizona
unit
state
background
male
adolesc
undergo
myeloabl
hematopoiet
stem
cell
transplant
hsct
develop
infertil
impair
spermatogenesi
report
rate
rang
nonmalign
diseas
myeloabl
regimen
replac
reduc
intens
condit
ric
hope
better
surviv
rate
less
organ
toxic
improv
qualiti
life
despit
increas
use
ric
regimen
hsct
effect
ric
fertil
remain
unknown
object
assess
fertil
follow
ric
hsct
young
adult
male
assess
gonad
function
semen
characterist
adolesc
male
year
receiv
singl
ric
hsct
phoenix
children
hospit
nonmalign
diseas
male
patient
minimum
year
ric
hsct
postpubert
develop
tanner
stage
iii
elig
studi
gonad
statu
assess
measur
fsh
lh
testosteron
inhibin
b
level
semen
analys
assess
fertil
indic
semen
volum
sperm
concentr
motil
viabil
forward
progress
morpholog
total
count
result
hormon
level
semen
analysi
obtain
patient
thu
far
median
time
transplant
semen
analysi
year
post
hsct
patient
show
abnorm
elev
lh
level
fsh
testosteron
total
free
inhibin
b
level
within
normal
rang
patient
sperm
morpholog
viabil
test
abl
perform
due
low
concentr
volum
result
total
motil
sperm
count
use
estim
fertil
potenti
essenti
patient
conclus
recruit
ongo
far
limit
result
suggest
ric
hsct
may
detriment
longterm
effect
male
fertil
multiinstitut
trial
may
appropri
due
small
patient
number
institut
current
explor
option
expand
center
consider
warrant
regard
decis
made
provid
way
improv
anticipatori
counsel
provid
patient
famili
prior
transplant
augment
prevent
care
patient
longterm
followup
current
male
patient
consid
ric
transplant
counsel
sperm
bank
prior
transplant
background
previou
systemat
literatur
review
identifi
publish
studi
defibrotid
treatment
patient
age
vodso
assess
surviv
defibrotidetr
pediatr
patient
year
per
studi
patient
exhibit
infecti
complic
least
viral
infect
four
patient
also
bacteri
infect
note
patient
develop
evid
fungal
infect
conclus
earli
institut
ecp
patient
high
risk
acut
gvhd
grade
effect
treat
agvhd
allow
aggress
steroid
taper
contribut
excel
overal
surviv
rate
infecti
complic
primarili
viral
bacteri
fungal
infect
high
risk
popul
background
vodso
lifethreaten
complic
hsct
condit
vodso
multiorgan
dysfunct
mod
may
associ
mortal
defibrotid
approv
treat
hepat
vodso
renalpulmonari
dysfunct
posthsct
us
sever
hepat
vodso
posthsct
patient
age
month
eu
publish
data
surviv
neuroblastoma
patient
vodso
posthsct
object
report
surviv
safeti
post
hoc
patient
neuroblastoma
vodso
posthsct
defibrotid
tind
trial
designmethod
vodso
diagnos
baltimor
modifi
seattl
criteria
biopsi
withwithout
mod
hsct
chemotherapi
defibrotid
treatment
mgkgday
recommend
day
post
hoc
analysi
base
adult
pediatr
patient
receiv
dose
defibrotid
includ
mod
result
among
patient
neuroblastoma
develop
vodso
hsct
posthsct
patient
male
femal
median
age
year
rang
year
age
month
year
year
patient
year
surviv
data
avail
neuroblastoma
patient
mod
without
mod
autolog
allogen
transplant
kaplanmei
estim
surviv
neuroblastoma
group
confid
interv
ci
mod
mod
subgroup
kaplanmei
estim
surviv
ci
ci
respect
overal
tind
hsct
popul
age
year
n
pediatr
autolog
hsct
subgroup
n
kaplanmei
estim
surviv
respect
treatment
emerg
advers
event
teae
occur
n
seriou
teae
common
multiorgan
failur
teae
lead
treatment
discontinu
n
common
pulmonari
hemorrhag
n
death
occur
n
multiorgan
failur
vodso
treatmentrel
advers
event
assess
investig
occur
n
common
pulmonari
hemorrhag
post
hoc
analysi
found
kaplanmei
estim
surviv
patient
neuroblastoma
vodso
posthsct
consist
outcom
pediatr
patient
autolog
hsct
safeti
profil
defibrotid
neuroblastoma
patient
consist
overal
hsct
popul
studi
defibrotid
studi
pediatr
patient
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
blood
stream
infect
occur
nearli
patient
undergo
hematopoiet
stem
cell
transplant
hsct
fever
often
first
symptom
time
administr
antibiot
associ
improv
outcom
thu
earli
recognit
fever
paramount
current
standard
care
soc
includ
episod
monitor
temperatur
hospit
patient
may
delay
fever
detect
therefor
continu
realtim
bodi
temperatur
measur
may
detect
fever
prior
current
soc
temptraq
food
drug
administr
clear
class
ii
medic
devic
consist
soft
comfort
dispos
patch
result
patient
start
pca
day
post
hct
male
median
age
aml
match
relat
donor
use
receiv
tbi
pca
initi
median
oral
mucos
alon
common
indic
major
patient
start
hydromorphon
start
morphin
start
fentanyl
start
continu
infus
pca
use
median
day
rang
day
median
pain
score
highest
pca
use
howev
inconsist
chart
numer
pain
score
patient
insuffici
data
determin
efficaci
pain
control
remain
patient
good
pain
control
moder
poor
pain
control
use
devis
scale
common
toxic
observ
respiratori
depress
howev
etiolog
often
multifactori
due
opiat
alon
analysi
ongo
assess
variabl
predict
pca
use
well
efficaci
pain
control
correl
current
report
scale
patient
percept
conclus
pca
use
common
pediatr
hct
yet
pain
control
remain
inadequ
need
better
evalu
pca
manag
especi
uniform
assess
pain
therebi
improv
qualiti
life
post
hct
children
nation
health
system
washington
district
columbia
unit
state
background
actinomycosi
rare
invas
anaerob
gramposit
bacteri
diseas
caus
actinomyc
spp
may
colon
oropathynx
gastrointestin
tract
urogeniti
tract
lead
abscess
respiratori
tract
actinomycosi
character
pulmonari
caviti
nodul
consolid
pleural
effus
although
actinomyc
nearli
alway
sensit
penicillin
frequent
resist
cephalosporin
variabl
sensit
fluoroquinolon
although
rare
children
immunosuppress
patient
increas
risk
actinomycosi
describ
case
nextgener
sequenc
identif
actinomycosi
male
histori
high
risk
bcell
acut
lymphoblast
leukemia
month
statu
post
match
unrel
donor
bone
marrow
transplant
complic
prolong
fever
persist
weight
loss
splenic
lesion
treat
posaconazol
levofloxacin
develop
fever
cough
set
neutropenia
blood
cultur
demonstr
staphylococcu
epidermidi
ct
show
micronodul
effus
consist
epi
prompt
bronchoscopi
bacteri
cultur
neg
patient
prescrib
threeweek
cours
vancomycin
rapid
improv
designmethod
next
gener
sequenc
ng
bronchoalveolar
levag
sampl
perform
univers
washington
laboratori
result
ng
assay
bronchoalveolar
lavag
show
major
abund
actinomyc
close
relat
meyeri
oodontolyticu
demonstr
actinomyc
patient
start
six
month
cours
amoxicillin
continu
clinic
improv
retrospect
splenic
nodul
presum
fungal
diseas
like
actinomycosi
partial
treat
levofloxacin
case
highlight
potenti
util
ng
diagnosi
rare
diseas
immunocompromis
patient
actinomycosi
demonstr
ng
led
chang
treatment
regimen
durabl
clinic
improv
actinomyc
often
mimic
malign
tuberculosi
nocardiosi
use
novel
test
target
appropri
therapi
reduc
exposur
unnecessari
medic
treat
differenti
diagnosi
final
highlight
actinomyc
consid
patient
present
unexplain
fever
weight
loss
night
sweat
haneen
shalabi
cynthia
delbrook
maryalic
stetlerstevenson
constanc
yuan
bonni
yate
terri
j
fri
nirali
n
shah
center
cancer
research
nation
cancer
institut
nation
institut
health
bethesda
maryland
unit
state
background
cart
therapi
effect
may
durabl
antigen
neg
escap
grow
problem
hct
relapsedrefractori
cur
particularli
mrd
neg
remiss
demonstr
direct
cart
therapi
effect
render
patient
mrd
neg
remiss
flow
cytometri
leukemia
free
surviv
posthct
high
pastorek
jesssica
bruce
michael
pulsiph
chloe
anthia
peter
bader
andr
willasch
jennif
see
jennif
hoag
wendi
pelleti
brent
logan
pintip
chitphakdithai
lori
wiener
univers
pittsburgh
pittsburgh
pennsylvania
unit
state
background
pediatr
hsct
perform
north
american
europ
year
ethic
expos
healthi
child
donat
procedur
risk
direct
medic
benefit
continu
topic
debat
pediatr
donor
may
experi
psycholog
distress
poorer
qualityoflif
donat
compar
healthi
control
although
factjaci
requir
relat
manag
pediatr
donor
unclear
standard
practic
exist
psychosoci
assessmentmanag
group
object
describ
transplant
center
practic
psychosoci
evalu
manag
pediatr
donor
year
examin
differ
practic
locat
cibmtrebmt
number
harvest
volum
designmethod
data
collect
via
singl
crosssect
survey
distribut
electron
cibmtr
ebmt
center
cibmtr
ebmt
center
complet
survey
center
written
elig
guidelin
pediatr
donor
also
process
ensur
donor
freeli
assent
donat
manag
transplant
physician
singl
physician
often
jointli
manag
donorrecipi
care
half
center
pediatr
donor
advoc
often
physician
social
worker
cost
largest
barrier
donor
advoc
center
perform
psychosoci
screen
donor
rare
declin
donor
base
psychosoci
concern
less
half
center
provid
postdon
psychosoci
followup
comparison
center
locat
indic
ebmt
center
like
physician
joint
donorrecipi
care
vs
p
less
like
psychosoci
assess
polici
vs
p
less
like
donor
advoc
vs
p
margin
like
postdon
psychosoci
followup
vs
p
larg
volum
center
like
psychosoci
assess
polici
mediumsmal
counterpart
vs
p
differ
key
psychosoci
manag
variabl
volum
although
center
written
guidelin
pediatr
donor
elig
mechan
ensur
assent
substanti
number
donor
undergo
psychosoci
assess
jointli
manag
recipi
singl
physician
without
assign
donor
advoc
receiv
psychosoci
followup
field
would
benefit
guidelin
develop
psychosoci
manag
pediatr
donor
background
germlin
mutat
gene
caus
mirag
myelodysplasia
infect
restrict
growth
adren
hypoplasia
genit
phenotyp
enteropathi
ataxiapancytopenia
syndrom
respect
associ
chromosom
delet
md
bone
marrow
failur
bmf
limit
data
outcom
hct
patient
describ
outcom
allogen
hct
patient
hematolog
disord
associ
mutat
result
seven
patient
underw
allogen
hct
primari
md
n
congenit
amegakaryocyt
thrombocytopenia
camt
n
dyskeratosi
congenita
n
retrospect
exom
sequenc
reveal
gainoffunct
mutat
n
n
gene
constitut
mosaic
monosomi
present
case
two
patient
featur
mirag
syndrom
unusu
find
panhypopituitar
laryng
cleft
glomerulosclerosi
note
one
case
anoth
case
mutat
hypospadia
bifid
scrotum
find
remain
patient
phenotyp
abnorm
median
age
hct
rang
patient
receiv
transplant
bone
marrow
match
unrel
n
hla
ident
sibl
n
unrel
cord
blood
ucb
n
five
md
patient
receiv
myeloabl
condit
busulfanbas
n
tbibas
n
patient
md
n
camt
n
receiv
reducedintens
condit
ric
fludarabin
cyclophosphamid
ratg
alemtuzumab
syndromerel
comorbid
diarrhea
infect
malnutrit
electrolyt
imbal
lung
diseas
hypoxia
present
patient
mirag
syndrom
one
patient
famili
mutat
md
morbid
obes
fail
engraft
follow
ric
doubl
ucbt
die
one
year
later
refractori
aml
patient
achiev
neutrophil
platelet
engraft
median
rang
day
respect
posttranspl
complic
includ
sever
hypertens
n
pericardi
effus
n
venoocclus
diseas
liver
n
recurr
aspir
pneumonia
n
one
patient
develop
grade
iii
agvhd
resolv
treatment
one
patient
develop
mild
skin
cgvhd
suffer
chronic
lung
diseas
surviv
patient
resolut
hematolog
disord
sustain
peripher
blood
donor
chimer
overal
surviv
median
followup
year
rang
patient
hematolog
disord
associ
germlin
mutat
toler
transplant
condit
without
unusu
unexpectedli
sever
toxic
allogen
hct
led
success
resolut
md
bmf
excel
overal
surviv
data
need
refin
transplant
approach
patient
signific
comorbid
develop
guidelin
longterm
followup
shyamli
singla
tiffani
simmswaldrip
andrew
koh
victor
aquino
background
steroidrefractori
acut
graft
versu
host
diseas
agvhd
potenti
fatal
complic
allogen
hematopoiet
stem
cell
transplant
hsct
basiliximab
monoclon
antibodi
singl
agent
combin
infliximab
antitnfmonoclon
antibodi
demonstr
efficaci
adult
cohort
steroidrefractori
agvhd
well
studi
pediatr
popul
adopt
use
basiliximab
infliximab
institut
standard
care
steroidrefractori
agvhd
pediatr
hsct
patient
determin
respons
surviv
hsct
children
receiv
basiliximab
infliximab
treatment
steroidrefractori
agvhd
designmethod
retrospect
review
children
receiv
basiliximab
infliximab
steroidrefractori
agvhd
refractori
septemb
decemb
complet
respons
cr
defin
resolut
clinic
sign
agvhd
partial
respons
pr
defin
least
one
grade
reduct
one
target
organ
eg
skin
gut
liver
without
increas
grade
anoth
target
organ
respons
defin
either
improv
progress
worsen
agvhd
least
one
organ
baselin
demograph
transplant
detail
laboratori
find
treatment
outcom
also
evalu
result
evalu
hsct
patient
children
median
age
yr
rang
yr
steroidrefractori
agvhd
receiv
combin
monoclon
antibodi
mab
therapi
median
time
start
steroid
therapi
initi
mab
day
overal
glucksberg
grade
agvhd
time
initi
mab
therapi
grade
n
ii
n
iii
n
iv
n
overal
respons
rate
patient
achiev
cr
patient
achiev
pr
patient
respons
day
follow
start
mab
therapi
median
overal
surviv
day
patient
exhibit
cr
pr
respons
respect
overal
surviv
year
follow
start
mab
therapi
background
role
high
dose
chemotherapi
hdc
autolog
stem
cell
rescu
ascr
patient
high
risk
advanc
metastat
relaps
soft
tissu
sarcoma
controversi
despit
multimod
chemotherapi
radiotherapi
local
control
measur
advanc
prognosi
patient
advanc
metastat
unresect
relaps
sarcoma
remain
poor
less
year
diseas
free
surviv
object
determin
consolid
myeloabl
hdc
ascr
improv
relaps
free
rf
overal
surviv
os
outcom
high
risk
patient
subgroup
perform
retrospect
review
high
risk
soft
tissu
sarcoma
patient
underw
hdc
ascr
children
hospit
montefior
bronx
ny
octob
januari
protocol
approv
albert
einstein
colleg
medicin
institut
review
board
result
patient
primari
metastat
high
risk
diseas
relaps
recurr
diseas
receiv
hdc
ascr
primari
diagnos
rhabdomyosarcoma
rm
n
alveolar
histolog
primari
site
nasopharynx
n
lower
extrem
n
ewe
sarcoma
ew
n
axial
site
pelvic
patient
median
age
year
rang
year
male
patient
complet
metabol
remiss
transplant
median
pre
transplant
comorbid
index
rang
patient
rm
ew
receiv
condit
carboplatin
etoposid
melphalan
remain
patient
ew
receiv
condit
busulfan
melphalan
topotecan
patient
receiv
peripher
blood
mobil
hematopoiet
stem
cell
transplant
stem
cell
mobil
achiev
high
dose
filgrastim
patient
except
one
requir
addit
plerixafor
median
recipi
bodi
weight
cell
dose
infus
rang
median
time
neutrophil
platelet
l
engraft
rang
day
respect
patient
develop
bk
viuria
one
grade
iii
hemorrhag
cystiti
develop
cmv
viremia
one
patient
asymptomat
ebv
viremia
graft
failur
sinusoid
obstruct
syndrom
transplant
relat
mortal
median
follow
posttranspl
day
rang
day
year
probabl
os
rf
respect
hdc
ascr
promis
therapeut
strategi
consolid
remiss
improv
surviv
select
high
risk
soft
tissu
sarcoma
patient
subgroup
prospect
clinic
trial
inform
impact
diseas
statu
prior
hdc
ascr
outcom
optim
condit
long
term
relaps
free
overal
surviv
background
absenc
minim
residu
diseas
paramount
cure
pediatr
acut
lymphoblast
leukemia
testi
may
harbor
occult
leukemia
diseas
may
result
treatment
failur
object
purpos
studi
assess
longterm
outcom
boy
without
testicular
leukemia
prehematopoiet
stem
cell
transplant
hsct
designmethod
retrospect
analysi
boy
highrisk
de
novo
hypodiploidi
recurrentrefractori
conduct
flow
cytometri
bone
marrow
mononuclear
cell
use
determin
remiss
statu
testicular
evalu
perform
physic
examin
wedg
biopsi
prehsct
median
age
time
transplant
year
patient
remiss
flow
cytometri
bone
marrow
mononuclear
cell
time
transplant
none
evid
clinic
appar
testicular
diseas
testicular
leukemia
detect
patient
underw
bilater
orchiectomi
develop
acut
graft
versu
host
diseas
gvhd
duodenum
sigmoid
colon
resolv
leukemia
remain
second
complet
remiss
free
hsctrelat
morbid
month
posthsct
patient
without
testicular
leukemia
die
median
month
rang
posthsct
adenoviru
infect
thrombot
microangiopathi
aspergillu
pneumonia
experienc
infect
staphylococcu
speci
corynebacterium
enterococcu
klebsiella
citrobact
e
coli
epstein
barr
viru
adenoviru
bk
viru
human
candida
albican
fusarium
aspergillu
yeast
fungu
experienc
gvhd
gi
tract
skin
liver
eye
mouth
lung
develop
second
neoplasia
right
lower
leg
leiomyosarcoma
one
patient
develop
bone
marrow
minim
residu
diseas
phenotyp
abnorm
cell
detect
month
match
sibl
hsct
reinduct
therapi
compris
weekli
dose
rituxan
cours
blinatumomab
donor
lymphocyt
infus
two
subsequ
bone
marrow
evalu
minim
residu
diseas
neg
thirteen
month
posthsct
residu
diseas
recur
receiv
inotumumab
overal
median
surviv
posttranspl
boy
month
rang
surviv
boy
month
rang
conclus
testicular
biopsi
detect
occult
leukemia
prehsct
testicular
leukemia
prehsct
appear
increas
risk
subsequ
relaps
hsctrelat
advers
event
compar
without
yaya
chu
nang
kham
su
sarah
alter
emili
k
jeng
peter
r
rhode
mathew
barth
dean
lee
hing
c
wong
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
rituximab
wide
use
frontlin
treatment
bnhl
includ
burkitt
lymphoma
bl
howev
patient
retreat
rituximab
relaps
limit
patient
treatment
option
novel
therapi
desper
need
relapsedrefractori
bnhl
patient
sever
strategi
overcom
rituximabresist
current
evalu
includ
engin
immun
cell
chimer
antigen
receptor
car
well
secondgener
antibodi
natur
killer
nk
cell
play
import
role
reject
tumor
howev
nk
therapi
limit
small
number
activ
nk
cell
unmodifi
peripher
blood
lack
tumor
target
specif
multipl
mechan
tumor
escap
nk
cell
immunosurveil
group
success
expand
function
activ
peripher
blood
nk
cell
expbnk
gener
fuse
superagonist
four
singlechain
rituximab
display
trispecif
bind
activ
recognit
molecul
tumor
cell
activ
nk
cell
enhanc
adcc
induc
apoptosi
blymphoma
cell
object
examin
significantli
enhanc
cytotox
expbnk
rituximabsensit
resist
bl
cell
designmethod
expbnk
expand
lethal
irradi
isol
use
miltenyi
nk
cell
isol
kit
gener
provid
altor
bioscienc
nk
receptor
express
cytotox
examin
previou
describ
ifng
granzym
b
level
examin
elisa
assay
equal
dose
rituximab
obinutuzumab
obinu
use
comparison
igg
use
control
car
expbnk
cell
gener
previous
describ
mrna
electropor
rituximabsensit
raji
andresist
bl
cell
use
target
cell
result
significantli
enhanc
expbnk
cytotox
rituximabsensit
raji
cell
rituximabresist
cell
resist
cell
compar
control
igg
rituximab
obinu
p
e
furthermor
confirm
enhanc
cytotox
measur
ifng
granzym
b
product
significantli
enhanc
ifng
granzym
b
product
expbnk
raji
compar
igg
p
rituximab
p
p
p
obinutuzumab
p
compar
car
expbnk
cell
expbnk
similar
cytotox
raji
car
expbnk
cell
p
conclus
significantli
enhanc
expbnk
activ
receptor
express
vitro
cytotox
rituximabsensit
resist
bl
cell
vivo
function
expbnk
rituximabsensit
resist
bl
cell
use
human
nsg
model
investig
background
cardiac
dysfunct
includ
left
ventricular
systol
dysfunct
lvsd
known
complic
stem
cell
transplant
sct
survivor
detect
lvsd
echocardiographi
import
popul
minim
research
determin
subclin
cardiac
dysfunct
exist
sct
patient
cardiopulmonari
exercis
test
cpet
valuabl
tool
assess
cardiac
function
determin
heart
respond
stress
exercis
studi
perform
determin
sct
patient
normal
lvsd
standard
echocardiographi
may
abnorm
cpet
determin
feasibl
cpet
well
addit
echocardiograph
paramet
detect
dysfunct
sct
patient
normal
eject
fraction
echocardiogram
designmethod
perform
crosssect
analysi
sct
survivor
least
year
post
sct
year
age
older
eject
fraction
low
end
normal
rang
echocardiogram
assess
exercis
capac
patient
cpet
subclin
cardiac
dysfunct
tissu
doppler
strain
analysi
echocardiogram
result
seven
patient
male
qualifi
complet
studi
far
averag
age
year
median
time
transplant
year
seven
patient
normal
eject
fraction
howev
four
patient
abnorm
cpet
abnorm
includ
abnorm
predict
peak
oxygen
consumpt
normal
best
predictor
function
capac
predict
oxygen
puls
normal
measur
cardiac
stroke
volum
ventilatori
effici
slope
normal
submaxim
exercis
data
use
patient
unabl
complet
maxim
effort
test
demonstr
lownorm
predict
anaerob
threshold
normal
day
patient
receiv
autolog
infus
mean
number
day
engraft
engraft
hsct
need
prompt
minim
durat
neutropenia
maxim
surviv
rate
data
demonstr
infus
hematopoiet
stem
cell
product
syring
iv
pump
effect
method
deliveri
stem
cell
product
delay
time
engraft
median
day
neutrophil
engraft
day
compar
data
nmdp
report
engraft
occur
within
day
main
limit
studi
small
sampl
size
due
number
transplant
done
center
howev
provid
evid
support
infus
stem
cell
product
via
pump
mechan
safe
altern
infus
graviti
method
process
hematopoiet
stem
cell
administr
john
hopkin
children
hospit
st
petersburg
florida
unit
state
background
leukem
relaps
remain
common
caus
treatment
failur
allogen
hematopoiet
cell
transplant
allohct
myeloid
malign
children
relaps
postallohct
die
diseas
make
intervent
minim
risk
high
prioriti
object
evalu
safeti
efficaci
posttranspl
azacitidin
relaps
prevent
children
undergo
allohct
myeloid
malign
designmethod
retrospect
review
chart
children
undergo
allohct
myeloid
malign
februari
novemb
john
hopkin
children
hospit
result
studi
period
children
age
year
median
underw
allohct
myeloid
malign
de
novo
acut
myeloid
leukemia
aml
mix
phenotyp
acut
leukemia
treatmentrel
aml
juvenil
myelomonocyt
leukemia
aml
transform
myelodysplasiaaml
thirteen
first
complet
remiss
greater
patient
receiv
fludarabinemelphalanthiotepa
condit
receiv
hlaident
relat
unrel
donor
receiv
haploident
bone
marrow
graft
posttranspl
cyclophosphamid
three
patient
never
receiv
plan
azacitidin
earli
relaps
earli
trm
leav
evalu
patient
azacitidin
dose
day
cycl
cycl
start
median
day
posttranspl
rang
twothird
patient
receiv
eight
cycl
five
patient
stop
therapi
earli
one
due
toxic
reason
includ
sever
gvhd
parent
prefer
relaps
cycl
delay
occur
patient
median
cycl
delay
per
patient
mostli
mild
myelosuppress
earli
cycl
patient
requir
blood
product
transfus
therapi
gcsf
use
three
patient
maintain
anc
l
dosemodif
made
patient
renal
tubular
acidosi
acut
kidney
injuri
myelosuppress
relaps
two
occur
patient
relaps
incid
patient
median
followup
month
rang
patient
receiv
azacitidin
die
transplantrel
mortal
conclus
administr
azacitidin
children
undergo
allohct
myeloid
malign
safe
feasibl
patient
success
receiv
plan
cycl
toxic
accept
trm
secondari
graft
failur
despit
limit
small
cohort
relaps
incidenceparticularli
patient
transplant
potenti
benefit
diseas
control
warrant
investig
followup
studi
background
despit
signific
improv
success
rate
hematopoiet
cell
transplant
hct
graft
failur
remain
import
complic
patient
transplant
sever
aplast
anemia
saa
second
allogen
hct
salvag
patient
overal
surviv
os
rate
report
low
object
identifi
patient
develop
drop
donor
chimer
graft
reject
andor
graft
failur
first
hct
saa
necessit
addit
hct
cellular
boost
defin
stem
cell
product
infus
without
preced
chemotherapi
evalu
treatmentrel
complic
os
